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ABSTRACT 
Different computational methods have been applied to the development of non-
steroidal inhibitors of steroidogenic enzymes for the treatment of hormone-sensitive 
diseases, like breast and prostate cancer and hypertension. 
A high-quality homology model of CYP17 was created and used for docking studies. 
Three binding modes were identified and SAR for different CYP17-inhibitor classes, 
substantiated by ab initio calculations, could be derived and used in further drug 
design leading to improved potency. 
Docking studies and ligand cluster analysis for a series of CYP19 inhibitors resulted 
in a binding mode, well explaining their different inhibitory potencies. The derived 
SAR were used in ongoing drug design, resulting so far in highly potent CYP19 
inhibitors. 
The kinetic cycle of 17β-HSD1 was hypothesized based on biochemical data, 
analysis of the crystal structures and a multi-trajectory MD approach and provided 
insights in protein motion. These were translated into the drug design process. An 
ensemble docking study was performed for bis(hydroxyphenyl)-arenes, potent 17β-
HSD1 inhibitors, and two conformation-dependent binding modes were identified. 
MD simulations and quantum-chemical calculations identified one of them as the 
more plausible, suggesting this class of compounds to dysfunction the enzyme 
dynamics. 
Two pharmacophore models were derived from CYP11B2 inhibitors and combined 
into a ligand- and structure-based approach, which led to a new class of potent 
CYP11B2 inhibitors. 
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ZUSAMMENFASSUNG 
Verschiedene computergestützte Methoden wurden in der Entwicklung von 
nicht-steroidalen Hemmstoffen steroidogener Enzyme angewandt. Diese 
Inhibitoren sollen zur Behandlung hormon-abhängiger Krankheiten eingesetzt 
werden. 
Ein qualitativ-hochwertiges CYP17 Homologiemodell wurde erstellt und in 
Docking Studien verwendet. Drei Bindungsmodi konnten identifiziert werden 
und Struktur-Wirkungsbeziehungen wurden für verschiedene CYP17 
Hemmstoffklassen abgeleitet und erfolgreich in eine weitere 
Hemmstoffentwicklung eingebaut. 
Dockingstudien und Clusteranalysen einer Reihe von CYP19 Inhibitoren 
ergaben einen plausiblen Bindungsmodus und die daraus gewonnenen 
Erkenntnisse führten in laufenden Projekten zu höchst potenten Hemmstoffen. 
Der kinetische Zyklus von 17β-HSD1 wurde postuliert basierend auf 
biochemischen Literaturdaten, Kristallstrukturenanalyse und einem multiplen 
MD-Ansatz, welcher wichtige Einblicke in die Dynamik des Enzyms lieferte. 
Diese wurden als ensemble docking Ansatz in die Entwicklung einer Klasse 
hochpotenter 17β-HSD1 Inhibitoren eingebaut und ergaben zwei 
Enzymkonformations-abhängige Bindungsmodi. MD-Simulationen und 
quantenchemische Methoden identifizierten einen davon als plausibler. Dabei 
scheinen Substanzen dieser Klasse die Enzymdynamik zu stören. 
Zwei Pharmakophormodelle wurden basierend auf CYP11B2-Hemmstoffen 
erstellt und in einen Ligand- und Struktur-basierten Ansatz eingebaut. Dieser 
führte zu einer neuen Klasse von potenten und selektiven CYP11B2-
Inhibitoren. 
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Chapter One. INTRODUCTION 
1.1 Steroidogenesis 
Steroidogenesis is an important step in the biosynthesis of steroids. Precisely, it describes the 
processes wherein desired forms of steroids are generated by transformation of other steroids. 
Products of steroidogenesis include steroidal hormones, generally synthesized from cholesterol 
in the gonads and adrenal glands, and grouped into five classes by the receptor to which they 
bind: progestagens (progesterone), androgens (testosterone), estrogens (17β-estradiol), 
glucocorticoids (cortisol) and mineralocorticoids (aldosterone). They play an important role in 
the regulatory mechanisms in human body, especially at the sexual level. Biosynthesis of steroid 
hormones (Fig. 1) requires a battery of oxidative enzymes located in both mitochondria and 
endoplasmic reticulum, belonging mainly to two enzyme families, namely cytochromes P450 
(CYPs) and hydroxysteroid dehydrogenases (HSDs). 
Because steroids and sterols are lipid-soluble, they can diffuse fairly freely from the blood 
through the cell membrane and into the cytoplasm of target cells. In the cytoplasm, the steroid 
may or may not undergo an enzyme-mediated alteration such as reduction, hydroxylation, or 
aromatization. In the cytoplasm these hormones can quite easily combine with a protein receptor, 
a large metalloprotein. Thus, the effects of the steroid hormones are mediated by slow genomic 
mechanisms through nuclear receptors as well as by fast nongenomic mechanisms through 
membrane-associated receptors and signaling cascades. 
The particular steroid hormone class synthesized by a given cell type depends upon its 
complement of peptide hormone receptors, its response to peptide hormone stimulation and its 
genetically expressed complement of enzymes. The following indicates which peptide hormone 
is responsible for stimulating the synthesis of the most important steroid hormones: 
• Luteinizing Hormone (LH): progesterone and testosterone 
• Adrenocorticotropic hormone (ACTH): cortisol 
• Follicle Stimulating Hormone (FSH): estradiol 
• Angiotensin II/III: aldosterone 
Steroid hormones are generally carried in the blood bound to specific carrier proteins such as sex 
hormone-binding globulin (SHBG) or corticosteroid-binding globulin. Further conversions and 
catabolism occur in the liver, in other "peripheral" tissues, and in the target tissues. All steroid 
hormones share the same cyclopentanoperhydrophenanthrene ring structure and carbon 
numbering system. Depending on the total number of carbon atoms per structure, steroids are 
classified in C-21 (pregnenolone), C-19 (testosterone) and C-18 steroids (estradiol). 
~ 2 ~
Figure 1. Steroidogenesis (taken from Wikipedia).1
1.1.1. Biosynthesis of steroid hormones.
The first reaction in converting cholesterol to C18, C19 and C21 steroids involves the cleavage 
of a 6-carbon group from cholesterol and is the principal and rate-limiting step in steroid 
biosynthesis. The enzyme system that catalyzes the cleavage reaction is known as P450-linked 
side chain cleaving enzyme (P450ssc or 20,22-desmolase) and is found primarily in the 
mitochondria of steroid-producing cells. Chronic regulation of steroidogenesis occurs principally 
at the level of transcription of the gene for P450 side chain cleavage (P450scc) 2, which is the 
enzymatically rate-limiting step. Subsequent to desmolase activity, pregnenolone moves to the 
cytosol, where further processing depends on the cell (tissue) under consideration. At this stage 
the acute regulation of steroidogenesis takes place mediated by steroidogenic acute regulatory 
protein (StAR), which facilitates the rapid influx of cholesterol into mitochondria. 
All the enzymes involved in the multi-step biosynthesis of steroid hormones act as hydroxylases, 
either cytochrome P450s (CYPs) or short-chain dehydrogenases/hydroxysteroid dehydrogenases 
(SDR/HSD), and have as such a nomenclature indicative of the site of hydroxylation (e.g. 17α-
hydroxylase (CYP17A1) and 17β-hydroxysteroid dehydrogenase (17β-HSD1) – hydroxylation 
of the carbon in 17 position, in α or β site of the steroid, respectively). The most important are:
 ~ 3 ~ 
 
• CYP11A1  (P450scc, P450c11a1, steroid 20α-hydroxylase, steroid 22-hydroxylase, 
cholesterol side chain cleavage enzyme) - adrenal mitochondria.  
• CYP11B1  (P450c11β, steroid 11β-hydroxylase) - inner mitochondrial membrane of 
adrenal cortex.  
• CYP11B2  (P450c18, aldosterone synthase, 18-hydroxylase) only in mitochondria of the 
adrenal zona glomerulosa. 
• CYP17A1  (P450c17, 17α-hydroxylase/17,20-lyase) - endoplasmatic reticulum (RE) of 
adrenal cortex, testes. 
• CYP21A1  (21-hydroxylase) - adrenal cortex. 
• CYP19A  (P450aro, aromatase) - RE of gonads, brain, adipose tissue. 
• 3β-HSD (3β-hydroxysteroid dehydrogenase/ Δ5-Δ4 isomerase) - ubiquitary 
Sex steroids (gonadal steroids, sex hormones) are steroid hormones that interact with vertebrate 
androgen, estrogen or progestin receptors. Natural sex steroids are made by the gonads (ovaries 
or testes), by adrenal glands, or by conversion from other sex steroids in other tissue such as liver 
or fat. The two main classes of sex steroids are androgens and estrogens, of which the most 
important human derivatives are testosterone and estradiol, respectively. Progestagens are often 
included as a third class of sex steroids, distinct from androgens and estrogens. Progesterone is 
the most important and only naturally-occurring human progestagen. In general, androgens are 
considered "male sex hormones", since they have masculinizing effects, while estrogens and 
progestagens are considered "female sex hormones", although all types are present in each 
gender, albeit at different levels.3 
1.1.2. Adrenal glands  
The adrenal cortex is responsible for the production of the 3 major classes of steroid hormones: 
glucocorticoids, which regulate carbohydrate metabolism; mineralocorticoids, which regulate the 
body levels of sodium and potassium; and androgens, male sex hormones. The adrenal cortex is 
composed of 3 main tissue regions (Fig. 2): zona glomerulosa, zona fasciculata, and zona 
reticularis. In order to be converted to pregnenolone in the adrenal cortex cholesterol must be 
transported into the mitochondria where CYP11A1 (P450ssc) resides. This transport process is 
mediated by the steroidogenic acute regulatory protein (StAR) and is the acute rate-limiting step 
in steroidogenesis. Although the pathway to pregnenolone synthesis is the same in all zones of 
the cortex, the zones are histologically and enzymatically distinct, with the exact steroid 
hormone product dependent on the enzymes present in the cells of each zone. This is the 
qualitative regulation of steroidogenesis, determining the class of steroid produced, and it is 
principally determined by P450c17 (CYP17): 
− Zona glomerulosa. Zona glomerulosa cells are unique in the adrenal cortex in containing 
P450c18 (CYP11B2, aldosterone synthase), which converts the C21 deoxy steroid 
corticosterone to aldosterone, the principal and most potent mineralocorticoid. P450c17 
is absent in this area of the adrenals, resulting in a missing pathway to the 
glucocorticoids (deoxycortisol and cortisol) and the androgens (dehydroepiandosterone 
(DHEA) and androstenedione). 
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− Zona fasciculata. In the presence of the 17α-hydroxylase, but not the 17,20 lyase, activity 
of CYP17 C21,17α-hydroxy steroids are produced, leading to the glucocorticoid 
cortisol.
− Zona reticularis. Both 17α- hydroxylase and 17,20 lyase activities of P450c17 are present 
and the androgen precursor dehydroepiandrosterone is produced. The discrimination 
between 17α-hydroxylase and 17,20 lyase activities is regulated by two 
posttranslational events, the serine phosphorylation of CYP17 and the allosteric action 
of cytochrome b5, both of which act to optimize the interaction of CYP17 with its 
obligatory electron donor, P450 oxidoreductase.
So, pregnenolone, moving from the mitochondria to the cytosol, is converted either to androgens 
or to 11-deoxycortisol and 11-deoxycorticosterone by enzymes of the endoplasmic reticulum. 
The latter 2 compounds then re-enter the mitochondrion, where the enzymes are located for 
tissue-specific conversion to glucocorticoids or mineralocorticoids, respectively.
Figure 2. Adrenal synthesis of steroid hormones from cholesterol (http://themedicalbiochemistrypage.org).4
1.1.3. Gonadal steroid hormones 
The biosynthetic pathway to sex hormones (Fig. 3) in male and female gonadal tissue (testes and 
ovaries, respectively) includes the production of the androgens androstenedione and 
dehydroepiandrosterone (DHEA). These are then converted into the two most important 
hormones testosterone (T) and estradiol (E2). T and E2 are under tight biosynthetic control, with 
short and long negative feedback loops that regulate the secretion of follicle stimulating hormone 
(FSH) and luteinizing hormone (LH) by the pituitary and gonadotropin releasing hormone 
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(GnRH) by the hypothalamus. Low levels of circulating sex hormone reduce feedback inhibition 
on GnRH synthesis (the long loop), leading to elevated FSH and LH.
In males, LH binds to Leydig cells, stimulating production of the principal Leydig cell hormone, 
testosterone. Testosterone (T) is secreted to the plasma and also carried to Sertoli cells by 
androgen binding protein. In Sertoli cells the Δ4 double bond of testosterone is reduced, 
producing dihydrotestosterone (DHT), the most potent of the male steroid hormones. 
Testosterone and dihydrotestosterone are carried in the plasma, and delivered to target tissue, by 
a specific gonadal steroid binding globulin.
In females, LH binds to thecal cells of the ovary, where it stimulates the synthesis of 
androstenedione and testosterone by the cAMP- and PKA-regulated pathway. An additional 
enzyme complex known as aromatase is responsible for the final conversion of the latter 
androgens into the estrogens. Aromatase is a complex endoplasmic reticulum enzyme found in 
the ovary and in numerous other tissues in both males and females. Its action involves 
hydroxylations that culminate in the cleavage of the C10-C19 bond and in aromatization of the A 
ring of the androgens.
Figure 3. Biosynthesis of sex hormones from cholesterol (http://themedicalbiochemistrypage.org).5
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1.1.4. Steroid hormone receptors. 
Unlike peptide hormone receptors that span the plasma membrane and bind ligand outside the 
cell, steroid hormone receptors are found in the cytosol and the nucleus. The steroid hormone 
receptors belong to the steroid and thyroid hormone receptor super-family of proteins, that 
includes not only the receptors for steroid hormones (androgen receptor, progesterone receptor, 
estrogen receptor), but also for thyroid hormone, vitamin D, retinoic acid, mineralocorticoids, 
and glucocorticoids. These receptors are ligand-activated proteins that regulate transcription of 
selected genes. When a ligand binds, they undergo a conformational change that renders them 
activated to recognize and bind to specific nucleotide sequences. These specific nucleotide 
sequences in the DNA are referred to as hormone-response elements. When ligand-receptor 
complexes interact with DNA they alter the transcriptional level (responses can be either 
activation or repression) of the associated gene. Thus, the steroid-thyroid receptors family has 
three distinct domains: a ligand-binding domain, a DNA-binding domain and a transcriptional 
regulatory domain. Although there is the commonly observed effect of altered transcriptional 
activity in response to hormone-receptor interaction, there are family member-specific effects 
with ligand-receptor interaction. Several receptors are induced to interact with other 
transcriptional mediators in response to ligand binding. Binding of steroid hormones leads to 
translocation of the ligand-receptor complex from the cytosol to the nucleus. 
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1.2 Endocrinology vs intracrinology –
pathophysiological role of steroid hormones
Biologically active hormones need to interact with their specific receptors located in the target 
tissues in order to unfold their physiological functions. We can distinguish four systems of 
hormone actions (see Fig. 4), localized on different levels.
Figure 4. Endocrine, paracrine, autocrine and intracrine secretion (taken from Labrie et al. 2000).6
The one which is investigated most is the endocrine system, influenced at various stages by the 
plasma concentration of biologically active hormones. These are synthesized and secreted from 
endocrine organs, such as adrenal cortex, gonads (testes and ovaries) or pituary gland, and then 
transported through the circulation, and act on their target tissues via binding to their specific 
receptors. In classical endocrine systems only a small amount of hormones produced and 
secreted is in general utilized in the target tissues or exerts their effects. The great majority of 
these hormones is actually metabolized or converted to inactive forms.
Additionally, hormones, locally produced from endocrine organs, can also act in the same cell 
(autocrine system) or neighboring cells (paracrine system) without their release into the 
circulation.
The forth, and more particular action system, is the intracrine one. The term intracrinology was 
created in 1988 by Labrie et al. focusing on the synthesis of active steroids in peripheral target 
tissues where steroid action is exerted in the same cells where synthesis takes place without 
release of the active hormones in the extracellular space and in the general circulation.7 A large 
proportion of androgens in men (approximately 50%) and estrogens in women (approximately 
75% before menopause, and close to 100% after menopause) were produced in peripheral 
hormone target tissues from abundantly present less active circulating precursor steroids (i.e. 
dehydroepiandrosterone (DHEA), DHEA-S (DHEA-sulfate) and/or androstenedione (4-
Adione)), where the enzymes involved in the formation of androgens and estrogens are 
expressed (Fig. 5). 
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Figure 5. Role of gonadal (testicular and ovarian) and adrenal sources of sex steroids in men and premenopausal 
women (adapted from Labrie et al. 2000).6
Since these steroids are not released in the circulation, the rate of formation of each active sex 
steroid thus depends upon the level of expression of the specific androgen- and estrogen-
synthesizing enzymes in each cell of each tissue. It is remarkable that humans, in addition to 
possessing a highly sophisticated endocrine system, have largely vested sex steroid formation in 
peripheral tissues.8 Active sex steroids are to a much larger degree or completely synthesized 
locally in peripheral tissues; this provides autonomous control to target tissues which are thus 
able to adjust the formation and metabolism of sex steroids according to local requirements. In 
contrast to the classical endocrine system, an intracrine system requires minimal amounts of 
biologically active hormones to exert their maximum hormonal effects. Therefore, the intracrine 
system is considered a remarkable efficient mode of hormone action and plays an important role, 
especially in the development of hormone-dependent neoplasms including human prostate, 
breast, endometrial, and ovarian malignancies.
The synthesis from DHEA of the most potent natural androgen, (DHT), and of the most potent 
natural estrogen, 17β-estradiol (E2), involves several enzymes, namely 3β-hydroxysteroid 
dehydrogenase/Δ5-Δ4 isomerase (3β-HSD), 17β-HSD, 5α-reductase and/or aromatase. 17β-
HSDs are required for both the synthesis of all active androgens and all active estrogens as well 
as for their inactivation. In the human, the continuous formation of sex steroids from DHEA in 
peripheral tissues is likely to play a major role in the maintenance of adequate functioning of 
most human tissues. It is important to mention that 40% of all cancers, namely breast, prostate, 
ovarian and uterine cancers, are sex steroid-sensitive and are thus prime candidates for 
approaches based upon control of intracrine activity.
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1.2.1. Prostate cancer (PC) 
Prostate cancer is the most common tumor and age-related cause of death in elder men 
worldwide.9-11 In about 80 % of the cases it is androgen dependent. Commonly, in PC androgens 
exert their action via the endocrine system, being synthesized in the testes, gonads and the 
adrenals by the P450c17 complex. Although, it has to be mentioned that besides the uptake and 
conversion of circulating adrenal androgens prostate cancer metastases may also be capable of de 
novo androgen biosynthesis from cholesterol and/or progesterone precursors, thus involving the 
intracrine system. 
About 90% of prostate cancers are diagnosed at an early stage. Nevertheless, the treatment 
selection is very difficult. Since prostate cancer is predominantly a disease of older men, many 
will die of other causes before a slowly growing PC can spread or cause symptoms. The age and 
underlying health of the man, as well as the grade and stage of the disease and response of the 
cancer to initial treatment, are important in prognosing the outcome of the disease. The decision 
whether or not to treat localized prostate cancer with curative intent is a patient trade-off between 
the expected beneficial and harmful effects in terms of patient survival and quality of life. 
In the course of studies on the hormonal therapy of prostate cancer, a surprising observation was 
that, while blood levels of testosterone were reduced by 90–95%, approximately 50% of DHT, 
the active intracellular androgen, was left in the prostate in men who had their testicles removed 
or had complete blockade of testicular androgen secretion following treatment with a luteinizing 
hormone releasing hormone (LHRH) agonist.12-14 This suggested that, in the absence of testicles, 
another source continued to provide androgens to the prostate. Indeed, the remaining 5-10% of 
the androgens is produced in the adrenals. The objective arose to block simultaneously the 
androgens of both testicular and adrenal origin at the start of treatment of prostate cancer 7b, 15, 
which led to the development of the so called combined androgen blockade (CAB). 
Currently the standard treatment for prostate carcinoma is CAB. This means orchiectomy or its 
therapeutic equivalent the medical castration by gonadotropin-releasing hormone (GnRH) 
analogues, which reduce the testicular androgen production, is accompanied by the use of a pure 
androgen receptor antagonist (flutamide, cyproterone acetate), in order to silence the stimulatory 
effects of the remaining androgens. However, CAB often leads to resistance which has been 
associated to androgen receptor mutations, causing the mutated receptor to recognize antagonists 
as agonist. Moreover, although the good results of CAB result in remissions lasting two to three 
years, nearly all patients will eventually progress to castration-resistant prostate cancer (CRPC), 
which is fatal in the majority of patients.16 
An alternative, pharmacological therapy is the total blockage of the androgen biosynthesis, 
which brings P450c17 complex and its central role in the androgen biosynthesis into focus. 
P450c17 complex consists of two proteins anchored to the endoplasmatic reticulum: the NADPH 
cytochrome P450 reductase (CPR) and the cytochrome P450 17 protein (CYP17),17 and is 
commonly located in both testicular and adrenal tissue but not in the prostate. CYP17 is a key 
branch point in androgen production and in the system of adrenal steroid hormone synthesis: as 
17α-hydroxylase, it distinguishes in the adrenal cortex between the synthesis of 
mineralocorticoids (e.g. aldosterone) and that of glucocorticoids (cortisol); as 17,20-lyase it 
distinguishes between the synthesis of glucocorticoids and C-19 precursors of androgens such as 
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DHEA. Thus, the therapies that inhibit the systemic biosynthesis of androgens through the 
targeting of CYP17 may represent a promising alternative, suitable for early and advanced 
(metastatic) PC, to the CAB approach and a rational approach in the treatment of CRPC. Indeed, 
blocking the biological pathway of androgen biosynthesis at an early stage, production of 
testosterone and all other androgens will be stopped in the testes, adrenals and in the castration-
resistant prostatic tumor, thus preventing the tumor from growing further and, according to 
recent studies, even delaying the development of bone metastasis for a period of up to eight 
years.18
1.2.2. Estrogen-dependent diseases (EED)
Estradiol originates from different sources before and after the menopause in women. In 
premenopausal women, the ovary or membrana granulosa of dominant follicles is the main 
source of abundant circulating estrogens. However, after menopause, the secretion of estradiol 
by the ovaries ceases and 100% of sex steroids are made locally in peripheral target intracrine 
tissues, primarily through conversion of androgens of both adrenal and ovarian origins, 
especially of zona reticularis origin of adrenal cortex. This conversion is catalyzed by the 
aromatase enzyme complex.
Figure 6. Local production of sex steroids in breast tissues.
Aromatase takes part in both the endo- and the intracrine biosynthesis of estrogens, while 17β-
HSD1 only in the intracrine (Fig. 6).19 Proof of the role of estrogen formation in peripheral 
intracrine tissues is well illustrated in women by the important benefits on breast cancer 
observed in postmenopausal women treated by a series of aromatase inhibitors.20 It is worth 
mentioning, that these two enzymes are not the only sources of 17β-estradiol to the hormone-
sensitive cancer.
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1.2.2.1. Breast cancer (BC)
Breast cancer is the widest hormone-dependent disease in women. It is asymptomatic and can be 
recognized only by analysis thorough mammography. 
The great majority of human breast carcinomas express estrogen receptor (ER) in carcinoma or 
parenchymal cells. These cases are termed hormone- or estrogen-dependent breast carcinoma, 
and estrogens, especially 17β-estradiol (E2), a biologically potent estrogen, contribute to a great 
extend to the growth and development of carcinoma cells and some of these carcinoma actually 
require estrogens for their continued growth and other biological processes.21 Breast carcinomas 
can be divided in two categories: estrogen receptor positive (ER+) and estrogen receptor 
negative (ER-) tumors. Around 50% of breast cancers in premenopausal women and 75% of 
breast cancers in postmenopausal women are ER+, i.e. the progression of the tumor is dependent 
on the physiological concentration of estrogens present in the diseased tissue.22
In addition to surgery, chemotherapy and radiotherapy, hormone-dependent breast cancers can 
be treated via different endocrine therapies: SERMs (Selective Estrogen Receptor Modulators), 
like tamoxifene and raloxifene constrain the estrogen action at the receptor level, aromatase 
inhibitors (AI, e.g. fadrozole, letrozole) suppress the estrogen formation by inhibiting the last 
step of E1 biosynthesis and GnRH analogues completely block the ovarian steroid formation. 
(Fig. 7).23
These strategies are already used in therapy but they show some limitations. Many breast tumors 
fail to respond to anti-estrogen therapy or progress after a period of time. SERMs are also known 
to induce carcinoma in other tissues like endometrium, where tamoxifene acts as an estrogen 
agonist. Aromatase inhibitors block the formation of estrogens but do not prevent the formation 
of the non-aromatic estrogen 5-androstene-3b-diol from DHEA which also stimulates the 
proliferation of cancer cells after binding to the ER. Aromatase inhibitors are restricted to 
postmenopausal women because in premenopausal women they induce a strong ovarian 
stimulation by hypothalamic/pituitary feedback. GnRH analogues do not affect adrenal 
formation of androgens which are converted into estrogens by peripheral aromatase.
Figure 7. Existing endocrine therapies.
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1.2.2.2. Endometriosis 
Endometriosis was first described by Rokitansky 24 and is one of the most common causes of 
pelvic pain and infertility in women. Endometriosis can affect any woman, from premenarche to 
postmenopause. It is primarily a disease of the reproductive years. Estimates about its prevalence 
vary, but 5–10% is a reasonable number, more common in women with infertility (20–50%) and 
women with chronic pelvic pain (about 80%). As an estrogen-dependent process, it can persist 
beyond menopause and persists in up to 40% of patients following hysterectomy. Endometriosis 
in postmenopausal women does occur and has been described as an aggressive form of this 
disease characterized by complete progesterone resistance and extraordinarily high levels of 
aromatase expression.25 
In endometriotic tissue aromatase and 17β-HSD1, but not 17β-HSD2, are overexpressed, which 
leads to an increased concentration of estradiol, which further stimulates the proliferation of 
these tissues. Attar et al. describe a positive feed-back mechanism, which leads to a permanent 
estradiol production in the endometrium, thus resulting in stimulation of growth and 
inflammation processes in the tissue.26 
In this condition endometrial tissue grows abnormally outside the uterus, often in locations such 
as the ovaries, fallopian tubes and abdominal cavity. It causes adhesions and scarring, pain, 
heavy bleeding and can damage the reproductive organs leading to infertility. The specific 
causes of endometriosis are still not clear. The most widely accepted theory developed by 
Sampson is that the disorder originates from retrograde menstruation of endometrial tissue 
through the fallopian tubes into the peritoneal cavity.27-28 
Currently available medical therapies are designed to suppress the estrogen biosynthesis. Oral 
contraceptives, androgenic agents and GnRH-analogues are used to inhibit the menstruation, a 
source of much of the pain associated with endometriosis and to restrain the growth of 
endometriotic tissue.29 Analgesics are also applied in combination to the classical hormonal 
therapy in order to relieve the pain triggered by endometriosis. However, the available therapies 
focused on the symptoms of the disease but do not provide a cure. Due to the alteration of the 
hormone balance, it leads also to several side effects such as weight gain and acne.30 
1.2.3. Congestive heart failure. 
Congestive heart failure (CHF) is a condition of insufficient cardiac output and reduced systemic 
blood flow, most frequently provoked by arterial hypertension and coronary artery disease, and 
goes along with dispnoea, fatigue and edema. The prognosis is poor: 30 % of the patients die 
within one year and the mortality rises to 60–70 % after five years.31 The progressive nature of 
the disease is a consequence of a neurohormonal imbalance and involves a chronic activation of 
the renin-angiotensin-aldosterone system (RAAS) in response to the reduced cardiac output and 
the reduced renal perfusion. Aldosterone and angiotensin II (Ang II) are released excessively, 
leading to increased blood volume and blood pressure as a consequence of epithelial sodium 
retention as well as Ang II mediated vasoconstriction and finally to a further reduction of cardiac 
output. The RAAS is pathophysiologically stimulated leading to a vicious circle of 
neurohormonal activation that counteracts the normal negative feedback loop regulation (Fig. 8). 
Aldosterone plays an important physiological role in the regulation of electrolyte homeostasis 
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and thereby blood pressure, exerting its function by binding to the mineralocorticoid receptor. 
Upon ligand binding, the protein-ligand complex is translocated to the cell nucleus, where it 
modulates the gene expression of proteins involved in electrolyte homeostasis.32
Recently, various studies on the pathophysiology of heart failure have revealed that aldosterone 
plays a role in the formation of myocardial hypertrophy, reactive myocardial fibrosis, vascular 
remodelling and electrolyte imbalance.33 This may contribute to the development of arrhythmias, 
hypertension and congestive heart failure.34-36
Figure 8. Pathophysiology of the renin-angiotensin-aldosterone system.
Until today, various drug classes targeting the RAAS have been developed, acting either by 
inhibition of the key regulator enzymes or by blocking the actions of the effector hormones (i.e. 
aldosterone, Ang II) by functional antagonism, affording a successful treatment of heart failure 
and hypertension. Their efficacy had been proven in two clinical studies, CONSENSUS trial 37
and SOLVD trial.38
First successes were gained by inhibiting the biosynthesis of Ang II with enalapril, an ACE 
inhibitor, but still a high level of mortality remained. Moreover, ACE independent pathways to 
AngII are not blocked and ACE inhibitors can indeed trigger an initial downregulation of 
circulating aldosterone, but increased levels of aldosterone may be seen after several months of 
therapy, presumably due to potassium stimulated secretion.39 This phenomenon termed 
‘aldosterone escape’ is a limiting factor of ACE inhibitors and shows that novel therapeutic 
concepts combating the effects of elevated aldosterone levels are needed.
On the other hand, in the two recent clinical studies RALES 40 and EPHESUS 41 the aldosterone 
receptor antagonists spironolactone and eplerenone were found to reduce mortality in patients 
with chronic congestive heart failure and in patients after myocardial infarction, respectively.
From this it can be derived that reducing aldosterone action is highly beneficial in the treatment 
of heart-failure and that it is particularly worthwhile to find new pharmacological ways to 
interfere with this hormone. The treatment with these antagonists, however, is accompanied with 
severe side effects like hyperkalemia.42
A novel therapy option, targeting cardiovascular diseases by interruption of the RAAS, is the 
blockade of aldosterone production, preferably by inhibiting CYP11B2, the key enzyme of its 
biosynthesis. Aldosterone synthase was proposed as a potential pharmacological target as early 
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as 1994 by our group 43, hypothesizing that inhibitors of CYP11B2 could serve for the treatment 
of hyperaldosteronism, congestive heart failure, and myocardial fibrosis.44 
Although the net outcome of aldosterone receptor blockade versus aldosterone synthesis 
inhibition apparently is similar, a number of potential advantages for the latter approach exists:45 
reduction of side effects as particularly observed for the antagonist spironolactone, prevention of 
compensatory aldosterone synthesis inherent to mineralocorticoid receptor blockade, and the 
fact, that no nonsteroidal inhibitor of a steroidogenic CYP enzyme is known to have affinity for a 
steroid receptor (fewer side effects on the endocrine system can be expected). 
Some aldosterone effects are not mediated by classical MR binding. These rapid actions are 
referred to as nongenomic effects, they are independent of gene transcription and translation, 
and, in most cases, they proved to be insensitive to specific MR antagonists.46 This because MR 
antagonists interfere at receptor level, one step after aldosterone biosynthesis, thus leaving 
aldosterone levels unaffected. Differently, CYP11B2 inhibition can reduce the pathologically 
elevated aldosterone levels induced by both genomic and non-genomic effects. 
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1.3 Potential target enzymes involved in steroidogenesis 
1.3.1. Cytochrome P450 (CYP) enzymes 
The cytochrome P450 proteins (CYPs) are a large ubiquitous monooxygenase heme protein 
family, which have a large and diverse set of substrate specificities and catalyze a range of 
biochemical transformations. The most common reactions catalyzed include monooxygenase 
reactions, e.g. insertion of one atom of oxygen into an organic substrate (RH) while the other 
oxygen atom is reduced to water: 
RH + O2 + 2H+ + 2e– → ROH + H2O 
The name cytochrome P450 is derived from the fact that these are colored ('chrome') cellular 
('cyto') proteins, with a "pigment at 450 nm", so named for the characteristic Soret peak formed 
by absorbance of light at wavelengths near 450 nm when the heme iron is reduced and 
complexed to carbon monoxide. 
CYPs are present in nearly every form of life and in february 2008 the CYP superfamily 
consisted of more than 7,000 named sequences in animals, plants, bacteria and fungi 
(http://drnelson.utmem.edu/CytochromeP450.html). In particular, human CYPs (57 CYP genes 
present in human genome; see Appendix A for full list) play a prominent role since they 
contribute massively to the metabolism of xenobiotics, such as drugs, environmental pollutants, 
and carcinogens. Moreover, biosynthesis of steroid hormones, bioavailability, bioactivation, 
toxicity, and drug-drug interactions may be associated with CYP-mediated bioconversions.47 
Seven of these 57 CYPs are targeted to mitochondria (type 1 P450s) and 50 are targeted to the 
endoplasmic reticulum (type 2 P450s). Among these 50, about 15 are involved in hepatic 
metabolism of drugs and xenobiotics, about 20 participate in the synthesis of steroids, sterols, 
bile acids, prostaglandins, retinoids and other endogenous compounds, and about 15 are ‘orphan’ 
enzymes, whose activity is yet unknown.48 The P450 proteins are categorized into families 
(>50%) and subfamilies (>60%) according to their sequence similarities, respectively.  
All structures of cytochrome P450s known so far show the same tertiary fold. The active site of 
the enzyme is next to the heme cofactor, buried in the core of the protein. It is usually isolated 
from the surrounding solvent.49 
The structure of mammalian CYPs is mainly α-helical with orthogonal bundle architecture with 
almost the same number of α-helixes (A-L) and β-sheets (10) (Fig. 9). Nevertheless, despite a 
highly conserved ternary structure, these enzymes share only a low sequence identity (<20 %) 
and homology (<30-40 %), underlining the functional importance of the conserved 20%. Typical 
structural features of CYPs are the F/G segment (F helix, F/G loop, G helix) perpendicular to the 
highly structurally conserved I helix with the segment housing the heme cofactor. This F/G 
segment, together with the B/C-loop control access to the CYP active site. The long I helix, 
extending through the whole CYP structure, presents a kink in proximity of the heme. Close to 
this kink we find a conserved acidic residue (Asp or Glu) and the catalytic threonine, presumably 
involved in the catalytic mechanism, by stabilizing the proton transfer. Moreover, several basic 
amino acids on the proximal side of the enzyme are maintained in nearly all CYPs, responsible 
for the anchoring of the redox partner of the CYP enzymes. 
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The active site of cytochrome P450 contains a heme iron center. The iron is tethered to the P450 
protein via a thiolate ligand derived from a cysteine residue. This cysteine and a dozen flanking 
residues (Cys pocket) are highly conserved in known CYPs, forming a short, characteristic loop 
(meander) which undergoes interactions with the redox partner and presumably plays a notable 
role in the conformational rearrangement of the CYP active site after the first electron-transfer. 
This conserved loop is the so-called “P450 signature” motif of 10 amino acids, including the 
invariant cysteine residue that ligates the heme iron to the protein, Phe-XX-Gly-Xb-XX-Cys-X-
Gly. The amino acid Xb is usually a basic amino acid that plays a key role in interactions with 
the reductase partner.50
Figure 9. Common fold of typical mammalian CYP19 (PDB code 3EQM) as front view with the most important 
secondary structure elements labeled.
While prokaryotic, bacterial P450s are soluble proteins, most eukaryotic P450s are membrane-
bound enzymes and are attached via a transmembrane N-terminal helix to either the endoplasmic 
reticulum or mitochondrial membranes. Additionally the F/G-segment, presenting two short α-
helixes F’ and G’, is merged into the membrane for a couple of Angstroms. These two helixes
place one active site substrate access in the lipid bilayer, enabling passive diffusion of lipophilic
substrates (i.e. steroids) from the lumen directly into the active site. This is one of the entrance 
pathways for the CYPs, but several other have been described (Fig. 10).49, 51-52
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Figure 10 (taken from Schleinkofer et al. 2005).51 Schematic representation of putative substrate access and product 
egress routes in P450s. (A) substrate access and product egress channel in soluble P450s. (B) One-way route 
through mammalian membrane-bound P450 (C) Soluble substrates access the active site. Substrate (S) and product 
(P) are depicted in magenta, heme cofactor (active site) in light pink and P450 in turquoise.
Although CYPs all have the heme-iron porphyrin ring, they are capable of very specific and 
selective hydroxylations. This is especially true for CYPs involved in steroidogenesis, which 
yield very high substrate specificity. Since the tertiary structure is highly conserved and all CYPs 
present the heme group, the active cavity needs to present specific pockets in order to 
accommodate the substrate in a specific way, which allows only particular hydroxylation pattern.
The difference in substrate conversion is likely to be caused by a difference in the relative 
positioning of the substrate above the heme in the active site. To be more specific, as 
exemplified by Roumen et al. for CYP11B2/B1,53 there should be a correlation between 
substrate selectivity and substrate hydroxylation distance, the distance between the heme iron 
and the substrate carbon. In other words, the binding mode of the natural substrate dictates which 
carbon atom is oxidized first, with conversion taking place on the carbon atom which is in 
closest proximity to the iron-oxygen complex (Fig. 11).
Figure 11. Localization of the steroidal substrate over the Fe=O (blue dot) exemplified for the steroidogenic 
enzymes CYP11B (11B2 – 11β-hydroxilation/18-hydroxylation/18-methyl oxidation; 11B1 - 11β-hydroxilation), 
CYP17 (17α-hydroxilation/17,20-lyase) and CYP19 (19-hydroxylation/aromatization).
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The reaction cycle of the heme proteins (Fig. 12) runs through an instable intermediate, called 
compound I or [Fe=O]-iron-oxo species. This is generally assumed to be a high valent iron-oxo 
derivative, where the iron is present in an oxidized, oxyferryl (Fe(IV)) form with a triplet spin 
state.54 Additionally, there might be either an oxidized porphyrin--cation radical or a tyrosine 
radical, the latter more likely since tyrosine and tryptophans close to the heme can reduce by 
intramolecular electron transfer the transiently formed porphyrin--cation radical.
Figure 12. The P450 catalytic cycle (see Appendix B for further descriptions).
Most CYPs require protein partners, which deliver one or more electrons to reduce the iron (and 
eventually molecular oxygen). Five general schemes are known:
1. CPR/cyb5/P450 systems (Fig. 13): employed by most eukaryotic microsomal CYPs, 
involve the reduction of cytochrome P450 reductase (variously CPR, POR, or 
CYPOR) by NADPH, and the transfer of reducing power as electrons to the CYP. 
Cytochrome b5 (cyp b5) can also contribute reducing power to this system after being 
reduced by cytochrome b5 reductase (CYB5R). The general scheme of electron flow
in the CPR/P450 system is:
NADPH  FAD  FMN  P450  O2
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Figure 13. Electron transport to microsomal forms of cytochrome P450. (Copyright W.L. Miller).55
2. CYB5R/cyb5/P450 systems: both electrons required by the CYP come from cytochrome 
b5. The ubiquitous electron-transport protein cytochrome b5 can serve as an effector 
(activator or inhibitor) of P450s. It was hypothesized that cytochrome b5 is involved in 
the transfer of the second electron to P450, either from CPR or NADH:cytochrome b5 
reductase (CBR):
NADPH  CPR  cyt b5 P450  O2
NADH  CBR  cyt b5 P450  O2
3. FR/Fd/P450 systems (Fig 14): mitochondrial and some bacterial P450 systems employ 
soluble Fe2S2 ferredoxins (Fd) that act as single electron carriers between FAD-
containingferredoxin reductase (FR) and P450. Adrenodoxin functions as a soluble
electron carrier between NADPH, adrenodoxin reductase and several membrane-
bound P450s (CYP11A, CYP11B, CYP27). The general scheme of electron flow in 
the P450 systems containing adrenodoxin-type ferredoxins is:
Figure 14. Electron transport to mitochondrial forms of cytochrome P450.
4. P450-only systems: prostacyclin synthase (CYP8) and thromboxane synthase (CYP5)
are examples of P450 enzymes which do not require a reductase or molecular oxygen 
for their catalytic activity. Substrates for all these enzymes are fatty acid derivatives 
containing partially reduced dioxygen (either hydroperoxy or epidioxy groups).
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CYPs have been extensively examined in mice, rats, and dogs, and less so in zebra fish, in order 
to facilitate use of these model organisms in drug discovery and toxicology. CYPs have also 
been heavily studied in insects, often to understand pesticide resistance.
Bacterial cytochrome P450s are often soluble enzymes and are involved in critical metabolic 
processes. Two examples that have contributed significantly to structural and mechanistic studies 
are cytochrome P450cam (CYP101), the first CYP solved by x-ray crystallography, and 
cytochrome P450 BM3 (CYP102A1), which unlike almost every other known CYP (except 
CYP505A1, cytochrome P450 foxy) constitutes a natural fusion protein between the CYP 
domain and an electron donating cofactor.
Substrate recognition sites. The active site of the CYP enzymes consists of the heme ring at 
one wall and six common substrate recognition sites (SRS), as defined by Gotoh for CYP2 
family enzymes (Fig. 15).56 SRS-1 is located between the B- and C-helixes, where an additional 
B’-helix is observed in some CYP enzymes. SRS-2 and SRS-3, or the C-terminus of the F-helix 
and the N-terminus of the G-helix, are located on the opposite wall of the active site from the 
heme ring. This area varies among CYP family members showing helixes and loops of different 
lengths and with none, one or two additional helixes (F’ and G’). SRS-4 is located in the I-helix, 
which protrudes through the whole enzyme and includes residues that are highly conserved 
among the CYP enzymes. Often in SRS-4 a so-called I-helix kink is present, leading to a break 
in the I-helix with two resulting segments. The active-site wall opposite the I-helix consists 
mainly of SRS-5, the hydrophobic coil between the K-helix and the β1-4-strand. SRS-6 is 
located in the β-sheet 4 or, more accurately, in the hairpin turn between the two strands β4-1 and 
β4-2. This site includes amino acids thought to be important not only to substrate recognition but 
also to the catalytic activity.
Figure 15. Structural elements corresponding to the substrate recognition sites (SRS) of CYP19. SRS-1 is coloured 
red, SRS-2 green, SRS-3 blue, SRS-4 yellow, SRS-5 cyan and SRS-6 magenta. Heme is represented as sticks.
~ 21 ~
1.3.1.1. CYP17 - 17α-hydroxylase/17,20 lyase
CYP17A1 (17α-hydroxylase/17,20 lyase/17,20 desmolase; steroid 17-alpha-monooxygenase; 
P450-C17) is a single member of the CYP17 family, coded by the CYP17A1 gene and consisting 
of 508 amino acid residues with total molecular weight of 57.4 kDa. It is involved in
steroidogenesis, where it converts pregnenolone and progesterone to their 17α-hydroxy forms. 
The CYP17 enzyme localizes to the endoplasmic reticulum of the Leydig cells in the testis, theca 
interna region of the ovaries, and zona fasciculata and reticularis in the adrenal glands. It is a key 
enzyme in the generation of androgens and estrogens in the adrenal glands and tumor tissue, and 
works by the catalysis of two independently regulated steroid reactions: 17α-hydroxylase and 
17,20-lyase. CYP17 needs to be activated by a post-translational phosphorylation; 57 although 
this seems to be required only for the 17,20-lyase, but not for the 17α-hydroxylase step. 
Moreover, the 17,20-lyase activity of CYP17 can be explicated only in presence of cytochrome 
b5, as mutagenesis studies confirm.58 Cyt b5 also acts as a second electron-donor in the catalytic 
cycle of CYP17, in addition to CPR, requested by most of the other CYPs. 
No crystal structure exists of CYP17, but several homology models have been build in the past in 
order to solve its catalytic mechanism and to study how substrates and inhibitors bind into the 
active site.59 
The 17α-hydroxylase activity converts pregnenolone (Preg) to 17α-hydroxypregnenolone 
(17OHPreg) and progesterone (P) to 17α-hydroxyprogesterone (17OHP), while C17,20-lyase 
converts 17OHPreg to dehydroepiandrosterone (DHEA) and 17OHP to androstenedione.60-62
P450c17 can drive sex steroid production by acting along the Δ5 pathway (Preg  17OHPreg 
DHEA  T) or, alternatively, along Δ4 pathway (P  17OHP  Δ4A) (Fig. 16). Both 
clinical observations of human adrenal physiology and direct biochemical assays of recombinant 
human P450c17 demonstrate that the 17, 20-lyase activity of the human enzyme strongly prefers 
the Δ5 pathway, catalyzing the conversion of 17OHPreg to DHEA approximately 20 times more 
efficiently than the conversion of 17OHP to Δ4A.63
Summarizing, the hydroxylase reactions are part of the synthetic pathway to cortisol as well as 
sex steroids, but the lyase reaction is only necessary for sex steroid synthesis.
Figure 16. Potential pathways of testosterone synthesis in the human testis (taken from Flück CE et al. 2003).63
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In congenital CYP17 deficiencies (congenital adrenal hyperplasia, CAH, less than 5%), the 
production of cortisol, androgens and estrogens is impaired, leading to the lack of sexual 
development.62 Nonetheless, the synthesis of corticosterone, a weaker glucocorticoid, is 
preserved. Hence, patients do not develop symptoms of adrenal insufficiency. However, higher 
levels of adrenocorticotrophic hormone (ACTH) are required before a new steady state is 
reached as corticosterone is a weaker glucocorticoid than cortisol. Raised levels of ACTH result 
in a syndrome of secondary mineralocorticoid excess, characterised by fluid overload, 
hypertension and hypokalaemia (Fig. 17). 
This syndrome may be effectively managed with mineralocorticoid antagonists, with or without 
low doses of glucocorticoids to suppress ACTH generation. ACTH suppression in turn leads to 
normalization of mineralocorticoid levels and a return of serum potassium and blood pressure to 
normal. A similar syndrome was observed with the selective inhibition of CYP17, for example 
by abiraterone acetate, confirming that CYP17 is inhibited.64
Since prostate cancer is typically a disease in older men, often presenting cardiovascular 
problems as well, we propose a selective dual-inhibition approach of CYP17 and CYP11B2, in 
order to manage the mineralocorticoid side effects, rising by the inhibition of CYP17.
Figure 17. The physiological effects of abiraterone acetate on the androgen biosynthesis pathway are indicated by 
arrows next to each steroid precursor (taken from Yap TA et al. 2008).64
1.3.1.2. CYP19 - Aromatase
Aromatase (estrogen synthetase, P450arom) is a single member of the CYP19 family, coded by 
the CYP19A1 gene and consisting of 503 amino acid residues with total molecular weight of 
57.9 kDa. It catalyzes the conversion of the androgens androstenedione, testosterone and 16α-
hydroxytestosterone to the aromatic estrogenic steroids estrone, 17β-estradiol and 17β,16α-
estriol, respectively, through the aromatization of the A ring of the substrate (three step process),
being the only enzyme in vertebrates known to catalyze the biosynthesis of all estrogens from 
androgens. Aromatase inhibitors therefore constitute a frontline therapy for estrogen-dependent 
breast cancer, representing the first successful hormone therapy targeting steroidogenesis as 
proven by various drugs on the market (letrozole, anastrazole, exemestane).
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Very recently the crystal structure of aromatse in complex with its natural substrate 
androstenedione at a resolution of 2.9 Å was published (PDB code 3eqm), becoming the first 
steroidogenic CYP enzyme being crystallized.65 
The catalytic complex consists of the aromatase enzyme and a NADPH cytochrome P450 
reductase, and facilitates the reaction with the required molar amount of NADPH.66 The whole 
complex is bound to the endoplasmic reticulum membrane in the cell. Aromatase is mostly 
expressed in the ovaries of pre-menopausal women, in the placenta of pregnant women and 
additionally in the peripheral adipose tissue, breast tissue and brain.67 It is overexpressed in or 
near breast cancer tissue and is responsible for the local estrogen production and proliferation of 
breast tumors.68 Peripherally synthesized estrogens act locally in an intracrine or paracrine 
manner without being released into the circulation and act by binding to specific estrogen 
receptor α (ERα) in the tumor cells thereby mediating transcription of genes regulating 
proliferation.69 
For the same reason, they were likely to cause fewer side-effects in patients. Aromatization of 
androgens to estrogens is the last in the series of reactions in steroid biosynthesis and is rate-
limiting for estrogen synthesis. Therefore, there are no steroids produced downstream to be 
affected by inhibition of aromatase. Also, although aromatase shares common features with other 
P-450 enzymes, the unique characteristics of the aromatization reaction, involving loss of the C-
19 carbon and conversion of the steroidal A ring to an aromatic ring, provide the opportunity to 
develop inhibitors selective for P450arom. 
Tamoxifen, an estrogen receptor antagonist blocks the action of estrogens by binding to the ER. 
For the past 30 years, tamoxifen has proven to be an effective first-line or adjuvant endocrine 
treatment for advanced breast cancer.23a Compounds selectively targeting aromatase and lacking 
estrogenic activity 70 were envisaged as being more effective than the antiestrogens. 23b, 71 
Today, three aromatase inhibitors have been approved by the FDA exemestane (Aromasin), a 
steroidal inhibitor similar to formestane and two non-steroidal inhibitors anastrozole (Arimidex), 
and letrozole (Femara). All have high potency and specificity for aromatase. The latter two 
inhibitors were based on inhibition of P-450 enzymes and were derived from drugs used as 
antifungal agents, such as ketoconazole, an inhibitor of fungal P-450 enzymes. Triazole and 
imidazole compounds possess a heteroatom, such as nitrogen containing heterocyclic moiety. 
This interferes with steroidal hydroxylation by binding with the heme iron of CYPs. These 
nonsteroidal compounds are reversible inhibitors of aromatase, whereas the steroidal inhibitors 
cause irreversible inactivation of the enzyme. Aromatase inhibitors are proving to be superior to 
tamoxifen in the advanced setting and are now replacing tamoxifen as first-line therapy.72 
1.3.1.3. CYP11B2 - Aldosterone synthase 
In humans the final steps of cortisol and aldosterone synthesis are catalyzed by 11β-hydroxylase 
(CYP11B1) and aldosterone synthase (CYP11B2), respectively.73 The corticosteroid 
synthesizing enzymes CYP11B2 and CYP11B1 are not coexpressed within the adrenal cortex. 
CYP11B1 is expressed at high levels in the zona fasciculata/reticularis of the adrenal cortex and 
oxidizes its substrate 11-deoxycortisol, giving rise to cortisol, the principal human 
glucocorticoid. Cortisol regulates energy mobilisation, stress response and is additionally 
involved in the immune response of the human body. In contrast, aldosterone is secreted and 
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CYP11B2 is expressed in low levels in the zona glomerulosa of the adrenal cortex and it the 
synthesis of the former steroid involves three consecutive reactions: initial 11β-hydroxylation of 
11-deoxycorticosterone to yield corticosterone, plus two subsequent CYP11B2 catalyzed 
oxidations at C18 and water release to form the mineralocorticoid aldosterone. So, a major 
difference between CYP11B1 and CYP11B2 is the lacking 18-hydroxylase activity. CYP11B1 
can only introduce a hydroxy group in 11β-position in both 11-deoxycortisol and 11-
deoxycorticosterone whereas CYP11B2 can also carry out oxidations in 18-position. 
The zonal distribution of CYP11B1 and 2 in the adrenal gland has recently been further 
investigated with surgically removed human adrenal gland cells, showing a higher concentration 
of CYP11B1 in the zona fasciculata than in the zona reticularis. Cortisol is usually secreted 100- 
to 1000-fold in excess over aldosterone, but this is not only due to transcriptional regulation of 
these enzymes, but also to differences in catalytic activities.74 
The primary protein sequences of CYP11B2 and CYP11B1 differ only in 32 out of 503 amino 
acid positions and in the mature enzymes which are bound to the inner mitochondrial membrane, 
only 29 out of 479 residues are not identical.75 This high sequence identity (approximately 93 %) 
is reflected in the shared 11β-hydroxylase function of both CYP11B isoforms. However, 
CYP11B1 is a pure 11β-hydroxylase catalyst without 18-hydroxylase activity and cannot even 
11β-hydroxylate 18-hydroxy-11-deoxycorticosterone.76 By contrast, CYP11B2 catalyzes also 
oxidations at the steroidal 18-position, mainly in the course of converting corticosterone to 18-
hydroxycorticosterone and subsequently to aldosterone, but it can also 18-hydroxylate cortisol. 
A series of site-directed mutagenesis experiments was performed attracting the putative I-helix. 
It was demonstrated by Böttner et al.77 that the aldosterone synthase activity decreases to 
approximately 10 % compared to the CYP11B2 wild type in the case of modifying the positions 
301 (leucine to proline), 302 (glutamic to aspartic acid), and 320 (alanine to valine) whereas the 
11β-hydroxylase activity simultaneously increases. Vice versa swapping the aldosterone 
synthase specific amino acid at position 320 of CYP11B1 from valine to alanine induced 
aldosterone synthase activity without significant impact on the 11β-hydroxylase efficacy.77 
Since no X-ray structure of CYP11B2, located in the inner mitochondrial membrane, is 
available, several homology models have been established, 53, 59b, 75b, 78 providing elementary 
insight into the protein structures and inhibitor binding modes. It has been shown by our group 
that docking into the homology models of CYP11B2 built on the X-ray structure of human 
CYP2C9 is a useful tool to explain differences in activity and selectivity of nonsteroidal 
aldosterone synthase inhibitors.79 
Aldosterone participates in the regulation of the salt and water household of the body and thus in 
the regulation of blood pressure. Pathological elevations in plasma aldosterone levels 
(hyperaldosteronism) increase blood pressure and play a detrimental role in cardiovascular 
diseases.80 Several mineralocorticoid receptor blockers had been developed so far to treat this 
pathological conditions, but all presented severe side-effects.81 Thus, inhibition of aldosterone 
formation with CYP11B2-inhibitors was proposed as a new pharmacological approach for the 
treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis.82 Non-
steroidal, selective inhibitors are to be preferred, because they can be expected to have less side 
effects on the endocrine system. The inhibitors must not affect other P450 (CYP) enzymes, like 
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11β-hydroxylase (key enzyme of glucocorticoid biosynthesis, CYP11B1) and other hepatic ones, 
responsible for drug metabolism.
1.3.2. Hydroxysteroid dehydrogenases (HSDs)
The hydroxysteroid dehydrogenases (HSDs) have molecular weights of about 35 to 45 kDa, do 
not have heme groups, and require NAD(H) or NADP(H) as cofactors. Most steroidogenic 
reactions catalyzed by P450 enzymes are due to the action of a single form of P450, but each of 
the reactions catalyzed by HSDs can be catalyzed by at least two, often very different isozymes. 
These enzymes include the 3α- and 3β-hydroxysteroid dehydrogenases, the two 11β-HSDs, and 
the 17β-HSDs. 
The hydroxysteroid dehydrogenases (HSDs) catalyze stereoselective reactions at specific 
positions of the steroid backbone.83 In fact, for each sex hormone an isoform pair is responsible 
for either inactivation or provision of an active ligand. This is achieved either by the oxidation of 
the alcohol group (oxidase activity) or by the reduction of the keto function (reductase activity, 
Fig. 18) on the steroid skeleton. These reductase/oxidase activities allow, therefore, the HSDs to 
function as a molecular switch.
Figure 18: general reaction catalyzed by hydroxysteroid dehydrogenases
The HSD family is split into 2 superfamilies: the short-chain dehydrogenase/reductase (SDR) 
family, characterized by a Rossman fold, and the aldo–keto reductase (AKR) family, 
characterized by a triosephosphate isomerase (TIM) barrel motif.84 The SDR family members 
often function as multimers and share a low sequence identity (less than 25%). Despite to this 
relatively low homology, SDR family members share identical protein folds.85 Part of the protein 
fold includes an arrangement of α-helix and β-strands (β-α-β) to produce the “Rossmann fold” 
motif for cofactor binding. They also contain a conserved catalytic motif of Tyr-X-X-X-Lys 
where Tyr is the catalytic general acid/base of the reaction.86
In contrast, the AKRs are monomeric, soluble enzymes utilising NAD(P)(H) as cofactor. They 
share a high amino acid sequence identity (>67%) compared to the SDR subfamily. Invariant to 
their active site is a catalytic tetrad consisting of Asp, Tyr, Lys and His motif. Site-directed 
mutagenesis supports the crucial role for the amino acids Tyr and Lys in the catalytic mechanism 
in a manner similar to that described for the SDR family but the disposition of these residues on 
the enzyme structure is different compared to the SDRs.87
The SDR enzymes include 11βHSDs 1 and 2, and 17βHSDs 1, 2, 3, and 4; the AKR enzymes 
include 17βHSD5 (AKR1C3), which is important in activation of androgenic precursors in 
peripheral tissues, such as the prostate.88
We can classify HSDs physiologically based on their activities as dehydrogenases or reductases. 
The dehydrogenases use NAD+ as their cofactor to oxidize hydroxysteroids to ketosteroids, and 
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the reductases mainly use NADPH to reduce ketosteroids to hydroxysteroids. Although these 
enzymes are typically bidirectional in vitro, they tend to function in only one direction in intact 
cells, with the direction determined by the cofactor(s) available.84 
1.3.2.1. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) 
As mentioned in chapter I, the synthesis from DHEA of the most potent natural androgen, DHT 
and of the most potent natural estrogen, 17β-estradiol (E2) involves several enzymes, namely 3β-
hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD), 17β-HSD, 5α-reductase and/or 
aromatase.  
17β-hydroxysteroid dehydrogenases (17β-HSDs) catalyze the interconversion between the active 
and inactive forms of specific steroidal hormones on the final steps of their biosynthesis, playing 
the key role in the last step of androgen and estrogen formation. 17β-HSDs are responsible for 
the stereospecific oxido-reduction reaction of hydroxy or carbonyl groups at position 17 of the 
steroid backbone using NAD(P)H or NAD(P)+ as cofactor.89 They are expressed in the gonads as 
well as in peripheral tissues. This enzyme family is responsible for the pre-receptor 
activation/inactivation of hormones in vivo, thus regulating the amount of active hormone 
available to bind to the specific receptor. 
Up to now, 15 mammalian 17β-HSDs are reported in vertebrates of which 12 are also present in 
humans, while 17β-HSD6 and 9 are only reported for rodents. With the exception of 17β-HSD5, 
which is a member of the aldoketo-reductase (AKR) family, all 17β-HSDs belong to the short 
chain dehydrogenase/reductase (SDR) superfamily.90 In vertebrates the enzymes show generally 
low sequence homology (15–20%) but some elements characteristic for SDR members are 
strongly maintained, e.g. the Rossman fold. Despite this structural conservation, substrate 
specificities among the family members are diverse and for some 17β-HSDs substrates such as 
fatty acids or bile acids are preferred over sex steroids.91 
17β-HSDs drive unidirectional reactions in intact cells while in cell homogenates it has been 
shown that these enzymes are able to catalyze either the oxidation or the reduction depending on 
which cofactor form (reducent or oxidant) is present. In cells, NADPH is a major source for 
electrons, and reducing equivalents from NADPH are used in different metabolic reactions. In 
contrast NAD+ is a versatile electron acceptor, and most enzymatic oxidations deposit these 
electrons on NAD+. To maintain this cofactor abundance, the cell constantly recycles these 
compounds from other oxidation states. 
As shown in Figure 19, the cellular concentration of NADPH is higher (500 times) than the 
NADP+ concentration. In contrast for the non phosphorylated cofactor NAD+ is generally 700 
times more abundant in cells than NADH.92 
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Figure 19. Interplay between metabolism and HSD reactions
Besides these cofactor concentration differences observed in intact cells, kinetic studies showed 
that the 17β-HSDs exhibit huge KM value differences between NADP(H) and NAD(H). This 
implicates that it in the cofactor binding sites of each 17β-HSD isoform amino acids must be 
present which allow the enzyme to distinguish the non-phosphorylated from the phosphorylated 
cofactor form.92
Crystal structure analysis of reductive HSD enzymes, such as 17β-HSD1, show that an arginine 
residue in the N-terminal region (R37 in 17β-HSD1) of the Rossmann fold is responsible for this
discrimination.93 The positively charged guanidinium group of the arginine forms a salt bridge 
with the 2’-phosphate moiety of NADPH, which further enhances the affinity of these enzymes
for NADPH (Fig. 20).
In contrast, oxidative SDRs like 17β-HSD2, contain a negatively charged amino acid at the
position corresponding to the stabilizing arginine of the reductive enzymes: the carboxylate
groups of aspartate and glutamate induce repulsive interactions with the 2’-phosphate group of
NADP+ but might be able to form hydrogen bonds with the 2’-OH function of NAD+ (Fig. 20)
enhancing therefore the affinity for the non-phosphorylated cofactor form.
Site-directed mutagenesis experiments demonstrated that exchanging this arginine with an 
aspartate moiety in the case of a reductive HSD enzyme increases the affinity for NADH (vs. 
NADPH), while exchanging this aspartate with arginine moiety in the case of an oxidative HSD 
enzyme enhances the affinity for NADP+ (vs. NAD+).94-95
Figure 20. Binding preferences of NADPH and NAD+ for reductive/oxidative HSDs.
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1.3.2.2. 17β Hydroxysteroid dehydrogenases type 1 (17β-HSD1)
17β-HSD type 1 (EC 1.1.1.62) was first described in 1958 by Langer & Engel.96 It is active as a 
soluble cytosolic homodimer, both subunits having a molecular mass of 34.9 kDa and containing
327 amino acids.97-98
It catalyzes predominantly the final step of the E2 biosynthesis, reducing estrone (E1) to 
estradiol (E2) and using NADPH as cofactor.99 As this reaction is the last step of the biosynthetic 
pathway to estradiol E2, which has a far stronger estrogenicity than E1, 17β-HSD1 plays a key 
role in activating estrogens and regulating their concentrations.
17β-HSD1 is abundantly expressed in the ovaries (in granulosa cells of developing follicles and 
placenta),100-101 but also present and active in peripheral tissues, among those breast and 
endometrium.102 Therein, E2 is biosynthesized in an intracrine pathway, i.e. 17β-HSD1 is 
expressed in situ and catalyzes the biosynthesis of E2 on-site. In the aforementioned tissues, 
estradiol can exert effects that cause or facilitate the progression of estrogen-dependent diseases, 
especially breast cancer and endometriosis. Thus, the discovery of inhibitors of 17β-HSD1 is of 
high pharmacological interest for the treatment of hormone-sensitive diseases, because reduced 
systemic effects can be expected compared to aromatase inhibitors (AI) which act both at an 
intracrine and at an endocrine level.
The first X-ray structure of 17β-HSD1 as native form was published in 1995.103 Since then 18
crystal structures of binary or ternary complexes with estrogenic and androgenic ligands or with 
steroid based inhibitors have been deposited in the Protein Data Bank (PDB).
The core of the monomeric form of 17β-HSD1 is a seven-stranded parallel β-sheet (βA to βG), 
surrounded by 6 parallel α-helixes, three on each side of the β-sheet (Fig. 21), bearing the 
classical Rossmann fold, which is associated with the NADPH binding. Five additional α-helixes
are located around the steroid binding domain.103
Figure 21. Common fold of 17β-HSD1 rendered as cartoon. The cofactor NADP(H) and the co-crystallized product 
E2 are presented as sticks in green and magenta, respectively. The three main dispositions of the highly flexible βF-
αG’-loop are depicted in yellow, blue and magenta, the C-terminal helix in cyan.
~ 29 ~
The analysis of the available crystal structures furnishes useful informations about the enzyme 
architecture: a substrate binding site, a cofactor binding pocket and an entry channel can be 
defined. As a member of the SDR superfamily, 17β-HSD1 contains the highly conserved and 
catalytically crucial tetrad Tyr-x-x-x-Lys sequence (Asn114, Ser 142, Tyr155 and Lys 159; Fig. 
22). The steroid binding pocket of 17β-HSD1, a narrow hydrophobic tunnel showing a high 
degree of complementarity to the substrate E1, can be divided into three regions: the first region 
recognizes the steroidal phenolic A-ring and contains His221 and Glu282, which could form 
hydrogen bonds with O3 of the steroid. The second region binds to the central hydrophobic core 
of the steroid and contributes to the main thermodynamic force favoring the binding of substrate 
(hydrophobic interactions with Val143, Leu149, Pro187, Val225, Phe226 and Phe259). 
Interestingly, two polar amino acids (Tyr218 and Ser 222) are located in this region without any
interaction with the substrate. The third region (catalytic region) surrounds the D-ring and 
contains Ser142, Tyr155, and Lys159.
Figure 22. Postulated mechanism of the reduction of E1 to E2 (13). The substrate E1 is represented in blue, the 
cofactor NADPH in red. The amino acids, which are either involved in the catalysis or are responsible for 
ligand/cofactor stabilization, are colored in black and residue labelled. The hydrogen bonds are in dashed lines while 
the proton transfers are highlighted with arrows.
17β-HSD1 shows a clear preference for estrogen substrates, but has also the ability to reduce 
some androgens, such as DHEA, into dihydrotestosterone.104-106 Because both estrogens and 
androgens (with C19) have 3- and 17-hydroxy or ketone groups, the critical residues that are 
expected to determine specificity for the estrogenic substrates must lie within the hydrophobic 
binding region.
For dihydrotestosterone and dehydroepiandrosterone, crystallization experiments (PDB code 
1DHT and 3DEY) confirmed this hypothesis by showing that the C19 methyl group causes a 
shift of the substrate compounds away from NADP+, resulting in a lower kcat value.106 Especially 
the rigidity of the fork-like side chain Leu149 forced the androgens to occupy a slightly different 
site than estradiol in the PDB complex 1FDT. Subsequently, a decrease of the binding affinity 
was observed, probably due to reduced Van der Waals interactions between Phe259 and the 
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ligand. Indeed, the Km value for dehydroepiandrosterone is more than 1000-fold greater than that 
for estrone, and the Km for dihydrotestosterone is about 10-fold greater than that for estradiol. 
In several site directed mutagenesis experiments the importance of Leu149 for substrate 
specificity as well as the identification of critical amino acid residues (Ser142, Tyr155, His221, 
Glu282) for enzyme activity and substrate binding could be determined.95, 107, 108 
17β-HSD1 can be inhibited at several sites, including the substrate binding pocket and the 
cofactor binding region including part of the Rossmann fold.109 The large majority of known 17-
HSD1 inhibitors, mainly steroids, was shown to compete with the natural substrate for its 
binding site. Although, so-called hybrid compounds have been synthesized, that combine 
moieties from NAD(P)H and estradiol analogs, occupying both the steroid and the cofactor 
binding site.110 
The major disadvantage of steroidal inhibitors lies in their generally unfavorable ADMET 
characteristics and low specificity due to cross-reactivity with other steroid metabolizing 
enzymes and steroid hormone receptors. Moreover, metabolizing enzymes might modify 
steroidal inhibitors at several positions of their steroid scaffold, leading to potentially bioactive 
metabolites and possible disturbances of steroid hormone metabolism. Therefore, there is 
currently a great interest for the identification of novel nonsteroidal 17β-HSD1 inhibitors. 
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Chapter Two. Aims of the study. 
Steroidal hormones play a predominant role in various hormone-sensitive events, like breast 
(BC) or prostate cancer (PC) and hypertension. The binding of these steroids to their specific 
receptors results in slow genomic or fast nongenomic effects, often crucial for cell proliferation 
or maintenance of physiological balance. This occurs especially in hormone-dependent diseases, 
where the steroidogenic enzymes are highly overexpressed in relation to normal tissues, like in 
case of BC or PC. Sex steroids, in particular, are well recognized to play a predominant role in 
the regulation of cell growth and differentiation of normal mammary glands. Interestingly, while 
estrogens stimulate the proliferation of hormone sensitive breast cancer tumor, 111 androgens 
exert an antiproliferative action in these cells.112 In other hormone-sensitive pathologies, 
however, like in hypertension, no overexpression of the steroidogenic enzymes was observed, 
whereas a systemic overproduction of mineralocorticoids could be responsible for a marked 
disbalance in the regulation of the systemic circulation.  
First-choice strategies, which are currently applied for the treatment of hormone-dependent 
disorders, can be roughly classified into surgical, i.e. castration, and pharmacological 
approaches, which consider the use of small molecules as drugs. The latter can be further 
subdivided into drugs affecting the production (biosynthesis) of the steroids (inhibitors), de facto 
eliminating the “source” of induced genomic and non-genomic effects, or hampering the steroid-
receptor interaction (agonists, antagonists), thus suppressing the “effects” induced by receptor-
ligand binding. Most of the strategies concerning the effects are associated with systemic side-
effects, resulting from an undiscriminated, widespread silencing of the receptor functionalities. 
The reason therefore is that different ligands can stimulate the same receptor-mediated 
responses, acting not only in the target cells/organs, but also in other compartments, where the 
inhibition of the protein functions can be crucial for the survival of the investigated biological 
system.  
There is a large body of evidence showing that in the human the local intracrine formation of 
active estrogens and androgens from inactive steroid precursors DHEA and DHEA-S regulates 
growth and function of peripheral target tissues, including the breast.8 Thus, the selective 
inhibition of steroidogenic enzymes expressed in these target organs (CYP19 and 17β-HSD1) is 
regarded to be a promising strategy for the treatment of such hormone dependent diseases (BC). 
However, apart of the intracrine formation, most of the steroidal hormones are produced distant 
from their site of action. Thus, the selective inhibition of enzymes (CYP17, CYP11B2 and 
CYP19) involved in the biosynthetic pathways placed in endocrine organs is also a valuable 
strategy,113 as several clinical studies confirmed.20, 37, 38, 41, 64 
Computational methodologies, like docking studies, comparative modeling and molecular 
dynamic simulations, as well as quantum chemical methods, are a powerful addition to the 
classical synthesis of inhibitors of steroidogenic enzymes based on traditional medicinal 
chemistry strategies. They have been applied, in order to identify and validate possible binding 
modes of known inhibitors, to investigate the influence of their different physicochemical 
properties (like molecular electrostatic potential distribution) on the inhibitory potency and to 
rationalize drug design of new inhibitors, which was performed ligand- and structure based. 
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Specifically, the aims of this thesis were: 
1. CYP17: 
• To build a homology model of the human CYP17 enzyme. 
• To dock several classes of CYP17 inhibitors in this model and to investigate the 
interactions formed with the enzyme, if possible, deriving suitable substitution patterns. 
• To calculate the molecular electrostatic potential (MEP) distribution of a series of 
imidazolyl-biaryls in order to elucidate the potency differences within this class of 
compounds. 
2. CYP19: 
• To dock non steroidal CYP19 inhibitors into the homology model of CYP19 (1TQA) in 
order to improve and focus the drug design of novel compounds and to rationalize the 
SAR on a biomolecular basis. 
3. 17β-HSD1: 
• To analyze the 17 (18, considering the two conformations in 1fdt) existing crystal 
structures of 17β-HSD1 and highlight their differences in order to assign the different 
identified conformations to enzyme forms occurring along the kinetic pathway. 
• To dock non steroidal 17β-HSD1 inhibitors into various, representative crystal 
structures of the enzyme with the aim of identifying the most reliable binding mode for 
the class of bis(hydroxyphenyl)-arenes. 
• To validate different binary (17β-HSD1-NADPH) and ternary (17β-HSD1-NADPH-E1) 
complexes by means molecular dynamic simulations, MM/PBSA methods and normal 
mode analysis in order to substantiate the hypothesis of the rapid equilibrium random 
bi-bi kinetic cycle and to determine the most plausible enzyme conformation at each 
step of the cycle. 
• To perform quantum chemical investigations on the class of bis(hydroxyphenyl)-arenes 
(“semi”-QMAR), in order to identify a common MEP distribution pattern responsible 
for high potency along this series. 
4. CYP11B2: 
• To create a pharmacophore model based on non steroidal CYP11B2 inhibitors. 
• To design a new class of non steroidal CYP11B2 inhibitors exploiting structural 
features derived from potent CYP19 inhibitors. 
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Chapter Three. Results and Discussion 
3.1 Androgen-dependent prostate cancer (PC) – 
selective CYP17 inhibition 
3.1.1. Homology model of CYP17  
The CYP17 enzyme is bundled in a catalytic complex with the catalytically crucial iron-binding 
porphyrin ring as a prosthetic group in the active site, an NADPH–cytochrome P450 reductase, 
which provides the reaction with the required amount of NADPH, and with cytochrome b5, 
responsible for enzyme activation and electron transfer (2nd step). The whole complex is bound 
to the endoplasmic reticulum in the cell. Due to the membrane-bound character of the complex, 
the crystal structure of the enzyme is yet to be solved. The lack of an experimental structure for 
CYP17 requires comparative modeling methods to be used in studying the overall protein fold 
and the geometry of the active site. One of the most powerful tools for creating a 3D structure of 
a protein is homology modeling. 
CYP17 is a distant relative of other CYP enzymes. Despite a low amino acid sequence identity 
(≈23 %) it posseses a common tertiary fold to most of the other CYP, which allows to derive its 
unkown structure from a known CYP one. Moreover, certain residues and the secondary 
structures are also conserved throughout the CYP enzyme families, thus α-helixes, β-strands, 
turns and loops might vary in length and amino acid constitution. 
After the first bacterial CYP enzyme was crystallized and its structure solved, these enzymes 
have been used as templates for modeling human cytochromes. Several groups have proposed 
CYP17 models that were based on bacterial cytochrome structures.59,114-116 In the past years 
various human mammalian CYP enzymes have been crystallized, representing better templates 
than the bacterial CYPs. In relation to our ongoing study concerning anti-prostate cancer drugs 
and enzymes deputed to androgen biosynthesis, we have built a three-dimensional model of 
human 17α-hydroxylase/17,20-lyase. Moreover, the aims of this homology model are to help 
rationalizing and speeding up the design of novel non-steroidal inhibitors of CYP17 and to study 
the binding of natural substrates and various designed inhibitors. 
We searched for templates evolutionally related to the target with the help of PSI-BLAST 117 and 
Pcons118 server. The identiﬁcation of structurally conserved regions (SCR) and structurally 
variable regions (SVR) was based on literature studies, with the assistance of secondary structure 
elements prediction with the PsiPred server.119 CYP2C9 resulted as one of the best templates 
among CYP enzymes with 28.9 % sequence identity. Sequence alignment is the most important 
part of the homology modelling process. With proteins sharing low sequence identity, this is by 
no means a trivial task. Gaps and insertions must be introduced to the target sequence to make 
the important residues match each other. The first alignment was obtained from the PSI-BLAST 
server and subsequently manually refined on the basis of the PsiPred secondary structure element 
predictions. Finally, a multiple sequence alignment was created with ESPRESSO 120 - the 3D 
routine of T-Coffee 121 - including as templates CYP2C9, 2C8, 2A6, 3A4 and 2B4, and a 
secondary structure profile was extracted from it and used for the final refinements of the 
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CYP17-CYP2C9 alignment. Different solutions were generated by focusing on the six substrate 
recognition sites (SRS) deﬁned for the CYP2 enzyme family by Gotoh (Chapter I, pg. 20).  
These SRS constitute the active site of the enzyme where the substrate binds and the catalytic 
reaction takes place. They can differ in length and amino acid composition. For example, the 
sequences of CYP17 and 2C9 in SRS-1 (between B- and C-helixes) have different lengths, and 
while PsiPred predicts a short 5-residue BC-helix for CYP17, the template 2C9 has a 7-residue 
helix flanking the active site. When performing the alignment, particular care has to be taken to a 
correct match between conserved residues in these SRS and the insertion of gaps. Problematic 
areas were SRS-2 and SRS-3, i.e. the C-terminus of F-helix, the N-terminus of G-helix and the 
loop between them. This area varies among cytochrome family members showing loops of 
different lengths and exhibiting one or two additional helixes (F’ and G’). Again the length of 
SRS-2 and SRS-3 is different for CYP2C9 and CYP17, as well as their amino acid sequence. 
SRS-4 is located in the so-called I-helix kink, directly involved in the catalytic process and 
presenting several residues conserved among the CYPs. Also CYP17 and CYP2C9 are highly 
similar in this region, as the following short extract of the alignment nicely shows (in blue the 
identical residues): 
 CYP2C9: D276-L277-F278-G279-A280-G281-T282-E283-T284-T285-S286-T287-T288-L289 
 CYP17:  D298-I299 -F300-G301-A302-G303-V304-E305-T306-T307-T308-S309-V310-V311 
Conserved residues E305 and T306 of CYP17, aligned with residues E283 and T284 of 2C9 
have been proven critical in mutagenesis studies.122-123 The active site wall opposite to the I-helix 
consists mainly of SRS-5, the coil between K-helix and β1-4-strand. For this site the alignment 
between CYP17 and 2C9 matches the hydrophobic nature of the template. Ile371 decreases the 
overall size of the active site slightly compared to the leucines of the template. The SRS-6 is 
located in the C-terminal loop, or more accurately, the hairpin turn between the two strands β4-1 
and β4-2. This last region is one of the less conserved for all CYP enzymes, and is described to 
be responsible for ligand binding. The ﬁnal alignment is shown in Figure 22. 
A set of models was built by means of MODELLER v8.0 124 based on the human mammalian 
CYP2C9 enzyme as template, whereas all three crystal structures of CYP2C9 deposited in the 
PDB, one holoenzyme (1og2, only with heme) and two ternary complexes cocrystallized with S-
warfarin (1og5) and flurbiprofen (1r9o), respectively, were used as template.  
Remarkably, S-warfarin is not bound close to the heme but placed in a secondary binding site, 
while flurbiprofen is oriented parallel to the I-helix and placed on the top of the heme.  
Despite flurbiprofen does not complex with the heme iron, we chose PDB entry 1r9o as 
template, due to the inward turned polar residues of the BC-loop and due to the biphenyl-like 
core of flurbiprofen similar to that of our CYP17-inhibitors, For the missing residues of the F/G 
segment in 1r9o we used the crystal 1og2_B as template, presenting two nicely solved helixes in 
the FG-loop. 
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Figure 22. Alignment of CYP17 with the amino acid sequences of the 2 crystal structures of CYP2C9, 1r9o – 
cocrystallized with flurbiprofen, and 1og2_B – presenting a water molecule at the sixth coordination position of the 
heme-iron. 
The C-terminus of the sequence was built using the loop-refine module of MODELLER. The 
prosthetic heme group was copied from the template in the modeling process and the 
coordination of sulfur in C442 to the heme iron was prepared for AMBER9 125 by setting the 
distance between sulfur and iron to 2.3A and by assigning to the whole heme group the DFT-
charges calculated by Favia et al. 126 Notably, the charge for the iron atom was adapted to 
docking needs, considering it 5-coordinated and with a charge of +1.58. The obtained model was 
put in a TIP3PBOX water box of 9 Å radius, equilibrated and simulated using MDS with 
AMBER9 for 200 ps. The trajectory was clustered on the basis of the backbone root mean square 
deviation (RMSD), and the representative structure of the biggest cluster was extracted and 
minimized. This structure was subjected to PROCHECK to analyze the quality of the model 
(Fig. 23) which was found to be good with a G-factor of -0.21 (values between 0 and -0.5 are 
considered to be good ones), no residues in a disallowed and > 98% in a favored region (Fig. 24). 
3.1.2. Molecular docking of CYP17 inhibitors  
The homology model was first validated by docking into it a set of active and inactive 
compounds by means of GOLD v3.0.1 software,127 with distance restraints set between the 
heme-iron and the nitrogen present in the heteroring of the inhibitors. In this way we do not force 
the inhibitor to coordinate with the iron, because a wrong angle between heme plane and 
heteroring plane (optimum 90°) can still hamper the complexation. GOLD was considered as a 
suitable docking software because it was able to reproduce the binding conformations of the 
cocrystallized ligands in four CYP complexes (PDB entries 1SUO, 1Z11, 1W0G and 1J0C). The 
results of the docking studies are presented hereafter in paper I-VII. The homology model 
showed a good capacity to comprehensively rationalize the SAR of the docked inhibitors and 
helped to further improve the drug design, while on the contrary almost no correlation between 
CYP17 inhibition IC50 values and GOLDSCORE values was observed.  
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Figure 23. 3D structure of the generated CYP17 model, with the different segments rainbow color-coded (BC-loop 
is cyan, I-helix yellow, F/G-segment green, C-terminal loop red, etc.). Heme is represented as red sticks.
Figure 24. The Ramachadran plot of the generated CYP17 homology model (amino acids are for 90.8% in core, 
7.2% in allowed, 1.9 % in generously allowed and 0% in disallowed regions, clustered by phi and psi angles).
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3.1.3. Molecular electrostatic potential (MEP) distribution of 
CYP17 inhibitors. 
“The electrostatic potential (ESP) is created in the space around a molecule by its nuclei and 
electrons (treated as static distributions of charge) and can be a very useful property for 
analyzing and predicting molecular reactive behavior. It is rigorously defined and it is 
particularly useful as an indicator of the sites or regions of a molecule to which an approaching 
electrophile, for example, is initially attracted.” 128  
Several CYP17 inhibitors were investigated with regards to the MEP distribution and it could be 
observed that those with a biaryl-core, subject of paper II require a particular ESP on the two 
aryl rings to gain high potency. Best example is the deleterial effect of a negative electrostatic 
potential on the C-ring (second aryl ring, close to the N-bearing heteroring; Fig. 25) on the 
biological activity. Optimally, this region should be almost neutral, to better fit to the I-helix and 
to interact with G301-A302-G303.  
 
Figure 25. MEP maps of compounds 27, 29, 30 and 31. The ESP surfaces were plotted with GaussView 3.0 in a 
range of ± 12,5 kcals/mol. 
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3.1.4. Articles published in CYP17 project – paper I-VII 
3.1.4.1. Paper I. 
 
Synthesis, Biological Evaluation and Molecular Modelling Studies of Novel ACD- and 
ABD-Ring Steroidomimetics as Inhibitors of CYP17 
 
Mariano A. E. Pinto-Bazurco Mendieta, Matthias Negri, Carsten Jagusch, Ulrike E. Hille, Ursula Müller-Vieira, 
Dirk Schmidt, Klaus Hansen, and Rolf W. Hartmann 
This article is protected by copyrights of ‘Bioorganic and Medicinal Chemistry Letters.’ 
Bioorg. Med. Chem. Lett. 2008, 18, 267–273 
Abstract 
Two novel classes of non-steroidal substrate mimetics were synthesised and examined for their potency as 
inhibitors of human CYP17. Selected compounds were tested for inhibition of hepatic CYP enzymes 3A4, 1A2, 2C9 
and 2C19. The most promising compound 15 showed a good inhibition of the target enzyme (31% and 66% at 0.2 
and 2 µM, respectively), and little inhibition of the most important hepatic enzyme CYP3A4 (6% and 19% 
inhibition at 0.2 and 2 µM, respectively) and the key enzyme of glucocorticoid biosynthesis CYP11B1 (3% and 23% 
inhibition at 0.2 and 2 µM, respectively). Docking studies revealed that this compound does not assume the same 
binding mode as steroidal ligands. 
Introduction 
Prostate cancer is the most common disease and age-related cause of death in elder men worldwide.1 Since it is 
in over 80% of the cases androgen dependent, the standard treatment is orchiectomy or its medicinal equivalent the 
chemical castration by gonadotropin-releasing hormone analogues, which reduce the testicular androgen 
production.2 Because these treatments do not affect adrenal androgen production, they are frequently combined with 
androgen receptor antagonists (flutamide, cyproterone acetate) to reduce the stimulatory effects of the remaining 
androgens.3 However, due to mutations in the androgen receptor, anti-androgens might be recognised as agonists,4,5 
making this so-called ‘combined androgen blockade’ therapy not suitable for all patients. 
The antimycotic ketoconazole has proven itself clinically as a good adjuvant therapy by reducing testosterone 
biosynthesis through inhibition of CYP17.6,7 Nevertheless, the toxicity drawbacks it showed have forced to suspend 
it from use.8 On the other hand, the steroidal CYP17 inhibitor abiraterone (Fig. 1) passed phase II clinical trials 
showing high activity in post-docetaxel castration refractory PC patients and seems to have no dose-limiting 
toxicity.9 All this makes CYP17 an interesting target, since it catalyses both the 17a-hydroxylation of pregnenolone 
and progesterone and the subsequent 17,20-lyase reaction cleaving the C17-C20 bond to yield the 17-keto androgens 
androstendione and dehydroandrostendione, the precursors of testosterone (Fig. 2).10 We also developed highly 
active steroidal inhibitors, which showed up to 3-fold higher activities against human CYP17 than abiraterone in 
vitro.11 In order to selectively inhibit CYP17 without the potential side effects of steroidal drugs12 non-steroidal 
substrate mimetics have been prepared before.12-16 In this work, in order to find a new core structure, two different 
clases of substrate analogues were synthesised (Fig. 3) which mimic the A-, C- and D-rings (compounds 1-11), and 
the A-, B- and D-rings of the substrate with benzene nuclei (compounds 12-17). Different nitrogen bearing 
heterocycles were introduced at different positions, since the heme complexation by an aromatic nitrogen is an 
important prerequisite for a high binding affinity.17 From previous work,14-16 it was known that the introduction of a 
fluorine in the A-ring strongly contributed to a better inhibition of our target enzyme. Hydroxyl groups were 
introduced, too, in order to mimic the oxygen functionality of the steroidal substrates. In the following, the 
synthesis, biological activities and molecular modelling studies are presented. Besides the CYP17 activity, inhibition 
of other CYP enzymes was examined, that is, selectivity towards hepatic CYP enzymes and CYP11B1 was 
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determined, since the latter is the key enzyme in glucocorticoid biosynthesis. The most promising structure was 
docked into our protein model, and the key interactions with the enzyme were elucidated. 
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Compound R X Y subst. pos. 
1 H N CH  
2 H CH N  
3 OMe N CH  
4 OH N CH  
6 H   1 
7 OMe   1 
8    2 
9 H   8 
12 OMe N CH  
13 OMe CH N  
14 OH N CH  
15 OH CH N  
16 OMe   3 
17 OH   4 
Figure 3. List of synthesised compounds 1-17. 
Figure 2. The role of CYP17 in androgen biosynthesis. Figure 1. The steroidal CYP17 
inhibitor abiraterone and ACD- and 
ABD-ring mimetics. Het: N-containing 
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Chemistry 
The syntheses of compounds 1-17 are shown in Schemes 1-9. In our aim to find the correct pattern for 
progesterone mimetics, different core structure alignments were synthetised, hence the diverse synthetical pathways. 
The substances can be divided in pyridyl (Schemes 1, 2, 3, 7) and imidazolyl (Schemes 4, 5, 6, 8, 9) compounds. 
The introduction of the pyridine moiety was achieved by means of Suzuki coupling18 (Method A), as well as the 
coupling of the naphthalenes and the phenyl rings. When the necessary bromides for the couplings were not 
commercially available, they were prepared either by bromination using NBS (Scheme 2) or with 
triphenylphosphine dibromide (Scheme 1). The imidazoles were introduced by performing a SNt reaction with 1,1-
carbonyl diimidazole (CDI) and the corresponding alcohol19 (Method D) in the last step. The alcohols were obtained 
from either the carboxylic acids (Method C) or from the aldehydes (Method E). In some cases the carbonyl group 
had first to be introduced (Scheme 5) or modified (Scheme 4) before reducing it to the corresponding alcohol. In 
some cases the methoxy-substituted compounds were submitted to an ether cleavage (Method B). For the 
preparation of compound 17, the hydroxyl group on the naphthalene had to be protected before the Suzuki coupling 
due to otherwise very low yields.18 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: (i) Br2, 
PPh3, acetonitrile, µw, 240°C, 10 min; (ii) 
Method A: 1a: 4-fluorophenylboronic acid (5a: 
2-methyl-4-fluorophenylboronic acid), Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (iii) Method A: 
1, 5: 3-pyridineboronic acid, Na2CO3, Pd(PPh3)4, 
toluene, 110°C, 16 h, for 2: 4-pyridineboronic 
acid, NaHCO3, Pd(PPh3)4, DMF, H2O, µW, 
150°C, 15 min. 
HO
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Br
Br
Het
F R
Br
F R
(i)
(ii) (iii)
1: R= H, Het= 3-Py
2: R= H, Het= 4-Py
10: R= Me, Het= 3-Py
1a: R= H
10a: R= Me
1b
Scheme 2. Reagents and conditions: (i) NBS, 
THF, 75°C, 2 h; (ii) Method A: 4a: 4-
fluorophenylboronic acid (11a: 3-pyridineboronic 
acid), Na2CO3, Pd(PPh3)4, toluene, 110°C, 16 h; 
(iii) Method A: 4: 3-pyridineboronic acid (11: 4-
fluorophenylboronic acid), Na2CO3, Pd(PPh3)4, 
PhMe, 110°C, 16 h; (iv) Method B: BBr3, DCM, -
78°C to 0°C, 16 h. 
O
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(i)
3: R= Me, Het2= 3-Py
4: R= H, Het2= 3-Py
11: R= Me, Het1= 4-F-Ph
3a: Het1= 4-F-Ph
11a: Het1= 3-Py
3b
Het1
(ii) (iii), (iv)
Scheme 3. Reagents and conditions: (i) 
Method A: 4-fluorophenylboronic acid, 
Na2CO3, Pd(PPh3)4, toluene, 110°C, 16 h; (ii) 
Method A: 3-pyridineboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h. 
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Scheme 4. 
Reagents and conditions: (i) Br2, Ag2SO4, H2SO4, 
65°C, 6 h; (ii) NaOH, HgO, acetic acid, H2O, 100°C, 
4 d; (iii) Method C: LiAlH4, THF, 75°C, 2 h; (iv) 
Method A: 4-fluorophenylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (v) Method D: CDI, 
imidazole, NMP, 170°C, 3 h. 
Scheme 5. 
Reagents and conditions: (i) TiCl4, 1,1-
dichloromethylmethylether, DCM, 70°C, 2 h; (ii) 
Method A: 4-fluorophenylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (iii) Method E: 
NaBH4, MeOH, THF, rt, 1 h; (iv) Method D: CDI, 
MeCN, 85°C, 2 d. 
Br Br
F
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F
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88a
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Scheme 6. 
Reagents and conditions: (i) Method C: LiAlH4, 
Et2O, 35°C, 4 h; (ii) Method A: 4-
fluorophenylboronic acid, Na2CO3, Pd(PPh3)4, 
toluene, 110°C, 16 h; (iii) Method D: CDI, 
imidazole, NMP, 180°C, 16 h. 
Br
Br
O
Br
RO
Het
(i)
(ii) 12-13,
(iii) 14-15
12: R=Me, Het=3-py
13: R=Me, Het=4-py
14: R=H, Het=3-py
15: R=H, Het=4-py
12a
Scheme 7. 
Reagents and conditions: (i) Method A: 6-
methoxynaphthalen-2-ylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (ii) Method A: 12: 
3-pyridineboronic acid (13: 4-pyridineboronic acid), 
Na2CO3, Pd(PPh3)4, toluene, 110°C, 16 h; (iii) 
Method B: BBr3, DCM, -78°C to 0°C, 16 h. 
Br
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O
O
O
O
(i)
(ii) (iii)
16
N
OH N
16a
16b
Scheme 8. 
Reagents and conditions: (i) Method A: 6-
methoxynaphthalen-2-ylboronic acid, Na2CO3, 
Pd(PPh3)4, toluene, 110°C, 16 h; (ii) Method E: 
NaBH4, MeOH, THF, rt, 1 h; (iii) Method D: CDI, 
acetonitrile, 85°C, 16 h. 
HO
Br
TBDMSO
CHO
HO
N N(iii), (iv), (v)
17
(i), (ii)
17c
Scheme 9. 
Reagents and conditions: (i) TBDMSCl, 
imidazole, DCM, rt, 16 h; (ii) Method A: Na2CO3, 
Pd(OAc)2, TBAB, toluene, EtOH, H2O, 110°C, 16 
h; (iii) Method E: NaBH4, MeOH, rt, 16 h; (iv) 
Method D: CDI, NMP, 170°C, 6 h; (v) TBAF, 
THF, rt, 16 h. 
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Results 
Biological Results. Inhibition of human CYP17 was determined by performing our previously described assay20 
at inhibitor concentrations of 0.2 and 2 µM. As source of human CYP17, our Escherichia coli system21 
(coexpressing human CYP17 and NADPH-P450 reductase) stably expressing human CYP17 was used. After 
homogenisation the 50,000g sediment was incubated with progesterone and NADPH as previously described.22 
Separation of the product was performed by HPLC using UV-detection. 
The 3- and the 4-pyridyl-substituted ACD mimetics (1-5) showed no or little inhibition, respectively, in contrast 
to the reference compounds ketoconazole and abiraterone (Table 1). Amongst our methylene-imidazolyl-substituted 
compounds (6-9), the 8-substituted one showed the best result (9). It can also be observed that the introduction of a 
2-methoxy group in compound 6 leads to a higher activity (7). Neither the introduction of a methyl substituent in the 
A-ring of 1 (10), nor the switch of the position of the A-ring from 6- to 5- (11) resulted in an active compound. 
Table 1. Inhibition of CYP17 by steroidal ACD-ring mimetics (compounds 1-11) 
 
                     1-4                                5                                   6-9                              10                               11 
 
Compound R X Y subst. pos. 
CYP17 % Inhibition a,b 
0.2 μM 2 μM 
1 H N CH  2 3 
2 H CH N  1 28 
3 OMe N CH  6 7 
4 OH N CH  0 0 
5     0 22 
6 H   1 2 19 
7 OMe   1 13 45 
8    2 3 14 
9 H   8 9 50 
10     3 3 
11     0 1 
a Ketoconazole (IC50 = 2780 nM); abiraterone (IC50 = 72 nM). 
b Data shown are the mean of at least one independent test in duplicate. Concentration of progesterone (substrate): 25 μM. The deviations 
were within < ±5 % 
Regarding the ABD mimetics (Table 2) it is striking that the class of the 4-pyridyl compounds (13, 15) showed 
again activity while the 3-pyridyl compounds (12, 14) were inactive. The cleavage of their methyl ether led to an 
enhancement of inhibition (14, 15). An increase in activity for compound 13 with 23 - 66% inhibition at 2 µM (15) 
could be observed, leading to the most active compound of this study. Analogous to the work done in the ACD 
class, the heterocycle was replaced by a methylene-imidazole moiety, and moderate activities for compounds 16 and 
17 were observed. 
Since CYP3A4 is the hepatic enzyme responsible for the metabolism of lipophilic substances and therefore of 
about 50% of current prescription drugs,23 a broader spectrum of our compounds were studied for their effects on 
this enzyme. Critical is the fact that this enzyme together with CYP2D6 and CYP1A2 shows pronounced genetic 
polymorphism.24 Selected compounds (3, 7, 15, 16) showed moderate to high activity towards the mentioned hepatic 
CYP enzymes (Table 3). Since compound 15 exhibited a very low activity of 19% inhibition at 10 µM towards 
CYP3A425 it was further tested on 2D6. At this enzyme, it showed inhibitions of 80% at 1 µM and 85% at 10 µM. 
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In further terms of selectivity, compound 15 was additionally tested on the steroidogenic CYP enzyme 
CYP11B1 which is involved in the glucocorticoid biosynthesis. For the assay,26 V79MZh11B1 cells expressing 
human CYP11B1 were used. Compound 15 showed very low activities of 3% at 0.2 µM and 23% at 2 µM. 
Table 2. Inhibition of CYP17 by steroidal ABD-ring mimetics (compounds 12-17) 
          
                                                      12-15                           16, 17 
Compound R X Y subst. pos. 
CYP17 % Inhibition a,b 
0.2 μM 2.0 μM 
12 OMe N CH  3 4 
13 OMe CH N  4 23 
14 OH N CH  0 8 
15 OH CH N  31 66 
16 OMe   3 0 28 
17 OH   4 24 61 
a Ketoconazole (IC50 = 2780 nM); abiraterone (IC50 = 72 nM). 
b Data shown are the mean of at least one independent test in duplicate. Concentration of progesterone (substrate): 25 μM. The 
deviations were within < ±5 % 
Table 3. Inhibition of hepatic CYP enzymes (1A2, 2C9, 2C19, 3A4) by compounds 3, 7, 15, 16 
 
Compound 
CYP1A2 
% Inhibitiona 
CYP2C9 
% Inhibitiona 
CYP2C19 
% Inhibitiona 
CYP3A4 
% Inhibitiona 
1.0 μM 10.0 μM 1.0 μM 10.0 μM 1.0 μM 10.0 μM 1.0 μM 10.0 μM 
3 40 87 66 54 68 28 64 86 
7 80 85 100 100 93 96 93 95 
15 98 98 94 97 86 89 6 19 
16 96 97 97 100 95 97 91 96 
KTZ b 8 38 21 75 24 1 1 4 
ABT b 36 53 17 51 3 7 7 7 
a Data shown are the mean of three independent tests. 
b KTZ: ketoconazole; ABT: abiraterone. The deviations were within < ±5 % 
Molecular Modelling. Since there is no crystal structure of CYP17 available we built a homology model of 
CYP17 using the X-ray structure of human CYP2C9 (PDB code 1r9o) as template, as described before by us.28 
Docking simulations were carried out by means of the GOLD v3.0.1 software. For the docking studies, our 
homology model was used running Linux Suse 10.1 on Intel® P4 CPU 3.00 GHz, and the energy minimisation was 
also performed as previously described.28 Compound 15 and the steroidal inhibitor abiraterone were docked as 
shown in Figure 4. 
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Figure 4. Docking complex between CYP17 and compounds 15 (cyan) and abiraterone (yellow). Heme, 
interacting residues and ribbon rendered tertiary structure of the active site are shown. Figure was generated with 
Pymol (http://www.pymol.org).
Besides the already described interaction between the sp2 hybridised nitrogen and the heme iron, the key 
interaction for compound 15 seems to be the H-bond net of the hydroxyl group on the naphthalene with the amino 
acids Arg109, His235, Lys231 and Asn202 in the active site of our target enzyme. Further, hydrophobic interactions 
between the aromatic core and Ile206, Gly301, Ala302, Glu305, Val366 and Val482 were observed.
For abiraterone, the same binding mode as described for the substrates was found.29,30 The lone pair of the sp2
hybridised nitrogen pointed perpendicular towards the heme iron. The steroidal scaffold was oriented almost parallel 
to the heme plane in the direction of the BC-loop. This pose was stabilised by hydrophobic interactions with Ile371, 
Ile112, Ala113 and Phe114.29,30 Additionally, the highly conserved Arg96 which is important for substrate binding 
and recognition, as shown by sitedirected mutagenesis,31 presented interactions of the same kind with the steroidal 
A-ring. Another important interaction was the H-bond between the hydroxyl group in C3 position and the backbone 
carbonyl group of Gln98.
Discussion and Conclusion
Relying on our molecular modelling studies, the inhibitory activity of compound 15 is supposed to be increased 
by introducing other polar groups like an H-bond donor in 7 position of the naphthalene, which could interact with 
Asp298. Other possible substitutions to increase activity and perhaps also selectivity towards hepatic CYP enzymes 
are chlorine or fluorine at the 1 position of the naphthalene, which should improve the hydrophobic interactions with 
the I-helix. Also a substituent at 3 position capable of undergoing H-bonds could interact with Glu204.
The selectivity against CYP1A2 and CYP2D6 could also be enhanced through different medicinal chemistry
strategies. It is described that planar, lipophilic structures32 like compound 15 have a great affinity towards 
CYP1A2. This planarity could be abolished by either dearomatising one of the benzene rings, or by specific ortho-
substitutions. Regarding CYP2D6, its high inhibition is not surprising, since compound 15 bears three important 
pharmacophores responsible for its inhibition: the aromatic nitrogen, the H-bond donor and the lipophilic core 
structure.33 Since CYP2D6 has a relatively small binding site, most of the changes or substitutions made on 
compound 15 might increase its selectivity against this enzyme.
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Summarising, we have discovered compound 15 which shows good inhibition values, a good selectivity towards 
the steroidogenic CYP11B1 and a modest selectivity against CYP3A4, the most relevant hepatic enzyme in 
xenobiotic metabolism. Compound 15 might therefore be a good candidate for further structure optimisation. Using 
our protein model, we made some suggestions of how to further increase activity and selectivity towards hepatic 
CYP enzymes. Molecular docking calculations were performed for compound 15. Since the GOLD docking 
program allows flexible docking of the compounds, no conformational search was employed to the ligand structures. 
GOLD gave the best poses by a genetic algorithm (GA) search strategy, and then various molecular features were 
encoded as a chromosome. 
Experimental Section 
Chemistry. Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR 
spectra were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an internal 
standard for spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (ElectroSpray Ionisation) 
and APCI (Atmospheric Pressure Chemical Ionisation) mass spectra were determined on a TSQ quantum (Thermo 
Electron Corporation) instrument. EI (Electron Ionisation) mass spectra were determined on a Trace GC Ultra 
(Thermo Electron Corporation) instrument. All reactions in the microwave were performed in a closed vessel in a 
CEM DiscoveryTM instrument equipped with an IR-sensor for temperature control. Column chromatography was 
performed using silica-gel 60 (50-200 µm), and reaction progress was determined by TLC analysis on Alugram® 
SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls and other compounds used as starting materials were 
commercially obtained (CombiBlocks, Chempur, Aldrich, Acros). 
1,6-Dibromonaphthalene, 1b. To an ice-cooled solution of triphenylphosphine (16.40 g, 62.50 mmol) in 
acetonitrile (30 mL) was carefully dropped bromine (3.20 mL, 62.50 mmol). Then naphthalene-1,6-diol (5.00 g, 
31.25 mmol) was added and the resulting mixture was heated for 2 hours at 80 °C. After that the solvent was 
evaporated under reduced pressure and the residue was heated in the microwave at 240 °C for 5 minutes. The crude 
was boiled in ethanol for 30 minutes, followed by hot and cold filtration. After evaporation under reduced pressure, 
the desired product was purified by chromatography on silica gel; yield: 6.35 g (71 %); white solid; Rf = 0.69 
(hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.32-7.35 (m, 2H), 7.65 (dd, J = 1.2, 9.0 Hz, 1H), 7.70 (d, J = 8.2 
Hz, 1H), 7.78 (d, J = 7.4 Hz, 1H), 7.99 (s, 1H), 8.10 (d, J = 9.0 Hz, 1H); MS (EI): m/z = 283.8, 285.8, 287.8 
[M++H]. 
Method A: Suzuki-Coupling. The corresponding brominated aromatic compound (1 eq) was dissolved in 
toluene (7 mL / mmol), a 10 % Na2CO3 aq solution (2 eq) and the corresponding boronic acid (1.5-2.0 eq) were 
added. The mixture was deoxygenated under reduced pressure and flushed with nitrogen. After repeating this cycle 
several times, Pd(PPh3)4 (5 mol%) was added and the resulting suspension was heated under reflux for 16 hours. 
After cooling and phase separation, the aqueous phase was extracted with ethyl acetate (3 x 25 mL). The combined 
organic phases were washed with brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated 
under reduced pressure. The compounds were purified by flash chromatography on silica gel. 
1-Bromo-6-(4-fluorophenyl)naphthalene, 1a. Synthesised according to Method A using compound 1b (0.75 g, 
2.62 mmol) and 4-fluorophenylboronic acid (0.45 g, 3.22 mmol); yield: 0.33 g (42 %); white solid; Rf = 0.78 
(hexane / EtOAc, 80:20); MS (EI): m/z = 312.9, 316.0 [M++H]. 
3-(6-(4-Fluorophenyl)naphthalen-1-yl)pyridine, 1. Synthesised according to Method A using compound 1a 
(0.18 g, 0.58 mmol) and 3-pyridineboronic acid (0.15 g, 1.16 mmol); yield: 0.05 g (31 %); light-yellow oil; Rf = 
0.57 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 3038 (w), 1602 (w), 1517 (m), 1501 (s), 1407 (w), 1229 (s), 1159 
(m), 1100 (w), 1026 (w), 965 (w), 888 (w), 844 (m), 823 (s), 792 (s), 759 (m), 715 (s), 659 (m), 539 (m); δH (CDCl3, 
500 MHz) 7.16-7.20 (m, 2H), 7.43 (dd, J = 1.1, 7.0 Hz, 1H), 7.47 (dd, J = 4.5, 7.7 Hz, 1H), 7.59 (dd, J = 7.1, 8.2 Hz, 
1H), 7.66-7.69 (m, 2H), 7.84-7.88 (m, 1H), 7.88-7.89 (m, 1H), 7.96 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 1.8 Hz, 1H), 
8.71 (d, J = 3.6 Hz, 1H), 8.79 (d, J = 1.1 Hz, 1H); δC (CDCl3, 125 MHz) 115.7, 115.9, 123.2, 125.9, 126.0, 126.1, 
127.5, 128.7, 128.9, 129.0, 130.6, 134.1, 136.2, 136.3, 136.79, 136.81, 137.3, 137.8, 148.5, 148.7, 150.6, 162.7 (d, J 
= 247.0 Hz, C-F); MS (ESI): m/z = 299.9 [M++H]. 
4-(6-(4-Fluorophenyl)naphthalen-1-yl)pyridine, 2. Synthesised according to Method A using compound 1a 
(0.10 g, 0.33 mmol) and 4-pyridineboronic acid (0.06 g, 0.43 mmol); yield: 0.09 g (94 %); light-yellow oil; Rf = 
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0.69 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 3054 (w), 1732 (w), 1601 (m), 1504 (s), 1432 (w), 1409 (w), 1264 
(w), 1231 (s), 1159 (m), 879 (w), 823 (s), 794 (s), 760 (s), 654 (m), 605 (w), 518 (w); δH (CDCl3, 500 MHz) 7.16-
7.20 (m, 2H), 7.43 (dd, J = 1.0, 7.1 Hz, 1H), 7.56-7.60 (m, 3H), 7.66-7.70 (m, 3H), 7.89 (d, J = 8.8 Hz, 1H), 7.98 (d, 
J = 8.3 Hz, 1H), 8.08 (d, J = 1.8 Hz, 1H), 8.84 (d, J = 3.3 Hz, 2H); δC (CDCl3, 125 MHz) 115.8, 115.9, 125.5, 125.6, 
125.9, 126.2, 126.3, 127.0, 128.9, 129.0, 129.4, 129.6, 134.0, 136.5, 136.6, 138.0, 149.5, 150.0, 162.7 (d, J = 247.1 
Hz, C-F); MS (ESI): m/z = 300.0 [M++H]. 
1-Bromo-6-(4-fluorophenyl)-2-methoxynaphthalene, 3a. Synthesised according to Method A using compound 
3b (1.00 g, 3.17 mmol) and 4-fluorophenylboronic acid (0.45 g, 3.17 mmol); yield: 0.84 g (84 %); white solid; Rf = 
0.57 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.05 (s, 3H), 7.15-7.19 (m, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.66 
(dd, J = 5.3, 8.8 Hz, 2H), 7.77 (dd, J = 1.9, 8.9 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.93 (d, J = 1.7 Hz, 1H), 8.28 (d, J 
= 8.9 Hz, 1H); δC (CDCl3, 125 MHz) 57.1 (CH3), 108.6, 114.1, 115.7, 115.9, 125.6, 126.9, 127.2, 128.76, 128.83, 
129.1, 130.0, 132.3, 136.1, 136.6, 136.7, 152.9, 162.6 (d, J = 246.7 Hz, C-F); MS (EI): m/z = 329.9, 332.9 [M++H].  
3-(6-(4-Fluorophenyl)-2-methoxynaphthalen-1-yl)pyridine, 3. Synthesised according to Method A using 
compound 3a (0.30 g, 0.91 mmol) and 3-pyridineboronic acid (0.14 g, 1.09 mmol); yield: 0.20 g (66 %); white 
solid: mp 147 °C; Rf = 0.57 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 2926 (m), 1599 (m), 1516 (m), 1496 (m), 
1460 (w), 1344 (w), 1257 (s), 1164 (w), 1134 (w), 1067 (s), 1025 (w), 823 (s), 804 (s), 750 (w), 717 (m), 626 (w), 
522 (w); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 7.14-7.17 (m, 2H), 7.41 (d, J = 9.1 Hz, 1H), 7.47 (dd, J = 4.9, 7.7 Hz, 
1H), 7.53 (d, J = 8.9 Hz, 1H), 7.59 (dd, J = 1.9, 8.9 Hz, 1H), 7.65 (dd, J = 5.3, 8.8 Hz, 2H), 7.76 (td, J = 1.9, 7.8 Hz, 
1H), 7.97-7.99 (m, 2H), 8.66 (d, J = 1.5 Hz, 1H), 8.68 (dd, J = 1.5, 4.9 Hz, 1H); MS (APCI): m/z = 320.3 [M++H]. 
2-Bromo-6-(4-fluorophenyl)naphthalene, 5a. Synthesised according to Method A using 2,6-
dibromonaphthalene (0.70 g, 2.47 mmol) and 4-fluorophenylboronic acid (0.35 g, 2.47 mmol); yield: 0.23 g (37 %); 
white solid; Rf = 0.80 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.16-7.19 (m, 2H), 7.58 (dd, J = 2.0, 8.7 Hz, 
1H), 7.66 (dd, J = 5.3, 8.8 Hz, 2H), 7.71 (dd, J = 1.8, 8.6 Hz, 1H), 7.75 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.6 Hz, 1H), 
7.95 (d, J = 1.0 Hz, 1H), 8.03 (d, J = 1.7 Hz, 1H); δC (CDCl3, 125 MHz) 115.7, 115.9, 119.9, 125.5, 126.5, 127.6, 
128.88, 128.94, 129.70, 129.74, 129.8, 132.1, 133.6, 136.78, 136.80, 138.1, 162.7 (d, J = 247.0 Hz, C-F); MS (EI): 
m/z = 299.8, 302.9 [M++H]. 
3-(6-(4-Fluorophenyl)naphthalen-2-yl)pyridine, 5. Synthesised according to Method A using compound 5a 
(0.15 g, 0.50 mmol) and 3-pyridineboronic acid (0.08 g, 0.65 mmol); yield: 0.07 g (47 %); light-yellow solid: mp 
126 °C; Rf = 0.72 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 2961 (m), 1728 (s), 1605 (m), 1516 (m), 1487 (m), 1377 
(w), 1286 (s), 1240 (s), 1122 (s), 1072 (s), 981 (w), 896 (m), 812 (s), 744 (m), 706 (m), 666 (m), 544 (w), 527 (m); 
δH (CDCl3, 500 MHz) 7.17-7.21 (m, 2H), 7.46 (dd, J = 4.9, 7.7 Hz, 1H), 7.53 (dd, J = 3.3, 5.7 Hz, 1H), 7.69 (dd, J = 
5.3, 8.8 Hz, 2H), 7.73 (dd, J = 3.3, 5.7 Hz, 1H), 7.75 (dd, J = 1.9, 4.7 Hz, 1H), 7.77 (dd, J = 1.9, 4.7 Hz, 1H), 7.98-
8.02 (m, 2H), 8.03 (d, J = 1.2 Hz, 1H), 8.05-8.08 (m, 2H), 8.65 (d, J = 3.7 Hz, 1H), 9.01 (s, 1H); δC (CDCl3, 125 
MHz) 115.7, 115.9, 123.8, 125.4, 125.5, 126.0, 126.2, 128.84, 128.89, 128.92, 128.99, 132.7, 133.2, 134.97, 135.02, 
136.94, 136.97, 138.3, 147.92, 147.94, 162.7 (d, J = 247.2 Hz, C-F); MS (ESI): m/z = 300.2 [M++H]. 
6-(4-Fluorophenyl)-1-naphthoic acid, 6a. Synthesised according to Method A using compound 6b (0.50 g, 
2.11 mmol) and 4-fluorophenylboronic acid (0.39 g, 2.74 mmol); yield: 0.45 g (85 %); white solid; Rf = 0.44 (DCM 
/ MeOH, 98:2); δH (CDCl3, 500 MHz) 5.16 (s, 2H), 7.16-7.20 (m, 2H), 7.46-7.53 (m, 2H), 7.68 (dd, J = 5.3, 8.7 Hz, 
2H), 7.75 (dd, J = 1.9, 8.7 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 1.7 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H); δC 
(CDCl3, 125 MHz) 63.7 (CH2), 115.7, 115.8, 124.4, 125.4, 125.8, 126.0, 126.3, 128.8, 128.9, 130.3, 134.0, 136.2, 
136.91, 136.93, 137.5, 162.6 (d, J = 246.8 Hz, C-F); MS (EI): m/z = 252.0 [M++H]. 
6-(4-Fluorophenyl)-2-methoxy-1-naphthaldehyde, 7b. Synthesised according to Method A using compound 
7c (1.00 g, 3.77 mmol) and 4-fluorophenylboronic acid (0.54 g, 3.77 mmol); yield: 0.63 g (60 %); white solid; Rf = 
0.32 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.08 (s, 3H), 7.15-7.19 (m, 2H), 7.34 (d, J = 9.2 Hz, 1H), 7.66 
(dd, J = 5.3, 8.8 Hz, 2H), 7.84 (dd, J = 2.1, 9.0 Hz, 1H), 7.92 (d, J = 2.0 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 9.34 (d, J 
= 9.0 Hz, 1H); MS (APCI): m/z = 322.2 [M++H]. 
(6-(4-Fluorophenyl)naphthalen-2-yl)methanol, 8a. Synthesised according to Method A using compound 8b 
(0.40 g, 1.69 mmol) and 4-fluorophenylboronic acid (0.29 g, 2.03 mmol); yield: 0.36 g (84 %); white solid; Rf = 
0.52 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 4.88 (s, 2H), 7.16-7.19 (m, 2H), 7.51 (dd, J = 1.4, 8.4 Hz, 1H), 
7.68 (dd, J = 5.3, 8.7 Hz, 2H), 7.70 (dd, J = 1.8, 8.5 Hz, 1H), 7.83 (s, 1H), 7.89 (dd, J = 5.2, 8.4 Hz, 2H), 7.98 (s, 
1H); δC (CDCl3, 125 MHz) 65.4 (CH2), 115.6, 115.8, 125.2, 125.4, 125.7, 128.5, 128.6, 128.86, 128.93, 132.4, 
133.1, 137.10, 137.12, 137.6, 138.5, 162.5 (d, J = 246.6 Hz, C-F); MS (APCI): m/z = 235.1, 236.0, 237.0 [M++H]. 
3-(4-Fluorophenyl)-1-naphthoic acid, 9a. Synthesised according to Method A using compound 9b (0.50 g, 
2.11 mmol) and 4-fluorophenylboronic acid (0.39 g, 2.74 mmol); yield: 0.42 g (78 %); white solid; Rf = 0.50 (DCM 
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/ MeOH, 98:2); δH (CDCl3, 500 MHz) 5.22 (s, 2H), 7.16-7.19 (m, 2H), 7.52-7.58 (m, 2H), 7.69 (dd, J = 5.3, 8.8 Hz, 
2H), 7.76-7.77 (m, 1H), 7.92-7.94 (m, 1H), 7.96 (s, 1H), 8.11-8.13 (m, 1H); δC (CDCl3, 125 MHz) 63.7 (CH2), 
103.2, 115.7, 115.8, 123.5, 126.0, 126.42, 126.44, 128.86, 128.92, 130.3, 134.1, 137.0, 162.6 (d, J = 246.9 Hz, C-F); 
MS (EI): m/z = 252.0 [M++H]. 
1-Bromo-6-(4-fluoro-2-methylphenyl)naphthalene, 10a. Synthesised according to Method A using compound 
1b (0.75 g, 2.62 mmol) and 2-methyl-4-fluorophenylboronic acid (0.50 g, 3.28 mmol); yield: 0.26 g (31 %); white 
solid; Rf = 0.85 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 2.29 (s, 3H), 6.98 (dt, J = 2.3, 8.4 Hz, 1H), 7.03 (dd, 
J = 2.5, 9.7 Hz, 1H), 7.27 (dd, J = 5.9, 8.6 Hz, 1H), 7.34-7.37 (m, 1H), 7.54 (dd, J = 1.7, 8.7 Hz, 1H), 7.74 (d, J = 
1.5 Hz, 1H), 7.80 (dd, J = 1.0, 7.6 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 8.28 (d, J = 8.7 Hz, 1H); δC (CDCl3, 125 MHz) 
20.6 (CH3), 112.6, 112.8, 116.8, 116.9, 117.0, 122.7, 126.5, 126.6, 126.8, 127.0, 127.3, 127.7, 127.9, 128.19, 
128.23, 128.7, 129.1, 129.4, 129.9, 130.1, 130.2, 130.6, 130.9, 131.3, 131.4, 131.6, 134.5, 137.09, 137.12, 137.9, 
138.0, 139.5, 162.2 (d, J = 246.0 Hz, C-F); MS (ESI): m/z = not ionisable [M++H]. 
3-(6-(4-Fluoro-2-methylphenyl)naphthalen-1-yl)pyridine, 10. Synthesised according to Method A using 
compound 10a (0.15 g, 0.48 mmol) and 3-pyridineboronic acid (0.09 g, 0.71 mmol); yield: 0.05 g (31 %); colourless 
oil; Rf = 0.51 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 3049 (w), 1585 (w), 1493 (s), 1408 (w), 1270 (m), 1222 (s), 
1186 (w), 1152 (m), 1025 (w), 965 (m), 866 (m), 836 (w), 810 (s), 794 (s), 761 (s), 717 (s), 657 (m), 583 (m); δH 
(CDCl3, 500 MHz) 2.30 (s, 3H), 6.98 (dt, J = 2.7, 8.4 Hz, 1H), 7.02 (dd, J = 2.6, 9.8 Hz, 1H), 7.28 (dd, J = 6.0, 8.4 
Hz, 1H), 7.42 (dd, J = 1.8, 8.7 Hz, 1H), 7.45 (dd, J = 0.9, 7.1 Hz, 1H), 7.46 (dd, J = 4.9, 7.8 Hz, 1H), 7.60 (dd, J = 
7.1, 8.2 Hz, 1H), 7.83 (d, J = 1.6 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.87 (td, J = 1.8, 7.8 Hz, 1H), 7.93 (d, J = 8.3 
Hz, 1H), 8.71 (dd, J = 1.6, 4.9 Hz, 1H), 8.80 (d, J = 2.1 Hz, 1H); δC (CDCl3, 125 MHz) 20.6, 20.7, 112.0, 112.6, 
112.7, 116.8, 117.0, 123.2, 125.1, 125.9, 127.4, 128.4, 128.5, 128.6, 130.4, 130.8, 131.3, 131.4, 133.7, 136.3, 137.3, 
137.4, 138.0, 138.9, 148.6, 150.6, 162.2 (d, J = 245.9 Hz, C-F); MS (ESI): m/z = 313.9 [M++H]. 
3-(5-Bromo-6-methoxynaphthalen-2-yl)pyridine, 11a. Synthesised according to Method A using compound 
3b (0.75 g, 2.41 mmol) and 3-pyridineboronic acid (0.36 g, 2.89 mmol); yield: 0.19 g (25 %); white solid; Rf = 0.22 
(DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 3.98 (s, 3H), 7.26 (d, J = 9.0 Hz, 1H), 7.34 (ddd, J = 0.7, 4.8, 7.9 Hz, 
1H), 7.72 (dd, J = 1.9, 8.8 Hz, 1H), 7.82 (d, J = 9.0 Hz, 1H), 7.90-7.92 (m, 2H), 8.25 (d, J = 8.8 Hz, 1H), 8.56 (dd, J 
= 1.5, 4.8 Hz, 1H), 8.90 (d, J = 1.9 Hz, 1H); δC (CDCl3, 125 MHz) 57.1, 108.5, 114.2, 123.6, 126.1, 126.8, 127.2, 
129.3, 129.9, 132.7, 133.6, 134.4, 136.0, 148.4, 148.6, 154.2, 190.7; MS (EI): m/z = 314.9, 316.0 [M++H]. 
3-(5-(4-Fluorophenyl)-6-methoxynaphthalen-2-yl)pyridine, 11. Synthesised according to Method A using 
compound 11a (0.10 g, 0.32 mmol) and 4-fluorophenylboronic acid (0.07 g, 0.48 mmol); yield: 0.08 g (77 %); white 
solid; Rf = 0.23 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 2840 (w), 1735 (w), 1599 (w), 1512 (m), 1488 (m), 1463 
(w), 1281 (w), 1256 (s), 1214 (m), 1159 (w), 1132 (w), 1068 (s), 1018 (w), 914 (w), 900 (w), 833 (m), 808 (s), 758 
(w), 715 (s), 689 (w), 625 (w), 556 (m), 535 (m); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 7.19-7.23 (m, 2H), 7.36 (dd, J 
= 5.5, 8.7 Hz, 2H), 7.42 (dd, J = 4.9, 7.8 Hz, 1H), 7.43 (d, J = 9.1 Hz, 1H), 7.56-7.60 (m, 2H), 7.96-8.00 (m, 2H), 
8.04 (s, 1H), 8.63 (dd, J = 1.3, 4.8 Hz, 1H), 8.96 (d, J = 1.8 Hz, 1H); δC (CDCl3, 125 MHz) 56.6, 114.3, 115.2, 
115.3, 123.7, 124.1, 125.5, 126.1, 126.2, 129.1, 129.7, 131.79, 131.81, 132.48, 132.54, 132.6, 133.2, 134.6, 136.6, 
148.2, 148.3, 154.3, 162.1 (d, J = 245.9 Hz, C-F); MS (ESI): m/z = 329.9 [M++H]. 
2-(3-Bromophenyl)-6-methoxynaphthalene, 12a. Synthesised according to Method A using 1,3-
dibromobenzene (0.93 mL, 7.43 mmol) and 3-methoxyphenylboronic acid (1.50 g, 7.43 mmol); yield: 1.82 g (78 
%); white solid; Rf = 0.68 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 4.88 (s, 2H), 7.17 (d, J = 2.5 Hz, 1H), 7.19 
(dd, J = 2.6, 8.9 Hz, 1H), 7.32-7.35 (m, 2H), 7.47-7.49 (m, 1H), 7.61-7.63 (m, 1H), 7.66 (dd, J = 1.8, 8.4 Hz, 1H), 
7.79-7.82 (m, 2H), 7.84-7.85 (m, 1H), 7.95 (d, J = 1.7, 1H); δC (CDCl3, 125 MHz) 55.4 (CH3), 105.6, 119.4, 123.0, 
125.7, 125.78, 125.82, 127.4, 128.5, 129.1, 129.8, 129.9, 130.2, 130.3, 131.1, 134.1, 134.8, 143.4, 158.0; MS (EI): 
m/z = 312.9, 316.0 [M++H]. 
3-(3-(6-Methoxynaphthalen-2-yl)phenyl)pyridine, 12. Synthesised according to Method A using compound 
12a (0.30 g, 0.96 mmol) and 3-pyridineboronic acid (0.15 g, 1.15 mmol); yield: 0.22 g (74 %); light-yellow solid: 
mp 157 °C; Rf = 0.71 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 2925 (w), 1605 (w), 1483 (w), 1385 (w), 1268 (w), 
1244 (m), 1205 (s), 1165 (m), 1026 (m), 858 (s), 819 (s), 792 (s), 714 (s); δH (CDCl3, 500 MHz) 3.95 (s, 3H), 7.19-
7.21 (m, 2H), 7.42 (dd, J = 4.9, 7.7 Hz, 1H), 7.59 (m, 2H), 7.73-7.77 (m, 2H), 7.82 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 
8.5 Hz, 1H), 7.90 (s, 1H), 7.99 (td, J = 1.6, 7.9 Hz, 1H), 8.03 (s, 1H), 8.63 (d, J = 4.1 Hz, 1H), 8.95 (d, J = 1.3 Hz, 
1H); δC (CDCl3, 125 MHz) 55.4, 105.6, 119.3, 123.7, 125.80, 125.84, 125.9, 126.1, 127.1, 127.4, 129.1, 129.6, 
129.7, 134.0, 134.7, 135.8, 142.2, 148.2, 148.3, 157.9; MS (ESI): m/z = 312.2 [M++H]. 
4-(3-(6-Methoxynaphthalen-2-yl)phenyl)pyridine, 13. Synthesised according to Method A using compound 
12a (0.40 g, 1.28 mmol) and 4-fluorophenylboronic acid (0.19 g, 1.53 mmol); yield: 0.26 g (67 %); white solid; Rf = 
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0.54 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 3058 (w), 1593 (s), 1546 (w), 1489 (m), 1386 (w), 1268 (w), 1244 
(m), 1205 (s), 1164 (w), 1025 (m), 895 (w), 857 (s), 828 (w), 816 (s), 795 (s), 707 (w), 616 (m), 573 (w), 537 (w), 
510 (w); δH (CDCl3, 500 MHz) 3.95 (s, 3H), 7.18 (d, J = 2.5 Hz, 1H), 7.20 (dd, J = 2.5, 8.9 Hz, 1H), 7.58-7.63 (m, 
4H), 7.76 (dd, J = 1.8, 8.5 Hz, 1H), 7.77 (td, J = 1.5, 7.4 Hz, 1H), 7.81 (d, J = 8.9 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 
7.93-7.94 (m, 1H), 8.02 (d, J = 1.5 Hz, 1H), 8.69-8.70 (m, 2H); δC (CDCl3, 125 MHz) 55.3, 105.5, 119.3, 121.6, 
121.7, 125.6, 125.7, 125.8, 125.9, 126.9, 127.4, 127.8, 129.05, 129.07, 129.1, 129.5, 129.7, 133.9, 135.7, 138.7, 
142.1, 148.3, 150.18, 150.24, 157.9; MS (ESI): m/z = 312.1 [M++H]. 
3-(6-Methoxynaphthalen-2-yl)benzaldehyde, 16b. Synthesised according to Method A using 3-
bromobenzaldehyde (1.50 g, 7.58 mmol) and 3-methoxyphenylboronic acid (1.00 mL, 8.33 mmol); yield: 1.81 g (91 
%); white solid; Rf = 0.51 (hexane / EtOAc, 80:20); MS (EI): m/z = 262.0 [M++H]. 
4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)benzaldehyde, 17c. Synthesised accord-ing to Method A 
using compound 17d (6.18 g, 18.30 mmol) and 4-formylphenylboronic acid (4.13 g, 27.50 mmol). Then the desired 
product was taken to the next step without further purification; yield: 6.07 g (91 %); Rf = 0.43 (hexane / EtOAc, 
90:10). 
1,6-Dibromo-2-methoxynaphthalene, 3b. To a solution of 2-bromo-6-methoxynaphthalene (3.65 g, 15.24 
mmol) in THF (30 mL) was added N-bromosuccinimide (3.01 g, 16.76 mmol). Then the solution was heated to 
reflux for 2 hours. After cooling to ambient temperature, it was diluted with water (50 mL) and extracted with ethyl 
acetate (3 x 25 mL). The combined organic phases were washed with 1 N HCl, brine, dried over Na2SO4 and 
evaporated under reduced pressure. Then the desired product was taken to the next step without further purification; 
yield: 4.82 g (100 %); white solid; Rf = 0.48 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.02 (s, 3H), 7.27 (d, J 
= 9.5 Hz, 1H), 7.60 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.92 (s, 1H), 8.08 (d, J = 9.1 Hz, 1H); δC (CDCl3, 
125 MHz) 57.0 (CH3), 108.7, 114.5, 118.1, 128.0, 129.8, 130.6, 130.9, 131.7, 154.0, 171.0; MS (ESI): m/z = not 
ionisable [M++H]. 
Method B: Ether cleavage with BBr3. To a solution of the corresponding ether (1 eq) in DCM (5 mL / mmol) at 
-78 °C was added 1 M borontribromide in DCM (5 eq). The resulting mixture was stirred at rt for 16 hours. Then 
water (25 mL) was added and the emulsion was stirred for further 30 minutes. The resulting mixture was extracted 
with ethyl acetate (3 x 25 mL). The combined organic phases were washed with brine, dried over Na2SO4 and 
evaporated under reduced pressure. Then the desired product was purified by chromatography on silica gel. 
6-(4-Fluorophenyl)-1-(pyridin-3-yl)naphthalen-2-ol, 4. Synthesised according to Method B using 3 (0.14 g, 
0.43 mmol) and BBr3 (2.20 mL, 2.20 mmol); yield: 0.10 g (75 %); light-yellow solid: mp 234 °C; Rf = 0.42 (DCM / 
MeOH, 95:5); IR (ATR) υ (cm-1) 2922 (w), 1595 (w), 1498 (s), 1350 (m), 1324 (w), 1291 (m), 1257 (w), 1228 (m), 
1188 (w), 1159 (w), 1052 (w), 943 (m), 846 (w), 816 (s), 769 (w), 710 (s), 662 (w), 638 (m), 520 (m); δH (CDCl3 + 
CD3OD, 500 MHz) 7.01-7.04 (m, 2H), 7.16 (d, J = 8.9 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.42-7.46 (m, 2H), 7.51-
7.53 (m, 2H), 7.72 (d, J = 8.9 Hz, 1H), 7.78 (dd, J = 1.6, 7.8 Hz, 1H), 7.84 (s, 1H), 8.48 (d, J = 4.6 Hz, 1H), 8.51 (s, 
1H).; δC (CDCl3 + CD3OD, 125 MHz) 115.8, 116.0, 117.59, 117.60, 118.8, 124.1, 124.7, 126.1, 126.4, 128.87, 
128.94, 129.1, 130.5, 133.0, 133.4, 135.2, 137.29, 137.32, 140.2, 147.4, 151.2, 152.4, 162.7 (d, J = 245.9 Hz, C-F); 
MS (ESI): m/z = 314.0 [M++H]. 
6-(3-(Pyridin-3-yl)phenyl)naphthalen-2-ol, 14. Synthesised according to Method B using 12 (0.09 g, 0.29 
mmol) and BBr3 (1.00 mL, 1.00 mmol); yield: 0.06 g (67 %); light-yellow solid: mp 223 °C; Rf = 0.47 (DCM / 
MeOH, 95:5); IR (ATR) υ (cm-1) 2962 (w), 1626 (w), 1596 (m), 1482 (w), 1428 (m), 1396 (w), 1260 (m), 1236 (m), 
1199 (m), 1104 (s), 1020 (s), 848 (w), 783 (s), 703 (s), 674 (w); δH (CDCl3 + CD3OD 500 MHz) 7.11 (dd, J = 2.4, 
8.8 Hz, 1H), 7.14 (d, J = 2.3 Hz, 1H), 7.45-7.48 (m, 1H), 7.50-7.52 (m, 2H), 7.52-7.56 (q, J = 7.6 Hz, 1H), 7.65-7.67 
(dd, J = 1.8, 8.6 Hz, 1H), 7.70-7.72 (m, 2H), 7.74 (d, J = 8.8 Hz, 1H), 7.83-7.84 (m, 1H), 7.95 (s, 1H), 8.04 (d, J = 
7.9 Hz, 1H), 8.56 (s, 1H), 8.88 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 109.0, 113.1, 118.8, 125.6, 125.7, 125.8, 
126.0, 127.0, 127.3, 128.6, 129.6, 129.8, 134.3, 135.0, 149.9, 155.0, 156.9, 160.2; MS (ESI): m/z = 298.3 [M++H]. 
6-(3-(Pyridin-4-yl)phenyl)naphthalen-2-ol, 15. Synthesised according to Method B using 13 (0.20 g, 0.64 
mmol) and BBr3 (2.60 mL, 2.60 mmol); yield: 0.16 g (86 %); light-yellow solid; Rf = 0.38 (DCM / MeOH, 95:5); IR 
(ATR) υ (cm-1) 3300-2450 (w), 1625 (w), 1598 (m), 1546 (w), 1494 (w), 1450 (w), 1398 (w), 1240 (m), 1218 (w), 
1203 (m), 1126 (w), 1069 (w), 1007 (m), 981 (w), 860 (m), 835 (m), 812 (w), 785 (s), 697 (m), 624 (m), 571 (w); δH 
((CD3)2SO, 500 MHz) 7.13 (dd, J = 2.4, 8.8 Hz, 1H), 7.17 (d, J = 2.2 Hz, 1H), 7.63-7.65 (m, 1H), 7.77-7.81 (m, 
2H), 7.84-7.88 (m, 5H), 8.13-8.14 (m, 1H), 8.22 (s, 1H), 8.66-8.68 (m, 2H), 9.83 (s, 1H); δC ((CD3)2SO, 125 MHz) 
108.4, 119.0, 121.4, 125.0, 125.3, 125.4, 126.7, 127.4, 127.9, 129.78, 129.81, 133.7, 134.0, 137.9, 141.2, 147.0, 
150.1, 155.6; MS (ESI): m/z = 298.2 [M++H]. 
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5-Bromobenzo[de]isochromene-1,3-dione, 6d. Synthesised according to Mitchell et al.34 To a solution of 
benzo[de]isochromene-1,3-dione (20.00 g, 100.92 mmol) in sulfuric acid (400 mL) was added silver sulfate (16.00 
g, 51.32 mmol) and then bromine (6.41 mL, 125.15 mmol) was carefully dropped. Then the resulting mixture was 
heated at 65 °C for 6 hours. After cooling to ambient temperature, the reaction mixture was filtered and then 
carefully poured into ice water (3.2 L). The precipitate was filtrated and washed first with water and then with 
ethanol. A further purification was not necessary; yield: 27.26 g (100 %); white-off solid; Rf = 0.72 (DCM / MeOH, 
95:5); MS (EI): m/z = 275.8, 278.9 [M++H]. 
6-Bromo-1-naphthoic acid, 6c. Synthesised according to Leuck et al.35 To a solution of 6d (10.10 g, 36.45 
mmol) and sodium hydroxide in water (240 mL) was added a solution of yellow mercury oxide (11.00 g, 50.86 
mmol) in water (30 mL) and acetic acid (10 mL). The resulting mixture was heated under reflux for 4 days. Then 5 
N hydrochloric acid (200 mL) was added and the mixture heated to reflux for 4 hours. After that, the crude was 
filtered at 0 °C. After fractional recrystallisation from acetic acid, the more soluble 6c remained in the mother 
liquor; yield: 2.10 g (23 %); white-off solid; Rf = 0.49 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.42-7.47 (m, 
2H), 7.51-7.52 (m, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 8.16 (d, J = 7.3 Hz, 1H), 8.86 (d, J = 8.6 
Hz, 1H); δC (CDCl3, 125 MHz) 124.6, 126.0, 126.2, 127.5, 127.7, 128.6, 130.6, 133.5, 134.0; MS (EI): m/z = 249.8, 
252.9 [M++H]. 
3-Bromo-1-naphthoic acid, 9c. Synthesised according to Leuck et al.35 To a solution of 6d (10.10 g, 36.45 
mmol) and sodium hydroxide in water (240 mL) was added a solution of yellow mercury oxide (11.00 g, 50.86 
mmol) in water (30 mL) and acetic acid (10 mL). The resulting mixture was heated under reflux for 4 days. Then 5 
N hydrochloric acid (200 mL) was added and the mixture heated to reflux for 4 hours. After that, the crude was 
filtered at 0 °C. After fractional recrystallisation from acetic acid, the less soluble 9c came in the early fractions; 
yield: 4.90 g (54 %); white-off solid; Rf = 0.39 (hexane / EtOAc, 80:20); δH (CDCl3, 500 MHz) 7.51-7.54 (m, 1H), 
7.59-7.62 (m, 1H), 7.76 (d, J = 8.2 Hz, 1H), 8.18 (d, J = 2.0 Hz, 1H), 8.40 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 8.7 Hz, 
1H); δC (CDCl3, 125 MHz) 118.2, 126.0, 127.4, 127.8, 128.5, 130.1, 134.6, 136.2; MS (EI): m/z = 249.8, 252.9 
[M++H]. 
Method C: Reduction with LiAlH4. To an ice-cooled solution of the corresponding carboxylic acid (1 eq) in 
THF or diethylether (5 mL / mmol) was carefully dropped LiAlH4 (10 eq) in diethylether (5 mL / mmol). Then the 
resulting mixture was heated to reflux for 1 hour. After cooling to ambient temperature, water (25 mL) was added, 
and after phase separation the aqueous phase was extracted with ethyl acetate (3 x 25 mL). The combined organic 
phases were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then the desired product 
was purified by chromatography on silica gel. 
(6-Bromonaphthalen-1-yl)methanol, 6b. Synthesised according to Method C using 6c (2.50 g, 9.96 mmol), 
LiAlH4 (3.90 g, 99.55 mmol) and additional 25 mL THF; yield: 2.19 g (87 %); white-off solid; Rf = 0.44 (hexane / 
EtOAc, 80:20); δH (CDCl3, 500 MHz) 5.09 (s, 2H), 7.44-7.47 (m, 1H), 7.51 (d, J = 6.9 Hz, 1H), 7.60 (dd, J = 2.1, 
9.0 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 9.0 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H); MS (EI): m/z = 235.9, 
238.9 [M++H]. 
(6-Bromonaphthalen-2-yl)methanol, 8b. Synthesised according to Method C using 6-bromo-2-naphthoic acid 
(3.00 g, 11.95 mmol) and LiAlH4 (4.68 g, 119.48 mmol); yield: 2.78 g (90 %); white solid; Rf = 0.19 (hexane / 
EtOAc, 80:20); δH (CDCl3, 500 MHz) 4.85 (s, 2H), 7.50 (dd, J = 1.6, 8.5 Hz, 1H), 7.55 (dd, J = 2.0, 8.8 Hz, 1H), 
7.70 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.78 (s, 1H), 8.00 (d, J = 1.6, 1H); δC (CDCl3, 125 MHz) 65.2, 
65.5, 119.8, 125.1, 125.3, 125.4, 125.9, 126.15, 126.18, 127.4, 127.7, 127.9, 128.3, 129.5, 129.6, 129.8, 131.8, 
134.0, 138.9; MS (EI): m/z = 235.9, 238.9 [M++H]. 
(3-Bromonaphthalen-1-yl)methanol, 9b. Synthesised according to Method C using 6c (2.50 g, 9.96 mmol), 
LiAlH4 (3.90 g, 99.55 mmol) and additional 25 mL THF; yield: 2.46 g (98 %); white-off solid; Rf = 0.34 (hexane / 
EtOAc, 80:20); δH (CDCl3, 500 MHz) 5.14 (s, 2H), 7.52-7.56 (m, 2H), 7.65 (d, J = 1.9 Hz, 1H), 7.78 (dd, J = 1.9, 
7.6 Hz, 1H), 7.97 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H); δC (CDCl3, 125 MHz) 62.8 (CH2), 119.4, 123.6, 126.6, 126.9, 
127.8, 128.1, 129.5, 130.1, 134.9, 138.4; MS (EI): m/z = 235.9, 238.9 [M++H]. 
Method D: CDI reaction. To a solution of the corresponding alcohol (1 eq) in NMP or acetonitrile (10 mL / 
mmol) was added CDI (5 eq) and imidazole (2 eq). Then the solution was heated to reflux for 16 hours. After 
cooling to ambient temperature, it was diluted with water (50 mL) and extracted with ethyl acetate (3 x 25 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then 
the desired product was purified by chromatography on silica gel. 
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1-((6-(4-Fluorophenyl)naphthalen-1-yl)methyl)-1H-imidazole, 6. Synthesised according to Method D using 
6a (0.15 g, 0.60 mmol), CDI (0.39 g, 2.38 mmol) and imidazole (0.04 g, 0.60 mmol); yield: 0.12 g (67 %); white 
solid; Rf = 0.39 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 3047 (w), 1604 (w), 1502 (s), 1287 (w), 1226 (s), 1159 
(m), 1107 (w), 1075 (w), 906 (w), 817 (s), 759(m), 736 (m), 662 (m), 508 (m); δH (CDCl3, 500 MHz) 5.61 (s, 2H), 
6.95 (s, 1H), 7.12 (s, 1H), 7.16-7.21 (m, 3H), 7.46-7.49 (m, 1H), 7.63 (s, 1H), 7.66 (dd, J = 5.3, 8.6 Hz, 2H), 7.74 
(dd, J = 1.8, 8.7 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H), 8.04 (d, J = 1.6 Hz, 1H); δC (CDCl3, 125 
MHz) 48.8, 115.4, 115.8, 115.9, 119.4, 119.5, 123.1, 126.0, 126.3, 126.4, 126.5, 126.6, 128.9, 129.0, 129.5, 129.9, 
131.1, 134.1, 136.5, 138.0, 141.2, 141.9, 162.7 (d, J = 247.1 Hz, C-F); MS (ESI): m/z = 303.1 [M++H]. 
1-((6-(4-Fluorophenyl)-2-methoxynaphthalen-1-yl)methyl)-1H-imidazole, 7. Synthesised according to 
Method D using 7a (0.10 g, 0.35 mmol) and CDI (0.12 g, 0.71 mmol) in acetonitrile as solvent; yield: 0.06 g (49 %); 
light-yellow solid: mp 128 °C; Rf = 0.52 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 1601 (w), 1503 (s), 1257 (s), 
1235 (s), 1162 (w), 1096 (s), 1075 (w), 1056 (w), 1026 (w), 904 (w), 844 (w), 823 (w), 788 (w), 733 (w), 662 (m), 
623 (m), 551 (m), 505 (s); δH (CDCl3, 500 MHz) 4.00 (s, 3H), 5.58 (s, 2H), 6.97 (d, J = 10.7 Hz, 2H), 7.14-7.18 (m, 
2H), 7.34 (d, J = 9.1 Hz, 1H), 7.58 (s, 1H), 7.63 (dd, J = 5.3, 8.7 Hz, 2H), 7.73 (dd, J = 1.9, 8.8 Hz, 1H), 7.93 (d, J = 
9.1 Hz, 1H), 7.96 (d, J = 1.8 Hz, 1H), 7.99 (d, J = 8.9 Hz, 1H); δC (CDCl3, 125 MHz) 40.6, 56.3, 113.3, 115.6, 
115.7, 115.8, 119.0, 122.5, 126.4, 127.1, 128.6, 128.7, 128.9, 129.2, 131.1, 131.9, 135.5, 136.6, 137.1, 155.7, 162.5 
(d, J = 246.7 Hz, C-F); MS (ESI): m/z = 333.1 [M++H]. 
1-((6-(4-Fluorophenyl)naphthalen-2-yl)methyl)-1H-imidazole, 8. Synthesised according to Method D using 
8a (0.15 g, 0.60 mmol) and CDI (0.50 g, 3.08 mmol) in acetonitrile as solvent; yield: 0.12 g (67 %); white solid: mp 
114 °C; Rf = 0.50 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 3099 (w), 1603 (m), 1503 (s), 1439 (w), 1293 (w), 1231 
(s), 1160 (w), 1105 (w), 1089 (w), 910 (m), 842 (m), 816 (s), 772 (w), 657 (s), 558 (m), 519 (w); δH (CDCl3, 500 
MHz) 5.29 (s, 2H), 6.96 (s, 1H), 7.13 (s, 1H), 7.15-7.19 (m, 2H), 7.29 (dd, J = 1.5, 8.5 Hz, 1H), 7.61 (s, 1H), 7.64-
7.67 (m, 3H), 7.72 (dd, J = 1.8, 8.5 Hz, 1H), 7.85-7.88 (m, 2H), 7.97 (s, 1H); δC (CDCl3, 125 MHz) 51.0, 115.7, 
115.9, 119.4, 125.4, 126.1, 126.2, 128.5, 128.9, 129.0, 129.2, 129.8, 132.3, 133.2, 133.7, 136.85, 136.88, 137.5, 
138.3, 162.6 (d, J = 246.9 Hz, C-F); MS (ESI): m/z = 302.9 [M++H]. 
1-((3-(4-Fluorophenyl)naphthalen-1-yl)methyl)-1H-imidazole, 9. Synthesised according to Method D using 
9a (0.15 g, 0.60 mmol), CDI (0.39 g, 2.38 mmol) and imidazole (0.04 g, 0.60 mmol); yield: 0.13 g (71 %); light-
yellow oil; Rf = 0.23 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 3057 (w), 1606 (w), 1511 (s), 1229 (s), 1160 (m), 
1107 (w), 1077 (w), 832 (s), 790 (w), 749 (m), 663 (m), 519 (w); δH (CDCl3, 500 MHz) 5.64 (s, 2H), 6.97 (s, 1H), 
7.13 (s, 1H), 7.14-7.17 (m, 2H), 7.38 (s, 1H), 7.53-7.58 (m, 2H), 7.60 (dd, J = 5.3, 8.6 Hz, 2H), 7.69 (s, 1H), 7.87-
7.89 (m, 1H), 7.94-7.96 (m, 1H), 8.00 (s, 1H); δC (CDCl3, 125 MHz) 48.9, 115.7, 115.8, 116.0, 119.5, 122.2, 123.6, 
124.7, 125.7, 126.3, 126.79, 126.82, 127.1, 127.2, 128.8, 128.9, 129.3, 129.5, 129.9, 131.9, 132.7, 134.1, 136.27, 
136.29, 137.2, 162.7 (d, J = 247.4 Hz, C-F); MS (ESI): m/z = 303.0[M++H]. 
1-(3-(6-Methoxynaphthalen-2-yl)benzyl)-1H-imidazole, 16. Synthesised according to Method D using 7a 
(0.20 g, 0.76 mmol) and CDI (0.38 g, 2.27 mmol) in acetonitrile as solvent; yield: 0.12 g (51 %); white solid: mp 
130 °C; Rf = 0.38 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 2966 (w), 1626 (w), 1603 (w), 1492 (w), 1453 (w), 
1388 (w), 1256 (m), 1227 (m), 1212 (m), 1073 (m), 1022 (s), 883 (w), 855 (s), 814 (s), 791 (m), 745 (s), 662 (s); δH 
(CDCl3, 500 MHz) 3.94 (s, 3H), 5.20 (s, 2H), 6.97 (s, 1H), 7.13-7.16 (m, 3H), 7.19 (dd, J = 2.5, 8.9 Hz, 1H), 7.44-
7.47 (m, 1H), 7.48-7.49 (m, 1H), 7.63-7.66 (m, 3H), 7.78-7.81 (m, 2H), 7.92 (d, J = 1.5 Hz, 1H); δC (CDCl3, 125 
MHz) 51.0, 55.3, 105.7, 119.3, 125.7, 125.8, 125.9, 126.1, 127.2, 127.4, 129.1, 129.5, 129.7, 134.0, 135.5, 136.7, 
142.1, 158.0; MS (ESI): m/z = 315.0 [M++H]. 
1-(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)benzyl)-1H-imidazole, 17a. Synthesi-sed according to 
Method D using 17b (3.46 g, 9.50 mmol) and CDI (7.70 g, 47.40 mmol). Then the desired product was taken to the 
next step without further purification; yield: 3.11 g (79 %); white solid; Rf = (DCM / MeOH, 98:2). 
6-Bromo-2-methoxy-1-naphthaldehyde, 7c. To a solution of 2-bromo-6-methoxy-naphthalene (5.00 g, 21.09 
mmol) in DCM (100 mL) was added TiCl4 (4.00 g, 21.09 mmol) and 1,1-dichloromethylmethylether (2.43 g, 
21.09mmol). Then the resulting mixture was stirred at 40 °C for 2 hours. After complete conversion, water (25 mL) 
was added, the phases were separated, and the aqueous layer was extracted with ethyl acetate (3 x 25 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then 
the desired product was taken to the next step without further purification; yield: g (100 %); white solid. 
Method E: Reduction with NaBH4. To an ice-cooled solution of the corresponding aldehyde (1 eq) in THF (5 
mL / mmol) was added NaBH4 (2 eq) in methanol (5 mL / mmol). Then the resulting mixture was stirred at rt for 1 
hour. After complete conversion, the solvent was distilled off under reduced pressure. Then water (25 mL) was 
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added, and the resulting mixture was extracted with ethyl acetate (3 x 25 mL). The combined organic phases were 
washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then the desired product was 
purified by chromatography on silica gel. 
(6-(4-Fluorophenyl)-2-methoxynaphthalen-1-yl)methanol, 7a. Synthesised according to Method E using 7b 
(0.28 g, 0.98 mmol) and NaBH4 (0.08 g, 1.96 mmol); yield: 0.25 g (91 %); white solid; Rf = 0.56 (DCM / MeOH, 
98:2); δH (CDCl3, 500 MHz) 4.01 (s, 3H), 5.21 (s, 2H), 7.15-7.18 (m, 2H), 7.33 (d, J = 9.1 Hz, 1H), 7.66 (dd, J = 
5.3, 8.9 Hz, 2H), 7.74 (dd, J = 1.9, 8.9 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 1.9 Hz, 1H), 8.18 (d, J = 8.9 
Hz, 1H); δC (CDCl3, 125 MHz) 55.9, 56.5, 113.5, 115.6, 115.8, 121.2, 123.7, 126.1, 126.5, 128.66, 128.72, 129.4, 
130.3, 131.9, 135.3, 136.98, 137.00, 155.3, 162.4 (d, J = 246.5 Hz, C-F); MS (APCI): m/z = 266.9 [M++H]. 
(3-(6-Methoxynaphthalen-2-yl)phenyl)methanol, 16a. Synthesised according to Method E using 16b (0.40 g, 
1.53 mmol) and NaBH4 (0.12 g, 3.05 mmol); yield: 0.40 g (100 %); white solid; Rf = 0.50 (DCM / MeOH, 98:2); 
MS (EI): m/z = 312.9, 316.0 [M++H]. 
(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)phenyl)methanol, 17b. Synthesised according to Method E 
using 17c. (4.55 g, 12.50 mmol) and NaBH4 (0.95 g, 25.00 mmol). Then the desired product was taken to the next 
step without further purification; yield: 3.46 g (76 %); white solid; Rf = 0.35 (hexane / EtOAc, 70:30). 
(6-Bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane, 17d. To a solution of 6-bromonaphthalen-2-ol (10.00 
g, 44.80 mmol) and imidazole (3.40 g, 49.30 mmol) in DCM (100 mL) was added dropwise a TBDMS-Cl (7.40 g, 
49.30 mmol) solution in DCM (50 mL). Then the resulting mixture was stirred at rt for 16 hours. After complete 
conversion, water (25 mL) was added, the phases separated, and the aqueous layer extracted with ethyl acetate (3 x 
25 mL). The combined organic phases were washed with brine, dried over Na2SO4 and evaporated under reduced 
pressure. Then the desired product was taken to the next step without further purification; yield: 14.81 g (98 %); 
white solid. 
6-(4-((1H-Imidazol-1-yl)methyl)phenyl)naphthalen-2-ol, 17. To a solution of 17a (3.11 g, 7.50 mmol) in THF 
(50 mL) was added dropwise a 1 M TBAF solution in THF (7.50 mL, 7.50 mmol). Then the resulting mixture was 
stirred at rt for 16 hours. After complete conversion, water (25 mL) and ethyl acetate (25 mL) were added, the 
phases separated, and the aqueous layer extracted with ethyl acetate (3 x 25 mL). The combined organic phases were 
washed with brine, dried over Na2SO4 and evaporated under reduced pressure. Then the desired product was 
purified by chromatography on silica gel; yield: 1.96 g (87 %); brown solid; Rf = 0.50 (EtOAc / MeOH, 95:5); IR 
(ATR) υ (cm-1) 3113 (w), 3026 (w), 1603 (m), 1516 (m), 1235 (s), 1198 (s), 1108 (m), 1080 (m), 831 (s), 806 (s); δH 
(CDCl3, 500 MHz) 5.21 (s, 2H), 6.90 (t, J = 1.0 Hz, 1H), 7.08 (dd, J = 2.4 Hz, J = 8.7 Hz, 1H), 7.11 (d, J = 2.3 Hz, 
1H), 7.20 (t, J = 1.2 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.67 (dd, J = 1.8 Hz, J = 8.6 Hz, 1H), 7.70-7.74 (m, 3H), 7.77 
(t, J = 0.9 Hz, 1H), 7.79 (d, J = 8.9 Hz, 1H), 8.03 (d, J = 1.3 Hz, 1H), 9.82 (s, 1H); δC (CDCl3, 125 MHz) 49.1 
(CH2), 108.4, 119.0, 119.5, 125.0, 125.1, 126.7, 126.8, 127.9, 128.1, 128.7 (Cq), 129.8, 133.7 (Cq), 133.8 (Cq), 136.5 
(Cq), 137.4 , 139.6 (Cq), 155.5 (C-OH); MS (ESI): m/z = 301.0 [M++H]. 
Molecular Modelling. Compound 15 was docked in 50 independent genetic algorithm (GA) runs using GOLD. 
Heme iron was chosen as active-site origin, while the radius was set equal to 19 Å. The automatic active-site 
detection was switched on. A distance constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-
hybridised nitrogen of the pyridine and the iron was set. Further, some of the GOLDSCORE parameters were 
modified to improve the weight of hydrophobic interaction and of the coordination between iron and nitrogen. The 
genetic algorithm default parameters were set as suggested by the GOLD authors. On the other hand, the annealing 
parameters of fitness function were set at 3.5 Å for hydrogen bonding and 6.5 Å for Van der Waals interactions. 
All 50 poses for compound 15 were clustered with ACIAP36, 37 and the representative structure of each 
significant cluster was selected. The quality of the docked representative poses was evaluated based on visual 
inspection of the putative binding modes of the ligands, as outcome of docking simulations and cluster analysis. 
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Abstract 
Novel chemical entities were prepared via Suzuki and SN reaction as AC-ring substrate mimetics of CYP17.  The 
synthesised compounds 1-31 were tested for activity using human CYP17 expressed in E. coli. Promising 
compounds were tested for selectivity against hepatic CYP enzymes (3A4, 2D6, 1A2, 2C9, 2C19, 2B6). Two potent 
inhibitors (27, IC50=373 nM/ 28, IC50=953 nM) were further examined in rats regarding their effects on plasma 
testosterone levels and their pharmacokinetic properties. Compound 28 was similarly active as abiraterone, and 
showed better pharmacokinetic properties (higher bioavailability, t1/2 9.5 h vs 1.6 h). Docking studies revealed two 
new binding modes different from the one of the substrates and steroidal inhibitors.  
Introduction 
Prostate cancer (PC) is currently the most common malignancy and age-related cause of death in elder men 
worldwide. In the US about 220,000 new cases of PC are expected to be newly diagnosed in the year 2007 and 
about 30,000 men will die of this disease.1 Approximately 80% of human prostatic tumors are androgen dependent. 
Consequently the standard treatment of PC is orchidectomy or its medicinal equivalent the chemical castration by 
gonadotropin-releasing hormone (GnRH) analogues, which reduce the testicular androgen production. A major 
disadvantage of these treatments is that they do not affect the adrenal androgen production. Therefore it is frequently 
combined with androgen receptor antagonists (flutamide, cyproterone acetate) to reduce the stimulatory effects of 
the remaining androgens. However, this so called “combined androgen blockade” is not effective in all patients as 
due to mutations in the androgen receptor, anti-androgens might act as agonists.2,3 Thus, the inhibition of CYP17 
(P45017, 17α-hydroxylase-C17,20-lyase) is a promising alternative to the combination of anti-androgens and GnRH 
analogues because testicular and adrenal androgen biosynthesis will both be reduced. 
CYP17, the cytochrome b5 modulated key enzyme in androgen biosynthesis,4 catalyses both the 17α-
hydroxylation of pregnenolone and progesterone and the subsequent 17,20-lyase reaction cleaving the C17-C20 
bond to yield the 17-keto androgens androstendione and dehydroandrostendione (DHEA), the precursors of 
testosterone.5  
Until now the antimycotic ketoconazole was the only CYP17 inhibitor used clinically for the treatment of 
advanced PC to reduce testosterone biosynthesis.6,7 However, this drug is not a very potent inhibitor of CYP17 and 
relatively non-selective regarding the inhibition of other CYP enzymes. Besides it shows a number of notable side 
effects including liver damage. These drawbacks motivated us and others to look for more active and selective 
CYP17 inhibitors (for reviews see: 8-13). 
Recently, the steroidal CYP17 inhibitor abiraterone passed phase II clinical trials showing high activity in post-
docetaxel castration refractory PC patients and seems to have no dose-limiting toxicity.14 We also developed highly 
active steroidal inhibitors, which showed up to 3 fold higher activities against human CYP17 than abiraterone in 
vitro.15 Because of the fact that steroidal drugs are known to show side effects which rely on their scaffold, we also 
developed nonsteroidal inhibitors.16-18 Important for the mode of action of steroidal and nonsteroidal inhibitors is a 
nitrogen bearing heterocycle which is capable of complexing the heme iron of the enzyme. In the class of imidazole-
methyl substituted biphenyls potent inhibitors were discovered.17,18 The biphenyl moiety of these inhibitors should 
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mimic the A- and the C-ring of the substrates (Chart I). Different substituents were introduced in the A-ring trying to 
achieve similar interactions as the oxygen at C3 of the substrates. In this study we exchanged the A- or the C-phenyl 
nuclei by different heterocycles in order to improve the potency of these AC-ring mimetics. In some compounds 
(27-31) methyl and ethyl substituents were introduced in the methylene bridge between imidazole ring and biphenyl 
moiety as we have seen that methyl substituents as well as the rigidified indane compounds are appropriate to 
increase CYP17 inhibition in some cases.17,18 
This approach was chosen to study other possible interactions between active site and ligand. In the following, 
the synthesis of the compounds shown in Scheme 1 and the determination of their inhibitory potency toward human 
CYP17 are described. Selected compounds were tested for their inhibition of hepatic CYP enzymes (3A4, 1A2, 2C9, 
2C19, 2B6 and 2D6). Two potent inhibitors, compounds 27 and 28 were examined for their potential of reducing 
plasma testosterone levels in rats and their pharmacokinetic properties. Docking studies and molecular electrostatic 
potential (MEP) calculations were performed in order to elucidate some interesting structure-activity relationships. 
Chart I. Schematic representation of Abiraterone and the scaffold of our biaryl inhibitors. 
 
Chemistry 
The syntheses of compounds 1-31 are shown in Schemes 2-8. After an eventual derivatisation of the A- or C-
ring, both rings were coupled by means of a palladium catalysed Suzuki cross coupling reaction (Method B), and a 
nitrogen containing heterocycle was attached subsequently. The derivatisations carried out on the rings were mostly 
brominations and reductions of the carbonyl compounds to the corresponding alcohols, since the Suzuki coupling is 
described to give higher yields when using carbonyl substituted compounds instead of alcohols.19 For the synthesis 
of some compounds, the introduction of the imidazole moiety before the coupling was possible (Schemes 4, 5), 
allowing a wider range of substitution patterns. Two different reaction types for the introduction of the 1H-
imidazole were used resulting in comparable yields, an SN2 reaction between imidazole and the corresponding 
bromide (Schemes 2, 5; Method A), and an SNt reaction between 1,1-carbonyl diimidazole (CDI) and the 
corresponding alcohol20 (Schemes 3, 4, 6 and 8; Method E). The carbonyl compound was generally reduced with 
NaBH4 (Schemes 3, 4, 6 and 8; Method C). For the synthesis of compounds 14, 30 and 31 the introduction of the 
alkyl substituent at the methylene bridge was performed via Grignard reaction (Schemes 3, 8; Method D). In order 
to introduce the C-C linked imidazole, a protection with trityl chloride was necessary before submitting the 
compound to a lithium-halogen exchange (Scheme 7) like reported previously by Tasaka et al.21 
N
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compound R1 R2 R3 X 
1 H OMe H  
2 H H H  
3 F H H  
4 F F H  
5 OMe H H  
6 H H OMe  
7 H NH2 H  
8 OMe OMe H  
10 H H H  
11 F H H  
12 OMe H H  
13 H OMe H  
14 F F H  
15 F F Et  
16 OMe OMe H  
17 H   CH 
18 F   CH 
19 CH2Cl   CH 
20 H   N 
22  H   
23  Et   
25 H H H O 
26 4-Me H H S 
27 H H Et S 
28 H H Me S 
29 4-Me H Et S 
30 4-Me F Et S 
31 2-Cl H Et S 
Scheme 1. List of synthesised compounds 1-31. 
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Results  
Biological results 
Inhibition of CYP17 was evaluated using human enzyme expressed in E.coli.22 The percent inhibition values of 
the compounds were determined with the 50,000 g sediment of the E. coli homogenate, progesterone (25 µM) as 
substrate and the inhibitors at a concentration of 0.2 µM and 2.0 µM. Separation of substrate and product was 
accomplished by HPLC using UV detection.23a 
The inhibitory activities of the C-ring modified compounds 1-16 toward human CYP17 are shown in Table 1. It 
becomes apparent that the C-ring pyridyl compounds 1-9 are inactive, independent from their substitution pattern at 
the A-ring. On the contrary, the C-ring thiophenyl compounds 10-16 show low to moderate activity. In case of the 
methylene bridge unsubstituted compounds (10-14, 16), it can be observed that the introduction of fluorine 
substituents and the 3-methoxy group in the A-ring does not alter the activity in regard to the unsubstituted 
compound whereas the 4-methoxy compounds (12, 16) exhibit reduced activity. Interestingly, the introduction of an 
ethyl group at the methylene bridge (compound 15) leads to a strong increase in activity for compound 14.  
Table 1. Inhibition of CYP17 by compounds 1-16 
N
N NR
3
R2
R1
S
N
R1
R2 N
R3
1-8 10-16
N
N N
9
F
 
 
Comp. 
Structures CYP17   
R1 R2 R3 % Inhibition 
a 
0.2 µM 2 μM 
1 H OMe H 0 1 
2 H H H 0 4 
3 F H H 5 5 
4 F F H 0 0 
5 OMe H H 0 0 
6 H H OMe 0 5 
7 H NH2 H 2 3 
8 OMe OMe H 1 2 
9    0 2 
10 H H H 0 21 
11 F H H 0 20 
12 OMe H H 0 13 
13 H OMe H 0 24 
14 F F H 7 25 
15 F F Et 17 68 
16 OMe OMe H 0 14 
a Concentration of progesterone (substrate): 25 μM; standard deviations were within < ±5 % 
In Table 2 the inhibition values of the A-ring modified compounds 17-31 are presented in comparison to 
ketoconazole and abiraterone. Neither the substitution by a pyridine (17-19) nor a pyrimidine (20) or a morpholine 
(21) leads to moderate activity. On the other hand in the class of the thiophenyl compounds 22-24 and 26-31 highly 
active inhibitors were obtained. The most active compounds bear an alkyl (methyl or ethyl) substituent at the 
methylene bridge. The ethyl compound 27 (IC50 = 373 nM) has a 3 fold higher activity compared to the methyl 
compound 28 (IC50 = 953 nM). The methyl group in 4-position of the thiophene in compound 29 (IC50 = 584 nM) 
slightly reduces the activity of compound 27. Both the insertion of a fluorine atom at the C-ring (compound 30, IC50 
= 236 nM) and the exchange of the 4-methyl group by a 2-chloro substituent at the thiophene (compound 31, IC50 = 
263 nM) increased the potency and led to the most active inhibitors of this study. 
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The selectivity of selected compounds toward hepatic CYP enzymes was investigated in regard of their 
important role in drug metabolism. The most critical one is CYP3A4 as it is involved in the metabolism of 50 % of 
the commercial drugs. Inhibition of this enzyme can result in severe side-effects because of a known genetic 
polymorphism. The compounds tested showed inhibition of this enzyme (Table 2). However, it was significantly 
lower than that for ketoconazole which is used clinically as an antimycotic. Besides 3A4 five other hepatic enzymes 
1A2, 2C9, 2C19, 2B6 and 2D6 are also important for drug metabolism; for CYP2D6 a genetic polymorphism is 
described too.  In contrast to ketoconazole and abiraterone our compounds showed strong inhibitory activities at 
concentrations of 10 µM (Table 3).  
Table 2. Inhibition of CYP17 and CYP3A4 by compounds 17-31 
N
N
N NH
OH
S
24
X
NR1
17-20
N
N
N
O
21
N
S
MeS
R1
22,23
N
R3
X
25-31
R2
R1N N
 
 
Comp. 
Structures Human CYP17 c Rat CYP17 c 
 
  
 
CYP3A4 
R1 R2 R3 X 
% Inhibition 
IC50 [nM] d IC50 [nM] d 
% Inhibition 
0.2 μM 2 μM 1 μM 10 μM 
17 H   CH 2 14     
18 F   CH 4 13     
19 CH2Cl   CH 9 24     
20 H   N 5 3     
21     5 12     
22 H    3 35     
23 Et    2 3     
24     7 49     
25 H H H O 3 29     
26 4-Me H H S 0 27     
27 H H Et S 28 83 373 562 88 92 
28 H H Me S 21 67 953 676 80 94 
29 4-Me H Et S 27 84 584    
30 4-Me F Et S 41 92 236  88 97 
31 2-Cl H Et S 40 85 263  87 97 
KTZ a     19 b 2780  96 98 
ABT a       72 220e 4 25 
 
a KTZ: ketoconazole; ABT: abiraterone. 
b % Inhibition at 1.0 μM 
c Concentration of progesterone (substrate): 25 μM; standard deviations were within < ±5 % 
d Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 % 
e Ref.: 15 
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Table 3. Inhibition of hepatic CYP enzymes by compounds 15, 27 and 28. 
 
Comp. 
CYP1A2 CYP2C9 CYP2C19 CYP2B6 CYP2D6 
% Inhibitionb % Inhibitionb % Inhibitionb % Inhibitionb % Inhibitionb 
1 μM 10 μM 1 μM 10 μM 1 μM 10 μM 1 μM 10 μM 1 μM 10 μM 
15 93 96 94 100 95 97     
27 98 100 81 74 95 100 60 87 24 77. 
28 97 100 75 89 87 99 49 87 17 68 
KTZ a 8 38 21 75 24 79 11 57 1 4 
ABT a 36 53 17 51 3 21 2 11 7 7 
a KTZ: ketoconazole; ABT: abiraterone. 
b standard deviations were within < ±5 % 
After it has been demonstrated that compounds 27 and 28 also inhibited the rat enzyme (Table 2), they were 
chosen for in vivo studies to investigate the influence of the methyl substituent versus the ethyl substituent at the 
methylene bridge. Both were evaluated for reduction of the plasma testosterone concentration (Table 4) and for 
pharmacokinetic parameters (Table 5) in male Wistar rats using abiraterone as a reference compound. All 
compounds reduced significantly the plasma testosterone levels. Compounds 27 and 28 showed strong effects 
already after 1 h. Abiraterone which was administered as a prodrug (acetate) exhibited maximum activity after 2 h. 
At 6 and 8 h abiraterone and compound 28 still showed high activity whereas compound 27 showed decreased 
effects. It is surprising that abiraterone is not more active than 28 since it is a stronger inhibitor of rat CYP17 (IC50 = 
220 nM, Table 2). This finding can be explained by the pharmacokinetic properties of the compounds which differ 
strongly. From Table 5 it becomes apparent, that abiraterone exhibits a low bioavailability. The plasma half-lives of 
compound 28 (9.5 h) and abiraterone (1.6 h) are also different. The comparatively long duration of activity seen 
after application of abiraterone acetate is caused by the fact that the ester cleavage gradually takes place. 
Table 4. Reduction of the plasma testosterone concentrations in rats by compounds 27 and 28 a 
Comp. 
Relative plasma testosterone level (%) b 
1h 2h 4h 6h 8h 
Control 143.1 ± 13.3 76.4 ±13.3 81.4 ± 24.6 109.6 ± 31.7 90.6 ± 22.8 
27 37.6 ± 14.8 c 30.5 ± 13.9 c 26.9 ± 12.1 d 62.6 ± 44.6 63.0 ± 26.4 
28 30.9 ± 7.2 e n.d. 25.9 ± 8.1 e 29.7 ± 12.6 c 34.1 ± 13.5 d 
Abiraterone 
acetate 
92.5 ± 43.1 44.0 ± 14.7 c 43.5 ± 12.4 d 43.3 ±12.8 c 35.6 ± 9.7 d 
a 27 and 28 were applied at a dose of 50 mg / kg body weight, abiraterone acetate at a dose of 56.02 mg / kg (corresponding to 50 mg / kg 
abiraterone) 
b The plasma testosterone concentrations at pre-treatment time points (-1, -0.5 and 0h) were averaged and set to 100 %. The values shown 
above are the relative levels compared to the pre-treatment value. 
c P < 0.05, d P < 0.01, e P < 0.001 
n.d.: not determined 
Table 5. Pharmacokinetic properties of compounds 27 and 28 a 
comp. t ½ z (h)b t max (h)b C max (ng / mL)b AUC0-∞ (ng x h / mL)b CL (l / kg / h)b 
27 3.8 1.0 1745 6700 7.48 
28 9.5 1.0 1277 24900 2.01 
abiraterone 
acetate 
1.6 2.0 592 4015 11.21 
a 27 and 28 were applied at a dose of 50 mg / kg body weight, abiraterone acetate at a dose of 56.02 mg / kg (corresponding to 50 mg / kg 
abiraterone) 
b t ½ z: terminal half-life; t max: time of maximal concentration; C max: maximal concentration; AUC0-∞: area under  the curve; CL: total body 
clearance (during elimination phase; assumes F=1) 
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Molecular modelling studies
No crystal structure for CYP17 is currently available, for that reason we built a homology model based on the 
crystal structure of human CYP2C9. Based on the different activities of compounds shown in table 1 and 2, docking
simulations were carried by means of the GOLD v3.0.1 software.25 The non chiral compound 22 and both 
enantiomers of compounds 23 and 27-31 were docked to explore the active site of the enzyme and to investigate 
their binding mode. Based on the suggestion that our compounds are substrate-mimetics, their binding mode was 
presumed to be similar to the one of the steroidal substrates and the steroidal inhibitors abiraterone and Sa4015.
Abiraterone was docked into our protein model and the same binding mode as described for the substrates was 
found.26-27 The lone pair of the sp2 hybridised nitrogen pointed perpendicular toward the heme iron. The steroidal 
scaffold was oriented almost parallel to the heme plane in the direction of the BC-loop. This pose was stabilized by 
hydrophobic interactions with Ile371, Ile112, Ala113 and Phe114.26-27 Additionally, the highly conserved Arg96 
which is important for substrate binding and recognition, as shown by site directed mutagenesis,28 showed 
interactions of the same kind with the steroidal A-ring. Another important interaction was the H-bond between the 
hydroxy group in C3 position and the backbone carbonyl group of Gln98.
Based on the analysis of the docking results of both enantiomers of our chiral compounds we could identify the 
eutomers (scoring values and deviations of docked pose of ligand to its global energetic minimum were considered). 
The poses of compound 22 and of the eutomers of 23 and 27-31 indicated two different orientations compared to 
that of the steroidal inhibitors, a primary binding mode 1 (BM1: 22, 23 R, GoldScore values: in a range from 48.35 
to 53.45; 29 R, 30 R, 31 R, GoldScore values: in a range from 67.68 to 72.02), preferred from the statistical and 
interaction pattern points of view, and an alternative binding mode 2 (BM2: 27 S, 28 S, GoldScore values: in a range 
from 64.85 to 69.89) (Figure 1). Compounds 22-23 and 27 showed poses in only one of the binding modes, while 
the other compounds were found in both ones with a clear preference for the binding mode as described above.
Starting point for these docking studies was the complexation of the heme iron by the sp2 hybridized imidazole 
nitrogen, as it is experimentally shown that CYP inhibitors with a sterically accessible aromatic nitrogen coordinate 
in this way.15 Both binding modes have in common the anchoring of the alkyl substituent in a hydrophobic pocket 
(Figure 1A and 1B) next to the heme, which is delimitated in its extent by the alkyl side-chains of Ile371, Val366, 
Ala367 and Thr306 (Figure 1A). The fact that compounds without methyl or ethyl substituents show no or little 
activity (Tables 1 and 2) indicates that interactions with this hydrophobic pocket are very important for inhibitory 
activity. Decisive for the different binding modes is the absence or presence of an ortho substituent at the thiophenyl 
ring leading to planar, thin (27, 28) or twisted, thicker (29-31) biaryl cores of the ligands. To better understand the 
influence of electron-withdrawing or -releasing substituents on both A- and C-rings on the binding mode, molecular 
electrostatic potential (MEP) maps were plotted with GaussView 3.053 in a range of ± 12.5 kcal/mol.
Figure 1. (A) Docking complexes between CYP17 and compounds 30 (green), 27 (magenta) and abiraterone 
(yellow). Further, haeme, interacting residues and ribbon rendered tertiary structure of the active site are shown. 
Figures were generated with Pymol (http://www.pymol.org). (B) A crosssection of the solvent accessible surface of 
CYP17 is shown in orange, revealing the active-site cavity with docked abiraterone (yellow) and all compounds in 
BM1 (29–31; green) and BM2 (27–28 magenta).
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Binding mode 2 (BM2):  
Striking in this binding mode are the sterical limitations for the biaryl moiety. This is the reason why only 
ligands with a planar conjugated π-system (27 and 28) bind in this mode. The described anchoring of the alkyl 
substituent in the hydrophobic pocket causes the biaryl core of compounds 27 and 28 to cross the I-helix at the kink. 
29 The thiophene-sulphur points toward the peptide bonds of Gln199 and Asn200 (F-helix), and undergoes 
electrostatic interactions with these amino acids. The thiophenyl ring forms hydrophobic interactions with the alkyl-
groups of Gln199, Asn202, Glu203 and Ile206. The C-ring interacts with the hydrophobic alkyl side-chains of 
Val304 and Glu305 (Figure 1).  
Binding mode 1 (BM1):  
Ligands which fit in this orientation carry an ortho-substituent (29-31). The latter disrupts the conjugated π-
system, thus twisting the angle between both rings and demanding more space. This hydrophobic, thicker biaryl core 
comes to lie almost parallel to the I-helix (Figure 1). The lipophilic region delimitated by the kink (Gly301-Ala302-
Gly303) allows good π-π-stacking with the C-ring. As MEP maps have shown, an electron withdrawing group at the 
C-ring, like fluorine (30), or in ortho-position on the thiophene, like chlorine (31), leads to a lower electron density 
on the C-ring (see Figure 2). As a consequence of this, an improvement of the π-π interactions between the π-system 
of this ring and the protein environment, namely the I-helix, could be observed. As a further evidence of this 
observation, compounds 1-9, bearing a pyridine as C-ring, highly increasing the electron density there (MEP map 
not shown), shows a total loss of activity.  
Additionally, the electronegative fluorine atom can form electrostatic interactions with the backbone atoms of 
Gly301, Ala302 and Val304, which is in agreement with the improved activity of compound 30. 
Further, in this binding mode the sulphur of the 3-thiophene points toward the polar side-chain of Arg109, 
allowing electrostatic interactions between the free electron pair (and perhaps d-orbitals) of the sulphur and the polar 
groups of Arg109 and Asp298. In addition the aromatic system of the thiophene ring undergoes T-shaped (edge-to-
face) packing with Phe114, which is stabilised by Arg109, forming a very strong complex. The sulphur atom of the 
2-thiophenyls (22, 23) is located in a different region, thus being unable to undergo these electrostatic interactions. 
This might be one reason for the lack of activity of these compounds. It is striking that in this binding mode there 
seems to be space for the annelation of additional rings at the A- or C-ring of the biaryl moiety. 
Both, the electron donating 5-ortho-methyl (29, 30) and the electron withdrawing 2-ortho-chlorine (31) 
substituents decrease the electron density on the thiophene and enhance its dipole moment (negatively charged on 
the sulphur-C2-bond and positively on the methyl group; see MEP figure 2). The resulting relatively weak 
electronegativity of sulphur confers a strong aromatic character on the thiophene ring, leading to better π-π-stacking 
with the enzyme.  
 
Figure 2. MEP of compounds 27, 29, 30 and 31. The electrostatic potential surfaces were plotted with GaussView 
3.0 in a range of ± 12,5 kcals/mol. 
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Even more, the 5-Me group points away from the heme and could form hydrophobic interactions with Ile206. In 
contrast, the chlorine in 31 points toward the heme and seems to be capable of both hydrophobic (with Ile112, 
Ala113 and the hydrophobic CH2-groups of Asp298) and electrostatic interactions (with the carboxylate group of 
Asp298, involved in a charge-cluster with Arg109 and His235). 
Discussion and Conclusion 
From the data shown in this paper it becomes apparent, that we succeeded in finding new lead compounds as 
inhibitors of CYP17. They are very potent toward the target enzyme and show less inhibition of CYP3A4 compared 
to ketoconazole which is used clinically. However, their inhibition of some other hepatic CYP enzymes is still too 
high and needs to be further improved. 
The structure-activity relationships obtained in this study demonstrate that an alkyl substituent at the methylene 
bridge fitting into the hydrophobic pocket near the heme strongly contributes to the inhibitory potency. It also seems 
that electron withdrawing groups like chlorine and fluorine at the A- or C-ring are appropriate for increasing 
inhibition and show influence on the binding mode.  
Very important is the finding that compounds of this series (27 and 28) showed strong in vivo activities and 
pharmacokinetic properties in the rat which were similar to those of abiraterone. 
Interestingly, in the molecular modelling studies two distinct binding modes of our biaryl compounds were 
discovered, differing from the binding of the steroidal substrates and inhibitors observed by us and others.26-27  From 
these findings the design of modified ligands which should show a stronger interaction with the active site could be 
possible. On the one hand enlargement of the ligands binding in BM1 might be envisaged by annelation of 
additional rings to the A- or C-ring. On the other hand it could also be examined to design compounds which fill 
both binding cavities. Compounds modified in that way should be good candidates for showing less inhibition of 
hepatic CYP enzymes than the compounds of the present study. Those compounds should clinically be superior to 
the GnRH analogues which are presently used for the treatment of androgen dependent prostate cancer as they 
additionally block adrenal androgen formation thus decreasing androgen levels below those of castration. 
Experimental Section 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli22 (coexpressing human CYP17 and NADPH-P450 reductase) and the 
assay was performed as previously described.23a  
Rat testicular CYP17 was obtained from adult male Sprague-Dawley rats and the assay was performed as 
previously described.23b 
Inhibition of hepatic CYP enzymes 
The recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were used 
and the manufacturer’s instructions (www.gentest.com) were followed. 
In vivo study 
The in vivo tests were performed in intact adult male Wistar rats (Harlan Winkelmann, Germany), 5 to 6 for each 
compound. These rats were cannulated with silicone tubing via the right jugular vein. The compounds were applied 
p.o. at 50 mg / kg body weight. The concentrations of testosterone in the rat plasma were determined using the 
Testosterone ELISA (EIA - 1559) from DRG Instruments according to the manufacturer’s instructions. The plasma 
drug levels were measured by LC-MS. Non-compartmental pharmacokinetic analysis of concentration vs time data 
was performed for each compound on the mean plasma level using a validated computer program (PK solution 2 
software; Summit Research Services, Montrose, USA). Plasma concentrations below the limit of detection were 
assigned a value of zero. 
Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra were 
recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a Bruker DRX-
500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an internal standard for 
spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray ionization) mass spectra 
were determined on a TSQ quantum (Thermo Electron Corporation) instrument. Elemental analyses were performed 
at the Department of Instrumental Analysis and Bioanalysis, Saarland University. Column chromatography was 
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performed using silica-gel 60 (50-200 µm), and reaction progress was determined by TLC analysis on Alugram® 
SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as starting materials were commercially 
obtained (CombiBlocks, Chempur, Aldrich, Acros). 
5-Bromo-2-picoline, 1c. 2-Picoline (46.60 g, 0.50 mol) was added under nitrogen to mechanically stirred 
aluminium chloride (200.00 g, 1.50 mol). This slurry was heated under stirring to 100 °C, and bromine (40.00 g, 
0.25 mol) was added over a period of 1 h. The heating was continued at 100 °C for 0.5 h. The reaction mixture was 
poured into 2 L of ice water containing 75 mL of concentrated HCl. Additional concentrated HCl was added until 
the mixture became acidic (pH 3). Excess NaHSO3 (solid) was added, and the mixture was left overnight at room 
temperature, filtrated, and extracted with methylene chloride (3 x 150 mL). The aqueous phase was alkalised with 
50% aqueous NaOH solution and extracted with ether (4 x 150 mL). The combined organic extracts were washed 
with brine (100 mL) and dried. Solvent removal gave a residue, which was chromatographed on silica gel using a 
mixture of EtOAc / MeOH (95:5) as solvent; yield: 4.56 g (26.7 mmol, 11 % of 0.25 mol bromine used); colourless 
solid; Rf = 0.68 EtOAc / MeOH, 95:5); δH (CDCl3, 500 MHz) 2.51 (s, 3H), 7.05 (d, J = 8.2 Hz, 1H), 7.68 (dd, J = 
2.5, 8.2 Hz, 1 H), 8.55 (d, J = 2.5 Hz, 1H); δC (CDCl3, 75 MHz) 23.8 (CH3), 117.6 (Cq), 124.6 (CH), 138.8 (CH), 
150.1 (CH), 156.9 (Cq); MS (ESI): m/z = 172 [M++H]. 
2-Bromo-5-(bromomethyl)pyridine, 1b. 2-Bromo-5-methylpyridine (3.00 g, 17.40 mmol) was dissolved in 40 
mL of dry carbon tetrachloride. To this solution was added N-bromsuccinimide (NBS) (3.41 g, 19.20 mmol) and 
benzoyl peroxide (0.23 g, 0.80 mmol) and the mixture was refluxed over night. After cooling, the succinimide was 
removed by filtration and the filtrate was concentrated under vacuum. The crude product was further purified by 
flash column chromatography on silica gel using a mixture of petroleum ether / EtOAc (95:5) as eluent; yield: 2.56 g 
(59 %); lachrymatory yellow needles; IR (ATR) υ (cm-1) 3030 (m), 2923 (w), 2365 (w), 1994 (w), 1577 (s), 1556 
(m), 1470 (s), 1451 (s), 1396 (m), 1379 (s), 1294 (s), 1097 (s), 920 (m), 838 (s), 810 (m), 727 (s), 645 (s), 623 (m); 
δH (CDCl3, 500 MHz) 4.14 (s, 2H), 7.47 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 8.2 Hz, 1H), 8.38 (s, 1H); MS (ESI): m/z = 
252 [M++H]. 
5-Bromo-2-(bromomethyl)pyridine, 9b. Compound 1c (3.00 g, 17.40 mmol) was dissolved in 40 mL of dry 
carbon tetrachloride. To this solution was added NBS (3.41 g, 19.20 mmol) and benzoyl peroxide (0.24 g, 0.80 
mmol) and the mixture was refluxed over night. After cooling, the succinimide was removed by filtration and the 
filtrate was concentrated under vacuum. The crude product was further purified by flash column chromatography on 
silica gel using petroleum ether / EtOAc (95:5) as eluent; yield: 1.70 g (39 %); lachrymatory lilac oil; IR (ATR) υ 
(cm-1) 3038 (m), 3006 (m), 2919 (w), 2361 (w), 1983 (w), 1575 (s), 1468 (s), 1448 (s), 1374 (s), 1290 (s), 1090 (s), 
1009 (s), 915 (m), 828 (s), 806 (m), 718 (s), 635 (s), 616 (m) δH (CDCl3, 500 MHz) 4.24 (s, 2H), 7.16 (d, J = 8.2 Hz, 
1H), 7.78 (dd, J = 2.5, 8.2 Hz, 1 H), 8.65 (d, J = 2.5 Hz, 1H); δC (CDCl3, 75 MHz) 24.1 (CH2), 118.4 (Cq), 126.5 
(CH), 138.8 (CH), 151.2 (CH), 157.8 (Cq); MS (ESI): m/z = 252 [M++H]. 
Method A: Nucleophilic Substitution with imidazole 
The α-brominated compound (1b, 9b), imidazole (2 eq), a catalytical amount of 18-crown-6 and anhydrous 
K2CO3 (1.5 eq) in dry acetonitrile were heated under reflux over night. After the solution was cooled down, the 
solvent was removed under reduced pressure. The residue was dissolved with water (10 mL / eq) and extracted three 
times with CH2Cl2 (15 mL / eq). The combined organic extracts were washed with brine, dried over anhydrous 
Na2SO4, filtered and evaporated. The crude material was purified by flash-chromatography on silica-gel, using 5% 
MeOH in CH2Cl2. 
5-((1H-Imidazol-1-yl)methyl)-2-bromopyridine, 1a. Synthesised according to Method A using 1b (1.32 g, 
5.26 mmol), imidazole (0.75 g, 11.00 mmol), K2CO3 (1.13 g, 8.16 mmol) and 18-crown-6; yield: 0.75 g (60 %); 
yellow solid; Rf = 0.33 (EtOAc / MeOH, 9:1); δH (CDCl3, 500 MHz) 5.12 (s, 2H), 6.88 (t, J = 1.2 Hz, 1H), 7.13 (s, 
1H), 7.28 (d, J = 2.5 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.56 (s, 1H), 8.28 (d, J = 2.5 Hz, 1H); MS (ESI): m/z = 239 
[M++H]. 
2-((1H-Imidazol-1-yl)methyl)-5-bromopyridine, 9a. Synthesised according to Method A using 9b (1.18 g, 
4.70 mmol), imidazole (0.72 g, 9.60 mmol), K2CO3 (1.00 g, 7.24 mmol) and 18-crown-6; yield: 0.81 g (72 %); 
yellow solid: Rf = 0.30 (EtOAc / MeOH, 9 :1); δH (CDCl3, 500 MHz) 5.19 (s, 2H), 6.83 (d, J = 8.5 Hz, 1H), 6.96 (bs, 
1H), 7.10 (s, 1H), 7.59 (s, 1H), 7.76 (dd, J = 2.1, 8.5 Hz, 1H), 8.62 (d, J = 2.1 Hz, 1H); MS (ESI): m/z = 239 
[M++H]. 
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1-(4-Bromobenzyl)-1H-imidazole, 17a. Synthesised according to Method A using 1-bromo-4-
(bromomethyl)benzene (6.25 g, 25.00 mmol), imidazole (6.80 g, 0.10 mol), K2CO3 (28.00 g, 0.20 mol) and 18-
crown-6; yield: 5.06 g (85 %); Rf = 0.19 (EtOAc); IR (ATR) υ (cm-1) 3111 (w), 1508 (m), 1489 (m), 1232 (m), 1072 
(s), 1012 (m), 802 (s), 744 (s), 662 (s), 607 (m); δH (CDCl3, 500 MHz) 5.00 (s, 2H), 6.81 (s, 1H), 6.94 (d, J = 8.4 Hz, 
2H), 7.02 (s, 1H), 7.40 (d, J = 8.4 Hz, 2H), 7.46 (s, 1H); δC (CDCl3, 125 MHz) 52.9 (CH2), 118.2 (CH), 121.3 (Cq), 
127.9 (CH), 129.0 (CH), 131.1 (CH), 134.2 (Cq), 136.3 (CH); MS (ESI): m/z = 239/237 [M++H]. 
Method B: Suzuki-Coupling 
The corresponding brominated aromatic compound (1 eq) was dissolved in toluene (7 mL / mmol), an aqueous 
2.0 M Na2CO3 solution (3.2 mL / mmol) and an ethanolic solution (3.2 mL / mmol) of the corresponding boronic 
acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure and flushed with nitrogen. 
After repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the resulting suspension was heated 
under reflux for 8 h. After cooling ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was 
separated. The water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed 
with brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel.  
5-((1H-Imidazol-1-yl)methyl)-2-(3-methoxyphenyl)pyridine, 1. Synthesised according to Method B using 
compound 1a (0.20 g, 0.84 mmol) and 3-methoxyphenylboronic acid (0.19 g, 1.26 mmol); yield: 0.05 g (18 %); 
yellow solid: mp 99 °C; Rf = 0.31 (CH2Cl2 / MeOH, 95:5); IR (ATR) υ (cm-1) 2962 (w), 2926 (w), 1565 (m), 1477 
(m), 1261 (m), 1072 (m), 1023 (s), 799 (m), 766 (s), 665 (m); δH (CDCl3, 500 MHz) 3.85 (s, 3H), 5.13 (s, 2H), 6.89 
(s, 1H), 6.94 (ddd, J = 0.9, 2.5, 8.2 Hz, 1H), 7.09 (s, 1H), 7.34 (t, J = 8.2 Hz, 1H), 7.44 (dd, J = 2.5, 8.2 Hz, 1H), 
7.49 (m, 1H), 7.54 (m, 1H), 7.66 (d, J = 8.2 Hz, 1H), 8.53 (d, J = 2.2 Hz, 1H); δC (CDCl3, 125 MHz) 48.0 (CH2), 
55.3 (CH3), 112.1 (CH), 115.3 (CH), 119,0 (CH), 119.2 (CH), 120.6 (CH), 129.8 (CH), 130.1 (Cq), 130.2 (CH), 
135.7 (CH), 137.2 (CH), 140.0 (Cq), 148.4 (CH), 157.3 (Cq), 160.0 (Cq); MS (ESI): m/z = 252 [M++H]. 
5-((1H-Imidazol-1-yl)methyl)-2-phenylpyridine, 2. Synthesised according to Method B using compound 1a 
(0.20 g, 0.84 mmol) and phenylboronic acid (0.20 g, 1.68 mmol); yield: 0.10 g (57 %); yellow solid: mp 99 °C; Rf = 
0.35 (CH2Cl2 / MeOH 95:5); IR (ATR) υ (cm-1) 2925 (s), 1503 (m), 1476 (s), 1344 (m), 1290 (m), 1110 (m), 1081 
(s), 908 (m), 839 (s), 731 (s), 625 (m); δH (CDCl3, 500 MHz) 5.19 (s, 2H), 6.94 (t, J =1.3 Hz, 1H), 7.13 (s, 1H), 
7.48-7.50 (m, 4H), 7.60 (s, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.97-7.99 (m, 1H); δC (CDCl3, 125 MHz) 48.1 (CH2), 
119.0 (CH), 120.6 (CH), 126.9 (CH), 128.8 (CH),  130.0 (CH), 130.4 (Cq), 135.7 (CH), 137.3 (CH), 138.6 (Cq), 
148.6 (CH) 157.7 (Cq); MS (ESI): m/z = 236 [M++H]. 
5-((1H-Imidazol-1-yl)methyl)-2-(4-fluorophenyl)pyridine, 3. Synthesised according to Method B using 
compound 1a (0.20 g, 0.84 mmol) and 4-fluorophenylboronic acid (0.23 g, 1.68 mmol); yield: 0.16 g (76 %); yellow 
solid: mp 95 °C; Rf = 0.15 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 3101 (w), 1598 (m), 1511 (m), 1478 (m), 1390 
(w), 1231 (m), 1083 (m), 1026 (w), 910 (w), 824 (w), 770 (m), 737 (s), 663 (m); δH (CDCl3, 500 MHz) 5.18 (s, 2H), 
6.92 (s, 1H), 7.12 (bs, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.48 (dd, J = 2.2, 8.2 Hz, 1H), 7.60 (s, 1H), 7.67 (d, J = 8.2 Hz, 
1H), 7.97 (dd, J = 5.4, 8.8 Hz, 2H), 8.57 (d, J = 1.9 Hz, 1H); δC (CDCl3, 125 MHz) 48.1 (CH2), 115.7 (d, 2JCF = 22.1 
Hz, CH), 119.0 (CH), 120.2 (CH), 128.7 (d, 3JCF = 8.6 Hz, CH), 130.0 (Cq), 130.4 (CH), 134.7 (d, 4JCF = 3.9 Hz, Cq), 
135.8 (CH), 137.3 (CH), 148.6 (CH), 156.6 (Cq), 163.7 (d, 1JCF = 249.5 Hz, Cq); MS (ESI): m/z = 254 [M++H]. 
5-((1H-Imidazol-1-yl)methyl)-2-(3,4-difluorophenyl)pyridine, 4. Synthesised according to Method B using 
compound 1a (0.20 g, 0.84 mmol) and 3,4-difluorophenylboronic acid (0.27 g, 1.68 mmol); yield: 0.21 g (91 %); 
yellow solid: mp 100 °C, Rf = 0.16 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 3106 (w), 2930 (w), 2856 (w), 1599 
(m), 1567 (m), 1523 (s), 1507 (s), 1481 (s), 784 (s); δH (CDCl3, 500 MHz) 5.18 (s, 2H), 6.92 (t, J = 1.3 Hz, 1H), 
7.13 (t, J = 1.3 Hz, 1H), 7.25 (ddd, J = 8.2, 8.5, 9.8 Hz, 1H), 7.49  (dd, J = 2.5, 8.2 Hz, 1H), 7.59 (s, 1H), 7.66 (dd, J 
= 0.6, 8.3 Hz, 1H), 7.69–7.73 (m, 1H), 7.86 (ddd, J = 2.2, 7.6, 11.4 Hz, 1 H), 8.56 (dd, J = 0.6, 2.3 Hz, 1H); δC 
(CDCl3, 125 MHz) 48.0 (CH2), 116.0 (d,2 JCF = 18.2 Hz, CH), 117.6 (d, 2JCF = 17.3 Hz, CH), 119.0 (CH), 120.2 
(CH),  122.8 (dd, 4JCF = 3.8 Hz, 3JCF = 6.7 Hz, CH), 130.4 (CH), 130.6 (Cq), 135.6 (dd, 4JCF = 3.8 Hz, 3JCF = 5.8 Hz, 
Cq), 135.9 (CH), 137.3 (CH), 148.6 (CH), 150.8 (dd, 2JCF = 20.2 Hz, 1JCF = 255.3 Hz, Cq), 151.3 (dd, 2JCF = 15.4 Hz, 
1JCF = 254.3 Hz, Cq), 155.3 (Cq); MS (ESI): m/z = 272 [M++H]. 
5-((1H-Imidazol-1-yl)methyl)-2-(4-methoxyphenyl)pyridine, 5. Synthesised according to Method B using 
compound 1a (0.40 g, 1.68 mmol) and 4-methoxyphenylboronic acid (0.38 g, 3.35 mmol); yield: 0.40 g (89 %); 
yellow solid: mp 138 °C; Rf = 0.15 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 2962 (w), 2928 (w), 1597 (m), 1478 
(m), 1249 (s), 1174 (m), 1023 (m), 828 (s), 814 (s), 762 (s); δH (CDCl3, 500 MHz) 3.86 (s, 3H), 5.16 (s, 2H), 6.92 (t, 
J = 1.3 Hz, 1H), 6.99 (d, J = 9.1 Hz, 2H), 7.11 (s, 1H), 7.46 (dd, J = 2.5, 8.2 Hz, 1H), 7.59 (s, 1H), 7.66 (d, J = 8.2 
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Hz, 1H), 7.94 (d, J = 9.1 Hz, 2H), 8.54 (d, J = 2.5 Hz, 1H); δC (CDCl3, 125 MHz) 48.1 (CH2), 55.4 (CH3), 114.2 
(CH), 119.0 (CH), 119.8 (CH), 128.2 (CH), 129.2 (Cq), 130.3 (CH), 131.2 (Cq), 135.7 (CH), 137.3 (CH), 148.5 
(CH), 157.4 (Cq), 160.8 (Cq); MS (ESI): m/z = 266 [M++H]. 
5-((1H-Imidazol-1-yl)methyl)-2-(2-methoxyphenyl)pyridine, 6. Synthesised according to Method B using 
compound 1a (0.20 g, 0.84 mmol) and 2-methoxyphenylboronic acid (0.19 g, 1.68 mmol); yield: 0.21 g (92 %); 
yellow solid: mp 103 °C; Rf = 0.15 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 2924 (m), 2854 (m), 1598 (m), 1477 
(s), 1395 (m), 1261 (m), 1237 (s), 1079 (m), 1022 (s), 835 (m), 795 (s), 665 (s); δH (CDCl3, 500 MHz) 3.85 (s, 3H), 
5.17 (s, 2H), 6.95 (bs, 1H), 7.00 (dd, J = 0.6, 8.5 Hz, 1H), 7.08 (dt, J = 1.1, 7.6 Hz, 1H), 7.12 (s, 1H), 7.38 (ddd, J 
=1.9, 7.6, 8.5 Hz, 1H), 7.44 (dd, J = 2.2, 8.5 Hz, 1H), 7.60 (s, 1H), 7.77 (dd, J = 1.9, 7.6 Hz, 1H), 7.83 (d, J = 8.2 
Hz, 1H), 8.60 (d, J = 1.6 Hz, 1H); δC (CDCl3, 125 MHz) 48.2 (CH2), 55.6 (CH3), 111.4 (CH), 119.1 (CH), 121.1 
(CH), 125.2 (CH), 128.3 (Cq), 129.5 (Cq), 130.2 (CH), 130.3 (CH), 131.1 (CH), 134.6 (CH), 137.3 (CH), 148.2 
(CH), 156.4 (Cq), 157.0 (Cq); MS (ESI): m/z = 266 [M++H]. 
3-(5-((1H-Imidazol-1-yl)methyl)pyridin-2-yl)benzenamine, 7. Synthesised according to Method B using 
compound 1a (0.20 g, 0.84 mmol) and 2-methoxyphenylboronic acid (0.29 g, 1.68 mmol); yield: 0.14 g (67 %); 
orange solid: mp 145 °C; Rf = 0.11 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 3406 (w), 3408 (w), 3323 (w), 3212 
(w), 2957 (m), 2924 (m), 2854 (m), 1630 (m), 1600 (s), 1476 (s), 1235 (m), 1105 (s), 1073 (s), 1026 (s), 787 (s), 758 
(s); δH (CDCl3, 500 MHz) 5.11 (s, 2H), 6.72 (ddd, J = 0.9, 2.4, 7.6 Hz, 1H), 6.89 (bs, 1H), 7.08 (bs, 1H), 7.21 (t, J = 
7.7 Hz, 1H), 7.28 (dt, J = 1.3, 7.8 Hz, 1H), 7.33 (t, J = 2.2 Hz, 1H), 7.41 (dd, J = 2.2, 8.2 Hz, 1H), 7.55 (bs, 1H), 
7.62 (d, J = 8.2 Hz, 1H), 8.50 (d, J = 2.2 Hz, 1H); δC (CDCl3, 125 MHz) 48.0 (CH2), 113.3 (CH), 116.0 (CH), 117.0 
(CH), 119.0 (CH), 120.5 (CH), 129.6 (CH), 129.9 (Cq),  130.1 (CH), 135.6 (CH), 137.2 (CH), 139.5 (Cq), 146.9 
(Cq),  148.3 (CH) 157.6 (Cq); MS (ESI): m/z = 251 [M++H]. 
5-((1H-Imidazol-1-yl)methyl)-2-(3,4-dimethoxyphenyl)pyridine, 8. Synthesised according to Method B using 
compound 1a (0.40 g, 1.68 mmol) and 3,4-dimethoxyphenylboronic acid (0.61 g, 3.36 mmol); yield: 0.47 g (94 %); 
yellow solid: mp 114 °C; Rf = 0.16 (EtOAc / MeOH 9:1); IR (ATR) υ (cm-1) 3110 (w), 3086 (w), 3002 (w), 2960 
(w), 2926 (w), 2855 (w), 1596 (m), 1519 (m), 1477 (m), 1280 (m), 1150 (m), 1022 (s), 808 (s), 764 (s), 666 (m); δH 
(CDCl3, 500 MHz) 3.93 (s, 3H), 3.98 (s, 3H), 5.16 (s, 2H), 6.92 (bs, 1H), 6.94 (d, J = 8.5 Hz, 1H), 7.11 (bs, 1H), 
7.46 (dd, J = 2.2, 8.5 Hz, 1H), 7.47 (dd, J = 2.2, 8.5 Hz, 1H), 7.58 (bs, 1H), 7.65 (d, J = 2.2 Hz, 1H), 7.67 (d, J = 8.5 
Hz, 1H), 8.54 (d, J = 2.2 Hz, 1H); δC (CDCl3, 125 MHz) 48.1 (CH2), 56.0 (CH3), 56.0 (CH3), 113.3 (CH), 110.0 
(CH), 111.1 (CH), 119.0 (CH), 119.5 (CH), 120.0 (CH), 129.4 (Cq), 130.3 (CH), 131.4 (Cq) 135.7 (CH), 148.4 (CH), 
149.4 (Cq), 150.3 (Cq),  157.3 (Cq); MS (ESI): m/z = 296 [M++H]. 
2-((1H-Imidazol-1-yl)methyl)-5-(4-fluorophenyl)pyridine, 9. Synthesised according to Method B using 
compound 9a (0.20 g, 0.84 mmol) and 4-fluorophenylboronic acid (0.23 g, 1.68 mmol); yield: 0.18 g (83 %); yellow 
solid: mp 90 °C; Rf = 0.11 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 3116 (w), 3046 (w), 2927 (w), 1064 (m), 1519 
(m), 1486 (s), 1393 (w), 1220 (s), 1163 (m), 1070 (s), 906 (w), 828 (s), 817 (s), 769 (s), 684 (s), 660 (s); δH (CDCl3, 
500 MHz) 5.29 (s, 2H), 7.02 (m, 2H), 7.14 (brs, 1H), 7.17 (t, J = 8.8 Hz, 2H), 7.52 (dd, J = 5.4, 8.8 Hz, 1H), 7.65 (s, 
1H), 7.79 (dd, J = 2.2, 8.2 Hz, 2H), 8.76 (d, J = 2.2 Hz, 1H); δC (CDCl3, 125 MHz) 52.3 (CH2), 116.2 (d, 2JCF = 22.1 
Hz, CH), 119.5 (CH), 121.1 (CH), 128.8 (d, 3JCF = 8.6 Hz, CH), 130.0 (CH), 130.4 (CH), 133.2 (d, 4JCF = 3.8 Hz, 
Cq), 135.2 (Cq), 135.4 (CH), 148.0 (CH), 154.9 (Cq), 163.0 (d, 1JCF = 247.6 Hz, Cq); MS (ESI): m/z = 254 [M++H]. 
4-Phenylthiophene-2-carbaldehyde, 10b. Synthesised according to Method B using phenylboronic acid (0.49 
g, 2.00 mmol) and 4-bromothiophen-2-carbaldehyde (0.38 g, 2.00 mmol); yield: 0.35 g (93 %); white solid: mp 57-
58 °C; Rf = 0.39 (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 3096 (w), 2838 (w), 1670 (s), 1597 (w), 1430 (m), 1247 (w), 
1180 (s), 1048 (w), 755 (s), 695 (m), 660 (s); δH (CDCl3, 500 MHz) 7.36 (m, 1H), 7.44 (dd, J = 7.3, 7.9 Hz, 2H), 
7.59 (dd, J = 1.3 Hz, 8.5 Hz, 2H), 7.85 (dd, J = 1.3 Hz, 1.6 Hz, 1H), 8.03 (d, J = 1.6 Hz, 1H), 9.97 (d, J = 1.3 Hz, 
1H); δC (CDCl3, 125 MHz) 115.3 (CH), 126.3 (CH), 128.0 (CH), 129.1 (CH), 129.6 (CH), 134.4 (Cq), 143.7 (Cq), 
144.4 (Cq), 183.0 (CH); MS (ESI): m/z = 189 [M++H]. 
4-(4-Fluorophenyl)-thiophene-2-carbaldehyde, 11b. Synthesised according to Method B using 4-
fluorophenylboronic acid (0.56 g, 4.00 mmol) and 4-bromothiophen-2-carbaldehyde (0.38 g, 2.00 mmol); yield: 
0.38 g (92 %); white solid: mp 76-78 °C; Rf = 0.34 (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 2945 (w), 2839 (w), 1665 
(s), 1547 (m), 1507 (s), 1435 (m), 1228 (s), 1216 (s), 1181 (m), 829 (s), 666 (s), 566 (s); δH (CDCl3, 500 MHz) 7.13 
(dd, J = 8.5, 8.8 Hz, 2H), 7.55 (dd, J = 5.4, 8.8 Hz, 2H), 7.79 (dd, J = 1.3, 1.6 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 9.97 
(d, J = 1.3 Hz, 1H); δC (CDCl3, 125 MHz) 116.0 (d, 2JCF = 22.1 Hz, CH), 128.0 (d, 3JCF = 8.6 Hz, CH), 129.3 (CH), 
130.6 (d, 4JCF = 3.6 Hz, Cq), 134.4 (CH), 142.6 (Cq), 144.6 (Cq), 162.6 (d, 1JCF = 247.6 Hz, Cq), 182.8 (CH); MS 
(ESI): m/z = 207 [M++H]. 
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4-(4-Methoxyphenyl)-thiophene-2-carbaldehyde, 12b. Synthesised according to Method B using 4-
methoxyphenylboronic acid (0.34 g, 2.25 mmol) and 4-bromthiophene-2-carbaldehyde (0.29 g, 1.50 mmol); yield: 
0.25 g (76 %); white solid: mp 72 °C; Rf = 0.34 (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 1512 (m), 1406 (m), 1309 
(m), 1246 (m), 1180 (m), 1026 (s), 832 (s), 756 (m), 521 (m); δH (CDCl3, 500 MHz) 3.85 (s, 3H), 6.96 (d, J = 8.8 
Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 7.75 (dd, J = 1.3, 1.6 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 9.96 (d, J = 1.3 Hz, 1H); 
δC (CDCl3, 125 MHz) 55.4 (CH3), 114.5 (CH), 127.3 (Cq), 127.5 (CH), 128.4 (CH), 134.5 (CH), 143.4 (Cq), 144.3 
(Cq), 159.6 (Cq), 183.0 (CH); MS (ESI): m/z = 219 [M++H]. 
4-(3-Methoxyphenyl)-thiophene-2-carbaldehyde, 13b. Synthesised according to Method B using 3-
methoxyphenylboronic acid (0.61 g, 4.00 mmol) and 4-bromothiophen-2-carbaldehyde (0.38 g, 2.00 mmol); yield: 
0.25 g (76 %); white solid: mp 225 °C; Rf = 0.41 (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 2836 (w), 1666 (s), 1600 
(m), 1458 (m), 1258 (m), 1161 (s), 1039 (m), 850 (m), 771 (s), 689 (m), 666 (s); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 
6.90 (ddd, J = 1.0, 2.5, 8.5 Hz, 1H), 7.11 (dd, J = 1.9, 2.5 Hz, 1H), 7.17 (ddd, J = 1.0, 1.9, 7.9 Hz, 1H), 7.36 (dd, J = 
7.9, 8.5 Hz, 1H), 7.85 (dd, J = 1.3, 1.6 Hz, 1H), 8.02 (d, J = 1.6 Hz, 1H), 9.97 (d, J = 1.3 Hz, 1H); δC (CDCl3, 125 
MHz) 55.3 (CH3), 112.3 (CH), 113.3 (CH), 118.8 (CH), 129.8 (CH), 130.1 (CH), 134.7 (CH), 135.7 (Cq), 143.5 
(Cq), 144.4 (Cq), 160.1 (Cq), 182.9 (CH); MS (ESI): m/z = 219 [M++H]. 
4-(3,4-Difluorophenyl)-thiophene-2-carbaldehyde, 14b. Synthesised according to Method B using 3,4-
difluorophenylboronic acid (0.63 g, 4.00 mmol) and 4-bromothiophen-2-carbaldehyde (0.38 g, 2.00 mmol); yield: 
0.43 g (96 %); white solid: mp 115-116 °C; Rf = 0.35 (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 3051 (w), 1658 (s), 
1517 (s), 1447 (m), 1352 (m), 1278 (s), 1190 (s), 852 (m), 816 (s), 772 (s), 670 (s), 601 (s), 574 (s); δH (CDCl3, 500 
MHz) 7.23 (ddd, J = 8.2, 8.5, 10.1 Hz, 1H), 7.29-7.32 (m, 1H), 7.38 (ddd, J = 2.2, 7.6, 11.4 Hz, 1H), 7.80 (dd, J = 
1.3, 1.6 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 9.97 (d, J = 1.3 Hz, 1H); δC (CDCl3, 125 MHz) 115.4 (d, 2JCF = 18.2 Hz, 
CH), 118.0 (d, 2JCF = 18.2 Hz, CH), 122.4 (dd, 4JCF = 3.8 Hz, 3JCF = 6.7 Hz, CH), 129.9 (CH), 131.6 (dd, 4JCF = 3.8 
Hz, 3JCF = 6.7 Hz, Cq), 134.1 (CH), 141.5 (Cq), 144.8 (Cq), 150.0 (dd, 2JCF = 58.5 Hz, 1JCF = 249.5 Hz, Cq), 150.1 
(dd, 2JCF = 59.5 Hz, 1JCF = 249.5 Hz, Cq), 182.7 (CH); MS (ESI): m/z = 225 [M++H]. 
3-(4-((1H-Imidazol-1-yl)methyl)phenyl)pyridine, 17. Synthesised according to Method B using compound 
17a (0.24 g, 1.00 mmol) and pyridine-3-boronic acid (0.25 g, 2.00 mmol); yield: 0.17 g (73 %); Rf = 0.20 (EtOAc / 
MeOH, 9:1); IR (ATR) υ (cm-1) 3384 (m), 3115 (w), 1509 (m), 1225 (s), 1081 (s), 1030 (m), 1005 (m), 804 (s), 747 
(s), 708 (s), 669 (s); δH (CDCl3, 500 MHz) 5.09 (s, 2H), 6.85 (s, 1H), 7.02 (s, 1H), 7.17 (d, J = 8.2 Hz, 2H), 7.27 
(ddd, J = 1.0, 4.7, 8.0 Hz, 1H), 7.47 (d, J = 8.2 Hz, 2H), 7.50 (s, 1H), 7.76 (ddd, J = 1.6, 2.4, 8.0 Hz, 1H), 8.50 (dd, J 
= 1.6, 4.7 Hz, 1H), 8.73 (d, J = 1.6 Hz, 1H); δC (CDCl3, 125 MHz) 49.4 (CH2), 118.2, 126.6, 126.7, 128.9, 133.3, 
134.8, 135.1, 136.5, 136.8, 147.0, 147.9; MS (ESI): m/z = 236 [M++H]. 
5-(4-((1H-Imidazol-1-yl)methyl)phenyl)-2-fluoropyridine, 18. Synthesised according to Method B using 
compound 17a (0.24 g, 1.00 mmol) and 4-fluorpyridine-3-boronic acid (0.28 g, 2.00 mmol); yield: 0.14 g (56 %); Rf 
= 0.20 (EtOAc); IR (ATR) υ (cm-1) 3108 (w), 1592 (m), 1497 (s), 1250 (s), 1075 (m), 813 (s), 737 (m), 684 (s); δH 
(CDCl3, 500 MHz) 5.10 (s, 2H), 6.85 (s, 1H), 6.91 (dd, J = 2.6, 8.6 Hz, 1H), 7.02 (s, 1H), 7.18 (d, J = 8.3 Hz, 2H), 
7.43 (d, J = 8.3 Hz, 2H), 7.50 (s, 1H), 7.86 (ddd, J = 2.6, 7.5, 10.1 Hz, 1H), 8.29 (d, J = 2.6 Hz, 1H); δC (CDCl3, 125 
MHz) 49.3 (CH2), 108.6 (d, 2JCF = 38.7 Hz, CH), 118.3 (CH), 126.6 (CH), 127.0 (CH), 129.0 (CH), 133.0 (d, 4JCF = 
4.6 Hz, Cq), 135.3 (CH), 135.7 (Cq), 136.4 (Cq), 138.6 (d, 3JCF = 7.7 Hz, CH), 144.7 (d, 3JCF = 15.5 Hz, CH), 162.0 
(d, 1JCF = 238.9 Hz, Cq); MS (ESI): m/z = 254 [M++H]. 
1-(4-(5-(Methylthio)thiophen-2-yl)benzyl)-1H-imidazole, 22. Synthesised according to Method B using 
compound 17a (0.12 g, 0.50 mmol) and 5-(methylsulfanyl)-2-thiophenylboronic acid (0.17 g, 1.00 mmol); light 
brown solid: mp 139–140 °C; Rf = 0.17 (EtOAc / MeOH, 10:1); IR (ATR) υ (cm-1) 1503 (m), 1442 (m), 1226 (m), 
1078 (s), 849 (m), 802 (s), 756 (s), 741 (s), 661 (s); δH (CDCl3, 500 MHz) 2.50 (d, J = 1.0 Hz, 3H), 5.11 (s, 2H), 
6.72-6.73 (m, 1H), 6.91 (t, J = 1.3 Hz, 1H), 7.09 (d, J = 1.6 Hz, 1H), 7.10 (s, 1H), 7.13 (d, J = 8.3 Hz, 2H), 7.52 (d, J 
= 8.3 Hz, 2H), 7.57 (s, 1H); δC (CDCl3, 125 MHz) 15.4 (CH3), 50.5 (CH2), 119.2 (CH), 123.3 (CH), 125.9 (CH), 
126.3 (CH), 127.8 (CH), 129.8 (CH), 134.6 (Cq), 134.8 (Cq), 137.4 (CH), 140.0 (Cq), 141.0 (Cq); MS (ESI): m/z = 
255 [M++H]. 
1-(4-(5-Methylsulfanyl-thiophen-2-yl)-phenyl)propan-1-one, 23b. Synthesised according to Method B from 
5-(methylthio)thiophen-2-yl-2-boronic acid (1.00 g, 6.30 mmol) and 1-(4-bromophenyl) propan-1-one (1.10 g, 5.20 
mmol); yield: 1.19 g (88 %); white solid; Rf =  0.63 (Hex / EtOAc, 4:1); IR (ATR) υ (cm-1) 1678 (s), 1597 (s), 1462 
(s), 1409 (m), 1349 (m), 1220 (s), 1181 (s), 1112 (m), 1012 (m), 949 (s), 796 (vs); δH (CDCl3, 500 MHz) 1.23 (t, J = 
7.3 Hz, 3H, CH3), 2.53 (s, 3H, S-CH3), 2.99 (q, J = 7.3 Hz, 2H, CH2), 6.76-6.77 (m, 1H), 7.22-7.26 (m, 1H), 7.60-
7.62 (m, 2H), 7.94-7.95 (m, 2H); δC (CDCl3, 125 MHz) 8.3 (CH3), 15.1 (S-CH3), 31.7 (CH2), 124.5, 125.3, 128.3, 
134.7, 138.3, 140.5, 141.3, 200.9 (CO); MS (ESI): m/z = 233 [M+-Et]. 
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1-(4-Bromophenyl)-2-methyl-1-(1-trityl-1H-imidazol-5-yl)propan-1-ol, 24a. The preparation of 24a has been 
reported previously by Tasaka, A. et al.21   
1-(1H-Imidazol-5-yl)-2-methyl-1-(4-(thiophen-3-yl)phenyl)propan-1-ol, 24. Synthesised according to Method 
B using compound 24a (0.17 g, 0.31 mmol) and thiophen-3-ylboronic acid (0.08 g, 0.62 mmol), and DME as 
solvent. The crude was then deprotected with pyridinium hydrochloride (0.05 g, 0.44 mmol) in MeOH (5 ml) at 80 
°C for 5 h; yield: 0.03 g (34 %); light-yellow solid; Rf = 0.36 (DCM / MeOH, 9:1); IR (ATR) υ (cm-1) 3122 (w), 
1506 (w), 1457 (w), 1179 (w), 1003 (w), 948 (w), 865(m), 779 (s), 733, 681 (m), 669 (m), 649 (m), 567 (m), 532 
(s), 517 (s); δH (CDCl3, 500 MHz) 0.77 (d, J = 6.1 Hz, 3H), 0.94 (d, J = 4.8 Hz, 3H), 2.50-2.60 (m, 1H), 6.91 (s, 
1H), 7.33 (s, 2H), 7.38 (s, 1H), 7.40-7.53 (m, 5H).; δC (CDCl3, 125 MHz) 17.3 (CH3), 17.3 (CH3), 30.3 (CH), 37.3 
(Cq), 120.1 (CH), 125.2, 125.4, 125.5, 125.8, 125.9, 125.9, 126.1, 126.2, 126.3, 126.4, 126.6, 134.1 (Cq), 141.9 (Cq); 
MS (ESI): m/z = [M++H]. 
1-(4-(Furan-3-yl)benzyl)-1H-imidazole, 25. Synthesised according to Method B using compound 17a (0.24 g, 
1.00 mmol) and furan-3-ylboronic acid (0.22 g, 2.00 mmol); yield: 0.16 g (73 %); Rf = 0.17 (EtOAc); IR (ATR) υ 
(cm-1) 3102 (w), 1518 (m), 1439 (m), 1242 (m), 1161 (m), 1071 (m), 872 (m), 784 (s), 751 (s), 662 (s), 597 (s); δH 
(CDCl3, 500 MHz) 5.05 (s, 2H), 6.61 (dd, J = 1.8, 0.9 Hz, 1H), 6.84 (t, J = 1.2 Hz, 1H), 7.03 (s, 1H), 7.09 (d, J = 8.2 
Hz, 2H), 7.39 (d, J = 8.2 Hz, 2H), 7.41 (m, 1H), 7.49 (s, 1H), 7.66 (s, 1H); δC (CDCl3, 125 MHz) 49.5 (CH2), 107.7 
(CH), 118.2 (CH), 124.8 (Cq), 125.4 (CH), 126.8 (CH), 128.9 (CH), 131.6 (Cq), 133.7 (Cq), 136.4 (CH), 137.7 (CH), 
142.8 (CH); MS (ESI): m/z = 225 [M++H]. 
1-(4-(4-Methylthiophen-3-yl)benzyl)-1H-imidazole, 26. Synthesised according to Method B using compound 
17a (0.24 g, 1.00 mmol) and furan-2-ylboronic acid (0.28 g, 2.00 mmol); red oil: bp > 200 °C; yield: 0.17 g (68 %); 
Rf = 0.35 (EtOAc / MeOH, 9:1); IR (ATR) υ (cm-1) 1505 (m),  1230 (m), 1075 (m), 792 (s), 729 (m), 662 (s); δH 
(CDCl3, 500 MHz) 2.25 (s, 3H), 5.16 (s, 2H), 6.95 (bs, 1H), 7.02-7.03 (m, 1H), 7.12 (bs, 1H), 7.18-7.20 (m, 3H), 
7.38 (d, J = 8.2 Hz. 2H), 7.60 (bs, 1H); δC (CDCl3, 125 MHz) 15.5 (CH3), 50.6 (CH2), 119.3 (CH), 122.2 (CH), 
123.3 (CH), 127.2 (CH), 129.1 (CH), 129.7 (CH), 134.8 (Cq), 136.0 (Cq), 137.2 (Cq), 137.4 (CH), 142.2 (Cq). 
1-(4-(4-Methylthiophen-3-yl)phenyl)propan-1-one, 29b. Synthesised according to Method B from 4-
methylthiophen-3-yl-3-boronic acid (0.80 g, 6.30 mmol) and 1-(4-bromophenyl)propan-1-one (1.36 g, 6.40 mmol); 
yield: 0.96 g (80 %); white solid; Rf = 0.68 (Hex / EtOAc, 4:1); δH (CDCl3, 500 MHz) 1.25 (t, J = 7.3 Hz, 3H, CH3), 
2.29 (s, 3H, CH3), 3.01-3.06 (q, 2H, CH2), 7.05-7.06 (m, 1H), 7.26-7.27 (m, 1H,), 7.48-7.50 (m, 2H), 8.00-8.02 (m, 
2H); δC (CDCl3, 125 MHz) 8.3 (CH3), 31.8 (CH2), 122.6, 123.9, 128.1, 128.6, 135.4, 135.9, 141.6, 142.0, 200.3 
(C=O); MS (ESI): m/z = 231 [M++H]. 
2-Fluoro-4-(4-methylthiophen-3-yl)benzaldehyde, 30b. Synthesised according to Method B from 4-bromo-2-
fluorobenzaldehyde (1.36 g, 6.40 mmol) and 4-methylthiophen-3-yl-3-boronic acid (1.42 g, 7.10 mmol). This 
compound was used directly in the next step without further purification. 
4-(2-Chlorothiophen-3-yl)-benzaldehyde, 31b. Synthesised according to Method B from 3-bromo-2-
chlorothiophene (0.20 g, 1.00 mmol) and 4-formylphenylboronic acid (0.30 g, 2.00 mmol); yield: 0.14 g (67 %); 
white solid: Rf = 0.37 (PE / EtOAc, 10:1); δH (CDCl3, 500 MHz) 7.10 (d, J = 5.7 Hz, 1H), 7.20 (d, J = 5.7 Hz, 1H), 
7.75 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 8.2 Hz, 2H), 10.06 (s, 1H, CHO); δC (CDCl3, 125 MHz) 123.3, 126.5, 128.2, 
129.0, 129.9, 135.3, 136.9, 140.2, 191.7 (CO) ; MS (ESI): m/z = 223 [M++H]. 
Method C: Reduction with NaBH4 
To an ice-cooled solution of the corresponding aldehyde or ketone (1 eq) in methanol (5 mL / mmol) was added 
NaBH4 (2 eq). Then the resulting mixture was heated to reflux for 30 minutes. After cooling to ambient temperature, 
the solvent was distilled off under reduced pressure. Then water (10 mL) was added, and the resulting mixture was 
extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried over MgSO4 
and evaporated under reduced pressure. Then the desired product was purified by chromatography on silica gel. 
4-Phenyl-2-thiophenemethanol, 10a. Synthesised according to Method C using 10b (0.31 g, 1.60 mmol) and 
NaBH4 (0.11 g, 2.90 mmol); yield: 0.27 g (88 %); white solid: mp 109-110 °C; Rf = 0.13 (PE / EtOAc, 10:1); IR 
(ATR) υ (cm-1) 3290 (m), 1596 (w), 1500 (w), 1449 (m), 1195 (m), 1158 (m), 1018 (s), 837 (m), 733 (s), 688 (s); δH 
(CDCl3, 500 MHz) 1.89 (bs, 1H, OH), 4.86 (s, 2H, CH2), 7.28-7.32 (m, 2H), 7.39 (d, J = 1.6 Hz, 1H), 7.40 (dd, J = 
7.3, 8.0 Hz, 2H), 7.57 (dd, J = 1.6, 8.0 Hz, 2H); δC (CDCl3, 125 MHz) 60.3 (CH2), 120.3 (CH), 124.7 (CH), 126.3 
(CH), 127.2 (CH), 128.8 (CH), 135.8 (Cq), 142.1 (Cq), 144.8 (Cq); MS (ESI): m/z = 191 [M++H]. 
4-(4-Fluorophenyl)-2-thiophenemethanol, 11a. Synthesised according to Method C using 11b (0.31 g, 1.50 
mmol) and NaBH4 (0.10 g, 2.70 mmol); yield: 0.27 g (87 %); white solid: mp 120-121 °C; Rf = 0.09 (PE / EtOAc, 
10:1); IR (ATR) υ (cm-1) 3354 (m), 1602 (m), 1511 (s), 1419 (m), 1246 (s), 1151 (m), 1026 (s), 839 (s), 752 (s), 566 
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(s); δH (CDCl3, 500 MHz) 1.90 (bs, 1H, OH), 4.86 (s, 2H), 7.08 (dd, J = 8.5, 8.8 Hz, 2H), 7.24-7.25 (m, 1H), 7.32 
(d, J = 1.6 Hz, 1H), 7.51 (dd, J = 5.4, 8.8 Hz, 2H); δC (CDCl3, 125 MHz) 60.2 (CH2), 115.6 (d, 2JCF = 21.1 Hz, CH), 
120.0 (CH), 124.6 (CH), 127.8 (d, 3JCF = 7.7 Hz, CH), 132.0 (d, 4JCF = 3.8 Hz, Cq), 141.1 (Cq), 145.0 (Cq), 162.2 (d, 
1JCF = 246.6 Hz, Cq); MS (ESI): m/z = 209 [M++H]. 
4-(4-Methoxyphenyl)-2-thiophenemethanol, 12a. Synthesised according to Method C using 12b (0.22 g, 1.00 
mmol) and NaBH4 (0.07 g, 1.80 mmol); yield: 0.19 g (84 %); white solid: mp 138 °C (Lit.40 136.5-138 °C); Rf = 
0.14 (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 1512  (m), 1406 (m), 1309 (m), 1246 (m), 1180 (m), 1026 (s), 832 (s), 
756 (m), 521 (m); δH (CDCl3, 500 MHz) 3.77 (s, 3H), 4.64 (d, J = 5.4 Hz, 2H), 5.47 (t, J = 5.4 Hz, 1H), 6.95 (d, J = 
8.8 Hz, 2H), 7.31-7.32 (m, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.59 (d, J = 8.8 Hz, 2H); δC (CDCl3, 125 MHz) 55.0 
(CH3), 58.3 (CH2), 114.1 (CH), 117.9 (CH), 122.7 (CH), 126.9 (CH), 128.0 (Cq), 140.3 (Cq), 147.0 (Cq), 158.3 (Cq); 
MS (ESI): m/z = 221 [M++H]. 
4-(3-Methoxyphenyl)-2-thiophenemethanol, 13a. Synthesised according to Method C using 13b (0.31 g, 1.40 
mmol) and NaBH4 (0.10 g, 2.50 mmol); yield: 0.29 g (95 %); colourless oil; Rf = 0.10 (PE / EtOAc, 10:1); IR (ATR) 
υ (cm-1) 3354 (m), 1600 (s), 1460 (m), 1285 (m), 1148 (s), 1038 (s), 841 (m), 784 (s), 753 (s), 688 (m); δH (CDCl3, 
500 MHz) 1.90 (bs, 1H), 3.85 (s, 3H), 4.86 (d, J = 3.5 Hz, 2H), 6.85 (ddd, J = 0.6, 2.5 Hz, J = 8.2 Hz, 1H), 7.10 (dd, 
J = 0.6, 2.5 Hz, 1H), 7.16 (ddd, J = 1.0, 1.6 Hz, 7.6 Hz, 1H), 7.29 (dd, J = 0.6, 1.3 Hz, 1H), 7.31 (dd, J = 7.6, 8.2 
Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H); δC (CDCl3, 125 MHz) 55.3 (CH3), 60.2 (CH2), 112.1 (CH), 112.6 (CH), 118.9 
(CH), 120.6 (CH), 124.8 (CH), 129.8 (CH), 137.1 (Cq), 142.0 (Cq), 144.7 (Cq), 160.0 (Cq); MS (ESI): m/z = 203 
[M+-OH]. 
4-(3,4-Difluorophenyl)-2-thiophenemethanol, 14a. Synthesised according to Method C using 14b (0.34 g, 1.50 
mmol) and NaBH4 (0.10 g, 2.70 mmol); yield: 0.27 g (80 %); white solid: mp 66 °C; Rf = 0.11 (PE / EtOAc, 10:1); 
IR (ATR) υ (cm-1) 3264 (m), 1605 (m), 1515 (s), 1279 (s), 1224 (m), 1170 (m), 1118 (m), 1013 (s), 816 (s), 759 (s), 
581 (s); δH (CDCl3, 500 MHz) 1.93 (bs, 1H), 4.85 (s, 2H), 7.16 (ddd, J = 1.6, 8.2, 8.5 Hz, 1H), 7.21-7.22 (m, 1H), 
7.24-7.28 (m, 1H), 7.33 (d, J = 1.6 Hz, 1H), 7.34 (ddd, J = 2.2, 7.6, 11.4 Hz, 1H); δC (CDCl3, 125 MHz) 115.1 (d, 
2JCF = 18.2 Hz, CH), 117.5 (d, 2JCF = 18.2 Hz, CH), 120.8 (CH), 122.3 (dd, 4JCF = 2.9 Hz, 3JCF = 5.8 Hz, CH), 124.3 
(CH), 132.9 (dd, 4JCF = 3.8 Hz, 3JCF = 6.7 Hz, Cq), 140.0 (d, 5JCF = 1.9 Hz, Cq), 145.4 (Cq), 149.0 (dd, 2JCF = 12.5 
Hz, 1JCF = 248.5 Hz, Cq), 150.0 (dd, 2JCF = 13.4  Hz, 1JCF = 248.5 Hz, Cq); MS (ESI): m/z = 209 [M+-OH]. 
(4-Bromothiophen-2-yl)methanol, 16b. Synthesised according to Method C using 4-bromothiophene-2-
carbaldehyde (1.00 g, 5.20 mmol) and NaBH4 (0.36 g, 9.40 mmol); yield: 0.99 g (98 %); colourless oil; Rf = 0.13 
(PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 3318 (m), 1528 (w), 1343 (w), 1147 (m), 1007 (s), 818 (s), 734 (s), 580 (s); 
δH (CDCl3, 500 MHz) 2.04 (bs, 1H), 4.78 (s, 2H), 6.92 (m, 1H), 7.17 (d, J = 1.6 Hz, 1H); δC (CDCl3, 125 MHz) 59.8 
(CH2), 109.3 (Cq), 122.6 (CH), 127.7 (CH), 145.3 (Cq); MS (ESI): m/z = 177/175 [M+-OH]. 
1-(4-(5-Methylsulfanylthiophen-2-yl)phenyl)-propan-1-ol, 23a. Synthesised according to Method C from 23b 
(0.79 g, 3.00 mmol); yield: 0.71 g (89 %); white solid; Rf = 0.58 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 3317 (br), 
1513 (m), 1465 (w), 1416 (w), 1261 (m), 1210 (w), 1008 (m), 970 (w), 946 (w), 823 (s), 803 (s); δH (CDCl3, 500 
MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 1.82 (m, 2H, CH2), 1.88 (d,  J = 3.1 Hz, 1H, OH),  2.51 (s, 3H, S-CH3), 4.58-
4.61 (m, 1H, CH),  6.72-6.73 (m, 1H), 7.10 -7.13 (m, 1H), 7.31 -7.33 (m, 2H), 7.52 -7.54 (m, 2H); δC (CDCl3, 125 
MHz) 10.1 (CH3), 15.4 (S-CH3), 31.8 (CH2), 75.7 (C-OH), 122.8, 125.4, 126.1, 126.4, 133.9, 139.4, 141.7, 143.3; 
MS (ESI): m/z = 217 [M+-SMe]. 
1-(4-Thiophen-3-ylphenyl)propan-1-one, 27b. This compound is commercial available. 
1-(4-Thiophen-3-ylphenyl)propan-1-ol, 27a. Synthesised according to Method C from 27b (0.42 g, 1.90 
mmol); yield: 0.41 g (91 %); white solid; Rf = 0.33 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 3307 (br), 2928 (w), 
1425 (w), 1261 (w), 1092 (m), 1044 (m), 973 (m), 865 (m), 844 (s), 728 (m), 690 (m); δH (DMSO, 500 MHz) 0.83 
(t, J = 7.3 Hz, 3H, CH3), 1.63 -1.65 (m, 2H, CH2), 4.45-4.46 (m, 1H, CH-OH), 7.35-7.37 (m, 2H), 7.53-7.55 (dd, J = 
1.6, 3.4 Hz, 1H), 7.63-7.64 (m, 1H), 7.66-7.68 (m, 2H), 7.81 (d, J = 1.3 Hz, 1.6 Hz, 1H); δC (DMSO, 125 MHz) 9.9 
(CH3), 31.8 (CH2), 73.2 (C-OH), 120.3, 122.5, 126.0, 126.2, 126.8, 133.4, 141.3, 144.9; MS (ESI): m/z = 201  [M+-
H2O]. 
1-(4-Thiophen-3-yl-phenyl)-ethanone, 28b. This compound has been reported by Reuben, D et al.41 
1-(4-Thiophen-3-ylphenyl)ethanol, 28a. Synthesised according to Method C from 28b (1.02 g, 5.10 mmol); 
yield: 0.86 (83 %); white solid; Rf = 0.4 (DCM); IR (ATR) υ (cm-1) 3290 (br), 1362 (w), 1290 (w), 1200 (w), 1072 
(m), 892 (m), 864 (m), 835 (m), 779 (s), 731 (m); δH (DMSO, 500 MHz) 1.35 (d, J = 6.6 Hz, 3H, CH3), 4.72 -7.43 
(m, 1H, CH-OH), 7.36-7.37 (m, 2H), 7.53 (dd, J = 1.6, 3.4 Hz 1H), 7.63-7.65 (m, 1H), 7.67-7.68 (m, 2H), 7.82 (dd, 
J = 1.3, 1.6 Hz, 1H); δC (DMSO, 125 MHz) 25.8 (CH3), 67.9 (CH-OH), 120.4, 125.8, 126.2, 127.0,133.4, 141.5, 
146.3; MS (ESI): m/z = 187  [M+-H2O]. 
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1-(4-(4-Methylthiophen-3-yl)-phenyl)propan-1-ol, 29a. Synthesised according to Method C from 29b (1.23 g, 
5.30 mmol); yield: 1.03 g (83 %); white solid: Rf = 0.55 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.6 
Hz, 3H, CH3), 1.81-1.83 (m, 2H, CH2), 2.27 (s, 3H, CH3), 4.63-4.66 (m, 1H, CH), 7.02-7.03 (m, 1H), 7.19-7.20 (m, 
1H), 7.38-7.42 (m, 4H); δC (CDCl3, 125 MHz) 9.9 (CH3), 15.3 (CH3), 31.6 (CH2), 121.8, 122.7, 125.7, 128.4, 135.9, 
136.1, 142.6, 143.0; MS (ESI): m/z = 233 [M++H]. 
Method D: Grignard reaction 
Under exclusion of air and moisture a 1.0 M EtMgBr (1.2 eq) solution in THF was added dropwise to a solution 
of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred over night at rt. Then ethyl acetate 
(10 mL) and water (10 mL) were added and the organic phase was separated. The organic phase was extracted with 
water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude products were purified by 
flash chromatography on silica gel.  
1-(4-(3,4-Difluorophenyl)-2-thiophen-1-yl)-1-propanol, 15a. Synthesised according to Method D using 14b 
(0.20 g, 0.89 mmol) and 1.0 M EtMgBr (0.98 mL, 0.98 mmol); yield: 0.18 g (79 %); colourless oil; Rf = 0.14 (PE / 
EtOAc, 10:1); δH (CDCl3, 500 MHz) 0.93 (t, J = 7.3 Hz, 3H, CH3), 1.80-1.88 (m, 2H, CH2), 1.96 (bs, 1H, OH), 4.79 
(t, J = 6.6 Hz, 1H, CHCH2), 7.09-7.13 (m, 1H), 7.16-7.18 (m, 1H), 7.19-7.22 (m, 1H), 7.23 (d, J = 1.6 Hz, 1H), 7.27 
(ddd, J = 1.6, 2.2, 7.6 Hz, 1H); δC (CDCl3, 125 MHz) 10.0 (CH3), 32.2 (CH2), 71.8 (CH), 115.0 (CH), 117.4 (CH), 
117.6 (CH), 119.8 (CH), 122.1 (CH), 122.6 (CH), 133.0 (Cq), 139.7 (Cq), 150.0 (Cq), 150.6 (Cq); MS (ESI): m/z = 
255 [M++H]. 
1-(2-Fluoro-4-(4-methylthiophen-3-yl)-phenyl)propan-1-ol, 30a. Synthesised according to Method D from 
30b (2.00 g, 4.90 mmol); yield: 0.73 g (30 %); white solid, Rf = 0.32 (Hex / EtOAc, 4:1); δH (CDCl3, 500 MHz) 0.98 
(t,  J = 7.6 Hz, 3H, CH3), 1.85-1.87 (m, 2H, CH2), 2.52 (s, 3H, CH3),  4.96 (t,  J = 6.3 Hz, 1H, CH), 7.03-7.04 (m, 
1H), 7.05-7.06 (m, 1H), 7.18-7.20 (m, 2H), 7.49-7.50 (m, 1H); δC (CDCl3, 125 MHz) 10.0 (CH3), 15.5 (CH3), 30.9 
(CH2), 70.0 (CHOH), 115.2, 122.3, 123.4, 124.5, 127.2, 130.0, 135.9, 138.0, 160.7; MS (ESI): m/z = 251 [M++H]. 
1-(4-(2-Chlorothiophen-3-yl)phenyl)propan-1-ol, 31a. Synthesised according to Method D from 31b (1.32 g, 
6.50 mmol); yield: 1.48 g (95 %); white solid: Rf = 0.30 (PE / EtOAc, 10:1); δH (CDCl3, 500 MHz) 0.81 (t, J = 7.6 
Hz, 3H, CH3), 1.69-1.71 (m, 2H, CH2), 2.07 (br, 1H, OH), 4.45 (t, J = 6.6 Hz, 1H, CH), 6.61-6.62 (m, 1H), 6.98-
6.99 (m, 1H), 7.18-7.20 (m, 2H), 7.40-7.41 (m, 2H); δC (CDCl3, 125 MHz) 10.2 (CH3), 31.8 (CH2), 75.7 (CH), 
122.8, 125.5, 126.1, 126.5, 127.1, 128.8, 133.9, 139.4, 141.7, 143.4; MS (ESI): m/z = 253 [M++H]. 
Method E: CDI reaction 
To a solution of the corresponding alcohol (1 eq) in NMP or acetonitrile (10 mL / mmol) was added CDI (5 eq). 
Then the solution was heated to reflux for 4 to 18 h. After cooling to ambient temperature, it was diluted with water 
(30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried 
over MgSO4 and evaporated under reduced pressure. Then the desired product was purified by chromatography on 
silica gel. 
1-((4-Phenylthiophen-2-yl)methyl)-1H-imidazole, 10. Synthesised according to Method E using 10a (0.19 g, 
1.00 mmol) and CDI (0.24 g, 1.50 mmol); yield: 0.09 g (38 %); light brown solid: mp 112-113 °C; Rf = 0.22 
(EtOAc); IR (ATR) υ (cm-1) 3110 (w), 1504 (m), 1430 (m), 1358 (w), 1230 (m), 1084 (m), 817 (m), 744 (s), 660 (s); 
δH (CDCl3, 500 MHz) 5.29 (s, 2H), 7.00 (t, J = 1.3 Hz, 1H), 7.10 (bs, 1H), 7.24-7.25 (m, 1H), 7.30 (tt, J = 1.3, 7.5 
Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H), 7.39 (dd, J = 7.5, 7.8 Hz, 2H), 7.53 (dd, J = 1.3, 7.8 Hz, 2H), 7.60 (s, 1H); δC 
(CDCl3, 125 MHz) 45.7 (CH2), 118.9 (CH), 120.8 (CH), 126.0 (CH), 126.3 (CH), 127.5 (CH), 128.9 (CH), 130.0 
(CH), 135.2 (Cq), 137.0 (CH), 139.2 (Cq), 142.4 (Cq); MS (ESI): m/z = 241 [M++H]. 
1-((4-(4-Fluorphenyl)thiophen-2-yl)methyl)-1H-imidazole, 11. Synthesised according to Method E using 11a 
(0.21 g, 1.00 mmol) and CDI (0.24 g, 1.50 mmol); yield: 0.12 g (49 %); brown oil; Rf = 0.20 (EtOAc); IR (ATR) υ 
(cm-1) 3088 (w), 1511 (s), 1224 (s), 1160 (m), 1075 (m), 830 (s), 761 (m), 661 (m), 565 (m); δH (CDCl3, 500 MHz) 
5.28 (s, 2H), 6.99 (t, J = 1.2 Hz, 1H), 7.07 (dd, J = 8.5, 8.8 Hz, 2H), 7.09 (bs, 1H), 7.17-7.18 (m, 1H), 7.31 (d, J = 
1.6 Hz, 1H), 7.48 (dd, J = 5.4 Hz, J = 8.8 Hz, 2H), 7.59 (brs, 1H); δC (CDCl3, 125 MHz) 45.6 (CH2), 115.7 (d, 2JCF = 
21.1 Hz, CH), 118.9 (CH), 120.5 (CH), 125.9 (CH), 127.9 (d, 3JCF = 8.6 Hz, CH), 129.9 (CH), 131.4 (d, 4JCF = 3.8 
Hz, Cq), 137.0 (CH), 139.4 (Cq), 141.4 (Cq), 162.3 (d, 1JCF = 246.6 Hz, Cq); MS (ESI): m/z = 259 [M++H]. 
1-((4-(4-Methoxyphenyl)thiophen-2-yl)methyl)-1H-imidazole, 12. Synthesised according to Method E using 
12a (0.16 g, 0.70 mmol) and CDI (0.16 g, 1.00 mmol); yield: 0.08 g (44 %); light brown solid: mp 140 °C; Rf = 0.20 
(EtOAc); IR (ATR) υ (cm-1) 2961 (w), 1517 (m), 1254 (m), 1077 (m), 1020 (s), 828 (s), 758 (s), 660 (m); δH 
(CDCl3, 500 MHz) 3.83 (s, 3H), 5.28 (s, 2H), 6.92 (d, J = 8.8 Hz, 2H), 6.99 (bs, 1H), 7.19 (bs, 1H), 7.27 (d, J = 1.6 
Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.59 (bs, 1H); δC (CDCl3, 125 MHz) 45.7 (CH2), 55.3 (CH3), 114.3 (CH), 118.9 
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(CH), 119.4 (CH), 126.0 (CH), 127.4 (CH), 128.1 (Cq), 129.9 (CH), 137.0 (CH), 139.0 (Cq), 142.1 (Cq), 159.1 (Cq); 
MS (ESI): m/z = 271 [M++H]. 
1-((4-(3-Methoxyphenyl)thiophen-2-yl)methyl)-1H-imidazole, 13. Synthesised according to Method E using 
13a (0.28 g, 1.30 mmol) and CDI (0.31 g, 1.90 mmol); yield: 0.11 g (31 %); brown solid: mp 48 °C; Rf = 0.27 
(EtOAc); IR (ATR) υ (cm-1) 3076 (w), 1591 (m), 1496 (m), 1261 (m), 1222 (m), 1175 (m), 1031 (m), 784 (s), 744 
(s), 659 (s); δH (CDCl3, 500 MHz) 3.84 (s, 3H), 5.27 (s, 2H), 6.85 (ddd, J = 1.0, 2.5, 8.2 Hz, 1H), 6.98 (t, J = 1.3 Hz, 
1H), 7.05 (dd, J = 1.6, 2.5 Hz, 1H), 7.09 (dd, J = 1.0, 1.3 Hz, 1H), 7.11 (ddd, J = 1.0, 1.6, 7.6 Hz, 1H), 7.22 – 7.23 
(m, 1H), 7.30 (dd, J = 7.6, 8.2 Hz, 1H), 7.37 (d, J = 1.6 Hz, 1H), 7.58 (bs, 1H); δC (CDCl3, 125 MHz) 45.6 (CH2), 
55.3 (CH3), 112.1 (CH), 112.7 (CH), 118.8 (CH), 118.9 (CH), 121.0 (CH), 126.1 (CH), 129.6 (Cq), 129.9 (CH), 
136.6 (Cq), 136.9 (CH), 139.1 (CH), 142.2 (Cq), 160.0 (Cq); MS (ESI): m/z = 271 [M++H]. 
1-((4-(3,4-Difluorophenyl)thiophen-2-yl)methyl)-1H-imidazole, 14. Synthesised according to Method E using 
14a (0.24 g, 1.10 mmol) and CDI (0.24 g, 1.50 mmol); yield: 0.12 g (41 %); light brown solid: mp 83 °C; Rf = 0.25 
(EtOAc); IR (ATR) υ (cm-1) 3092 (w), 1605 (m), 1515 (s), 1439 (m), 1268 (m), 1226 (m), 1070 (m), 819 (s), 766 
(s), 664 (m), 575 (m); δH (CDCl3, 500 MHz) 5.19 (s, 2H), 6.90 (t, J = 1.3 Hz, 1H), 7.00 (dd, J = 1.0, 1.3 Hz, 1H), 
7.06 (dt, J = 8.2, 10.9 Hz, 1H), 7.05–7.06 (m, 1H), 7.12–7.15 (m, 1H), 7.21 (ddd, J = 1.9, 7.3, 11.4 Hz, 1H), 7.23 (d, 
J = 1.6 Hz, 1H), 7.50 (s, 1H); δC (CDCl3, 125 MHz) 45.4 (CH2), 115.1 (d, 2JCF = 18.2 Hz, CH), 117.5 (d, 2JCF = 17.3 
Hz, CH), 118.8 (CH), 121.2 (CH), 122.1 (dd, 3JCF = 5.8 Hz, 4JCF = 2.9 Hz, CH), 125.5 (CH), 129.8 (CH), 132.3 (dd, 
3JCF = 5.8 Hz, 4JCF = 3.8 Hz, Cq), 136.9 (CH), 139.8 (Cq), 140.1 (Cq), 149.7 (dd, 1JCF = 249.5 Hz, 2JCF = 12.5 Hz, 
Cq), 150.3 (dd, 1JCF = 248.6 Hz, 2JCF = 13.5 Hz, Cq); MS (ESI): m/z = 277 [M++H]. 
1-(1-(4-(4-Fluorophenyl)thiophen-2-yl)propyl)-1H-imidazole, 15. Synthesised according to Method E using 
15a (0.15 g, 0.60 mmol) and CDI (0.29 g, 1.80 mmol); yield: 0.08 g (45 %); brown oil; Rf = 0.29 (DCM / MeOH, 
98:2); IR (ATR) υ (cm-1) 1606 cm-1 (w), 1516 (s), 1277 (m), 1222 (m), 1117 (w), 1072 (w), 815 (s), 770 (s), 662 
(m); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.4 Hz, 3H), 2.22-2.34 (m, 2H), 5.26 (dd, J = 6.3, 8.8 Hz, 1H), 7.01 (bs, 1H), 
7.09-7.10 (m, 1H), 7.11 (bs, 1H), 7.15 (ddd, J = 8.0, 8.5, 9.9 Hz, 1H), 7.20-7.23 (m, 1H), 7.30 (ddd, J = 2.2, 7.5, 
11.5 Hz, 1H), 7.31 (d, J = 1.3 Hz, 1H), 7.65 (bs, 1H); δC (CDCl3, 125 MHz) 10.9 (CH3), 30.0 (CH2), 58.9 (CH), 
115.2 (d, 2JCF = 18.2 Hz, CH), 117.2 (CH), 117.6 (d, 2JCF = 17.3 Hz, CH), 120.5 (CH), 122.2 (dd, 3JCF = 6.7 Hz, 4JCF 
= 3.8 Hz, CH), 124.1 (CH), 129.8 (CH), 132.5 (dd, 3JCF = 6.7 Hz, 4JCF = 3.8 Hz, Cq), 136.4 (CH), 140.0 (Cq), 145.2 
(Cq), 149.7 (dd, 1JCF = 247.5 Hz, 2JCF = 12.5 Hz, Cq), 150.5 (dd, 1JCF = 249.5 Hz, 2JCF = 13.5 Hz, Cq); MS (ESI): m/z 
= 305 [M++H]. 
1-((4-Bromothiophen-2-yl)methyl)-1H-imidazole, 16a. Synthesised according to Method E using 16b (0.74 g, 
3.81 mmol) and CDI (1.24 g, 7.67 mmol); yield: 0.72 g (78 %); colourless oil; Rf = 0.17 (EtOAc); δH (CDCl3, 500 
MHz) 5.23 (s, 2H), 6.88-6.89 (m, 1H), 6.94 (s, 1H), 7.09 (s, 1H), 7.18 (d, J = 1.6 Hz, 1H), 7.55 (s, 1H); δC (CDCl3, 
125 MHz) 45.2 (CH2), 109.8 (Cq), 118.8 (CH), 123.3 (CH), 129.2 (CH), 130.2 (CH), 137.0 (CH), 139.9 (Cq); MS 
(ESI): m/z = 245/243 [M++H]. 
2-(4-((1H-Imidazol-1-yl)methyl)phenyl)-5-(chloromethyl)pyridine, 19. Synthesised according to Method E 
using compound 19a (0.49 g, 2.10 mmol) and CDI (0.68 g, 4.20 mmol); yield: 0.22 g (37 %); Rf = 0.15 (EtOAc / 
MeOH, 95:5); IR (ATR) υ (cm-1) 1507 (m), 1458 (s), 1384 (m), 1231 (m), 1104 (s), 1024 (m), 814 (m), 739 (s), 662 
(s); δH (CDCl3, 500 MHz) 3.94 (s, 2H), 5.09 (s, 2H), 6.89 (t, J = 1.3 Hz, 1H), 7.08 (t, J = 1.3 Hz, 1H), 7.09 (d, J = 
8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.2 Hz, 1H), 7.40 (dd, J = 2.5, 8.2 Hz, 1H), 7.53 (s, 1H), 8.24 (d, J 
= 2.2 Hz, 1H); δC (CDCl3, 125 MHz) 37.8 (CH2), 50.5 (CH2), 119.2 (CH), 124.1 (CH), 127.8 (CH), 129.4 (CH), 
129.7 (CH), 134.7 (Cq), 135.0 (CH), 137.3 (CH), 139.1 (CH), 139.5 (Cq), 149.6 (Cq), 149.7 (Cq); MS (ESI): m/z = 
284 [M++H]. 
5-(4-((1H-Imidazol-1-yl)methyl)phenyl)pyrimidine, 20. Synthesised according to Method E using compound 
20a (0.11 g, 0.60 mmol) and CDI (0.28 g, 1.10 mmol); yield: 0.08 g (57 %); white solid: mp 135–138 °C; Rf = 0.29 
(EtOAc / MeOH, 10:1); δH (CDCl3, 500 MHz) 5.18 (s, 2H), 6.92 (s, 1H), 7.10 (s, 1H), 7.28 (d, J = 8.1 Hz, 2H), 7.55 
(d, J = 8.1 Hz, 2H), 7.57 (bs, 1H), 8.91 (s, 2H), 9.19 (s, 1H); δC (CDCl3, 125 MHz) 50.3 (CH2), 119.2 (CH), 127.5 
(CH), 128.2 (CH), 130.0 (CH), 133.5 (Cq), 134.3 (CH), 137.2 (Cq), 137.4 (Cq), 154.8 (CH), 157.7 (CH); MS (ESI): 
m/z = 237 [M++H]. 
4-(4-((1H-Imidazol-1-yl)methyl)phenyl)morpholine, 21. Synthesised according to Method E using compound 
21a (0.33 g, 1.60 mmol) and CDI (0.52 g, 3.20 mmol); light yellow oil: bp > 200 °C; Rf = 0.22 (EtOAc); IR (ATR) υ 
(cm-1) 2854 cm-1 (w), 1613 (m), 1518 (m), 1450 (m), 1230 (s), 1117 (s), 926 (s), 826 (s), 664 (s); δH (CDCl3, 500 
MHz) 1.82 (d, J = 7.0 Hz, 3H), 3.15 (m, 4H), 3.85 (m, 4H), 5.27 (q, J = 7.0 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 6.90 
(bs, 1H), 7.05 (bs, 1H), 7.07 (d, J = 8.6 Hz, 2H), 7.56 (bs, 1H); δC (CDCl3, 125 MHz) 22.0 (CH3), 49.0 (CH2), 56.0 
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(CH), 66.8 (CH2), 115.6 (CH), 117.8 (CH), 127.1 (CH), 129.3 (CH), 132.4 (Cq), 136.0 (CH), 151.0 (Cq); MS (ESI): 
m/z = 257 [M++H]. 
1-(1-(4-(5-Methylsulfanyl-thiophen-2-yl)-phenyl)-propyl)-1H-imidazole, 23. Synthesised according to 
Method E from 23a  (0.60 g, 2.30 mmol); yield: 0.40 g (56 %); white solid: mp 86 °C; Rf = 0.48 (DCM / MeOH, 
98:2); IR (ATR) υ (cm-1) 3119 (w), 2967 (w), 1684 (w), 1512 (m), 1461 (m), 1232 (s), 1071 (s), 1022 (m), 908 (s), 
836 (s), 786 (s), 741 (s), 665 (s); δH (DMSO, 500 MHz) 0.93 (t, J = 7.3 Hz, 3H, CH3), 2.16-2.18 (m, 2H, CH2),  2.42 
(s, 3H, S-CH3), 4.92 (t, J = 7.6 Hz, 1H, CH),  6.63-6.64 (m, 1H), 6.87-6.88 (m, 1H), 7.01-7.03 (m, 2H), 7.09-7.11 
(m, 2H), 7.42-7.44 (m, 2H), 7.53 (s, 1H); δC (DMSO, 125 MHz) 11.1 (CH3), 15.4 (S-CH3), 28.5 (CH2), 63.0 (C-
OH), 117.6, 123.2, 125.8, 126.3, 127.0, 129.6, 134.6, 136.3, 138.9, 139.9, 141.0; MS (ESI): m/z = 285 [M+- Et]. 
1-(1-(4-Thiophen-3-yl-phenyl)propyl)-1H-imidazole, 27.  Synthesised according to Method E from 27a (0.32 
g, 1.40 mmol)); yield: 0.37 g (87%); white solid: mp 128 °C; Rf = 0.55  (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 
3134 (w), 2930 (w), 1798 (vs), 1528 (w), 1479 (m), 1401 (vs), 1321 (s), 1265 (vs), 837 (m); δH (DMSO, 500 MHz) 
0.91 (t, J = 7.3 Hz, 3H, CH3), 1.95 (m, 1H, CH2), 2.05-2.7 (m, 1H, CH2), 5.83-5.85 (m, 1H, CH), 7.09-7.10 (m, 1H), 
7.52-7.53 (m, 2H), 7.55 (d, J = 8.2 Hz, 1H), 7.63-7.65 (m, 1H), 7.67 (t, J = 1.6 Hz, 1H), 7.73-7.75 (m, 2H), 7.88-
7.89 (m, 1H), 8.37-8.38 (m, 1H); δC (DMSO, 125 MHz) 9.4 (CH3), 28.5 (CH2), 117.4, 121.2, 126.0, 126.8, 127.0, 
130.3, 135.1, 137.2, 137.6, 140.8, 147.6; MS (ESI): m/z = 269 [M++H]. 
1-(1-(4-Thiophen-3-ylphenyl)ethyl)-1H-imidazole, 28. Synthesised according to Method E from 28a (0.50 g, 
2.45 mmol); yield: 0.63 g (87 %); white solid: mp 153 °C; Rf = 0.57 (DCM / MeOH, 98:2); IR (ATR) υ (cm-1) 3136 
(w), 1745 (vs), 1476 (m), 1392 (s), 1259 (m), 836 (m); δH (DMSO, 500 MHz) 1.67 (d, J = 6.3 Hz, 3H, CH3), 6.03-
6.06 (q, 1H, CH), 7.08-7.09 (m, 1H), 7.53-7.55 (m, 3H), 7.63-7.64 (m, 2H), 7.75-7.77 (m, 2H), 7.88-7.89 (m, 1H), 
8.34-8.36 (m, 1H); δC (DMSO, 125 MHz) 27.6 (CH3), 121.5, 126.1, 127.6, 134.9, 137.3, 141.3,  147.5; MS (ESI): 
m/z = 255 [M++H]. 
1-(1-(4-(4-Methylthiophen-3-yl)phenyl)propyl)-1H-imidazole, 29. Synthesised according to Method E from 
29a (0.90 g, 3.90 mmol); yield: 0.23 (21 %); white solid; Rf = 0.35 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 2969 
(w), 2932 (w), 1494 (m), 1455 (w), 1223 (s), 1072 (s), 906 (m), 790 (vs), 734 (s), 663 (vs); δH (CDCl3, 500 MHz) 
0.99 (t, J = 7.3 Hz, 3H, CH3), 2.22-2.25 (m, 3H), 5.06 (t,  J = 7.6 Hz, 1H, CH), 6.99-7.01 (m, 1H), 7.02-7.03 (m, 
1H), 7.10-7.11 (m, 1H), 7.17-7.18 (m, 1H),  7.21-7.23 (m, 2H), 7.35-7.37 (m, 2H), 7.62-7.63 (m, 1H); δC (CDCl3, 
125 MHz) 11.1 (CH3), 15.5 (CH3), 28.6 (CH2), 63.1 (CH), 117.7, 120.2, 122.2, 123.2, 126.5, 128.9, 129.6, 136.0, 
136.4, 137.0, 139.0, 142.3; MS (ESI): m/z = 283 [M++H]. 
1-(1-(2-Fluoro-4-(4-methylthiophen-3-yl)phenyl)propyl)-1H-imidazole, 30. Synthesised according to Method 
E from 30a (0.73 g, 2.90 mmol); yield: 0.12 g (22 %); white solid; Rf = (PE / EtOAc, 10:1); IR (ATR) υ (cm-1) 2970 
(w), 1624 (m), 1572 (m), 1493 (m), 1446 (w), 1407 (w), 1280 (m), 1223 (s), 1111 (m), 1073 (m), 906 (m), 865 (m), 
791 (vs), 732 (s); δH (CDCl3, 500 MHz) 0.96 (t, J = 7.3 Hz, 3H, CH3), 2.25 (m, 5H), 5.37 (t, J = 6.9 Hz, 1H, CH), 
7.03-7.05 (m, 2H), 7.11-7.13 (m, 2H), 7.20-7.22 (m, 3H), 7.65-7.66 (m, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 15.4 
(CH3), 27.7 (CH2), 56.6 (CH), 115.9, 117.8, 122.6, 123.8, 124.8, 125.9, 127.1, 129.3, 135.7, 136.4, 139.1, 141.0, 
158.9, 160.9; MS (ESI): m/z = 301 [M++H]. 
1-(1-(4-(2-Chlorothiophen-3-yl)-phenyl)propyl)-1H-imidazole, 31. Synthesised according to Method E from 
31a ( 0.81 g, 3.20 mmol); yield: 0.32 g (33 %); yellow oil; Rf = 0.36 (DCM / MeOH, 20:1); IR (ATR) υ (cm-1) 2967 
(w), 1495 (m), 1410 (w), 1260 (m), 1224 (m), 1109 (m), 1072 (s), 1024 (s), 906 (m), 876 (s), 812 (vs), 719 (vs), 663 
(vs), 622 (vs), 549 (m); δH (CDCl3, 500 MHz) 0.96 (t, J = 7.3 Hz, 3H, CH3), 2.25 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.04 
(t, J = 7.6 Hz, 1H, CH), 6.97 (s, 1H), 7.00 (d, J = 6.0 Hz), 7.09 (s, 1H), 7.13 (d, J =  5.7 Hz, 1H), 7.23 (d, J = 8.2 Hz, 
2H), 7.53 (d, J = 8.2 Hz, 2H), 7.61 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.5 (CH2), 62.9 (CH), 117.6, 122.8, 
125.0, 126.5, 128.2, 128.8, 129.5, 133.9, 136.3, 137.2, 139.5; MS (ESI): m/z = 303 [M++H], 235 [M+-Im]. 
Docking studies 
Ligands. All molecular modelling studies were performed on Intel(R) P4 CPU 3.00GHz running Linux Suse 
10.1. The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, Missouri, USA) 
and energy-minimized in MMFF94s force-field42 as implemented in Sybyl. The resulting geometries for our 
compounds were then subjected to ab initio calculation employing the B3LYP functional43-44 in combination with a 
6-31G* basis set using the package Gaussian03 (Gaussian, Inc., Pittsburgh, PA, 2003).  
Homology modelling. A homology model was build with MODELLER v8.0,45-46 using the X-ray structure of 
human CYP2C9 (PDB (http://www.rcsb.org) code 1R9O, Res. 1.9 Å) as template. The two amino acid sequences 
were globally aligned with T-COFFEE47 and then manually refined considering the predicted secondary structure of 
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CYP17 (secondary structure prediction by PSIPRED48 to give an overall sequence identity percentage of 
approximately 30 %). The heme group was included in model building. 
The resulting best homology model was first checked with the BIOPOLYMER module of SYBYL and AMBER 
charges were loaded. Hydrogens at histidine residues were positioned at the ε-nitrogen. Serine residues were 
considered to be neutral, whereas all basic and acidic residues were considered protonated and deprotonated, 
respectively. This structure was minimized for 200 steps with the steepest descent minimizer as implemented in 
SYBYL with the backbone atoms kept at fixed positions in order to achieve a low energy conformation and a 
satisfactory protein geometry containing no conformationally disallowed regions. Finally the chosen homology 
model was validated using different online tools (PROCHECK49 and WHATIF50). 
Docking. Molecular docking calculations were performed for various inhibitors of Table 1 and 2. Since the 
GOLD docking program allows flexible docking of the compounds, no conformational search was employed to the 
ligand structures. GOLD gave the best poses by a genetic algorithm (GA) search strategy, and then various 
molecular features were encoded as a chromosome. 
Ligands were docked in 50 independent genetic algorithm (GA) runs using GOLD. Heme iron was chosen as 
active-site origin, while the radius was set equal to 19 Å. The automatic active-site detection was switched on. A 
distance constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-hybridised nitrogen of the 
imidazole and the iron was set. Further, some of the GOLDSCORE parameters were modified to improve the weight 
of hydrophobic interaction and of the coordination between iron and nitrogen. The genetic algorithm default 
parameters were set as suggested by the GOLD authors. On the other hand, the annealing parameters of fitness 
function were set at 3.5 Å for hydrogen bonding and 6.5 Å for Van der Waals interactions.  
All 50 poses for each compound were clustered with ACIAP51,52 and the representative structure of each 
significant cluster was selected. The quality of the docked representative poses was evaluated based on visual 
inspection of the putative binding modes of the ligands, as outcome of docking simulations and cluster analysis. 
MEP. For each docked compound geometry optimization was performed at the B3LYP/6-31G* level by means 
of the Gaussian03 software and the molecular electrostatics potential map (MEP) was plotted using GaussView3, 
the 3-D molecular graphics package of Gaussian.53 These electrostatic potential surfaces were generated by mapping 
6-31G* electrostatic potentials onto surfaces of molecular electron density (isovalue = 0.002 electron/Å).54 
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Abstract 
Abiraterone, a steroidal cytochrome P450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently 
undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. Since 
steroidal compounds often show side effects attributable to their structure, we have tried to replace the sterane 
scaffold by nonsteroidal core structures. The design and synthesis of 20 new abiraterone mimetics are described. 
Their activities have been tested with recombinant human CYP17 expressed in E. coli. Promising compounds were 
further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4. Compounds 19 and 20 
showed comparable activity to abiraterone (IC50 values of 144 and 64 nM vs 72 nM) and similar or even better 
selectivity against the other CYP enzymes. Selected compounds were also docked into our homology model, and the 
same binding modes as for abiraterone were found. 
Introduction 
Prostate cancer (PC) is the most common tumor and age-related cause of death in elder men worldwide.1 
Because of the advanced age of the patients, less invasive approaches are needed. Accordingly, the treatment of 
choice is ‘watchful waiting,’2 followed by radiation therapy only when it is necessary. Since PC is androgen 
dependent in over 80% of the cases, another current standard treatment is orchiectomy, the surgical removal of the 
testes, usually applied to patients under 70 years old. The reduction of testicular androgen production by 
gonadotropin-releasing hormone (GnRH) analogues,3 a ‘medical castration’, is often preferred over the surgical one 
and can also be used for treating older patients. Nevertheless, castration whether surgical or medical reduces 
maximally 90-95% of the daily testosterone production, which is often not enough to stop the tumor from growing, 
since prostate levels of testosterone and dihydrotestosterone are still about 25% and 10%, respectively, even after 
three months of treatment with a GnRH agonist.4 
The remaining 5-10% of the androgens are produced in the adrenals. In the 1980s, Labrie5 hypothesized that 
additionally counteracting adrenal androgens by application of antiandrogens would further inhibit tumor growth. 
This approach, known as ‘combined androgen blockade’ (CAB), has been widely used in the past. The results have 
been partially positive, especially in patients with minimal disease and good performance status. However, it must 
be mentioned that antiandrogen therapy is associated with notable side effects.6 Another drawback of CAB is that in 
refractory PC regression is observed after discontinuation of antiandrogen administration. This led to the hypothesis 
that under antiandrogen treatment androgen receptor mutations occur causing PC cells to recognize antagonists as 
agonists.7 
An alternative target proposed in the recent past is the cytochrome P450 enzyme 17α-hydroxylase-17,20-lyase 
(CYP17). This enzyme is localized in the endoplasmic reticulum in the testes as well as in the adrenals and is the 
key enzyme for androgen biosynthesis. Its inhibition should stop the production of androgens both in the testes and 
in the adrenals, and therefore, inhibitors of CYP17 should be more effective for treating androgen-dependent PC 
than GnRH analogues. Proof of principle was achieved by the unspecific CYP inhibitor ketoconazole, which 
clinically turned out to be a good adjuvant therapeutic capable of reducing testosterone levels.8 Nevertheless, the 
side effects shown by this antimycotic compound are the reason that it is not used anymore.9 
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CYP17 catalyzes two reactions, the 17α-hydroxylation of pregnenolone and progesterone to the corresponding 
17α alcohols and the subsequent 17,20-lyase reaction cleaving the C17-C20 bond. This yields the 17-keto androgens 
androstendione and dehydroepiandrosterone, precursors of all other androgens, including testosterone (Chart 1). 
 
 
 
 
 
 
 
Chart 1. The role of CYP17 in androgen biosynthesis 
The side effects of ketoconazole caused others10 and our group to develop steroidal11 and nonsteroidal12,13 
inhibitors. One compound, the steroidal CYP17 inhibitor abiraterone (Chart 2), is currently undergoing phase II 
clinical trials showing high activity in postdocetaxel castration refractory PC patients. In contrast to ketoconazole, it 
seems to have no dose-limiting toxicity.14 
Because steroidal compounds often show side effects due to interactions with steroid receptors,15 it is our aim to 
develop nonsteroidal compounds. In this work, we present the design, synthesis, in vitro evaluation regarding 
activity and selectivity and modeling studies of nonsteroidal analogues of abiraterone (Chart 3). 
 
Chart 2. Substrate, abiraterone and synthesized mimetics 
O 
O 
O 
O 
O H 
O 
O 
1. step 
CYP17, NADPH, O2 
- H2O 
testosterone 
H 2. step 
CYP17, NADPH, O2 
- CH3COOH 
progesterone  
(or pregnenolone) 
17β-hydroxyprogesterone 
17β-hydroxysteroid 
dehydrogenase type 3 
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Design 
The three most important structural features of abiraterone are the aromatic nitrogen-containing heterocycle, the 
hydrophobic steroidal core, and the hydroxy group mimicking the oxygen at the 3-position of the substrates. All of 
them are similarly important for a high affinity to the enzyme. CYP enzymes have the particularity of bearing a 
heme moiety in their binding site. The complexation of the Fe2+ of the heme with an sp2 hybridized nitrogen as in 
pyridyl and imidazolyl is widely described.16 In recent studies13 we showed that a biphenyl moiety can replace the 
steroidal core AC-rings and that a biphenyl moiety furnished with an imidazolyl-methylene group ensures high 
CYP17 inhibitory activity (Chart 2). Introduction of alkyl substituents at the methylene bridge13b,f (for example, 
compound A13f) and first attempts to rigidify the structures resulting in indane compounds (like compound B13b) 
increased activity. Interestingly, 4-fluoro substituted compounds in general showed very high inhibitory activity. 
Compound A, the indane ring opened analogue to compound B, was more active in the rat and showed a longer 
plasma half-life and higher bioavailability compared to abiraterone, while its in vitro activity with regard to potency 
and selectivity was not as outstanding as that of the steroidal compound. In this work we want to elucidate whether 
it is possible to further increase activity and especially selectivity by additional attempts to rigidify the biphenyl 
structure and to exchange the heterocycle. The resulting compounds are mimics of the steroidal compound 
abiraterone. For the design of the synthesized compounds, the steroidal core was replaced by an indane (mimicking 
the steroidal C- and D-rings) or tetrahydronaphthalene scaffold (for expansion of the D-ring) connected to an A-ring 
mimicking phenyl moiety. Electron donating and withdrawing substituents (including hydroxy and fluoro) were 
introduced in different positions at the phenyl ring. The iron-complexing aromatic nitrogen was represented by a 3- 
or 4-pyridine moiety. 
CH2
R1
R2
n
3
4
N
CH2
R1
R2
n
3
4
N
CH2
R1
R2
n
3
4
N
HO
  
1-7                                  8-14                                 15-20 
Compound R1 R2 n N 
1 F H 1 3 
2 F H 1 4 
3 OMe H 1 4 
4 OMe F 1 4 
5 F H 2 4 
6 F F 2 4 
7 OMe F 2 4 
8 F H 1 3 
9 F H 1 4 
10 OMe H 1 4 
11 F H 2 4 
12 F F 2 4 
13 OH OH 2 4 
14 OH F 2 4 
15 F H 1 3 
16 F H 1 4 
17 F H 2 4 
18 F F 2 4 
19 OH OH 2 4 
20 OH F 2 4 
Chart 3. List of synthesized compounds 1-20 
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Three classes of mimetically relevant compounds were synthesized. Compounds 1-7, hydroxylated at the C17 
mimicking position, are analogues of the steroidal substrates for the second enzymatic step (lyase reaction). 
Compounds 7-14 bearing a double bond are structurally analogous to abiraterone. The saturated alkanes 15-20 show 
the highest similarity to the first-step (hydroxylase reaction) substrates. 
In the following, the synthesis, determination of activity, and selectivity and molecular modeling studies of the 
synthesized abiraterone analogues are presented. Besides CYP17 inhibitory activity, inhibition of other CYP 
enzymes was examined to exclude possible side effects due to unspecific heme iron complexation. Thus, selectivity 
toward CYP11B1 and CYP11B2 was determined, since their biological relevance relies on the fact that CYP11B1 is 
involved in glucocorticoid biosynthesis while CYP11B2 catalyzes the last step in mineralocorticoid formation. 
Special attention was given to the most crucial hepatic enzyme CYP3A4, since it is involved in the metabolism of 
over 50% of all prescription drugs.17 The most interesting compounds were docked into our homology-approach 
derived protein model and the binding modes in the active site discussed. 
Chemistry 
The syntheses of compounds 1-20 are shown in Schemes 1 and 2. In our aim to rigidify our biphenylic core 
structure by connecting the methylene bridge with the C-ring mimicking phenyl moiety, we synthesized indane 
derivatives (Scheme 1), which can be considered abiraterone analogues, and expanded the nonaromatic ring by one 
methylene group yielding tetrahydronaphthalene derivatives (Scheme 2). Different substitution patterns at the A-
ring mimicking phenyl substituent were used. Suzuki coupling18 (Method A) using 5-bromoindanone for the 
abiraterone analogues and 1-tetralon-6-yl trifluoromethanesulfonate, synthesized from the respective alcohol, for the 
tetrahydronaphthalenes yielded the indanones 1a-4a and the tetralones 5a-7a. The pyridine moiety was introduced 
by means of a nucleophilic addition (Method B) with the corresponding lithium pyridinyl salt to yield the tertiary 
alcohols 1-7 and 13a. The condensation to the corresponding alkenes was performed in HCl/isopropanol (8-12, 
Method C) or in HBr/H2O (13 and 14, Method E). The latter method was applied when a simultaneous ether 
cleavage was desired. The hydration to the saturated rings was carried out with Pearlman’s catalyst (Pd(OH)2), 
resulting in compounds 15-20 (Method D). 
Scheme 1. Synthesis of indane derivatives.  
a
b c
d
1 - 4
1a - 4a
O
Br
O
R1
R2
R1
R2
HO Ar
R1
R2
Ar
R1
R2
Ar
8 - 10
15, 16
1: R1 = F, R2 = H, Ar = 3-Py
2: R1 = F, R2 = H, Ar = 4-Py
3: R1 = OMe, R2 = H, Ar = 4-Py
4: R1 = OMe, R2 = F, Ar = 4-Py
8: R1 = F, R2 = H, Ar = 3-Py
9: R1 = F, R2 = H, Ar = 4-Py
10: R1 = OMe, R2 = H, Ar = 4-Py
15: R1 = F, R2 = H, Ar = 3-Py
16: R1 = F, R2 = H, Ar = 4-Py
xHCl
xHCl
 
Reagents and conditions: a: Method A: Na2CO3, R1R2C6H3B(OH)2, Pd(PPh3)4, toluene, H2O, reflux, 8 h; b: Method B: 3-iodopyridine 
or 4-bromopyridine, n-BuLi, THF, Et2O, -78 °C - rt, 3h; c: Method C: HCl in i-propanol, rt, 2h; d: Method D: Pd(OH)2, ethanol, THF, 
H2, rt, 3h. 
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Scheme 2. Synthesis of tetrahydronaphthalene derivatives.  
O
O
O
HO
O
TfO
O
R2
R1
R2
R1
HO
R2
R1
R2
R1
5: R1 = F, R2 = H
6: R1 = F, R2 = F
7: R1 = OMe, R2 = F
11: R1 = F, R2 = H
12: R1 = F, R2 = F
13: R1 = OH, R2 = OH
14: R1 = OH, R2 = F
17: R1 = F, R2 = H
18: R1 = F, R2 = F
19: R1 = OH, R2 = OH
20: R1 = OH, R2 = F
d
a b c
e f
5 - 7, 13a 11 - 14 17 - 20
N
N N
5a - 7a, 13b5b5c
or a for
7 and 13a
11, 12, 17 and 18 as HCl salts
13, 14, 19 and 20 as HBr salts  
Reagents and conditions: a: Method E: HBr, reflux, 16 h; b: pyridine, Tf2O, DCM, 0 °C - rt, 3h; c: Method A: Na2CO3, 
R1R2C6H3B(OH)2, Pd(PPh3)4, toluene, H2O, reflux, 8 h; d: Method B: 3-iodopyridine or 4-bromopyridine, n-BuLi, THF, Et2O, -78 °C - rt, 
3h; e: Method C: HCl in i-propanol, rt, 2h; f: Method D: Pd(OH)2, ethanol, THF, H2, rt, 3h. 
Results 
Biological Results. Inhibition of human CYP17 was determined by performing our previously described 
assay.13d  
For the source of human CYP17, E. coli19 coexpressing human CYP17 and NADPH-P450 reductase were used. 
After homogenization, the 50 000 g sediment was incubated with progesterone (25 μM) and the inhibitor.12a 
Separation of the product was performed by HPLC using UV detection. The IC50 values determined for compounds 
1-20 are shown in Table 1. 
The compounds can be divided into two classes according to the CD-ring mimicking moiety, namely in indane 
and hydronaphthalene derivatives, and also into three classes regarding the pyridyl bearing C atom, that is in 
alcohols, alkenes, and alkanes. Most of the indane derivatives, either bearing a 3-pyridyl or a 4-pyridyl substituent, 
showed no or little CYP17 inhibition. Only compound 2, with a moderate inhibition of 333 nM, and compound 16 
(IC50 = 233 nM) were active. Interestingly, both compounds contain a 4-pyridyl group as iron-complexing 
heterocycle and a fluorine at R1. 
The hydronaphthalenes were more potent than the indanes, showing a broad range of activity. The alkenes (11-
14) were weaker inhibitors than the corresponding compounds with a single bond, the alcohols (5-7) and 
tetrahydronaphthalenes (17-20). The inhibition values range from about 200 to over 5000 nM, while for the single 
bond compounds the values range mostly from around 100 to 500 nM. An important condition for inhibitory activity 
in the class of the alkanes is a 4-pyridyl substituent. In the 4-position of the phenyl ring (R1) a F or OH group and in 
3-position (R2) H, F, or OH led to highly active compounds. Interestingly, the 3,4-di-F-substituted compound 18 
only showed moderate activity. One explanation for this finding might be the electron withdrawing effect of the two 
F atoms at the phenyl ring. The most potent compounds were the 4-OH compounds 19 and 20 (IC50 = 144 and 64 
nM). A hydroxy substituent in 4-position of the phenyl ring also makes the alkenes from the 4-pyridyl substituted 
dihydronaphthalene type potent inhibitors (compounds 13 and 14). In the class of the indenes, 3-pyridyl substitution, 
as in abiraterone, led to an active compound (8) whereas 4-pyridyl substitution does not (9). It is striking, that 11 out 
of the 20 synthesized compounds were more active than ketoconazole. The most potent compound 20 showed a 
slightly higher inhibition compared to abiraterone (IC50 = 72 nM). Our seven most potent compounds from this work 
were more active than compound A (345 nM), and regarding compound B (670 nM), nine showed significantly 
higher inhibitory activities for CYP17. In the whole cell assay, i.e., E. coli coexpressing human CYP17 and 
NADPH-P450 reductase,12f the most active compound of this series, 20, was also highly active (IC50 < 200 nM). 
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Table 1. Inhibition of CYP17 by alcohols 1-7, alkenes 8-4 and alkanes 15-20 
                                          1-7                            8-14                           15-20 
Structures a CYP17 IC50 [nM] b 
R1 R2 n N Comp. a Alcohols Comp. a Alkenes Comp. a Alkanes 
Indanes 
F H 1 3 1 > 20,000 8 2346 15 > 20,000 
F H 1 4 2 333 9 > 20,000 16 233 
OMe H 1 4 3 > 20,000 10 > 5,000   
OMe F 1 4 4 > 10,000     
Hydronaphthalenes 
F H 2 4 5 587 11 > 5,000 17 163 
F F 2 4 6 423 12 > 5,000 18 1222 
OMe F 2 4 7 > 5,000     
OH OH 2 4   13 307 19 144 
OH F 2 4   14 188 20 64 
KTZ c 2780 
ABT d 72 
a Compounds 8-12 and 15-18 were tested as HCl salts and 13, 14, 19 and 20 as HBr salts 
b Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. Concentration of progesterone 
(substrate) was 25 μM 
c KTZ: ketoconazole 
d ABT: abiraterone 
Since the target enzyme contains a heme in its binding site, hence CYP/P450 enzyme, which is crucial for the 
enzymatic reaction and for binding the iron-complexing nitrogen containing inhibitors, the latter compounds were 
tested for selectivity against other CYP enzymes. Accordingly, selected compounds were tested for inhibitory 
activity on the steroidogenic CYP enzymes CYP11B1 and CYP11B2, key enzymes in glucocorticoid and 
mineralocorticoid biosynthesis. For the assay,20 V79MZh11B1 cells expressing human CYP11B1 and 
V79MZh11B2 cells expressing human CYP11B2 were used. The IC50 values determined for selected compounds 
are shown in Table 2. 
With the exception of compounds 4 and 7 showing IC50 values of 291 and 686 nM toward CYP11B1, 
respectively, the other tested compounds exhibited IC50 values above 1 μM. Most of the compounds (2, 6, 11-14, 17-
19) turned out to be more selective than abiraterone (IC50 = 1608 nM), and all compounds were more selective 
compared to ketoconazole (127 nM) regarding the cortisol forming enzyme. Concerning compound A (66% 
inhibition at 0.2 μM), all compounds from this study showed much higher selectivity. 
The inhibition of CYP11B2 observed with the evaluated compounds was a little higher showing IC50 values 
between 121 and 2324 nM. Compared to abiraterone (IC50 = 1751 nM), compounds 6 and 13 exhibited a similar 
selectivity whereas compound 19 (IC50 = 2324 nM) was more selective than the reference. Compared to 
ketoconazole (IC50 = 67 nM) and compound A (66% inhibition at 0.2 μM), all compounds were more selective with 
the exception of compound 11 (IC50 = 121 nM). 
The synthesized compounds were also evaluated for inhibition of the most crucial hepatic CYP enzyme CYP3A4 
in regard to its important role in drug metabolism. Except for compound 9 (IC50 = 159 nM) and compound 13 (IC50 
= 357 nM), the IC50 values for compounds 1-20 were between 632 and >20000 nM. These compounds were more 
selective than ketoconazole (72 nM) and compound A (88% at 1 μM). Most of the compounds were even more 
selective than abiraterone (IC50 = 2704 nM). 
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Table 2. Inhibition of CYP11B1, CYP11B2 and CYP3A4 by compounds 1-20 
                                           1-7                            8-14                      15-20 
Comp.a 
Structures CYP11B1 b CYP11B2 b CYP3A4 b 
R1 R2 n N IC50 [nM] IC50 [nM] IC50 [nM] 
1 F H 1 3 n.d. c n.d. > 20,000 
2 F H 1 4 > 10,000 816 3231 
3 OMe H 1 4 n.d. n.d. 3291 
4 OMe F 1 4 291 436 3364 
5 F H 2 4 1159 840 8757 
6 F F 2 4 3109 1676 13841 
7 OMe F 2 4 686 945 15190 
8 F H 1 3 n.d. n.d. 6947 
9 F H 1 4 n.d. n.d. 159 
10 OMe H 1 4 n.d. n.d. 2394 
11 F H 2 4 > 10,000 121 4199 
12 F F 2 4 > 20,000 311 3643 
13 OH OH 2 4 > 10,000 1492 357 
14 OH F 2 4 2748 991 2114 
15 F H 1 3 n.d. n.d. 1697 
16 F H 1 4 1076 543 1093 
17 F H 2 4 > 5,000 518 2173 
18 F F 2 4 > 20,000 567 2300 
19 OH OH 2 4 2135 2324 632 
20 OH F 2 4 1370 587 3386 
KTZ d 127 67 72 
ABT e 1608 1751 2704 
a Compounds 8-12 and 15-18 were tested as HCl salts and 13, 14, 19 and 20 as HBr salts 
b Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. Concentration of progesterone 
(substrate) was 25 μM 
c n.d.: not determined 
d KTZ: ketoconazole 
e ABT: abiraterone 
Molecular Modeling. Since there is no crystal structure of CYP17 available, we recently built a homology 
model using the X-ray structure of human CYP2C9 (PDB ID 1r9o) as template.13e Docking simulations with energy 
minimized compounds were carried out by means of the GOLD 3.2 software running Linux CentOS 5.1 on an 
Intel® P4 CPU 3.00 GHz computer, using a slightly modified GOLDSCORE function with goldscore.P450_pdb 
parameters, for a better evaluation of hydrophobic interactions. From every class, the most potent compounds were 
docked into this protein model, and in the case of chiral compounds, both enantiomers were docked. 
In Figure 1 two binding modes of the substrate pregnenolone are shown: one already described by others21 (SM1 
mode) and an additional one (SM2). Poses in SM1 occur more often (approximately 7:3) with an overall better 
scoring with respect to those in SM2. Furthermore, pregnenolone was also docked with CHEMSCORE, a scoring 
function with a higher assessment of the hydrophobic interactions, showing poses mostly in SM1 (>9:1). 
Interestingly, great similarities between SM2 and the orientation of our previously described biphenyl compound A 
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can be observed (there are actually two very similar modes described as BM1 and BM213e). Like the substrate, the 
steroidal inhibitor abiraterone is also able to bind in both modes but showing a good complexation with the heme 
iron only in SM1 (Figure 1). The same is true for compound B, the ring-closed analogue of compound A (not 
shown).
Figure 1. Both binding modes of the substrate pregnenolone (SM1, cyan, and SM2, yellow; the red arrow indicates 
the position of the C17 atoms, rendered as red spheres) are shown as docking complex with CYP17. For 
comparison, the two orientations of compound A (in the formerly described binding modes BM1, blue, and BM2, 
green13f) and abiraterone (magenta) are given. Heme, interacting residues and ribbon rendered tertiary structure of 
the active site are also represented. Figures were generated with Pymol (http://www.pymol.org).
The R and S configurated abiraterone analogues of the alcohol and alkane class also bind in both modes. 
Interestingly, a correlation between the inhibitory activities of the compounds of each class and the score values 
could be observed. In the case of highly active compounds, the percentage of poses presenting a good iron-nitrogen 
coordination is higher than for weak inhibitors. For enantiomers of a given racemic compound, one enantiomer 
always shows a preference for poses in one binding mode while the other enantiomer prefers to dock in the 
alternative one. In the case of the alcohols, in Figure 2 exemplified by compound 5, the R enantiomer binds 
predominantly in the SM1 mode (9:1) while the S enantiomer binds in SM2 (8:2). The opposite relation can be seen 
for the alkanes (Figure 2).
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Figure 2. Docking complexes of CYP17 and compounds 5 (R enantiomer in SM1 - bluegreen; S enantiomer in SM2 
- violet) and 20 (S enantiomer in SM1 - magenta; R enantiomer in SM2 - green). A dashed yellow line is 
representing the H-bond between the OH in C17 and the Gly301.
The most important interactions in SM1, besides heme iron complexation, are hydrophobic interactions with 
Ala113, Phe114, Ile371, Pro372, and Val482 and, depending on substituents R1 and R2, polar ones with the 
backbone of Glu98 and Met99 and the carboxyl group of Asp103. Furthermore, an H-bond formation between the 
OH group of R-alkohols and the backbone carbonile of Gly301 was observed, which could act as an additional 
stabilizing factor. Regarding SM2, the same interactions as described in refs 13e and 13f were found.
Low activity compounds did not show a real clustering in SM1 mode and were characterized by an unsuitable 
binding angle between the N lone electron pair and the heme plane (compound 12, Figure 3). On the other hand, the 
highly active alkenes 13 and 14 bind preferentially in SM2 mode and present a good complexation of the heme iron 
and a strong binding due to their 3,4-di-OH or 3-F,4-OH substitution.
Discussion and Conclusion
In the class of the indanes the 3-pyridyl substituted unsaturated compound 8, which is analogous to abiraterone, 
showed inhibitory activity in contrast to the respective alcohols and alkanes. In the case of the corresponding 4-
pyridyl substituted compounds, it is the other way around: the alcohols and the alkanes were active, while the 
unsaturated compounds did not show activity. However, it became apparent that the five-membered ring, though 
analogous to the substrate and abiraterone, is not favorable for CYP17 inhibition. On the other hand, the expansion 
of this ring by one methylene group resulting in the hydronaphthalenes led to very potent and selective compounds. 
Summarizing, we have discovered nine very potent abiraterone analogues, four of them (14, 17, 19, and 20) showing 
an IC50 value below 200 nM and one of them (20, IC50 = 64 nM) being slightly more active than abiraterone. These 
compounds showed low inhibition of the CYP enzymes considered for selectivity issues CYP11B1, CYP11B2 and 
the hepatic CYP3A4. Owing to their promising in vitro profile, presently compounds 20 and 19 are separated into 
their enantiomers and extensively evaluated for their in vivo activities and pharmacokinetics in the rat.
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Figure 3. Docking complexes of CYP17 and compounds 11 (yellow; its lone electron pair at the nitrogen and the 
axis of the octahedral heme iron atom are shown), 13 (cyan) and 14 (magenta).
Experimental Section
Chemistry. IR spectra were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra 
were measured on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS 
was used as an internal standard for spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI 
(electrospray ionization) mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) 
instrument. Column chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was 
determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as 
starting materials were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros).
Method A: Suzuki-Coupling. 5-Bromoindan-1-one (10 mmol) for compounds 1-4 or 5b (10 mmol) for 
compounds 5-7 and the corresponding boronic acid (15 mmol) were dissolved in toluene (70 mL) and Na2CO3
(30mL, 2.0 M, aq). The mixture was deoxygenated under reduced pressure and flushed with N2. After repeating this 
3 times, Pd(PPh3)4 (5 mol %) was added and the resulting suspension was heated under reflux for 8 h. After cooling, 
the phases were separated and the water phase was extracted 2 times with EtOAc. Then the combined organic 
extracts were dried over Na2SO4, and concentrated under reduced pressure. The purification was performed by Si-
gel flash-chromatography.
5-(4-Fluorophenyl)-2,3-dihydroinden-1-one (1a). Synthesized from 5-Bromoindan-1-one and 4-
fluorophenylboronic acid according to Method A; yield = 95 %; δH (CDCl3, 500 MHz) 2.66-2.69 (m, 2H), 3.12-3.14 
(m, 2H), 7.09 (t, J = 8.7 Hz, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.53 (dd, J = 5.3 Hz, J = 8.7 Hz, 2H), 7.56 (s, 1H), 7.75 
(d, J = 8.0 Hz, 1H); δC (CDCl3, 125 MHz) 14.08, 22.63, 25.86, 26.97, 31.57, 36.50, 49.43, 115.84, 116.01, 124.17, 
125.02, 126.62, 129.11, 129.17, 136.01, 146.64, 155.86, 162.07, 164.05, 206.40.
5-(4-Methoxyphenyl)-2,3-dihydroinden-1-one (3a). Synthesized from 5-Bromoindan-1-one and 4-
methoxyphenylboronic acid according to Method A; yield = 42 %. Since the so obtained ketone was used directly 
for the nucleophilic addition no analytics was performed.
5-(3-Fluoro-4-methoxyphenyl)-2,3-dihydroinden-1-one (4a). Synthesized from 5-Bromoindan-1-one and 3-
fluoro-4-methoxyphenylboronic acid according to Method A; yield = 99 %; δH (CDCl3, 500 MHz) 2.64-2.67 (m,
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2H), 3.11 (t, J = 5.7 Hz, 2H), 3.87 (s, 3H), 6.97 (t, J = 8.7 Hz, 1H), 7.27-7.32 (m, 2H), 7.46 (d, J = 8.7 Hz, 1H), 7.53 
(s, 1H), 7.71 (d, J = 8.0 Hz, 1H); δC (CDCl3, 125 MHz) 25.85, 36.50, 56.35, 113.71, 115.01, 115.20, 123.20, 123.23, 
124.17, 124.58, 126.24, 128.43, 128.55, 131.91, 131.94, 132.04, 132.14, 133.15, 133.22, 135.91, 146.03, 147.90, 
148.01, 151.37, 153.82, 155.93, 206.40. 
6-(4-Fluorophenyl)-3,4-dihydronaphthalen-1(2H)-one (5a). Synthesized from 5b and 4-fluorophenylboronic 
acid according to Method A; yield = 89 %; δH (CDCl3, 500 MHz) 2.05-2.10 (m, 2H), 2.59 (t, J = 6.8 Hz, 2H), 2.92 
(t, J = 6.1 Hz, 2H), 7.05 (t, J = 8.7 Hz, 1H), 7.32 (s, 1H), 7.38 (dd, J = 1.7 Hz, J = 8.2 Hz, 1H), 7.48 (dd, J = 5.3 Hz, 
J = 8.8 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H); δC (CDCl3, 125 MHz) 23.29, 29.91, 39.14, 115.76, 115.93, 125.33, 
127.12, 127.90, 128.89, 128.96, 131.46, 136.13, 144.92, 145.01, 161.98, 163.95, 198.00. 
6-(3,4-Difluorophenyl)-3,4-dihydronaphthalen-1(2H)-one (6a). Synthesized from 5b and 3,4-
difluorophenylboronic acid according to Method A; yield = 87 %. Since the so obtained ketone was used directly for 
the nucleophilic addition no analytics was performed. 
6-(3-Fluoro-4-methoxyphenyl)-3,4-dihydronaphthalen-1(2H)-one (7a). Synthesized from 5b and 3-fluoro-4-
methoxyphenylboronic acid according to Method A; yield = 59 %; δH (CDCl3, 500 MHz) 2.07-2.12 (m, 2H), 2.60 (t, 
J = 6.3 Hz, 2H), 2.94 (t, J = 6.1 Hz, 2H), 3.86 (s, 3H), 6.96 (t, J = 8.7 Hz, 1H), 7.27-7.30 (m, 2H), 7.33 (s, 1H), 7.39 
(dd, J = 1.6 Hz, J = 8.2 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H); δC (CDCl3, 125 MHz) 23.28, 29.92, 39.14, 56.33, 113.62, 
114.82, 114.98, 123.01, 124.97, 126.70, 127.94, 131.37, 132.98, 133.03, 144.39, 145.04, 147.80, 147.88, 151.59, 
153.55, 198.01. 
6-(3,4-Dimethoxyphenyl)-3,4-dihydronaphthalen-1(2H)-one (13b). Synthesized from 5b and 3,4-
dimethoxyphenylboronic acid according to Method A; yield = 87 %. Since the so obtained ketone was used directly 
for the nucleophilic addition no analytics was performed. 
Method B: Nucleophilic Addition of the Heterocycle. 3-Iodopyridine (4 mmol) – or either 4-Bromopyridine (4 
mmol) for the 4-pyridyl compounds, after basic extraction of its hydrochloride salt with Et2O (20 mL) and NaHCO3 
(satd, aq), followed by drying over Na2SO4 and concentration under reduced pressure – was prepared in Et2O and 
THF (3:2, 50 mL) at -78°C. Then n-BuLi in hexanes (1.6 N, 4.4 mmol) was added and after 5 sec the corresponding 
ketone (4 mmol) in THF (20 mL) was added at once and the mixture was left stirring for additional 3 h at room 
temperature. After neutralization with NH4Cl (satd, aq), the phases were separated, the aqueous layer extracted 2 
times with EtOAc and the combined organic extracts dried over Na2SO4 and concentrated under reduced pressure. 
The purification was performed by Si-gel flash-chromatography. 
5-(4-Fluorophenyl)-1-(pyridin-3-yl)-2,3-dihydro-1H-inden-1-ol (1). Synthesized from 1a and 3-Iodopyridine 
according to Method B; yield = 55 %; IR (ATR) υ (cm-1) 2925, 1604, 1516, 1482, 1418, 1223, 1159, 1060, 1027, 
822, 713, 685, 605, 537, 507; δH (CDCl3, 500 MHz) 2.36-2.47 (m, 2H), 2.85-2.89 (m, 1H), 3.08-3.14 (m, 1H), 6.98-
7.04 (m, 3H), 7.14-7.16 (m, 1H), 7.24-7.26 (d, J = 7.9 Hz, 1H), 7.36 (s, 1H), 7.41-7.44 (m, 2H), 7.69 (d, J = 7.9 Hz, 
1H), 8.29 (s, 1H), 8.48 (s, 1H); δC (CDCl3, 125 MHz) 14.19, 21.03, 29.89, 44.96, 60.41, 83.55, 115.57, 115.74, 
123.07, 123.69, 124.34, 126.30, 128.44, 128.54, 128.73, 128.79, 132.03, 132.11, 133.88, 137.15, 141.02, 142.31, 
144.74, 146.32, 147.32, 147.77, 161.54, 163.50, 171.20; m/z = 305.17 [M++H]. 
5-(4-Fluorophenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol (2). Synthesized from 2a and 4-
Bromopyridine according to Method B; yield = 50 %;IR (ATR) υ (cm-1) 2931, 1601, 1515, 1482, 1412, 1223, 1159, 
1066, 822, 676, 601, 533, 518; δH (CDCl3 + CD3OD, 500 MHz) 2.37-2.47 (m, 2H), 2.92-2.98 (m, 1H), 3.15-3.21 (m, 
1H), 7.00 (d, J = 7.9 Hz, 1H), 7.04 (t, J = 8.6 Hz, 2H), 7.29-7.31 (m, 3H), 7.41 (s, 1H), 7.41-7.47 (m, 2H), 8.38 (d, J 
= 4.8 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 29.90, 44.32, 83.82, 115.44, 115.61, 121.16, 123.46, 124.31, 
126.17, 128.63, 128.69, 137.05, 140.95, 144.75, 145.90, 148.70, 156.88, 161.46, 163.42; m/z = 306.21 [M++H]. 
5-(4-Methoxyphenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol (3). Synthesized from 3a and 4-
Bromopyridine according to Method B; yield = 45 %; IR (ATR) υ (cm-1) 3165, 2957, 2837, 1606, 1519, 1482, 1456, 
1287, 1249, 1182, 1113, 1069, 1039, 1022, 1002, 815, 671, 510, 542; δH (CDCl3 + CD3OD, 500 MHz) 2.34-2.46 (m, 
2H), 2.91-2.97 (m, 1H), 3.12-3.20 (m, 1H), 3.77 (s, 3H), 6.90 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 7.9 Hz, 1H), 7.30-
7.32 (m, 3H), 7.42 (s, 1H), 7.44 (d, J = 8.8 Hz, 2H), 8.38 (d, J = 6.2 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 
29.95, 44.43, 55.29, 83.93, 114.19, 121.15, 123.15, 124.20, 125.93, 128.16, 133.49, 141.61, 144.69, 145.29, 148.81, 
156.77, 159.17; m/z = 318.18 [M++H]. 
5-(3-Fluoro-4-methoxyphenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol (4). Synthesized from 4a and 4-
Bromopyridine according to Method B; yield = 56 %; δH (CDCl3, 500 MHz) 2.39-2.48 (m, 2H), 2.93-2.98 (m, 1H), 
3.14-3.19 (m, 1H), 3.85 (s, 3H), 6.93-6.98 (m, 2H), 7.21-7.30 (m, 5H), 7.40 (s, 1H), 8.40 (d, J = 6.2 Hz, 2H); δC 
(CDCl3, 125 MHz) 30.03, 44.69, 56.36, 84.27, 113.65, 114.81, 114.96, 120.92, 122.74, 123.37, 124.30, 126.11, 
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134.09, 134.14, 140.74, 144.92, 145.99, 147.16, 147.24, 149.23, 151.57, 153.53, 155.83; m/z = 336.11 [M++H]. 
6-(4-Fluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (5). Synthesized from 5a and 4-
Bromopyridine according to Method B; yield = 44 %; δH (CDCl3 + CD3OD, 500 MHz) 1.75-1.82 (m, 1H), 2.00-2.08 
(m, 2H), 2.09-2.16 (m, 1H), 2.86-3.00 (m, 2H), 6.98 (d, J = 8.1 Hz, 1H), 7.07 (t, J = 8.8 Hz, 2H), 7.27 (dd, J = 2.0 
Hz, J = 8.1 Hz, 1H), 7.33-7.34 (m, 3H), 7.51 (dd, J = 5.4 Hz, J = 8.6 Hz, 2H), 8.40 (d, J = 6.3 Hz, 2H); δC (CDCl3 + 
CD3OD, 125 MHz) 23.05, 33.68, 44.68, 77.96, 119.19, 119.40, 126.04, 128.82, 131.06, 132.35, 132.43, 133.59, 
140.68, 140.71, 141.91, 143.24, 143.34, 152.16, 153.76. 165.19, 167.64; m/z = 320.06 [M++H]. 
6-(3,4-Difluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (6). Synthesized from 6a and 4-
Bromopyridine according to Method B; yield = 40 %; IR (ATR) υ (cm-1) 3063, 1603, 1568, 1525, 1492, 1411, 1320, 
1272, 1230, 1198, 1119, 1068, 986, 907, 874, 816, 773, 734, 671; δH (CDCl3 + CD3OD, 500 MHz) 1.81-1.89 (m, 
1H), 1.99-2.07 (m, 2H), 2.12-2.18 (m, 1H), 2.89-3.00 (m, 2H), 6.99 (d, J = 8.1 Hz, 1H), 7.19 (q, J = 8.4 Hz, 1H), 
7.24-7.26 (m, 2H), 7.30-7.37 (m, 4H), 8.48 (d, J = 6.0 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 20.77, 31.35, 
42.36, 117.31, 117.45, 118.95, 119.09, 123.19, 124.35, 124.38, 124.40, 124.43, 126.74, 128.95, 131.14, 139.75, 
140.18, 141.49, 150.36, 159.83, 192.24; m/z = 338.13 [M++H]. 
6-(3-Fluoro-4-methoxyphenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (7). Synthesized from 7a 
and 4-Bromopyridine according to Method B; yield = 64 %; δH (CDCl3 + CD3OD, 500 MHz) 1.70-1.77 (m, 1H), 
1.94-2.03 (m, 2H), 2.03-2.10 (m, 1H), 2.82-2.93 (m, 2H), 3.84 (s, 3H), 6.92 (dd, J = 2.7 Hz, J = 8.1 Hz, 2H), 6.96 
(dt, J = 2.4 Hz, J = 8.4 Hz, 1H), 7.19-7.28 (m, 6H), 8.35-8.36 (m, 2H); δC (CDCl3 + CD3OD, 125 MHz) 19.02, 
29.67, 40.64, 56.06, 73.93, 113.57, 114.23, 114.42, 121.91, 122.37, 122.40, 124.55, 126.74, 129.50, 133.67, 133.73, 
137.88, 138.78, 139.11, 146.84, 146.94, 148.20, 151.14, 153.58, 159.42; m/z = 350.13 [M++H]. 
6-(3,4-Dimethoxyphenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol (13a). Synthesized from 13b 
and 4-Bromopyridine according to Method B; yield = 48 %. Since the so obtained alcohol was used directly for the 
condensation no analytics was performed. 
Method C: Condensation with HCl. The corresponding alcohol (1 mmol) was refluxed in HCl in i-PrOH (10 
mL, 3N) for 2 h. Afterwards, the resulting solution was concentrated under reduced pressure and washed 3 times 
with Et2O. No further purification was necessary. 
3-(5-(4-Fluorophenyl)-3H-inden-1-yl)pyridine hydrochloride (8). Synthesized from 1 according to Method C; 
yield = 96 %; IR (ATR) υ (cm-1) 3051, 1601, 1514, 1468, 1229, 1189, 1161, 1104, 1027, 976, 940, 879, 821, 772, 
716, 678, 557, 521; δH (CDCl3, 500 MHz) 3.53 (s, 2H), 6.61-6.62 (m, 1H), 7.06 (t, J = 8.7 Hz, 2H), 7.32 (dd, J = 4.8 
Hz, J = 7.8 Hz, 1H), 7.44 (dd, J = 1.4 Hz, J = 7.8, 1H), 7.49-7.52 (m, 3H), 7.65 (s, 1H), 7.83-7.85 (m, 1H), 8.55-
8.56 (d, J = 4.0 Hz, 1H), 8.81 (s, 1H); δC (CDCl3, 125 MHz) 38.54, 115.56, 115.73, 120.16, 123.06, 123.50, 125.46, 
128.70, 128.76, 131.75, 132.81, 134.83, 137.51, 137.59, 141.72, 142.47, 145.37, 148.79, 148.91, 161.41, 163.37; 
MS (ESI): m/z = 288.13 [M++H]. 
4-(5-(4-Fluorophenyl)-3H-inden-1-yl)pyridine hydrochloride (9). Synthesized from 2 according to Method C; 
yield = 100 %; IR (ATR) υ (cm-1) 3482, 3414, 3100-2500, 2075, 1997, 1632, 1602, 1679, 1555, 1469, 1383, 1262, 
1221, 1190, 1157, 1097, 1029, 948, 882, 829, 819, 787, 562, 552, 527; δH (CDCl3, 500 MHz) 3.20-3.22 (m, 2H), 
7.08 (t, J = 8.8 Hz, 2H), 7.30 (s, 1H), 7.54 (dd, J = 1.7 Hz, J = 8.1 Hz, 1H), 7.58 (dd, J = 5.4 Hz, J = 8.8 Hz, 2H), 
7.69 (d, J = 8.1 Hz, 1H), 7.76 (d, J = 1.4 Hz, 1H), 8.30 (d, J = 6.8 Hz, 2H), 8.81 (d, J = 6.8 Hz, 2H); δC (CDCl3, 125 
MHz) 116.53, 116.71, 121.29, 124.36, 126.43, 126.75, 129.90, 129.96, 138.56, 139.74, 141.01, 141.67, 142.35, 
142.96, 146.93, 155.08, 162.98, 164.93; m/z = 287.96 [M++H]. 
4-(5-(4-Methoxyphenyl)-3H-inden-1-yl)pyridine hydrochloride (10). Synthesized from 3 according to 
Method C; yield = 99 %; IR (ATR) υ (cm-1) 3404, 3061, 1632, 1605, 1517, 1496, 1469, 1244, 1185, 1036, 1020, 
815, 768, 566; δH (CDCl3 + CD3OD, 500 MHz) 3.24-3.27 (m, 2H), 3.78 (s, 3H), 6.92 (d, J = 8.8 Hz, 2H), 7.43 (s, 
1H), 7.50 (d, J = 8.8 Hz, 2H), 7.53 (dd, J = 1.7 Hz, J = 8.1 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 1.7 Hz, 
1H), 8.23 (d, J = 6.7 Hz, 2H), 8.80 (d, J = 6.7 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 54.88, 114.03, 119.55, 
122.91, 124.95, 125.20, 127.89, 133.02, 138.59, 139.21, 140.25, 140.92, 141.10, 144.94, 153.90, 159.08; m/z = 
301.16 [M++H]. 
4-(6-(4-Fluorophenyl)-3,4-dihydronaphthalen-1-yl)pyridine hydrochloride (11). Synthesized from 4 
according to Method C; yield = 100 %; IR (ATR) υ (cm-1) 3047, 2536, 1634, 1601, 1489, 1228, 1160, 825, 754, 
733; δH (CDCl3, 500 MHz) 2.58-2.61 (m, 2H), 2.94 (t, J = 7.8 Hz, 2H), 6.55 (t, J = 4.7 Hz, 1H), 6.95 (d, J = 7.9 Hz, 
1H), 7.14 (t, J = 8.7 Hz, 2H), 7.38 (d, J = 7.9 Hz, 1H), 7.46 (s, 1H), 7.56 (dd, J = 5.3 Hz, J = 8.7 Hz, 2H), 7.93 (d, J 
= 5.6 Hz, 2H), 8.79 (d, J = 5.6 Hz, 2H); δC (CDCl3, 125 MHz) 23.92, 27.76, 115.72, 115.90, 124.88, 125.37, 125.91, 
127.01, 128.50, 128.56, 130.58, 135.87, 136.21, 137.39, 140.65, 140.67, 158.45, 161.71, 163.68, 190.74; m/z = 
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302.10 [M++H]. 
4-(6-(3,4-Difluorophenyl)-3,4-dihydronaphthalen-1-yl)pyridine hydrochloride (12). Synthesized from 5 
according to Method C; yield = 98 %;IR (ATR) υ (cm-1) 3067, 1634, 1604, 1522, 1493, 1276, 1200, 1119, 911, 815, 
773, 729, 614; δH (CDCl3, 500 MHz) 2.57-2.61 (m, 2H), 2.94 (t, J = 8.0 Hz, 2H), 6.57 (t, J = 4.8 Hz, 1H), 6.96 (d, J 
= 8.0 Hz, 2H), 7.23 (q, J = 8.5 Hz, 1H), 7.29-7.31 (m, 1H), 7.36 (d, J = 8.5 Hz, 1H), 7.37-7.41 (m, 1H), 7.44 (s, 1H), 
7.92 (s, 1H), 7.93 (s, 1H), 8.81 (s, 1H), 8.82 (s, 1H); δC (CDCl3, 125 MHz) 23.86, 27.71, 115.77, 115.91, 117.63, 
117.76, 122.83, 122.85, 122.87, 122.90, 124.97, 125.35, 125.91, 126.94, 131.12, 136.10, 136.14, 137.54, 139.48, 
140.73, 149.11, 149.21, 149.52, 149.62, 151.10, 151.20, 151.50, 151.60, 158.26, 190.74; m/z = 320.11 [M++H]. 
Method D: Hydration with Pearlman's catalyst. Pearlman's catalyst (10 mass %) and the corresponding 
alkene was prepared in EtOH and THF (2:1, 5mL) under H2 atmosphere. The mixture was left stirring for 3 h, then 
the catalyst was filtered off 3 times and the solution concentrated under reduced pressure. The obtained solid was 
washed 3 times with Et2O. No further purification was necessary. 
3-(5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-1-yl)pyridine hydrochloride (15). Synthesized from 8 
according to Method D; yield = 99 %; δH (CDCl3, 500 MHz) 1.92-1.98 (m, 1H), 2.65-2.71 (m, 1H), 2.95-3.06 (m, 
2H), 4.51 (s, 1H), 6.84 (d, J = 6.9 Hz, 1H), 7.00 (t, J = 8.6 Hz, 2H), 7.24 (d, J = 6.9 Hz, 1H), 7.38-7.41 (m, 3H), 
7.76 (s, 1H), 8.13 (d, J = 5.0 Hz, 1H), 8.49 (s, 1H), 8.55 (s, 1H); δC (CDCl3, 125 MHz) 31.60, 36.55, 48.36, 115.64, 
115.66, 115.83, 115.87, 123.89, 123.91, 124.83, 126.54, 126.56, 128.78, 128.84, 140.48, 144.91, 145.03; m/z = 
290.10 [M++H]. 
4-(5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-1-yl)pyridine hydrochloride (16). Synthesized from 9 
according to Method D; yield = 100 %;IR (ATR) υ (cm-1) 3220, 2927, 2855, 1700, 1621, 1578, 1507, 1439, 1349, 
1251, 1215, 1153, 1040, 1027, 986, 914, 831, 806, 784, 748, 699, 668; δH (CDCl3, 500 MHz) 2.03-2.09 (m, 1H), 
2.72-2.78 (m, 1H), 3.03-3.13 (m, 2H), 4.60 (s, 1H), 6.93 (d, J = 7.1 Hz, 1H), 7.06 (t, J = 8.6 Hz, 2H), 7.32 (d, J = 6.7 
Hz, 1H), 7.45-7.47 (m, 3H), 7.68 (s, 2H), 8.71 (s, 2H); δC (CDCl3, 125 MHz) 31.80, 36.19, 51.29, 115.66, 115.83, 
123.80, 125.02, 126.28, 126.45, 128.72, 128.78, 136.83, 140.75, 140.99, 141.34, 145.22, 161.61, 166.50; m/z = 
290.17 [M++H]. 
4-(6-(4-Fluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)pyridine hydrochloride (17). Synthesized from 11 
according to Method D; yield = 97 %; IR (ATR) υ (cm-1) 3049, 1634, 1605, 1518, 1492, 1223, 1160, 1098, 997, 
911, 823, 727, 642; δH (CDCl3, 500 MHz) 1.82-1.90 (m, 3H), 2.33-2.37 (m, 1H), 2.94-3.00 (m, 2H), 4.46 (s, 1H), 
6.78 (d, J = 7.5 Hz, 1H), 7.12 (t, J = 8.6 Hz, 2H), 7.30 (d, J = 6.8 Hz, 1H), 7.39 (s, 1H), 7.53 (dd, J = 5.3 Hz, J = 8.6 
Hz, 2H), 7.67 (s, 2H), 8.71 (s, 2H); δC (CDCl3, 125 MHz) 20.06, 29.23, 32.58, 45.49, 115.54, 115.71, 125.26, 
126.85, 128.21, 128.43, 128.49, 130.20, 133.17, 136.25, 136.28, 138.09, 139.61, 140.45, 161.51, 163.48, 168.11, 
190.64; m/z = 304.10 [M++H]. 
4-(6-(3,4-Difluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)pyridine hydrochloride (18). Synthesized from 
12 according to Method D; yield = 98 %; IR (ATR) υ (cm-1) 3392, 1634, 1604, 1522, 1494, 1269, 1197, 1119, 998, 
925, 909, 875, 811, 772, 726, 643; δH (CDCl3, 500 MHz) 1.82-1.90 (m, 3H), 2.33-2.37 (m, 1H), 2.94-3.00 (m, 2H), 
4.46 (s, 1H), 6.79 (d, J = 6.2 Hz, 1H), 7.22 (q, J = 8.4 Hz, 2H), 7.26-7.28 (m, 2H), 7.34-7.38 (m, 2H), 7.66 (s, 2H), 
8.72 (s, 2H); δC (CDCl3, 125 MHz) 20.12, 29.31, 32.64, 45.58, 115.82, 115.96, 117.55, 117.69, 122.86, 122.88, 
125.28, 126.94, 128.29, 130.45, 133.90, 138.39, 138.61, 140.64, 167.99, 190.74; m/z = 322.11 [M++H]. 
4-(5-(Pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)benzene-1,2-diol hydrobromide (19). Synthesized 
from 13 according to Method D; yield = 98 %;IR (ATR) υ (cm-1) 3172, 2930, 1634, 1603, 1524, 1495, 1446, 1263, 
1196, 1114, 805, 634; δH (CDCl3 + CD3OD, 500 MHz) 1.73-1.80 (m, 3H), 2.19-2.24 (m, 1H), 2.81-2.89 (m, 2H), 
4.27-4.32 (m, 1H), 6.63-6.65 (m, 1H), 6.81 (d, J = 8.2 Hz, 1H), 6.88-6.90 (m, 1H), 7.00 (s, 1H), 7.17 (d, J = 8.0 Hz, 
1H), 7.28 (s, 1H), 7.45-7.51 (m, 2H), 8.59 (s, 2H); δC (CDCl3 + CD3OD, 125 MHz) 20.18, 29.33, 32.56, 45.39, 
113.74, 115.36, 118.77, 124.72, 126.50, 127.66, 129.98, 137.81, 144.22, 144.65; m/z = 318.65 [M++H]. 
2-Fluoro-4-(5-(pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)phenol hydrobromide (20). Synthesized 
from 14 according to Method D; yield = 96 %; IR (ATR) υ (cm-1) 3066, 1635, 1607, 1525, 1494, 1366, 1293, 1215, 
1117, 911, 872, 812, 780, 727, 644; δH (CDCl3 + CD3OD, 500 MHz) 1.84-1.92 (m, 3H), 2.34-2.40 (m, 1H), 2.92-
3.00 (m, 2H), 4.48-4.50 (m, 1H), 6.76 (d, J = 8.0 Hz, 1H), 7.02 (t, J = 8.8 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 7.26-
7.28 (m, 2H), 7.38 (s, 1H), 7.73 (s, 1H), 7.74 (s, 1H), 8.79 (s, 1H), 8.80 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 
24.03, 33.17, 36.48, 49.51, 118.12, 118.27, 121.90, 126.73, 128.77, 131.08, 131.69, 134.12, 136.34, 136.39, 
136.79, 142.06, 143.29, 144.45, 148.04, 148.15, 154.59, 156.50, 173.21; m/z = 320.08 [M++H]. 
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Method E: Ether Cleavage and Condensation with HBr. The corresponding ether was refluxed overnight in 
HBr (100 mL for compound 5c, 3 mL for compounds 13 and 14). For compound 5c, after reaction completion water 
(100 mL) was added, the mixture was cooled down and filtered. The solid was washed 3 times with water and no 
further purification was needed. For compounds 13 and 14, after reaction completion the mixture was neutralized 
with solid NaHCO3 and extracted 3 times with EtOAc. The combined organic extracts were dried over Na2SO4, 
concentrated under reduced pressure and purified by Si-gel flash-chromatography. 
6-Hydroxy-1-tetralone (5c). Synthesized from 6-methoxy-1-tetralone according to Method E; yield = 89 %; δH 
(CDCl3, 500 MHz) 2.01-2.06 (m, 2H), 2.56 (t, J = 6.8 Hz, 2H), 2.83 (t, J = 6.1 Hz, 2H), 6.66 (d, J = 6.1 Hz, 1H), 
6.74 (dd, J = 2.4 Hz, J = 8.6 Hz, 1H), 7.38 (s, 1H), 7.91 (d, J = 8.6 Hz, 1H); δC (CDCl3, 125 MHz) 23.27, 29.92, 
38.80, 114.60, 114.66, 125.75, 130.20, 147.82, 161.28, 198.69. 
4-(5-(Pyridin-4-yl)-7,8-dihydronaphthalen-2-yl)benzene-1,2-diol hydrobromide (13). Synthesized from 13a 
according to Method E; yield = 65 %; IR (ATR) υ (cm-1) 3127, 1634, 1605, 1533, 1503, 1396, 1315, 1252, 1205, 
1123, 806, 788, 752, 617; δH (CDCl3 + CD3OD, 500 MHz) 2.53-2.55 (m, 2H), 2.87 (t, J = 7.8 Hz, 2H), 6.53-6.55 
(m, 1H), 6.83-6.89 (m, 2H), 6.94-6.96 (m, 1H), 7.28-7.31 (m, 1H), 7.40-7.41 (m, 1H), 7.94-7.96 (m, 2H), 8.77-8.79 
(m, 2H); δC (CDCl3 + CD3OD, 125 MHz) 27.23, 31.01, 117.13, 118.87, 122.01, 127.96, 128.02, 128.97, 129.45, 
129.78, 131.43, 132.96, 135.65, 139.43, 139.55, 140.53, 144.17, 144.88, 148.02, 148.27, 162.74; m/z = 316.18 
[M++H]. 
2-Fluoro-4-(5-(pyridin-4-yl)-7,8-dihydronaphthalen-2-yl)phenol hydrobromide (14). Synthesized from 7 
according to Method E; yield = 28 %; IR (ATR) υ (cm-1) 3385, 1605, 1522, 1489, 1437, 1416, 1313, 1291, 1278, 
1221, 1199, 1168, 117, 1067, 1008, 909, 891, 874, 823, 806778, 735, 667, 621; δH (CDCl3 + CD3OD, 500 MHz) 
2.49-2.53 (m, 2H), 2.94 (t, J = 7.9 Hz, 2H), 6.25-6.27 (m, 1H), 7.02 (q, J = 8.4 Hz, 2H), 7.26 (d, J = 8.1 Hz, 1H), 
7.31 (s, 1H), 7.34 (d, J = 5.8 Hz, 1H), 7.39-7.42 (m, 3H), 8.58 (d, J = 5.7 Hz, 2H); δC (CDCl3 + CD3OD, 125 MHz) 
24.90, 29.47, 50.22, 50.37, 50.39, 50.55, 50.57, 115.51, 115.66, 117.44, 119.29, 124.08, 124.10, 125.27, 125.75, 
126.63, 127.40, 131.57, 133.51, 134.13, 134.18, 138.60, 1388.77, 140.54, 145.40, 145.52, 150.25 150.87, 152.09; 
m/z = 318.08 [M++H]. 
1-Tetralon-6-yl trifluoromethanesulfonate (5b). 6-Hydroxy-1-tetralone (5 g, 30.83 mmol) was prepared with 
pyridine (2.77 mL, 33.91 mmol) in dry DCM (100 mL) at 0°C. After carefully adding trifluoromethanesulfonic 
anhydride (5.10 g, 30.83 mmol) over 1 min, the reaction mixture was left stirring for 3 h at room temperature. 
Afterwards, excess trifluoromethanesulfonic anhydride was neutralized and the crude was washed 2 times with 
water, the organic phase dried over Na2SO4 and concentrated under reduced pressure. Further purification was 
performed by Si-gel flash-chromatography; yield = 30 %; δH (CDCl3, 500 MHz) 2.08-2.14 (m, 2H), 2.61 (t, J = 6.8 
Hz, 2H), 2.95 (t, J = 6.1 Hz, 2H), 7.12-7.14 (m, 2H), 8.06 (d, J = 8.4 Hz, 1H); δC (CDCl3, 125 MHz) 22.90, 29.73, 
38.77, 119.68, 119.94, 121.36, 130.04, 132.39, 147.11, 152.34, 196.40. 
Biological Assays. CYP17 Preparation and Assay. As source of human CYP17, our E. coli system19 
(coexpressing human CYP17 and NADPH-P450 reductase) was used and the assay was performed as previously 
described12a using unlabeled progesterone as substrate and applying HPLC with UV-detection for separation. 
Inhibition of CYP11B1 and CYP11B2. V79MZh11B1 or V79MZh11B222 cells expressing the respective 
human enzyme were used and our assay procedure using [4-14C]-11-deoxycorticosterone was performed.20 
Inhibition of CYP3A4. The recombinantly expressed enzymes from baculovirus-infected insect microsomes 
and cytochrome b5 (BD Supersomes™) were used and the manufacturer’s instructions (www.gentest.com) were 
followed. 
Molecular Modeling. Various inhibitors of Tables 1 were docked into our CYP17 homology model by means of 
the GOLD v3.2 software23 using GOLDSCORE and CHEMSCORE. Since the GOLD docking program allows 
flexible docking of the compounds, no conformational search was employed to the ligand structures. GOLD gave 
the best poses by a genetic algorithm (GA) search strategy, and then various molecular features were encoded as a 
chromosome. 
The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, Missouri, USA) and 
energy-minimized in MMFF94s force-field24 as implemented in Sybyl.  
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Ligands were docked in 50 independent GA runs using GOLD. Heme iron was chosen as active site origin, 
while its radius was set equal to 19 Å. The automatic active site detection was switched on. Furthermore, a distance 
constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-hybridized nitrogen of the pyridine and the 
iron of the heme was set. Additionally, the goldscore.p450_pdb parameters were used and some of the 
GOLDSCORE parameters were modified to improve the weight of hydrophobic interaction and of the coordination 
between iron and nitrogen. The genetic algorithm default parameters were set as suggested by the GOLD authors.23 
On the other hand, the annealing parameters of fitness function were set at 3.5 Å for hydrogen bonding and 6.5 Å for 
Van der Waals interactions. 
All 50 poses for each compound were clustered with ACIAP25 and the representative structure of each significant 
cluster was selected. After the docking simulations and cluster analysis were performed, the quality of the docked 
representative poses was evaluated based on visual inspection of the putative binding modes of the ligands. The 
latter were further evaluated by means of Silver v3.1.1, the postprocessing tool of GOLD, and at last by 
GOLDSCORE. 
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Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole 
substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17) - part 
II: Core rigidification and influence of substituents at the methylene bridge. 
 
Qingzhong Hu, Matthias Negri, Kerstin Jahn-Hoffmann, Yan Zhuang, Sureyya Olgen, Marc Bartels, Ursula 
Müller-Vieira, Dirk Schmidt, Thomas Lauterbach, Rolf W. Hartmann 
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Abstract. 
Thirty-five novel substituted imidazolyl methylene biphenyls have been synthesised as CYP17 inhibitors for the 
potential treatment of prostate cancer. Their activities have been tested with recombinant human CYP17 expressed 
in E. coli. Promising compounds were tested for selectivity against CYP11B1, CYP11B2 and hepatic CYP enzymes 
3A4, 1A2, 2B6, and 2D6. The core rigidified compounds (30-35) were very active however, they were also rather 
unselective. Another rather potent and more selective inhibitor (compound 23, IC50 = 345 nM) was further examined 
in rats regarding plasma testosterone levels and pharmacokinetic properties. Compared to the reference Abiraterone, 
23 was more active in vivo, showed a longer plasma half-life (10 hours) and a higher bioavailability. Using our 
CYP17 homology protein model, docking studies with selected compounds were performed to study possible 
interactions between inhibitors and amino acid residues of the active site. 
Introduction. 
It has been illuminated that the growth of up to 80 % of prostate carcinoma, the most common malignancy and 
cause of death for male elders, depends on androgen stimulation. Thus, inhibition of androgen formation or 
prevention of androgens unfolding activity will effectively prevent cancer cell proliferation. Currently the standard 
therapy for prostate carcinoma is the so called “combined androgen blockade” (CAB), which means orchidectomy 
or treatment with gonadotropin-releasing hormone (GnRH) analogues (chemical castration) combined with 
androgen receptor antagonists.1 Anti-androgens are used to prevent adrenal androgens which are not affected by the 
former strategies from unfolding stimulatory effects. However, CAB often leads to resistance which can be 
associated with androgen receptor mutations. The mutated androgen receptor recognizes antagonists as agonists, and 
the efficiency of this therapy is whittled away. Total blockage of the androgen biosynthesis could be a more 
promising alternative, which brings CYP17 and its central role in the androgen biosynthesis into focus. CYP17, 
located in both testicular and adrenal tissue,2 is the key enzyme catalyzing 17α-hydroxylation and subsequent C17-
C20 bond cleavage of pregnenolone and progesterone to form DHEA and androstenedione, which are then 
converted to testosterone and DHT.3 
From Ketoconazole, the first medication which has been used clinically as CYP17 inhibitor, to Abiraterone 
which entered into phase II clinical trial very recently, several types of CYP17 inhibitors have been synthesised and 
tested (representative structures are shown in Chart 1). Almost all the inhibitors, steroidal or non-steroidal, are 
mimics of the natural substrates pregnenolone and progesterone. Although lots of steroidal inhibitors are very 
potent,4 especially Abiraterone,5 the potential drawback of these compounds should not be ignored: the relative short 
half-life or poor bioavailability,6 the first pass effect when orally administered 7 and the affinity toward steroid 
receptors which might result in side effect no matter acting as agonists or antagonists. All of these shortcomings 
indicated the necessity to develop non-steroidal CYP17 inhibitors. In the past decade, a wide variety of non-steroidal 
compounds has been described, the most important of these were tetrahydronaphthalenes (A),8 m-pyridinyl 
substituted esters (CB7645 and C),9 1H-imidazol-4-yl substituted alcohols (D and E)10 and 1-(m-pyridinyl)-3-phenyl 
substituted heterocycles (B).11 
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Chart 1. Structures of typical CYP17 inhibitors 
Our group has reported a series of imidazolyl and triazolyl substituted biphenyls as potent CYP17 inhibitors.12 
Recently heterocyclic modifications of the core structure were performed with the more promising biphenyl 
methylene imidazoles. They have been published recently as part I of this study to further improve biological 
properties. 13 In the present paper, modifications such as the introduction of different substituents at the methylene 
bridge as well as the A ring and core rigidifications have been made leading to compounds 1–35 (general structures 
shown in Chart 2).  
Besides the syntheses and the determination of inhibitory activities towards human CYP17, the inhibitions of 
selected compounds against CYP11B1, CYP11B2, and hepatic CYP enzymes 3A4, 1A2, 2B6, and 2D6 are 
described. Furthermore, compound 23, as the most selective inhibitor, was examined for its potency of reducing 
plasma testosterone concentration and its pharmacokinetic properties in rats. Moreover, molecular docking studies 
with both enantiomers of selected compounds, if existing, were carried out using our homology model of CYP1713 
for getting a closer insight into the interaction between active site amino acids and the ligands. 
 
Chart 2. General structures of synthesised compounds 1-35. 
Chemistry. 
For the synthesis of compounds 1-10 and 12-35 (Scheme 1-7), basically the following strategy was used: the 
corresponding ketone or aldehyde intermediates were obtained commercially or synthesised by Suzuki coupling 
(Method C) from the corresponding bromides and boronic acids.13 Subsequently they were converted to the alcohols 
by reduction with NaBH4 (Method D) or Grignard reaction (Method B). The alcohol intermediates were reacted 
with 1, 1-carbonyl diimidazole (CDI) (Method A) to give, in a SNt reaction, the desired products.14 In the case of 
some sensitive intermediates, certain protecting groups were employed and subsequently removed: tert-
butyldimethylsilyl (TBDMS) or tert-butyldiphenylsilyl (TBDPS) for hydroxy groups and tert-butoxycarbonyl (Boc) 
for amino groups. The conversion of the hydroxy compound 26 to the chloro compound 27 was achieved using 
SOCl2 (Scheme 5). In some cases, the carbazole core was constructed by ring closure of the o-nitro substituted 
biphenyl refluxed with phosphorous acid triethyl ester (Scheme 7). The only exception from this strategy was the 
synthesis of compound 11 (Scheme 1). This compound was simply prepared from 1-(4-bromobenzyl)-1H-imidazole 
and 4-trifluoromethylphenylboronic acid by means of Suzuki coupling (Method C). 
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Biological Results, Modelling Studies and Discussion 
CYP17 inhibition of all compounds was evaluated using the 50,000g sediment after homogenation of E.coli 
expressing human CYP17 as well as cytochrome P450 reductase.12d The assay was run with progesterone (25 µM) 
as substrate and NADPH as cofactor. Separation of substrate and product was accomplished by HPLC using UV 
detection.15a IC50 values are presented in comparison to Ketoconazole and Abiraterone in Tables 1-4. 
Inheriting from ref. compound 1,12b the influence of different substituents on the methylene bridge was 
investigated (Table 1). From the inhibitory activity values, it becomes apparent that increasing the length of R2 
would largely influence the potency. The introduction of two-carbon alkyl substituents, like Et (1), and even more 
bulky ones like i-Pr (3) and t-Bu (6), increased the potency of the compounds compared to ref. comp. 1 (IC50 = 910 
nM), resulting in inhibitors with IC50 values in a range from 300 to 450 nM. Interestingly, the further prolongation 
of the alkyl chain by another carbon atom led to moderate (2, R2: n-Pr, IC50 = 580 nM) or low active inhibitors (5, 
R2: i-Bu, IC50 = 2100 nM). However, adding another C atom to the alkyl R2 gave again a very potent compound (4, 
R2: n-Bu, IC50 = 300 nM). Furthermore, it could be observed that the activity of the compounds with a bulky group 
was reduced dramatically as expected, like benzyl, phenyl (8 and 9 with IC50 values around 800 nM), cyclohexyl (7, 
IC50 = 1050 nM) and biphenyl (10, IC50 = 2300 nM). 
In the modelling studies, it was observed that all docked compounds showed two binding modes, named BM1 
and BM2, which were identified previously for other biaryl type inhibitors.13, 17 These binding modes are different 
from the proposed substrate binding mode. 18,19 In BM1 the biaryl plane is oriented almost parallel to the I-helix, and 
principally ligands bearing a R1-substituent were found in this mode (in Fig. 1, compound 22 is taken as an 
example). The substituted A-ring is located next to a polar pocket18 delimitated by Arg109, Lys231, His235, and 
Asp298, which tolerates different substitution patterns. On the other hand, in BM2 the biaryl plane crosses the I-
helix, avoiding the interaction with the polar pocket. It is a less permissive binding mode, which tolerates only 
planar ligands with an un- or fluorine substituted A-ring (compound 2 shown in Fig. 1). 
~ 99 ~
Table 1. Inhibition of CYP17 by compounds 1-10
N
R2
N
1-10
Compounds R2 CYP17 IC50 [nM] b
Ref 1 Me 910
1 Et 450
2 n-Pr 580
3 i-Pr 310
4 n-Bu 300
5 i-Bu 2100
6 t-Bu 460
7 Cyclohexyl 1050
8 Benzyl 780
9 Phenyl 790
10 Biphenyl 2300
KTZ a 2780
ABT a 72
a KTZ: Ketoconazole; ABT: Abiraterone.
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 %.
Nonetheless, for both binding orientations similar hydrophobic and π–π interactions can be observed,13,17 namely 
between the biphenyl core and Phe114 as well as between the biphenyl moiety and apolar parts of amino acids of the 
F-helix (Asn202 and Ile206) and I-helix (Gly301, Ala302, Val304, and Glu305) (Fig. 1).
Figure 1. Representation of the two found binding modes BM1 and BM2, exemplified by compounds 22 (magenta,
BM1) and 2 (yellow, BM2). Furthermore, heme, interacting residues and ribbon rendered tertiary structure of the 
active site are shown. Figures were generated with Pymol (http://www.pymol.org).
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Compounds 1, 2, 4, 5, 6, and ref. compound 1 were docked into our CYP17 model with the aim of explaining the 
influence of the different R2 substituents. For all R-enantiomers bearing a short alkyl substituent (Et, i-Pr, t-Bu or 
Me) at the methylene bridge, the preferred binding mode was BM1; whereas for the corresponding S-enantiomers, 
BM2 seemed to be the most probable. Based on the requisites for each binding mode, 13,17 both orientations seem to 
be possible for compounds 1, 6, and ref. compound 1. On the other hand, although poses in BM2 could also be 
observed, the preferred orientations for compounds 2, 4, and 5 seem to be BM1, regardless of which enantiomer was 
considered. This might be caused by the presence of a longer and bulkier substituent on the methylene bridge.
The results revealed an orientation of the R2 group towards a tiny hydrophobic pocket, formed by amino acids 
Ala367-Pro368-Met369-Leu370-Ile371 (Fig. 2A). Et, i-Pr, and t-Bu substituents can undergo hydrophobic 
interactions with this apolar environment close to the heme without steric clashes due to their reduced length. 
However, for compounds 2 (n-Pr) and 5 (i-Bu) steric hindrance and hydrophobic repulsion perish the possibility of 
additional hydrophobic interactions, thus reducing their inhibitory potencies. As for compound 4, the results indicate 
that the n-Bu group can interact not only with amino acids Ile371 and Ala367, like n-Pr does, but also with Val366, 
Pro368, and Val382 as additional contacts. This leads to the stabilization of its orientation, and makes it a potent 
inhibitor (Fig. 2A).
Figure 2. A cross-section of the solvent accessible surface of the active site is given with a A) closer look to the
orientation of the R2 methylene linker substituents (compounds 2 (light blue), 4 (green), 5 (magenta), 6 (violet), 23
(orange) and 27 (yellow)) with their surrounding amino acids and a B) more in-depth view of the A-ring substituents 
(compounds 30 (cyan), S-23 (yellow), R-22 (magenta) and ref. comp. 1 (R; green) and interacting residues.
It can also be observed that different R1 substituents on the A ring show a strong influence on the activity of the 
imidazole substituted biphenyls. Exhibiting the same ethyl group at the methylene bridge, the A ring substitution 
dispersed the inhibitory potency of the corresponding compounds strongly ranging from no to strong inhibition 
(Table 2). It becomes apparent that hydrophobic and electronegative groups in R1 led to almost inactive compounds.
However, when R1 is a small polar substituent, capable of H-bond formation, the compounds turned out to be very 
active (22, R1 = OH, IC50 = 375 nM; 23, R1 = F, IC50 = 345 nM).
Docking of both enantiomers of ligands 22 and 23 into the active site of our CYP17 model revealed that BM1 is 
preferred for S-22, R-22, and R-23. There is obviously hydrogen bond formation between R1 and the polar 
surrounding of Arg109, Asp298, Lys231, and His235 (Fig. 2B). However, the S-enantiomer of compound 23 was 
found to bind in BM2 as long as the small H-bond accepting fluorine group can interact with Gln199 and Asn202 
(Fig. 2B).
As it is known that fluorine compounds are more stable in vivo than hydroxy compounds, R1 was sustained to be 
fluorine, and the influence of substituents at the methylene bridge was further investigated (Table 3). Interestingly, 
the single ethyl group turned out to be the best, while twin alkyl substituted analogues (24–25) showed lower 
inhibitory potency than their single substituted analogues (23, ref. compound 2). This is obviously due to the steric
clashes with amino acids of the I-helix kink and the reduced flexibility of these ligands. Moreover, the similar 
activity of compound 27 (2-chloroethyl, IC50 = 756 nM) and compound 2 (n-Pr) and the total loss of activity for the 
2-hydroxylethyl analogue (26) demonstrate the necessity of a hydrophobic side chain on the methylene bridge.
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Table 2. Inhibition of CYP17 by compounds 11-23 
N
R2
N
11-23R
1
 
Compounds R1 R2 CYP17 IC50 [nM] b 
11 CF3 H >5000 
12 OCF3 Et >5000 
13 SMe Et 3100 
14 CN Et >5000 
15 Me Et >5000 
16 Et Et 2000 
17 N(Me)2 Et >>5000 
18 N(Et)2 Et >>5000 
19 morpholino Et 2200 
20 NHBoc Et 1700 
21 NHAc Et >5000 
22 OH Et 375 
23 F Et 345 
KTZ a   2780 
ABT a   72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 %. 
 
Table 3. Inhibition of CYP17 by compounds 23-29 
N
R2
N
R1
R3
23-29
 
Compounds R1 R2 R3 CYP17 IC50 [nM] b 
Ref 2 F Me H 1100 
23 F Et H 345 
24 F Me Me 3800 
25 F Et Et 1300 
26 F (CH2)2OH H >5000 
27 F (CH2)2Cl H 756 
28 F CH=CH2 H >5000 
29 H CH=CH2 H 1400 
KTZ a    2780 
ABT a    72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments.  The 
deviations were within ±10 %. 
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Rigidification of the biphenyl core to form a carbazole or 9H-fluorene ring (Table 4) led to the most potent series 
of compounds (30–35). The planar conjugated scaffolds apparently contributed most to the inhibitory potency, 
probably due to the reduced degrees of freedom. Once again, inhibitors furnished with groups capable of forming 
hydrogen bonds turned out to be more active, with the hydroxy substituted 9H-fluorene analogue (30) being the 
most potent compound of this study (IC50 = 99 nM, 28-fold more potent than Ketoconazole). Moreover, the 
importance of an alkyl substituent on the spacer has been demonstrated again, as can be seen from the higher 
activity of the methyl compound 32 showing an IC50 value of 112 nM (for this compound an IC50 value of 4 nM is 
reported23) compared to the corresponding non-substituted analogue 31 (IC50 = 388 nM). 
Table 4. Inhibition of CYP17 by compounds 30-35 
 
Comp. R4 R5 X CYP17 IC50 [nM] b 
30 O
 
M
 
C
 
99 
31 H H C
 
388 
32 H M
 
C
 
112 
33 F M
 
C
 
168 
34 H M
 
N
 
282 
35 F M
 
N
 
118 
KTZ a    2780 
ABT a    72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments.  The 
deviations were within ±10 %. 
For the docking studies of selected compounds from Table 4 (30, 32 and 35), similar results were achieved as 
obtained for the non-rigidified compounds. Two binding modes, BM1 and BM2, were identified. The former 
seemed to be preferred, based on the internal energies of the docked inhibitors and the visual inspection of possible 
interactions, regardless which enantiomer was considered. The same H-bond interactions were found as described 
above (Figs. 1 and 2B). Moreover, the poses were also stabilized by the electrostatic interactions with carbon chain 
of Glu305 (Fig. 3). 
 
Figure 3. Docking complex between CYP17 and compounds 30 (cyan), S-23 (yellow), R-22 (magenta) and ref. 
comp. 1 (R; green). Heme, interacting residues and ribbon rendered tertiary structure of the active site are shown. 
30-35 
N
R5
N
R4
X
 ~ 103 ~ 
 
The inhibition of selected compounds toward hepatic CYP enzymes was determined (Table 5), because of their 
important role in drug metabolism and drug-drug interaction. Although the compounds tested showed inhibition of 
CYP3A4, it was lower than that of Ketoconazole. Interestingly, compound 20 showed only little inhibition (52 % at 
1 µM), possibly due to the bulky t-Boc amino group it bears. However, CYP1A2 inhibition shown by the test 
compounds was much higher than that of Ketoconazole. Compounds 23 and 27 showed good selectivity toward 
CYP 2B6 and 2D6. 
Table 5. Inhibition of hepatic CYP enzymes by selected compounds. 
Comp. 
% Inhibition b 
CYP3A4 CYP1A2 CYP2B6 CYP2D6 
20 52 n.d. a n.d. n.d. 
23 88 97 46 54 
25 95 51 n.d. n.d. 
27 86 96 34 32 
30 89 93 n.d. n.d. 
32 89 98 n.d. n.d. 
34 88 99 n.d. n.d. 
35 75 n.d. n.d. n.d. 
KTZ a 96 8 11 1 
ABT a 4 36 2 7 
a KTZ: Ketoconazole; ABT: Abiraterone; n.d.: not determined. 
b Inhibition at a concentration of 1 μM; standard deviations were within < ±5 %; All the data are the mean values of at least 3 independent 
tests. 
Furthermore, selectivity toward CYP11B1 and CYP11B2 - the most important steroidogenic enzymes being 
responsible for adrenal corticoid biosynthesis - has been determined as another criterion to evaluate safety. 
CYP11B1 catalyzes 11β-hydroxylation in cortisol biosynthesis, whereas CYP11B2 is responsible for the final three 
steps (11β-hydroxylation, 18-hydroxylation, and 18-oxidation) in aldosterone biosynthesis. Inhibition of these two 
enzymes could cause hyponatremia, hyperkalemia and a series of recessive disorders, such as adrenal hyperplasia 
and hypovolemic shock.20 Tested at a concentration of 0.2μM, compound 23 showed less inhibition on both 
enzymes (11B2: 66 %; 11B1: 66 %) compared to compound 30 (11B1: 96 %; 11B2: 98 %). Therefore compound 23 
was further tested in rats. 
The in vivo evaluation of compound 23, including the ability of reducing plasma testosterone concentration 
(Table 6) and the determination of pharmacokinetic properties (Table 7), was performed in male Wistar rats after 
oral application using Abiraterone as reference compound. The plasma concentrations of testosterone were 
determined by ELISA assay and plasma drug concentrations were measured using LC-MS. Although applied as 
acetate, only the signals of the free Abiraterone were monitored. It is obvious that both compounds significantly 
reduced the plasma testosterone concentration. It is striking that compound 23, which was less active in vitro, was 
much more active in vivo than Abiraterone at each time point checked. Importantly, after 24 hours compound 23 
still showed strong inhibitory activity, while Abiraterone exhibited at this time point plasma testosterone 
concentrations 6 fold higher than that of the untreated control. This activity profile can be explained by the 
pharmacokinetic properties of the compounds. Compound 23 exhibited a plasma half-life of 10 hours, while 
Abiraterone only showed 1.6 hours. The fact that Abiraterone had to be administrated as acetate prodrug, which is 
inactive as CYP17 inhibitor, could explain the reduced inhibitory activity of the steroidal compound. However, 
application of the acetate should prolong the plasma half-life having no influence on the AUC of the parent 
compound. The superiority of compound 23 becomes apparent by comparing the AUCs of the two compounds, 
leading to the conclusion that the bioavailability of compound 23 is much better. 
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Table 6. Reduction of the plasma testosterone concentrations in rats by compound 23 a 
Comp. Relative plasma testosterone level (%) 
b 
1h 2h 4h 6h 8h 24h 
Control 143.1 ± 13.3 76.4 ±13.3 81.4 ± 24.6 109.6 ± 31.7 90.6 ± 22.8 80.6 ± 21.0 
23 16.5 ± 5.7 d 11.7 ± 5.0 d 13.9 ± 8.0 d 13.9 ± 7.1 d 13.4 ± 6.2 d 36.7 ± 27.4 d 
ABT e 92.5 ± 43.1 d 44.0 ± 14.7 d 43.5 ± 12.4 d 43.3 ±12.8 c 35.6 ± 9.7 d 476.0 ± 238.6 
a Compound 23 was applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 mg / kg body 
weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each treatment group; 
each sample was tested for 3 times. 
b The average plasma testosterone concentrations (1.81 ng / mL) at pre-treatment time points (-1, -0.5 and 0 h) were set to 100 %. The 
values shown are the relative levels compared to the pre-treatment value. 
c P < 0.05, d P < 0.01. e ABT: Abiraterone. 
Table 7. Pharmacokinetic properties of compound 23 a 
Compounds t1/2 z(h)b t max (h)b C max (ng / mL)b AUC0-∞ (ng x h / mL)b Clint (l / kg / h)b 
23 10.0 6.0 3288 70729 0.7 
Abiraterone  1.6 2.0 592 4015 11.2 
a Compound 23 was applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 mg / kg body 
weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each treatment group; 
each sample was tested for 3 times. 
b t ½ z: terminal half-life; t max: time of maximal concentration; C max: maximal concentration; AUC0-∞: area under the curve; Clint: intrinsic 
hepatic clearance. 
Conclusion 
Herein, we reported the synthesis and evaluation of bioactivity of a series of substituted and core rigidified 
biphenyl methylene imidazoles as CYP17 inhibitors. We found clearer SAR for biphenyl type CYP17 inhibitors, 
comparing to previous work,12,13 that alkyl groups at the methylene bridge, if in suitable length, can strongly 
improve the inhibitory potency. Analogues substituted with polar substituents at the A ring, capable of H-bond 
formation, always led to potent inhibitors. Besides, rigidification of the biphenyl core to form a carbazole or 9H-
fluorene ring also significantly elevated the activity to give a series of CYP17 inhibitors more potent than previously 
reported, 12,13 probably due to their planar conjugated scaffolds. Moreover, one of the best compounds in vitro, 
compound 23 showed potent activity in vivo, a long plasma half-life and a high bioavailability. 
However, further structure modifications have to be performed with the aim of reducing the CYP1A2 inhibition - 
the enzyme responsible for the metabolism of approximately 10 % of the prescription drugs - before a candidate for 
the treatment of prostate cancer can be propagated. Furthermore, because of being tested as racemic mixtures, it is 
likely that one enantiomer of compound 23 would be more potent and selective than the other. A separation of the 
enantiomers is presently being performed. 
Experimental Section 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli (coexpressing human CYP17 and cytochrome P450 reductase) and the 
assay was performed as previously described.12d, 16a 
Inhibition of hepatic CYP enzymes 
The recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were used 
and the manufacturer’s instructions (www.gentest.com) were followed. 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [4-14C]-11-deoxycorticosterone 
as substrate. The assay was performed as previously described. 16c, d 
In vivo study 
The in vivo tests were performed with intact adult male Wistar rats (Harlan Winkelmann, Germany), 5-6 for 
each treatment group. These rats were cannulated with silicone tubing via the right jugular vein. Compound 23 was 
applied po at 50 mg/kg body weight, while Abiraterone was administrated as acetate at 56 mg/kg body weight 
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(equivalent to Abiraterone at 50 mg/kg body weight). The concentrations of testosterone in the rat plasma were 
determined using the Testosterone ELISA (EIA - 1559) from DRG Instruments according to the manufacturer’s 
instructions. The plasma drug levels were measured by LC-MS. Non-compartmental pharmacokinetic analysis of 
concentration versus time data was performed for each compound on the mean plasma level using a validated 
computer program (PK solution 2 software; Summit Research Services, Montrose, USA). Plasma concentrations 
below the limit of detection were assigned a value of zero. 
Chemistry 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra were 
recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H and 13C NMR spectra were measured on a Bruker 
DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an internal 
standard for spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray ionization) 
mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. Elemental analyses 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University.The purities of the 
final compounds were controlled by Surveyor®-LC-system. Purities were greater than 98 %.Column 
chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was determined by TLC 
analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as starting materials 
were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros). 
Method A: CDI reaction 
To a solution of the corresponding alcohol (1 eq) in N-methylpyrrolidone (NMP) or acetonitrile (10 mL / mmol) 
was added CDI (5 eq). Then the solution was heated to reflux for 4 to 18 h. After cooling to ambient temperature, it 
was diluted with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phases were 
washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product was purified 
by chromatography on silica gel. 
1-(1-Biphenyl-4-yl-propyl)-1H-imidazole, 1. Synthesised according to Method A using 1a (0.50 g, 2.36 mmol) 
and CDI (1.91 g, 11.78 mmol); yield: 0.13 g (21 %); yellow solid: mp 75-77 °C; Rf = 0.31 (DCM / MeOH, 10:1); δH 
(CDCl3, 500 MHz) 0.99 (t, J = 7.5 Hz, 3H, CH3), 2.26-2.32 (m, 2H, CH2), 5.09 (t, J = 7.5 Hz, 1H, CH), 6.99 (s, 1H), 
7.11 (s, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.33-7.37 (m, 1H), 7.42-7.46 (m, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 
8.4 Hz, 2H), 7.69 (s, 1H); MS (ESI): m/z = 263 [M++H]. 
1-(1-Biphenyl-4-yl-butyl)-1H-imidazole, 2. Synthesised according to Method A using 2a (0.50 g, 2.21 mmol) 
and CDI (1.79 g, 11.05 mmol); yield: 0.16 g (27 %); brownis oil; Rf = 0.29 (DCM / MeOH, 10:1); δH (CDCl3, 500 
MHz) 0.98 (t, J = 7.5 Hz, 3H, CH3), 1.31-1.39 (m, 2H, CH2), 2.14-2.28 (m, 2H, CH2), 5.17 (t, J = 7.5 Hz, 1H, CH), 
6.99 (s, 1H), 7.10 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 7.5 Hz, 2H), 7.45 (dd, J = 7.5, 8.4 Hz, 2H), 7.54-7.57 
(m, 4H), 7.66 (s, 1H); MS (ESI): m/z = 277 [M++H]. 
1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole, 3. Synthesised according to Method A using 3a (0.50 g, 
2.36 mmol) and CDI (1.91 g, 11.78 mmol); yield: 0.20 g (33 %); white solid: mp 124-125 °C; Rf = 0.31 (DCM / 
MeOH, 10:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.5 Hz, 6H, (CH3)2), 2.56-2.65 (m, 1H, CH(Me)2), 4.67 (d, J = 7.5 
Hz, 1H, CH), 7.05 (s, 1H), 7.07 (s, 1H), 7.32-7.38 (m, 3H), 7.42-7.45 (m, 2H), 7.55-7.58 (m, 4H), 7.67 (s, 1H); MS 
(ESI): m/z = 277 [M++H]. 
1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole, 4. Synthesised according to Method A using 4a (0.50 g, 2.08 mmol) 
and CDI (1.69 g, 10.40 mmol); yield: 0.15 g (25 %); brownish oil; Rf = 0.30 (DCM / MeOH, 10:1); δH (CDCl3, 500 
MHz) 0.89 (t, J = 7.5 Hz, 3H, CH3), 1.28-1.37 (m, 2H, CH2), 1.39-1.43 (m, 2H, CH2), 2.20-2.26 (m, 2H, CH2), 5.14 
(t, J = 7.7 Hz, 1H, CH), 6.99 (s, 1H), 7.12 (s, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.35 (m, 1H), 7.43 (dd, J = 7.9, 8.4 Hz, 
2H), 7.54-7.57 (m, 4H), 7.68 (s, 1H); MS (ESI): m/z = 291 [M++H]. 
1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole, 5. Synthesised according to Method A using 5a (0.50 g, 
2.08 mmol) and CDI (1.69 g, 10.40 mmol); yield: 0.16 g (27 %); brownish oil; Rf = 0.30 (DCM / MeOH, 10:1); δH 
(CDCl3, 500 MHz) 0.96 (d, J = 7.5 Hz, 6H, C(CH3)2), 1.46-1.53 (m, 1H, CH(Me)2), 1.99-2.20 (m, 2H, CH2), 5.14 (t, 
J = 9.5 Hz, 1H, CH), 6.99 (s, 1H), 7.09 (s, 1H), 7.25 (d, J = 8.0 Hz, 2H), 7.35 (m, 1H), 7.43 (dd, J = 7.9, 8.4 Hz, 
2H), 7.54-7.57 (m, 4H), 7.65 (s, 1H); MS (ESI): m/z = 291 [M++H]. 
1-(1-Biphenyl-4-yl-2,2-dimethyl-propyl)-1H-imidazole, 6. Synthesised according to Method A using 6a (0.50 
g, 2.08 mmol) and CDI (1.69 g, 10.40 mmol); yield: 0.15 g (25 %); white solid: mp 150-151 °C; Rf = 0.30 
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(DCM/MeOH, 10:1); δH (CDCl3, 500 MHz) 1.07 (s, 9H, C(CH3)3), 4.92 (s, 1H, CH), 7.08 (s, 1H), 7.24 (s, 1H), 
7.32-7.36 (m, 1H), 7.41-7.45 (m, 4H), 7.55-7.57 (m, 4H), 7.72 (s, 1H); MS (ESI): m/z = 291 [M++H]. 
1-(1-Biphenyl-4-yl-cyclohexyl-methyl)-1H-imidazole, 7. Synthesised according to Method A using 7a (0.50 g, 
1.87 mmol) and CDI (1.52 g, 9.34 mmol); yield: 0.19 g (32 %); white solid: mp 118-121 °C; Rf = 0.32 (DCM / 
MeOH, 10:1); δH (CDCl3, 500 MHz) 0.89-1.03 (m, 2H, cyclohexyl), 1.15-1.28 (m, 3H, cyclohexyl), 1.52-1.60 (m, 
2H, cyclohexyl), 1.71-1.77 (m, 3H, cyclohexyl), 2.22-2.23 (m, 1H, cyclohexyl), 4.72 (t, J = 10.1 Hz, 1H, CH), 7.04 
(s, 1H), 7.06 (s, 1H), 7.32-7.37 (m, 3H), 7.43 (dd, J = 7.5, 8.8 Hz, 2H), 7.54-7.57 (m, 4H), 7.63 (s, 1H); MS (ESI): 
m/z = 317 [M++H]. 
1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole, 8. Synthesised according to Method A using 8a (0.50 g, 
1.82 mmol) and CDI (1.48 g, 9.11 mmol); yield: 0.14 g (23 %); yellow solid: mp 99-101 °C [Ref: 98-100 °C 22]; Rf 
= 0.29 (DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 3.50 (d, J = 7.5 Hz, 2H, CH2), 5.09 (t, J = 7.5 Hz, 1H, CH), 
6.95(s, 1H), 7.01 (d, J = 8.0 Hz, 2H), 7.06 (s, 1H), 7.22-7.24 (m, 3H), 7.28 (d, J = 8.4 Hz, 2H), 7.35-7.37 (m, 1H), 
7.42-7.45 (m, 2H), 7.48 (s, 1H), 7.56-7.58 (m, 4H); MS (ESI): m/z = 325 [M++H]. 
1-(1-Biphenyl-4-yl-2-phenyl-methyl)-1H-imidazole, 9. Synthesised according to Method A using 9a (0.50 g, 
1.92 mmol) and CDI (1.56 g, 9.60 mmol); yield: 0.07 g (12 %); yellow oil; [Ref: mp 142 °C 23]; Rf = 0.35 (DCM / 
MeOH, 10:1); δH (CDCl3, 500 MHz) 6.57 (s, 1H, CH), 6.89(s, 1H), 7.13-7.19 (m, 5H), 7.35-7.38 (m, 4H), 7.42-7.47 
(m, 3H), 7.56-7.59 (m, 4H); MS (ESI): m/z = 311 [M++H]. 
1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole, 10. Synthesised according to Method A using 10a (0.50 g, 1.49 
mmol) and CDI (1.21 g, 7.43 mmol); yield: 0.07 g (13 %); yellow oil; [Ref: mp 120 °C 23]; Rf = 0.37 (DCM / 
MeOH, 10:1); δH (CDCl3, 500 MHz) 6.95 (s, 1H), 7.16 (s, 1H), 7.21-7.23 (m, 4H), 7.35-7.38 (m, 2H), 7.43-7.47 (m, 
4H), 7.55-7.61 (m, 10H); MS (ESI): m/z = 387 [M++H]. 
1-(1-(4'-(Trifluoromethoxy)biphenyl-4-yl)propyl)-1H-imidazole, 12. Synthesised according to Method A 
using 12a (0.50 g, 2.10 mmol) and CDI (2.00 g, 12.40 mmol); yield: 0.16 g (21 %); brownis oil; Rf = 0.51 (DCM / 
MeOH, 95:5); δH (CDCl3, 500 MHz) 0.99 (t, J = 7.5 Hz, 3H, CH3), 2.26-2.32 (m, 2H, CH2), 5.09 (t, J = 7.5 Hz, 1H, 
CH), 7.00 (s, 1H), 7.13 (s, 1H), 7.28-7.31 (m, 4H), 7.54-7.59 (m, 4H), 7.66 (s, 1H); δC (CDCl3, 125 MHz) 11.1 
(CH3), 28.6 (CH2), 63.0 (CH), 117.6 (CH), 119.5(CF3), 121.2 (CH), 127.0 (Im-C5), 127.5 (CH) 127.6 (CH), 128.4 
(CH), 129.5 (Cq), 136.4 (Cq), 139.1 (Cq), 139.7, 139.8 (Cq) 148.8 (Cq); MS (ESI): m/z = 347 [M++H]. 
1-(1-(4'-(Methylsulfanyl)biphenyl-4-yl)propyl)-1H-imidazole, 13. Synthesised according to Method A using 
13a (0.67 g, 2.6 mmol) and CDI (2.00 g, 12.40 mmol); yield: 0.12 g (15 %); beige solid; Rf  = 0.44 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.96 (t, J = 7.0 Hz, 3H, CH3), 2.24-2.28 (m, 2H, CH2), 2.52 (s, 3H, SCH3), 5.04 (t, J = 
7.0 Hz, 1H, CH), 6.97 (s, 1H), 7.10 (s, 1H), 7.23-7.26 (m, 2H), 7.30-7.33 (m, 2H), 7.47-7.50 (m, 2H), 7.52-7.54 (m, 
2H), 7.63 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 15.8 (SCH3), 28.6 (CH2), 63.0 (CH), 117.7 (Im-C4), 126.9 
(CH), 127.0 (CH), 127.2 (CH), 127.4 (CH), 129.5 (Cq), 136.4 (Cq), 137.1 (Cq), 138.0 (Cq), 139.2 (CH), 140.4 (CH); 
MS (ESI): m/z = 309 [M++H]. 
4'-(1-(1H-Imidazol-1-yl)propyl)biphenyl-4-carbonitrile, 14. Synthesised according to Method A using 14a 
(0.46 g, 1.93 mmol) and CDI (1.5 g, 9.30 mmol); yield: 0.14 g (25 %); brown oil; Rf = 0.40 (DCM/MeOH, 95:5); δH 
(CDCl3, 500 MHz) 0.98 (t, J = 7.0 Hz, 3H, CH3), 2.22-2.30 (m, 2H, CH2), 5.08 (t, J = 7.0 Hz, 1H, CH), 6.97 (s, 1H), 
7.10 (s, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.61-7.68 (m, 3H), 7.73 (d, J = 8.0 Hz, 2H); δC 
(CDCl3, 125 MHz) 11.1 (CH3), 28.5 (CH2), 62.9 (CH), 111.2 (C-4´), 117.6 (C-N), 118.7 (Im-C4), 127.2 (CH), 127.6 
(CH), 129.6 (Cq), 132.6 (CH), 136.3 (Cq),  139.0 (CH), 140.9 (Cq), 144.7 (Cq); MS (ESI): m/z = 288 [M++H]. 
1-(1-(4'-Methylbiphenyl-4-yl)propyl)-1H-imidazole, 15. Synthesised according to Method A using 15a (0.57 
g, 2.5 mmol) and CDI (2.0 g, 12.50 mmol); yield: 0.20 g (29 %); yellow solid: mp 71-72 °C; Rf  = 0.26 (EtOAc); δH 
(CDCl3, 500 MHz) 0.88 (t, J = 7.3 Hz, 3H, CH3), 2.16 (q, J = 7.3 Hz, 2H, CH2), 2.30 (s, 3H, PhCH3), 4.95 (t, J = 7.3 
Hz, 1H, CH), 6.89 (s, 1H), 7.00 (s, 1H), 7.12-7.18 (m, 4H), 7.37 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.54 
(s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 21.0 (PhCH3), 28.5 (CH2), 63.0 (CH), 117.6, 126.81, 126.86, 127.3, 
129.5, 136.3, 137.3, 138.9, 140.9, 142.1; MS (ESI): m/z = 277 [M++H]. 
1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole, 16. Synthesised according to Method A using 16a (0.64 g, 
2.6 mmol) and CDI (2.1 g, 13.12 mmol); yield: 0.14 g (18 %); yellowish oil; Rf  = 0.30 (EtOAc); δH (CDCl3, 500 
MHz) 0.89 (t, J = 7.3 Hz, 3H, CH3), 1.20 (t, J = 7.6 Hz, 3H, CH3), 2.18 (quint, J = 7.3 Hz, 2H, CH2), 2.61 (q, J = 7.6 
Hz, 2H, CH2), 4.97 (t, J = 7.3 Hz, 1H, CH), 6.90 (s, 1H), 7.02 (s, 1H), 7.14-7.21 (m, 4H), 7.41 (d, J = 8.2 Hz, 2H), 
7.47 (d, J = 8.5 Hz, 2H), 7.57 (s, 1H); δC (CDCl3, 125 MHz) 10.1 (CH3), 14.5 (CH3), 27.5 (CH2), 27.6 (CH2), 62.1 
(CH), 116.7, 125.9, 126.0, 126.4, 127.3, 128.3, 135.3, 136.7, 137.8, 140.0, 142.1; MS (ESI): m/z = 291 [M++H]. 
[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-dimethyl-amine, 17. Synthesised according to Method A using 
17a (0.59 g, 2.31 mmol) and CDI (0.56 g, 3.47 mmol); yield: 0.18 g (25 %); white solid: mp 117-119 °C; Rf = 0.33 
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(DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 2.24 (q, J = 7.3, 7.6 Hz, 2H, CH2), 2.99 
(s, 6H, N-CH3), 5.01 (t, J = 7.6 Hz, 1H, CH), 6.78 (d, J = 9.1 Hz, 2H), 6.97 (s, 1H), 7.09 (s, 1H), 7.20 (d, J = 8.5 Hz, 
2H), 7.47 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 7.62 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 28. 6 (CH2), 
40.4 (N-CH3), 63.0 (CH), 112.6, 117.6, 126.5, 126.8, 127.6, 129.4, 136.4, 137.7, 141.0, 150.1; MS (ESI): m/z = 306 
[M++H]. 
Diethyl-[4'-(1H-imidazol-1-yl-propyl)-biphenyl-4-yl]-amine, 18. Synthesised according to Method A using 
18a (0.70 g, 2.47 mmol) and CDI (0.61 g, 3.70 mmol); yield: 0.16 g (19 %); white solid: mp 109-111 °C; Rf = 0.33 
(DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 1.19 (t, J = 6.9 Hz, 6H, N-CH3), 2.24 (q, 
J = 7.3, 7.6 Hz, 2H, CH2), 3.39 (q, J = 6.9 Hz, 4H, N-CH2), 5.01 (t, J = 7.6 Hz, 1H, CH), 6.73 (d, J = 9.1 Hz, 2H), 
6.97 (s, 1H), 7.09 (s, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.62 (s, 1H); 
δC (CDCl3, 125 MHz) 11.1 (CH3), 12.6 (N-CH3), 28.6 (CH2), 44.3 (N-CH2), 63.0 (CH), 111.8, 117.6, 126.3, 126.8, 
127.7, 129.4, 136.4, 137.5, 141.1, 147.3; MS (ESI): m/z = 334 [M++H]. 
4-[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-morpholine, 19. Synthesised according to Method A using 
19a (0.70 g, 2.37 mmol) and CDI (0.58 g, 3.55 mmol); yield: 0.27 g (33 %); white solid: mp 119-121 °C; Rf = 0.17 
(DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 2.24 (q, J = 7.3, 7.6 Hz, 2H, CH2), 3.20 
(t, J = 4.7 Hz, 4H), 3.86 (t, J = 4.7 Hz, 4H), 5.02 (t, J = 7.6 Hz, 1H, CH), 6.92-6.95 (m, 3H), 7.08 (s, 1H), 7.21 (d, J 
= 8.5 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.61 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 
28.5 (CH2), 48.9, 62.9 (CH), 66.7, 115.6, 117.6, 126.7, 126.8, 127.6, 129.4, 131.5, 136.3, 138.3, 140.5, 150.6; MS 
(ESI): m/z = 348 [M++H]. 
[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-carbamic acid tert-butyl ester, 20. Synthesised according to 
Method A using 20a (1.23 g, 3.75 mmol) and CDI (0.91 g, 5.63 mmol); yield: 0.33 g (23 %); white solid: mp 204-
206 °C; Rf = 0.29 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.3 Hz, 3H, CH3), 1.53 (s, 9H, t-Bu), 
2.26 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.04 (t, J = 7.6 Hz, 1H, CH), 6.57 (s, 1H, CONH), 6.97 (s, 1H), 7.09 (s, 1H), 7.24 
(d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.51-7.53 (m, 4H), 7.62 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 
28.3 (t-Bu), 28.6 (CH2), 63.0 (CH), 118.8, 126.9, 127.1, 127.5, 129.5, 137.9, 138.8, 140.5; MS (ESI): m/z = 378 
[M++H]. 
1-[1-(4'-Fluoro-biphenyl-4-yl)-propyl]-1H-imidazole, 23. Synthesised according to Method A using 23a (1.23 
g, 5.34 mmol) and CDI (4.33 g, 26.70 mmol); yield: 0.52 g (35 %); brown oil; Rf = 0.6 (DCM / MeOH, 95:5); δH 
(CDCl3, 500 MHz) 0.97 (t, J = 7.3 Hz, 3H, CH3), 2.27 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.06 (t, J = 7.6 Hz, 1H, CH), 
6.97 (s, 1H), 7.09-7.14 (m, 3H), 7.25 (d, J = 8.9 Hz, 2H), 7.51-7.53 (m, 4H), 7.62 (s, 1H); δC (CDCl3, 125 MHz) 
11.1 (CH3), 28.6 (CH2), 63.0 (CH), 115.6, 115.7, 117.7, 127.0, 127.4, 128.6, 128.7, 129.5, 136.4, 136.5, 139.3, 
140.1, 161.6, 163.6; MS (ESI): m/z = 281 [M++H]. 
1-(2-(4'-Fluorobiphenyl-4-yl)propan-2-yl)-1H-imidazole, 24. Synthesised according to Method A using 24a 
(0.23 g, 1.0 mmol) and CDI (0.36 g, 2.20 mmol); yield: 0.05 g (19 %); Rf  = 0.27 (DCM / MeOH, 95:5); δH (CDCl3, 
500 MHz) 1.94 (s, 6H, CH3), 6.94-6.96 (m, 1H), 7.10-7.15 ( m, 5H), 7.47-7.36 (m, 4H), 7.67-7.69 (m, 1H); δC 
(CDCl3, 125 MHz) 31.5 (CH3), 60.3 (CH), 116.1, 117.0, 125.2, 127.3, 129.2, 132.6, 139.4, 145.4, 163.7; MS (ESI): 
m/z = 281 [M++H]. 
1-(3-(4'-Fluorobiphenyl-4-yl)pentan-3-yl)-1H-imidazole, 25. Synthesised according to Method A using 25a 
(0.26 g, 1.00 mmol) and CDI (0.36 g, 2.20 mmol); yield: 0.13 g (43 %); Rf  = 0.33 (DCM / MeOH, 95:5); δH (CDCl3, 
500 MHz) 0.75 (s, 6H, CH3), 2.26-2.30 (q, 4H, CH2),  6.84-6.86 (m, 1H), 7.08-7.09 (m, 1H), 7.10-7.13 (m, 2H), 
7.17-7.20 (m, 2H), 7.48-7.55 (m, 4H), 7.62-7.63 (m, 1H); δC (CDCl3, 125 MHz) 8.3 (CH3), 30.5 (CH2), 66.1 (CH), 
116.3, 119.7, 127.6, 129.9, 136.2, 139.1, 142.8; MS (ESI): m/z = 309 [M++H]. 
1-(1-(4'-Fluorobiphenyl-4-yl)allyl)-1H-imidazole, 28. Synthesised according to Method A  using 28a (1.14 g, 5.00 
mmol) and CDI (1.80 g, 10.10 mmol); yield: 0.57 g (41 %); Rf  = 0.27 (DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 
4.73-4.74 (m, 2H, CH2), 6.30-6.35 (m, 1H, CH), 6.54-6.57 (m, 1H, CH), 6.98 (s, 1H), 7.10-7.12 (m, 3H), 7.42-7.44 
(m, 2H), 7.50-7. 56 (m, 5H); δC (CDCl3, 125 MHz) 49.3 (CH), 116.5, 124.9, 127.4, 128.6, 130.8, 133.2, 135.2, 
137.0, 140.3, 161.7; MS (ESI): m/z = 279 [M++H]. 
1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole, 29. Synthesised according to Method A  using 29a (0.30 g, 1.00 mmol) and 
CDI (0.36 g, 2.20 mmol); yield: 0.09 g (32 %); Rf  = 0.21 (DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 4.73-4.75 (m, 
2H, CH2), 6.30-6.35 (m, 1H, CH), 6.56-6.57 (m, 1H, CH), 6.98 (s, 1H), 7.12-7.13 (m, 1H), 7.34-7.37 (m, 1H), 7.43-
7.46 (m, 4H), 7.56-7.60 (m, 5H); δC (CDCl3, 125 MHz) 49.3 (CH), 119.4 (=CH2), 123.8, 127.0, 129.4, 133.2, 134.5, 
137.7, 140.9; MS (ESI): m/z = 297 [M++H]. 
1-((9H-Fluoren-2-yl)methyl)-1H-imidazole, 31. Synthesised according to Method A using 31a (0.32 g, 1.63 
mmol) and CDI (0.53 g, 3.26 mmol); yield: 0.16 g (40 %); Rf = 0.31 (MeOH / EtOAc, 5:95); colourless solid: mp 
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183-185 °C; δH (CDCl3, 500 MHz) 3.87 (s, 2H, CH2), 5.18 (s, 2H), 6.94 (bs, 1H), 7.11 (bs, 1H), 7.19 (d, J = 8.5 Hz, 
1H), 7.30-7.33 (m, 2H), 7.38 (dd, J = 7.3, 7.6 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.59 (bs, 1H), 7.75 (d, J = 7.9 Hz, 
1H), 7.77 (d, J = 7.6 Hz, 1H); δC (CDCl3, 125 MHz) 36.8 (CH2), 51.0 (CH2), 119.3 (CH), 120.0 (CH), 120.2 (CH), 
124.0 (CH), 125.1 (CH), 126.1 (CH), 126.8 (CH), 127.1 (CH), 129.7 (CH), 134.4 (Cq), 137.4 (CH), 140.9 (Cq), 
141.9 (Cq), 143.3 (Cq), 144.1 (Cq); MS (ESI): m/z = 247 [M++H]. 
1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole, 32. Synthesised according to Method A using 32a (1.00 g, 4.70 
mmol) and CDI (1.53 g, 9.50 mmol); yield: 0.62 g (51 %); Rf = 0.58 (MeOH / EtOAc, 5:95); light yellow solid: mp 
109-110 °C; δH (CDCl3, 500 MHz) 1.90 (d, J = 6.9 Hz, 3H, CH3), 3.86 (s, 2H, CH2), 5.41 (q, J = 6.9 Hz, 1H, CH), 
6.96 (t, J = 1.3 Hz, 1H), 7.10 (bs, 1H), 7.17-7.19 (m, 1H), 7.29 (bs, 1H), 7.31 (dd, J = 1.3, 7.6 Hz, 1H), 7.37 (t, J = 
7.8 Hz, 1H), 7.53 (bd, J = 7.6 Hz, 1H), 7.63 (bs, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H); δC (CDCl3, 
125 MHz) 22.2 (CH3), 36.9 (CH2), 56.8 (CH), 118.0 (CH), 120.0 (CH), 120.1 (CH), 122.6 (CH), 124.8 (CH), 125.0 
(CH), 126.8 (CH), 127.0 (CH), 129.2 (CH), 136.0 (CH), 139.9 (Cq), 140.9 (Cq), 141.8 (Cq), 143.3 (Cq), 144.0 (Cq); 
MS (ESI): m/z = 261 [M++H]. 
1-[1-(7-Fluoro-9H-fluoren-2-yl)-ethyl]-1H-imidazole, 33. Synthesised according to Method A using 33a (1.00 
g, 4.38 mmol) and CDI (1.87 g, 1.16 mmol); yield: 0.44 g (36 %); Rf = 0.24 (MeOH / EtOAc, 5:95); yellow oil; δH 
(CDCl3, 500 MHz) 1.90 (d, J = 6.9 Hz, 3H, CH3), 3.85 (s, 2H, CH2), 5.41 (q, J = 7.0 Hz, 1H, CH), 6.96 (s, 1H), 
7.05-7.09 (m, 2H), 7.18 (d, J = 7.9 Hz, 1H), 7.22 (dd, J = 1.8, 8.6 Hz, 1H), 7.28 (bs, 1H), 7.63 (bs, 1H), 7.67-7.70 
(m, 2H); δC (CDCl3, 125 MHz) 22.2 (CH3), 36.9 (CH2), 56.8 (CH), 112.4 (d, CH), 114.1 (d, CH), 118.0 (CH), 119.8 
(CH), 120.9 (CH), 122.6 (CH), 125.0 (CH), 129.2 (CH), 136.0 (CH), 137.0 (Cq), 139.7 (Cq), 141.0 (Cq), 143.7 
(Cq), 145.5 (Cq), 161.6 (Cq); MS (ESI): m/z = 279 [M++H]. 
2-(1-Imidazol-1-yl-ethyl)-9H-carbazole, 34. Synthesised according to Method A using 34a (0.22 g, 1.02 mmol) 
and CDI (0.33 g, 2.04 mmol); yield: 0.08 g (29 %); Rf = 0.40 (MeOH / EtOAc, 5:95); δH (CDCl3, 500 MHz) 1.90 (d, 
J = 6.9 Hz, 3H), 5.46 (q, J = 6.9 Hz, 1H), 6,97 (bs, 1H), 7.05-7.07 (m, 2H), 7.11 (bs, 1H), 7.22 (ddd, J = 1.9, 6.4, 8.0 
Hz, 1H), 7.38-7.43 (m, 2H), 7.65 (bs, 1H), 8.02 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H); δC (CDCl3, 125 MHz) 
22.4 (CH3), 57.2 (CH), 108.0 (CH), 110.8 (CH), 117.3 (CH), 118.3 (CH), 119.4 (CH), 120.3 (CH), 120.5 (CH), 
122.7 (Cq), 123.1 (Cq), 126.0 (CH), 128.8 (CH), 136.0 (CH), 139.2 (Cq), 140.0 (Cq), 140.2 (Cq); MS (ESI): m/z = 
262 [M++H]. 
2-(1-(1H-Imidazol-1-yl)ethyl)-7-fluoro-9H-carbazole, 35. Synthesised according to Method A  using 35a 
(0.30 g, 1.30 mmol) and CDI (0.42 g, 2.60 mmol); yield: 0.08 g (23 %); Rf = 0.11 (EtOAc); δH (CDCl3, 500 MHz) 
1.93 (d, J = 7.0 Hz, 3H), 5.64 (q, J = 7.0 Hz, 1H), 6.90 (ddd, J = 2.2, 8.5, 9.6 Hz, 1H), 6.99 (t, J = 1.3 Hz, 1H), 7.07 
(ddd, J = 0.6, 1.6, 8.2 Hz, 1H), 7.11 (dd, J = 2.2, 9.6 Hz, 1H), 7.18 (t, J = 1.3 Hz, 1H), 7.28 (d, J = 1.6 Hz, 1H), 7.80 
(bs, 1H), 7.96-7.99 (m, 2H); δC (CDCl3, 125 MHz) 22.5 (CH3), 58.6 (CH), 98.2 (d, CH), 107.9 (d, CH), 109.4 (CH), 
118.6 (CH), 119.7 (CH), 120.6 (Cq), 121.1 (CH), 122.2 (CH), 123.8 (Cq), 128.9 (CH), 137.4 (CH), 140.4 (Cq), 142.2 
(Cq), 142.8 (Cq), 163.5 (Cq); MS (ESI): m/z = 280 [M++H]. 
Method B: Grignard reaction 
Under exclusion of air and moisture a 1.0 M Grignard reagent (1.2 eq) solution in THF was added dropwise to a 
solution of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred at room temperature 
overnight. Subsequently ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was separated. 
The organic phase was extracted with water and brine, dried over Na2SO4, and evaporated under reduced pressure. 
The crude products were purified by flash chromatography on silica gel.  
1-Biphenyl-4-yl-3-methyl-butan-1-ol, 5a. Synthesised according to Method B using Biphenyl-4-carbaldehyde 
(1.00 g, 5.48 mmol) and a 1.0 M iso-butylmagnesiumbromide solution in THF (7.13 mL, 7.13 mmol); yield: 0.96 g 
(73 %); Rf = 0.28 (PE / EtOAc, 5:1); δH (CDCl3, 500 MHz) 0.97 (d, J = 4.9 Hz, 6H, CH3),  1.51-1.58 (m, 1H, CH), 
1.72 (s, br, 1H, OH), 1.75-1.81 (m, 2H, CH2), 4.79 (t, J = 2.7 Hz, 1H, CH), 7.33 (t, J = 7.5 Hz, 1H), 7.43 (d, J = 8.4 
Hz, 4H), 7.57 (d, J = 8.4 Hz, 4H); MS (ESI): m/z = 241 [M++H]. 
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-biphenyl-4-yl]-propan-1-ol, 22b. Synthesised according to method B 
using 22c (3.30 g, 10.6 mmol) and 1.0 M EtMgBr (12.7 mL). Yield: 1.89 g (52 %); Rf = 0.40 (PE / EtOAc, 9:1); δH 
(CDCl3, 500 MHz) 0.23 (s, 6H), 0.95 (t, J = 7.3 Hz, 3H), 1.00 (s, 9H), 1.76-1.89 (m, 2H), 4.64 (t, J = 6.6 Hz, 1H), 
6.90 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H); MS (ESI): m/z 
= 344 [M++H]. 
3-(4'-Fluorobiphenyl-4-yl)pentan-3-ol, 25a. Synthesised according to Method B using 23b (0.58 g, 2.53 mmol) 
and a 1.0 M ethylmagnesiumbromide solution in THF (25.0 mL, 25.0 mmol); yield: 0.58 g (89 %); Rf  = 0.28 
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(DCM); δH (CDCl3, 500 MHz): 0.79-0.92 (s, 6H, CH3), 1.68 (s, br, 1H, OH), 1.82-1.93 (m, 4H, CH2), 7.10-7.14 (m, 
2H), 7.43-7.45 (m, 2H), 7.51-7.58 (m, 4H); MS (ESI): m/z = 259 [M++H]. 
Method C: Suzuki-Coupling 
The corresponding brominated aromatic compound (1 eq) was dissolved in toluene (7 mL / mmol), an aqueous 
2.0 M Na2CO3 solution (3.2 mL / mmol) and an ethanolic solution (3.2 mL / mmol) of the corresponding boronic 
acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure and flushed with nitrogen. 
After repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the resulting suspension was heated 
under reflux for 8 h. After cooling ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was 
separated. The water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed 
with brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel.  
1-((4'-(Trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole, 11. Synthesised according to Method C using 1-
(4-bromobenzyl)-1H-imidazole (0.24 g, 1.00 mmol) and 4-trifluoromethylphenylboronic acid (0.38 g, 2.00 mmol); 
yield: 0.24 g (80 %); brown oil; Rf = 0.14 (EtOAc); δH (CDCl3, 500 MHz) 5.17 (s, 2H, CH2), 6.93 (bs, 1H), 7.11 (bs, 
1H), 7.24 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 7.9 Hz, 2H), 7.59 (bs, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 8.5 Hz, 
2H); δC (CDCl3, 125 MHz) 50.4 (CH2), 119.2 (CH), 123.1 (Cq), 125.2 (Cq), 125.7 (CH), 127.3 (CH), 127.7 (CH), 
127.8 (CH), 129.8 (CH), 136.2 (Cq), 137.4 (CH), 139.7 (Cq), 143.8 (Cq); MS (ESI): m/z = 303 [M++H]. 
1-(4'-Fluorobiphenyl-4-yl)propan-1-one, 23b. Synthesised according to Method C using 4-
bromopropiophenone (1.23 g, 6.65 mmol) and 4-fluorophenylboronic acid (1.38 g, 6.47 mmol); yield: 1.20 g (79 
%); Rf = 0.45 (Hex / EtOAc, 10:1); δH (CDCl3, 500 MHz) 1.24-1.27 (t, J = 7.3 Hz, 3H, CH3), 3.01-3.06 (m, 2H, 
CH2), 6.97-7.01 (m, 1H), 7.06-7.11 (m, 1H), 7.58-7.61 (m, 2H), 8.02-8.04 (m, 2H); MS (ESI): m/z = 229 [M++H]. 
1-(4'-Fluoro-2'-nitrobiphenyl-4-yl)ethanone, 35c. Synthesised according to Method C using 4-fluoro-1-iodo-
2-nitrobenzene  (1.20 g , 4.50 mmol) and 4-acetylbenzeneboronic acid (1.48 g, 9.00 mmol); yield: 1.01 g (87 %); Rf 
= 0.19 (petrolether / EtOAc, 10:1); δH (CDCl3, 500 MHz) 2.64 (s, 3H, CH3), 7.38 (d, J = 8.5 Hz, 2H), 7.39-7.41 (m, 
1H), 7.43 (dd, J = 5.5, 8.5 Hz, 1H), 7.67 (dd, J = 2.5, 8.0 Hz, 1H), 8.01 (d, J = 8.5 Hz, 2H); δC (CDCl3, 125 MHz) 
26.6 (CH3), 112.1 (d, CH), 119.9 (d, CH), 128.3 (CH), 128.7 (CH), 131.7 (Cq), 133.2 (CH), 136.8 (Cq), 141.3 (Cq), 
161.6 (d, Cq), 197.4 (Cq ); MS (ESI): m/z = 259 [M+-H]. 
Method D: Reduction with NaBH4 
To an ice-cooled solution of the corresponding aldehyde or ketone (1 eq) in methanol (5 mL / mmol) was added 
NaBH4 (2 eq). Then the resulting mixture was heated to reflux for 30 minutes. After cooling to ambient temperature, 
the solvent was distilled off under reduced pressure. Subsequently water (10 mL) was added, and the resulting 
mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried 
over MgSO4 and evaporated under reduced pressure. Then the desired product was purified by chromatography on 
silica gel. 
1-(4'-Fluoro-biphenyl-4-yl)-propan-1-ol, 23a. Synthesised according to Method D using 22b (1.20 g, 5.26 
mmol) and NaBH4 (0.30 g, 7.89 mmol); yield: 1.15 g (95 %); the compound was directly used in the next step 
without further purification and characterization. 
1-(9H-Carbazol-2-yl)ethanol, 34a. Synthesised according to Method D using 1-(9H-carbazol-2-yl)ethanone 
(0.50 g, 2.39 mmol) and NaBH4 (0.16 g, 4.30 mmol); yield: 0.42 g (83 %); Rf  = 0.12 (petrolether / EtOAc, 5:1); 
light yellow solid: mp 192-194 °C; δH (CDCl3, 500 MHz) 1.41 (d, J = 6.6 Hz, 3H, CH3), 3.13 (bs, 1H), 4.88 (q, J = 
6.6 Hz, 1H), 7.03 (ddd, J = 1.2, 7.3, 7.9 Hz, 1H), 7.07 (dd, J = 1.6, 8.2 Hz, 1H), 7.22 (ddd, J = 1.2, 7.2, 8.2 Hz, 1H), 
7.30 (dt, J = 1.0, 8.2 Hz, 1H), 7.37-7.39 (m, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 9.62 (bs, 1H); δC 
(CDCl3, 125 MHz) 25.5 (CH3), 69.9 (CH2), 107.3 (CH), 110.4 (CH), 116.4 (CH), 118.4 (CH), 119.5 (CH), 119.6 
(CH), 121.8 (Cq), 122.6 (Cq), 124.9 (CH), 139.7 (Cq), 139.8 (Cq), 144.4 (Cq); MS (ESI): m/z = 210 [M+-H]. 
1-(7-Fluoro-9H-carbazol-2-yl)ethanol, 35a. Synthesised according to Method D using 35b (0.25 g, 1.12 mmol) 
and NaBH4 (0.08 g, 2.02 mmol); yield: 0.21 g (82 %); Rf = 0.19 (petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 
1.50 (d, J = 6.4 Hz, 3H), 4.94 (q, J = 6.4 Hz, 1H), 6.85 (ddd, J = 2.3, 8.5, 8.8 Hz, 1H), 7.08 (dd, J = 2.3, 9.8 Hz, 1H), 
7.15 (dd, J = 1.2, 8.2 Hz, 1H), 7.43 (bs, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.93 (dd, J = 5.5, 8.5 Hz, 1H); δC (CDCl3, 125 
MHz) 26.0 (CH3), 71.5 (CH), 98.0 (d, CH), 107.5 (d, CH), 108.6 (CH), 118.2 (CH), 120.5 (CH), 120.8 (Cq), 121.8 
(d, CH), 123.2 (Cq), 142.2 (Cq), 142.4 (Cq), 145.1 (Cq), 163.2 (d, Cq); MS (ESI): m/z = 212 [M+-OH]. 
4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-ylamine, 21a. To a solution of 20 (0.32 g, 0.85 mmol) in DCM (10 
mL) was added TFA (0.63 mL, 8.5 mmol) slowly in an ice bath. Subsequently it was stirred at room temperature 
overnight. DCM (10 mL) and water (10 mL) were added and the organic phase was separated. The organic phase 
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was extracted with water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude products 
were purified by flash chromatography on silica gel; yield: 0.22 g (95 %); Rf = 0.35 (PE / EtOAc, 2:1); the 
compound was directly used in the next step without further purification and analysis. 
N-[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-acetamide, 21. To a solution of 21a (0.07 g, 0.25 mmol) in 
THF (10 mL) were added DMAP (0.02 g, 0.13 mmol) and triethylamine (0.1 mL). After cooling to 0 °C in an ice 
bath, acetyl chloride was dropped into the reaction solution slowly. Then it was stirred in the ambient temperture 
overnight. After neutralized to pH = 7 with sodium bicarbonate in an ice bath, ethyl acetate (10 mL) and water (10 
mL) were added and the organic phase was separated. The organic phase was extracted with water and brine, dried 
over Na2SO4, and evaporated under reduced pressure. The crude products were purified by flash chromatography on 
silica gel; yield: 0.33 g (23 %); white solid: mp 221-223 °C; Rf = 0.27 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 
0.97 (t, J = 7.3 Hz, 3H, CH3), 2.20 (s, 3H, CH3CO), 2.26 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.05 (t, J = 7.6 Hz, 1H, CH), 
6.99 (s, 1H), 7.11 (s, 1H), 7.23 (d, J = 8.2 Hz, 2H), 7.49-7.58 (m, 6H), 7.72 (s, 1H); δC (CDCl3, 125 MHz) 11.0 
(CH3), 24.6 (CH3CO), 28.5 (CH2), 63.2 (CH), 120.1, 126.9, 127.5, 127.5, 135.9, 137.6, 140.5, 168.4; MS (ESI): m/z 
= 320 [M++H]. 
4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-ol, 22. To a solution of 22a (0.85 g, 2.16 mmol) in anhydrous THF (20 
mL) was added TBAF (2.4 mL, 2.4 mmol) and subsequently the solution was stirred at room temperature for 4 h. 
The reaction was terminated with the addition of methanol and the solvent was removed under reduced pressure. 
Then the desired product was purified by chromatography on silica gel. Yield: 0.22 g (37 %); Yellow solid; Rf = 
0.21 (Hex / EtOAc, 5:1); δH (DMSO-d6, 500 MHz) 0.82 (t, J = 7.3 Hz, 3H), 2.21 (m, 2H), 5.23 (t, J = 7.3 Hz, 1H), 
6.82 (d, J = 8.8 Hz, 2H), 6.90 (s, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H),  
7.82 (s, 1H), 9.55 (s, 1H); δC (DMSO-d6, 125 MHz) 10.9 (CH3), 27.4 (CH2), 61.5 (CH), 115.6 (CH), 117.7 (CH), 
126.0 (CH), 127.1 (CH), 127.6 (CH), 128.4 (Cq), 130.3 (CH), 130.7 (Cq), 139.3 (CH), 139.5 (Cq), 157.1 (Cq); MS 
(ESI): m/z = 279 [M++H]. 
3-(4'-Fluorobiphenyl-4-yl)-3-(1H-imidazol-1-yl)propan-1-ol, 26. 26a (0.241 g, 0.45 mmol) was dissolved by 
slowly adding dropwise  to 15 mL THF and 1M TBAF (0.55 mL, 0.55 mmol) in THF.  1 hour later, according to 
TLC (DCM / methanol, 95:5) the deprotection was quantitative.  The batch was diluted with a large quantity of ethyl 
acetate and extracted three times with water and once with brine, then dried over MgSO4 and the solvent removed 
under reduced pressure.  The crude product was subsequently purified by column chromatography; yield: 0.09 g (67 
%); Rf = 0.34 (DCM / MeOH, 9:1); δH (CDCl3, 500 MHz) 2.43-2.49 (m, 2H, CH2), 3.50-3.54 (m, 1H), 3.68-3.72 (m, 
1H), 5.56-5.59 (q, 1H, CH), 6.98 (m, 1H), 7.08 (m, 1H´), 7.1-7.14 (m, 2H), 7.26-7.29 (m, 2H), 7.48-7.51 (m, 4H), 
7.56 (m, 1H); δC (CDCl3, 125 MHz) 37.1 (CH2), 50.5 (CH), 57.7 (CH2-OH), 116.3, 127.6, 128.6, 129.8, 136.8, 
137.2, 139.9, 140.0, 161.4; MS (ESI): m/z = 297 [M++H]. 
1-(3-Chloro-1-(4'-fluorobiphenyl-4-yl)propyl)-1H-imidazole, 27. 26 (0.044 g, 0.148 mmol) was dissolved in 
10 mL dry DCM and mixed with 13 µL thionyl chloride.  The batch was stirred for 2 hours at room temperature; 
according to the TLC control, the reaction was quantitative (DCM as solvent).  The batch was diluted with a large 
quantity of DCM and water.  The organic phase was separated off and extracted 5 times with water and once with 
brine, then dried over MgSO4 and  the solvent removed under reduced pressure; yield: 0.05 g (99 %); Rf  = 0.63 
(DCM / MeOH, 9:1); δH (CDCl3, 500 MHz) 2.87-2.97 (m, 2H, CH2), 3.50-3.60 (m, 2H, CH2Cl), 5.80-5.83 (m, 1H, 
CH),  7.11-7.16 (m, 2H), 7.16-7.17 (m, 1H), 7.35-7.37 (m, 1H), 7.49-7.53 (m, 4H), 7.58-7.60 (m, 2H), 9.51-9.53 (m, 
1H); δC (CDCl3, 125 MHz) 34.2 (CH2), 41.4 (CH2Cl), 61.8 (CH), 119.6, 122.9, 116.5, 128.4, 129.4, 135.7, 136.3, 
137.6, 136.4, 142.5, 163.5; MS (ESI): m/z = 315 [M++H]. 
1-(7-(tert-Butyldimethylsilyloxy)-9H-fluoren-2-yl)ethanone, 30c. Imidazole (0.17 g, 2.45 mmol) and 1-(7-
hydroxy-9H-fluoren-2-yl)ethanone  (0.50 g , 2.23 mmol) were dissolved in 20 mL DCM. Then tert-
butyldimethylsilylchloride (0.37 g, 2.45 mmol) dissolved in 3 mL DCM were slowly added. The resulting mixture 
was stirred for 18 h at room temperature. Afterwards the mixture was extracted with water and brine. The organic 
phase was separated, dried over Na2SO4 and evaporated; yield: 0.58 g (77 %); Rf = 0.40 (petrolether / EtOAc, 10:1); 
MS (ESI): m/z = 339 [M++H]. 
7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol, 30. 30a (0.16 g, 0.40 mmol) was dissolved in 10 mL THF and 
1M TBAF (0.41 mL, 0.41 mmol) solution in THF was added dropwise.  After 1 hour according to TLC (DCM / 
methanol 95:5) the deprotection was quantitative.  The batch was diluted with a large quantity of ethyl acetate and 
extracted three times with water and once with brine, then dried over MgSO4 and the solvent removed under 
reduced pressure; yield: 0.10 g (90 %); Rf  = 0.12 (MeOH / EtOAc, 5:95); orange solid: mp 217-218 °C; δH (CDCl3, 
500 MHz) 1.81 (d, J = 6.9 Hz, 3H), 3.70 (s, 2H), 5.31 (q, J = 6.9 Hz, 1H), 6.77 (dd, J = 2.2, 8.2 Hz, 1H), 6.90 (s, 
1H), 6.93 (s, 1H), 6.95 (s, 1H), 7.06 (d, J = 7.9 Hz, 1H), 7.18 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.52 (d, J = 7.9 Hz, 
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1H), 7.55 (s, 1H); δC (CDCl3, 125 MHz) 21.9 (CH3), 36.6 (CH2), 56.9 (CH), 112.0 (CH), 114.1 (CH), 118.1 (CH), 
118.8 (CH), 120.6 (CH), 122.4 (CH), 124.7 (CH), 128.2 (CH), 132.8 (Cq), 135.6 (CH), 137.9 (Cq), 142.0 (Cq), 143.2 
(Cq), 145.2 (Cq), 156.6 (Cq); MS (ESI): m/z = 277 [M++H]. 
1-(7-Fluoro-9H-carbazol-2-yl)ethanone, 35b. 35c was dissolved in 3 mL P(OEt)3 and refluxed for 16 h. The 
resulting mixture was directly purified using column chromatography; yield: 0.28 g (53 %); Rf = 0.13 (petrolether / 
EtOAc, 5:1); δH (CDCl3, 500 MHz) 2.54 (s, 3H), 6.79 (ddd, J = 2.3, 8.6, 9.5 Hz, 1H), 7.01 (dd, J = 2.3, 9.6 Hz, 1H), 
7.65 (dd, J = 1.6, 8.2 Hz, 1H), 7.85 (dd, J = 5.4, 8.5 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.93 (dd, J = 0.6, 1.6 Hz, 1H), 
10.53 (bs, 1H); δC (CDCl3, 125 MHz) 26.5 (CH3), 97.4 (d, CH), 107.3 (d, CH), 110.9 (CH), 118.4 (Cq), 119.0 (CH), 
119.2 (CH), 121.6 (d, CH), 126.2 (Cq), 133.6 (Cq), 139.7 (Cq), 142.0 (d, Cq), 162.2 (d, Cq), 197.8 (Cq); MS (ESI): 
m/z = 227 [M++H]. 
Docking studies 
All molecular modelling studies were performed on Intel(R) P4 CPU 3.00GHz running Linux Suse 10.1.  
Ligands. The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, Missouri, 
USA) and energy-minimized in MMFF94s force-field 24a as implemented in Sybyl. The resulting geometries for our 
compounds were then subjected to ab initio calculation employing the B3LYP functional 24b-24c in combination with 
a 6-31G* basis set using the package Gaussian03 (Gaussian, Inc., Pittsburgh, PA, 2003). 
Docking. Various inhibitors were docked into our CYP17 homology model by means of the GOLD v3.0.1 
software.25 Since it is known that non-steroidal inhibitors of CYP enzymes primary interact by complexation of the 
heme iron with their sp2 hybridized nitrogen 16b a distance constraint of a minimum of 1.9 and a maximum of 2.5 Å 
between the nitrogen of the imidazole and the iron was set.  
Ligands were docked in 50 independent genetic algorithm (GA) runs using GOLD. Heme iron was chosen as 
active-site origin, while the active site radius was set equal to 19 Å. The automatic active-site detection was 
switched on. Furthermore, some of the GOLDSCORE parameters were modified to improve the weight of 
hydrophobic interaction and of the coordination between iron and nitrogen. The genetic algorithm default 
parameters were set as suggested by the GOLD authors. On the other hand, the annealing parameters of fitness 
function were set at 3.5 Å for hydrogen bonding and 6.5 Å for Van der Waals interactions. 
All 50 poses for each compound were clustered with ACIAP 26 and the representative structure of each 
significant cluster was selected. The quality of the docked representative poses was evaluated based on visual 
inspection of the putative binding modes of the ligands, as outcome of docking simulations and cluster analysis. 
Further the different interaction patterns were manually analyzed using Silver 1.1, 25b a program included for use 
with GOLD and used to post-process docking results. 
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doi:10.1016/j.bmc.2008.07.011. 
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Abstract 
Twenty-one novel compounds originating from two classes of annulated biphenyls were synthesised as mimetics 
of the steroidal A- and C-rings and examined for their potency as inhibitors of human CYP17. Selected compounds 
were tested for inhibition of the hepatic CYP enzyme 3A4. Potent CYP17 inhibitors were found for each class, 
compound 9 (17 and 71% at 0.2 and 2 µM, respectively) and 21 (591 nM). Compound 21 showed only weak 
inhibition of CYP3A4 (32 and 64% at 2 and 10 µM, respectively). Both compounds, however, exhibited moderate to 
strong inhibition of the glucocorticoid-forming enzyme CYP11B1. The most interesting compounds were docked 
into our protein model. They bound into one of the modes which we have previously published. New interaction 
regions were identified. 
Introduction 
Prostate cancer is a major cause of death in elderly men worldwide.1 It is widely demonstrated that high 
androgen levels (testosterone and dihydrotestosterone) stimulate tumor growth in prostate cancer.2 Thus, androgen 
receptor antagonists3 and gonadotropin-releasing hormone analogues4 are used as a standard therapy. The major 
drawback of these therapies is the fact that they do not reduce androgen concentrations or only affect testicular 
androgen production, allowing androgens still to be produced in the adrenals. 
Therefore, a new promising target is 17α-hydroxylase-17, 20-
lyase (CYP17), the key enzyme for the biosynthesis of 
androgens. It is catalyzing the conversion of pregnenolone or 
progesterone to DHEA or androstenedione, respectively. Even 
more, this target has already clinically proven success with the 
antimicotic ketoconazole which is also a weak inhibitor of 
CYP17.5 In previous works, we could demonstrate in-vitro and 
in-vivo activity for steroidal6 and non-steroidal7-10, 11 compounds. 
Some of these compounds had been designed as mimetics of the 
steroidal AC-rings (Chart 1).10, 11 Since they had shown a high 
activity and a good selectivity, we chose them for further 
optimizations. 
Very recently,12 we found new highly potent and selective 
compounds, which showed better pharmacokinetic and 
pharmacodynamic profiles than abiraterone, a CYP17 inhibitor 
currently undergoing clinical phase II,13 by replacing the A-ring-
mimicking benzene nucleus with different heterocycles. 
In order to further explore the spatial limitations surrounding 
the A- and C-ring binding regions, in this work, we expand the 
corresponding biphenyl rings by annulations of different 
aromatic and non-aromatic rings. In this way, two different 
compound classes were synthesised (Chart 2), by either 
N
N
R1
R2N
N
R
O
HO
A
C
B
D
C
A
D
B
Pregnenolone
ABD-ring mimetics ACD-ring mimetics
N
N
R1
R2N
N
R C
A
C
A
A-ring annulated C-ring annulated
D
A
HO
A
C
B
D
Abiraterone
N
n
n
Chart 1. Substrate, abiraterone, described 
ABD- and ACD-ring mimetic CYP17 
inhibitors and A- and C-ring annulated 
compounds of the present study. 
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annealing the C-ring (compounds 1-11) or by otherwise annealing the A-ring (compounds 12-21). Like in previous 
works,10-12 1-imidazole linked with a methylene spacer was introduced as nitrogen-bearing heterocycle, since the 
complexation of the heme iron by an aromatic nitrogen is an important prerequisite for inhibition of cytochrome 
P450 enzymes.14 We have also shown10-12 that the introduction of a fluorine, hydroxy, and methoxy group in the A-
ring strongly contributed to a better inhibition of our target enzyme. 
In the following, the synthesis, CYP17 inhibitory activities, and molecular modelling studies are presented and 
these data are compared to the ones recently obtained with ABD- and ACD-ring mimetics (Chart 1).9 Besides, for 
reasons of selectivity, inhibition of the most crucial hepatic CYP enzyme CYP3A4 was monitored, and for selected 
compounds inhibition of the glucocorticoid-forming enzyme CYP11B1 was also determined. The most promising 
compounds were docked into our protein model, and the key interactions with the enzyme were elucidated. 
Chemistry 
The syntheses of compounds 1-21 are shown in Schemes 1-7. In pursuing our aim to explore the binding regions 
surrounding the A- and C-rings, different aromatic and non-aromatic moieties were annulated to the A (Schemes 1-
5) or C (Schemes 6, 7) ring. The coupling of the biphenylic moiety was achieved by means of Suzuki coupling15 
(Method C) except for the synthesis of compounds 1 and 2 (Scheme 1) where a Negishi coupling had to be applied. 
When the necessary bromides for the couplings were not commercially available, they were prepared by 
bromination using NBS (N-bromosuccinimide) (Scheme 3). The imidazoles were introduced by performing a SNt 
reaction with 1,1’-carbonyldiimidazole (CDI) and the corresponding alcohol16 (Method A) or via SN2 reaction of an 
alkyl bromide with imidazole (Scheme 3). 
N
H
F
N NS
R1O
X
R1O
N N
R3
R2
N
N
R1
N N N
 
                 1, 2                                  3                                    4, 5                                  6-11 
N
R1X
N
R2
N
S
N
N N NO
O
N N
R2
 
             12-16                                17                                   18                                   19-21 
Compound R1 R2 R3 X 
1 Me    
2 H    
4 p-F-(C6H4)    
5 3-thiophenyl    
6 Me H H CH 
7 H H H CH 
8 Me Et H N 
9 H Et H N 
10 Me Et Et N 
11 H Et Et N 
12  Et  S 
13  Et  NH 
14  H  O 
15  H  S 
16  H  NH 
19 OMe H   
20 H H   
21 OH Et   
Chart 2. List of synthesizsed compounds 1-21. 
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The alcohols were obtained from either the carboxylic derivatives (Schemes 1, 4) or from the aldehydes 
(Methods D, E). In most cases, the methoxy-substituted compounds were submitted to an ether cleavage (Method 
B). For the preparation of compound 21, the hydroxyl group on the naphthalene had to be protected before the 
Suzuki coupling due to otherwise very low yields.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6c 6b
6a 6: R= CH3
7: R= H
Br Br
COOH
Br
O RO
N N
OH
OH
(ii)(i)
(iii) (iv), (v)
Scheme 3. Synthesis route of compounds 4 and 5 
Reagents and conditions: (i) NBS, CCl4, 75°C, 16 
h; (ii) Imidazole, K2CO3, 18-crown-6, acetonitrile, 
100°C, 16 h; (iii) Method C1: 4-
fluorophenylboronic acid (5: 3-thiophenylboronic 
acid), Na2CO3, Pd(PPh3)4, toluene/MeOH/H2O, 
70°C, 5 h. 
Scheme 1. Synthesis route of compounds 1 and 2 
Reagent and conditions: (i) a: 4-bromo-anisole, 
tert-BuLi, THF, -78°C, 30 min; b: ZnCl2, 0°C, 30 
min; c: PdCl2(PPh3)2, 16 h; (ii) LiBH4, toluene, THF, 
Et2O, 110°C, 16 h; (iii) Method A1: CDI, imidazole, 
NMP, 180°C, 16 h; (iv) Method B: BBr3, DCM, -
78°C to 0°C, 16 h. 
Br
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1a 1: R= CH32: R= H
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3b 3a 3
N (i) N
Br Br
4a
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4: R = p-F-(C6H4)
5: R = 3-thiophenyl
Br
N
Br
N N
N
R
N N(ii) (iii)
Scheme 2. Synthesis route of compound 3 
Reagent and conditions: (i) Method C1: Na2CO3, Pd(PPh3)4, toluene/EtOH/H2O, reflux, 5 h; (ii) Method 
D: NaBH4, MeOH, rt, 2 h; (iii) Method A2: CDI, acetonitrile, reflux, 18 h. 
(i)
8b
8a, 10a 8: R1= H, R2= CH3
9: R1= H, R2= H
10: R1= CH2CH3, R2= CH3
11: R1= CH2CH3, R2= H
NBr
CHO
N
CHO
O
N
O R1
OH
N
R2O R1
N N(iii), (iv)
(ii)
Y
X
Br
(HO)2B
CHO
+ Y
X
CHO
Y
X
OH
R
Y
X
N
R
N
(i) (ii) or (iii)
(iv) 12: X= S, Y= CH, R= Et 13: X= NH, Y= CH, R= Et14: X= O, Y= CH, R= H 15: X= S, Y= CH, R= H
16: X= NH, Y= CH, R= H
17: R= H 18: R= H
12b-16b 12a-18a
12-18 O
O
S
N
Scheme 4. Synthesis route of compounds 6 and 7 
Reagents and conditions: (i) KMnO4, pyridine, 
H2O, 50°C, 4 d; (ii) LiAlH4, Et2O, 35°C, 16 h; (iii) 
Method C2: 4-methoxyphenylboronic acid, Cs2CO3, 
Pd(OAc)2, TBAB, toluene/EtOH/H2O, 110°C, 16 h; 
(iv) Method A1: CDI, imidazole, NMP, 180°C, 2 d; 
(v) Method B: BBr3, DCM, -78°C to 0°C, 16 h. 
Scheme 6. Synthesis route of compounds 12-18 
Reagents and conditions: (i) Method C1: Pd(PPh3)4, TBAB, Na2CO3, toluene/EtOH/H2O, reflux, 16 h; (ii) 
Method E: 12a-13a: EtMgBr, THF, 0°C to rt, 16 h; (iii) Method D: 14a-18a: NaBH4, MeOH, reflux, 2 h; (iv) 
Method A1: CDI, NMP, reflux, 3 h. 
Scheme 5. Synthesis route of compounds 8-11 
Reagents and conditions: (i) Method C2: 4-
methoxyphenylboronic acid, Cs2CO3, Pd(OAc)2, 
TBAB, toluene/EtOH/H2O, 110°C, 16 h; (ii) Method 
E: EtMgBr, THF, 0°C to rt, 16 h; (iii) Method A1: 
CDI, imidazole, NMP, 180°C, 1-2.5 d; (iv) Method B: 
BBr3, DCM, -78°C to 0°C, 16 h. 
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Results 
Biological Results. Inhibition of CYP17 was evaluated using human enzyme expressed in E. coli.17 The percent 
inhibition values of the compounds were determined with the 50,000 g sediment of the E. coli homogenate, 
progesterone (25 µM) as substrate and the inhibitors at concentrations of 0.2 and 2.0 µM. Separation of substrate 
and product was accomplished by HPLC using UV detection.7 
In contrast to the reference compound ketoconazole, the C-ring-annulated compounds (1-11, Table 1) mostly 
showed moderate to no inhibition with exception of the quinoline compound 9, which showed 71% inhibition at 2 
µM. The prolongation of the C-ring in compounds 1-5 led to non-active compounds. The quinolines 8-11 bearing an 
ethyl moiety at the methylene linker showed an overall better activity than the naphthalenes 6 and 7. 
Table 1. Inhibition of CYP17 by C-ring annulated compounds 1-11 
N
H
F
N NS
R1O
X
R1O
N N
R3
R2
N
N
R1
N N N
 
                   1, 2                              3                                      4, 5                                   6-11 
Comp. 
Structures CYP17 
R1 R2 R3 X 
% Inhibition a 
0.2 μM 2 μM 
1 Me    0 18 
2 H    6 13 
3     0 12 
4 p-F-(C6H4)    1 12 
5 3-thiophenyl    0 11 
6 Me H H CH 0 5 
7 H H H CH 1 12 
8 Me Et H N 3 32 
9 H Et H N 17 71 d 
10 Me Et Et N 6 57 
11 H Et Et N 5 57 
KTZ b     19 c 
a Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. Concentration of progesterone 
(substrate) was 25 μM.  
b KTZ: ketoconazole. 
c % inhibition at 1.0 μM. 
d IC50= 817 nM 
Y
X
Br
(HO)2B
CHO
+ Y
X
CHO
Y
X
OH
R
Y
X
N
R
N
(i) (ii) or (iii)
(iv) 12: X= S, Y= CH, R= Et 13: X= NH, Y= CH, R= Et14: X= O, Y= CH, R= H 15: X= S, Y= CH, R= H
16: X= NH, Y= CH, R= H
17: R= H 18: R= H
12b-16b 12a-18a
12-18 O
O
S
N
Scheme 6. Synthesis route of compounds 12-18 
Reagents and conditions: (i) Method C1: Pd(PPh3)4, TBAB, Na2CO3, toluene/EtOH/H2O, reflux, 16 h; (ii) 
Method E: 12a-13a: EtMgBr, THF, 0°C to rt, 16 h; (iii) Method D: 14a-18a: NaBH4, MeOH, reflux, 2 h; (iv) 
Method A1: CDI, NMP, reflux, 3 h. 
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The A-ring-annulated compounds (12-21, Table 2) showed moderate to good activities. However, they did not 
exceed the activity of compound 9. The most active compounds in this class showing percent-inhibition values of 
more than 70% at 2 µM are compound 13 bearing an indole (H-bond donor) and compounds 19 and 21 bearing a 
methoxy group (H-bond acceptor) or a hydroxyl group (H-bond acceptor and donor), respectively, at the 6-position 
of a naphthalene. Absence of these substituents in the latter compounds diminishes the inhibitory activity 
(compound 20). The introduction of an ethyl moiety at the methylene linker led to an increase in activity for 
compounds 15 to 12 and 16 to 13. All other aromatic heterocycles resulted in only moderate inhibitors. 
When comparing the activities of the compounds of this study to the ones of the parent compounds,11 it must be 
mentioned that the structural modifications did not increase activities. 
Regarding selectivity against other CYP enzymes, a broader spectrum of our compounds was tested for 
inhibition of the hepatic enzyme CYP3A4. This enzyme is responsible for the metabolism of lipophilic substances 
and, therefore, responsible for about 50% of current prescription drugs.18 While compounds 12-19 showed a strong 
inhibition of this enzyme (>85% inhibition at 2 µM), compound 21 exhibited low inhibitory activity towards 
CYP3A4 (32% at 2 µM and 64% at 10 µM). 
Thus, compound 21 together with the most promising compound 9 of the C-ring-annulated class of compounds, 
were further tested for inhibition of the steroidogenic enzyme CYP11B1. Its importance relies on the fact that it 
catalyzes the last step in glucocorticoid formation, namely the transformation of 11-deoxycortisol into cortisol. For 
the assay,19 V79MZh11B1 cells expressing human CYP11B1 were used. Both compounds showed strong inhibition 
of the enzyme at the tested concentrations (9: 86 and 94% at 0.2 and 2 µM; 21: 81 and 95% at 0.2 and 2 µM). 
Table 2. Inhibition of CYP17 by A-ring annulated compounds 12-21 
N
R1X
N
R2
N
S
N
N N NO
O
N N
R2
 
             12-16                             17                                            18                                  19-21 
Comp. 
Structures CYP17 
R1 R2 X 
% Inhibition a 
0.2 μM 2 μM 
12  Et S 7 40 
13  Et NH 21 75 d 
14  H O 5 27 
15  H S 0 21 
16  H NH 2 39 
17    5 39 
18    0 17 
19 OMe H  19 74 e 
20 H H  7  43 
21 OH Et  16 74 f 
KTZ b    19 c 
a Data shown were obtained by performing the tests in duplicate. The deviations were within < ±5 %. Concentration of progesterone 
(substrate) was 25 μM.  
b KTZ: ketoconazole. 
c % inhibition at 1.0 μM. 
d IC50= 667 nM. 
e IC50= 703 nM. 
f IC50= 591 nM. 
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Molecular Modelling. Using selected compounds, we explored the binding modes of the A- and C-ring-
annulated biphenyls. Several active and less active compounds (C-ring: 6-11 (R, S); A-ring: 13 (R, S), 16, 17, 19 (R, 
S) and 21) were docked by means of the GOLD v 3.0.1 software20 in the active site of our homology model of 
CYP17.12
Aware of the limitations of docking,21 the resulting poses of each compound were clustered with AClAP 
(autonomous hierarchical agglomerative cluster analysis)22 and the representative poses of each cluster were 
subjected to a critical visual inspection. H-bonds, π-π, and hydrophobic interactions, as well as steric clashes were 
measured and evaluated. The necessity of iron-nitrogen complexation14 for inhibitory activity was also considered. 
Furthermore, the GOLD v 3.0.1 software, used with a slightly modified GOLDSCORE, was tested on different 
crystallised CYP enzymes. This program could reproduce quite well the correct orientation of co-crystallised ligands 
(data not shown). Moreover, GOLD v 3.0.1 produced reliable poses for abiraterone in our CYP17 model,12 oriented 
like described for pregnenolone.23 With these findings, the obtained results can be considered very probable.
All compounds principally showed poses in BM1 – one of two binding modes we have identified for biphenyl 
type inhibitors12 – with the modified biaryl-skeleton oriented almost parallel to the I-helix (Fig. 1). Furthermore, the 
observed increase in activity caused by the ethyl group at the methylene spacer can be explained by the anchoring 
function of this substituent, namely by hydrophobic interactions with the tiny hydrophobicpocket next to the heme, 
as already described.12
(A)                                   (B)
Figure 1. A cross-section of the solvent accessible surface of CYP17 is shown, revealing the active-site cavity with 
docked: (A) C-ring annulated 6 (green), 7 (yellow), 8 (magenta) and 9 (cyan) and (B) A-ring annulated compounds 
13 (cyan), 19 (magenta) and 21 (yellow). Further, heme, interacting residues and ribbon rendered tertiary structure 
of the active site are shown. Figures were generated with Pymol (http://www.pymol.org).
Regarding the docked C-ring annulated compounds, both enantiomers of compounds 6-11 showed mainly one 
binding mode, except for compounds 6 and 7, which switch the annealed ring towards or opposite the I-helix (Fig. 
1A). The annealed ring is directed towards the kink of the I-helix,12 stabilised in its orientation by π-π and 
hydrophobic interactions with the residues Phe114, Gly301-Ala302, Glu305, Thr306, Ile371, and Val482 (Fig. 1A).
Nevertheless, for all three compound couples sterical hindrance, changing in its extend from pair to pair (8-9 < 6-7 <
10-11) between the annulated C-ring and the surrounding amino acids, was observed. The extension of the annealed 
ring system, like the introduction of a space-demanding group, e. g. ethyl was crucial, as seen by the reduced 
activity of compounds 10 and 11 with respect to 8 and 9.
For the inhibitory activity of compounds 8-11, the presence of the aromatic nitrogen in the annealed C-ring was 
striking; it delocalizes the negative charge of the ring system and is capable of H-bond formation with the 
catalytically important Thr306 and the 1-N of the imidazole.
Compounds 6-11 (R, S) showed the ability of forming an H-bond net between the R1 substituent of the A-ring 
(Table 1) and the amino acids Arg109 and His235, as it was already observed for their parent compounds.9 OH
showed the highest activity values, leading to the conclusion that an H-bond donor group in this position was 
necessary.
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As for the A-ring annulated compounds, 13 (R, S), 16 (R, S), 17, 19 (R, S) and 21 were docked into our 
homology model (Fig 1B). Even these elongated compounds are basically oriented in BM1. However, the extension 
of the A-ring caused a shift in the interaction area. The substituent R1 showed H-bond formations with Asn202, 
Lys231, His235, and, eventually, Arg109, but even hydrophobic interactions between the OMe group in R1and 
Ile198 and Ile238. Almost the same hydrophobic interactions, as reported previously,12 between the aromatic core 
structure and the prevalently hydrophobic surroundings of the active site could be observed. Additionally, the 
extended A-ring can undergo π-π and hydrophobic interactions with Phe114, Ile205, His235, Gly297, and Thr294. 
Comparing compounds 13 and 16-17, the presence of a H-bond donor hetero-atom in the annealed A-ring appeared 
necessary for H-bond formation with His235 and Asn202, with the intent to mimic the para-OH of some of the most 
active parent compounds.9 
Discussion and Conclusion 
Similar to our ABD-mimetics,9 the annulation at the A-ring led mostly to low to moderately active compounds 
with exception of 9 which showed good inhibition of CYP17. On the other hand, the annealing of an additional ring 
at the C-ring resulted in moderately to highly active compounds, similar to our findings in the class of ACD-ring 
mimetic inhibitors.9 
The best compounds in terms of activity in each class are 9 for the A-ring-expanded and 21 for the C-ring-
annulated compounds. Compound 21 is also selective against CYP3A4. Based on both biological results and 
molecular modelling studies (Fig. 1), we conclude that space occupancy in both the A-ring and the C-ring area is 
appropriate for the design of new lead structures. The presence of specific heteroatoms, especially N in the annealed 
rings, is recommended, since this structure modification is capable of H-bond formation and of modifying the 
electrostatic properties of the annealed ring system. The importance for CYP17 activity of an ethyl substituent at the 
methylene linker was reiterated as well. 
One of our goals in this work was the discovery of a new, more complex lead structure, with the aim of 
increasing potency and selectivity towards other CYP enzymes. This was achieved with compounds 9 and 21. For 
further increasing the activity of compound 9, we suggest an lead structure optimised by substitution of the annealed 
ring with a 5-membered aromatic ring bearing a heteroatom, like imidazole, or the exchange of the whole bicyclic 
structure at the C-ring with a 7-membered ring. These modified compounds are likely to better fit in the active site, 
due to reduced steric hindrance and hydrophobic repulsion. 
Experimental Section 
Chemistry. Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR 
spectra were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an internal 
standard for spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray ionization) 
mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. Elemental analyses 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University. Column 
chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was determined by TLC 
analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as starting materials 
were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros). 
Methyl 5-(4-methoxyphenyl)benzo[b]thiophene-2-carboxylate, 1b. To a solution of 1-bromo-4-
methoxybenzene (1.32 mL, 10.52 mmol) in dry THF (20 mL) cooled at -78 °C t-BuLi (1.5 M, 14.48 mL, 21.72 
mmol) was added slowly. After 30 min ZnCl2 (0.5 M, 24.53 mL, 12.26 mmol) was added carefully and after 10 min 
it was let to warm up to rt. After additional 20 min methyl 5-bromobenzo[b]thiophene-2-carboxylate (1.90 g, 7.00 
mmol) and bis-(triphenylphosphine)-palladium (II)-dichloride (0.49 g, 0.70 mmol) were prepared in dry THF (30 
mL) under protecting atmosphere and the reagent was added at 0 °C and the reaction mixture left stirring overnight. 
yield: 1.45 g (69 %); Rf = 0.35 (PE / EtOAc, 2:1); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 3.96 (s, 3H), 7.01 (d, J = 8.8 
Hz, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.67 (dd, J = 1.8 Hz, J = 8.5 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 8.01 (s, 1H), 8.09 
(s, 1H). 
(5-(4-Methoxyphenyl)benzo[b]thiophen-2-yl)methanol, 1a. To a solution of 1b (0.55 g, 1.84 mmol) in THF 
(30 mL), toluene (15 mL) and diethyl ether (15 mL) LiBH4 (0.05 g, 2.21 mmol) was added and heated to reflux for 2 
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h. yield: 0.47 g (95 %); Rf = 0.53 (PE / EtOAc, 2:1); δH (CDCl3, 500 MHz) 3.87 (s, 3H), 4.95-5.01 (m, 2H), 6.99-
7.01 (m, 3H), 7.53 (dd, J = 1.8 Hz, J = 8.4 Hz, 1H), 7.56-7.59 (m, 2H), 7.85 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H). 
Method A: CDI reaction. To a solution of the corresponding alcohol (1 eq) in NMP or acetonitrile (10 mL / 
mmol) was added CDI (5 eq). Then the solution was heated to reflux for 4 to 18 h. After cooling to ambient 
temperature, it was diluted with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic 
phases were washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product 
was purified by chromatography on silica gel. 
1-((5-(4-Methoxyphenyl)benzo[b]thiophen-2-yl)methyl)-1H-imidazole, 1. Synthesised according to Method 
A1 using 1a (0.25 g, 0.93 mmol) and CDI (1.20 g, 7.40 mmol); yield: 0.20 g (68 %); white solid: mp 169 °C; Rf = 
0.44 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm-1) 3106 (w), 1607 (w), 1516 (m), 1453 (w), 1436 (w), 1277 (m), 1254 
(m), 1231 (m), 1194 (w), 1072 (w), 1031 (m), 1015 (w), 908 (w), 806 (s), 744 (s), 667 (m); δH (CDCl3, 500 MHz) 
3.86 (s, 3H), 5.35 (s, 2H), 6.99-7.01 (m, 3H), 7.12 (s, 1H), 7.17 (s, 1H), 7.52-7.56 (m, 3H), 7.62 (s, 1H), 7.80 (d, J = 
8.4 Hz, 1H), 7.86 (s, 1H); δC (CDCl3, 125 MHz) 46.3, 55.3, 114.3, 119.1, 121.5, 122.6, 123.3, 124.2, 128.3, 130.0, 
133.4, 137.2, 137.9, 138.3, 139.8, 139.8, 159.1. 
3-((1H-Imidazol-1-yl)methyl)-6-(4-fluorophenyl)-1H-indole, 3. Synthesised according to Method A2 using 3a 
(0.25 g, 1.04 mmol) and CDI (0.34 g, 2.08 mmol); yield: 0.15 g (52 %); brown solid: mp 171-173 °C; Rf = 0.24 
(EtOAc / MeOH, 95:5); δH (CDCl3, 500 MHz) 5.29 (s, 2H), 6.91 (bs, 1H), 7.02 (bs, 1H), 7.06 (t, J = 8.8 Hz, 2H), 
7.18 (dd, J = 1.7 Hz, J = 8.3 Hz, 1H), 7.28 (d, J = 2.5 Hz, 1H), 7.41 (d, J = 8.5 Hz, 1H), 7.50 (d, J = 1.7 Hz, 1H), 
7.52 (dd, J = 5.3 Hz, J = 8.8 Hz, 2H), 7.71 (bs, 1H), 10.90 (bs, 1H); δC (CDCl3, 125 MHz) 42.8 (CH2), 110.1 (CH), 
115.5 (CH), 118.4 (CH), 119.3 (CH), 119.8 (CH), 121.8 (Cq), 124.7 (CH), 125.5 (Cq), 128.7 (CH), 128.9 (CH), 
135.1 (CH), 136.8 (Cq), 137.2 (Cq), 138.0 (Cq), 162.1 (CF); MS (ESI): m/z = 292 [M++H]. 
1-((4-(4-Methoxyphenyl)naphthalen-1-yl)methyl)-1H-imidazole, 6. Synthesised according to Method A1 
using 6a (0.38 g, 1.42 mmol) and CDI (1.84 g, 11.35 mmol); yield: 0.37 g (83 %); white solid: mp 192 °C; Rf = 0.25 
(EtOAc / MeOH, 95:5); IR (ATR) υ (cm-1) 3109 (w), 1609 (m), 1507 (s), 1460 (w), 1392 (w), 1284 (m), 1246 (s), 
1176 (w), 1108 (w), 1076 (w), 1031 (m), 830 (m), 770 (m), 735 (w), 664 (w); δH (CDCl3, 500 MHz) 3.89 (s, 3H), 
5.61 (s, 2H), 6.97 (s, 1H), 7.04 (d, J = 8.6 Hz, 2H), 7.11 (s, 1H), 7.19 (d, J = 7.3 Hz, 1H), 7.36 (d, J = 7.3 Hz, 1H), 
7.39 (d, J = 8.6 Hz, 2H), 7.46-7.49 (m, 1H), 7.53-7.56 (m, 1H), 7.61 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 
8.4 Hz, 1H); δC (CDCl3, 125 MHz) 48.8, 53.4, 55.3, 113.8, 119.4, 122.5, 125.7, 126.1, 126.4, 126.7, 127.3, 129.6, 
130.4, 131.0, 131.1, 132.2, 132.5, 137.5, 141.2, 159.1; (ESI): m/z = 315 [M++H]. 
8-(1-(1H-Imidazol-1-yl)propyl)-5-(4-methoxyphenyl)quinoline, 8. Synthesised according to Method A1 using 
8a (0.40 g, 1.36 mmol) and CDI (0.88 g, 5.45 mmol); yield: 0.24 g (51 %); white solid: mp 135 °C; Rf = 0.27 
(EtOAc / MeOH, 95:5); IR (ATR) υ (cm-1) 2967 (w), 1609 (m), 1515 (s), 1465 (w), 1284 (m), 1248 (s), 1176 (m), 
1110 (w), 1074 (w), 1031 (m), 824 (s), 735 (w), 666 (m), 541 (w), 530 (w), 514 (w); δH (CDCl3, 500 MHz) 1.06 (t, J 
= 7.3 Hz, 3H), 2.33-2.49 (m, 2H), 3.89 (s, 3H), 6.64-6.67 (m, 1H), 7.04 (d, J = 8.7 Hz, 2H), 7.06 (s, 1H), 7.13 (m, 
1H), 7.35 (d, J = 8.7 Hz, 2H), 7.38 (dd, J = 4.1 Hz, J = 8.6 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.55 (d, J = 7.5 Hz, 
1H), 7.79 (s, 1H), 8.25 (dd, J = 1.7 Hz, J = 8.6 Hz, 1H), 8.94 (dd, J = 1.7 Hz, J = 4.1 Hz, 1H);δC (CDCl3, 125 MHz) 
11.4, 28.2, 55.4, 57.0, 114.0, 118.0, 121.2, 125.3, 126.8, 127.0, 128.9, 131.0, 131.4, 134.7, 137.1, 137.8, 140.3, 
145.7, 149.4, 159.3; (ESI): m/z = 344 [M++H]. 
8-(1-(1H-Imidazol-1-yl)propyl)-2-ethyl-5-(4-methoxyphenyl)quinoline, 10. Synthesised according to Method 
A1 using 10a (0.40 g, 1.25 mmol) and CDI (1.61 g, 9.96 mmol); yield: 0.27 g (59 %); white solid: mp 157 °C; Rf = 
0.24 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm-1) 2969 (w), 1609 (s), 1576 (w), 1517 (s), 1498 (w), 1460 (w), 1285 
(w), 1247 (s), 1177 (m), 1110 (w), 1072 (w), 1032 (m), 825 (w), 738 (m), 664 (m); δH (CDCl3, 500 MHz) 1.08 (t, J 
= 7.3 Hz, 3H), 1.47 (t, J = 7.6 Hz, 3H), 2.37-2.51 (m, 2H), 3.06 (q, J = 7.6 Hz, J = 15.1 Hz, 2H), 3.91 (s, 3H), 6.69 
(m, 1H), 7.05 (d, J = 8.7 Hz, 2H), 7.14 (s, 1H), 7.27 (d, J = 3.8 Hz, 1H), 7.35-7.39 (m, 3H), 7.55 (d, J = 7.5 Hz, 1H), 
7.82 (s, 1H), 8.15 (d, J = 8.7 Hz, 1H); δC (CDCl3, 125 MHz) 11.4, 13.2, 28.0, 31.9, 55.4, 57.1, 113.9, 117.9, 121.1, 
125.1, 125.3, 125.8, 128.8, 131.0, 131.7, 134.7, 137.1, 137.2, 140.0, 145.2, 159.2, 162.6; (ESI): m/z = 372 [M++H]. 
1-(1-(4-(Benzo[b]thiophen-5-yl)phenyl)propyl)-1H-imidazole, 12. Synthesised according to Method A1 using 
12a (1.33 g, 4.94 mmol) and CDI (4.00 g, 24.7 mmol); yield: 0.51 g (32 %); white solid: mp 101-103 °C; Rf = 0.24 
(DCM / MeOH, 20:1); IR (ATR) υ (cm-1) 1496 (m), 1223 (m), 1073 (m), 805 (vs), 758 (s), 702 (s), 663 (s); δH 
(CDCl3, 500 MHz) 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.28 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.08 (t, J = 7.6 Hz, 1H, CH), 
7.00 (s, 1H), 7.13 (s, 1H), 7.29 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 5.4 Hz, 1H), 7.49 (d, J = 5.4 Hz, 1H), 7.55 (dd, J = 
1.7, 8.4 Hz , 1H), 7.64 (dd, J = 1.7, 8.3 Hz, 2H), 7.73 (s, 1H), 7.93 (d, J = 8.4 Hz, 1H), 8.00 (s, 1H); δC (CDCl3, 125 
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MHz) 11.1 (CH3), 28.6 (CH2), 63.3 (CH), 117.8, 120.0, 121.9, 122.8, 123.7, 124.0, 127.0, 127.2, 127.8, 128.7, 
136.1, 136.7, 138.8, 139.1, 139.4, 140.2, 141.3; MS (ESI): m/z = 319 [M++H]. 
5-(4-(1-(1H-Imidazol-1-yl)propyl)phenyl)-1H-indole, 13. Synthesised according to Method A1 using 13a 
(1.10 g, 4.38 mmol) and CDI (3.55 g, 21.88 mmol); yield: 0.33 g (25 %); white solid: mp 158-159 °C; Rf = 0.15 
(DCM / MeOH, 20:1); IR (ATR) υ (cm-1) 3143 (br), 1593 (w), 1471 (w), 1222 (w), 1075 (m), 891 (s), 805 (s), 772 
(s), 739 (s), 660 (m), 574 (w), 539 (w); δH (CDCl3, 500 MHz) 0.86 (t, J = 7.3, 3H, CH3), 2.15 (q, J = 7.23, 7.6 Hz, 
2H, CH2), 4.93 (t, J = 7.6 Hz, 1H, CH), 6.50 (s, 1H), 6.90 (s, 1H), 7.04 (s, 1H), 7.13-7.17 (m, 3H), 7.30 (dd, J = 8.5, 
9.5 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.67 (s, 1H), 7.74 (s, 1H), 8.89 (s, 1H); δC (CDCl3, 125 MHz) 11.0 (CH3), 
28.4 (CH2), 63.5 (CH), 102.6, 111.4, 119.0,121.4, 125.2, 127.7, 128.4, 130.8, 132.1, 135.6, 135.8, 137.3, 142.6; MS 
(ESI): m/z = 302 [M++H]. 
1-(4-(Benzofuran-5-yl)benzyl)-1H-imidazole, 14. Synthesised according to Method A1 using 14a (0.50 g, 2.23 
mmol) and CDI (1.81 g, 11.1 mmol); yield: 0.26 g (43 %); white solid: mp 127-129 °C; Rf = 0.22 (DCM / MeOH, 
20:1); IR (ATR) υ (cm-1) 3109 (w), 1511 (m), 1463 (m), 1439 (m), 1249 (m), 1130 (m), 1107 (m), 1083 (m), 1028 
(s), 909 (m), 876 (m), 836 (m), 802 (vs), 779 (s), 748 (vs), 704 (m), 662 (vs), 631 (m), 523 (s); δH (CDCl3, 500 
MHz) 5.17 (s, 2H, CH2), 6.82 (d, J = 3.0 Hz, 1H), 6.95 (s, 1H), 7.12 (s, 1H), 7.23 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 
5.4 Hz, 1H), 7.55~7.60 (m, 4H), 7.66 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H); δC (CDCl3, 125 MHz) 50.5 (CH2), 119.7, 
123.8, 127.7, 127.9, 129.9, 135.5, 137.4, 141.7,145.7; MS (ESI): m/z = 275 [M++H]. 
1-(4-(Benzo[b]thiophen-5-yl)benzyl)-1H-imidazole, 15. Synthesised according to Method A1 using 15a (0.7 g, 
2.91 mmol) and CDI (2.36 g, 14.6 mmol); yield: 0.18 g (21 %); white solid: mp 164-165 °C; Rf = 0.25 (DCM / 
MeOH, 20:1); IR (ATR) υ (cm-1) 1434 (w), 908 (m), 807 (m), 759 (m), 708 (m), 663 (m); δH (CDCl3, 500 MHz) 
5.18 (s, 2H, CH2), 6.95 (s, 1H), 7.12 (s, 1H), 7.25 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 5.4 Hz, 1H), 7.49 (d, J = 5.4 Hz, 
1H), 7.55 (d, J =8.4 Hz, 1H), 7.59 (s, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 8.4 Hz, 1H), 8.00 (s, 1H); δC 
(CDCl3, 125 MHz) 50.5 (CH2), 119.3, 121.93, 122.83, 123.7, 124.1, 127.3, 127.9, 129.9, 135.0, 139.1, 140.2, 141.4; 
MS (ESI): m/z = 291 [M++H]. 
5-(4-((1H-Imidazol-1-yl)methyl)phenyl)-1H-indole, 16. Synthesised according to Method A1 using 16a (0.80 
g, 3.58 mmol) and CDI (3.55 g, 21.88 mmol); yield: 0.24 g (25 %); white solid: mp 217-218 °C; Rf = 0.16 (DCM / 
MeOH, 20:1); IR (ATR) υ (cm-1) 1509 (m), 1232 (m), 1099 (m), 1072 (m), 915 (m), 883 (m), 801 (m), 732 (s), 662 
(m), 619 (m), 574 (s), 528 (m); δH (CDCl3, 500 MHz) 5.16 (s, 2H, CH2), 6.61-6.63 (m, 1H), 6.97 (s, 1H), 7.13 (s, 
1H), 7.22 (d, J = 8.4 Hz, 2H), 7.25 (s, 1H), 7.43 (dd, J = 8.4, 9.4 Hz, 2H), 7.61 (s, 1H), 7.63 (d, J = 8.3 Hz, 2H), 
7.84 (s, 1H), 8.31 (s, 1H); δC (CDCl3, 125 MHz) 50.6 (CH2), 103.0, 111.3, 119.2, 121.6, 127.6, 127.8, 128.4, 130.8, 
132.4, 134.0, 135.5, 140.53, 142.63; MS (ESI): m/z = 274 [M++H]. 
6-(4-((1H-Imidazol-1-yl)methyl)phenyl)benzo[d]thiazole, 17. Synthesised according to Method A1 using 17a 
(0.40 g, 1.66 mmol) and CDI (2.15 g, 13.26 mmol); yield: 0.29 g (70 %); white solid: mp 143 °C; Rf = 0.47 (EtOAc / 
MeOH, 95:5); IR (ATR) υ (cm-1) 3370 (w), 2927 (w), 2856 (w), 1708 (w), 1506 (m), 1468 (m), 1441 (m), 1391 (m), 
1284 (w), 1232 (m), 1108 (w), 1077 (m), 1030 (w), 886 (w), 813 (s), 739 (s), 697 (w), 663 (s); δH (CDCl3, 500 
MHz) 5.18 (s, 2H), 6.95 (s, 1H), 7.13 (s, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.64 (bs, 1H), 7.71 (dd, J = 1.8 Hz, J = 8.5 
Hz, 1H), 8.12 (m, 1H), 8.18 (d, J = 8.5 Hz, 1H); δC (CDCl3, 125 MHz) 50.6, 119.3, 120.1, 123.8, 125.8, 127.9, 
128.0, 134.6, 135.3, 138.1, 140.6, 152.7, 154.3. 
1-((4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)methyl)-1H-imidazole, 18. Synthesised according to 
Method A1 using 18a (0.13 g, 0.54 mmol) and CDI (0.70 g, 4.30 mmol); yield: 0.06 g (43 %); white solid: mp 149 
°C; Rf = 0.38 (EtOAc / MeOH, 95:5); IR (ATR) υ (cm-1) 3112 (w), 3041 (w), 2930 (w), 2877 (w), 1728 (w), 1677 
(w), 1588 (w), 1497 (s), 1309 (s), 1284 (m), 1246 (m), 1068 (s), 897 (m), 876 (w), 807 (m), 748 (m), 699 (w), 662 
(w), 530 (w); δH (CDCl3 + CD3OD, 500 MHz) 5.13 (s, 2H), 6.88 (d, J = 8.3 Hz, 1H), 6.96 (bs, 1H), 7.00-7.04 (m, 
3H), 7.18 (d, J = 8.0 Hz, 2H), 7.36 (s, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.64 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 
17.8, 29.8, 31.0, 51.1, 64.8, 64.8, 116.0, 117.9, 120.1, 120.3, 127.6, 128.2, 128.9, 134.1, 134.5, 137.6, 141.1, 143.8, 
144.1; (ESI): m/z = 293 [M++H]. 
1-(1-(4-(6-Methoxynaphthalen-2-yl)phenyl)propyl)-1H-imidazole, 19. Synthesised according to Method A1 
using 19a (0.75 g, 1.71 mmol) and CDI (1.50 g, 9.30 mmol); yield: 0.23 g (39 %); white solid: mp 136-138 °C; Rf = 
0.27 (DCM / MeOH, 95:5); IR (ATR) υ (cm-1), 2936 (w), 1676 (s), 1602 (m), 1502 (m), 1462 (m), 1200 (s), 1021 
(m), 844 (s), 814 (s), 665 (s), 532 (m); δH (CDCl3, 500 MHz) 0.98 (t, J=7.25 Hz, 3H, CH3), 2.27-2.30 (m, 2H, CH2), 
3.94 (s, 3H, OCH3), 5.06 (t, J=7.61 Hz, 1H, CH), 6.99 (s, 1H, Im-H5), 7.11 (s, 1H, Im-H4), 7.16-7.19 (m, 2H, 
Aromat), 7.28 (d, J=8.19 Hz, 2H, Aromat), 7.65 (s, 1H, Im-H2), 7.66-7.68 (m, 3H, Aromat), 7.80 (t, J=8.51 Hz, 2H, 
Aromat), 7.95 (d, J=1.26 Hz, 1H, Aromat); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.6 (CH2), 55.3 (CH), 63.0 (OCH3), 
105.6 (C-5´), 117.7 (Im-C4), 119.2 (C-7´), 125.6, 125.7 (Im-C5, C-3´), 127.0, 127.3 (C-1´, C-4´), 127.6 (C-3, C-5), 
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129.1 (C-2, C-6), 129.7 (C-8), 133.9 (C-2´), 135.4 (C-4), 139.0 (C-1), 141.0 (Im-C2), 157.9 (C-6´); MS (ESI): m/z = 
343 [M+-H]. 
1-(1-(4-(Naphthalen-2-yl)phenyl)propyl)-1H-imidazole, 20. Synthesised according to Method A1 using 20a 
(0.50 g, 1.9 mmol) and CDI (1.50 g, 9.30 mmol); yield: 0.23 g (39 %); white solid: mp 136-138 °C; Rf = 0.29 (DCM 
/ MeOH, 95:5); IR (ATR) υ (cm-1), 1687 (m), 1499 (s), 1223 (m), 1072 (m), 1015 (m), 809 (vs), 758 (s), 733 (s), 
662 (s); δH (CDCl3, 500 MHz) 0.98 (t, J=7.25 Hz, 3H, CH3), 2.24-2.33 (m, 2H, CH2), 5.08 (t, J=7.56 Hz, 1H, CH), 
7.00 (t, J=1.26 Hz, 1H, Im-H5), 7.11 (t, J=1.26 Hz, 1H, Im-H4), 7.30 (d, J=7.88 Hz, 2H, aromat), 7.47-7.53 (m, 2H, 
aromat), 7.65 (s, 1H, Im-H2), 7.69-7.72 (m, 3H, aromat), 7.85-7.92 (m, 3H, aromat), 8.01 (d, J=1.57 Hz, 1H, 
aromat); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.6 (CH2), 63.1 (CH), 117.7 (Im-C4), 125.3 (C-3´), 125.8, 126.1, 126.4 
(Im-C5, C-7´, C-8´), 127.1 (C-1´), 127.6, 127.8, 128.1, 128.5 (C-3, C-5, C-5´, C-8´), 129.6 (C-4´), 132.7, 132.6 (C-
2, C-6), 136.4 (C-4, C-2´), 137.6 (C-1), 139.4 (Im-C2); MS (ESI): m/z = 313 [M++H]. 
1-(3-(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)phenyl)pentan-3-yl)-1H-imidazole, 21a. Synthesised 
according to Method A1 using 21b (1.00 g, 2.5 mmol) and CDI (2.06 g, 12.7 mmol); brown oil; the crude product 
was directly used in the next step without further purification and analysis. 
Method B: Ether cleavage with BBr3. To a solution of the corresponding ether (1 eq) in DCM (5 mL / mmol) 
at -78 °C was added 1 M borontribromide in DCM (5 eq). The resulting mixture was stirred at rt for 16 hours. Then 
water (25 mL) was added and the emulsion was stirred for further 30 minutes. The resulting mixture was extracted 
with ethyl acetate (3 x 25 mL). The combined organic phases were washed with brine, dried over Na2SO4 and 
evaporated under reduced pressure. Then the desired product was purified by chromatography on silica gel.  
4-(2-((1H-Imidazol-1-yl)methyl)benzo[b]thiophen-5-yl)phenol, 2. Synthesised according to Method B using 1 
(0.15 g, 0.47 mmol) and BBr3 (2.35 mL, 2.34 mmol); yield: 0.05 g (32 %); white solid: mp 211 °C; Rf = 0.42 (DCM 
/ MeOH, 95:5); IR (ATR) υ (cm-1) 3349 (w), 2959 (w), 1733 (w), 1609 (w), 1515 (s), 1448 (w), 1277 (s), 1242 (w), 
1231 (w), 1194 (w), 1108 (m), 1030 (w), 951 (w), 885 (w), 809 (s), 749 (s), 658 (m), 547 (w); δH (CDCl3 + CD3OD, 
500 MHz) 5.43 (s, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.02 (bs, 1H), 7.11 (bs, 1H), 7.25 (s, 1H), 7.44-7.52 (m, 3H), 7.72 
(bs, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.85 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 116.3, 122.0, 123.1, 124.4, 124.8, 
128.9, 133.1, 138.9, 138.9, 140.3, 140.6, 157.2. 
4-(4-((1H-Imidazol-1-yl)methyl)naphthalen-1-yl)phenol, 7. Synthesised according to Method B using 6 (0.15 
g, 0.48 mmol) and BBr3 (1.90 mL, 1.90 mmol); yield: 0.08 g (52 %); white solid: mp 197 °C; Rf = 0.42 (DCM / 
MeOH, 95:5); IR (ATR) υ (cm-1) 3600-2900 (w), 1610 (w), 1509 (m), 1437 (w), 1391 (w), 1264 (s), 1214 (w), 1172 
(w), 1091 (m), 951 (w), 834 (s), 770 (w), 734 (s), 654 (w), 574 (w); δH (CDCl3 + CD3OD, 500 MHz) 6.89 (d, J = 8.4 
Hz, 2H), 7.04 (s, 1H), 7.15 (s, 1H), 7.21 (d, J = 8.4 Hz, 2H), 7.28-7.30 (m, 1H), 7.31 (s, 1H), 7.36-7.39 (m, 1H), 
7.44-7.47 (m, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.29 (bs, 1H); δC (CDCl3 + CD3OD, 125 MHz) 
115.3, 122.4, 126.3, 126.4, 127.2, 127.6, 131.1, 131.3, 132.5, 156.6; (ESI): m/z = 301 [M++H]. 
4-(8-(1-(1H-Imidazol-1-yl)propyl)quinolin-5-yl)phenol, 9. Synthesised according to Method B using 8 (0.10 g, 
0.29 mmol) and BBr3 (1.46 mL, 1.46 mmol); yield: 0.06 g (63 %); white solid: mp 174 °C; Rf = 0.42 (DCM / 
MeOH, 95:5); IR (ATR) υ (cm-1) 3500-2600 (w), 1610 (m), 1515 (s), 1458 (w), 1397 (w), 1269 (s), 1227 (w), 1172 
(w), 1108 (w), 1089 (w), 826 (s), 797 (w), 736 (s), 669 (w); δH (CDCl3 + CD3OD, 500 MHz) 0.95 (t, J = 7.2 Hz, 
3H), 2.30-2.41 (m, 2H), 6.58 (m, 1H), 6.91 (d, J = 8.5 Hz, 2H), 6.07 (bs, 1H), 7.14 (bs, 1H), 7.18 (d, J = 8.5 Hz, 
2H), 7.28-7.32 (m, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.99 (bs, 1H), 8.22 (d, J = 8.5 Hz, 1H), 
8.81 (m, 1H); δC (CDCl3 + CD3OD, 125 MHz) 11.3, 27.8, 57.8, 60.7, 115.5, 115.6, 119.0, 121.4, 125.8, 125.9, 
126.8, 127.2, 127.3, 130.0, 131.1, 131.1, 135.3, 135.9, 137.3, 141.4, 145.7, 149.6, 157.1; (ESI): m/z = 330 [M++H]. 
4-(8-(1-(1H-Imidazol-1-yl)propyl)-2-ethylquinolin-5-yl)phenol, 11. Synthesised according to Method B using 
10 (0.15 g, 0.40 mmol) and BBr3 (2.00 mL, 2.00 mmol); yield: 0.09 g (58 %); white solid: mp 142 °C; Rf = 0.69 
(DCM / MeOH, 95:5); IR (ATR) υ (cm-1) 3600-2800 (w), 2968 (w), 2932 (w), 1733 (s), 1608 (s), 1579 (w), 1518 
(s), 1457 (w), 1398 (w), 1269 (s), 1225 (m), 1172 (m), 1108 (w), 951 (w), 824 (s), 734 (m), 659 (w); δH (CDCl3 + 
CD3OD, 500 MHz) 0.94 (t, J = 7.2 Hz, 3H), 1.30 (t, J = 7.5 Hz, 3H), 2.29-2.43 (m, 2H), 2.89-2.93 (m, 2H), 6.57-
6.60 (m, 1H), 6.88 (d, J = 8.1 Hz, 2H), 6.99 (s, 1H), 7.12 (s, 1H), 7.15-7.18 (m, 3H), 7.29 (d, J = 7.4 Hz, 1H), 7.53 
(d, J = 7.4 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.13 (s, 1H); δC (CDCl3 + CD3OD, 125 MHz) 11.0, 13.0, 27.1, 31.6, 
58.1, 115.2, 119.1, 121.0, 125.2, 125.33, 125.34, 126.2, 130.2, 130.8, 134.2, 134.8, 137.5, 141.0, 145.0, 156.4, 
162.9; (ESI): m/z = 358 [M++H]. 
Method C: Suzuki-Coupling. The corresponding brominated aromatic compound (1 eq) was dissolved in 
toluene (7 mL / mmol), an aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol) and an ethanolic solution (3.2 mL / 
mmol) of the corresponding boronic acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced 
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pressure and flushed with nitrogen. After repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the 
resulting suspension was heated under reflux for 8 h. After cooling ethyl acetate (10 mL) and water (10 mL) were 
added and the organic phase was separated. The water phase was extracted with ethyl acetate (2 x 10 mL). The 
combined organic phases were washed with brine, dried over Na2SO4, filtered over a short plug of celite® and 
evaporated under reduced pressure. The compounds were purified by flash chromatography on silica gel.  
6-(4-Fluorophenyl)-1H-indole-3-carbaldehyde, 3b. Synthesised according to Method C1 using 6-bromo-1H-
indole-3-carbaldehyde (0.45 g, 2.00 mmol) and 4-fluorophenylboronic acid (0.57 g, 4.05 mmol); yield: 0.35 g (73 
%); yellow oil; Rf = 0.57 (petrolether / EtOAc, 1:2); IR (ATR) υ (cm-1) 3228 (m), 2806 (w), 1646 (s), 1618 (m), 
1518 (m), 1386 (m), 1198 (m), 1110 (s), 1083 (s), 811 (s), 670 (s), 593 (m), 517 (s); δH (CDCl3, 500 MHz) 6.84 (t, J 
= 8.8 Hz, 2H), 7.15 (dd, J = 1.6 Hz, 8.2 Hz, 1H), 7.30 (dd, J = 5.4 Hz, 8.8 Hz, 2H), 7.33 (m, 1H), 7.63 (d, J = 3.2 
Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 9.71 (s, 1H), 11.42 (bs, 1H); δC (CDCl3, 125 MHz) 109.7 (CH), 114.8 (CH), 118.0 
(Cq), 121.0 (Cq), 121.1 (CH), 123.0 (Cq), 128.1 (CH), 135.3 (Cq), 136.8 (CH), 137.1 (Cq), 137.3 (Cq), 161.4 (CF), 
184.2 (CH); MS (ESI): m/z = 238 [M+-H]. 
2-((1H-Imidazol-1-yl)methyl)-6-(4-fluorophenyl)quinoline, 4. Synthesised according to Method C1 using 4a 
(0.24 g, 0.84 mmol) and 4-fluorophenylboronic acid (0.23 g, 1.68 mmol); yield: 0.23 g (92 %); yellow solid, Rf = 
0.15 (EtOAc/MeOH 9/1); IR (ATR) υ (cm-1) 3125 (w), 3094 (w), 2926 (w), 1602 (m), 1515 (m), 1498 (m), 1431 
(m), 1224 (s), 824 (s), 771 (m), 657 (m); δH (CDCl3, 500 MHz) 5.43 (s, 2H), 7.04 (t, J = 1.3 Hz, 1H), 7.08 (d, J = 8.5 
Hz, 1H), 7.15 (bs, 1H), 7.18 (t, J = 8.5, 2H), 7.66 (m, 2H), 7.69 (bs, 1H), 7.93 (d, J = 2.2 Hz, 1H), 7.96 (dd, J = 2.2, 
8.5 Hz, 1H), 8.12 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H); δC (CDCl3, 125 MHz) 53.2 (CH2), 115.9 (d, 2JCF = 22 
Hz, CH), 119.1 (CH), 119.6 (CH), 125.1 (CH), 127.6 (CH), 128.3 (Cq), 128.4 (CH), 129.0 (d,³ J = 7.7 Hz, CH), 
129.6 (CH), 129.7 (CH), 130.2 (CH), 136.2 (d,4 J CF = 2.9 Hz, Cq), 137.7 (CH), 137.8 (CH), 138.8 (Cq), 146.9 (Cq), 
156.2 (Cq), 162.8 (d, 1J CF = 248.0 Hz, CF); MS (ESI): m/z = 304 [M++H]. 
2-((1H-Imidazol-1-yl)methyl)-6-(thiophen-3-yl)quinoline, 5. Synthesised according to Method C1 using 5a 
(0.24 g, 0.84 mmol) and 3-thiophenylboronic acid (0.22 g, 1.68 mmol); yield: 0.22 g (88 %); yellow solid; Rf = 0.11 
(EtOAc/MeOH 9/1); IR (ATR) υ (cm-1) 3104 (w), 2963 (w), 2926 (m), 1597 (m), 1506 (m), 1318 (m), 1068 (m), 
828 (s), 782 (s), 753 (s), 660 (s); δH (CDCl3, 500 MHz) 5.43 (s, 2H), 7.04 (t, J = 1.3 Hz, 1H), 7.06 (d, J = 8.5 Hz, 
1H), 7.15 (t, J = 0.9 Hz, 1H), 7.46 (dd, J = 2.8, 5.0 Hz, 1H), 7.52 (dd, J = 1.6, 5.0 Hz, 1H), 7.62 (dd, J = 1.3, 2.8 Hz, 
1H), 7.69 (bs, 1H), 7.99 (d, J = 1.9 Hz, 1H), 8.02 (dd, J = 2.2, 8.8 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.14 (d, J = 8.5 
Hz, 1H); δC (CDCl3, 125 MHz) 53.2 (CH2), 119.1 (CH), 119.6 (CH), 121.5 (CH), 124.2 (CH), 126.3 (CH), 126.8 
(CH), 127.7 (Cq), 129.4 (CH), 129.6 (CH), 130.2 (CH), 134.4 (Cq), 137.6 (CH), 137.8 (CH), 141.2 (Cq), 146.9 (Cq), 
155.9 (Cq); MS (ESI): m/z = 292 [M++H]. 
(4-(4-Methoxyphenyl)naphthalen-1-yl)methanol, 6a. Synthesised according to Method C2 using 6b (0.40 g, 
1.69 mmol) and 4-methoxyphenylboronic acid (0.39 g, 2.53 mmol); yield: 0.42 g (94 %); white solid; Rf = 0.57 
(petrolether / EtOAc, 1:2); δH (CDCl3, 500 MHz) 3.90 (s, 3H), 5.20 (s, 2H), 7.04 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 7.2 
Hz, 1H), 7.40 (d, J = 8.7 Hz, 2H), 7.45-7.48 (m, 1H), 7.56 (d, J = 7.2 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 
8.4 Hz, 1H); δC (CDCl3, 125 MHz) 55.4, 63.8, 113.7, 123.9, 125.0, 125.9, 126.2, 126.4, 126.9, 131.1, 131.5, 132.2, 
133.0, 135.4, 140.5, 159.0. 
5-(4-Methoxyphenyl)quinoline-8-carbaldehyde, 8b. Synthesised according to Method C2 using 6-bromo-1H-
indole-3-carbaldehyde (3.00 g, 12.71 mmol) and 4-methoxyphenylboronic acid (2.90 g, 19.06 mmol); yield: 2.75 g 
(82 %); white solid; Rf = 0.63 (petrolether / EtOAc, 1:2); δH (CDCl3, 500 MHz) 7.06 (d, J = 8.7 Hz, 2H), 7.41 (d, J = 
8.7 Hz, 2H), 7.45 (d, J = 4.1 Hz, J = 8.6 Hz, 1H), 7.61 (d, J = 7.5 Hz, 1H), 8.33-8.34 (m, 2H), 9.03-9.04 (m, 1H), 
11.48 (s, 1H); δC (CDCl3, 125 MHz) 55.4, 114.1, 121.5, 121.8, 126.2, 126.7, 126.9, 128.8, 129.3, 130.5, 130.9, 
131.0, 134.2, 134.8, 136.3, 146.7, 148.1, 150.9, 151.3, 159.8, 192.6. 
4-(Benzo[b]thiophen-5-yl)benzaldehyde, 12b. Synthesised according to Method C1 using 5-
bromobenzo[b]thiophene (1.90 g, 8.92 mmol) and 4-formylphenylboronic acid (1.74 g, 11.6 mmol); yield: 1.71 g 
(80 %); white solid; Rf = 0.35 (petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 7.41 (d, J = 5.4 Hz, 1H), 7.51 (d, J 
= 5.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 7.9 Hz, 2H), 7.97 (d, J = 8.2 Hz, 3H), 8.07 (s, 1H), 10.07 (s, 1H, 
CHO); δC (CDCl3, 125 MHz) 122.3, 123.0, 123.6, 124.0, 127.5, 127.8, 130.3, 135.0, 126.1, 139.9, 140.2, 147.3, 
191.9. 
4-(1H-Indol-5-yl)benzaldehyde, 13b. Synthesised according to Method C1 using 5-bromo-1H-indole (0.10 g, 
0.51 mmol) and 4-formylphenylboronic acid (0.1 g, 0.66 mmol); yield: 0.07 g (65 %); white solid; Rf = 0.25 
(petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 6.64 (t, J = 2.8 Hz, 1H), 7.27 (t, J = 3.1 Hz, 1H), 7.48 (s, 1H), 
7.74 (dd, J = 1.8, 8.5 Hz, 2H), 7.92 (s, 1H), 8.04 (dd, J = 1.8, 8.5 Hz, 2H), 8.29 (s, br, 1H), 10.05 (s, 1H, CHO); δC 
(CDCl3, 125 MHz) 103.2, 111.4, 119.6, 121.7, 125.1, 127.2, 128.4, 128.5, 132.0, 135.8, 147.0, 192.1. 
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4-(Benzofuran-5-yl)benzaldehyde, 14b. Synthesised according to Method C1 using 5-bromobenzofuran (1.90 
g, 9.64 mmol) and 4-formylphenylboronic acid (1.88 g, 12.5 mmol); yield: 0.53 g (25 %); yellow oil; Rf = 0.33 
(petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 6.83-6.84 (m, 1H), 7.54-7.60 (m, 2H), 7.68 (d, J = 2.2 Hz, 1H), 
7.76 (d, J = 8.2 Hz, 2H), 7.84 (d, J = 1.6 Hz, 1H), 7.94 (dd, J = 1.8, 8.4 Hz, 2H), 10.05 (s, 1H, CHO); δC (CDCl3, 
125 MHz) 106.8, 111.8, 120.1, 123.9, 127.8, 130.2, 134.8, 145.9, 147.6, 155.0, 191.9. 
(4-(Benzo[d]thiazol-6-yl)phenyl)methanol, 17a. Synthesised according to Method C1 using 6-
bromobenzo[d]thiazole (0.50 g, 2.34 mmol) and 4-(hydroxymethyl)phenylboronic acid (0.53 g, 3.50 mmol); yield: 
0.50 g (89 %); white solid; Rf = 0.26 (petrolether / EtOAc, 1:2); δH (CDCl3, 500 MHz) 4.77 (s, 2H), 7.48 (d, J = 8.4 
Hz, 2H), 7.64-7.68 (m, 3H), 7.74 (dd, J = 1.8 Hz, J = 8.5 Hz, 1H), 8.15 (s, 1H), 8.20 (d, J = 8.5 Hz, 1H), 9.03 (s, 
1H); δC (CDCl3, 125 MHz) 64.9, 120.1, 123.6, 125.9, 127.6, 127.6, 128.5, 128.6, 132.0, 132.0, 132.1, 132.1, 134.5, 
138.8, 139.7, 140.4. 
(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)methanol, 18a. Synthesised according to Method C1 using 6-
bromo-2,3-dihydrobenzo[b][1,4]dioxine (0.50 g, 2.33 mmol) and 4-(hydroxymethyl)phenylboronic acid (0.53 g, 
3.49 mmol); yield: 0.15 g (27 %); white solid; Rf = 0.62 (petrolether / EtOAc, 1:2); δH (CDCl3, 500 MHz) 4.29 (s, 
1H), 4.71 (s, 1H), 6.93 (d, J = 8.3 Hz, 1H), 7.08 (dd, J = 2.2 Hz, J = 8.3 Hz, 1H), 7.12 (d, J = 2.2 Hz, 1H), 7.40 (d, J 
= 8.3 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H); δC (CDCl3, 125 MHz) 64.4, 64.4, 65.1, 115.8, 117.5, 120.1, 126.9, 127.4, 
134.4, 139.4, 140.0, 143.2, 143.7. 
Method D: Reduction with NaBH4. To an ice-cooled solution of the corresponding aldehyde or ketone (1 eq) 
in methanol (5 mL / mmol) was added NaBH4 (2 eq). Then the resulting mixture was heated to reflux for 30 
minutes. After cooling to ambient temperature, the solvent was distilled off under reduced pressure. Then water (10 
mL) was added, and the resulting mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic 
phases were washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product 
was purified by chromatography on silica gel. 
(6-(4-Fluorophenyl)-1H-indol-3-yl)-methanol, 3a. Synthesised according to Method D using 3b (0.30 g, 1.25 
mmol) and NaBH4 (0.86 g, 2.26 mmol); yield: 0.27 g (89 %); Rf = 0.55 (PE / EtOAc, 1:2); the crude product was 
directly used in the next step without further purification and analysis. 
(4-(Benzo[b]thiophen-5-yl)phenyl)methanol, 14a. Synthesised according to Method D using 14b (0.30 g, 1.26 
mmol) and NaBH4 (0.10 g, 2.52 mmol); yield: 0.28 g (92 %); Rf = 0.30 (PE / EtOAc, 2:1); the crude product was 
directly used in the next step without further purification and analysis. 
1-(4-(Benzo[b]thiophen-5-yl)phenyl)propan-1-ol, 15a. Synthesised according to Method D using 15b (0.30 g, 
1.36 mmol) and NaBH4 (0.11 g, 2.71 mmol); yield: 0.28 g (91 %); Rf = 0.30 (PE / EtOAc, 2:1); the crude product 
was directly used in the next step without further purification and analysis. 
1-(4-(6-Methoxynaphthalen-2-yl)phenyl)propan-1-ol, 19a. Synthesised according to Method D using 19b 
(1.93 g, 6.40 mmol) and NaBH4 (0.48 g, 12.8 mmol); yield: 0.711 g (38 %); Rf = 0.59 (DCM / MeOH, 98:2); the 
crude product was directly used in the next step without further purification and analysis. 
1-(4-(Naphthalen-2-yl)phenyl)propan-1-ol, 20a. Synthesised according to Method D using 20b (1.80 g, 6.40 
mmol) and NaBH4 (0.48 g, 12.8 mmol); yield: 1.34 g (80 %); Rf = 0.62(DCM / MeOH, 98:2); the crude product was 
directly used in the next step without further purification and analysis. 
6-Bromo-2-(bromomethyl)quinoline 4b. 6-Bromo-2-methylquinoline (3.00 g, 13.5 mmol) was dissolved in 40 
mL of dry carbon tetrachloride. To this solution was added NBS (2.63 g, 14.8 mmol) and dibenzoyl peroxide (0.16 
g, 0.70 mmol) and the mixture was refluxed over night. After cooling, the succinimide was removed by filtration 
and the filtrate was concentrated under vacuum. The crude product was further purified by flash column 
chromatography on silica gel using petroleum ether / EtOAc (95 : 5) as eluent; yield: 1.71 g (42%); lachrymatory 
lilac oil; Rf = 0.46 (hexane / EtOAc 95 : 5); IR (ATR) υ (cm-1) 3054 (w), 3038 (w), 2928 (w), 2855 (w), 1589 (m), 
1484 (s), 1373 (m), 1304 (m), 1200 (s), 1190 (s), 1060 (s), 899 (s), 830 (s), 792 (s), 775 (m), 735 (s), 694 (s), 597 
(s), 550 (s); δH (CDCl3, 500 MHz) 4.68 (s, 2H), 7.59 (d, J = 8.5 Hz, 1H), 7.79 (dd, J = 2.1, 9.1 Hz, 1H), 7.93 (d, J = 
8.8 Hz, 1H), 7.98 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H); δC (CDCl3, 125 MHz) 34.0 (CH2), 121.0 (CH), 122.0 
(CH), 128.4 (Cq), 129.6 (CH), 131.0 (CH), 133.4 (CH), 136.2 (Cq), 157.4 (Cq), 157.9 (Cq); MS (ESI): m/z =302 [M+ 
+ H]. 
2-(1H-Imidazol-1-ymethyl)-6-bromoquinoline 4a. The α-brominated compound 4b (1.89 g, 6.28 mmol), 
imidazole (0.86 g, 12.55 mmol), anhydrous K2CO3 (1.29 g, 9.42 mmol) and a catalytical amount of 18-crown-6 in 
dry acetonitrile were heated under reflux over night. After the solution was cooled down, the solvent was removed 
under reduced pressure. The residue was dissolved with water (10 mL/eq) and extracted three times with CH2Cl2 (15 
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mL/eq). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and 
evaporated. The crude material was purified by flash chromatography on silica-gel, using 5% MeOH in CH2Cl2; 
yield: 1.1 g (61%); Rf = 0.23 (EtOAc / MeOH 9 : 1); IR (ATR) υ (cm-1) 3098 (w), 1593 (m), 1488 (s), 1291 (m), 
1235 (m), 1086 (m), 1030 (m), 824 (s), 733 (s), 658 (s); δH (CDCl3, 500 MHz) 5.39 (s, 2H), 7.01 (t, J = 1.3 Hz, 1H), 
7.06 (d, J = 8.5 Hz, 1H), 7.13 (t, J = 1.3 Hz, 1H), 7.66 (s, 1H), 7.79 (dd, J = 2.2, J = 9.1 Hz, 1H), 7.91 (d, J = 9.1 Hz, 
1H), 7.96 (d, J = 2.2 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H) ); δC (CDCl3, 125 MHz) 55.0 (CH2), 119.5 (CH), 119.5 (CH), 
120.9 (CH), 129.6 (Cq), 130.2 (CH), 130.8 (CH), 133.6 (CH), 136.6 (CH), 137.7 (Cq), 146.2 (Cq), 156.6 (Cq); MS 
(ESI): m/z = 289 [M+ + H]. 
4-Bromo-1-naphthoic acid, 6c. 4-Bromo-1-methyl naphthalene (20.0 g, 88.65 mmol) was preheated to 90 °C in 
a water / pyridine 1 : 1 mixture (170 mL) and KMnO4 (57.2 g, 354.6 mmol) was added over a period of 3 h every 30 
in in equal portions. yield: 1.60 g (7 %); Rf = 0.37 (PE / EtOAc, 2:1); δH (CDCl3 + CD3OD, 500 MHz) 7.56-7.61 (m, 
2H), 7.78 (d, J = 7.9 Hz, 1H), 8.00 (d, J = 7.9 Hz, 1H), 8.26-8.28 (m, 1H), 8.91-8.93 (m, 1H); δC (CDCl3 + CD3OD, 
125 MHz) 126.5, 127.6, 127.7, 128.4, 128.7, 129.1, 130.5, 132.3, 132.6. 
(4-Bromonaphthalen-1-yl)methanol, 6b. To a solution of 6c (0.60 g, 2.39 mmol) in THF (10 mL) LiAlH4 (0.91 
g, 3.90 mmol) in THF (5 mL) was added slowly and heated to reflux overnight. yield: 1.65 g (83 %); Rf = 0.74 (PE / 
EtOAc, 2:1); δH (CDCl3, 500 MHz) 5.12 (s, 2H), 7.37 (d, J = 7.6 Hz, 1H), 7.58-7.64 (m, 2H), 7.76 (d, J = 7.6 Hz, 
1H), 8.11 (d, J = 7.8 Hz, 1H), 8.31 (d, J = 7.8 Hz, 1H); δC (CDCl3, 125 MHz) 123.2, 124.0, 125.5, 127.1, 127.2, 
127.9, 129.4, 132.1, 132.3, 136.3. 
Method E: Grignard reaction. Under exclusion of air and moisture a 1.0 M EtMgBr (1.2 eq) solution in THF 
was added dropwise to a solution of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred 
over night at rt. Then ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was separated. The 
organic phase was extracted with water and brine, dried over Na2SO4, and evaporated under reduced pressure. The 
crude products were purified by flash chromatography on silica gel. 
1-(5-(4-Methoxyphenyl)quinolin-8-yl)propan-1-ol, 8a. Synthesised according to Method E using 8b (1.00 g, 
3.80 mmol) and NaBH4 (15.20 mL, 15.20 mmol); yield: 0.47 g (43 %); Rf = 0.47 (PE / EtOAc, 2:1); δH (CDCl3, 500 
MHz) 1.05 (t, J = 7.4 Hz, 3H), 1.97-2.20 (m, 2H), 3.90 (s, 3H), 5.04-5.07 (m, 1H), 7.04 (d, J = 8.6 Hz, 2H), 7.35-
7.38 (m, 3H), 7.43 (d, J = 7.3 Hz, 1H), 7.56 (d, J = 7.3 Hz, 1H), 8.30 (d, J = 8.6 Hz, 1H), 8.82-8.83 (m, 1H); δC 
(CDCl3, 125 MHz) 11.0, 31.9, 55.4, 113.9, 120.6, 126.8, 127.1, 127.4, 131.1, 131.5, 135.4, 139.2, 139.5, 146.8, 
147.9, 150.3. 
1-(2-Ethyl-5-(4-methoxyphenyl)quinolin-8-yl)propan-1-ol, 10a. Synthesised according to Method E using 8b 
(1.00 g, 3.80 mmol) and NaBH4 (15.20 mL, 15.20 mmol); yield: 0.43 g (39 %); Rf = 0.52 (PE / EtOAc, 2:1); δH 
(CDCl3, 500 MHz) 1.03 (t, J = 7.4 Hz, 3H), 1.41 (t, J = 7.6 Hz, 3H), 2.02-2.19 (m, 2H), 2.98-3.03 (m, 2H), 3.89 (s, 
3H), 4.95-4.98 (m, 1H), 7.03 (d, J = 8.6 Hz, 2H), 7.24 (d, J = 8.8 Hz, 1H), 7.34-7.36 (m, 3H), 7.48 (d, J = 7.3 Hz, 
1H), 8.19 (d, J = 8.8 Hz, 1H). 
1-(4-(Benzo[b]thiophen-5-yl)phenyl)propan-1-ol, 12a. Synthesised according to Method E using 12b (0.35 g, 
1.47 mmol) and a 1.0 M ethylmagnesium bromide solution in THF (1.91 mL, 1.91 mmol); yield: 0.34 g (85 %); Rf = 
0.30 (PE / EtOAc, 2:1); the crude product was directly used in the next step without further purification and 
analysis. 
1-(4-(1H-Indol-5-yl)phenyl)propan-1-ol, 13a. Synthesised according to Method E using 13b (0.50 g, 2.26 
mmol) and a 1.0 M ethylmagnesium bromide solution in THF (2.94 mL, 2.94 mmol); yield: 0.51 g (89 %); Rf = 0.30 
(PE / EtOAc, 2:1); the crude product was directly used in the next step without further purification and analysis. 
3-(4-(6-(tert-Butyldimethylsilyloxy)naphthalen-2-yl)phenyl)pentan-3-ol, 21b. Synthesised according to 
Method E using 21c (6.07 g, 16.7 mmol) and EtMgBr (1 M, 18.4 mL, 18.4 mmol, 1.1 eq); yield: 1.37 g (21%); 
yellow solid; Rf = 0.73 (hexane / EtOAc, 7 : 3); the crude product was directly used in the next step without further 
purification and analysis. 
(6-Bromonaphthalen-2-yloxy)(tert-butyl)dimethylsilane, 21d. To a solution of 6-bromonaphthalen-2-ol (10 g, 
44.8 mmol) and imidazole (3.4 g, 49.3 mmol, 1.1 eq) in dichloromethane was slowly added a solution of tert-
butyldimethylsilyl chloride (7.4 g, 49.3 mmol, 1.1 eq) in dichloromethane. After being stirred for 4 h at rt the 
reaction mixture was poured into water, extracted with dichloromethane, washed with water and brine, and dried 
over Na2SO4. Solvent removal under reduced pressure lead to a pale oil, which was purified by chromatography on 
silica gel; yield: 14.5 g, (96%); yellow oil; Rf = 0.63 (hexane); δH (CDCl3, 500 MHz) 0.25 (s, 6H), 1.02 (s, 9H), 7.09 
(dd, J = 2.2, J = 8.8 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 2.2, J = 8.8 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 
7.63 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H); δC (CDCl3, 125 MHz) -4.3 (CH3), 18.2 (Cq), 25.7 (CH3), 114.9 
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(CH), 117.3 (CBr), 123.1 (CH), 128.3 (CH), 128.4 (Cq), 129.4 (CH), 129.6 (CH), 130.3 (CH), 133.1 (Cq), 153.8 
(COR); MS (ESI): m/z = 337 [M+ + H]. 
6-(4-(3-(1H-Imidazol-1-yl)pentan-3-yl)phenyl)naphthalen-2-ol, 21. To a solution of the silyl-protected phenol 
21a (crude product, 2.5 mmol) in anhydrous tetrahydrofuran (25 mL) was added tetrabutylammonium fluoride (3 
mL, 1 M) and the solution was stirred for 4 h. The reaction was terminated with the addition of methanol and the 
solvent was removed under reduced pressure. Then, the desired product was purified by chromatography on silica 
gel; yield = 50 mg (6%); brown solid; Rf = 0.31 (EtOAc/MeOH 95/5); IR (ATR) υ (cm-1) 2975 (w), 2874 (w), 1602 
(s), 15 10 (m), 1498 (m), 1251 (s), 1205 (s), 858 (s), 831 (s); δH (CDCl3, 500 MHz) 0.65 (t, J = 7.3 Hz, 6H), 2.27-
2.31 (m, 4H), 6.94 (bs, 1H), 7.06 (bs, 1H), 7.10 (dd, J = 2.4 Hz, J = 8.8 Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 7.22 (d, J 
= 8.8 Hz, 2H), 7.70-7.76 (m, 4H), 7.80 (bs, 1H), 7.82 (d, J = 8.8 Hz, 1H), 8.07 (bs, 1H), 9.84 (s, 1H); δC (CDCl3, 
125 MHz) 7.6 (CH3), 28.9 (CH2), 65.7 (CH), 108.4 (CH), 117.1 (CH), 118.4 (CH), 119.0 (CH), 125.0 (CH), 125.0 
(CH), 126.2 (CH), 126.6 (CH), 126.7 (CH), 127.9 (Cq), 128.1 (Cq), 129.7 (CH), 133.5 (Cq), 133.8 (Cq), 139.0 (Cq), 
142.9 (CH), 155.5 (COH); MS (ESI): m/z =357 [M++H]. 
Biological Assays. CYP17 Preparation and Assay. As source of human CYP17, our E. coli system17 (co-
expressing human CYP17 and NADPH-P450 reductase) was used and the assay was performed as previously 
described7 taking unlabeled progesterone as substrate and applying HPLC with UV-detection for separation. 
Inhibition of Hepatic CYP Enzymes. The recombinantly expressed enzymes from baculovirus-infected insect 
microsomes (BD Supersomes™) were used and the manufacturer's instructions (www.gentest.com) were followed. 
Inhibition of CYP11B1. V79MZh11B1 cells expressing the respective human enzyme were used and our assay 
procedure using [4-14C]-11-deoxycorticosterone was applied.19 
Molecular Modelling. All molecular modelling studies were performed on Intel® P4 CPU 3.00 GHz running 
Linux Suse 10.1. 
Ligands. The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, Missouri, 
USA) and energy-minimised in MMFF94s force-field24 as implemented in Sybyl. The resulting geometries for our 
compounds were then subjected to ab initio calculation employing the B3LYP functional25 in combination with a 6-
31G* basis set using the package Gaussian03 (Gaussian, Inc., Pittsburgh, PA, USA, 2003). 
Docking. Various inhibitors of Tables 1 and 2 were docked into our CYP17 homology model by means of the 
GOLD v 3.0.1 software.20 Since the GOLD docking program allows flexible docking of the compounds, no 
conformational search was employed to the ligand structures. GOLD gave the best poses by a genetic algorithm 
(GA) search strategy, and then various molecular features were encoded as a chromosome. 
Ligands were docked in 50 independent GA runs using GOLD. Heme iron was chosen as active site origin, 
while its radius was set equal to 19 Å. The automatic active site detection was switched on. Furthermore, a distance 
constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-hybridised nitrogen of the imidazole and 
the iron of the heme was set. Additionally, some of the GOLDSCORE parameters were modified to improve the 
weight of hydrophobic interaction and of the coordination between iron and nitrogen. The genetic algorithm default 
parameters were set as suggested by the GOLD authors.20 On the other hand, the annealing parameters of fitness 
function were set at 3.5 Å for hydrogen bonding and 6.5 Å for van-der-Waals interactions. 
All 50 poses for each compound were clustered with ACIAP22 and the representative structure of each 
significant cluster was selected. The quality of the docked representative poses was evaluated based on the 
GOLDSCORE values, which give a good measure of the found binding mode, and on visual inspection of the 
putative binding modes of the ligands, as outcome of docking simulations and cluster analysis. 
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Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships 
and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. 
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Abstract. 
Recently, the steroidal CYP17 inhibitor Abiraterone entered phase II clinical trial for the treatment of androgen 
dependent prostate cancer. As 17α-hydroxylase-17,20-lyase (CYP17) catalyzes the last step in androgen 
biosynthesis, inhibition of this target should affect not only testicular but also adrenal androgen formation. Therefore 
CYP17 inhibitors should be advantageous over existing therapies, for example with GnRH analogues. However, 
steroidal drugs are known for side-effects which are due to affinities for steroid receptors. Therefore we decided to 
synthesize non-steroidal compounds mimicking the natural CYP17 substrates pregnenolone and progesterone. The 
synthesis and biological evaluation of a series of 15 novel and highly active non-steroidal CYP17 inhibitors are 
reported. The compounds were prepared via Suzuki-cross-coupling, Grignard reaction and CDI-assisted SNt-reaction 
with imidazole and their inhibitory activity was examined with recombinant human CYP17 expressed in E. coli. 
Promising compounds were further tested for their selectivity against the hepatic enzyme CYP3A4 and the 
glucocorticoid forming enzyme CYP11B1. All compounds turned out to be potent CYP17 inhibitors. The most 
active compounds 7 and 8 were much more active than Ketoconazole showing activity comparable to Abiraterone 
(IC50 values of 90 and 52 nM vs 72 nM). Most compounds also showed higher selectivities than for Ketoconazole, 
but turned out to be less selective than Abiraterone. Docking studies using our CYP17 protein model were 
performed with selected compounds to study the interactions between the inhibitors and the amino acid residues of 
the active site.  
Introduction. 
Prostate Cancer (PC) is the most prevalent cancer in men in the US and Europe [1]. Since about 80% of patients 
with PC have androgen-dependent disease and respond to hormonal ablation, the presently used treatment is surgical 
castration (orchidectomy) or its medical equivalent, the application of gonadotropin-releasing hormone (GnRH) 
analogs to suppress testicular androgen biosynthesis [2]. However, only testicular production of androgens is 
affected by these strategies, the adrenal formation of androstendione is not and even after 3 months treatment with a 
GnRH agonist, prostate levels of testosterone and dihydrotestosterone are still about 25 and 10%, respectively [3]. 
Therefore, there is frequently combination with antiandrogens to counteract the stimulatory effect of androgens on 
the androgen receptor [4]. However, it is speculated that due to mutations in the androgen receptor, anti-androgens 
might be recognized as agonists [5, 6], making this so called “combined androgen blockade” therapy not suitable for 
all patients. 
A promising novel target for the treatment of prostate cancer is 17α-hydroxylase-17,20-lyase (CYP17), the 
cytochrome b5 modulated key enzyme [7] for the biosynthesis of androgens, catalysing the 17α-hydroxylation of 
pregnenolone and progesterone and the subsequent cleavage of the C 20,21-acetyl group to yield the corresponding 
androgens dehydroepiandrosterone and androstendione (Fig. 1) [8]. Proof of principle was achieved by the 
antimycotic Ketoconazole, which clinically turned out to be a good adjuvant therapeutic capable of reducing 
testosterone levels through unspecific inhibition of CYP17 [9, 10]. Nevertheless, the side-effects it showed were the 
reason why it was not generally accepted [4]. These drawbacks motivated us and others to look for more active and 
selective CYP17 inhibitors (for reviews see: [11-16]). Recently, the steroidal CYP17 inhibitor Abiraterone (Fig.2) 
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passed phase II clinical trials showing high activity in post-docetaxel castration refractory PC patients and seems to 
have no dose-limiting toxicity [17]. 
 
Figure. 1. The role of CYP 17 in androgen biosynthesis 
 
Figure. 2: Schematic presentation of Abiraterone and the scaffold of our biaryl inhibitors 
In previous works, we described novel in vitro and in vivo active steroidal [18-22] and non-steroidal [22-35]  
CYP17 inhibitors. Important for the mode of action of these compounds is a nitrogen-bearing heterocycle which is 
capable of complexing the heme iron of the enzyme. Very recently we demonstrated that some imidazole-methyl 
substituted biphenyls designed as AC-ring steroidal mimetics are good CYP17 inhibitors showing moderate 
selectivity toward other CYP enzymes [32]. 
In this work, in order to further increase the inhibitory activity of these compounds, different substitution 
patterns of methoxy- and hydroxy-groups in the A-ring and further selected functional groups in the A- and C-ring 
were examined. Methyl and ethyl substituents were introduced into the methylene bridge between the biphenyl 
moiety and the imidazole ring, as we found in previous works [30], that these substituents increase inhibitory 
potency.  
In the following we report about the synthesis of compounds 1–15 (Table 1) and the evaluation of their 
inhibitory activities toward CYP17 and, for reasons of selectivity, the hepatic enzyme CYP3A4 and the 
glucocorticoid forming enzyme CYP11B1. Furthermore molecular modelling studies were performed with selected 
compounds. 
Chemistry 
The syntheses of compounds 1 – 15 are shown in Schemes 1 and 2. Regarding the functional groups attached to 
the A-ring, the substances can be divided in alkoxy- and hydroxy-substituted compounds. In case of the methoxy- 
and ethoxy-substituted compounds 1, 2 and 9 – 12 (Scheme 1), commercially available substituted phenylboronic 
acids were coupled to bromopropiophenone in a Suzuki reaction [36] yielding the ketones 9b – 12b, and were 
subsequently reduced with NaBH4 to the corresponding secondary alcohols 1a, 2a and 9a – 12a. The ketones 1b 
and 2b were commercially available. 
The hydroxy-substituted compounds 3–8 and 13-15 (Scheme 2) were also prepared via Suzuki cross-coupling 
reaction using phenylboronic acids carrying the carbonyl function and substituted bromophenols to yield the ketones 
3b–8b, 13c–14c and 15b. Most of the bromophenols latter compounds (3d, 4d, 13d–15d) were commercially 
available. Demethylation of bromoveratrole and 1-bromo-3,5-dimethoxybenzene was achieved with BBr3 (Method 
A) to yield 5d and 6d. The introduction of the ethyl substituent at the methylene bridge between the biphenylic core 
and the imidazole was performed by Grignard reaction, yielding the desired secondary alcohols 3a–8a and 13a–15a.  
All these secondary alcohols 1a–15a were subjected to a SN1 reaction with N,N’-carbonyldiimidazole (CDI) to 
give the imidazole-substituted compounds 1–15 as racemates [37].  
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Table 1. Inhibition of CYP17 by compounds 1-15 
N
N
R3
R2
R1
R4
1 - 15
R5
 
Comp. 
Structures CYP17  
R1 R2 R3 R4 R5 
% Inhibition a IC50 b 
0.2 μM 2 μM [nM] 
Ref1 c H OH H H H 1 32  
1 H OMe H H Me 9 40  
2 OMe H H H Me 8 59  
3 H OH H H Et 27 80 231 
4 OH H H H Et 55 89 164 
5 OH OH H H Et 56 91 152 
6 OH H OH H Et 48 90 195 
7 H OH H F Et 64 94 90 
8 OH OH H F Et 69 95 52 
9 H OMe H H Et 2 36  
10 OMe H H H Et 31 83 188 
11 OMe OMe H H Et 9 58  
12 H OEt H H Et 3 25  
13 Me OH Me H Et 28 78 379 
14 Me OH H H Et 45 89 261 
15 Cl OH H H Et 44 89 217 
KTZ d        2780 
ABT d        72 
a Concentration of progesterone (substrate): 25 μM; standard deviations were within < ±5 % 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 % 
c From Ref [32]; the IC50 value of 0.31 µM cited therein was obtained using a different source of the enzyme: human testicular microsoma 
d KTZ: ketoconazole, ABT: abiraterone 
Scheme 1. Reagents and conditions: (i) R2R3C6H3B(OH)2, Na2CO3, Pd(PPh3)4, toluene/MeOH/H2O, 70 °C, 5 h; 
(ii) NaBH4, MeOH, reflux, 2 h; (iii) CDI, NMP, 170 °C, 7 h 
The phenolic OH-groups had to be silyl-protected before the Grignard reaction. In most cases this synthetic step 
was performed before the Suzuki-reaction, as the chromatographic purification after the cross-coupling was easier 
with the protected compounds. For the final deprotection of the silylated compounds, TBAF was used as standard 
reagent. 
(i) (iii)
Br
O R3
R2
R1
OH
R3
R2
R1
N N
R1
O
R1
R3
R2
1: R1= Me, R2= OMe, R3= H
2: R1= Me, R2= H, R3= OMe
9: R1= Et, R2= OMe, R3= H
10: R1= Et, R2= H, R3= OMe
11: R1= Et, R2= R3= OMe
12: R1= Et, R2= OEt, R3= H
(ii)
1a: R1= Me, R2= OMe, R3= H
2a: R1= Me, R2= H, R3= OMe
9a: R1= Et, R2= OMe, R3= H
10a: R1= Et, R2= H, R3= OMe
11a: R1= Et, R2= R3= OMe
12a: R1= Et, R2= OEt, R3= H
1b: R1= Me, R2= OMe, R3= H
2b: R= Me, R2= H, R3= OMe
9b: R1= Et, R2= OMe, R3= H
10b: R1= Et, R2= H, R3= OMe
11b: R1= Et, R2= R3= OMe
12b: R1= Et, R2= OEt, R3= H
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Scheme 2. Reagents and conditions: (i) TBDMSCl, CH2Cl2, imidazole, rt, 12 h; (ii) CHOR4C6H3B(OH)2, 
Na2CO3, Pd(PPh3)4, toluene/MeOH/H2O, 70 °C, 5 h; (iii) EtMgBr, THF, rt, 5 h; (iv) CDI, NMP, 170 °C, 7 h; (v) 
TBAF, THF, rt, 12 h. 
Results  
Biological results 
Inhibition of human CYP17 was determined by performing our previously described assay [33] at inhibitor 
concentrations of 0.2 and 2 µM. In case of the most potent inhibitors IC50 values were determined. As source of 
human CYP17, our E. coli system [38] stably expressing human CYP17 and NADPH-P450 reductase was used. 
After homogenisation the 50,000 g sediment was incubated with progesterone (25 µM) as substrate and NADPH as 
previously described [27]. Separation of the product was accomplished by HPLC using UV-detection. 
The inhibitory activities of compounds 1 – 15 and the reference compounds Abiraterone, Ketoconazole and Ref1 
[32] toward human CYP17 are shown in Table 1. The compounds can be divided in two classes according to the 
substituents at the A-ring, namely hydroxy and methoxy derivatives and also in two classes regarding substitution at 
the methylene bridge, in methyl and ethyl bearing compounds. All compounds were tested as racemates and showed 
inhibitory activity. The methoxy substituted compounds turned out to be weaker inhibitors compared to the 
corresponding hydroxy analogues. An exception to this is the 3-OCH3 compound 10 which showed a similar high 
activity than the corresponding hydroxy compound 4 (IC50 = 188 nM and 164 nM). Comparing 10 which bears an 
ethyl group at the methylene bridge with the correspondingly substituted methyl compound 2 clearly showed the 
significance of the alkyl substitution in this position, which we already have seen with similar compounds [30, 32, 
34, 39]. Furthermore it is striking that methoxy substitution in para position (R2) is not tolerated as the 
corresponding compounds 1, 9 and 11 showed little activites. 
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The hydroxy compounds 3 - 8 and 13 – 15 showed very high inhibition (IC50 = 379 - 52 nM) with up to fifty fold 
better IC50 values than the reference Ketoconazole (IC50 = 2780 nM). They also turned out to be much more active 
than Ref1 which is certainly due to the ethyl group at the methylene linker. The additional introduction of 
substituents in compound 3 led to interesting findings. In case of the A-ring, substitution with another OH group is 
favourable (5), while CH3 or Cl groups did not increase activity (13 – 15). Introduction of a F in the C-ring, 
however, increased the potency and led to the most active inhibitors of this study, compounds 7 and 8 (IC50 = 90 and 
52 nM), the latter even exceeding Abiraterone (IC50 = 72 nM). 
Regarding selectivity against other CYP enzymes, most compounds were tested for inhibition of the hepatic 
enzyme CYP3A4 at concentrations of 1 and 10 µM. This enzyme is involved in the metabolism of 50 % of the 
drugs. Its inhibition leads to drug-drug interactions by prolonging the half-lives of other coadministered drugs. All 
of the tested compounds showed inhibition of CYP3A4. The ones carrying only one hydroxy substituent at the A-
ring (Ref1 and compounds 3, 4, 7; IC50 > 100 nM, data shown in supplementary material) were less potent than 
Ketoconazole (IC50 = 72 nM), which means they are more selective than the reference. The methoxy-substituted 
compounds 9, 10 and 11 were even more selective (IC50 > 200 nM), however, not reaching Abiraterone (IC50 = 2704 
nM) 
Additionally, the most promising compounds were tested for inhibition of the steroidogenic CYP enzyme 
CYP11B1, which is catalyzing the key step in glucocorticoid biosynthesis. For the assay [40], V79MZh11B1 cells 
expressing human CYP11B1 were used and the compounds were tested at concentrations 0.2 and 2 µM. While 
compounds 3, 4, 6, 7, 14 and 15 showed high inhibition of this enzyme at both concentrations (>89% at 0.2 µM and 
>95% at 2.0 µM, data shown in supplementary material), compounds 5, 8 and 13 exhibited less inhibitory activity 
toward this enzyme (38 – 51% at 0.2 µM). Interestingly, in contrast to the inhibition of CYP3A4, here the 
compounds with two vicinal OH-groups showed a very high selectivity and were better than Ketoconazole (61% at 
0.2 µM). However, they did not reach Abiraterone (IC50 = 1608 nM). Because of this lack of selectivity, the 
compounds were not further tested for inhibition of other steroidogenic CYP enzymes like CYP11B2 and CYP19. 
Molecular modelling studies 
Both enantiomers, if existing, of selected energy minimized compounds (3–11, 13–15) were docked into our 
CYP17 model  by means of the GOLD v3.2 software [41] running Linux CentOS 5.1 on Intel(R) P4 CPU 3.00GHz. 
A slightly modified GOLDSCORE function with goldscore.P450_pdb.parameters, for better evaluation of 
hydrophobic interactions, was used. The experimentally proven complexation of the heme iron with sp2 hybridized 
nitrogen [22] was considered in these studies by applying a distance constraint between those two atoms.  
For both enantiomers of almost all docked compounds the statistical significant binding mode was BM1 – the 
alternative mode BM2 was less prevalent (Figure 3). These two binding modes could be previously identified by us 
for biphenylic CYP17 inhibitors [26, 32]. In BM1 the biaryl skeleton is oriented parallel to the I-helix pointing the 
A-ring next to a polar area. Hydrophobic and π-π interactions between the conjugated biphenyl core and Phe114 as 
well as apolar amino acid residues (Gly301, Ala302, Glu305, Ala367 and Ile371) were observed for all compounds. 
The ethyl group at the methylene spacer has an important stabilizing role, as already described by us [34]. It 
anchors in a tiny hydrophobic pocket next to the heme, delimitated in its extend by Val366 and Ile371. 
The analysis of the docking results was focused on the interaction of the A-ring with the corresponding amino 
acid residues, since most of the variations on the compounds presented in this article are located here. Regarding the 
substituents in para position, it can be observed that a hydroxy group is involved in a H-bond net with Arg109, 
Lys231, His235 and Asp298. In contrast to this, for a methoxy group there is steric hindrance due to His235, 
Arg109 and the proximal I-helix residues. Depending on the different kind of substituents at the meta position, the 
R1 group is oriented toward the F-/G-helix (Asn202, Lys231), if R1 is MeO or Me or toward Asp298 for OH. The 
latter group forms a strong H-bond with the carboxylate (r = 1.9 Å). In case of the Cl-substituent, it was not possible 
to determine an unequivocal orientation, because of the bivalent interaction character of this halogen. Looking at the 
exact orientation of the MeO group, it becomes apparent that it is oriented toward a small hydrophobic pocket, 
delimitated in its extent by Ile238, Lys231, Ile206, Asn202 and Gln199. Its methyl group is placed at about 3.5 – 5 
Å from the hydrophobic interaction partners of the mentioned amino acids, while its oxygen showed a reasonable H-
bond with Lys231. 
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Striking for compounds 7 and 8 is the influence of the fluorine in the C-ring which reduces its electrostatic 
potential. Thus interactions with the backbone atoms of Gly301, Ala302 and Val304 are formed as we already have 
observed with other inhibitors of this class [32].
Figure 3. Presentation of the two found binding modes BM1 (compounds 8 yellow and 15 green-blue) and BM2 
(compound 6 magenta). Heme (cyan), interacting residues and ribbon rendered tertiary structure of the active site are 
shown. Figure was generated with Pymol (http://www.pymol.org).
Discussion and Conclusion
CYP17 is the pivotal enzyme in the biosynthesis of androgens, which are known to promote prostatic tumor 
growth. GnRH analogs have been shown to be useful in the treatment of prostate cancer by reducing the androgen 
formation. As outlined above inhibitors of CYP17 could be more efficient therapeutics as they should not only affect 
testicular androgen formation but also adrenal biosynthesis.
The present work describes a series of new imidazole substituted biphenyls. As they are very potent inhibitors of 
the target enzyme, our search for new substitution patterns increasing the activity of known biphenylic compounds 
[30-35, 39] (e.g. Ref1) was successful. Regarding the structure-activity relationships obtained in this study, the 
importance of an ethyl substituent at the methylene bridge was demonstrated and could be explained in the 
modelling study. With respect to A-ring substitution a strong enhancement of the inhibitory activity was achieved by 
intrction of hydroxy groups, especially by two vicinal groups in R1 and R2. A very important role plays the fluorine 
substituent in the C-ring leading to the most active compounds 7 and 8.
All synthesized compounds are much more potent than the reference Ketoconazole and two compounds reached 
the inhibitory activity of Abiraterone, which is under clinical investigation. Regarding selectivity toward the hepatic 
CYP3A4 and the glucocorticoid forming CYP11B1, most of the compounds turned out to be superior to 
Ketoconazole. However, none of the novel compounds reached the selectivity of the steroidal inhibitor Abiraterone. 
Therefore further structural optimization has to be performed to overcome this weakness. In our opinion this should 
be worthwhile as nonsteroidal inhibitors should not interfere with steroid hormone receptors as steroidal drugs do. 
These studies are presently being performed. The structurally modified compounds will not only be tested for 
CYP3A4 and CYP11B1 selectivity but also for inhibition of other important hepatic CYP enzymes and 
steroidogenic CYPs like CYP11B2 and CYP19. As the enantioselectivity of the enzyme is an interesting aspect, the 
enantiomeric separation of the structural optimized compounds will be performed and the enantiomers will be 
evaluated.
Experimental Section
CYP17 preparation and assay.
As source of human CYP17, our E. coli system [38] coexpressing human CYP17 and NADPH-P450 reductase 
was used and the assay was performed as previously described [27] using unlabeled progesterone as substrate and 
applying HPLC with UV-detection for separation.
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Inhibition of hepatic enzyme CYP3A4 
The recombinantly expressed enzyme from baculovirus-infected insect microsomes (Supersomes) was used and 
the manufacturer’s instructions (www.gentest.com) were followed. 
Inhibition of CYP11B1  
V79MZh11B1 cells expressing CYP11B1 were used and our assay procedure with [4-14C]-11-
deoxycorticosterone was applied [42].  
Chemistry Section 
General. 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra were 
recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a Bruker DRX-
500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an internal standard for 
spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray ionization) mass spectra 
were determined on a TSQ quantum (Thermo Electron Corporation) instrument. Elemental analyses were performed 
at the Department of Instrumental Analysis and Bioanalysis, Saarland University. Column chromatography was 
performed using silica-gel 60 (50-200 µm), and reaction progress was determined by TLC analysis on Alugram® 
SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as starting materials were obtained 
commercially (CombiBlocks, Chempur, Aldrich, Acros). 
Method A: Boron Tribromide Cleavage of Phenolic Methyl Ethers 
To a solution of the corresponding methyl ether in dichloromethane (300 mL) cooled in an ice bath was added 
BBr3 (1.5 eq per MeO) dropwise. After 2 h, the mixture was allowed to warm to room temperature and then stirred 
overnight. Methanol (10 mL) was added dropwise to terminate the reaction, the mixture was poured into water and 
stirred for another 2 h. Then saturated NaHCO3-solution (100 mL) was added, and the mixture was extracted with 
dichloromethane. The extracts were washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4 and 
concentrated. The resulting crude product was subjected to flash chromatography using silica gel. 
4-Bromo-benzene-1,2-diol (5d) 
Synthesised according to Method A using 4-bromo-1,2-dimethoxybenzene (8.00 g, 36.9 mmol) and BBr3 (25.00 
g, 100 mmol); pale oil; yield: 6.57 g (94 %); Rf = 0.38 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 5.18 (s, 1H), 
5.33 (s, 1H), 6.74 (d, J = 8.5 Hz, 1H), 6.93 (dd, J = 2.2, 8.5 Hz, 1H), 7.02 (d, J = 2.2 Hz, 1H); δC (CDCl3, 125 
MHz): 112.6, 116.7, 118.7, 124.0, 142.7, 144.4; MS (ESI): m/z = 190 [M++H]. 
5-Bromo-benzene-1,3-diol (6d) 
Synthesised according to Method A using 1-bromo-3,5-dimethoxybenzene (8.00 g, 36.9 mmol) and BBr3 (25.00 
g, 100 mmol); pale oil; yield: 6.77 g (97 %). Rf = 0.38 (DCM / MeOH, 98:2); δH (CDCl3, 500 MHz): 5.20 (s, 2H), 
6.28 (t, J = 2.2 Hz, 1H), 6.67 (d, J = 2.2 Hz, 2H); MS (ESI): m/z = 190 [M++H]. 
Method B: Protection of Phenols as TBDMS Ethers 
To a solution of the corresponding phenol and imidazole (1.1 eq per OH) in dichloromethane, a solution of tert-
butyldimethylsilyl chloride in dichloromethane was slowly added (1.1 eq per OH). After being stirred for 4 h at rt, 
the reaction mixture was poured into water, extracted with dichloromethane, washed with water and brine and dried 
over Na2SO4. Solvent removal under reduced pressure led to a pale oil, which was purified by chromatography on 
silica gel. 
(4-Bromo-phenoxy)-tert-butyl-dimethyl-silane (3c) 
Synthesised according to Method B using 4-bromophenol (3d) (3.00 g, 17.3 mmol); pale oil; yield: 4.80 g (94 
%); Rf = 0.84 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 0.19 (s, 6H), 0.98 (s, 9H), 6.72 (d, J = 8.8 Hz, 2H), 7.32 
(d, J = 8.8 Hz, 2H); δC (CDCl3, 125 MHz): -4.5, 18.2, 25.6, 113.6, 121.9, 132.3, 154.8; MS (ESI): m/z = 288 
[M++H]. 
(3-Bromo-phenoxy)-tert-butyl-dimethyl-silane (4c)  
Synthesised according to Method B using 3-bromophenol (4d) (5.00 g, 28 mmol); pale oil; yield: 8.21 g (quant.); 
Rf = 0.81 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 0.19 (s, 6H), 0.98 (s, 9H), 6.79 – 6.81 (m, 1H), 7.01 – 7.12 
(m, 3H); MS (ESI): m/z = 288 [M++H]. 
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4-Bromo-1,2-bis-(tert-butyl-dimethyl-silanyloxy)-benzene (5c) 
Synthesised according to Method B using 5d (3.57 g, 18.9 mmol); pale oil; yield: 6.64 g (84 %); Rf = 0.59 
(hexane); δH (CDCl3, 500 MHz): 0.19 (s, 6H), 0.21 (s, 6H), 0.98 (s, 9H), 0.99 (s, 9H), 6.69 (d, J = 8.5 Hz, 1H), 6.92 
(dd, J = 2.5, 8.5 Hz, 1H), 6.95 (d, J = 2.5 Hz, 1H); δC (CDCl3, 125 MHz): -4.18, -4.14, 18.42, 18.44, 25.86, 25.89, 
112.7, 122.2, 124.2, 124.3, 146.4, 147.9; MS (ESI): m/z = 418 [M++H]. 
1-Bromo-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-benzene (6c) 
Synthesised according to Method B using 6d (7.17 g, 38.0 mmol); pale oil; yield: 14.45 g (91 %); Rf = 0.73 
(hexane); δH (CDCl3, 500 MHz): 0.20 (s, 12H), 0.97 (s, 18H), 6.26 (t, J = 2.2 Hz, 1H), 6.63 (d, J = 2.2 Hz, 2H); MS 
(ESI): m/z = 418 [M++H]. 
4'-(tert-Butyl-dimethyl-silanyloxy)-3',5'-dimethyl-biphenyl-4-carbaldehyde (13b)  
Synthesised according to Method B using 13c (0.92 g, 4.07 mmol); white solid; yield: 1.32 g (93 %); Rf = 0.33 
(hexane / EtOAc, 10:1); δH (CDCl3, 500 MHz): 0.25 (s, 6H), 1.08 (s, 9H), 2.31 (s, 6H), 7.28 (s, 2H), 7.70 (d, J = 8.3 
Hz, 2H), 7.89 (d, J = 8.3 Hz, 2H), 10.01 (s, 1H, CHO); δC (CDCl3, 125 MHz): -3.2, 17.6, 18.4, 25.8, 126.7, 127.4, 
128.9, 129.8, 132.0, 134.2, 146.7, 152.6, 191.4; MS (ESI): m/z = 227 [M++H]. 
4'-(tert-Butyl-dimethyl-silanyloxy)-3'-methyl-biphenyl-4-carbaldehyde (14b)  
Synthesised according to Method B using 14c (0.96 g, 4.07 mmol); white solid; yield: 1.40 g (95 %); Rf = 0.33 
(hexane / EtOAc, 10:1); δH (CDCl3, 500 MHz): 0.26 (s, 6H), 1.04 (s, 9H), 2.29 (s, 3H), 6.85 (d, J = 8.3 Hz, 1H), 
7.36 (dd, J = 2.3, 8.3 Hz, 1H), 7.44 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H), 10.03 (s, 1H); δC 
(CDCl3, 125 MHz): -4.4, 16.8, 25.5, 118.6, 125.4, 126.8, 130.0, 134.3, 146.8, 154.4, 191.7; MS (ESI): m/z = 227 
[M++H]. 
(4-Bromo-2-chloro-phenoxy)-tert-butyl-dimethyl-silane (15c)  
Synthesised according to Method B using 4-bromo-2-chlorophenol (15d) (1.00 g, 4.82 mmol); white solid; yield: 
1.40 g (91 %); Rf = 0.45 (hexane / EtOAc, 20:1); δH (CDCl3, 500 MHz): 0.22 (s, 6H), 1.02 (s, 9H), 6.75 (d, J = 8.6 
Hz, 1H), 7.23 (dd, J = 2.5, 8.6 Hz, 1H), 7.48 (d, J = 2.5 Hz, 1H); δC (CDCl3, 125 MHz): -4.7, 25.3, 112.9, 121.6, 
126.6, 130.2, 132.5, 150.7; MS (ESI): m/z = 322 [M++H]. 
Method C: Suzuki-Coupling 
To a solution of the corresponding bromobenzene derivative (1.0 eq) in toluene (7 mL / mmol), an aqueous 
Na2CO3 solution (2.0 M; 3.2 mL / mmol) and an ethanolic solution (3.2 mL / mmol) of the corresponding boronic 
acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure and flushed with nitrogen. 
After having repeated this cycle several times, Pd(PPh3)4 (4 mol%) was added, and the resulting suspension was 
heated under reflux for 8 h. After cooling, ethyl acetate (10 mL) and water (10 mL) were added. The organic phase 
was separated and the water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were 
washed with brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. 
The compounds were purified by flash chromatography using silica gel.  
4'-(tert-Butyl-dimethyl-silanyloxy)-biphenyl-4-carbaldehyde (3b) 
Synthesised according to Method C using 3c (4.80 g, 16.7 mmol) and 4-formylphenylboronic acid (5.01 g, 33.4 
mmol); yellow solid; yield: 3.80 g (73 %); Rf = 0.65 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 0.25 (s, 6H), 1.02 
(s, 9H), 6.94 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.92 (d, J = 8.2 Hz, 2H), 10.03 
(s, 1H); δC (CDCl3, 125 MHz): -4.4, 18.2, 25.6, 120.6, 127.0, 127.6, 128.4, 130.2, 134.7, 146.8, 156.4, 191.8; MS 
(ESI): m/z = 297 [M++H]. 
3'-(tert-Butyl-dimethyl-silanyloxy)-biphenyl-4-carbaldehyde (4b)  
Synthesised according to Method C using 4c (6.66 g, 22.9 mmol) and 4-formylphenylboronic acid (5.10 g, 34.5 
mmol); yellow solid; yield: 3.70 g (52 %); Rf = 0.60 (hexane / EtOAc 9/1); the compound was directly used in the 
next step without further purification and analysis. 
3',4'-Bis-(tert-butyl-dimethyl-silanyloxy)-biphenyl-4-carbaldehyde (5b)  
Synthesised according to Method C using 5c (5.30 g, 12.7 mmol) and 4-formylphenylboronic acid (2.80 g, 19.0 
mmol); yellow solid; yield: 3.30 g (58 %); Rf = 0.40 (hexane / EtOAc, 9:1); the compound was directly used in the 
next step without further purification and analysis. 
3',5'-Bis-(tert-butyl-dimethyl-silanyloxy)-biphenyl-4-carbaldehyde (6b)  
Synthesised according to Method C using 6c (11.0 g, 26.3 mmol) and 4-formylphenylboronic acid (6.00 g, 39.4 
mmol); yellow solid; yield: 7.67 g (66 %); Rf = 0.59 (hexane / EtOAc, 9:1); the compound was directly used in the 
next step without further purification and analysis. 
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4'-(tert-Butyl-dimethyl-silanyloxy)-3-fluoro-biphenyl-4-carbaldehyde (7b) 
Synthesised according to Method C using 3c (3.50 g, 11.9 mmol) and 3-fluor-4-formylphenylboronic acid (3.00 
g, 17.9 mmol); yellow solid; yield: 3.80 g (73 %); Rf = 0.47 (hexane / EtOAc, 9:1); the compound was directly used 
in the next step without further purification and analysis. 
3',4'-Bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-biphenyl-4-carbaldehyde (8b)  
Synthesised according to Method C using 5c (5.0 g, 12.0 mmol) and 3-fluor-4-formylphenylboronic acid (3.00 g, 
17.9 mmol); yellow solid; yield: 3.70 g (67 %); Rf = 0.68 (hexane / EtOAc, 9:1); the compound was directly used in 
the next step without further purification and analysis. 
1-(4'-Methoxy-biphenyl-4-yl)-propan-1-one (9b)  
Synthesised according to Method C using 4'-bromopropiophenone (2.0 g, 9.4 mmol) and 4-
methoxyphenylboronic acid (2.14 g, 14.1 mmol); yellow solid; yield: 2.12 g (94 %); Rf = 0.29 (DCM / hexane, 1:1); 
δH (CDCl3, 500 MHz): 1.25 (t, J = 7.3 Hz, 3H), 3.02 (q, J = 7.3 Hz, 2H), 3.86 (s, 3H), 7.00 (d, J = 8.8 Hz, 2H), 7.57 
(d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.5 Hz, 2H), 8.01 (d, J = 8.5 Hz, 2H); δC (CDCl3, 125 MHz): 8.3, 31.8, 55.4, 114.4, 
126.6, 128.3, 128.6, 132.3, 135.0, 145.1, 159.9, 200.4; MS (ESI): m/z = 241 [M++H]. 
1-(3'-Methoxy-biphenyl-4-yl)-propan-1-one (10b)  
Synthesised according to Method C using 4'-bromopropiophenone (2.0 g, 9.4 mmol) and 3-
methoxyphenylboronic acid (2.14 g, 14.1 mmol); orange solid; yield: 2.30 g (96 %); Rf = 0.29 (DCM / hexane, 1:1); 
δH (CDCl3, 500 MHz): 1.25 (t, J = 7.3 Hz, 3H), 3.04 (q, J = 7.3 Hz, 2H), 3.88 (s, 3H), 6.95 (ddd, J = 0.6, 2.5, 8.2 
Hz, 1H), 7.15 (t, J = 2.5 Hz, 1H), 7.20 – 7.22 (m, 1H), 7.39 (t, J = 8.2 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 8.03 (d, J = 
8.5 Hz, 2H); δC (CDCl3, 125 MHz): 8.3, 31.8, 55.3, 113.0, 113.5, 119.7, 127.3, 128.5, 130.0, 135.8, 141.4, 160.0, 
200.4; MS (ESI): m/z = 241 [M++H]. 
1-(3',4'-Dimethoxy-biphenyl-4-yl)-propan-1-one (11b)  
Synthesised according to Method C using 4'-bromopropiophenone (2.00 g, 9.4 mmol) and 3,4-
dimethoxyphenylboronic acid (2.57 g, 14.1 mmol); orange solid; yield: 2.41 g (95 %); Rf = 0.37 (DCM); δH (CDCl3, 
500 MHz): 1.25 (t, J = 7.3 Hz, 3H), 3.03 (q, J = 7.3 Hz, 2H), 3.94 (s, 3H), 3.97 (s, 3H), 6.97 (d, J = 8.2 Hz, 1H), 
7.14 (d, J = 2.2 Hz, 1H), 7.20 (dd, J = 2.2, 8.2 Hz, 1H), 7.64 (d, J = 8.5 Hz, 2H), 8.02 (d, J = 8.5 Hz, 2H); MS (ESI): 
m/z = 271 [M++H]. 
1-(4'-Ethoxy-biphenyl-4-yl)-propan-1-one (12b) 
Synthesised according to Method C using 4'-bromopropiophenone (0.86 g, 4.0 mmol) and 4-
ethoxyphenylboronic acid (1.00 g, 6.02 mmol); yellow solid; yield: 0.96 g (94 %); Rf = 0.32 (hexane / EtOAc, 9:1); 
δH (CDCl3, 500 MHz): 1.25 (t, J = 7.3 Hz, 3H), 1.45 (t, J = 6.9 Hz, 3H), 3.03 (q, J = 7.3 Hz, 2H), 4.10 (q, J = 6.9 
Hz, 2H), 6.68 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 8.2 Hz, 2H), 8.01 (d, J = 8.2 Hz, 2H); MS 
(ESI): m/z = 255 [M++H]. 
4'-Hydroxy-3',5'-dimethyl-biphenyl-4-carbaldehyde (13c) 
Synthesised according to Method C using 4-bromo-2,6-dimethylphenol (13d) (1.00 g, 4.97 mmol) and 4-
formylphenyl boronic acid (0.89 g, 5.9 mmol); white solid; yield: 0.92 g (82 %); Rf = 0.30 (hexane / EtOAc, 5:1); δH 
(CDCl3, 500 MHz): 2.33 (s, 6H), 4.81 (bs, 1H), 7.28 (s, 2H), 7.69 (d, J = 8.3 Hz, 2H), 7.90 (d, J = 8.3 Hz, 2H), 
10.03 (s, 1H); δC (CDCl3, 125 MHz): 15.8, 126.4, 126.8, 127.4, 130.0, 131.4, 134.3, 152.7, 191.7; MS (ESI): m/z = 
227 [M++H]. 
4'-Hydroxy-3'-methyl-biphenyl-4-carbaldehyde (14c)  
Synthesised according to Method C using 4-bromo-2-methylphenol (14d) (1.00 g, 5.35 mmol) and 4-
formylphenyl boronic acid (0.96 g, 6.4 mmol); white solid; yield: 0.96 g (85 %); Rf = 0.31 (hexane / EtOAc, 5:1); δH 
(CDCl3, 500 MHz): 2.34 (s, 3H), 5.23 (bs, 1H), 6.89 (d, J = 8.3 Hz, 1H), 7.37 (dd, J = 2.3, 8.3 Hz, 1H), 7.43 (bs, 
1H), 7.70 (d, J = 8.3 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H), 10.03 (s, 1H); δC (CDCl3, 125 MHz): 15.7, 115.2, 124.3, 
125.9, 126.8, 130.1, 131.9, 134.3, 146.8, 154.4, 191.9 (CHO); MS (ESI): m/z = 213 [M++H]. 
4'-(tert-Butyl-dimethyl-silanyloxy)-3'-chloro-biphenyl-4-carbaldehyde (15b) 
Synthesised according to Method C using 15c (1.40 g, 4.35 mmol) and 4-formylphenyl boronic acid (0.78 g, 5.5 
mmol); white solid; yield: 1.22 g (81 %); Rf = 0.33 (hexane / EtOAc, 10:1); δH (CDCl3, 500 MHz): 0.27 (s, 6H), 
1.06 (s, 9H), 6.98 (d, J = 8.4 Hz, 1H), 7.41 (dd, J = 2.3, 8.4 Hz, 1H), 7.65 (d, J = 2.3 Hz, 1H), 7.69 (d, J = 8.3 Hz, 
2H), 7.93 (d, J = 8.4 Hz, 2H), 10.04 (s, 1H); δC (CDCl3, 125 MHz): -4.4, 25.6, 121.1, 126.4, 127.1, 129.1, 130.3, 
133.7, 135.1, 145.6, 152.1, 191.8; MS (ESI): m/z = 348 [M++H]. 
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Method D: Grignard-Reaction 
Under exclusion of air and moisture, an EtMgBr-solution (1.0 M in THF, 1.2 eq) solution in THF was added 
dropwise to a solution of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred overnight 
at rt. Then water (10 mL) and ethyl acetate (10 mL) were added. The organic phase was separated and washed with 
water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude products were purified by 
flash chromatography using silica gel.  
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-biphenyl-4-yl]-propan-1-ol (3a) 
Synthesised according to Method D using 3b (3.30 g, 10.6 mmol) and EtMgBr (1.0 M in THF, 12.7 mL, 12.7 
mmol); white solid; yield: 1.89 g (52 %); Rf = 0.40 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 0.23 (s, 6H), 0.95 
(t, J = 7.3 Hz, 3H), 1.00 (s, 9H), 1.76 – 1.89 (m, 2H), 4.64 (t, J = 6.6 Hz, 1H), 6.90 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 
8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H); MS (ESI): m/z = 344 [M++H]. 
1-[3'-(tert-Butyl-dimethyl-silanyloxy)-biphenyl-4-yl]-propan-1-ol (4a) 
Synthesised according to Method D using 4b (3.70 g, 11.9 mmol) and EtMgBr (1.0 M, 14.3 mL, 14.3 mmol); 
white solid; yield: 2.02 g (45 %); Rf = 0.40 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 0.27 (s, 6H), 0.97 (t, J = 
7.3 Hz, 1H), 1.05 (s, 9H), 1.76 – 1.91 (m, 2H), 2.15 – 2.38 (m, 1H), 4.65 (t, J = 6.6 Hz, 1H), 6.86 (m, 1H), 7.11 (m, 
1H), 7.21 (d, J = 7.9 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.41 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H); δC (CDCl3, 
125 MHz): -4.4, 9.9, 21.2, 25.7, 29.2, 77.1, 118.8, 119.0, 120.1, 126.9, 127.1, 129.6, 139.6, 140.5, 142.2, 156.0; MS 
(ESI): m/z = 344 [M++H]. 
1-[3',4'-Bis-(tert-butyl-dimethyl-silanyloxy)-biphenyl-4-yl]-propan-1-ol (5a) 
Synthesised according to Method D using 5b (6.09 g, 13.7 mmol) and EtMgBr (1.0 M, 16.4 mL, 16.4 mmol); 
white solid; yield: 1.55 g (25 %); Rf = 0.62 (hexane / EtOAc, 7:3); δH (CDCl3, 500 MHz): 0.22 (s, 6H), 0.23 (s, 6H), 
0.88 (t, J = 7.3 Hz, 3 H),1.00 (s, 9H), 1.01 (s, 9H), 1.68 – 1.81 (m, 2H), 2.51 (bs, 1H), 4.52 (t, J = 6.6 Hz, 1H), 6.86 
(d, J = 8.2 Hz, 1H), 7.02 (dd, J = 2.2, 8.2 Hz, 1H), 7.08 (d, J = 2.2 Hz, 1H), 7.31 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 8.2 
Hz, 2H); δC (CDCl3, 125 MHz): -4.08, -4.12, 10.1, 18.38, 18.39, 25.90, 25.92, 31.7, 75.5, 119.7, 119.9, 121.2, 126.3, 
126.5, 134.3, 139.8, 143.1, 146.4, 146.9; MS (ESI): m/z = 474 [M++H]. 
1-[3',5'-Bis-(tert-butyl-dimethyl-silanyloxy)-biphenyl-4-yl]-propan-1-ol (6a)  
Synthesised according to Method D using 6b (6.85 g, 15.5 mmol) and EtMgBr (1.0 M, 18.6 mL, 18.6 mmol); 
yellow solid; yield: 3.60 g (49 %); the compound was directly used in the next step without further purification and 
analysis. 
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-3-fluoro-biphenyl-4-yl]-propan-1-ol (7a) 
Synthesised according to Method D using 7b (3.01 g, 9.10 mmol) and EtMgBr (1.0 M, 10.9 mL, 10.9 mmol); 
white solid; yield: 1.30 g (40 %); Rf = 0.48 (hexane / EtOAc, 9:1); δH (CDCl3, 500 MHz): 0.25 (s, 6H), 0.98 (t, J = 
7.3 Hz, 3H), 1.03 (s, 9H), 1.79 – 1.89 (m, 2H), 2.33 (bs, 1H), 4.94 – 4.97 (m, 1H), 6.91 (d, J = 8.8 Hz, 2H), 7.20 (dd, 
J = 1.9, 12.0 Hz, 1H), 7.33 (dd, J = 1.9, 8.2 Hz, 1H), 7.44 – 7.46 (m, 3H); MS (ESI): m/z = 361 [M++H]. 
1-[3',4'-Bis-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-biphenyl-4-yl]-propan-1-ol (8a) 
Synthesised according to Method D using 8b (3.71 g, 8.00 mmol) and EtMgBr (1.0 M, 9.6 mL, 9.6 mmol); 
yellow solid; yield: 1.36 g (35 %); Rf = 0.34 (hexane / EtOAc, 9:1); the compound was directly used in the next step 
without further purification and analysis. 
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-3',5'-dimethyl-biphenyl-4-yl]-propan-1-ol (13a)  
Synthesised according to Method D using 13b (1.32 g, 3.88 mmol) and EtMgBr (1.0 M, 4.65 mL, 4.65 mmol) 
solution in THF. Yield: 1.24 g (86 %); Rf = 0.15 (hexane / EtOAc, 10:1); white solid; δH (CDCl3, 500 MHz): 0.24 (s, 
6H), 0.95 (t, J = 7.4 Hz, 3H), 1.08 (s, 9H), 1.77-1.88 (m, 2H), 1.93 (bs, 1H), 2.29 (s, 6H), 4.62 (t, J = 6.5 Hz, 1H), 
7.23 (s, 2H), 7.37 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H); δC (CDCl3, 125 MHz): -3.2, 9.9, 17.7, 25.8, 31.5, 
75.5, 125.9, 126.4, 127.1, 128.6, 133.4, 140.0, 142.5, 151.6; MS (ESI): m/z = 227 [M++H]. 
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-3'-methyl-biphenyl-4-yl]-propan-1-ol (14a)  
Synthesised according to Method D using 14b (1.40 g, 4.29 mmol) with EtMgBr (1.0 M, 4.71 mL, 4.71 mmol) 
solution in THF; white solid; yield: 1.24 g (81 %); Rf = 0.15 (hexane / EtOAc, 10:1); the compound was directly 
used in the next step without further purification and analysis. 
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-3'-chloro-biphenyl-4-yl]-propan-1-ol (15a)  
Synthesised according to Method D using 15b (1.22 g, 3.52 mmol) with EtMgBr (1.0 M, 3.87 mL, 3.87 mmol) 
solution in THF; white solid; yield: 1.05 g (79 %); Rf = 0.18 (hexane / EtOAc, 10:1); the compound was directly 
used in the next step without further purification and analysis. 
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Method E: Reduction with NaBH4 
To an ice-cooled solution of the corresponding aldehyde or ketone (1.0 eq) in methanol (5 mL / mmol) was 
added NaBH4 (2.0 eq). The resulting mixture was heated to reflux for 30 minutes. After cooling to ambient 
temperature, the solvent was distilled off under reduced pressure. Water (10 mL) was added, and the aqueous layer 
was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried over 
MgSO4 and evaporated under reduced pressure. The desired product was purified by chromatography using silica 
gel. 
1-(4'-Methoxy-biphenyl-4-yl)-ethanol (1a)  
Synthesised according to Method E using 1-(4'-methoxybiphenyl-4-yl)ethanone (1b) (0.23 g, 1.00 mmol) and 
NaBH4 (0.15 g, 3.98 mmol); colourless solid; yield: 0.13 g (58 %); Rf = 0.16 (hexane / EtOAc, 10:1); the compound 
was directly used in the next step without further purification and analysis. 
1-(3'-Methoxy-biphenyl-4-yl)-ethanol (2a)  
Synthesised according to Method E using 1-(3'-methoxybiphenyl-4-yl)ethanone (2b) (0.62 g, 2.71 mmol) and 
NaBH4 (0.19 g, 4.88 mmol); colourless solid; yield: 0.45 g (72 %); Rf = 0.17 (hexane / EtOAc, 10:1); IR (ATR) ῦ 
(cm-1): 3388 (m), 1600 (m), 1481 (m), 1295 (m), 1214 (s), 1053 (m), 832 (s), 777 (s), 695 (m); δH (CDCl3, 500 
MHz): 1.54 (d, J = 6.4 Hz, 3H), 1.77 (bs, 1H), 3.87 (s, 3H), 4.96 (q, J = 6.4 Hz, 1H), 6.90 (dd, J = 2.2, 8.2 Hz, 1H), 
7.12 (bt, J = 2.2 Hz, 1H), 7.17 - 7.19 (m, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.45 (d, J = 8.2 Hz, 2H), 7.58 (d, J = 8.2 Hz, 
2H); δC (CDCl3, 125 MHz): 25.1, 55.3, 70.1, 112.6, 112.8, 119.6, 125.8, 127.3, 129.7, 140.3, 142.4, 145.0, 159.9; 
MS (ESI): m/z = 211 [M++H-H2O]. 
1-(4'-Methoxy-biphenyl-4-yl)-propan-1-ol (9a)  
Synthesised according to Method E using 9b (2.12 g, 8.80 mmol) and NaBH4 (0.64 g, 17 mmol); white solid; 
yield: 1.85 g (87 %); Rf = 0.37 (DCM); δH (CDCl3, 500 MHz): 0.95 (t, J = 7.6 Hz, 3H), 1.77 – 1.89 (m, 3H), 3.85 (s, 
3H), 4.64 (t, J = 6.6 Hz, 1H), 6.98 (d, J = 8.5 Hz, 2H), 7.39 (d, J = 8.5 Hz, 2H), 7.52 – 7.55 (m, 4H); δC (CDCl3, 125 
MHz): 10.2, 31.8, 55.3, 75.8, 114.2, 126.4, 126.7, 128.1, 133.4, 140.1, 143.0, 159.1; MS (ESI): m/z = 243 [M++H]. 
1-(3'-Methoxy-biphenyl-4-yl)-propan-1-ol (10a) 
Synthesised according to Method E using 10b (2.30 g, 9.00 mmol) and NaBH4 (0.76 g, 20 mmol); white solid; 
yield: 1.87 g (86 %); Rf = 0.37 (DCM); δH (CDCl3, 500 MHz): 0.95 (t, J = 7.3 Hz, 3H), 1.78 – 1.90 (m, 3H), 3.88 (s, 
3H), 4.65 (t, J = 6.4 Hz, 1H), 6.98 (ddd, J = 0.6, 2.5, 8.2 Hz, 1H), 7.17 (t, J = 2.5 Hz, 1H), 7.22 – 7.24 (m, 2H), 7.71 
(d, J = 8.5 Hz, 2H), 8.06 (d, J = 8.5 Hz, 2H); δC (CDCl3, 125 MHz): 10.3, 31.8, 55.3, 76.1, 113.0, 113.4, 119.7, 
127.4, 128.2, 130.0, 135.8, 141.4, 159.9; MS (ESI): m/z = 243 [M++H]. 
1-(3',4'-Dimethoxy-biphenyl-4-yl)-propan-1-ol (11a) 
Synthesised according to Method E using 11b (2.41 g, 8.90 mmol) and NaBH4 (0.76 g, 20 mmol); yellow solid; 
yield: 2.03 g (84 %); Rf = 0.31 (DCM); δH (CDCl3, 500 MHz): 0.99 (t, J = 7.3 Hz, 3H), 1.81- 1.90 (m, 3H), 3.82 (s, 
3H), 3.84 (s, 3H), 4.59 (t, J = 6.6 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 7.07 (d, J = 2.2 Hz, 1H), 7.11 (dd, J = 2.2, 8.2 
Hz, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H); MS (ESI): m/z = 273 [M++H]. 
1-(4'-Ethoxy-biphenyl-4-yl)-propan-1-ol (12a) 
Synthesised according to Method E using 12b (1.32 g, 5.20 mmol) and NaBH4 (0.39 g, 10 mmol); white solid; 
yield: 1.14 g (86 %); Rf = 0.16 (hexane / EtOAc 9:1); δH (CDCl3, 500 MHz): 0.95 (t, J = 7.3 Hz, 3H), 1.42 (t, J = 6.6 
Hz, 3H), 2.22 - 2.29 (m, 2H), 4.07 (q, J = 6.6 Hz, 2H), 5.03 (t, J = 7.7 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 7.40 (d, J = 
8.2 Hz, 2H), 7.53 – 7.56 (m, 4H); MS (ESI): m/z = 257 [M++H] 
Method F: CDI reaction (Compounds 1, 2, 9 – 12) 
To a solution of the corresponding alcohol (1.0 eq) in N-Methyl-2-pyrrolidon (NMP) or acetonitrile (10 mL / 
mmol), CDI (5.0 eq) was added at rt. The solution was heated to reflux for 4 to 18 h. After cooling to ambient 
temperature, the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The 
combined organic phases were washed with brine, dried over MgSO4 and evaporated under reduced pressure. The 
crude product was purified via chromatography using silica gel. 
1-[1-(4'-Methoxy-biphenyl-4-yl)-ethyl]-1H-imidazole (1) 
Synthesised according to Method F using 1a (0.20 g, 0.88 mmol) and CDI (0.28 g, 1.8 mmol) in acetonitrile; 
colourless solid; yield: 0.12 g (49 %); Rf = 0.15 (EtOAc); IR (ATR) ῦ (cm-1): 1605 (m), 1595 (s), 1247 (s), 1209 (m), 
1185 (m), 1036 (m), 822 (s), 747 (m), 664 (s); δH (CDCl3, 500 MHz): 1.89 (d, J = 6.9 Hz, 3H), 3.84 (s, 3H), 5.37 (q, 
J = 6.9 Hz, 1H), 6.96 (bs, 1H), 6.97 (d, J = 9.0 Hz, 2H), 7.10 (bs, 1H), 7.18 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 9.0 Hz, 
2H), 7.52 (d, J = 8.2 Hz, 2H), 7.61 (bs, 1H); δC (CDCl3, 125 MHz): 22.0 (CH3), 55.3 (CH), 56.3 (CH3), 114.3 (CH), 
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117.9 (CH), 126.4 (CH), 127.1 (CH), 128.1 (CH), 129.4 (CH), 132.8 (Cq), 136.1 (CH), 139.8 (Cq), 140.7 (Cq), 159.4 
(Cq); MS (ESI): m/z = 279 [M++H]. 
1-[1-(3'-Methoxy-biphenyl-4-yl)-ethyl]-1H-imidazole (2) 
Synthesised according to Method F using 2a (0.39 g, 1.7 mmol) and CDI (0.55 g, 3.4 mmol) in acetonitrile; 
colourless oil; yield: 0.21 g (44 %); Rf = 0.31 (EtOAc / MeOH, 95:5); IR (ATR) ῦ (cm-1): 1599 (w), 1566 (w), 1481 
(m), 1296 (m), 1260 (m), 1220 (s), 1031 (s), 1013 (s), 787 (s); δH (CDCl3, 500 MHz): 1.89 (d, J = 6.9 Hz, 3H), 3.85 
(s, 3H), 5.39 (q, J = 6.9 Hz, 1H), 6.90 (ddd, J = 1.0, 2.5, 8.2 Hz, 1H), 6.97 (bs, 1H), 7.08 (dd, J = 1.6, 2.5 Hz, 1H), 
7.09 (bs, 1H), 7.14 (ddd, J = 1.0, 1.6, 7.9 Hz, 1H), 7.20 (d, J = 8.2 Hz, 2H), 7.35 (t, J = 7.9 Hz, 1H), 7.55 (d, J = 8.2 
Hz, 2H), 7.63 (bs, 1H); δC (CDCl3, 125 MHz): 21.0 (CH3), 55.3 (CH3), 56.3 (CH), 112.8 (CH), 112.9 (CH), 118.0 
(CH), 119.5 (CH), 126.4 (CH), 127.6 (CH), 129.3 (CH), 129.8 (CH), 136.0 (CH), 140.5 (Cq), 141.0 (Cq), 141.8 (Cq), 
160.0 (Cq); MS (ESI): m/z = 279 [M++H]. 
1-[1-(4'-Methoxy-biphenyl-4-yl)-propyl]-1H-imidazole (9)  
Synthesised according to Method F using 9a (2.12 g, 8.8 mmol) and CDI (7.29 g, 45.0 mmol) in NMP; yellow 
solid; yield: 0.28 g (11 %) Rf = 0.52 (EtOAc  / NH3 (aq, 25%) 97.5:2.5); IR (ATR) ῦ (cm-1): 2962 (w), 2932 (w), 
1605 (m), 1497 (s), 1254 (s), 818 (s); δH (CDCl3, 500 MHz): 0.97 (t, J = 7.3 Hz, 3H), 2.24 – 2.30 (m, 2H), 3.84 (s, 
3H), 5.10 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 8.5 Hz, 2H), 7.00 (bs, 1H), 7.13 (bs, 1H), 7.25 (d, J = 8.5 Hz, 2H), 7.49 (d, 
J = 8.5 Hz, 2H), 7.52 (d, J = 8.5 Hz, 2H), 7.89 (bs, 1H); δC (CDCl3, 125 MHz): 11.0 (CH3), 28.4 (CH2), 55.3 (O-
CH3), 63.4 (CH), 114.3 (CH), 117.9 (CH), 127.0 (CH), 127.1 (CH), 127.9 (Cq), 128.0 (CH), 132.7 (Cq), 136.0 (CH), 
137.9 (Cq), 140.9 (Cq), 159.4 (COMe); MS (ESI): m/z = 293 [M++H]. 
1-[1-(3'-Methoxy-biphenyl-4-yl)-propyl]-1H-imidazole (10)  
Synthesised according to Method F using 10a (2.30 g, 9.0 mmol) and CDI (7.29 g, 45.0 mmol) in NMP; yellow 
solid; yield: 0.89 g (30 %); Rf = 0.52 (EtOAc / NH3 (aq, 25%) 97.5:2.5); IR (ATR) ῦ (cm-1): 2967 (w), 2935 (w), 
1503 (s), 1249 (s), 1218 (s), 1024 (s), 806 (s); δH (CDCl3, 500 MHz): 0.95 (t, J = 7.3 Hz, 3H), 2.22 – 2.28 (m, 2H), 
3.84 (s, 3H), 5.05 (t, J = 7.9 Hz, 1H), 6.89 (dd, J  = 2.2, 8.2 Hz, 1H), 6.98 (bs, 1H), 7.08 (t, J = 2.2 Hz, 1H), 7.10 (bs, 
1H), 7.13 (d, J = 7.9 Hz, 1H), 7.24 (d, J = 7.9 Hz, 2H), 7.34 (t, J = 7.9 Hz, 1H), 7.54 (d, J = 8.2 Hz, 2H), 7.69 (bs, 
1H); δC (CDCl3, 125 MHz): 11.0 (CH3), 28.5 (CH2), 55.2 (CH3-O), 63.0 (CH), 112.8 (CH), 112.8 (CH), 117.7 (CH), 
119.5 (CH), 126.0 (CH), 127.5 (CH), 129.0 (Cq), 129.8 (CH), 136.2 (Cq), 139.2 (Cq), 140.9 (Cq), 141.7 (CH), 159.9 
(COMe); MS (ESI): m/z = 293 [M++H]. 
1-[1-(3',4'-Dimethoxy-biphenyl-4-yl)-propyl]-1H-imidazole (11) 
Synthesised according to Method F using 11a (2.41 g, 8.90 mmol) and CDI (7.29 g, 45.0 mmol) in NMP; amber 
oil; yield: 0.69 g (24 %); Rf = 0.47 (EtOAc / NH3 (aq, 25%) 97.5:2.5); IR (ATR) ῦ (cm-1): 2967 (w), 2937 (w), 2875 
(w), 2838 (w), 1668 (m), 1604 (m), 1583 (m), 1480 (s), 1294 (s), 1101 (s), 816 (s), 778 (s), 743 (s); δH (CDCl3, 500 
MHz): 0.99 (t, J = 7.3 Hz, 3H), 2.28- 2.35 (m, 2H), 3.92 (s, 3H), 3.94 (s, 3H), 5.21 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 
8.2 Hz, 1H), 7.05 (bs, 1H), 7.07 (d, J = 2.2 Hz, 1H), 7.11 (dd, J = 2.2, 8.2 Hz, 1H), 7.21 (bs, 1H), 7.30 (d, J = 8.2 
Hz, 2H), 7.55 (d, J = 8.2 Hz, 2H), 8.29 (bs, 1H); δC (CDCl3, 125 MHz): 11.0 (CH3), 28.5 (CH2), 55.9 (O-CH3), 55.9 
(O-CH3), 62.9 (CH), 110.3 (CH), 111.4 (CH), 117.6 (CH), 119.3 (CH), 126.9 (CH), 127.1 (CH), 129.4 (CH), 133.2 
(Cq), 136.3 (CH), 138.7 (Cq), 140.8 (Cq), 148.8 (Cq), 149.1 (Cq); MS (ESI): m/z = 323 [M++H]. 
1-[1-(4'-Ethoxy-biphenyl-4-yl)-propyl]-1H-imidazole (12)  
Synthesised according to Method F using 12a (1.14 g, 4.45 mmol) and CDI (3.61 g, 22.3 mmol) in NMP; brown 
solid; yield: 0.60 g (45 %); Rf = 0.66 (EtOAc / MeOH 95:5); IR (ATR) ῦ (cm-1): 3115 (w), 2976 (w), 2936 (w), 2877 
(w), 1606 (m), 1497 (s), 1245 (s), 1043 (s), 827 (s), 815 (s), 784 (s), 740 (s), 665 (s); δH (CDCl3, 500 MHz) 0.95 (t, J 
= 7.3 Hz, 3H), 1.42 (t, J = 6.9 Hz, 3H), 2.22 - 2.29 (m, 2H), 4.07 (q, J = 6.9 Hz, 2H), 5.03 (t, J = 7.7 Hz, 1H), 6.95 
(d, J = 8.8 Hz, 2H), 6.97 (bs, 1H), 7.09 (bs, 1H), 7.22 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8,2 
Hz, 2H), 7.63 (bs, 1H); δC (CDCl3, 125 MHz): 11.1 (CH3), 14.8 (CH3), 28.6 (CH2), 63.1 (CH), 63.5 (CH2), 114.8 
(CH), 117.7 (CH), 126.9 (CH), 127.0 (CH), 128.0 (CH), 129.3 (Cq), 132.6 (CH), 136.3 (CH), 138.4 (Cq), 140.7 (Cq), 
158.7 (Cq); MS (ESI): m/z = 307 [M++H]. 
Method G: CDI reaction and Deprotection with TBAF (Compounds 3 – 8, 13 - 15) 
To a solution of the corresponding alcohol (1.0 eq) in NMP (10 mL / mmol) CDI (5.0 eq) was added at rt. The 
solution was heated to reflux for 4 to 18 h. After cooling to ambient temperature,the reaction miture was diluted 
with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with 
brine, dried over MgSO4 and evaporated under reduced pressure. The crude intermediate of the silyl-protected 
phenol was directly diluted in anhydrous THF, tetrabutylammonium fluoride solution was added (1.0 M in THF, 1.1 
eq per TBDMS), and the reaction mixture was stirred for 4 h. The reaction was quenched by addition of methanol, 
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and the solvent was removed under reduced pressure. The crude product was purified by chromatography using 
silica gel. 
4'-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol (3)  
Synthesised according to Method G using 3a (0.85 g, 2.16 mmol); yellow solid; yield: 0.22 g (37 %); Rf = 0.21 
(hexane / EtOAc, 5:1); IR (ATR) ῦ (cm-1): 2963 (w), 2930 (w), 2364 (w),1607 (m), 1588 (m), 1498 (s), 1272 (m), 
1070 (s), 808 (s), 748 (m), 658 (m); δH (DMSO-d6, 500 MHz): 0.82 (t, J = 7.3 Hz, 3H), 2.21 – 2.25 (m, 2H), 5.23 (t, 
J = 7.3 Hz, 1H), 6.82 (d, J = 8.8 Hz, 2H), 6.90 (s, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 7.54 (d, J 
= 8.5 Hz, 2H),  7.82 (s, 1H), 9.55 (s, 1H); δC (DMSO-d6, 125 MHz): 10.9 (CH3), 27.4 (CH2), 61.5 (CH), 115.6 (CH), 
117.7 (CH), 126.0 (CH), 127.1 (CH), 127.6 (CH), 128.4 (Cq), 130.3 (CH), 130.7 (Cq), 139.3 (CH), 139.5 (Cq), 157.1 
(Cq); MS (ESI): m/z = 279 [M++H]. 
4'-(1-Imidazol-1-yl-propyl)-biphenyl-3-ol (4) 
Synthesised according to Method G using 4a (1.32 g, 3.36 mmol); yellow solid; yield: 0.20 g (21 %); Rf = 0.13 
(EtOAc / MeOH, 9:1); IR (ATR) ῦ (cm-1) 2963 (w), 2361 (w), 1583 (m), 1564 (m), 1477 (s), 817 (s), 781 (s), 740 
(s); δH (DMSO-d6, 500 MHz): 0.83 (t, J = 7.3 Hz, 3H), 2.17 – 2.22 (m, 2H), 5.24 – 5.26 (m, 1H), 6.73 –  6.76 (m, 
1H), 6.91 (bs, 1H), 6.99 (t, J = 2.2 Hz, 1H), 7.04 (ddd, J = 0.9, 2.2, 7.6 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.33 (t, J = 
1.3 Hz, 1H), 7.41 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.2 Hz, 2H), 7.83 (t, J = 0.9 Hz, 1H), 9.55 (s, 1H); δC (DMSO-d6, 
125 MHz): 10.9 (CH3), 27.4 (CH2), 61.5 (CH), 113.4 (CH), 114.4 (CH), 117.4 (CH) 117.7 (CH), 126.7 (CH), 127.1 
(CH), 128.5 (CH), 129.8 (CH), 136.4 (CH), 140.4 (Cq), 141.0 (Cq), 157.7 (COH); MS (ESI): m/z = 279 [M++H]. 
4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,4-diol  (5)  
Synthesised according to Method G using 5a (1.00 g, 1.92 mmol); yellow solid; yield: 0.19 g (34 %); Rf = 0.31 
(EtOAc / MeOH. 95:5); IR (ATR) ῦ (cm-1): 3285 (m), 3157 (m), 2963 (m), 2931 (m), 2874 (m), 2828 (m), 1770 (m), 
1952 (s), 1945 (s), 1495 (s), 1304 (s), 1219 (s), 1086 (s), 805 (s), 755 (s); δH (DMSO-d6, 500 MHz): 0.81 (t, J = 7.3 
Hz, 3H), 2.18 –  2.24 (m, 2H), 5.20 – 5.23 (m, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.88 – 6.92 (m, 2H), 7.00 (d, J = 2.2 
Hz, 1H), 7.31 (t, J = 1.3 Hz, 1H), 7.35 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.82 (bs, 1H), 9.01 (bs, 1H), 
9.06 (bs, 1H); MS (ESI): m/z = 295 [M++H]. 
4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,5-diol (6) 
Synthesised according to Method G using 6a (2.00 g, 3.83 mmol); yellow solid; yield: 0.06 g (5 %); Rf = 0.38 
(EtOAc / MeOH, 95 :5); IR (ATR) ῦ (cm-1): 2975 (w), 1595 (m), 1488 (m), 1351 (m), 1167 (s), 1111 (m), 1091 (m), 
1077 (m), 1014 (m), 831 (s), 820 (s), 803 (s), 742 (s); δH (DMSO-d6, 500 MHz) 0.82 (t, J = 7.3 Hz, 3H), 2.15 - 2.28 
(m, 2H), 5.23 – 5.26 (m, 1H), 6.21 (t, J = 2.1 Hz, 1H), 6.44 (d, J = 2.1 Hz, 2H), 6.91 (s, 1H), 7.31 (s, 1H), 7.38 (d, J 
= 8.2 Hz, 2H), 7.49 (d, J = 8.2 Hz, 2H), 7.82 (s, 1H), 9.36 (s, 2H); δC (DMSO-d6, 125 MHz): 10.9 (CH3), 27.5 
(CH2), 61.5 (CH), 101.7 (CH), 104.7 (CH), 117.7 (CH), 126.6 (CH), 127.0 (CH), 128.5 (CH), 132.5 (Cq), 136.4 
(CH), 139.9 (Cq), 141.5 (Cq), 158.7 (COH); MS (ESI): m/z = 295 [M++H]. 
3'-Fluoro-4'-(1-imidazol-1-yl-propyl)-biphenyl-4-ol (7) 
Synthesised according to Method G using 7a (crude product); yellow solid; yield: 0.05 g; Rf = 0.4 (EtOAc / 
MeOH, 95:5); IR (ATR) ῦ (cm-1): 2974 (w), 2360 (m), 2341 (m), 1607 (m), 1494 (s), 1283 (m), 1223 (m), 1077 (m), 
840 (m), 827 (s), 765 (m); δH (DMSO-d6, 500 MHz): 0.84 (t, J = 7.3 Hz, 3H), 2.14 – 2.32 (m, 2H), 5.47 – 5.50 (m, 
1H), 6.83 (d, J = 8.5 Hz, 2H), 6.90 (bs, 1H), 7.30 (t, J = 1.3 Hz, 1H), 7.41 – 7.44 (m, 3H),  7.51 (d, J = 8.5 Hz, 2H), 
7.81 (bs, 1H), 9.67 (s, 1H); MS (ESI): m/z = 297 [M++H]. 
3'-Fluoro-4'-(1-imidazol-1-yl-propyl)-biphenyl-3,4-diol (8) 
Synthesised according to Method G using 8a (crude product); yellow solid; yield: 0.05 g; Rf = 0.45 
(EtOAc/MeOH, 95:5); IR (ATR) ῦ (cm-1): 1500 (s), 1413 (m)1279 (m), 1264 (s), 1109 (s), 1089 (s), 859 (s), 812 (s), 
785 (m), 742 (m);  δH (CDCl3, 500 MHz): 1.00 (t, J = 7.3 Hz, 3H), 2.26 –  2.32 (m, 2H), 5.35 (t, J = 7.9 Hz, 1H), 
6.93 – 6.97 (m, 2H), 7.01 (t, J = 1.3 Hz, 1H), 7.03 (d, J = 1.9 Hz, 1H), 7.10 (t, J = 1.3 Hz, 1H), 7.14 (dd, J = 1.9, 
12.0 Hz, 1H), 7.17 (d, J = 7.9 Hz, 1H), 7.24 (dd, J = 1.9, 8.2 Hz, 1H), 7.78 (s, 1H); MS (ESI): m/z = 313 [M++H]. 
4'-(1-Imidazol-1-yl-propyl)-3,5-dimethyl-biphenyl-4-ol (13) 
Synthesised according to Method G using 13a (0.30 g, 0.71 mmol) and TBAF solution (1.0 M in THF, 0.78 mL, 
0.78 mmol); white solid; yield: 0.19 g (85 %); Rf = 0.22 (hexane / EtOAc, 5:1); IR (ATR) ῦ (cm-1): 2927 (w), 1705 
(w), 1484 (s), 1188 (m), 1076 (w), 923 (m), 817 (w), 731 (s), 662 (s), 543 (w); δH (CDCl3, 500 MHz): 0.95 (t, J = 
7.3 Hz, 3H, CH3), 2.23 – 2.26 (m, 2H), 2.31 (s, 6H), 5.04 (t, J = 7.6 Hz, 1H), 6.97 (s, 1H), 7.09 (s, 1H), 7.18 (s, 2H), 
7.20 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 8.2 Hz, 2H), 7.63 (s, 1H); δC (CDCl3, 125 MHz): 11.1 (CH3), 16.2 (CH2), 28.6 
(CH3), 30.9 (CH3), 63.1 (CH), 117.7 (CH), 126.8 (Cq), 127.1 (CH), 127.2 (CH), 129.3 (CH), 136.3 (Cq), 138.2 (Cq), 
141.1 (Cq); MS (ESI): m/z = 307 [M++H]. 
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4'-(1-Imidazol-1-yl-propyl)-3-methyl-biphenyl-4-ol (14) 
Synthesised according to Method G using 14a (0.24 g, 0.59 mmol) and TBAF solution (1.0 M in THF, 0.89 mL, 
0.89 mmol); white solid; yield: 0.14 g (83 %); Rf = 0.22 (hexane / EtOAc, 5:1); IR (ATR) ῦ (cm-1): 2933 (w), 2361 
(w), 1602 (m), 1499 (s), 1398 (m), 1278 (s), 1129 (w), 1087 (w), 1075 (m), 927 (w), 815 (s), 739 (m), 659 (m); δH 
(CDCl3, 500 MHz): 0.97 (t, J = 7.3 Hz, 3H), 2.23 – 2.29 (m, 2H), 2.32 (s, 3H), 5.04 (t, J = 7.6 Hz, 1H), 6.81 (d, J = 
8.3 Hz, 1H), 7.01 (s, 1H), 7.13 (s, 1H), 7.19-7.23 (m, 3H), 7.33 (d, J = 1.9 Hz, 1H), 7.50 (d, J = 8.3 Hz, 2H), 7.67 (s, 
1H); δC (CDCl3, 125 MHz): 11.1 (CH3), 16.2 (CH2), 28.5 (CH3), 63.3 (CH), 115.2 (CH), 117.9 (CH), 124.8 (CH), 
125.4 (CH), 126.8, 127.0 (CH), 128.9 (CH), 129.6 (CH), 131.1 (CH), 136.2 (Cq), 137.9 (Cq), 141.2 (Cq), 154.9 
(COH); MS (ESI): m/z = 293 [M++H]. 
3-Chloro-4'-(1-imidazol-1-yl-propyl)-biphenyl-4-ol (15)  
Synthesised according to Method G using 15a (0.27 g, 0.63 mmol) and TBAF solution (1.0 M in THF, 0.91 mL, 
0.91 mmol); white solid; yield: 0.18 g (86 %); Rf = 0.25 (hexane / EtOAc, 5:1); IR (ATR) ῦ (cm-1): 2360(m), 1497 
(s), 1293 (s), 1054 (m), 810 (s), 735 (m), 659 (m); δH (CDCl3, 500 MHz): 0.96 (t, J = 7.3 Hz, 3H), 2.23 - 2.29 (m, 
2H), 5.04 (t, J = 7.3 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 7.04 (s, 1H), 7.13 (s, 1H), 7.19-7.23 (m, 3H), 7.47 (d, J = 1.9 
Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.80 (s, 1H); δC (CDCl3, 125 MHz): 11.0 (CH3), 28.4 (CH2), 63.5 (CH), 116.9 
(CH), 118.1 (CH), 126.6 (CH), 127.0 (CH), 127.1(CH), 127.9 (CH), 135.8 (Cq), 139.9 (Cq); MS (ESI): m/z = 313 
[M++H]. 
Docking studies 
Ligands 
All molecular modelling studies were performed on Intel(R) P4 CPU 3.00GHz running Linux Suse 10.1. The 
structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, Missouri, USA) and energy-
minimized in MMFF94s force-field [43] as implemented in Sybyl. The resulting geometries for our compounds 
were then subjected to ab initio calculation employing the B3LYP functional [44, 45] in combination with a 6-31G* 
basis set using the package Gaussian03 (Gaussian, Inc., Pittsburgh, PA, 2003).  
Docking 
Molecular docking calculations were performed for various inhibitors of Table 1. Since the GOLD docking 
program allows flexible docking of the compounds, no conformational search was employed to the ligand structures. 
GOLD gave the best poses by a genetic algorithm (GA) search strategy, and then various molecular features were 
encoded as a chromosome.  
Ligands were docked in 50 independent genetic algorithm (GA) runs using GOLD. Heme iron was chosen as 
active-site origin, while the radius was set equal to 19 Å. The automatic active-site detection was switched on. A 
distance constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-hybridised nitrogen of the 
imidazole and the iron was set. Further, some of the GOLDSCORE parameters were modified to improve the weight 
of hydrophobic interaction and of the coordination between iron and nitrogen. The genetic algorithm default 
parameters were set as suggested by the GOLD authors [41]. On the other hand, the annealing parameters of fitness 
function were set at 3.5 Å for hydrogen bonding and 6.5 Å for Van der Waals interactions.  
All 50 poses for each compound were clustered with ACIAP [46, 47] and the representative structure of each 
significant cluster was selected. The quality of the docked representative poses was evaluated based on visual 
inspection of the putative binding modes of the ligands, as outcome of docking simulations and cluster analysis. 
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Abstract. 
It has been illuminated that the growth of most prostate carcinoma depends on androgen stimulation. Therefore 
the inhibition of CYP17 to block androgen biosynthesis is regarded as a promising therapy. Based on our previously 
identified lead compound Ref 1, a series of fluorine substituted biphenyl methylene imidazoles were designed, 
synthesized and evaluated as CYP17 inhibitors, to elucidate the influence of fluorine on in vitro and in vivo activity. 
It has been found that meta- F substitution on the C- ring improved the activity, whereas ortho- substitution reduced 
the potency. Docking studies which were performed with our human CYP17 homology model suggest multi-polar 
interactions between fluorine and Arg109, Lys231, His235 and Glu305. As expected, introduction of fluorine also 
prolonged the plasma half-life. The SARs obtained confirm the reliability of the protein model and result in 
compound 9 (IC50 = 131 nM) as stong CYP17 inhibitor showing potent activity in the rat, a high bioavailability and 
a long plasma half-life (12.8 hours). 
Introduction. 
As the most common malignancy in male elders, prostate carcinoma also acts as a major cause of death. 1 It has 
been illuminated that the growth of up to 80 % of prostate carcinoma depends on androgen stimulation. Therefore, 
segregation of tumour cells from androgen will effectively prevent cancer cell proliferation. Since more than 90 % 
of testosterone is produced in testes, orchidectomy or treatment with gonadotropin-releasing hormone (GnRH) 
analogues 2 (chemical castration) are applied in clinic. As this therapy has no effect on the minor amount of 
androgen produced in the adrenals, androgen receptor antagonists are employed additionally. This is the current 
standard therapy for prostate carcinoma, the so called “combined androgen blockade” (CAB). 3 However, CAB 
often leads to resistance which can be associated with androgen receptor mutations. The mutated androgen receptor 
recognizes antagonists and glucocoticoids as agonists, finally resulting in the collapse of CAB therapy. 4  
The shortcomings of CAB waken a more promising alternative: total blockage of androgen biosynthesis, which 
means inhibition of cytochrome P450-17 (17α-hydroxylase-17, 20-lyase, CYP17). CYP17 is one of six CYP 
enzymes involved in steroid biosynthesis. Like all CYP enzymes, CYP17 consists of a heme and an apoprotein 
moiety. Although all potent inhibitors interfere with the heme, which is common to CYP enzymes, by complexing 
its central iron ion, it is nevertheless possible to selectively inhibit these enzymes as has been demonstrated with 
CYP19 (aromatase, estrogen synthase) 5 and CYP11B2 (aldosterone synthase).6 While aromatase inhibitors are 
already in clinical use, 5a the first highly potent and selective CYP11B2 inhibitors have been identified just recently, 
6 some of which are extremely selective.  
CYP17, located in both testicular and adrenal tissue, 7 is the key enzyme catalyzing the conversion of 
pregnenolone and progesterone to dehydroepiandrosterone (DHEA) and androstenedione, respectively. DHEA can 
be transformed into androstenedione by 3β-HSD, which is subsequently converted into the most potent androgen 
dihydrotestosterone (DHT) in androgen target cells through two enzymatic steps catalyzed by 17β-HSD1 or 3 and 
steroid 5α-reducatase (5αR). Thus, inhibition of CYP17 could annihilate the androgen production both in testes and 
in adrenals. Furthermore, targeting genetically stable human tissue instead of cancer cells would avoid the resistance 
caused by mutation. 
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Ketoconazole (Chart 1), an antimycotic agent showing non-selective inhibition of CYP17, is the first medication 
which has been used clinically in treatment of prostate carcinoma. Although withdrawn because of side-effects, 
Ketoconazole shows good curative effects, 8 which demonstrates the feasibility of prostate carcinoma treatment via 
CYP17 inhibition. Since then, in mimicry of the physiological substrates, many steroidal CYP17 inhibitors were 
synthesized by others 9 and our group, 10 including Abiraterone (Chart 1), which has entered into phase II clinical 
trial recently. However, the affinity of steroidal compounds toward steroid receptors, which often results in side 
effects no matter acting as agonists or antagonists, prompted us to develop non-steroidal CYP17 inhibitors. 11, 12 
Our group has reported about series of biphenyl methylene imidazoles as potent CYP17 inhibitors. 12 A 
promising lead compound 1-[1-(4'-fluoro-biphenyl-4-yl)-propyl]-1H-imidazole 12g (Ref 1, Chart 1) was identified in 
the optimization process. In the present investigation this compound was further modified to elevate potency, 
selectivity as well as pharmacokinetic properties. Since fluorine is known to be able to form multi-polar interactions 
with several amino acids 13e-l and due to its capability to enhance metabolic stability, the biphenyl core was 
substituted with additional fluorine atoms leading to compounds 1-22. Exchanging the 1-imidazolyl group by a 5-
imidazolyl moiety while maintaining 4-fluoro-phenyl as A- ring, compounds 23-26 were subsequently obtained. 
Furthermore, besides determination of inhibitory activities toward human CYP17 in vitro, selected compounds were 
examined for their potency to reduce plasma testosterone concentration and for their pharmacokinetic properties in 
rats. Moreover, computational investigations were performed: molecular docking studies using our homology model 
of human CYP17 12e to elucidate the enzyme-inhibitor interactions and quantum mechanical studies to explore the 
influence of fluorine substitution on potency and pharmacokinetic properties of this type of CYP17 inhibitors. 
Chart 1. Typical CYP17 inhibitors 
Drug design 
Fluorine, as the most electronegative atom, has been widely employed to prevent undesired metabolism because 
of the strong C-F bonds. Besides the increase of metabolic stability, fluorine can also improve other 
pharmacokinetic properties by means of influencing pKa, elevating lipophilicity and reducing plasma protein 
binding.13 Recently, multi-polar interactions between fluorine and some amino acid residues, responsible for the 
enhanced binding potency, have also been reported. 13e-l Based on these findings, fluorophilicity and fluorophobicity 
in protein active site have been discussed, 13c, d and systemic fluorine scan was recommended in drug discovery and 
lead optimization. 
We found that fluorine substituted at the para- position of the A- ring could significantly increase the inhibitory 
potency of biphenyl methylene imidazole type CYP17 inhibitors, resulting in compound Ref 1 (IC50 value 345 nM). 
12g Besides the complexation of the heme iron, recognized as the main anchor point for non-steroidal CYP inhibitors 
(first notified for CYP19 inhibitors 5b-c), by a heterocyclic nitrogen, polar interactions between this fluorine atom and 
the guanidinium side chain of Arg109 and the amino side chain of Lys231 were observed for Ref 1 and considered 
as important for binding affinity 12g (Fig. 1). The A- ring is presumably stabilized by a strong T-shaped arene 
quadrupole interaction with Phe114, a conformationally flexible residue responsible for dividing the CYP17 active 
site into two lobes. Furthermore, some more amino acid residues such as Asn, Arg or Gln were identified close to 
the A- or C- ring, which might provide the potential for additional fluorine substituents to form multi-polar 
interaction with H-X (where X = N, O, S) 13h-l and backbone C=O (in an orthogonal manner), 13e-f or even with the 
H-Cα. 13c, 13g Consequntly, the following strategies to increase the inhibitory potency and the metabolic stability of 
Ref 1 were applied: a) shifting the fluorine to other positions in the A- ring; b) additional introduction of fluorine 
atoms on the A- or C- ring in order to identify new interaction areas. Since these modifications change the molecular 
electrostatic potentials (MEP) of the compounds, the protein pocket surrounding of the C- ring was scrutinized with 
the aim to identify potential interaction areas influenced by MEP variations, especially the backbone π-systems of 
amino acids such as Gly301-Ala302. 
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Figure 1. Amino acid residues surrounding Ref 1: Arg109 and Lys231 interact with the para- F on the A- ring. 
Some more amino acid residues around the A- ring or C- ring might form additional multi-polar interactions with 
further F substituents.
Results and Discussion
Chemistry. The syntheses of compounds 1-26 are shown in Schemes 1-3. For 1-imidazole analogues 1-22, a 
general synthetic strategy was employed: ketone or aldehyde intermediates were obtained by means of Suzuki 
coupling (Method C) from the corresponding bromides and boronic acids. 14 Subsequently they were converted to 
the alcohols by reduction with NaBH4 (Method D) or Grignard reaction (Method B). The alcohol intermediates 
reacted with 1, 1-carbonyl diimidazole (CDI) to give the racemic mixtures of the desired products, which were not 
separated into their enantiomers. Using different reaction conditions, such as solvent and reaction temperature, 
different products were obtained in this SNt reaction. After refluxing in NMP for 4 hours (Method A), 15 biphenyl 
methylene imidazoles were obtained; whereas boiling in THF for 4 days (Method E) gave imidazole-1-carboxylic 
acid biphenyl esters as major products. Distinguishing between these two products is easy as the chemical shifts of 
imidazole 2-H in biphenyl methylene imidazoles are around 7.6 ppm, whereas they are beyond 8.2 ppm in 
imidazole-1-carboxylic acid biphenyl esters. 15 Moreover, the proton chemical shift of CH is 5.1 ppm in the biphenyl 
methylene imidazoles, whereas in the imidazole-1-carboxylic acid biphenyl esters it is 5.9 ppm. Additionally, the 
strong carbonyl signal in the IR spectra contributes to the identification of the latter class of compounds. For the 
synthesis of the 5-imidazole analogues (23-26) trityl was employed as protecting group for imidazole. The alcohol 
intermediates, commercially available or obtained by reaction of imidazolyl lithium with aldehyde, underwent 
elimination of the H2O group in acidic environment to give the corresponding isopropylidene product, which was 
subsequently saturated by hydrogenation of the double bond. 
Scheme 1.
Reagents and conditions: (i) Method C: Pd(PPh3)4, Na2CO3, toluene, reflux, 6h; (ii) Method D: 1b-2b, 4b, 6b-7b, 9b, 13b, 15b, 17b,
19b-21b: NaBH4, MeOH; (iii) Method B: 9b, 13b, 15b, 17b: EtMgBr, THF; (iv) Method E: 2a, 4a, 7a, 9a, 11a: CDI, THF, reflux, 4 
days; (v) Method A: 1a-22a: CDI, NMP, reflux, 4h.
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Scheme 2. 
 
Reagents and conditions: (i) Method C: 4-fluoro boronic acid, Pd(PPh3)4, Na2CO3, toluene, reflux, 6h; (ii) a. imidazole, n-BuLi, TrtCl, 
THF, 0 °C, 2h; b. n-BuLi, tert-Bu-diMe-SiCl, THF, 0 °C, 2h; c. n-Buli, 1b, THF, rt, 8h; (iii) pyridinium hydrochloride, MeOH, 60 °C, 4h. 
Scheme 3.  
 
Reagents and conditions: (i) a. Method C: 4-fluoro boronic acid, Pd(PPh3)4, Na2CO3, toluene, reflux, 6h; b. pyridinium hydrochloride, 
MeOH, 60 °C, 4h; (ii) HCl / i-PrOH, 80 °C, 2h; (iii) Pd(OH)2, ethanol, THF, H2, rt, 3h 
In vitro activity. CYP17 inhibition of all compounds was evaluated using the 50,000 sediment after 
homogenation of E.coli expressing human CYP17 as well as cytochrome P450 reductase. 12d The assay was run with 
progesterone as substrate and NADPH as cofactor. Separation of substrate and product was accomplished by HPLC 
using UV detection. 16 IC50 values are presented in comparison to Ketoconazole and Abiraterone in Tables 1-2. 
It is striking that in the series of 1-imidazole compounds (1-22), a sharp structure activity relationship is 
observed. The analogues can be divided into 3 classes regarding the fluorine substitution on the C- ring, i.e. without 
F, meta- F and ortho- F (positions relative to the A- ring, Table 1).  
It can be seen that, in the class of compounds without fluorine on the C- ring, additional substitution at the A- 
ring by fluorine, methyl or methoxy (1, 2, 4, 6 and 7), did not enhance the inhibitory activity compared to Ref 1 
(IC50 = 345 nM). For example, extra fluorine substitution at meta- or ortho- position of the A- ring, resulting in 
3’,4’- di F (2) and 2’,4’- di F (4) analogues, decreased activity somewhat (IC50 = 803 and 985 nM, respectively). 
Interestingly, 2’,5’- di F substitution (7) exhibited similar inhibitory potency (IC50 = 956 nM) as seen with the 2’,4’- 
di F analogue.  
Importantly, the introduction of fluorine at the meta- position of the C- ring significantly increased the inhibitory 
potency. Compound 9 showed an IC50 value of 131 nM, being 3 fold more potent than Ref 1. Similar improvements 
can be found for the other compounds in this class (13, 15 and 17, IC50 values around 350 nM) being 3 fold more 
potent than the corresponding compounds without F at the C- ring (2, 4 and 7, respectively, IC50 values around 900 
nM). Moreover, it can be seen that the analogue with only one para- F at the A- ring (9) is more potent than other 
analogues with multi- F on the A- ring as mentioned above. A similar ranking of potency can be observed for multi- 
F analogues in this class of compounds too: the 3’,4’-di F compound (13, IC50 = 305 nM) being more potent than the 
others, e. g. the 2’,5’-di F compound (15, IC50 = 381 nM) and  the 2’,4’-di F compound (17, IC50 = 364 nM).  
On the contrary, ortho- F substitution at the C ring decreased activity. Compound 19 (IC50 = 657 nM) was less 
potent than the corresponding analogues with meta- F (9, IC50 = 131 nM) or without F (Ref 1, IC50 = 345 nM). 
However, compound 19 exhibited stronger inhibition compared to compound 21 furnished with two fluorine 
substituents in 3’,4’- position as expected. 
Moreover, all imidazole-1-carboxylic acid biphenyl esters (3, 5, 8, 10 and 12) were found to be inactive. This is 
probably due to the fact that these molecules are too large to fit into the binding pocket. Noteworthy is the 
importance of the ethyl substituent at the methylene bridge, as already reported, 12g i.e. that ethyl substitution results 
in more potent compounds compared to the corresponding non- or methyl substituted analogues. 
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Table 1. Inhibition of CYP17 by compounds 1-22 
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Ref 1, 1-2, 4, 6-7, 9, 11, 13-22 3, 5, 8, 10, 12
 
Compd. R1 R2 R3 IC50 a Compd. R1 R2 R3 IC50 a Compd. R1 R2 R3 IC50 a 
Ref 1 4'-F H Et 345 9 4'-F m-F Et 131 19 4'-F o-F Et 657 
     10 4'-F m-F Et 4643      
     11 4'-F m-F H 2110 20 4'-F o-F H 2800 
     12 4'-F m-F H >5000      
1 4'-F, 2'-Me H Et 951           
2 3',4'-di F H Et 803 13 3',4'-di F m-F Et 305 21 3',4'-di F o-F Et 825 
3 3',4'-di F H Et >5000 14 3',4'-di F m-F H >5000      
4 2',4'-di F H Et 985 15 2',4'-di F m-F Et 381      
5 2',4'-di F H Et >5000 16 2',4'-di F m-F H >5000 22 2',4'-di F o-F H >5000 
6 2',4'-di F, 3'-MeO H Me >10000           
7 2',5'-di F H Et 956 17 2',5'-di F m-F Et 364      
8 2',5'-di F H Et >5000 18 2',5'-di F m-F H 1640      
KTZb    2780      ABTb    72 
a Concentration of inhibitors required to give 50 % inhibition. The mean values of at least three experiments are given in nM within ±10 % 
deviation 
b KTZ: Ketoconazole; ABT: Abiraterone. 
Furthermore, 5-imidazole was employed instead of 1-imidazole leading to compounds 23-26 as shown in table 2. 
It is apparent that compounds with a hydroxy group substituted at the methylene bridge are inactive. Nonetheless, 
isopropyl substitution resulted in an active compound (26, IC50 = 502 nM), which was, however, less potent 
compared to Ref 1. Surprisingly, the compound with an isopropylidene substitution (25) turned out to be very potent 
(IC50 = 159 nM). 
Table 2. Inhibition of CYP17 by compounds 23-26. 
No R5 R6 IC50a 
23 OH H >>10000 
24 OH i-Pr >5000 
25 i-Propylidene 159 
26 H i-Pr 502 
KTZb   2780 
ABTb   72 
a Concentration of inhibitors required to give 50 % inhibition. The mean values of at least three experiments are given in nM within ±10 % 
deviation. 
b KTZ: Ketoconazole; ABT: Abiraterone. 
Finally, inhibition values of the most active compounds 9, 13, 15, 17 and 25 toward the hepatic enzyme 
CYP3A4 were also determined, because of its important role in drug metabolism and drug-drug interaction. It turned 
out that the compounds tested showed only marginal inhibition (around 50 % at 10 µM), clearly lower than that 
shown by Ketoconazole (98 % at 10 µM).  
R5 R6
HN N
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Computational modelling studies. 
Docking. Compounds Ref 1, 9, 11, 13, 15, 17 and 19, both enantiomers if existing, were docked into the 
homology model of human CYP17 12e by means of two commercial docking softwares, GOLD_v4.0 17 and FlexX 
3.1.3, 18 in order to elucidate their binding into the active site of the enzyme. The docking with GOLD was 
performed with both the scoring functions GOLDSCORE and CHEMSCORE, while FlexX was used with the 
FlexX-Pharm module, with the iron of the heme chosen as pharmacophoric constraint. A clustering with AClAP 19
of all the docking poses of the three procedures resulted in one main, statistical predominant binding mode (BM1)
12e and two minor representative clusters. Interestingly, each of the latter two clusters solely consisted of either the 
S- (BM2) 12e or the R- (BM-ABT) 12h enantiomers respectively (Fig. 2). This finding indicates that, together with the 
necessary perpendicular interaction angle between imidazole N and heme Fe to ensure sufficient coordination, the 
orientation of the hydrophobic pocket, which is occupied by the substituent on the methylene bridge, limits the pose 
distribution of different enantiomers. This geometrical restriction forces the S- enantiomers into BM2 area and the 
R- enantiomers into BM-ABT. However, as the intersection of both areas, BM1 is a better area for both enantiomers 
to bind to. 
Figure 2. Presentation of the three main binding modes, exemplified by compounds 9 (magenta, BM1), 15 (red, 
BM2) and 13 (blue, BM-ABT). Heme, interacting residues and ribbon rendered tertiary structure of the active site 
are shown. Polar interactions are marked with red solid lines, whereas π-π stacking and metal complexation with 
cyan dotted lines. Figure was generated with MOE (http:// www.chemcomp.com).
It can be observed for BM1 that a conjugated scaffold orienting almost parallel to the I-helix is one of the key 
factors for high activity as previously described. 12g According to our docking studies this extended π-system 
obviously interacts not only with the π-system of the amino acid backbone in the I-helix (i.e. Gly301, Ala302, 
Gly303, Val304), but also with Phe114, which is oriented perpendicular toward the A- ring (Fig. 2 BM1) to form a 
quadrupole-quadrupole interaction. More importantly, fluorine in the molecule showed profound influence on the 
affinity for the enzyme. This can be explained by the obviously existing interactions of the para- F substituent with 
Arg109, Lys231 and His235 (Fig. 2). When the fluorines were shifted to other positions in the A- ring resulting in 
2’,5’-di F analogues, a decrease of activities can be observed. Obviously, the interactions mentioned above can no
longer be maintained. These observations nicely validate the reliability of our protein model. Furthermore, the 
elevated activity of C- ring meta- F substituted compounds can be explained by a multi-polar interaction between F 
and the N-H group of Glu305 (Fig. 2) stabilizing the π-π interaction between the C- ring and the backbone π-system 
of Gly301-Ala302.
Additionally, a further flexible docking run was performed with GOLDv4.0-GOLDSCORE, with the side chains 
of Phe114, Arg109, Lys231, Asn202, Glu305, and Ile371 being set freely rotatable. Very similar results were 
observed as seen for the docking runs with the rigid side chains (data not shown). 
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MEP maps. To obtain an insight which physicochemical parameters might influence biological activity, the 
charge density distribution was considered and the molecular electrostatic potentials (MEPs) of selected compounds 
were determined. The geometry of these compounds (Ref 1, 2, 9, 13, 15, 17 and 25) was optimized in the gas phase 
at the B3LYP/6-311++G** (d,p) 20 level of density functional theory (DFT) by means of Gaussian 03. 21 MEPs of 
electron density were plotted for every compound with GaussView 3.09. 22
The introduction of a second fluorine or the shift of fluorine into another position on the A- ring always leads to 
a reduction of the A- ring electron density, which can be clearly seen in the different MEP maps of compounds 9,
13, 15, 17 and 25 (Fig. 3A). This observation correlates with the different electron-withdrawing effects of the 
fluorine in meta- or para- position (σ values of +0.337 and +0.067, respectively). This reduction of electron density 
weakens the T-shaped interaction of the A- ring with Phe114, and consequently decreases the inhibitory potency of 
the compound. 
The lower inhibitory potency of compounds with ortho- F substitution on the C- ring (19 and 21) might be due to 
the adverse effect that the fluorine exerts on the overall charge density of the biphenyl system by deforming the 
conjugated π-π system and by concentrating the electrons on the fluorine. However, for meta- F compounds (9, 13,
15 and 17) it seems that fluorine induces an increase in electron distribution on the imidazole ring, as visualized in 
the MEP maps of compounds Ref 1 and 9 (Fig. 3C), which is linked with an augmented inhibitory potency of the 
compounds. An analogous phenomenon was observed for compound 25, where the isopropylidene strengthened the 
π-π system and extended the conjugation over the whole molecule (Fig. 3B).
Figure 3. (A) Structure, CYP17 inhibitory activity and MEP maps (bottom and top view) of compounds 9 and 13.
For compounds 15 and 17, nearly the same MEP maps (not shown) as for of compound 13 were observed. (B) MEP 
maps of compound 25, highlighting in the side-views of the conjugated π-π system, enhanced by the isopropylidene 
substituent on the methylene bridge. The electrostatic potential surfaces shown in (A) and (B) were plotted with 
GaussView 3.0 in a range of -6 to +12 kcal/mol. (C) Transparent color-coded front and back view of the 
electrostatic potential maps of the imidazoles of both Ref 1 and compound 9, in a range of -15.7 to +0 kcal/mol, 
illustrative for the influence exerted on the electron distribution of the imidazole by fluorine substitutents on the C-
ring.
In vivo activity. The in vivo evaluation of the most potent compounds 9, 13, 15 and 17, including the ability of 
reducing plasma testosterone concentration (Table 3) and the determination of pharmacokinetic properties (Table 4) 
was performed in male Wistar rats after oral application. Abiraterone which was administered as acetate to improve 
its oral absorption and Ref 1 were used as reference compounds. The plasma concentrations of testosterone were 
determined using an ELISA assay and plasma drug concentrations were measured using LC-MS. In the case of 
Abiraterone acetate only the signals of free Abiraterone were monitored, as the acetate is inactive as CYP17 
inhibitor. As can be seen from table 3 all compounds significantly reduced the plasma testosterone concentration. It 
is striking at each time point investigated that all non-steroidal compounds, which were less active in vitro, exhibited 
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higher activities in vivo than Abiraterone. After 24 hours, compound 9 and Ref 1 still showed strong inhibitory 
activity, compounds 13 and 17 showed almost no inhibition, whereas compound 15 and Abiraterone exhibited an 
increase of testosterone levels above control at this time point, probably caused by feed-back stimulation. As 
expected this activity profile correlates to the pharmacokinetic properties of the compounds. Abiraterone exhibited a 
plasma half-life of only 1.6 hours, while the half-lifes of other compounds are much longer (10 hours for Ref 1 and 
12.8 hours for 9). Accordingly, the AUC values of the test compounds, except for compound 17, are higher than for 
Abiraterone, indicating better bioavailability properties. Interestingly, the introduction of an additional fluorine into 
the C- ring of Ref 1 prolongs plasma half-life (9), whereas introduction of further fluorine atoms into the A-ring 
reduces half-lives strongly (13, 15 and 17, half-lives between 2 to 6 hours). 
Table 3. Reduction of the plasma testosterone concentrations in rats by selected compounds a 
Comp. 
Relative plasma testosterone level (%) b 
1h 2h 4h 6h 8h 24h 
Control 171.7 ± 62.3 117.7 ±48.0 141.2 ± 80.9 244.3 ± 126.4 188.6 ± 67.0 184.8 ± 82.2 
9 23.4 ± 5.5 f 18.4 ± 4.2 f 16.9 ± 3.9 f 18.1 ± 5.2 f 21.1 ± 5.9 f 40.7 ± 11.9 e 
13 21.9 ± 4.6 f 15.2 ± 3.2 f 14.9 ± 3.6 f 17.0 ± 4.5 f 19.5 ± 5.6 f 182.2 ± 86.9 
15 52.0 ± 14.7 e 46.8 ± 13.2 e 46.5 ± 12.6 e 44.0 ± 13.1 e 49.7 ± 15.4 e 317.8 ± 76.9 e 
17 30.6 ± 7.9 f 27.9 ± 11.3 e 74.5 ± 60.5 88.4 ± 68.8 62.4 ± 14.6 138.5 ± 61.9 
Ref 1 16.5 ± 5.7 e 11.7 ± 5.0 e 13.9 ± 8.0 e 13.9 ± 7.1 e 13.4 ± 6.2 e 36.7 ± 27.4 e 
ABT c 92.5 ± 43.1 d 44.0 ± 14.7 d 43.5 ± 12.4 d 43.3 ±12.8 c 35.6 ± 9.7 d 476.0 ± 238.6 
a Compounds 9, 13, 15 and 17 were applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 
mg / kg body weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each 
treatment group; each sample was tested for 3 times. 
b The average plasma testosterone concentrations (1.97 ng / mL) at pre-treatment time points (-1, -0.5 and 0 h) were set to 100 %. The 
values shown are the relative levels compared to the pre-treatment value. 
c ABT: Abiraterone.  
d P < 0.05, e P < 0.01, f P < 0.001 
Table 4. Pharmacokinetic properties of selected compounds a 
Compounds t 1/2 z(h)b t max (h)b C max (ng / mL)b AUC 0-∞ (ng * h / mL)b 
9 12.8 2.0 1036 24000 
13 6.1 8.0 1106 17750 
15 4.2 6.0 803 11100 
17 2.2 1.0 145 650 
Ref 1 10.0 6.0 3288 70729 
Abiraterone 1.6 2.0 592 4015 
a Compounds 9, 13, 15 and 17 were applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 
mg / kg body weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each 
treatment group; each sample was tested for 3 times. 
b t ½ z: terminal half-life; t max: time of maximal concentration; C max: maximal concentration; AUC 0-∞: area under the curve. 
Conclusion 
Herein, we reported the design, synthesis and bioactivity evaluation of a series of fluorine substituted biphenyl 
methylene imidazoles as CYP17 inhibitors. Fluorine substitution was found to show profound influence on the in 
vitro and in vivo activities, as well as the pharmacokinetic profiles.  
It has been unveiled that fluorine in the meta- position of the C- ring increased the activity compared to the non-
substituted analogues, whereas ortho- substitution reduced the potency. Compounds furnished with fluorine at the 
A- ring always followed the same activity ranking: 4’-F > 3’,4’-di F > 2’,5’-di F ≥ 2’,4’-di F.  
Although the compounds are racemates, it is not likely that one enantiomer would be much more potent than the 
other, because both S and R enantiomers predominately adapt BM1 according to our docking studies. 
Moreover, the biological data were well deciphered by docking studies and MEP mapping of selected 
compounds. The multi-polar interactions between the C- ring fluorine substituents and interacting amino acids 
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residues significantly increased the binding affinities compared to the parent compound. The charge distribution 
difference on both the A- and the C- ring indicates π-π stacking (i.e. with both Phe114 and Gly301-Ala302), 
hydrophobic and Van der Waals interactions as determinants for activity.  
Furthermore, it could be demonstrated once again that fluorine substituted in an appropriate position, like in the 
C- ring, prolongs the plasma half life; in an unsuitable position, however, it decreases the t1/2 value of the parent 
compound. This phenomenon might be due to a decrease in metabolic stability and is interesting for further 
investigations in the future. 
Finally, after the modification compound 9 is identified as strong CYP17 inhibitor showing potent activity in 
vivo, a high bioavailability and a long plasma half-life. Thus, Compound 9 appears to be an optimal candidate which 
after further structural optimization could be the first non-steroidal CYP17 inhibitor to be applied clinically. CYP17 
inhibitors should be superior to the presently used GnRH analogues as mentioned above due to the fact that they 
reduce not only testicular but also adrenal androgen formation. Nevertheless, PC treatment could be further 
optimized by combining CYP17 inhibitors with inhibitors of androgen activation to DHT, catalyzed by 17β-HSD1 23 
and / or 17β-HSD3, as well as 5α-reductase. 24 
Experimental Section 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli (coexpressing human CYP17 and cytochrome P450 reductase) and the 
assay was performed as previously described. 12d, 16 
Inhibition of hepatic CYP enzymes 
The recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were used 
and the manufacturer’s instructions (www.gentest.com) were followed. 
In vivo study 
The in vivo tests were performed with intact adult male Wistar rats (Harlan Winkelmann, Germany), 5 to 6 for 
each treatment group. These rats were cannulated with silicone tubing via the right jugular vein. Compounds 9, 13, 
15 and 17 were applied p.o. with doses of 50 mg / kg body weight, while Abiraterone was administrated as acetate 
56 mg / kg body weight (equivalent to Abiraterone 50 mg / kg body weight). The concentrations of testosterone in 
the rat plasma were determined using the ELISA (EIA - 1559) from DRG Instruments according to the 
manufacturer’s instructions. The plasma drug levels were measured by LC-MS. Non-compartmental 
pharmacokinetic analysis of concentration vs time data was performed for each compound on the mean plasma level 
using a validated computer program (PK solution 2 software; Summit Research Services, Montrose, USA). Plasma 
concentrations below the limit of detection were assigned a value of zero. 
Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra were 
recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H and 13C NMR spectra were measured on a Bruker 
DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an internal 
standard for spectra obtained in CDCl3. All coupling constants (J) are given in Hz. ESI (electrospray ionization) 
mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. The purities of the 
final compounds were controlled by Surveyor®-LC-system. Purities were greater than 98 %. Column 
chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was determined by TLC 
analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as starting materials 
were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros etc). 
Method A: CDI reaction in NMP 
To a solution of the corresponding alcohol (1 eq) in NMP or acetonitrile (10 mL / mmol) was added CDI (5 eq). 
Then the solution was heated to reflux for 4 to 18 h. After cooling to ambient temperature, it was diluted with water 
(30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried 
over MgSO4 and evaporated under reduced pressure. Then the desired product was purified by chromatography on 
silica gel. 
1-[1-(4'-Fluoro-2'-methyl-biphenyl-4-yl)-propyl]-1H-imidazole (1). Synthesized according to Method A using 
1a (0.15 g, 0.61 mmol) and CDI (0.20 g, 1.23 mmol); yield: 0.06 g (32 %); colorless oil; Rf = 0.27 (DCM / MeOH, 
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95:5); δH (DMSO, 500 MHz) 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.23 (s, 3H, CH3), 2.24-2.30 (m, 2H, CH2), 5.07 (t, J = 
7.6 Hz, 1H, CH), 6.90-6.93 (m, 1H), 6.95-6.97 (m, 1H), 7.01 (s, 1H), 7.11 (s, 1H), 7.14 (dd, J = 6.0, 8.4 Hz, 1H), 
7.22-7.26 (m, 4H), 7.67 (s, 1H); MS (ESI): m/z = 295 [M++H].  
1-[1-(3',4'-Difluoro-biphenyl-4-yl)-propyl]-1H-imidazole (2). Synthesized according to Method A  using 2a 
(0.27 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.09 g (27 %); colorless oil; Rf = 0.29 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.23-2.31 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.06 (t, J = 7.6 
Hz, 1H, CH), 6.97-7.02 (m, 1H), 7.10-7.14 (m, 1H), 7.18-7.28 (m, 4H), 7.23-7.37 (m, 1H), 7.49 (m, 2H), 7.62-7.66 
(m, 1H, Im-2H); MS (ESI): m/z = 299 [M++H]. 
1-[1-(2',4'-Difluorobiphenyl-4-yl)propyl]-1H-imidazole (4). Synthesized according to Method A  using 4a 
(0.27 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.12 g (36 %); colorless oil; Rf = 0.34 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.85 (t, J = 7.3 Hz, 3H, CH3), 2.12-2.18 (m, 2H, CH2), 4.96 (t, J = 7.6 Hz, 1H, CH), 
6.77-6.85 (m, 2H), 6.87-6.90 (m, 1H), 6.99-7.02 (m, 1H), 7.13-7.15 (m, 2H), 7.23-7.28 (m, 1H), 7.35-7.37 (m, 2H), 
7.62-7.68 (m, 1H, Im-2H); MS (ESI): m/z = 299 [M++H]. 
1-[1-(2',4'-Difluoro-3'-methoxybiphenyl-4-yl)ethyl]-1H-imidazole (6). Synthesized according to Method A 
using 6a (0.30 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.34 g (71 %); yellow oil; Rf = 0.30 (DCM / 
MeOH, 95:5); δH (CDCl3, 500 MHz) 1.72-1.79 (d, J = 7.5 Hz, 3H, CH3), 3.91 (s, 3H, OCH3), 5.18-5.31 (q, J = 7.5 
Hz, 1H, CH), 6.82-6.84 (m, 1H), 6.83-6.86 (m, 1H), 6.89-6.93 (m, 1H), 6.97-6.99 (m, 1H), 7.09-7.10 (m, 2H), 7.34-
7.36 (m, 2H), 7.50-7.51 (m, 1H, Im-2H); MS (ESI): m/z = 315 [M++H]. 
1-[1-(2',5'-Difluorobiphenyl-4-yl)propyl]-1H-imidazole (7). Synthesized according to Method A  using 7b 
(0.27 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.13 g (41 %); colorless oil; Rf = 0.38 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.26 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.05 (t, J = 7.6 Hz, 
1H, CH), 6.97-7.01 (m, 2H), 7.08-7.12 (m, 3H,), 7.25-7.27 (m, 2H), 7.49-7.51 (m, 2H), 7.62-7.65 (m, 1H, Im-2H); 
MS (ESI): m/z = 299 [M++H]. 
1-[1-(3,4'-difluorobiphenyl-4-yl)propyl]-1H-imidazole (9). Synthesized according to Method A  using 9a 
(0.38 g, 1.53 mmol) and CDI (0.47 g, 2.88 mmol); yield: 0.08 g (17 %); yellow oil; Rf = 0.38 (DCM / MeOH, 95:5); 
δH (CDCl3, 500 MHz) 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.21-2.31 (m, 2H, CH2), 5.38 (t, J = 7.5 Hz, 1H, CH), 7.01 (s, 
1H), 7.08 (s, 1H), 7.10-7.14 (m, 2H), 7.19-7.25 (m, 2H), 7.27-7.29 (m, 1H), 7.40-7.51 (m, 2H), 7.64 (s, 1H, Im-2H); 
MS (ESI): m/z = 299 [M++H]. 
1-[(3,4'-Difluorobiphenyl-4-yl)methyl]-1H-imidazole (11). Synthesized according to Method A using 11a 
(0.28 g, 1.27 mmol) and CDI (0.41 g, 2.54 mmol); yield: 0.11 g (31 %); colorless oil; Rf = 0.53 (EtOAc / MeOH, 
95:5); δH (CDCl3, 500 MHz) 5.20 (s, 2H, CH2), 6.98 (s, br, 1H), 7.10 (s, br, 1H), 7.11-7.16 (m, 3H), 7.26-7.31 (m, 
2H), 7.50 (dd, J = 5.4, 8.8 Hz, 2H), 7.64 (s,br, 1H, Im-2H); MS (ESI): m/z = 271 [M++H]. 
1-[1-(3,3',4'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (13). Synthesized according to Method A  using 
13a (0.40 g, 1.70 mmol) and CDI (0.53 g, 3.20 mmol); yield: 0.11 g (20 %); colorless oil; Rf = 0.35 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.22-2.33 (m, 2H, CH2), 5.39 (t, J = 7.6 Hz, 1H, CH), 
7.01 (s, 1H), 7.09 (s, 1H), 7.20-7.29 ( m, 5H), 7.31-7.35 (m, 1H), 7.64 (s, 1H, Im-2H); MS (ESI): m/z = 317 
[M++H]. 
1-[(3,3',4'-trifluorobiphenyl-4-yl)methyl]-1H-imidazole (14). Synthesized according to Method A  using 14a 
(0.35 g, 1.67 mmol) and CDI (0.53 g, 3.20 mmol); yield: 0.10 g (23 %); white powder: mp 60-61 °C; Rf = 0.26 
(DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 5.19 (s, 2H, CH2), 6.97 (s, 1H), 7.10 (s, 1H), 7.11-7.14 (m, 2H), 7.20-
7.28 (m, 3H), 7.31-7.35 (m, 1H), 7.59 (s, 1H,  Im-2H); MS (ESI): m/z = 289 [M++H]. 
1-[1-(2',3,4'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (15). Synthesized according to Method A  using 
15a (0.27 g, 1.14 mmol) and CDI (0.35 g, 2.10 mmol); yield: 0.09 g (24 %); colorless oil;  Rf = 0.37 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.23-2.32 (m, 2H, CH2), 5.40 (t, J = 7.6 Hz, 1H, CH), 
6.89-6.97 (m, 2H), 7.02 (s, 1H), 7.08 (s, 1H), 7.19-7.27 (m, 3H), 7.34-7.38 (m, 1H), 7.64 (s, 1H, Im-2H); MS (ESI): 
m/z = 317 [M++H]. 
1-[(2',3,4'-Trifluorobiphenyl-4-yl)methyl]-1H-imidazole (16). Synthesized according to Method A using 16a 
(0.18 g, 0.76 mmol) and CDI (0.24 g, 1.51 mmol); yield: 0.09 g (42 %); orange oil; Rf = 0.52 (EtOAc / MeOH, 
95:5); δH (CDCl3, 500 MHz) 5.20 (s, 2H, CH2), 6.89-6.97 (m, 2H), 6.98 (s, br, 1H), 7.10 (s, br, 1H), 7.12 (dd, J = 
7.9, 8.2 Hz, 1H), 7.24-7.27 (m, 2H), 7.36 (ddd, J = 6.4, 8.5, 8.8 Hz, 1H), 7.61 (s, br, 1H, Im-2H); MS (ESI): m/z = 
289 [M++H]. 
1-[1-(2',3,5'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (17). Synthesized according to Method A using 
17a (0.40 g, 1.70 mmol) and CDI (0.53 g, 3.20 mmol); yield: 0.14 g (26 %); colorless oil; Rf = 0.38 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.23-2.32 (m, 2H, CH2), 5.40 (t, J = 7.6 Hz, 1H, CH), 
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7.00-7.04 (m, 2H), 7.08-7.14 (m, 2H), 7.20-7.24 (m, 1H), 7.26-7.30 (m, 2H), 7.64 (s, 1H, Im-2H); MS (ESI): m/z = 
317 [M++H]. 
1-[(2',3,5'-Trifluorobiphenyl-4-yl)methyl]-1H-imidazole (18). Synthesized according to Method A  using 18a 
(0.17 g, 0.71 mmol) and CDI (0.23 g, 1.43 mmol); yield: 0.09 g (45 %); light yellow solid: mp 125-126 °C; Rf = 
0.48 (EtOAc / MeOH, 95:5); δH (CDCl3, 500 MHz) 5.21 (s, 2H, CH2), 6.98 (s, br, 1H), 7.00-7.05 (m, 1H), 7.08-7.16 
(m, 4H), 7.28-7.31 (m, 2H), 7.64 (s, br, 1H, Im-2H); MS (ESI): m/z = 289 [M++H]. 
1-[1-(2,4'-Difluorobiphenyl-4-yl)propyl]-1H-imidazole (19). Synthesized according to Method A  using 19a 
(0.31 g, 1.22 mmol) and CDI (0.40 g, 2.46 mmol); yield: 0.11 g (31 %); colorless oil; Rf = 0.56 (EtOAc / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.3 Hz, 3H), 2.21-2.27 (m, 2H), 5.04 (t, J = 7.7 Hz, 1H), 6.96-6.99 (m, 2H), 
7.02 (dd, J = 1.9, 7.9 Hz, 1H), 7.11 (s, br, 1H), 7.12 (t, J = 8.6 Hz, 2H), 7.37 (t, J = 7.9 Hz, 1H), 7.47 (ddd, J = 1.3, 
5.4, 8.8 Hz, 1H), 7.64 (s, br, 1H, Im-2H); MS (ESI): m/z = 299 [M++H]. 
1-(2,4'-Difluoro-biphenyl-4-ylmethyl)-1H-imidazole (20). Synthesized according to Method A  using 20a 
(0.10 g, 0.44 mmol) and CDI (0.40 g, 2.46 mmol); yield: 0.05 g (42 %); white solid: mp 93-94 °C; Rf = 0.52 (EtOAc 
/ MeOH, 95:5); δH (CDCl3, 500 MHz) 5.15 (s, 2H, CH2), 6.90-6.98 (m, 3H), 7.11-7.13 (m, 2H), 7.25-7.27 (m, 3H), 
7.36-7.39 (m, 1H), 7.60 (s, 1H, Im-2H); MS (ESI): m/z = 271 [M++H]. 
1-[1-(2,3',4'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (21). Synthesized according to Method A using 
21a (0.28 g, 1.03 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.09 g (29 %); light brown oil; Rf = 0.53 (EtOAc / 
MeOH, 95:5); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.4 Hz, 3H), 2.20-2.28 (m, 2H), 5.04 (t, J = 7.6 Hz, 1H), 6.96-6.99 
(m, 2H), 7.03 (dd, J = 1.9, 7.9 Hz, 1H), 7.11 (s, br, 1H), 7.18-7.23 (m, 2H), 7.31-7.34 (m, 1H), 7.35 (t, J = 8.0 Hz, 
1H), 7.64 (s, br, 1H, Im-2H); MS (ESI): m/z = 317 [M++H]. 
1-(2,2',4'-Trifluoro-biphenyl-4-ylmethyl)-1H-imidazole (22). Synthesized according to Method A  using 22a 
(0.10 g, 0.39 mmol) and CDI (0.40 g, 2.46 mmol); yield: 0.06 g (54 %); white solid: mp 112-113 °C; Rf = 0.47 
(EtOAc / MeOH, 95:5); δH (CDCl3, 500 MHz) 5.21 (s, 2H, CH2), 6.90-6.98 (m, 4H), 7.02 (d, J = 7.8 Hz, 1H), 7.16 
(s, 1H), 7.33-7.35 (m, 2H), 7.85 (s, 1H, Im-2H); MS (ESI): m/z = 289 [M++H]. 
Method B: Grignard reaction 
Under exclusion of air and moisture a 1.0 M EtMgBr (1.2 eq) solution in THF was added dropwise to a solution 
of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred over night at rt. Then ethyl acetate 
(10 mL) and water (10 mL) were added and the organic phase was separated. The organic phase was extracted with 
water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude products were purified by 
flash chromatography on silica gel.  
Method C: Suzuki-Coupling 
The corresponding brominated aromatic compound (1 eq) was dissolved in toluene (7 mL / mmol), an aqueous 
2.0 M Na2CO3 solution (3.2 mL / mmol) and an ethanolic solution (3.2 mL / mmol) of the corresponding boronic 
acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure and flushed with nitrogen. 
After repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the resulting suspension was heated to 
reflux for 8 h. After cooling down, ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was 
separated. The water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed 
with brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel.  
1-(4'-Fluorobiphenyl-4-yl)-1-(1H-imidazol-5-yl)-2-methylpropan-1-ol (24). Synthesized according to Method 
C using 1-(4-Bromophenyl)-2-methyl-1-(1-trityl-1H-imidazol-5-yl)propan-1-ol (0.50 g, 0.93 mmol) and 4-
fluorophenyl boronic acid (0.23 mg, 1.63 mmol). After workup, the crude was stirred with pyridinium hydrochloride 
(0.17 g, 1.5 mmol) in MeOH (40 mL) at 60° C for 4 hours. Then the reaction was quenched by adding saturated 
NaHCO3 aq (10 mL). After 20 mL EtOAC were added, the phases separated. The water phase was extracted 2 times 
with EtOAc (20 mL), the combined organic extracts were dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography; yield: 0.21 g (73 %); colorless oil; Rf = 0.17 
(EtOAc / MeOH, 95:5);  δH (CDCl3, 500 MHz) 0.82 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 2.63 (m, 1H),  
7.01 (s, 1H), 7.10 (dd, J = 8.7, 8.8 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.53 (dd, J = 5.4, 8.7 Hz, 2H), 7.58 (s, 1H), 
7.62 (d, J = 8.3 Hz, 2H); m/z = 311 [M++H]. 
Method D: Reduction with NaBH4 
To an ice-cooled solution of the corresponding aldehyde or ketone (1 eq) in methanol (5 mL / mmol) was added 
NaBH4 (2 eq). Then the resulting mixture was heated to reflux for 30 minutes. After cooling to ambient temperature, 
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the solvent was distilled off under reduced pressure. Then water (10 mL) was added, and the resulting mixture was 
extracted with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine, dried over MgSO4 
and evaporated under reduced pressure. Then the desired product was purified by chromatography on silica gel. 
Method E: CDI reaction in THF 
To a solution of the corresponding alcohol (1 eq) in THF (10 mL / mmol) was added CDI (2 eq). Then the 
solution was heated to reflux at 70 ℃ for 4 days. After cooling to ambient temperature, the mixture was poured into 
water and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were washed with brine, dried over 
MgSO4 and evaporated under reduced pressure. Then the desired product was purified by chromatography on silica 
gel. 
Imidazole-1-carboxylic acid 1-(3',4'-difluoro-biphenyl-4-yl)-propyl ester (3). Synthesized according to 
Method E  using 2a (0.10 g, 0.42 mmol) and CDI (0.14 g, 0.83 mmol); yield: 0.09 g (37 %); white solid: mp 49-50 
°C; Rf = 0.29 (DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 1.01 (t, J = 14.8 Hz, 3H, CH3), 2.01-2.21 (q, J = 14.8, 
15.5 Hz, 2H, CH2), 5.88 (t, J = 15.5 Hz, 1H, CH), 7.15 (s, 1H), 7.22-7.29 (m, 2H), 7.32-7.34 (m, 1H), 7.36-7.38 (m, 
1H), 7.46 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 8.35 (s, 1H, Im-2H); MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 1-(2',4'-difluoro-biphenyl-4-yl)-propyl ester (5). Synthesized according to 
Method E  using 4a (0.21 g, 0.85 mmol) and CDI (0.28 g, 1.69 mmol); yield: 0.11 g (43 %); white solid: mp 76-77 
°C; Rf = 0.29 (DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 1.01 (t, J = 14.8 Hz, 3H, CH3), 2.03-2.19 (q, J = 14.8, 
15.5 Hz, 2H, CH2), 5.87 (t, J = 15.5 Hz, 1H, CH), 6.89-7.06 (m, 2H), 7.09-7.11 (m, 1H),  7.36-7.40 (m, 1H), 7.45-
7.48 (m, 3H), 7.52 (dd, J = 1.6, 1.9 Hz, 2H), 8.24 (s, 1H, Im-2H); MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 1-(2',5'-difluoro-biphenyl-4-yl)-propyl ester (8). Synthesized according to 
Method E  using 7a (0.12 g, 0.46 mmol) and CDI (0.15 g, 0.93 mmol); yield: 0.10 g (69 %); white solid: mp 77-78 
°C; Rf = 0.29 (DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 1.01 (t, J = 14.8 Hz, 3H, CH3), 2.02-2.20 (q, J = 14.8, 
15.5 Hz, 2H, CH2), 5.88 (t, J = 15.5 Hz, 1H, CH), 6.93-7.02 (m, 1H), 7.09-7.15 (m, 3H),  7.46-7.48 (m, 3H), 7.52-
7.55 (m, 2H), 8.23 (s, 1H, Im-2H); MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 1-(3,4'-difluoro-biphenyl-4-yl)-propyl ester (10). Synthesized according to 
Method E  using 7a (0.19 g, 0.75 mmol) and CDI (0.24 g, 1.50 mmol); yield: 0.10 g (69 %); colorless oil; Rf = 0.29 
(DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 1.01 (t, J = 14.8 Hz, 3H, CH3), 2.02-2.20 (q, J = 14.8, 15.5 Hz, 2H, 
CH2), 5.88 (t, J = 15.5 Hz, 1H, CH), 6.14 (s, 1H), 7.26-7.28 (m, 2H),  7.19-7.25 (m, 1H),  7.34-7.35 (m, 1H), 7.42-
7.48 (m, 2H), 7.50-7.53 (m, 2H), 8.22 (s, 1H, Im-2H); MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 3,4'-difluoro-biphenyl-4-ylmethyl ester (12). Synthesized according to Method 
E  using 11a (0.26 g, 1.20 mmol) and CDI (0.39 g, 2.40 mmol); yield: 0.09 g (28 %); white solid: mp 220-221°C; Rf 
= 0.29 (DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 5.33 (s, 2H, CH2), 7.07 (s, 1H), 7.12-7.15 (t, J = 17.4 Hz, 2H), 
7.20 (s, 1H), 7.29 (d, J = 11.0 Hz, 1H), 7.33-7.35 (m, 2H), 7.49-7.52 (m, 2H), 8.32 (s, 1H, Im-2H); MS (ESI): m/z = 
315 [M++H]. 
(4'-Fluorobiphenyl-4-yl)(1H-imidazol-5-yl)methanol (23). A solution of 23a (0.10 g, 0.20 mmol) in MeOH (5 
mL) was stirred with pyridinium hydrochloride (35 mg, 0.30 mmol) at 60° C for 4 hours. Then the reaction was 
quenched by adding saturated NaHCO3 aq (10 mL), 20 mL EtOAC were added and the phases separated. The water 
phase was extracted 3 times with EtOAc (20 mL), the combined organic extracts were dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by flash chromatography; yield: 0.05 g (91 %); 
colorless oil; Rf = 0.19 (EtOAc / MeOH, 95:5); δH (CDCl3 + d6-DMSO, 500 MHz) 2.99 (s, 1H), 5.84 (s, 1H), 6.87 
(s, 2H), 7.02-7.06 (m, 2H), 7.41-7.47 (m, 6H); m/z = 269 [M++H]. 
5-(1-(4'-Fluorobiphenyl-4-yl)-2-methylprop-1-enyl)-1H-imidazole (25). Compound 24 (0.10 mg, 0.32 mol) 
was refluxed in an i-PrOH solution of HCl (10 mL, 3N) for 2 hours. Afterwards, the resulting solution was 
concentrated under reduced pressure and washed 3 times with Et2O. No further purification was necessary; yield: 
0.07 g (77 %); colorless oil; Rf = 0.29 (EtOAc / MeOH, 95:5); δH (CDCl3, 500 MHz) 1.80 (s, 3H), 2.05 (s, 3H), 6.98 
(s, 1H), 7.12 (dd, J = 8.7, 8.8 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 7.54 (dd, J = 5.3, 8.7 Hz, 
2H), 7.63 (s, 1H); m/z = 293 [M++H]. 
5-(1-(4'-Fluorobiphenyl-4-yl)-2-methylpropyl)-1H-imidazole (26). Pearlman's catalyst (5 mg, 7.12 µmol) and 
25 (50 mg, 0.17 mmol) were prepared in EtOH and THF (2:1, 5mL) under H2 atmosphere. The mixture was left 
stirring for 3 hours, then the catalyst was filtered off 3 times and the solution concentrated under reduced pressure. 
The obtained solid was washed 3 times with Et2O. No further purification was necessary; yield: 50 mg (100%); 
yield: 0.07 g (77 %); colorless oil; Rf = 0.29 (EtOAc / MeOH, 95:5);δH (CDCl3, 500 MHz) 0.86 (d, J = 6.6 Hz, 3H, 
CH3), 0.99 (d, J = 6.6 Hz, 3H, CH3), 3.60 (d, J = 9.4 Hz, 1H, CH), 6.90 (s, 1H), 7.09 (dd, J = 8.7, 8.8 Hz, 2H), 7.36 
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(d, J = 8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 7.51 (dd, J = 5.4, 8.7 Hz, 2H), 7.55 (s, 1H); m/z = 295 [M++H]. 
Docking studies 
Ligands. All molecular modeling studies were performed on Intel(R) P4 CPU 3.00GHz running Linux 
CentOS5.2. The structures of the inhibitors were built with SYBYL 8 (Sybyl, Tripos Inc., St. Louis, Missouri, USA) 
and energy-minimized in MMFF94s force-field 25 as implemented in Sybyl.  
Docking. Molecular docking calculations were performed for various inhibitors of Table 1. Since the GOLD 
docking program allows flexible docking of the compounds, no conformational search was employed to the ligand 
structures. GOLD gave the best poses by a genetic algorithm (GA) search strategy. Ligands were docked in 50 
independent genetic algorithm (GA) runs for each of the three GOLD-docking runs. Heme iron was chosen as 
active-site origin, while the radius was set equal to 19 Å. The automatic active-site detection was switched on. A 
distance constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-hybridised nitrogen of the 
imidazole and the iron was set. Additionally, the goldscore.p450_pdb parameters were used and some of the 
GOLDSCORE parameters were modified to improve the weight of hydrophobic interaction and of the coordination 
between iron and nitrogen. The genetic algorithm default parameters were set as suggested by the GOLD authors. 
On the other hand, the annealing parameters of fitness function were set at 3.5 Å for hydrogen bonding and 6.5 Å for 
Van der Waals interactions.  
Analogously as for GOLD, no conformational search was performed prior docking with FlexX, since the ligands 
are docked according to an incremental fragment docking strategy. Standard parameter settings were used except for 
“base placement”, which was set on single interaction scan, and “chemical parameters”, in which the maximum 
overlap volume of the subroutine “clash handling” was set at a range of 3.6 Å. Additionally the “FlexX-Pharm” 
module was employed, setting the heme iron as an octahedrical coordinating metal pharmacophore point. The very 
same iron atom was chosen as active site center and amino acid residues within 16 Å were considered as part of the 
active site. 
All the poses resulting from three docking runs (GOLD-chemscore, GOLD-GOLDSCORE and FlexX) for each 
compound were clustered with ACIAP 19 and the representative structure of each significant cluster was selected. 
After the docking simulations and cluster analysis were performed, the quality of the docked representative poses 
was evaluated based on visual inspection of the putative binding modes of the ligands. The latter were further 
evaluated by means of MOE (www.chemcmpd.com) with its LigX module and evaluated by means of the various 
scoring functions (GOLDSCORE, CHEMSCORE and the empirical FlexX Score). 
MEP. For each docked compound geometry optimization was performed employing the B3LYP hybrid 
functional 20 in combination with a 6-311++G (d,p) basis set using the package Gaussian03 (Gaussian, Inc., 
Pittsburgh, PA, 2003). The molecular electrostatic potential (MEP) maps were plotted using GaussView, version 
3.0, the 3D molecular graphics package of Gaussian. These electrostatic potential surfaces were generated by 
mapping 6-311++G** electrostatic potentials onto surfaces of molecular electron density (isovalue = 0.004 
electron/Å) and the ESP values on the surface color-coded ranging from -6 (red) to +12 (blue) kcal/mol.  
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3.1.5. Conclusions and Outlook
In the first chapter of this doctoral thesis a good quality homology-based CYP17 model was built 
using, despite the low sequence identity (28.9%), a human CYP crystal structure as template
(CYP2C9). This model shows a good geometrical profile and was used for docking studies 
performed with the softwares GOLD and FlexX. The model presents a polar SRS-1 and a 
hydrophobic SRS-5, which influences strongly the ligand binding (Fig. 26).
Figure 26. Active site of CYP17 rendered with FG-segment in cyan, BC-loop in red, I-helix orange, C-terminal 
loop violet and the β-domain in green. The SRS-1 (polar) and SRS-5 (hydrophobic) are circled in magenta and 
yellow, respectively, with the most important residues rendered as sticks and labelled.
Three different binding modes (Fig. 27) could be identified for the different classes of CYP17 
inhibitors and the substrate pregnenolone (paper I-VII). In BM1 the biaryl skeleton is oriented 
parallel to the I-helix pointing the A-ring next to the polar area SRS-1. In BM2 the biaryl 
skeleton crosses the I-helix at the height of the I-helix kink (Gly301-Val304), pointing the A-ring 
toward the backbone of the F-helix. Only structures with a small substituent (R=H, F) in para 
position of the A-ring can occupy this pose. BM3 resembles the preferred substrate binding 
mode (paper III), with the hydrophobic skeleton placed parallel to the heme-plane, pointing the 
A-ring toward the BC-loop.
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Figure 27. Docking complex of CYP17 with the three main binding modes (BM1-BM3), observed for different 
classes of CYP17 inhibitors. FG-segment and BC-loop are colored like in Fig. 26 in cyan and red, respectively,
whereas I-helix and hydrophobic β1-4 sheet are shown in green and orange, respectively.
Despite a spurious correlation between the IC50 values and the scoring functions of the docking 
software (data not shown), the model could explain the differences in the binding affinities of 
our in-house CYP17 inhibitors (papers I-VII) for the various binding modes. These binding 
modes were partially substantiated by the MEP investigations performed for some classes of 
inhibitors, confirming the quality of the homology model and the trustworthiness of the docking 
modes. Thus the CYP17 homology model became a precious tool in designing new inhibitors,
especially for the choice of substituents on the A-ring and on the methylene-linker characterizing 
all bi-aryl based inhibitors.
In order to validate the binding modes identified for the classes of CYP17 inhibitors presented in 
papers I-VII a series of molecular dynamic studies should be performed. Moreover, snapshots of 
the stable parts of the dynamics should be used for free energy and, especially, free binding 
affinity calculations by means of MM-PBSA methods. This combination should lead to a reliable 
interpretation of the binding of the already developed inhibitor classes and furthermore fasten the 
rational drug design of a new generation of CYP17 inhibitors with an increased molecular 
complexity and a better potency and selectivity profile.
MD simulations conducted on a CYP17-pregnenolone complex should also be performed to gain 
insights in the binding mode of the substrate and in the entrance and egress pathways followed 
by pregnenolone approaching to the heme and the active site. These studies should envisage 
important contributions to the kinetic mechanism occurring for CYP17, especially when 
combined to QMMM studies focused on the electron transfer and especially the hydroxylation 
and subsequent lyase reaction.
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3.2 Estrogen-dependent breast cancer (BC) -     
selective CYP19 inhibition
3.2.1. Molecular docking of non-steroidal aromatase 
inhibitors
In order to rationalize the different aromatase inhibitory potencies observed for a series of 
imidazolylmethylenebenzophenones in paper VII representative compounds were docked in the 
homology model (PDB entry 1TQA) built by Favia et al. 126 by means of GOLD software. In 
particular, we investigated the insertion of the imidazolylmethylene-group and the presence of 
additional substituents on the benzophenone core.
The two most potent compounds 1b and 1d (paper VII) shared a similar binding mode, showing 
a good complexation between the sp2-hybridized nitrogen of the imidazoles and the heme iron,
and being involved in a H-bond network with Asp309 and Ser478 (Fig. 28). Moreover, the 
docking poses of these highly flexible AI envisaged the capability of aromatase, in the form of 
the homology model 1tqa, to host sterically more hindered substituents, like the additional 4’-
Phe group (1d), close to the C-terminal loop, stabilized by π-π stackings with His475 and 
His480.
Figure 28. Docking complexes between aromatase and 1a (yellow), 1b (orange), 1d (cyan), and 3 (green). The 
heme iron atom at the bottom of the picture is depicted as a violet ball. Critical residues of the aromatase active site 
are rendered as sticks.
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3.2.2. Articles published in CYP19 project – paper VIII 
 
Imidazolylmethylbenzophenones: a novel class of potent and selective aromatase inhibitors 
 
Silvia Gobbi, Andrea Cavalli, Matthias Negri, Katarzyna E. Schewe, Federica Belluti, Lorna Piazzi, Rolf W. 
Hartmann, Maurizio Recanatini, Alessandra Bisi 
This article is protected by copyrights of ‘Journal of Medicinal Chemistry’ 
J. Med. Chem. 2007, 50, 3420–3422. 
Abstract 
Suppression of tumor and plasma estrogen levels by inhibition of aromatase is one of the most effective treatments 
for postmenopausal breast cancer patients. Starting from an easy-synthetically accessible benzophenone scaffold, a 
new class of potent and selective aromatase inhibitors was synthesized. Compounds 1b and 1d proved to be among 
the most potent inhibitors described so far. 
Estrogens are known to be implicated in breast cancer occurrence and development, and different strategies have 
been devised in order to control or block the progression of hormone-dependent breast cancer. The action of 
estrogens on their receptor can be blocked by the use of selective estrogen receptor modulators (SERMs), like 
tamoxifen. These compounds have been widely used as first line therapy in post-menopausal women with advanced 
breast cancer, but they are known to possess proestrogenic effects particularly on the endometrium and vascular 
system, and this partial agonism has been associated with possible development of tumors.1 A different approach 
comes from the reduction of hormone levels by inhibition of cytochrome P450 aromatase (CYP19),2 a key enzyme 
involved in the synthesis of estrogens, promoting the aromatization of the A ring of androgen precursors. Third 
generation aromatase inhibitors (AIs), such as letrozole, anastrozole and exemestane, are now considered a valid 
alternative to tamoxifene as first line treatment of advanced breast cancer.3 The search for potent and selective 
aromatase inhibitors still remains an attractive subject, since some interesting compounds have recently been 
developed by different groups working in the field.4-7 In addition, in a previous paper, we described some 
xanthenone-based molecules as potent inhibitors.8 
In this letter, we report a new class of potent and selective inhibitors of aromatase, characterized by a rather 
flexible imidazolylmethylbenzophenone scaffold, which offers the advantage of a large synthetic accessibility. 
Moreover, these compounds could allow us to establish whether the conformationally constrained scaffold of the 
previously synthesized series of molecules is an essential element for optimal interaction with the enzyme and to 
determine the best positioning on this scaffold of the imidazole nitrogen that coordinates the iron atom of the heme 
group. To this aim, the position of the imidazole ring on the benzophenone moiety was varied, substituents were 
introduced on the phenyl ring carrying the imidazole, since the same pattern of substitution was also present in the 
previous series, and an additional benzene was placed on the other phenyl ring in order to explore the spatial 
requirements of that part of the molecule. The structures of the new compounds are reported in Chart 1. 
Chart 1. Structures of the studied compounds 
O
CH2 N N
O
R
CH2 N N
R1
1a-d, 2-5 1e   
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The synthesis was performed, according to Scheme 1, via Friedel-Craft acylation of benzene or biphenyl with 
the appropriately substituted benzoyl chloride to give 6a-d, 7, 9 and 10, followed by bromination of the methyl 
group with NBS and subsequent substitution with imidazole to provide compounds 1a-d and 2-4. 2-methyl-5-
nitrobenzoic acid 8, which was not commercially available, was prepared via nitration of o-toluic acid. For the 
synthesis of compound 5, 2-methyl-5-nitrobenzophenone 9 was reduced with H2 and Pd/CaCO3 to give 2-methyl-5-
aminobenzophenone 11 and the amino group was substituted by a bromine atom to give 12 via the formation of the 
diazonium salt followed by addition of CuBr. This intermediate was then reacted as reported above to provide the 
final compound. 
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Scheme 1. Syntheses of the new compounds. Reagents and conditions: i) SOCl2, reflux then AlCl3 or 
trifluoromethansulfonic acid, benzene or biphenyl, rt ii) NBS, benzoyl peroxide, CCl4, reflux; iii) imidazole, 
CH3CN, N2, reflux; iv) KNO3, H2SO4, 0 °C; v) THF, H2, Pd/CaCO3, rt; vi) HBr, NaNO2, 0 °C, then hot CuBr 
solution, rt. 
The new compounds were tested for inhibition of aromatase using human placental microsomes incubated with 
1ß[3H]androstenedione and measuring the tritiated water formed during the aromatisation of the substrate, as 
previously described.9 The inhibitory activity of the compounds towards 17β-hydroxylase/17,20-lyase (CYP17), 
another cytochrome P450 involved in the synthesis of androgens, was also assessed in order to evaluate their 
selectivity towards related enzymes. For the CYP17 inhibition tests E.coli cells overexpressing human CYP17 and 
P450 reductase were used.10 Another benzophenone derivative (1e),11 previously reported in the literature as part of 
a large series of azole compounds tested for inhibition of aromatase, was also included in the evaluation and tested 
in our assays. 
The results reported in Table 1 showed that all tested compounds were highly selective toward aromatase with 
respect to liase and some of them exhibited activity in the low nanomolar range. Interestingly, despite an increase in 
conformational flexibility, this series of molecules turned out to be more potent than the conformationally 
constrained series of compounds previously reported.8 It can promptly be observed that the position of the imidazole 
side chain is of crucial importance for the activity, since moving it from position 2 (compound 1a) to 3 (1b) on the 
benzophenone nucleus led to a hundred-fold increase in potency. Compound 1e, in which the imidazolylmethyl 
chain is in position 4, whose previously reported IC50 value was 10 nM,11 proved to be significantly less active when 
tested in our assay (IC50 = 252 nM), showing activity comparable to the ortho-derivative 1a. The introduction of a 
nitro group in both 1b and 1a, leading to compounds 2 and 3 respectively, was of no significant influence for the 
most active one 1b, but highly beneficial for 1a, since it increased its potency of more than one log unit. Looking at 
this result in view of the possible binding mode of these molecules at the enzyme active site (see below) and 
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assuming that the coordination of the heme iron by the imidazole moiety would be the primary interaction, it could 
be reasoned that, while the ketone in compound 1b could be located at the optimal distance from the imidazole 
moiety in order to properly interact via H-bond with the enzyme, this is not possible for 1a. If this is the case, the 
nitro group is only critical for compound 3, as its position relative to the imidazole could be the appropriate one in 
order to give the molecule the possibility to establish a correct H-bond interaction with the enzyme. 
Table 1. Biological activities of the new compounds towards CYP19 and CYP17. 
compound R R1 
CH2imid 
position 
CYP19a 
IC50 nMc 
CYP17b 
% inhib. at 2.5 
μM 
1a - - 2 560 - 
1b - - 3 7.3 - 
1c Ph - 2 260 24 
1d Ph - 3 5.3 NT 
1e - - 4 252 NT 
2 - 6-NO2 3 31 - 
3 - 5-NO2 2 25.9 - 
4 Ph 5-NO2 2 17.7 17 
5 - 5-Br 2 400 15 
Fadrozole    52 - 
aSubstrate 1β[3H]androstenedione 500 nM; bSubstrate progesterone 25 μM. cThe given values are mean values of at least three 
experiments. The deviations were within ± 5%. NT=not tested. “-“=no activity detected. 
A further evidence to support this hypothesis came from the introduction on the structure of 1a of a bromine 
atom which, unlike the nitro group, is devoid of H-bond potential, leading to compound 5: the potency did not 
improve by the introduction of this substituent. Activity seemed to be slightly influenced by the presence of an 
additional phenyl ring in position 4’. For compounds 1a, 1b, and 3 the introduction of this additional substituent 
(compounds 1c, 1d and 4 respectively) led to an increase in potency which, though small, still showed that a bulky 
group in that position could be beneficial. In particular, compound 1d proved to be among the most potent inhibitors 
synthesized so far (IC50 = 5.3 nM). 
To further investigate the SAR of the present series of derivatives and to additionally validate the previously 
postulated ‘H-bonding hypothesis’,8 docking experiments were also performed, using the recently developed 
homology-built aromatase model (PDB code 1TQA).12 In Figure 1, the putative binding modes of compounds 1a 
(yellow), 1b (orange), 1d (cyan), and 3 (green) as outcome of docking simulations and cluster analysis13,14 are 
reported. Docking simulations were carried out constraining ligands to properly coordinate the heme iron atom, 
while leaving the rest of the molecules free to move (see Supporting Information). It clearly arose that the meta (1b) 
and the ortho (1a) derivatives interacted with the target in a quite different way. In details, the carbonyl oxygen atom 
of 1b was positioned at ~ 3-4 Å from the carboxyl group of Asp309 of the I-helix and ~ 5-6 Å from the hydroxyl 
group of Ser478 of the C-terminal loop. Both residues could reasonably interact by means of H-bond with 1b 
carbonyl group, thus accounting for the higher activity of this compound relative to 1a, in which the same moiety is 
not properly oriented to establish similar interactions. A comment is required on Asp309 that in this study was 
treated as ionized. While in this form it obviously cannot interact by means of H-bond, it is widely accepted that 
during the aromatization Asp309 can be protonated, and therefore able to favorably interact with our compound.15  
Concerning Ser478, both ligand-16,17 and target-based18-20 computational studies point to this residue as a 
fundamental amino acid for the interaction with nonsteroidal aromatase inhibitors belonging to different classes. 
Also mutagenesis experiments show that this residue is one of the amino acids located in the aromatase active site 
and involved in the interaction with ligands.21 The proposed binding mode (Figure 1) well confirmed the difference 
in potency between the meta- (1b, IC50 = 7.3 nM) and the ortho-derivative (1a, IC50 = 560 nM). 
~ 172 ~
Figure 1. Docking complexes between aromatase and 1a (yellow), 1b (orange), 1d (cyan), and 3 (green) as outcome 
of docking simulations carried out with GOLD and cluster analysis performed with AClAP. The heme iron atom at 
the bottom of the picture is depicted as a violet ball. Moreover, some aromatase active site amino acids are also 
explicitly indicated.
In Figure 1, the putative binding mode of 3, carrying a NO2 group in para position with respect to the 
methylimidazole chain, is also reported. Docking simulations clearly pointed out the possibility for this additional 
group to establish H-bond interactions with Ser478, thus accounting for the significantly increased potency (IC50 =
25.9 nM) with respect to the parent compound 1a. Furthermore, to investigate the effects of the introduction of 
bulky substituents on the benzophenone scaffold, docking simulations were also performed with 1d, namely the 
meta derivative with an additional phenyl ring in position 4’. A pose representative of a statistically populated 
cluster is reported in Figure 1. This binding mode showed that aromatase can accommodate sterically hindered 
ligands in this region of its active site, as 1d proved to be the most potent aromatase inhibitor that we reported so far, 
with an IC50 value of 5.3 nM.
In conclusion, a new class of highly potent and selective aromatase inhibitors was synthesized, which combine 
remarkable activity (in the low nanomolar range) with higher accessibility via straightforward synthetic procedures 
when compared to the conformationally constrained xanthone-derivatives.8 Compound 1d turned out to be our most 
potent aromatase inhibitor, comparable to currently marketed drugs. Docking simulations in combination with 
cluster analysis were also carried out, providing a fairly good explanation for the binding mode of the present series 
of new inhibitors at the aromatase active site.
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3.2.3. Conclusions and Outlook 
The combination of docking simulations and ligand cluster analysis performed in paper VIII 
provided a fairly good explanation for the binding mode of the present series of new inhibitors at 
the aromatase active site. It represented a valid starting point for further drug design studies, 
especially focused on the position of the nitro group and the insertion of the 
methyleneimidazolyl group. First compounds were obtained in ongoing drug design showing 
aromatase inhibition values close to the best values reported so far in literature (data not shown; 
soon to be puplished). 
Recently the crystal structure of aromatase was solved (PDB entry 3eqm), co-crystallized with 
androstenedione. In order to validate the identified docking poses for the imidazolylmethylene-
benzophenones obtained with the aromatase homology model 1tqa, new docking studies using 
the aromatase x-ray 3eqm should be performed. Furthermore, molecular dynamic studies 
conducted on the docked poses of compounds 1b and 1d (paper VIII) would be advisable, with 
the aim to investigate induced-fit motions which could improve further drug design.  
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3.3 Estrogen-dependent endometriosis –         
selective 17β-HSD1 inhibition 
3.3.1. X-ray Analysis  
In paper XI a structural analysis was performed of the 18 crystal structures of 17β-HSD1 (Table 
1) available in the PDB Brookhaven database.129 Superimposition of all crystal structures gave a 
mean backbone root mean-square distance (RMSD) value of ca. 0.55 Å (ca. 1.5 Å if all atoms 
are considered). This highlights the rigid functional three-dimensional structure typical of the 
short-chain dehydrogenases/reductases (SDR), consisting of a rigid β-α-β fold with a core of 
parallel β-strands fanning across the center and α-helixes draped on the outside.85a Moreover, the 
tertiary structure resulted in a rigid cofactor binding site (COF) at the N-terminus, comprising 
Rossman fold and GXXXGXG motif (where G is glycine and X is any other amino acid), plus 
the YXXXK (where Y is Tyr155 and K is Lys159) sequence that participates in catalysis, and a 
structurally variable substrate binding site (SUB) at the C-terminus. 
Table 1. Summary of the 17 (18) crystal structures of 17β-HSD.  
PDB-ID 
Amino 
acid 
number 
Complex 
liganda 
Res. 
(Å) Chain 
backbone cluster of 
entry-loopb mutants 
active site volume (Å3) of ternary 
complex calculated with castP 
(loop helix residues) COF SUB 
1A27 285 EST, NAP 1.90 A cl2 -- 
1855 
1232 / 66% 623 / 34% 
1BHS 284 -- 2.20 A 
cl1 
-- 2214 
A191-E194 
1DHT 284 DHT 2.24 A 
cl1 
-- 1944 
M193-V196 
1EQU 284 EQI, NAP 3.00 A/B 
cl2 (_A) / cl1 (_B) 
-- 
2403 
M193-V196 1606 / 67% 797 / 33% 
1FDS 282 EST 1.70 A -- -- 2323 
1FDT_A 285 EST, NAP 2.20 A cl2 -- 
2000 
1255  / 63% 745 / 37% 
1FDT_B 285 EST, NAP 2.20 A cl2 -- 
2259 
1583 / 70% 676 / 30% 
1FDU 281 EST, NAP 2.70 A-D 
cl2 (_C) 
H221L C: 1645 
M193-K195 
1FDV 285 NAD 3.10 A-D 
cl2 (_A, _C) 
H221L A: 1892 / C: 2051 
E194-V196 
1FDW 279 EST 2.70 A -- H221Q 2301 
1I5R 285 HYC 1.60 A cl3 -- 2755 
1IOL 284 EST 2.30 A 
cl1 
-- 2296 
A191-V196 
1JTV 278 TES 1.54 A -- -- 1855 
1QYV 276 NAP 1.81 A -- -- 2906 
1QYW 276 5SD, AP2 1.63 A -- -- 1858 
1QYX 277 ASD, AP2 1.89 A -- -- 1888 
3DHE 284 AND 2.30 A 
cl1 
-- 2152 
M193-V196 
3DEY 277 DHT 1.70 A - --  
Detailed informations are given regarding a complexed ligands (EST estradiol, NAP nicotinamide-adenine-dinucleotide phosphate 
(NADP+), DHT dihydrotestosterone, EQI equilin, NAD nicotinamide-adenine-dinucleotide (NAD+), HYC O5’-[9-(3,17β-dihydroxy-
1,3,5(10)-estratrien-16β-yl)-nonanoyl] adenosine, TES testosterone, 5SD 5α-androstane-3,17-dione, ASD 4-androstene-3,17-dione, AP2 2'-
monophosoadenosine 5'-diphosphoribose, AND  3β-hydroxy-5-androstene-17-one), number of chains,  b βFαG’-loop backbone clusters (cl1 
loop close to the αG’-helix, cl2 loop placed in front of the nicotinamide moiety of the cofactor, cl3 loop shifted towards the cofactor), 
mutants and active site volumes calculated with castP.130 
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The only highly flexible part is the βFαG' loop, strongly modulating shape and volume of the 
active site (including both COF and SUB), and the C-terminal helix. It delimits the SUB and is 
probably involved in entrance and exit mechanisms of small molecules as well as in the 
enzymatic catalysis.
Several different conformations of the long, flexible βFαG' loop were identified, with the loop 
occurring either as a disordered coil or presenting a turn-helix-turn motif. Moreover, high b-
factor values characterize the loop residues and in seven crystal structures the loop is not fully 
resolved. The multiplicity of conformations suggests various enzyme substates for 17β-HSD1, 
subjected to fast dynamic motions and secondary structure rearrangements with direct 
implication of the loop residues Thr190-Leu197 in the catalytic cycle.
Then, only the eleven full-length crystal structures of 17β-HSD1 were superimposed. Clustering
according to the backbone RMSD (ca. 3 Ǻ) of the five loop residues Phe192-Val196 neglected 
active site volume changes and its output was limited to ascribe the presence of gates in the three 
identified clusters cl1, cl2 and cl3 (Fig. 29; representative structures: 1IOL, 1A27 and 1I5R, 
respectively). 
Figure 29. Representative structures of the three βFαG’-loop conformations cl1 (yellow, PDB entry 1iol), cl2
(magenta, 1a27) and cl3 (blue, 1i5r), clustered according to the backbone RMSD of the five residues Phe192-
Val196. Moreover, αG’-helix (green) and C-terminal helix (cyan) are rendered in cartoon, NADPH and E2 in sticks 
and the rest of the enzyme (active site) as electrostatic surface.
Thus, clustering according to the all-atom RMSD (ca. 6 Å) of the same loop residues led to the 
identification of five clusters, with Phe192 and Met193 showing the largest influence on shape 
and volume variations. Phe192, in particular, emerged as an important marker for the 
conformational variations, since its side chain presents the largest RMSD deviation (ca. 10 Å)
and it rotates for about 200 degrees around the loop axis (Fig. 30). The two extremes in the 
orientation of the side chain of Phe192 corresponded to the major changes of the active site 
volumes of all wild type enzyme (E)-NADPH-estradiol (E2) complexes, where the ratio volume 
SUB/volume COF changes from 30:70 of 1fdtB to 37:63 of 1fdtA (Table 1).
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Figure 30. Different orientations of Phe192 for the 5 clusters obtained by all-atom RMSD classification of the five 
loop residues (rendered in sticks, color-coded blue-violet) and for the 17 intermediate positions (rendered in lines, 
magenta) obtained by simulating the transition from 1fdtA to 1fdtB, the two extremes in the Phe192 rotation, using 
the Yale Morph Server.131
3.3.2. Rapid equilibrium random bi-bi kinetic cycle –               
a hypothesis.
The kinetic mechanism for 17β-HSD1 is not fully clarified, although, it had been reported in 
literature to follow a rapid equilibrium random bi-bi mechanism.132a This is a peculiarity of 17β-
HSD1, like the long βFαG’-loop, with respect to the other HSD family members, which follow a
sequential ordered bi-bi kinetic mechanism.87, 132b
Inspired by a recent work of Cooper et al.,133 which elucidated the complete kinetic mechanism 
for the rat liver 3α-HSD taking into account the different enzyme crystal structures, in paper XI
enzyme conformations were assigned to each of the five steps of which the random bi-bi kinetic 
mechanism consists (Fig. 31). Furthermore, the kinetic cycle was hypothesized and the specific 
role played by the flexible loop was elucidated for each reaction step (Fig. 32).
Supported by X-ray analysis and biochemical and thermodynamic data,84, 132b, 134 NADPH was 
assumed to enter and bind first, inducing a conformational rearrangement of the βFαG’-loop.
The hypothesized random bi-bi kinetic cycle was validated through a set of molecular dynamic 
(MD) simulations performed on apoform (2 MDs), binary (E-NADPH; 3MDs) and ternary 
complexes (E-NADPH-E1; 3 MDs). The eight MD simulations were designed based on four 
crystal structures (1fdtA, 1i5r, 1fdtB and 1bhs), in order to cover the conformational ensemble of 
the flexible βFαG’-loop. In fact, the enzyme was investigated in its opened-state (1fdtA) -
characterized by a fused COF and SUB and by Phe192 turned outwards, in a semi-opened 
(occluded) state (1i5r) - with the loop shifted towards the COF and Phe192 more buried than in 
1fdtA, and in its closed-state (1fdtB) - which mimics the ternary complex at the catalytic 
moment and presents a closed SUB and Phe192 pointing inwards perpendicular to the catalytic 
Tyr155.
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Figure 31. Random bi-bi kinetic mechanism of the catalytic cycle of 17β-HSD1 (in red the herein proposed path). 
To each of the five steps one or more crystal structures were assigned. Side chains of the βFαG’-loop residues 
Phe192, Met193, Glu194 and Lys195 are rendered as sticks and the orientation of the loop (blue circle) with respect 
to the αG’-helix (gray triangle and rendered as cartoon) is represented. Arrows 1-3 indicate the entrance and egress 
gates.
Figure 32. Schematic representation of the catalytic cycle, with detailed informations about the role of the loop in
the various steps.
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The different final complexes obtained from these eight dynamic simulations substantiated the 
importance of the presence of a ligand in either the SUB (E1) or the COF (NADPH) in order to 
stabilize the enzyme. Occupying one or both binding pockets influenced the motions of the 
flexible loop and induced concerted conformational changes of αG-helix and C-terminal helix. 
Moreover, the MDs of the ternary complexes, especially the one performed using the closed 
(1fdtB) and the occluded (1i5r) enzyme substates, highlighted the importance of the residues 
Ser142/Tyr155 and His221/Glu282, involved in the hydrogen bond network anchoring E1 in the 
SUB and in the hydride transfer (Fig. 33).
Figure 33. Overlay of the representative clusters of complex E(1fdtB)-NADPH-E1 (initial position - yellow, stable 
segment of MD – blue, final complex after 17 ns of MD – red).
Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) methods,135 in combination 
with normal mode analysis, were exploited to calculate the absolute free energies (ΔG) and free 
binding energies (ΔΔGbind) of the complexes, leading to the determination of the most probable
conformations to which E1 and NADPH bind in the 5 steps of the catalytic cycle. Furthermore, 
these methods validated the binding mode of E1 at the catalytic moment and supported the 
closed substate of the enzyme as the one occurring at the catalytic moment. Additionally, 
insights into the high adaptability of the loop at the different steps were ensured, in particular 
with regard to its importance in stabilizing the cofactor and substrate. Mutagenesis experiments 
for selected loop residues would give a final proof to our findings.
3.3.3. Validating the binding mode of bis(hydroxyphenyl)-
arenes: docking and MDs 
Starting point in the investigation of the binding mode of a series of bis(hydroxyphenyl)-arenes 
were docking simulations performed on a closed state crystal structure of 17β-HSD1 (1fdtB).136
These inhibitors were based on a (m-hydroxyphenyl)-X-(p-hydroxyphenyl) core, with X being a 
heterocycle (chart 1). From these studies resulted that the inhibitors bind into the SUB, 
mimicking the substrate, and forming hydrogen bonds with Ser142/Tyr155 and His221/Glu282. 
However, no correlation between the inhibitory potency of the compounds and the scoring 
functions could be found. It became also not clear why the different central heterocycles led to 
different inhibitions.
~ 182 ~
Chart 1. Structures and inhibitory activity of two non-steroidal 17β-HSD1 inhibitors, compound 1 and 6, of the 
series of the bis(hydroxyphenyl)-arenes, as well as of the substrate estrone (E1) and the product estradiol (E2).
Based on the crystal structure analysis (see 3.3.1.) an ensemble of 3D-structures of the enzyme 
was identified and used for new docking studies (paper IX-X). These resulted again in a
steroidal, but mostly in an alternative binding mode for the class of bis(hydroxyphenyl)-arenes.
The latter mode (Fig. 34) was found only for crystal structures with space below the cofactor (i.e. 
1fdtA), presenting the inhibitor bound with the m-hydroxyphenyl-X moiety to the phosphor-
nicotinamide moiety of NADPH. Thus, a synergistic interaction with the cofactor could be 
observed instead of a competition between inhibitor and NADPH for the COF. The inhibitor was
flanked on its sides by Tyr155 and the flexible loop, while its p-hydroxyphenyl ring occupied the 
SUB.
Figure 34. Docking poses of compound 6 and estrone (rosa) in the closed (left, PDB entry 1fdtB, yellow) and in the 
opened state of the enzyme (right, PDB entry 1fdtA, blue), leading to the steroidal (cyan, left) and the alternative 
binding mode (green, right), respectively. 
In order to validate the identified binding modes, four MD simulations were performed on
ternary complexes with compound 1 (chart 1; 1 shows the same binding mode as 6 in Fig 34), a
very potent representative of the bis(hydroxyphenyl)-arenes (50 nM IC50). Two MDs were 
conducted with 1 in the alternative binding mode, respectively for the open (1fdtA) and the semi-
open (1i5r) enzyme forms, while the other two MDs for the close state (1fdtB) of 17β-HSD1, 
with compound 1 in the steroidal binding mode. Interestingly the first two dynamic simulations 
ended with compound 1 close to its starting position (Fig. 35a), maintaining the hydrogen bond 
between its m-OH group and the phosphate close to the nicotinamide ring and the π-π stacking 
with the nicotinamide moiety. Moreover, a clear adaptation of the enzyme to the inhibitor could 
be observed and free energies values (ΔG and ΔΔGbind) in good agreement with the inhibitory 
potency (i.e. ΔG of -8.44 and -29.84 kcal/mol for 1fdtA and 1i5r, respectively) could be 
calculated with MM-PBSA-methods.
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On the contrary, for the two MD simulations with compound 1 placed in the SUB, the stable part 
of the simulation resulted with the inhibitor pushed away from its starting pose, ending either 
perpendicular to the estradiol plane or lying completely out of the SUB (Fig. 35b). These 
observations, bad ΔG values (-1.53 and +3.13 kcal/mol) and the long MD runs necessary for 
complex stability in terms of RMSD, led to consider the steroidal binding mode as a minor one 
for this class of inhibitors, more likely as a transition step on the egress pathway.
Figure 35. Analysis of the MD simulations performed on the four E-NADPH-compound 1 complexes. a.) Overlay 
of initial (violet) and final poses of compound 1 in the alternative binding mode (yellow - 1fdtA (D1), blue – 1i5r 
(D2)). b.) Overlay in the steroid binding mode (1fdtB), with the final poses of compound 1 rendered as sticks 
(yellow/orange D3a and magenta D3b; starting conformations of amino acids are colored blue).
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3.3.4. Validating the binding mode of bis(hydroxyphenyl)-
arenes: “semi-QMAR”
Since docking studies could not elucidate the reason for the different inhibitory activities 
observed among the bis(hydroxyphenyl)-arene series due to the presence of different central 
heterorings, a ligand-based approach was followed in paper IX. Quantum chemical 
investigations were performed on a set of representative compounds by means of Gaussian03 
software 137 and the molecular electrostatic potentials were plotted on the electron densities of the 
five compounds with GaussView 3.0.138 For a better comparison the MEP maps were divided 
into three different regions, each corresponding to one aromatic ring of the compounds.
Trying to establish a semi-quantitative MEP-activity relationship (“semi-QMAR”), optimal ESP 
ranges for area I, II and III for high inhibition activity were identified: for region I ESP from -1.7
to -1.2*10-2, for region II -1.6 to -0.9*10-2 and for region III -1.2 to -0.5*10-2 Hartree. Similarly, 
the optimal Δ values of ESP for each region were determined: 0.5, 0.7 and 0.7 Hartree, 
respectively. The shift of a certain ESP distribution range on the scale or the change of the Δ 
value results in a decrease of inhibitory activity (Fig 36).
Figure 36. (A) Structure and 17β-HSD1 inhibitory activity of compounds 1-5 ordered by increasing activity; (B)
MEP maps, dorsal and ventral view; (C1) ESP distribution range (Hartree; *10-2); (C2) mean value of distribution 
range (Hartree, *10-2); (C3) ∆ of ESP; (D) “semi-QMAR”. MEP surfaces were plotted with GaussView 3.0.
The high importance of the location of the heteroatoms on the central aromatic ring on the MEP 
maps was well demonstrated with the two 1,3-thiazoles 1 and 4 (Fig. 36) , which only differ by 
the position of the nitrogen in the thiazole moiety. The change of the position of the nitrogen in 
the thiazole ring has a decisive influence on the electronic distribution in each area, as the IC50
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values of 1 and 4 demonstrated (50 nM vs 1000 nM, respectively). Furthermore, a 
complementarity between the MEP of nicotinamide ring of the cofactor and the m-
hydroxyphenyl ring (region I) of these compounds was observed, suggesting π-π stackings
between cofactor and inhibitor (Fig. 37).
Figure 37. Differences in the MEP maps of compounds 1 and 4 in region I (m-hydroxyphenyl ring) and III (p-
hydroxyphenyl ring) and the complementarity to the nicotinamide moiety of NADPH. MEP are color-coded in a 
range of 2.5 (red) to -15 kcal/mol (blue).
In order to verify complementarity of the MEPs and the electrostatic nature of the binding, a set 
of 5 ternary complexes formed by the catalytic residues (Asn114, Ser142, Tyr155 and Lys159),
NADPH and compounds 1 to 5 (Fig. 36), respectively, was created and one binary complex 
catalytic residues-NADPH.
For compound 1 the MEP maps for binary and ternary complex had been calculated (Fig.36a).
Comparing their MEP maps, changes in the color scale for the area corresponding to the 
nicotinamide ring could be observed. They varied from red in the binary complex, standing for a 
negative ESP and a reactive area, to green/yellow in the ternary complex, indicating a neutral, 
less reactive area. Thus, compound 1 seemed to neutralize the electrostatic potential distribution 
of the nicotinamide ring (Fig. 38a) as a consequence of the electron rearrangement occurring
after the π-π interaction between ligand and nicotinamide moiety. This ab initio approach 
resulted in an overall good correlation with the biological data (Fig. 38b), explicated by a 
correlation factor r of 0.92. However, this correlation is depleted of part of its statistical 
significance due to the reduced number of data points considered.
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Figure 38. a) Differences of the electrostatic potential distribution for binary and ternary complex, enzyme-
NADPH-1 and enzyme-NADPH, respectively, and b) correlation between the pIC50 values of compounds 1-5 and 
the energy difference between the two complexes (ΔE).
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3.3.5. Articles published in 17β-HSD1 project – paper IX-XI 
3.3.5.1. Paper IX. 
 
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) 
substituted azoles, thiophenes, benzenes and aza-benzenes as potent and selective non-
steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) 
 
Emmanuel Bey, Sandrine Marchais-Oberwinkler, Ruth Werth, Matthias Negri, Yaseen A. Al-Soud, Patricia 
Kruchten, Alexander Oster, Martin Frotscher, Barbara Birk and Rolf W. Hartmann 
This article is protected by copyrights of ‘Journal of Medicinal Chemistry.’ 
J. Med. Chem.. 2008, 51, 6725-6739 
Abstract 
17β-Estradiol (E2), the most potent female sex hormone, stimulates the growth of mammary tumours and 
endometriosis via activation of the estrogen receptor α (ERα). 17β-Hydroxysteroid dehydrogenase type 1 (17β-
HSD1), which is responsible for the catalytic reduction of the weakly active estrogen estrone (E1) into E2, is 
therefore discussed as a novel drug target. Recently, we have discovered a 2,5-bis(hydroxyphenyl) oxazole to be a 
potent inhibitor of 17β-HSD1. In this paper, further structural optimizations were performed: 39 bis(hydroxyphenyl) 
azoles, thiophenes, benzenes and aza-benzenes were synthesized and their biological properties were evaluated. The 
most promising compounds of this study show enhanced IC50 values in the low nanomolar range, a high selectivity 
toward 17β-HSD2, a low binding affinity to ERα, a good metabolic stability in rat liver microsomes and a 
reasonable pharmacokinetic profile after peroral application. Calculation of the molecular electrostatic potentials 
revealed a correlation between 17β-HSD1 inhibition and the electron density distribution. 
Introduction 
Estrogens, the most potent one being 17β-estradiol (E2), act as female sex hormones and are predominantly 
produced before menopause by the ovaries. They unfold their activity by stimulation of the estrogen receptors (ERs) 
α and β. Besides their physiological effects, they are, however, also involved in the initiation and progression of 
estrogen-dependent diseases like mammary tumor1 and endometriosis.2 Presently, the three main endocrine therapies 
for the treatment of breast cancer are:3,4 inhibition of estrogen biosynthesis by aromatase inhibitors or GnRH 
agonists or antagonists and interference with the estrogen action at the receptor level by selective estrogen receptor 
modulators (SERMs) or pure antiestrogens.5 Besides specific disadvantages of each therapeutic concept, all of these 
strategies have in common that they reduce estrogen levels systemically leading to the corresponding side effects. 
A softer approach could be inhibition of the enzyme involved in the last step of the E2 biosynthesis: 17β-
hydroxysteroid dehydrogenase (17β-HSD) which is able to convert estrone (E1) into E2. There are three subtypes 
(1, 7 and 12) described, the most important of which is 17β-HSD1. The primary function of 17β-HSD7 and 17β-
HSD12 is supposed to be in the cholesterol synthesis6 and in the regulation of the lipid biosynthesis,7 respectively. 
Moreover, Day et al.8 showed that 17β-HSD12, although highly expressed in breast cancer cell lines, is inefficient in 
E2 formation.  
17β-HSD1 is NAD(P)H-dependent and intracellularly converts the weak estrogen E1 into the strong estrogen 
E2. As it is often over-expressed in breast cancer cells9-12 and endometriosis,13 17β-HSD1 is regarded as a promising 
novel target for the treatment of estrogen-dependent diseases. Appropriate inhibitors of this enzyme should exhibit 
less side effects compared to the current treatments as they should selectively reduce the concentration of active E2 
in the diseased tissues.14 
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As a biological counterpart, 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the deactivation of 
E2 into E1. It protects the cell from excessively high concentrations of active estrogens15 and should therefore not be 
affected by inhibitors of 17β-HSD1. In addition 17β-HSD1 inhibitors should not show affinity to the ERs to avoid 
intrinsic estrogenic effects. 
17β-HSD1 was crystallized with different steroidal ligands.16-24 The published X-ray structures provide insight 
into the active site, a narrow hydrophobic tunnel with polar contacts at each end. On one side His221/Glu282 are 
located, on the other Ser142/Tyr155 (two members of the catalytic tetrad).25 Surprisingly, close to the hydrophobic 
B/C region of the steroid two polar amino acids, Tyr218 and Ser222, can be found which do not interact with E2.  
Several steroidal and non-steroidal inhibitors of 17β-HSD1 have been described. The first report on steroidal 
compounds by Penning26 was as early as 1996. In the last few years several articles of other groups followed.27 
Regarding the non-steroidal inhibitors, only four compound classes have been described so far, all of them very 
recently: thienopyrimidinones A,28,29 biphenyl ethanones B,30 and from our group 6-(hydroxyphenyl) naphthols 
C31,32 and bis(hydroxyphenyl) azoles D33 (Chart 1).  
Chart 1: Non-steroidal 17β-HSD1 inhibitors 
 
The most promising compound in the latter series was the 2,5-bis(hydroxyphenyl) oxazole E with an IC50 of 310 
nM and a selectivity factor of 56 against 17β-HSD2. In general it was discovered that the inhibitory activity of these 
compounds depends on the existence of hydroxy rather than methoxy groups on the phenyl substituents and on the 
OH substitution pattern, meta-para and para-meta substituted compounds being more active than para-para 
substituted ones. Furthermore it became apparent that inhibition also depends on the nature of the heterocycle. 
Hydrogen bond donor functions turned out to be inappropriate, whereas in several compounds H-bond acceptor 
atoms were favorable. This finding led to the hypothesis that active compounds are capable of interacting with 
Tyr218 or Ser222 via H-bonds.33 
In order to enhance activity and selectivity and to get a better insight into the interaction of these compounds 
with the active site of 17β-HSD1, the significance of the OH groups will be further evaluated and other five-
membered heterocycles, especially sulfur containing ones, will be investigated. Furthermore it will be evaluated, 
whether six-membered rings are also appropriate to connect the two hydroxyphenyl moieties. 
In the following we describe the synthesis of 39 bis(hydroxyphenyl) azoles, thiophenes, benzenes and aza-
benzenes (Chart 2) as well as the determination of their 17β-HSD1 inhibitory activity and selectivity toward 17β-
HSD2, ERα and ERβ. Furthermore, cell permeability using CaCo-2 cells, metabolic stability in rat liver 
microsomes, inhibition of the most important hepatic CYP enzymes and pharmacokinetic properties in the rat of 
selected compounds are determined. For a better understanding of the SARs molecular electrostatic potentials 
(MEPs) were calculated. 
Chart 2: Title compounds 
 
S N
N
R'
R
O
R''
R'''
O
N
OH
OH
OH
O
R''
n
 
R
R'
HO
X
YV
W
Y
X
W
R
D
OH
HO
OH
Z
A B C
E
 ~ 189 ~ 
 
Chemistry 
Starting from the commercially available dibrominated heterocycles and methoxylated benzene boronic acids, 
compounds 1 to 8, 19 to 28, 31 and 32 were prepared via two successive Suzuki reactions34 followed by a 
demethylation step using borontribromide35 as reagent. The Suzuki cross-coupling was carried out using three 
different methods. Intermediates 1ii to 8ii, 18ii to 27ii and 1i to 8i were prepared following Method A (aq. sodium 
carbonate, toluene, Pd(PPh3)4, reflux, 4 h) and compounds 31ii, 32ii, 19i to 28i, 31i and 32i were synthesized using 
Method B (sodium carbonate, THF/water (1:1), Pd(PPh3)4, reflux, 20 h). During the first cross coupling reaction 
leading to the mono(methoxyphenyl) substituted derivatives 1ii-8ii, 18ii-27ii, 31ii, 32ii no disubstituted compounds 
were obtained indicating that the (methoxyphenyl)bromo azoles and thiophenes are less reactive than their dibromo 
aryl precursors. The bromo intermediate 18ii was treated with n-BuLi in anhydrous THF and subsequently 
hydrolyzed with water to yield the mono methoxylated thiophene 18i. The methoxy groups of 1i to 8i, 18i to 28i, 31i 
and 32i were cleaved with boron tribromide (Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h, Scheme 1). 
Scheme 1a: Synthesis of compounds 1 to 8, 18 to 28, 31 and 32 
 
aReagents and conditions: a. for compounds 1ii to 8ii, 18ii to 27ii and 1i to 8i: Method A: aq. Na2CO3, toluene, Pd(PPh3)4, reflux, 4 h; 
for compounds 31ii, 31i, 32ii, 32i and 19i to 28i: Method B: Na2CO3, THF/water (1:1), Pd(PPh3)4, reflux, 20 h; b. 1. n-BuLi, THF dry, -
78 °C, 15 min, 2. water; c. Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h. 
The 1,3,4-thiadiazole 9 was prepared in a three step synthetic pathway based on the method described by 
Gierczyk and Zalas.36 The 3-methoxybenzoyl chloride was treated with hydrazine monohydrate to give the resulting 
3-methoxy-N’-(3-methoxybenzoyl)benzohydrazide, which was cyclized into the corresponding thiadiazole using 
Lawesson reagent in DME under microwave assisted conditions. In a last step, the methoxy substituents were 
cleaved with boron tribromide (Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h). 
The synthesis of the 1,2,4-thiadiazoles 10 and 11 is shown in Scheme 2. The commercially available 4-
methoxybenzonitrile and 3-hydroxybenzonitrile were converted into the thioamide intermediates 10ii and 11i, 
respectively, using aqueous ammonium sulfide under microwave assisted reaction.37 These thioamides were 
submitted to strong acidic conditions resulting in a mixture of the thiadiazoles 10i and 11 which were separated by 
column chromatography. The bis(methoxyphenyl) compound could not be isolated. Compound 10i was 
demethylated with boron tribromide (Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h, Scheme 2). 
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Scheme 2a: Synthesis of compounds 10 and 11 
 
aReagents and conditions: a. conc. HCl, 38 °C, 8 h; b. Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h. 
The synthesis of compounds 12 to 15 is presented in Scheme 3. The dimethoxylated-1,2,4-triazoles 12i to 15i 
were synthesized by reaction of the N-acylimidates38 12ii to 15ii with methylhydrazine (Method D: MeNHNH2, 
CH2Cl2, 30-40 °C, 4 h). The methoxy groups of compounds 12i to 15i were cleaved with borontrifluoride dimethyl 
sulfide complex35 (Method F: BF3 ּ◌SMe2, CH2Cl2, rt, 20 h, Scheme 3). 
Scheme 3a: Synthesis of compounds 12 to 15 
 
aReagents and conditions: a. CH2Cl2, NEt3, 30-40 °C, 6 h; b. Method D: MeNHNH2, CH2Cl2, 30-40 °C, 4 h; c. Method F: BF3 ּ◌SMe2, 
CH2Cl2, rt, 20 h. 
Compound 16 was prepared according to Sharpless39 using 3-azidophenol and 3-hydroxyphenyl acetylene. 
Compounds 17, 29, 30, 37 and 38 were obtained, under microwave assisted conditions, in a one pot synthesis 
(Method C: DME/EtOH/water (1:1:1), Cs2CO3, Pd(PPh3)4, MW (150 W, 150 °C, 15 bar, 15 min)) with benzene 
boronic acid for 17, hydroxylated benzene boronic acid for 29, 30, 37 and 38 and the corresponding dibrominated 
heterocycle.  
The synthesis of compounds 33 to 36 is depicted in Scheme 4. Starting from the commercially available 
dibrominated benzene and methoxylated benzene boronic acids, compounds 33 to 36 were prepared via two 
successive Suzuki reactions following the conditions of Method A. In the first reaction only the mono substituted 
compounds 33ii and 35ii were obtained due to the fact that the (methoxyphenyl)bromobenzenes are less reactive 
than the dibromobenzenes. Consequently, longer reaction times were required for the second cross coupling reaction 
(20 versus 4 h). The methoxy groups of compounds 33i-36i were cleaved using boron tribromide (Method E: BBr3, 
CH2Cl2, -78 °C to rt, 18 h, Scheme 4). 
1,2,4,5-Tetrazine 39 was synthesized following the procedure described by Guither et al.40 Briefly, 3-
hydroxybenzonitrile was refluxed with hydrazine monohydrate and sulfur. Treatment with sodium nitrite led to 
cyclization resulting in 3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol 39. 
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Scheme 4a: Synthesis of compounds 33 to 36 
 
aReagents and conditions: a. Method A: Na2CO3 10 % in water, toluene, Pd(PPh3)4, reflux, 4 h; b. Method E: BBr3, CH2Cl2, -78 °C to rt, 
18 h. 
Biological results 
Activity: inhibition of human 17β-HSD1 
Placental enzyme was partially purified following a described procedure.41 Tritiated E1 was incubated with 17β-
HSD1, cofactor and inhibitor. The amount of labelled E2 formed was quantified by HPLC. Compounds showing 
less than 10 % inhibition at 1 μM were considered to be inactive.  
The inhibition values of the test compounds are shown in Table 1. It becomes apparent that eleven compounds 
are more active than the previously described oxazole E33 (IC50= 310 nM). 
All methoxy compounds (data not shown) and para-para dihydroxylated derivatives are inactive except 
phenylene 34 which is a weak inhibitor (IC50> 1000 nM). The shift of one hydroxy substituent from the para- into 
the meta- position leads to highly active compounds except for thiazoles 1, 7 (IC50 values> 1000 nM) and 5 (IC50> 
5000 nM) which have a weak inhibitory activity and triazoles 12 and 14 which are inactive. Moving the second OH 
substituent also in meta position (meta-meta derivatives) results in potent compounds except for triazole 16 which is 
a weak inhibitor (IC50> 5000 nM) and selenophene 30 and triazole 15 which are inactive. 
The exchange of the para-OH group of the highly active thiophene 22 (IC50= 69 nM) with hydrogen reduces 
activity (compound 19, IC50= 342 nM). More dramatically, the replacement of the meta-OH function of compound 
22 with hydrogen results in the inactive compound 20. Similarly, the exchange of the meta-hydroxyphenyl moiety as 
well as the two hydroxy groups of 22 with hydrogens leads to the inactive compounds 17 and 18. This exemplifies 
the importance of the existence of two OH substituents and their positions at the phenyl moieties with at least one 
being in the meta position. 
The synthesized thiazoles 1 to 8 show lower activities than the thiophene analogues 17 to 28 except compound 3 
(IC50= 50 nM) which exhibits similar inhibition as 22 (IC50= 69 nM) and 27 (IC50= 77 nM). The introduction of a 
second nitrogen (compounds 9 to 11) in the heterocyclic scaffold of these potent inhibitors does not strongly reduce 
activity (9, IC50= 336 nM; 11, IC50= 169 nM). For meta-meta disubstituted compounds the introduction of nitrogen 
in compound 4 decreases activity slightly (9, IC50= 336 vs 243 nM), whereas introduction in compound 8 increases 
activity (11, IC50= 169 vs 455 nM), as it is observed for the meta-para disubstituted compound 7 (10, IC50= 413 vs 
>1000 nM).  
Moving the hydroxyphenyl moiety of the highly active thiophene 22 (IC50= 69 nM) from position 5 to the 3 
position decreases activity dramatically (32, IC50> 1000 nM). Exchange of the sulfur atom of the potent thiophene 
23 (IC50= 173 nM) with selenium results in the inactive compound 30. 
In case of the six-membered rings, benzene and some of its aza-analogues were investigated. The 1,3-
bis(hydroxyphenyl) substituted phenylenes were not active, whereas the 1,4-disubstituted compounds showed some 
activity, the most active benzene compound being the meta-meta derivative 35 (IC50= 173 nM). The introduction of 
one or more nitrogens into the central benzene ring of 35 (compounds 37 to 39) results in an increase (pyridine 37, 
IC50= 101 nM), no change (tetrazine 39, IC50= 201 nM) and a decrease of inhibitory activity (pyrazine 38, IC50= 
1000 nM). 
Furthermore in Table 1, the angles between the two phenyl moieties are presented as a structural parameter. No 
correlation to the activities of the corresponding compounds can be observed. 
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Selectivity: inhibition of human 17β-HSD2 and affinities for ERα and ER β  
Since 17β -HSD2 catalyzes the inactivation of E2 to E1, inhibitory activity toward this enzyme must be avoided. 
The 17β -HSD2 inhibition was determined using an assay similar to the 17β -HSD1 test. Placental microsomes were 
incubated with tritiated E2 in the presence of NAD+ and inhibitor. Separation and quantification of labelled product 
(E1) was performed by HPLC using radio detection. A selection of the most potent 17β-HSD1 inhibitors was tested 
for inhibition of 17β-HSD2. IC50 values and selectivity factors (IC50 HSD2 / IC50 HSD1) are presented in Table 1. 
It is striking that most meta-meta bis(hydroxyphenyl) substituted inhibitors present only poor selectivity except 
for compounds 37 and 39 which show high selectivity factors of 34 and 25, respectively. The meta-para/para-meta 
disubstituted inhibitors mostly show higher selectivity with compound 3 exhibiting the highest selectivity factor of 
80. 
A further prerequisite for 17β -HSD1 inhibitors to be used as potential drugs is that these compounds do not 
show affinity for ERα and ERβ, or only a marginal one, since binding to these receptors could counteract the 
therapeutic efficacy. The binding affinities of selected compounds were determined using recombinant human 
protein in a competition assay applying [3H]-E2 and hydroxyapatite (Table 2). All tested compounds show very 
marginal or marginal affinity to the ERs. 
Table 1: Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 1-39, O-O distances and phenyl-het-phenyl 
angles 
 
compound Het R1 R2 d(Å)a αb 
IC50 (nM)c selectivity 
factorf 17β-
HSD1d 
17β-
HSD2e 
1 
 
4-OH 3-OH 11.9< d< 12.7 
153 
>1000 nt  
2 4-OH 4-OH 13.6 ni nt  
3 3-OH 4-OH 11.9< d< 12.7 50 4004 80 
4 3-OH 3-OH 10.1< d< 11.7 243 2500 10 
         
5 
 
4-OH 3-OH 10.5< d< 12.0 
130 
>5000 nt  
6 4-OH 4-OH 12.5 ni nt  
7 3-OH 4-OH 10.5< d< 12.0 >1000 nt  
8 3-OH 3-OH 9.0< d< 11.2 455 2220 5 
         
9 
 
3-OH 3-OH 9.9< d< 11.5 157 336 nt  
         
10 
 
3-OH 4-OH 9.7< d< 11.9 
128 
413 2194 5 
11 3-OH 3-OH 8.5< d< 11.2 169 602 3 
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Table 1 continued 
compound Het R1 R2 d(Å)a αb 
IC50 (nM)c selectivity 
factorf 17β-
HSD1d 
17β-
HSD2e 
12 
 
4-OH 3-OH 10.2< d< 11.9 
145 
ni nt  
13 4-OH 4-OH 12.4 ni nt  
14 3-OH 4-OH 10.2< d< 11.9 ni nt  
15 3-OH 3-OH 8.7< d< 11.4 ni nt  
16 
 
3-OH 3-OH 8.7< d< 11.2 147 >5000 nt  
17 
 
H H 
 
147 
ni nt  
18   ni nt  
19 3-OH H 342 2337 7 
20 4-OH H ni nt  
21 4-OH 4-OH 13.5 ni nt  
22 3-OH 4-OH 11.8< d< 12.8 69 1953 28 
23 3-OH 3-OH 9.8< d< 11.8 173 745 4 
24 
 
3-OH H  
136 
>5000 nt  
25 4-OH 3-OH 10.4< d< 12.0 151 1690 11 
26 4-OH 4-OH 12.3 ni nt  
27 3-OH 4-OH 10.4< d< 12.0 77 1271 16 
28 3-OH 3-OH 8.5< d< 11.4 185 559 3 
29 
 
4-OH 4-OH 13.8 
162 
ni nt  
30 3-OH 3-OH 10.4< d< 11.3 ni nt  
31 
 
4-OH 4-OH 8.1 
69 
ni nt  
32 3-OH 4-OH 6.2< d< 8.9 >1000 nt  
33 
 
4-OH 3-OH 9.3< d< 12.1 
120 
>1000 nt  
34 4-OH 4-OH 12.3 >1000 nt  
35 
 
3-OH 3-OH 11.4< d< 12.4 
180 
173 2259 13 
36 3-OH 4-OH 13.1 471 4509 9 
37 
 
3-OH 3-OH 11.6< d< 12.3 180 101 3399 34 
38 
 
3-OH 3-OH 11.4< d< 12.2 180 1000 5502 5 
39 
 
3-OH 3-OH 11.3< d< 12.2 180 201 5102 25 
aO-O distance between the hydroxy substituents, for E2 d= 11.0 Å; bAngle between the two phenyl moieties in °; cMean values of three 
determinations, standard deviation less than 12 % except 3: 18 % for 17β-HSD1; dHuman placental, cytosolic fraction, substrate [3H]-E1 + 
E1 [500 nM], cofactor NADH [500 μM]; eHuman placental, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 
μM], fIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not tested. 
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Table 2: Binding affinities for the human estrogen receptors α and β of selected compounds 
compound 
RBAa (%) 
ERαb ERβb 
3 <0.01 0.01< RBA< 0.1 
22 0.1< RBA< 1 1.5 
25 0.01< RBA< 0.1 0.1< RBA< 1 
27 0.01< RBA< 0.1 0.1< RBA< 1 
35 <0.001 0.01< RBA< 0.1 
37 0.01< RBA< 0.1 <0.01 
aRBA (relative binding affinity), E2: 100 %, mean values of three determinations, standard deviations less than 10 %; bHuman 
recombinant protein, incubation with 10 nM [3H]-E2 and inhibitor for 1 h. 
Further biological evaluation  
The intrinsic estrogenic activity of a representative compound of each class was determined using the ER-
positive mammary tumor T-47D cell line. No agonistic, i.e. no stimulatory effect was observed after application of 
the inhibitors even at a concentration 1000 fold higher than E2 (data not shown). 
A selection of active and selective compounds was investigated for permeation of CaCo-2 cells. These cells 
exhibit morphological and physiological properties of the human small intestine42 and are a generally accepted 
model for the prediction of peroral absorption. Depending on the Papp data obtained, compounds can be classified as 
low (Papp (·10-6 cm/sec) < 1), medium (1 < Papp < 10) or highly permeable (Papp > 10)). Thiazole 3 shows medium 
cell permeation while thiophenes 22, 25 and phenylene 35 exhibit high cell permeability (Table 3). 
Table 3: CaCo-2 cell permeation of highly active 17β-HSD1 inhibitors 
compound Papp(·10-6 cm/s)a,b classification 
3 7.8 medium 
22 22.0 high 
25 14.4 high 
35 12.5 high 
atenolol 0.1 low 
testosterone 9.4 medium 
ketoprofene 25.7 high 
aPermeability of reference compounds similar to the values described [atenolol,71 testosterone,67 ketoprofene72]; bPapp: apparent 
permeability coefficient, mean values of three determinations, standard deviations less than 10 %. 
A representative compound of the thiazole, thiophene and phenylene class (compounds 4, 25 and 35) was 
evaluated for their phase 1 metabolic stability using rat liver microsomes. Samples were taken at defined time points 
and the remaining percentage of parent compound was determined by LC-MS/MS. Half-life and intrinsic clearance 
were evaluated and compared to the two reference compounds diazepam and diphenhydramine (Table 4). All tested 
compounds show longer half lives than the antihistaminic drug diphenhydramine (values in the range between 12.6 
and 22.7 min vs 6.8 min). 
The same compounds (4, 25 and 35) were further investigated for inhibition of the six most important human 
hepatic enzymes: CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4. All compounds show very low inhibition of CYP1A2, 
2B6, 2C19 and 2D6 (IC50> 4 μM). In case of CYP2C9 and CYP3A4 (4: 2.1 and 0.8, 25: 0.8 and 1.9, 35: 1.9 and 2.1 
μM, respectively) inhibition was higher, but still clearly below the IC50 values of 17β-HSD1 inhibition. These 
results indicate a low risk of drug-drug interaction caused by CYP-inhibition. 
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Table 4: Half-lives and intrinsic clearances of compounds 4, 25 and 35 in rat liver microsomesa 
compound half-life (min) 
CLintb 
(µL /min 
/mg protein) 
4 12.6 367.2 
25 18.6 248.5 
35 22.7 203.4 
diazepamc 40.8 113.3 
diphenhydraminec 6.8 679.6 
a0.33 mg/mL protein, NADP+-regenerating system, [inhibitor]: 1 μM, incubation at 37 °C, samples taken at 0, 15, 30 and 60 min, 
determination of parent compound by MS; bCLint: intrinsic body clearance; cvalues of reference compounds similar to described values. 
The pharmacokinetic profiles of the most active and selective azole compound 3 and one of the six-membered ring 
compounds (39) were determined in rats after oral administration in a cassette. The most potent six-membered ring 
compound 37 was not chosen as it was unstable in buffer over 24 h. Each group consisted of 4 male rats and the 
compounds were administered in doses of 10 mg/kg. Plasma samples were collected over 24 h and plasma 
concentrations were determined by HPLC-MS/MS. The pharmacokinetic parameters are presented in Table 5. 
Maximal plasma concentration (Cmax) and AUC value are much higher for compound 39 compared to compound 3. 
Table 5: Pharmacokinetic parameters of compound 3 and 39 in male rats after oral application of 10 mg/kg 
parameters 
compound 
3 39 
Cmax obs (ng/mL)a 7.8 106.0 
Cz (ng/mL)b 6.6 54.0 
tmax obs (h)c 8.0 3.0 
tz (h)d 10.0 10.0 
t1/2z (h)e 1.5 1.2 
AUC0-tz (ng/mL)f 99.2 1204.0 
aCmax obs: maximal measured concentration; bCz: last analytical quantifiable concentration; ctmax obs: time to reach the maximum measured 
concentration; dtz: time of the last sample which has an analytically quantifiable concentration; et1/2z: half-life of the terminal slope of a 
concentration time curve; fAUC0-tz: area under the concentration time curve up to the time tz of the last sample. 
Computational Chemistry 
To obtain an insight which physicochemical parameter might influence biological activity, the charge density 
distribution was considered and the molecular electrostatic potentials (MEPs) of selected compounds were 
determined. The geometry of the compounds had been fully optimized in the gas phase at the B3LYP/6-311++G 
(d,p) level of density functional theory (DFT). MEPs were plotted for every compound on its electron density with 
GaussView 3.09. The electrostatic potential distribution of the charge density is presented by a color code ranging 
from –3.1 ·10-2 to 4.5 ·10-2 Hartree (Figures 1 and 2 and Supporting Information). For better comparison, the MEPs 
of different compounds were divided into 3 regions corresponding to each aromatic system. 
In Figure 1, the MEPS of five-membered heterocyclic compounds are arranged based on their increasing 
inhibitory potency. While the positions of the hydroxyphenyl moieties are fixed, the nature of the heterocycle is 
varied. It becomes apparent that the heterocycle influences the ESP distribution of the whole molecule. In order to 
rationalise these MEPs, the ESP distribution ranges (C1), the mean values of the distribution ranges (C2) and the Δ 
of ESP (C3) were analyzed: negative ESP values (red/orange/yellow) in region I and II and less negative to almost 
neutral ESP values (green/yellow) in region III are obviously an important factor for high inhibitory potency. Trying 
to establish a semi-quantitative MEP-activity relationship (“semi-QMAR”) optimal ESP ranges for areas I, II and III 
for potent inhibition were identified (hydrogens and the OH groups were not considered): for region I ESP from –
1.7 to –1.2 ·10-2, for region II –1.6 to –0.9 ·10-2 and for region III –1.2 to –0.5 ·10-2 Hartree. Similarly, the optimal ∆ 
values of ESP for each region were determined: 0.5, 0.7 and 0.7 Hartree, respectively. Both the shift of a certain 
ESP distribution range on the scale and the change of the ∆ value result in a decrease of inhibitory activity. The 
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combination of these two criteria is substantiated with +, – and 0 in Figure 1.D indicating favorable, unfavorable and 
neutral impact on activity.
Figure 1. (A) Structure and 17β-HSD1 inhibitory activity of F,33 E,33 and compounds 1, 3, 17 ordered by increasing 
activity; (B) MEP maps, dorsal and ventral view; (C1) ESP distribution range (Hartree; ·10-2); (C2) mean value of 
distribution range (Hartree, ·10-2); (C3) ∆ of ESP; (D) “semi-QMAR”. MEP surfaces were plotted with GaussView 
3.09.
Figure 2. (A) Structure and 17β-HSD1 inhibitory activity of compounds 29 and 31 to 33 ordered by increasing 
activity; (B) MEP maps, dorsal and ventral view; (C1) ESP distribution range (Hartree;·10-2); (C2) mean value of 
distribution range (Hartree,·10-2); (C3) ∆ of ESP; (D) “semi-QMAR”. MEP surfaces were plotted with GaussView 
3.09.
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Compound F33 exhibits a polarization between top and bottom sides of the molecule: the vertex-side (NH) has 
positive ESP values, while on the opposite side (N-C) negative to neutral values are predominant. This polarisation 
(∆= 7.2 ·10-2 Hartree) results in an inactive compound, indicating that the ESP of the central heterocycle is crucial 
for 17β-HSD1 inhibitory activity. 
A good example for the change in activity is well demonstrated by the ESP distribution in region III for thiazoles 1 
and 3 (Figure 1 C1 and C2). The dramatic loss of activity of compound 1 (IC50> 1000 nM) in comparison to 3 (IC50= 
50 nM) is due to a non optimal electron density distribution.  
The MEP maps of the six-membered ring compounds are depicted in Figure 2. A similar charge density 
distribution was observed except for the only planar compound of this series, tetrazine 33, which showed no 
polarization between top and bottom side of the molecule. It remains to be clarified whether this is the reason for the 
reasonable activity of compound 33.  
Discussion and conclusion 
The present paper shows that compound E from a previous study33 could be optimized. The most active and 
selective thiazole 3 shows an IC50 value of 50 nM and a selectivity factor of 80 (compound E, IC50= 310 nM, 
selectivity factor: 56). 
The biological results obtained confirm similar findings described in our previous article:33 the OH substitution 
pattern of our compounds is decisive for inhibitory activity. Compaison of the mono hydroxylated thiophenes 19 
and 20 (meta- and para-, respectively) shows that the meta-hydroxy group is crucial for activity. The inactivity of 
compound 18 indicates that the phenyl moiety of the meta-hydroxyphenyl thiophene 19 is also important for 
potency. The replacement of the meta-hydroxy group of 19 with hydrogen leading to the inactive compound 17 
demonstrates the importance of the hydrogen bond interaction for activity. 
As observed for the previously described bis(hydroxyphenyl) derivatives,33 the distance between the two 
oxygens obviously has to be close to the value observed for the substrate (d= 11 Å). The para-para disubstituted 
compounds show distances longer than 12.5 Å. They are all inactive. Concerning the meta-para and meta-meta 
disubstituted compounds, which have O-O distances between 8.5 and 12.8 Ǻ, medium to high inhibitory activities 
are observed for most compounds. They could be able to establish hydrogen bond interactions with His221/Glu282 
and Ser142/Tyr155. However, the inactivity of thiazoles 1, 5, 7 and triazoles 12 to 16, which are all meta-para and 
meta-meta disubstituted, indicates that this distance is not the only decisive criterion for activity. The heterocycle 
also influences the inhibitory potencies of the compounds.  
In the five-membered ring series, the potency of 1,2,3-triazoles described previously33 led us to further 
investigate this class of compounds. The inactivity of compounds 12 to 15 shows that either the nitrogen distribution 
in the ring or the methyl group are not tolerated by the enzyme. The replacement of the N-Me moiety of 14 with 
sulfur (compound 10) leading to a fairly potent compound indicates that S in this position has a positive influence. 
To further investigate the role of the nitrogen in the ring, thiazoles 1 to 8 and thiophenes 21 to 28, 31 and 32 were 
investigated. The fact that thiazole 3 and thiophene 22 exhibit almost identical potencies shows that the nitrogen 
does not contribute to binding, i.e. that there is obviously no hydrogen bond interaction.  
In this report, we could also show that six-membered rings are appropriate for the design of highly active 17β-
HSD1 inhibitors. Comparison of the almost equipotent phenylene 35, pyridine 37 and tetrazine 39 confirms the 
hypothesis that nitrogens are tolerated in the ring but do not contribute to a specific interaction. 
The role of the angle between the two hydroxyphenyl moieties was also investigated in order to find out whether 
there is a correlation between this parameter and the inhibitory potency. The broad range of angles calculated (128° 
for 11 to 180° for 37, two highly active compounds) could not be correlated with high or low inhibitory potency 
indicating that the enzyme presents some flexibility for ligand binding. Interestingly, for smaller angles between the 
two hydroxyphenyl groups, as in case of compounds 10 and 11 (N atom at the vertex), the meta-meta substitution 
results in a higher activity, while for larger angles, in presence of a sulfur atom at the vertex of the five-membered 
heterocycle (2,5-disubstituted thiazoles and 2,5-disubstituted thiophenes), the optimal substitution pattern is meta-
para/para-meta. This phenomenon will be further investigated. 
Our finding that there exists a correlation between the MEPs and the biological activities of the compounds 
(semi-QMAR) might be exploited for further structure optimization underlining the relevance of this descriptor for 
biological activity. Furthermore, the MEPs could be used to investigate how these inhibitors approach and bind to 
the enzyme as it is described for genistein and the estrogen receptor.43 
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Interestingly the exchange of a CH in the thiophene 22 by a N leading to the thiazole 3 increases selectivity 
toward 17β-HSD2 dramatically (IC50 17β-HSD2 / IC50 17β-HSD1, 28 vs 80). In general, the most potent compounds 
exhibit a really low affinity for the ERα and ERβ and show no stimulation of cell proliferation (agonistic effect) in 
the ER-positive T-47D cell line. It is worth mentioning that 3 in spite of its good CaCo-2 permeability shows a 
really low bioavailability compared to 39. Glucuronidation and/or sulfatation might be responsible for the low 
plasma levels of the parent compounds.  
In the present report, we described the synthesis of bis(hydroxyphenyl) azoles, thiophenes, benzenes, aza-
benzenes and the evaluation of their biological properties. The most promising compounds of this study, 3, 22 and 
39, show a high selectivity toward 17β-HSD2, a low binding affinity to the ERα, a high CaCo-2 permeability and a 
reasonable pharmacokinetic profile after peroral application. These new compounds should be useful tools to further 
investigate in vivo 17β-HSD1 as a target for the treatment of estrogen-dependent diseases. 
Experimental section 
Chemical methods 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, 
Lancaster, Roth, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 μm) coated with silica, preparative thin layer 
chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and reaction progress was 
monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel).  
Melting points were measured on a Mettler FP1 melting point apparatus and are uncorrected. 
IR spectra were recorded on a Bruker Vector 33 spectrometer (neat sample). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in δ (parts per million: ppm), by reference to the hydrogenated residues of deuteriated 
solvent as internal standard (CDCl3: δ = 7.24 ppm (1H NMR) and δ = 77 ppm (13C NMR), CD3OD: δ = 3.35 ppm 
(1H NMR) and δ = 49.3 ppm (13C NMR), CD3COCD3: δ = 2.05 ppm (1H NMR) and δ = 29.9 ppm (13C NMR), 
CD3SOCD3: δ = 2.50 ppm (1H NMR) and δ = 39.5 ppm (13C NMR). Signals are described as s, d, t, dd, m, dt for 
singlet, doublet, triplet, doublet of doublets, multiplet and doublet of triplets, respectively. All coupling constants (J) 
are given in hertz (Hz). 
Mass spectra (ESI) were recorded on a TSQ Quantum (Thermo/Fischer) instrument. Elemental analyses were 
performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University. 
5-Bromo-2-(4-methoxyphenyl)-1,3-thiazole (1ii),44 4-methoxythiobenzamide (10ii),45 3-bromo-2-(4-
methoxyphenyl)thiophene (31ii),46 3-bromo-4'-methoxybiphenyl (33ii),47 4'-bromo-3-methoxybiphenyl (35ii),48 2-
(4-methoxyphenyl)-5-(3-methoxyphenyl)-1,3-thiazole (1i),49 2,5-bis(4-methoxyphenyl)-1,3-thiazole (2i),50 2,4-
bis(4-methoxyphenyl)-1,3-thiazole (6i),35 3-hydroxythiobenzamide (11i),16 2,5-bis(4-methoxyphenyl)thiophene 
(21i),51 2,4-bis(4-methoxyphenyl)thiophene (26i),52 2,3-bis(4-methoxyphenyl)thiophene (31i),53 3,4''-dimethoxy-
1,1':3',1''-terphenyl (33i),54 4,4''-dimethoxy-1,1':3',1''-terphenyl (34i),54 4,4'-(1,3-thiazole-2,5-diyl)diphenol (2),55 
4,4'-(1,3-thiazole-2,4-diyl)diphenol (6),35 3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol (11),56 3,3'-(1H-1,2,3-triazole-
1,4-diyl)diphenol (16),57 2,5-diphenylthiophene (17),58 4,4'-thiene-2,5-diyldiphenol (21),51 4,4'-thiene-2,4-
diyldiphenol (26),55 1,1':3',1''-terphenyl-3,4''-diol (33),59 1,1':3',1''-terphenyl-4,4''-diol (34),60 1,1':4',1''-terphenyl-
3,3''-diol (35),59 1,1':4',1''-terphenyl-3,4''-diol (36),59 3,3'-pyrazine-2,5-diyldiphenol (38),61 3,3'-(1,2,4,5-tetrazine-
3,6-diyl)diphenol (39)40 were prepared following described procedures. 
General procedure for Suzuki coupling 
Method A: 
A mixture of arylbromide (1 eq), methoxybenzene boronic acid (1 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.005 eq) in an oxygen free toluene/water (1:1) solution was stirred at 100 
°C for 4 h under nitrogen. The reaction mixture was cooled to rt. The aqueous layer was extracted with ethyl acetate. 
The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated to 
dryness. The product was purified by CC. 
Method B: 
A mixture of arylbromide (1 eq), methoxybenzene boronic acid (1.2 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.005 eq) in an oxygen free tetrahydrofurane/water (1:1) solution was 
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stirred at 100 °C for 20 h under nitrogen. The reaction mixture was cooled to rt. The aqueous layer was extracted 
with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by CC. 
Method C: 
A mixture of aryl dibromide (1 eq), methoxybenzene boronic acid (2.4 eq), caesium carbonate (4 eq) and 
tetrakis(triphenylphosphine) palladium (0.001 eq) was suspended in an oxygen free DME/EtOH/water (1:1:1) 
solution. The reaction mixture was exposed to microwave irradiation (15 min, 150 W, 150 °C, 15 bar). After 
reaching rt, water was added and the aqueous layer was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered and concentrated to dryness. The product was 
purified by preparative TLC. 
Method D: General procedure for synthesis of 1,2,4-triazoles: 
A solution of acyl chloride (1 eq) in dichloromethane was added dropwise to a mixture of ethyl imino ester (1 
eq) and dry triethylamine (1 eq) in 20 mL dichloromethane and heated to 30-35 °C for 6 h. After cooling to rt, the 
mixture was poured into 3 % NaHCO3 solution (25 mL). The layers were separated and the organic layer was 
washed with water, dried over sodium sulfate and evaporated to dryness under reduced pressure. The resulting N-
acylimino esters 12ii to 15ii were heated to 30-35°C with methyl hydrazine (2 eq) in CH2Cl2 for 4 h. The solvent 
was removed under reduced pressure and the 1,2,4-triazoles 12i to 15i were crystallized from CH2Cl2/ Et2O. 
General procedure for ether cleavage 
Method E: 
To a solution of methoxybenzene derivative (1 eq) in dry dichloromethane at -78 °C (dry ice/acetone bath), 
boron tribromide in dichloromethane (1 M, 3 eq per methoxy function) was added dropwise. The reaction mixture 
was stirred for 20 h at rt under nitrogen. Water was added to quench the reaction, and the aqueous layer was 
extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, 
evaporated to dryness under reduced pressure and purified by preparative TLC. 
Method F:  
To a solution of bis(methoxyphenyl) derivative (1 eq) in dry dichloromethane, borontrifluoride dimethyl sulfide 
complex (75 eq) was added dropwise at rt. The reaction mixture was stirred for 20 h. Water was added to quench the 
reaction and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with 
brine, dried over sodium sulfate, evaporated to dryness under reduced pressure and purified by preparative TLC. 
3-[2-(4-Hydroxyphenyl)-1,3-thiazol-5-yl]phenol (1). The title compound was prepared by reaction of 5-(3-
methoxyphenyl)-2-(4-methoxyphenyl)-1,3-thiazole (1i) (40 mg, 0.13 mmol) and boron tribromide (0.81 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 77 % (28 
mg); MS (ESI): 270 (M+H)+; Anal. (C15H11NO2S) C, H, N. 
5-Bromo-2-(3-methoxyphenyl)-1,3-thiazole (3ii). The title compound was prepared by reaction of 2,5-
dibromo-1,3-thiazole (500 mg, 2.06 mmol), 3-methoxybenzeneboronic acid (376 mg, 2.47 mmol), sodium carbonate 
(437 mg, 4.12 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 10 μmol) according to method A. The 
product was purified by CC (dichloromethane/methanol 95:5); yield: 50 % (278 mg). 
2-(3-Methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (3i). The title compound was prepared by reaction of 
5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (3ii) (250 mg, 0.93 mmol), 4-methoxybenzeneboronic acid (170 mg, 
1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 58 % (160 mg). 
3-[5-(4-Hydroxyphenyl)-1,3-thiazol-2-yl]phenol (3). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (3i) (40 mg, 0.13 mmol) and boron tribromide (0.81 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 80 % (50 
mg); MS (ESI): 270 (M+H)+; Anal. (C15H11NO2S) C, H, N. 
2,5-Bis(3-methoxyphenyl)-1,3-thiazole (4i). The title compound was prepared by reaction of 5-bromo-2-(3-
methoxyphenyl)-1,3-thiazole (3ii) (250 mg, 0.93 mmol), 3-methoxybenzeneboronic acid (170 mg, 1.11 mmol), 
sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 μmol) according to 
method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 40 % (111 mg). 
3,3'-(1,3-Thiazole-2,5-diyl)diphenol (4). The title compound was prepared by reaction of 2,5-bis(3-
methoxyphenyl)-1,3-thiazole (4i) (100 mg, 0.36 mmol) and boron tribromide (2.02 mmol) according to method E. 
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The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 85 % (82 mg); MS (ESI): 270 
(M+H)+; Anal. (C15H11NO2S) C, H, N. 
4-Bromo-2-(4-methoxyphenyl)-1,3-thiazole (5ii). The title compound was prepared by reaction of 2,4-
dibromo-1,3-thiazole (500 mg, 2.06 mmol), 4-methoxybenzeneboronic acid (376 mg, 2.47 mmol), sodium carbonate 
(437 mg, 4.12 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 10 μmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 55 % (305 mg). 
2-(4-Methoxyphenyl)-4-(3-methoxyphenyl)-1,3-thiazole (5i). The title compound was prepared by reaction of 
4-bromo-2-(4-methoxyphenyl)-1,3-thiazole (5ii) (250 mg, 0.93 mmol), 3-methoxybenzeneboronic acid (170 mg, 
1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 52 % (143 mg). 
3-[2-(4-Hydroxyphenyl)-1,3-thiazol-4-yl]phenol (5). The title compound was prepared by reaction of 2-(4-
methoxyphenyl)-4-(3-methoxyphenyl)-1,3-thiazole (5i) (70 mg, 0.24 mmol) and boron tribromide (1.44 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 78 % (50 
mg); MS (ESI): 268 (M-H)-; Anal. (C15H11NO2S) C, H, N. 
4-Bromo-2-(3-methoxyphenyl)-1,3-thiazole (7ii). The title compound was prepared by reaction of 2,4-
dibromo-1,3-thiazole (500 mg, 2.06 mmol), 3-methoxybenzeneboronic acid (376 mg, 2.47 mmol), sodium carbonate 
(437 mg, 4.12 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 10 μmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 50 % (270 mg). 
2-(3-Methoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazole (7i). The title compound was prepared by reaction of 
4-bromo-2-(3-methoxyphenyl)-1,3-thiazole (7ii) (250 mg, 0.93 mmol), 4-methoxybenzeneboronic acid (170 mg, 
1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 79 % (218 mg). 
3-[4-(4-Hydroxyphenyl)-1,3-thiazol-2-yl]phenol (7). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazole (7i) (70 mg, 0.24 mmol) and boron tribromide (1.44 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 80 % (52 
mg); MS (ESI): 268 (M-H)-; Anal. (C15H11NO2S) C, H, N. 
2,4-Bis(3-methoxyphenyl)-1,3-thiazole (8i). The title compound was prepared by reaction of 4-bromo-2-(3-
methoxyphenyl)-1,3-thiazole (7ii) (250 mg, 0.93 mmol), 3-methoxybenzeneboronic acid (170 mg, 1.11 mmol), 
sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 μmol) according to 
method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 18 % (50 mg). 
3,3'-(1,3-Thiazol-2,4-diyl)diphenol (8). The title compound was prepared by reaction of 2,4-bis(3-
methoxyphenyl)-1,3-thiazole (8i) (70 mg, 0.24 mmol) and boron tribromide (1.44 mmol) according to method E. 
The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 78 % (50 mg); MS (ESI): 268 (M-
H)-; Anal. (C15H11NO2S) C, H, N. 
3,3’-(1,2,4-Thiadiazol-2,5-diyl)diphenol (9). A solution of 3-hydroxythiobenzamide (100 mg, 0.17 mmol, 2 eq) 
in DMSO (10 ml) was stirred for 5 h at rt with 3 ml concentrated chlorhydric acid. The crude mixture was poured 
into water and the resulting precipitate was filtered, washed with water and dried overnight in a desiccator; yield: 92 
% (41 mg); MS (ESI): 269 (M-H)-. Anal. (C14H10N2O2S) C, H, N. 
3-[3-(4-Methoxyphenyl)-1,2,4-thiadiazol-5-yl]phenol (10i). A solution of 4-methoxythiobenzamide (10ii) (318 
mg, 1.90 mmol, 1 eq) in DMSO was heated for 8 h at 38 °C with 3-hydroxythiobenzamide (11i) (290 mg, 1.90 
mmol, 1 eq) and concentrated hydrochloric acid (193 μL, 1.90 mmol, 1 eq). After cooling to rt, the crude mixture 
was poured into water and the resulting precipitate was collected by filtration. The mixture of 10i and 11 was 
separated by CC (hexane/ethyl acetate 8:2); yield: 30 % (70 mg) for 10i and 42 % (215 mg) for 11. 
3-[3-(4-Hydroxyphenyl)-1,2,4-thiadiazol-5-yl]phenol (10). The title compound was prepared by reaction of 3-
[3-(4-methoxyphenyl)-[1,2,4]-thiadiazol-5-yl]-phenol (10i) (150 mg, 0.53 mmol) and boron tribromide (1.59 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 91 % (130 
mg); MS (ESI): 271 (M+H)+; Anal. (C14H10N2O2S) C, H, N. 
3-(3-Methoxyphenyl)-5-(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (12i). The title compound was 
prepared from para-anisoyl chloride (170 mg, 1.0 mmol), ethyl 3-methoxybenzimidate (179 mg, 1.0 mmol) and 
methyl hydrazine (92 mg, 2.0 mmol) according to method D; yield: 85 % (250 mg); m.p. 108-110 °C (CH2Cl2/ 
Et2O); MS (ESI): 296 (M+H)+. 
3-[5-(4-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (12). The title compound was prepared by 
reaction of 3-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (12i) (100 mg, 0.37 mmol) and 
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borontrifluoride dimethyl sulfide complex (27.75 mmol) according to method F. The product was purified by 
preparative TLC (ethyl acetate); yield: 46 % (42 mg); MS (ESI): 268 (M+H)+. 
3,5-Bis(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (13i). The title compound was prepared from para-
anisoyl chloride (170 mg, 1.0 mmol), ethyl 4-methoxybenzimidate (179 mg, 1.0 mmol) and methyl hydrazine (92 
mg, 2.0 mmol) according to method D; yield: 78 % (230 mg); m.p. 141-143 °C (CH2Cl2/ Et2O); MS (ESI): 296 
(M+H)+. 
4-[5-(4-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (13). The title compound was prepared by 
reaction of  3,5-bis(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (13i) (100 mg, 0.37 mmol) and borontrifluoride 
dimethyl sulfide complex (27.7 mmol) according to method F. The product was purified by preparative TLC (ethyl 
acetate); yield: 63 % (57 mg); MS (ESI): 268 (M+H)+. 
3-(4-Methoxyphenyl)-5-(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (14i). The title compound was 
prepared from meta-anisoyl chloride (170 mg, 1.0 mmol), ethyl 4-methoxybenzimidate (179 mg, 1.0 mmol) and 
methyl hydrazine (92 mg, 2.0 mmol) according to method D; yield: 77 % (227 mg); m.p. 114-116 °C (CH2Cl2/ 
Et2O); MS (ESI): 296 (M+H)+. 
4-[5-(3-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (14). The title compound was prepared by 
reaction of 3-(4-methoxyphenyl)-5-(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (14i) (100 mg, 0.37 mmol) and 
borontrifluoride dimethyl sulfide complex (27.7 mmol) according to method F. The product was purified by 
preparative TLC (ethyl acetate); yield: 53 % (48 mg); MS (ESI): 268 (M+H)+. 
3,5-Bis(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (15i). The title compound was prepared from meta-
anisoyl chloride (170 mg, 1.0 mmol), ethyl 3-methoxybenzimidate (179 mg, 1.0 mmol) and methyl hydrazine (92 
mg, 2.0 mmol) according to method D; yield: 67 % (198 mg); m.p. 67-69 °C (CH2Cl2/ Et2O); MS (ESI): 296 
(M+H)+. 
3-[5-(3-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (15). The title compound was prepared by 
reaction of 3,5-bis(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (15i) (100 mg, 0.37 mmol) and borontrifluoride 
dimethyl sulfide complex (27.7 mmol) according to method F. The product was purified by preparative TLC (ethyl 
acetate); yield: 64 % (58 mg); MS (ESI): 268 (M+H)+. 
2-Bromo-5-(3-methoxyphenyl)thiophene (18ii). The title compound was prepared by reaction of 2,5-
dibromothiophene (465 μL, 4.13 mmol), 3-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium carbonate 
(876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 μmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 41 % (445 mg). 
2-(3-Methoxyphenyl)thiophene (18i). To a solution of 2-bromo-5-(3-methoxyphenyl)thiophene (18ii) (100 mg, 
0.37 mmol, 1 eq) in dry THF cooled to -78 °C for 5 min, n-BuLi (1.6 M in hexane, 0.28 mL, 0.44 mmol, 1.2 eq) was 
added dropwise and stirred for 15 min at -78 °C. The crude mixture was carefully hydrolyzed by addition of water 
(10 ml) and layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over magnesium sulfate and evaporated to dryness under reduced pressure; yield: 98 
% (69 mg). 
3-(2-Thienyl)phenol (18). The title compound was prepared by reaction of 2-(3-methoxyphenyl)thiophene (18i) 
(80 mg, 0.42 mmol) and boron tribromide (1.26 mmol) according to method E. The product was purified by 
preparative TLC (hexane/ethyl acetate 7:3); yield: 85 % (63 mg); MS (ESI): 177 (M+H)+; Anal. (C10H8OS) C, H, N. 
2-(3-Methoxyphenyl)-5-phenylthiophene (19i). The title compound was prepared by reaction of 2-bromo-5-(3-
methoxyphenyl)thiophene (18ii) (400 mg, 1.52 mmol), benzeneboronic acid (223 mg, 1.82 mmol), sodium 
carbonate (322 mg, 3.04 mmol) and tetrakis(triphenylphosphine) palladium (8.8 mg, 7.6 μmol) according to method 
B. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 70 % (283 mg). 
3-(5-Phenyl-2-thienyl)phenol (19). The title compound was prepared by reaction of 2-(3-methoxyphenyl)-5-
phenylthiophene (19i) (100 mg, 0.37 mmol) and boron tribromide (2.22 mmol) according to method E. The product 
was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 81 % (75 mg); MS (ESI): 253 (M+H)+; Anal. 
(C16H12OS) C, H, N. 
2-Bromo-5-(4-methoxyphenyl)thiophene (20ii). The title compound was prepared by reaction of 2,5-
dibromothiophene (V= 465 μL, 4.13 mmol), 4-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium 
carbonate (876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 μmol) according to method 
A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 75 % (815 mg). 
2-(4-Methoxyphenyl)-5-phenylthiophene (20i). The title compound was prepared by reaction of 2-bromo-5-(4-
methoxyphenyl)thiophene (20ii) (400 mg, 1.52 mmol), benzeneboronic acid (223 mg, 1.82 mmol), sodium 
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carbonate (322 mg, 3.04 mmol) and tetrakis(triphenylphosphine) palladium (8.8 mg, 7.6 μmol) according to method 
B. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 75 % (303 mg). 
4-(5-Phenyl-2-thienyl)phenol (20). The title compound was prepared by reaction of 2-(4-methoxyphenyl)-5-
phenylthiophene (20i) (100 mg, 0.37 mmol) and boron tribromide (2.22 mmol) according to method E. The product 
was purified by preparative TLC (dichloromethane/methanol 99:1); yield: 95 % (89 mg); MS (ESI): 253 (M+H)+; 
Anal. (C16H12OS) C, H, N. 
2-(3-Methoxyphenyl)-5-(4-methoxyphenyl)thiophene (22i). The title compound was prepared by reaction of 
2-bromo-5-(3-methoxyphenyl)thiophene (18ii) (150 mg, 0.57 mmol), 4-methoxybenzeneboronic acid (223 mg, 0.68 
mmol), sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 μmol) 
according to method B. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 75 % (126 mg). 
3-[5-(4-Hydroxyphenyl)-2-thienyl]phenol (22). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-5-(4-methoxyphenyl)thiophene (22i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 93 % (127 
mg); MS (ESI): 269 (M+H)+; Anal. (C16H12O2S) C, H, N. 
2,5-Bis(3-methoxyphenyl)thiophene (23i). The title compound was prepared by reaction of 2-bromo-5-(3-
methoxyphenyl)thiophene (18ii) (150 mg, 0.57 mmol), 3-methoxybenzeneboronic acid (223 mg, 0.68 mmol), 
sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 μmol) according to 
method B. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 78 % (132 mg). 
3,3'-Thiene-2,5-diyldiphenol (23). The title compound was prepared by reaction of 2,5-bis(3-
methoxyphenyl)thiophene (23i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) according to method E. 
The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 95 % (130 mg); MS (ESI): 269 
(M+H)+; Anal. (C16H12O2S) C, H, N. 
4-Bromo-2-(3-methoxyphenyl)thiophene (24ii). The title compound was prepared by reaction of 2,4-
dibromothiophene (1.00 g, 4.13 mmol), 3-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium carbonate 
(876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 μmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 72 % (782 mg). 
2-(3-Methoxyphenyl)-4-phenylthiophene (24i). The title compound was prepared by reaction of 4-bromo-2-(3-
methoxyphenyl)thiophene (24ii) (250 mg, 0.93 mmol), benzeneboronic acid (137 mg, 1.12 mmol), sodium 
carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 4.64 μmol) according to method 
B. The product was purified by CC (petroleum ether/ethyl acetate 7:3); yield: 91% (225 mg). 
3-(4-Phenyl-2-thienyl)phenol (24). The title compound was prepared by reaction of 2-(3-methoxyphenyl)-4-
phenylthiophene (24i) (225 mg, 0.85 mmol) and boron tribromide (3.6 mmol) according to method E. The product 
was purified by preparative TLC (dichloromethane/methanol 99:1); yield: 69 % (147 mg); MS (ESI): 253 (M+H)+. 
4-Bromo-2-(4-methoxyphenyl)thiophene (25ii). The title compound was prepared by reaction of 2,4-
dibromothiophene (1.00 g, 4.13 mmol), 4-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium carbonate 
(876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 μmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 78 % (847 mg). 
2-(4-Methoxyphenyl)-4-(3-methoxyphenyl)thiophene (25i). The title compound was prepared by reaction of 
4-bromo-2-(4-methoxyphenyl)thiophene (25ii) (150 mg, 0.57 mmol), 3-methoxybenzeneboronic acid (223 mg, 0.68 
mmol), sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 μmol) 
according to method B. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 70 % (118 mg). 
3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol (25). The title compound was prepared by reaction of 2-(4-
methoxyphenyl)-4-(3-methoxyphenyl)thiophene (25i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 80 % (109 
mg); MS (ESI): 267 (M-H)-; Anal. (C16H12O2S) C, H, N. 
2-(3-Methoxyphenyl)-4-(4-methoxyphenyl)thiophene (27i). The title compound was prepared by reaction of 
4-bromo-2-(3-methoxyphenyl)thiophene (24ii) (150 mg, 0.57 mmol), 4-methoxybenzeneboronic acid (223 mg, 0.68 
mmol), sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 μmol) 
according to method B. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 70 % (118 mg). 
3-[4-(4-Hydroxyphenyl)-2-thienyl]phenol (27). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-4-(4-methoxyphenyl)thiophene (27i) (150 mg, 0.51 mmol) and boron tribromide solution (3.06 
mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 85 % 
(116 mg); MS (ESI): 267 (M-H)-; Anal. (C16H12O2S) C, H, N. 
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2,4-Bis(3-methoxyphenyl)thiophene (28i). The title compound was prepared by reaction of 4-bromo-2-(3-
methoxyphenyl)thiophene (24ii) (150 mg, 0.57 mmol), 3-methoxybenzeneboronic acid (223 mg, 0.68 mmol), 
sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 μmol) according to 
method B. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 72 % (121 mg). 
3,3'-Thiene-2,4-diyldiphenol (28). The title compound was prepared by reaction of 2,4-bis(3-
methoxyphenyl)thiophene (28i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) according to method E. 
The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 88 % (120 mg); MS (ESI): 267 (M-
H)-; Anal. (C16H12O2S) C, H, N. 
4,4’-(Seleniene-2,5-diyl)diphenol (29). The title compound was prepared by reaction of 2,5-
dibromoselenophene (150 mg, 0.52 mmol), 4-hydroxybenzeneboronic acid (172 mg, 1.25 mmol), caesium carbonate 
(679 mg, 2.08 mmol) and tetrakis(triphenylphosphine) palladium (6.0 mg, 5.2 μmol) according to method C. The 
product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 49 % (81 mg); MS (ESI): 317 (M+H)+; 
Anal. (C16H12O2Se) C, H, N. 
3,3’-(Seleniene-2,5-diyl)diphenol (30). The title compound was prepared by reaction of 2,5-
dibromoselenophene (150 mg, 0.52 mmol), 3-hydroxybenzeneboronic acid (172 mg, 1.25 mmol), caesium carbonate 
(679 mg, 2.08 mmol) and tetrakis(triphenylphosphine) palladium (6.0 mg, 5.2 μmol) according to method C. The 
product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 42 % (69 mg); MS (ESI): 317 (M+H)+; 
Anal. (C16H12O2Se) C, H, N. 
3-Bromo-2-(4-methoxyphenyl)thiophene (31ii). The title compound was prepared by reaction of 2,3-
dibromothiophene (234 μL, 2.1 mmol), 4-methoxybenzeneboronic acid (383 mg, 2.52 mmol), sodium carbonate 
(403 mg, 4.2 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 μmol) according to method B. The 
product was purified by CC (hexane); yield: 70 % (387 mg).  
4,4'-(Thiene-2,3-diyl)diphenol (31). The title compound was prepared by reaction of 2,3-bis(4-
methoxyphenyl)thiophene (31i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) according to method E. 
The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 70 % (95 mg); MS (ESI): 269 
(M+H)+; Anal. (C16H12O2S) C, H, N. 
3-Bromo-2-(3-methoxyphenyl)thiophene (32ii). The title compound was prepared by reaction of 2,3-
dibromothiophene (234 μL, 2.1 mmol), 3-methoxybenzeneboronic acid (383 mg, 2.52 mmol), sodium carbonate 
(403 mg, 4.2 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 μmol) according to method B. The 
product was purified by CC (hexane); yield: 58 % (320 mg). 
2-(3-Methoxyphenyl)-3-(4-methoxyphenyl)-thiophene (32i). The title compound was prepared by reaction of 
3-bromo-2-(3-methoxyphenyl)thiophene (32ii) (150 mg, 0.57 mmol), 4-methoxybenzeneboronic acid (223 mg, 0.68 
mmol), sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 μmol) 
according to method B. The product was purified by CC (hexane/ethyl acetate 7:3); yield 40 % (68 mg). 
3-[3-(4-Hydroxyphenyl)-2-thienyl]phenol (32). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-3-(4-methoxyphenyl)thiophene (32i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 56 % (77 
mg); MS (ESI): 269 (M+H)+; Anal. (C16H12O2S) C, H, N. 
3,3''-Dimethoxy-1,1':4',1''-terphenyl (35i). The title compound was prepared by reaction of 4'-bromo-3-
methoxybiphenyl (35ii) (500 mg, 1.90 mmol), 3-methoxybenzeneboronic acid (346 mg, 2.28 mmol), sodium 
carbonate (403 mg, 3.80 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 9.5 μmol) according to an 
adaptation of method A (heating the mixture 20 h instead of 4 h). The product was purified by CC (hexane/ethyl 
acetate 95:5); yield: 14 % (77 mg).  
3,4''-Dimethoxy-1,1':4',1''-terphenyl (36i). The title compound was prepared by reaction of 4'-bromo-3-
methoxybiphenyl (35ii) (500 mg, 1.90 mmol), 4-methoxybenzeneboronic acid (346 mg, 2.28 mmol), sodium 
carbonate (403 mg, 3.80 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 9.5 μmol) according to an 
adaptation of method A (heating the mixture 20 h instead of 4 h). The product was purified by CC (hexane/ethyl 
acetate 95:5); yield: 90 % (496 mg). 
3,3'-Pyridine-2,5-diyldiphenol (37). The title compound was prepared by reaction of 2,5- dibromo pyridine 
(150 mg, 0.63 mmol), 3-hydroxybenzeneboronic acid (231 mg, 1.52 mmol), caesium carbonate (821 mg, 2.52 
mmol) and tetrakis(triphenylphosphine) palladium (7.3 mg, 6.3 μmol) according to method C. The product was 
purified by preparative TLC (dichloromethane/methanol 98:2); yield: 67 % (111 mg); MS (ESI): 262 (M-H)-; Anal. 
(C17H13NO2) C, H, N. 
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Biological Methods 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described 
procedures.22,62 Fresh human placenta was homogenized and centrifuged. The pellet fraction contains the 
microsomal 17β-HSD2, while 17β-HSD1 was obtained after precipitation with ammonium sulfate from the 
cytosolic fraction. 
Inhibition of 17β-HSD1  
Inhibitory activities were evaluated by a well established method with minor modifications.41, 63, 64 Briefly, the 
enzyme preparation was incubated with NADH [500 µM] in the presence of potential inhibitors at 37 °C in a 
phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA 1mM. Inhibitor stock solutions were 
prepared in DMSO. Final concentration of DMSO was adjusted to 1 % in all samples. The enzymatic reaction was 
started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]- E1 (final concentration: 500 nM, 0.15 μCi). After 
10 min, the incubation was stopped with HgCl2 and the mixture was extracted with ether. After evaporation, the 
steroids were dissolved in acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in 
a C18 rp chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a HPLC-
system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of the steroids were 
performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The conversion rate was calculated 
according to following equation: . Each value was calculated from at least 
three independent experiments.  
Inhibition of 17β-HSD2 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal fraction 
was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 7-3H]-E2 (final 
concentration: 500 nM, 0.11 μCi) for 20 min at 37 °C. Further treatment of the samples and HPLC separation was 
carried out as mentioned above. 
ER affinity 
The binding affinity of select compounds to the ERα and ERβ was determined according to Zimmermann et al.65 
Briefly, 0.25 pmol of ERα or ERβ, respectively, were incubated with [2, 4, 6, 7-3H]-E2 (10 nM) and test compound 
for 1 h at rt. The potential inhibitors were dissolved in DMSO (5 % final concentration). Non-specific-binding was 
performed with diethylstilbestrol (10 µM). After incubation, ligand-receptor complexes were selectively bound to 
hydroxyapatite (5 g/ 60 mL TE-buffer). The formed complex was separated, washed and resuspended in ethanol. 
For radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were 
measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). For determination of the relative 
binding affinity (RBA), inhibitor and E2 concentrations required to displace 50 % of the receptor bound labelled E2 
were determined. RBA values were calculated according to the following equation: 
. The RBA value for E2 was arbitrarily set at 100 %. 
Evaluation of the estrogenic activity using T-47D cells 
Phenol red-free medium was supplemented with sodium bicarbonate (2 g/L), streptomycin (100 µg/mL), insuline 
zinc salt (10 µg/mL), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 U/mL) and DCC-FCS 5% 
(v/v). RPMI 1640 (without phenol red) was used for the experiments. Cells were grown for 48 h in phenol red-free 
medium. Compounds 4, 10, 22, 25, 35 and 36 were added at a final concentration of 100 nM. Inhibitors and E2 were 
diluted in ethanol (final ethanol concentration was adjusted to 1 %). As a positive control E2 was added at a final 
concentration of 0.1 nM. Ethanol was used as negative control. Medium was changed every two to three days and 
supplemented with the respective additive. After eight days of incubation, the cell viability was evaluated measuring 
the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT). The cleavage of MTT to a 
blue formazan by mitochondrial succinat-dehydrogenase was quantified spectrophotometrically at 590 nm as 
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described by Denizot and Lang66 with minor modifications. The control proliferation was arbitrarily set at 1 and the 
stimulation induced by the inhibitor was calculated according to following equation: 
. Each value is calculated as a mean value of 
at least three independent experiments 
Caco-2 transport experiments 
Caco-2 cell culture and transport experiments were performed according to Yee67 with small modifications. Cell 
culture time was reduced from 21 to 10 days by increasing seeding density from 6.3·104 to 1.65·105 cells per well. 
Four reference compounds (atenolol, testosterone, ketoprofene, erythromycin) were used in each assay for 
validation. The compounds were applied to the cells as a mixture (cassette dosing) to increase the throughput. The 
initial concentration of the compounds in the donor compartment was 50 µM (0.2 M MES, pH: 6.5, containing 
either 1 % ethanol or DMSO). Samples were taken from the acceptor side after 0 min, 60, 120 and 180 min and 
from the donor side after 0 and 180 min. Each experiment was run in triplicate. The integrity of the monolayers was 
checked by measuring the transepithelial electrical resistance (TEER) before the transport experiments and by 
measuring lucifer yellow permeability after each assay. All samples of the CaCo-2 transport experiments were 
analyzed by LC/MS/MS after dilution with buffer of the opposite transwell chamber (1:1, containing 2 % acetic 
acid). The apparent permeability coefficients (Papp) were calculated using equation , where  is the 
appearance rate of mass in the acceptor compartment, A the surface area of the transwell membrane, and c0 the 
initial concentration in the donor compartment. 
Metabolic stability assay 
The assay was performed with liver microsomes from male Sprague Dawley rats (BD Gentest, USA). Stock 
solutions (10 mM in acetonitrile) were diluted to give working solutions in 20 % acetonitrile. The incubation 
solutions consisted of a microsomal suspension of 0.33 mg/mL of protein in phosphate buffer 100 mM pH 7.4 and 
90 µL NADP+-regenerating system (NADP+ 1 mM, glucose-6-phosphate 5 mM, glucose–6-phosphate 
dehydrogenase 5 U/mL, MgCl2 5 mM).  
The reaction was initiated by the addition of test compound (final concentration 1 μM) to the pre-incubated 
microsomes/buffer mix at 37 °C. The samples were removed from the incubations after 0, 15, 30, and 60 min and 
processed for acetonitrile precipitation. The samples were analyzed by LC-MS/MS. Two control groups were run in 
parallel: positive controls (PC; n= 1) using 7-ethoxycoumarin as reference compound to prove the quality of the 
microsomal enzymatic activity and negative controls (NC; n= 1), using boiled microsomes (boiling water bath, 25 
min) without regenerating system to ensure that the potential apparent loss of parent compound in the assay 
incubation is due to metabolism. The amount of compound in the samples was expressed in percentage of remaining 
compound compared to time point zero (= 100 %). These percentages were plotted against the corresponding time 
points and the half-life time was derived by a standard fit of the data. 
Intrinsic clearance (Clint) estimates were determined using the rate of parent disappearance. The slope (-k) of the 
linear regression from log [test compound] versus time plot was determined as well as the elimination rate constant: 
k= ln2/t1/2. The equation expressing the microsomal Clint can be derived: Clint=k*V*fu [µl/min/mg protein], where fu 
is the unbound fraction. V gives a term for the volume of the incubation expressed in μL / mg protein. As fu is not 
known for the tested compound, the calculation was performed with fu =1 (V= incubation volume [µL]/microsomal 
protein[mg] = 6667). 
Inhibition of human hepatic CYPs 
The commercially available P450 inhibition kits from BD GentestTM (Heidelberg, Germany) were used 
according to the instructions of the manufacturer. Compounds 4, 25 and 35 were tested for inhibition of the 
following enzymes: CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4. Inhibitory potencies were determined as IC50-values. 
In-Vivo Pharmacokinetics 
Male Wistar rats weighing 300-330 g (Janvier France) were housed in a temperature- controlled room (20-22 °C) 
and maintained in a 12h light/12h dark cycle. Food and water were available ad libitum. They were anesthetized 
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with a ketamine (135 mg/kg)/ xylyzine (10 mg/kg) mixture and cannulated with silicone tubing via the right jugular 
vein and attached to the skull with dental cement.68 Prior to the first blood sampling, animals were connected to a 
counterbalanced system and tubing to perform blood sampling in the freely moving rat.  
Compounds 3 and 39 were applied orally in a cassette dosing in 4 rats at the dose of 10 mg/kg body weight by 
using a feeding needle. The compounds were dissolved in a mixture labrasol/water (1:1) and given at a volume of 
5mL/kg. Blood samples (0.2 mL) were taken at 0, 1, 2, 3, 4, 6, 8, 10 and 24 h postdose and collected in heparinised 
tubes. They were centrifuged at 3000g for 10 min, and plasma was harvested and kept at -20 °C until analyzed.  
HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor-HPLC-system coupled 
with a TSQ Quantum (Thermo/Fisher) triple quadrupole mass spectrometer equipped with an electrospray interface 
(ESI).  
Computational chemistry 
Distance and angle calculations 
All distances and angles were calculated after energy minimisation using Hyperchem v. 6.0. 
MEP 
For selected compounds ab initio geometry optimisations were performed gas phase at the B3LYP/6-311**G 
(d,p) level of density functional theory (DFT) by means of the Gaussian03 software and the molecular electrostatics 
potential map (MEP) was plotted using GaussView 3.09, the 3D molecular graphics package of Gaussian.69 These 
electrostatic potential surfaces were generated by mapping 6-311G** electrostatic potentials onto surfaces of 
molecular electron density (isovalue = 0.002e/Å). The MEP maps are color coded, where red stands for negative 
values (3.1*10-2 Hartree) and blue for positive ones (4.5*10-2 Hartree).70 
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3.3.5.2.  Paper X. 
 
New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -
benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase 
Type 1 (17β-HSD1) Inhibitory Activity and Selectivity 
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Kruchten, Alexander Oster, Martin Frotscher, Barbara Birk and Rolf W. Hartmann 
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Abstract 
17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is responsible for the catalytic reduction of weakly active 
E1 to highly potent E2. E2 stimulates the proliferation of hormone-dependent diseases via activation of the estrogen 
receptor α (ERα). Due to the overexpression of 17β-HSD1 in mammary tumors, this enzyme should be an attractive 
target for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of potent 17β-
HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes and benzenes. In this paper, different substituents were 
introduced into the core structure and the biological properties of the corresponding inhibitors were evaluated. 
Computational methods and analysis of different X-rays of 17β-HSD1 lead to identification of two different binding 
modes for these inhibitors. The fluorine compound 23 exhibits an IC50 value of 8 nM and is the most potent non-
steroidal inhibitor described so far. It also shows a high selectivity (17β-HSD2, ERα) and excellent pharmacokinetic 
properties after peroral application to rats. 
Introduction. 
Estrogens are involved in the regulation of the female reproduction system. However, it is also well known that 
17β-estradiol (E2), the natural ligand of the estrogen receptors (ERs) α and β, plays a critical role in the 
development of several estrogen-dependent pathologies like breast cancer1 and endometriosis.2 
Until now, hormone-dependent breast cancers are treated using three different endocrine therapies:3,4 aromatase 
inhibitors and GnRH analogues disrupt the estrogen biosynthesis while selective estrogen receptor modulators 
(SERMs) or pure antiestrogens5 prevent E2 to unfold its action at the receptor level. Besides specific disadvantages 
of each therapeutic approach, all of these strategies have in common a rather radical reduction of estrogen levels in 
the whole body leading to significant side effects. 
A softer approach could be the inhibition of an enzyme of the 17β-hydroxysteroid dehydrogenase (17β-HSD) 
family, especially one which is responsible for the E2 formation from estrone (E1). Until now, three subtypes (1, 7 
and 12) are able to catalyze this reaction, the most important being 17β-HSD1. The primary physiological role of 
17β-HSD7 and 17β-HSD12 is supposed to be in the cholesterol synthesis6,7 and in the regulation of the lipid 
biosynthesis,8 respectively. In addition, Day et al.9 recently, showed that 17β-HSD12, although highly expressed in 
breast cancer cell lines, is inefficient in E2 formation. 
17β-HSD1, which is responsible for the intracellular NAD(P)H-dependent conversion of the weak E1 into the 
highly potent estrogen E2, is often overexpressed in breast cancer cells10-13 and endometriosis.14 Inhibition of this 
enzyme is therefore regarded as a promising novel target for the treatment of estrogen-dependent diseases. 
Recently, two groups9,15,16 reported about the in-vivo efficacy of 17β-HSD1 inhibitors to reduce E1 induced 
tumour growth using two different mouse models and indicating that the 17β-HSD1 enzyme is a suitable target for 
the treatment of breast cancer. 
In order to not counteract the therapeutic efficacy of 17β-HSD1 inhibitors, it is very important that the 
compounds are selective toward 17β-HSD2, the enzyme which catalyzes the deactivation of E2 into E1. 
Additionally, to avoid intrinsic estrogenic effects, the inhibitors should not show affinity to the estrogen receptors  
and β.  
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During the last decade, several groups reported on 17β-HSD1 inhibitors, most of them having steroidal 
structures.17-20 Recently non-steroidal cores have been published too. Until today four classes of compounds are 
described: thienopyrimidinones,21,22 biphenyl ethanones23 and from our group (hydroxyphenyl)naphthalenes24-26 and 
bis(hydroxyphenyl)azoles, thiophenes, benzenes and aza-benzenes.27-32 The most promising compounds of the later 
series are thiophenes 1, 7 and 33, thiazole 36 and phenylene 41 exhibiting IC50 values toward 17β-HSD1 in the 
nanomolar range and high selectivity toward 17β-HSD2 and the ERs (Chart 1). 
Chart 1: Described bis(hydrophenyl)azoles, thiophenes, benzenes and aza-benzenes 
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7
IC50= 216 nM
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IC50= 77 nM
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IC50= 173 nM
A
inactive
B
IC50= 310 nM
 
In the following, we will report on structural optimizations which led to the discovery of new highly potent and 
selective 17β-HSD1 inhibitors (Chart 2).  
Chart 2: Title compounds 
S
X
OH
OH
R1
R2 R3
R4
R1
R2
R5
1-37 38-42
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Design 
Up to now, several crystal structures of human 17β-HSD1 were resolved: as apoenzyme (i.e. PDB code: 
1BHS33), as binary complex (enzyme-E2, i.e. PDB code: 1IOL34) or as ternary complex (enzyme-E2-NADP+: i.e. 
PDB code 1FDT;35 1A27;36 enzyme-HYC (hybride inhibitor): PDB code: 1I5R37).  
The analysis of the ternary complexes available from 17β-HSD1 provides useful knowledge about the 
architecture of the enzyme and important hints for structure based drug design: a substrate binding site (SUB) and a 
cofactor binding pocket (COF) are present as well as the most important amino acids responsible for substrate and 
cofactor anchoring. The SUB is a narrow hydrophobic tunnel containing two polar regions at each end: 
His221/Glu282 on the one side and Ser142/Tyr155 on the other side, corresponding to the binding oxygens in 3- and 
17-hydroxy group of E2. Additionally a flexible loop can be identified which is not well resolved in almost all the 
structures. 
From previous results obtained in the class of bis(hydroxyphenyl)azoles, thiophenes, benzenes and aza-
benzenes,27,28 a SAR study highlighted four structural features which are important for high 17β-HSD1 inhibitory 
activity: 1. one hydroxyphenyl moiety on the core structure is not sufficient for a high potency, 2. only the meta-
para and meta-meta dihydroxy substitution pattern (O-O distance in the same range as observed for the steroid, d = 
11 Å) are active, 3. the presence of the meta-hydroxy group is more important for inhibitory activity than the para-, 
4. only central aromatic rings without hydrogen bond donor function like thiophene, thiazole, benzene exhibit 
inhibitory activity. It was also shown that a correlation seems to exist between the activity of the compounds and the 
electrostatic potential distribution of the molecules:28 to be active the ESP values of the different regions of the 
inhibitor have to be in an appropriate range. 
In the present report, we will present the structure optimization of this class of compounds leading to an increase 
in activity and in selectivity of these inhibitors. First, the influence of the bioisosteric exchange of one OH group on 
the enzyme activity will be determined. Secondly, the space availability around the inhibitors and the nature of the 
most appropriate substituents will be investigated by substitutions, either on the heterocycle, or on the 
hydroxyphenyl moieties. The nature of the substituents will be varied in order to investigate the possible interactions 
between the inhibitor and the enzyme. Thirdly, computational studies (docking studies and ESP calculations) will be 
performed in order to identify the most plausible binding mode for this class of compounds. Furthermore the 
selectivity toward 17β-HSD2 and the ERs α and β will be determined as well as the potency of the compounds in T-
47D cells and inhibition of the two most important hepatic CYP enzymes. Finally, the pharmacokinetic profile of 
the two most promising candidates will be evaluated in rats after oral administration. 
Chemistry 
The synthesis of compounds 1 to 11, 21 to 25 and 32 is presented in Scheme 1. Starting from the mono-
brominated key intermediate 1b and the appropriate commercially available boronic acids, the preparation of 
compounds 1a to 11a, 21a to 25a and 32a was accomplished via Suzuki cross coupling reaction38 under microwave 
assisted conditions (Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 
min). The resulting disubstituted thiophenes were subsequently submitted to ether cleavage with borontribromide28 
(Method C: BBr3, CH2Cl2, -78 °C to rt, 18 h) leading to compounds 1 to 11, 21 to 25 and 32 (Scheme 1). In case of 
intermediate 25a, the boronic acid 25b was prepared in a three step synthesis pathway: first, an iodine substituent 
was selectively introduced in position 2 of the para-bromoanisole (compound 25d) using (diacetoxyiodo) benzene.39 
Then, a selective Suzuki reaction on the iodo-position of 25d under Method B (Na2CO3, toluene/water (1:1), 
Pd(PPh3)4, reflux, 20 h) led to the intermediate 25c and the corresponding boronic acid 25b was prepared using n-
butyl lithium and triethyl borate followed by hydrolysis with diluted hydrochloric acid. 
 
 ~ 214 ~ 
 
Scheme 1a: Synthesis of compounds 1 to 11, 21 to 25 and 32 
S
MeO
B(OH)2
S
OH
S
MeO
OMe
Br
OMe
Br
I
OMe
Br
Ph
OMe
B(OH)2
Ph
S
MeO
OMe
Ph
Br +
a b
b
1b R1
R2
R2
R1
1a-11a
21a-24a
32a
1-11
21-25
32
R1
R2
+ 1b
25a25b25c25d
d ec f
 
cmpd R1 R2 cmpd R1 R2 
1 OH H 9 H N
H
SO2  
2 H H 10 H N
H
SO2
 
3 F H 11 H NH
SO2  
4 NH2 H 21 OH CH3 
5 SH H 22 OH OH 
6 CN H 23 OH F 
7 H OH 24 OH CF3 
8 H F 25 OH Ph 
   32 F F 
aReagents and conditions: (a) Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min; (b) BBr3, 
CH2Cl2, -78 °C to rt, 18 h; (c) PhI(OAc)2, I2, AcOEt, 60 °C, 5 h; (d) Ph-B(OH)2, Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 
20 h; (e) 1. n-BuLi, dry THF, 5 min, -78 °C, 2. B(OEt)3, 2 h -78°C to rt, 3. HCl 1N, rt; (f) Method B: Na2CO3, toluene/water (1:1), 
Pd(PPh3)4, reflux, 20 h. 
The preparation of compounds 31 and 33 to 42 is similar to the synthetic pathway presented in Scheme 1 for 
compounds 1 to 11. The first Suzuki coupling was carried out according to Method B with the corresponding 
dibrominated heterocycle and the methoxylated benzene boronic acid. The resulting mono substituted compounds 
31b and 33b to 42b were submitted to a second cross coupling reaction under microwave assisted conditions 
following Method A. The compounds were subsequently demethylated with boron tribromide to yield compounds 
31 and 33 to 42. 
The synthesis of compounds 12, 14 and 15 is depicted in Scheme 2. The key intermediate mono methoxylated 
dibromothiophene 12c was prepared following two successive Suzuki coupling reactions according to Method B 
(Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 h) from 2,3,5-tribromothiophene and methoxybenzene boronic 
acid. The reaction time of both cross couplings was carefully controlled (restricted to 4 h) in order to get a selective 
bromine replacement each time. Intermediates 12a, 14a, and 15a were obtained via a third Suzuki coupling using 
Method B. The methoxy substituents were cleaved in a last step, using boron tribromide (Method C: BBr3, CH2Cl2, -
78 °C to rt, 18 h).  
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Scheme 2a: Synthesis of compounds 12, 14 and 15 
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aReagents and conditions: (a) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 h; (h) boronic acid, Method B: Na2CO3, 
toluene/water (1:1), Pd(PPh3)4, reflux, 20 h; (d) BBr3, CH2Cl2, -78 °C to rt, 18 h. 
Compound 13 was synthesized under microwave assisted conditions in a one pot reaction using 2,5-dibromo-3-
methylthiophene and 3-hydroxyphenyl boronic acid following Method A (Cs2CO3, DME/EtOH/water (1:1:1), 
Pd(PPh3)4, MW (150 W, 150 °C, 15 bars)) for 15 min. 
The synthesis of the molecules bearing an additional substituent on the meta-hydroxyphenyl moiety of thiophene 
1 (compounds 16 to 20) is shown in Scheme 3. Intermediate 16c was prepared via Suzuki reaction from the para-
methoxylated benzene boronic acid and the 2,5-dibromothiophene following Method B heating the reaction 4 h 
instead of 20 h in order to avoid any dicoupling reaction. Treatment of 16c with n-butyl lithium and triethyl borate 
afforded after hydrolysis with diluted hydrochloric acid the corresponding boronic acid 16b. The resulting 
compound was subjected to an additional cross coupling reaction which was carried out with the appropriate 
bromine derivative following Method A for compounds 17a to 20a and Method B for compound 16a. The 
hydrolysis of the methoxy groups with boron tribromide (Method C) led to compounds 16 to 20. 
Scheme 3a: Synthesis of compounds 16 to 20 
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aReagents and conditions: (a) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 h; (b) 1.n-BuLi, anhydrous THF, -78 °C, 15 
min, 2. B(OEt)3, THF, -78 °C to rt, 2 h, 3. HCl 1N; (c) Method A for 17a-20a (Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 
W, 150 °C, 15 bars), 15 min); Method B for 16a (Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h); (d) BBr3, CH2Cl2, -78 °C to rt, 18 
h. 
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The synthesis of compounds 26 to 28 substituted in ortho-position of the para-OH group is depicted in Scheme 
4. The preparation of the key intermediate 26b started from the commercially available 3-formyl-4-methoxyphenyl 
boronic acid. Reduction of the aldehyde function using sodium borohydride followed by a cross coupling reaction 
with 1b under microwave irradiation according to Method A (Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW 
(150 W, 150 °C, 15 bars), 15 min) afforded the disubstituted thiophene 26c. The alcohol function of 26c was 
subsequently oxidized with pyridinium chlorochromate to yield to the key aldehyde 26b. It was subjected to the 
Horner-Wadworths-Emmons conditions40 to introduce the acrylic ester moiety (intermediate 26a). Hydrolysis of the 
ester function using lithium hydroxide,25 amide bond formation with aniline, EDCI and HOBt41 afforded compound 
27a The catalytic double bond hydrogenation of 27a was performed using Perlman’s catalyst.42 The ether functions 
of 26a, 27a and 28a were deprotected using boron tribromide (Method C) to give the desired compounds 26 to 28.  
Scheme 4a: Synthesis of compounds 26 to 28  
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aReagents and conditions: (a) NaBH4, THF/EtOH (1:1), 0 °C to rt, 2 h; (b) Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, 
MW (150 W, 150 °C, 15 bars), 15 min; (c) PCC, CH2Cl2, rt, 30 min; (d) NaH, THF dry, rt, 4 h; (e) BBr3, CH2Cl2, -78 °C to rt, 18 h; (f) 1. 
LiOH, THF/H2O (2:1), reflux, 20 h, 2. aniline, EDCI, HOBt, CH2Cl2, reflux, 20 h; (g) Pd(OH)2, THF/EtOH (1:1), H2, rt, 20 h. 
The synthesis of the difluorinated thiophenes 29 and 30 is presented in Scheme 5. These compounds were 
obtained after two successive cross coupling reactions: in a first step 2,5-dibromothiophene reacted with 3-fluoro-4-
methoxyphenyl boronic acid following Method B (Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h). In a 
second step, the resulting mono substituted thiophene 29b was subsequently submitted to a second cross coupling 
reaction under microwave irradiation (Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 
°C, 15 bars), 15 min) to yield the intermediates 29a and 30a. Ether cleavage with boron tribromide led to the final 
compounds 29 and 30. 
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Scheme 5a: Synthesis of compounds 29 to 30 
SBr Br
B(OH)2
F
OMe
S
F
OMe
B(OH)2
OMe
S
MeO
OMe
F
+
Br +
a
b
c
29b 
R 29a R= 3-F
30a R= 4-F
R
29-30  
aReagents and conditions: (a) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h ; (b) Method A: Cs2CO3, DME/EtOH/water 
(1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min; (c) BBr3, CH2Cl2, -78 °C to rt, 18 h. 
Biological Results 
Activity: inhibition of human 17β-HSD1 
Placental enzyme was partially purified following a described procedure.27,28 Tritiated E1 was incubated with 
17β-HSD1, cofactor and inhibitor. After HPLC separation of substrate and product, the amount of labelled E2 
formed was quantified. The inhibition values of the test compounds are shown in Tables 1 to 5. Thiophenes 1, 2, 7 
and 33, thiazole 36 and phenylenes 38 and 41, identified in our previous article,28 were used as reference 
compounds. 
It was first investigated whether one of the two hydrophenyl moieties could be exchanged by another functional 
group having similar properties. Recent results28 showed that the meta-hydroxy group is highly important for 
activity and was therefore maintained in the core structure. The exchange of the para-hydroxy group on the meta-
para disubstituted thiophene (1, IC50= 69 nM) by a bioisosteric function (F, NH2, SH) resulted in moderate (3, IC50= 
717 nM) or weak inhibitors (4 and 5, IC50> 5000 nM) of 17β-HSD1 (Table 1). Moving the F atom from the para- 
(compound 3) to the meta-position (compound 8) led to a small increase in activity (8, IC50= 535 nM vs. 3, IC50= 
717 nM). Replacement of the meta-fluorine for a methylsulfonamide moiety (9) did not improve the activity (9, 
IC50= 523 nM vs. 8, IC50= 535 nM), while a compound bearing a bulky substituent like tolylsulfonamide (11, IC50= 
350 nM) showed comparable activity to the mono hydroxylated thiophene (2, IC50= 342 nM) indicating that there is 
some space in this region of the enzyme for substitution but it is unlikely that specific interactions between the 
tolylsulfonamide moiety and amino acids of the active site take place. The insertion of a C1-linker between the 
phenyl moiety and the methylsulfonamide group was detrimental for the activity (9, IC50= 523 nM vs. 10, IC50> 
1000 nM). It can be therefore concluded that the two hydroxy functions are necessary for high activity and the para-
hydroxy group can not be replaced by a bioisoteric group. 
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Table 1: Effect of the exchange of one OH substituent for other functional groups on human 17β-HSD1 and 17β-
HSD2 inhibitory activities. 
S
OH R
S
OH
R
1-6 2
7-11  
cmpd R IC50 (nM)a 
selectivity 
factord cmpd R IC50 (nM)
a selectivity factord 
  17β- 
HSD1b 
17β- 
HSD2c 
   17β- 
HSD1b 
17β- 
HSD2c  
1 OH 69 1950 28 7 OH 173 745 4 
2 H 342 2337 7 2 H 342 2337 7 
3 F 717 3655 5 8 F 535 1824 3 
4 NH2 >5000 nt  9 N
H
SO2  
523 1575 3 
5 SH >5000 nt  10 N
H
SO2
 
>1000 nt  
6 CN >1000 nt  11 NH
SO2  
350 276 1 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, substrate 3H-E1 + E1 [500 
nM], cofactor NADH [500 μM], cHuman placenta, microsomal fraction, substrate 3H-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 
(17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not tested 
In order to improve the activity and the selectivity of our inhibitors, substituents capable to establish further 
interactions with the enzyme were added either on the heterocycle or on the hydroxyphenyl moieties. Additional 
functional groups were introduced in both of the meta-para 2,5-bis(hydroxyphenyl)thiophene 1 (IC50 = 69 nM) and 
the meta-meta 2,5-disubstituted derivative 7 (IC50 = 173 nM). 
Concerning substitution on the heterocycle, two kinds of hydrophobic substituents (Me, Ph) were introduced in 
position 3 on the thiophene ring to investigate the space availability around the core (Table 2). The meta-meta 
thiophenes bearing a methyl (compound 13) or phenyl (compound 14) as well as the meta-para thiophene bearing a 
hydroxyphenyl substituent (compound 12) showed a reduction of activity compared to the reference compound 7 
(IC50= 216 nM vs. IC50> 1000 nM, 567 nM and 493 nM for 12, 13 and 14, respectively). It is striking that only in 
case of the meta-meta disubstituted series the insertion of a polar meta-hydroxyphenyl substituent leads to an 
increase in activity (15, IC50= 119 nM vs. 12, IC50> 1000 nM). This exemplifies that there is space available for 
further substitution around the heterocycle only in case of the meta-meta bis(hydroxyphenyl) substitution pattern 
and that the third meta-OH group is certainly at an appropriate distance to establish supplementary hydrogen bond 
interactions with the active site. 
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Table 2: Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds bearing a supplementary substituent on the 
thiophene core structure 
S
R
OH OH
S
R
OH
OH
7
13-15
1
12
 
cmpd R 
IC50 (nM)a 
selectivity 
factord cmpd R IC50 (nM)
a selectivity factord 
17β- 
HSD1b 
17β- 
HSD2c 
   17β- 
HSD1b 
17β- 
HSD2c 
 
1 H 69 1950 28 7 H 173 745 4 
     13 CH3 567 856 1 
     14 
 
493e nt  
12 
OH
 
>1000 nt  15 
OH
 
119 188 2 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, substrate 3H-E1 + E1 [500 
nM], cofactor NADH [500 μM], cHuman placenta, microsomal fraction, substrate 3H-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 
(17β-HSD2)/ IC50 (17β-HSD1); epredicted value, obtained with the LOGIT transformed; ni: no inhibition, nt: not tested 
Concerning the substitution of the hydroxyphenyl rings, different groups were introduced either on the meta-
hydroxyphenyl ring (compounds 16 to 20) or on the para-hydroxyphenyl moiety (compounds 21 to 28, Table 3). 
The synthesis of compounds bearing ortho-(to the heterocycle)-substituents at the hydroxyphenyl moieties was not 
considered, as the conformational constraints induced by the ortho-effect will not allow the compound to adopt a 
planar geometry. Planarity of our structures was considered as necessary to mimic the steroidal substrate.27,28 
Introduction of a substituent in position 5 on the meta-hydroxyphenyl moiety resulted in case of a methyl group 
in a reduction of activity (16, IC50= 629 nM vs. 1, IC50= 69 nM). The introduction of a fluorine atom led to a slight 
increase in activity in comparison to the unsubstituted compound 1 (17, IC50= 42 nM vs. 1, IC50= 69 nM). Moving 
these functional groups to position 4 gave a highly active fluorinated compound 19 (IC50= 113 nM) and a very weak 
methylated inhibitor 18 (IC50> 5000 nM). Substituents have also been introduced in position 5 on the para-
hydroxyphenyl ring: a polar group like hydroxy (compound 22) or a bulky substituent like the phenyl (compound 
25) in ortho- of the para-OH induced a decrease in activity compared to thiophene compound 1 (IC50= 69 nM vs. 
IC50= 402 nM and >5000 nM for 22 and 25, respectively). The introduction of a fluorine substituent into the same 
position led to the highly potent compound 23 (IC50= 8 nM) while substituents like methyl or trifluoromethyl 
showed similar or slightly better activities compared to the reference compound 1 (IC50= 69 nM vs. IC50= 46 nM 
and 38 nM for 21 and 24, respectively). Other functional groups showing a higher flexibility like ethylacrylate 
(compound 26), phenylacrylamide (compound 27) or phenylpropaneamide (compound 28) were also synthesized 
and the resulting compounds 26, 27 and 28 turned out to have weaker inhibitory activity compared to the 
unsubstituted thiophene 1 (IC50= 69 nM vs. 130, 427 and 620 nM for 26, 27 and 28, respectively). The low activity 
of the unconjugated compound 28 indicates that an overall distributed electronic density is an important parameter 
for activity. These results indicate that there is space available in this area for substituents but the nature of the 
substituents is probably not yet optimal (Table 3). 
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Table 3: Effect of a supplementary substituent on the hydroxyphenyl moieties on the inhibition of the human 17β-
HSD1 and 17β-HSD2 
S
OH
OH
S
OH
OH
R
1
16-20
R
21-28
4
5
 
cmpd R 
IC50 (nM)a 
selectivity 
factord 
17β- 
HSD1b 
17β- 
HSD2c 
 
1 H 69 1950 28 
16 5-CH3 629 2584 4 
17 5-F 42 463 11 
18 4-CH3 >5000 nt  
19 4-F 113 183 2 
20 4-OH >5000 nt  
21 CH3 46 1971 49 
22 OH 402 1636 4 
23 F 8 940 118 
24 CF3 38 97 3 
25 Ph >5000 nt  
26 
O
OEt  
130 502 4 
27 
O
N
H  
427 468 1 
28 
O
N
H  
620 982 2 
aMean values of three determinations, standard deviation less than 15 %; bHuman placenta, cytosolic fraction, substrate 3H-E1 + E1 [500 
nM], cofactor NADH [500 μM], cHuman placenta, microsomal fraction, substrate 3H-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 
(17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not tested 
The influence of the introduction of a second fluorine on the highly active thiophene 23 (IC50= 8 nM), either one 
F on each hydroxyphenyl ring or two F on the same hydroxyphenyl moiety, was also examined (Table 4). When the 
two F were located on each hydroxyphenyl moieties, the 4-substituted fluoro derivative (compound 30) is slightly 
more potent than the one with the fluorine in 5-position (29, IC50= 29 nM, vs. 30 IC50= 17 nM). A small decrease in 
activity was observed when the two fluorine substituents were present at the same hydroxyphenyl ring (compound 
31, IC50= 56 nM). The exchange of the para-OH function of 23 by a fluorine atom (compound 32) confirmed the 
essential role of this para-hydroxy moiety as previously observed. 
Methyl and fluorine substituents have been identified as functional groups able to increase the inhibitory activity 
of the 2,5-bis(hydroxyphenyl) thiophene 1. Previously28 we reported that other central core structures like 2,4-
thiophene, 2,5-thiazole and 1,4-benzene lead to highly active compounds. The influence of an additional methyl or 
fluorine substituent at these structures was therefore also investigated (Table 5). Introduction of CH3 or F into the 
para-hydroxyphenyl ring of 33, 36 and 38 resulting in compounds 34, 35, 37, 39 and 40 led to similarly active 
derivatives in case of 34 and 35 (IC50= 64 nM vs. 21, IC50= 46 nM). A decrease in inhibitory activity in the thiazole 
and in the benzene classes of compounds was observed compared to the thiophene family (37, IC50= 143 nM vs. 21, 
IC50= 46 nM; 40 and 41, IC50= 123 nM and 51 nM, respectively vs. 23, IC50= 8 nM). Amongst the investigated 
molecules, introduction of a methyl or fluorine substituent led only in the class of the bis(hydroxyphenyl) 
thiophenes to an increase in activity. 
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Table 4: Effect of two additional fluorine atoms on the 17β-HSD1 and 17β-HSD2 inhibitory activity 
S
OH
OH
F
S
OH
OH
F
F
S
OH
F
F
23
29-30
R1
31 32
4
5
 
cmpd R1 
IC50 (nM)a selectivity 
factord 17β- 
HSD1b 
17β- 
HSD2c 
23 H 8 940 118 
29 5-F 29 227 8 
30 4-F 17 218 13 
31  56 312 6 
32  780 2640 3 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, substrate 3H-E1 + E1 [500 
nM], cofactor NADH [500 μM], cHuman placenta, microsomal fraction, substrate 3H-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 
(17β-HSD2)/ IC50 (17β-HSD1); nt: not tested. 
Table 5: Influence of the core and a supplementary substituent on the inhibition of the human 17β-HSD1 and 17β-
HSD2 
OH
cycle
R2
R1
21-23
33-42  
cmpd cycle R1 R2 
IC50 (nM)a 
selectivity 
factord 
17β- 
HSD1b 
17β- 
HSD2c 
 
21 
S  
CH3 OH 46 1971 49 
23 F OH 8 940 118 
       
33 
S  
H OH 77 1270 16 
34 CH3 OH 64 869 14 
35 F OH 64 510 8 
       
36 
S
N
 
H OH 50 4000 80 
37 CH3 OH 143 2023 14 
       38 
 
H OH 471 4509 10 
39 CH3 OH 171 1248 7 
40 F OH 123 872 7 
41 OH H 173 2259 21 
42 OH F 51 253 5 
aMean values of three determinations, standard deviation less than 13 %; bHuman placenta, cytosolic fraction, substrate 3H-E1 + E1 [500 
nM], cofactor NADH [500 μM], cHuman placenta, microsomal fraction, substrate 3H-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], dIC50 
(17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not tested 
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Selectivity: inhibition of 17β-HSD2 and affinities to the estrogen receptors α and β 
In order to gain insight into the selectivity of the most active compounds, inhibition of 17β-HSD2 and the 
relative binding affinities to the estrogen receptors α and β were determined. 
Since 17β-HSD2 catalyzes the inactivation of E2 into E1, inhibitory activity toward this enzyme must be 
avoided. The 17β-HSD2 inhibition was determined using an assay similar to the 17β-HSD1 test. Placental 
microsomes were incubated with tritiated E2 in the presence of NAD+ and inhibitor. Separation and quantification of 
labelled product (E1) was performed by HPLC using radio detection. A selection of the most potent 17β-HSD1 
inhibitors was tested for inhibition of 17β-HSD2. IC50 values and selectivity factors (IC50 HSD2 / IC50 HSD1) are 
presented in Tables 1 to 5. 
Mono-hydroxylated compounds (Table 1) exhibited a poor selectivity regarding 17β-HSD2, the most selective 
one being compound 5 with a selectivity factor of 5. This finding suggests that the para-OH is important for activity 
as well as for selectivity (selectivity of the para-meta derivative 1: 28). Introduction of further substituents (Tables 2 
to 5) into the highly active bis(hydroxyphenyl) scaffold induced a loss of selectivity against 17β-HSD2 except in 
case of compounds 21 and 23, which exhibit excellent selectivity factors of 49 and 118, respectively. 
A further prerequisite for 17β-HSD1 inhibitors to be used as potential drugs is that they do not show affinity for 
ERα and ERβ, since binding to these receptors could counteract the therapeutic concept of selective 17β-HSD1 
inhibition. The binding affinities of the most selective compounds of this study were determined using recombinant 
human protein in a competition assay applying [3H]-E2 and hydroxyapatite (Table 6). All tested compounds show 
very marginal to marginal affinity to the ERs except compound 23, which binds weakly to ERβ (RBA= 1 %). 
Compound 21 was evaluated for estrogenic effects on the ER-positive, mammary tumor T47D cell line. No 
agonistic, i.e. stimulatory effect was observed after application of compound 21 even at a concentration 1000 fold 
higher compared to E2.  
Table 6: Binding affinities for the human estrogen receptors α and β of selected compounds 
cmpd 
RBAa (%) 
ERαb ERβb 
1 0.1< RBA <1 1.5 
17 0.1< RBA <1 0.1< RBA <1 
21 < 0.01 < 0.01 
23 0.01< RBA <0.1 1 
30 0.1 0.01< RBA <0.1 
34 0.01< RBA <0.1 0.01< RBA <0.1 
37 0.01< RBA <0.1 < 0.01 
aRBA (relative binding affinity), E2: 100 %, mean values of three determinations, standard deviations less than 10 %; bHuman recombinant 
protein, incubation with 10 nM 3H-E2 and inhibitor for 1 h. 
Further biological evaluations 
Additionally, the intracellular potency of compounds 21, 23 and 37 on E2 formation was evaluated using a cell 
line which expresses both 17β-HSD1 and 17β-HSD2 (T47D cells). The compounds inhibited the formation of E2 
after incubation with labelled E1 showing IC50 values of 426 nM, 282 nM and 362 nM for 21, 23 and 37, 
respectively. These results indicate that the compounds are able to permeate the cell membrane and inhibit the 
transformation of E1 into E2. 
The same compounds (21, 23 and 37) were further investigated for inhibition of three human hepatic enzymes: 
CYP3A4, CYP2D6 and CYP2C19. The three compounds showed very little to weak inhibition of the hepatic CYP 
enzymes (10> IC50> 1.50 μM) except for CYP3A4 (IC50= 0.50 and 0.82 μM for 21 and 23, respectively) and 
CYP2C19 (IC50= 0.94 μM for 21) for which an enhanced inhibition was observed. 
The relatively high inhibition of CYP3A4 by 21 and 23 has to be taken into consideration for the further 
optimization process but should not have an impact on the proof of concept in vitro. 
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The pharmacokinetic profiles of the two most active and selective compounds of this study (21 and 23) were 
determined in rats after oral administration in a cassette dosing approach. Each group consisted of 4 male rats and 
the compounds were administered in doses of 10 mg/kg. Plasma samples were collected over 24 h and plasma 
concentrations were determined by HPLC-MS/MS. The pharmacokinetic parameters are presented in Table 7. The 
maximal concentration (Cmax obs) as well as the AUC-value is higher for compound 23 (Cmax= 1388.2 ng/mL, AUC= 
19407 ng/mL) than for compound 21 (Cmax= 905.0 ng/mL, AUC= 12275 ng/mL). The maximal plasma 
concentration (tmax obs) for compounds 21 and 23 was reached after 4.0 and 8.0 h, respectively. These data show that 
both compounds exhibit excellent pharmacokinetic properties in the rat and might therefore be good candidates for 
further experiments in disease-oriented rat models. 
Table 7: Pharmacokinetic parameters of compounds 21 and 23 in male rats after oral application (10 mg/kg) 
parametersa 
cmpd 
21 23 
Cmax obs (ng/mL) 905.0 1388.2 
Cz (ng/mL) 43.3 24.9 
tmax obs (h) 4.0 8.0 
tz (h) 24.0 24.0 
t1/2z (h) 3.8 2.7 
AUC0-∞ (ng/mL) 12275 19407 
a Cmax obs, maximal measured concentration; Cz, last analytical quantifiable concentration;tmax obs, time to reach the maximum measured 
concentration; tz, time of the last sample which has an analytical quantifiable concentration; t1/2z, half-life of the terminal slope of a 
concentration time curve; AUC0-∞, area under the concentration- time curve extrapolated to infinity. 
Computational chemistry 
Molecular modelling 
From the biological results it became apparent that introduction of a fluorine atom in ortho-position to the para-
OH phenyl thiophene (compound 23) led to a significant increase in the 17β-HSD1 inhibitory activity. To get an 
insight into the binding mode of this compound and to better understand the favourable interactions achieved by this 
inhibitor in the active site, computational studies were performed by means of the docking software GOLDv3.2 and 
Autodock 4.1. 
The choice of the 3D-structure of the enzyme, i.e. crystal structure, as well as the oxidation state of the cofactor 
i.e. NADPH or NADP+, used for the docking studies are crucial for obtaining reliable results.  
We focused on X-ray structures of 17β-HSD1 having a high resolution and showing a ternary complex (to get 
closer to the in vivo conditions). Three structures fulfilled these criteria: 1FDT and 1A27 both describing the ternary 
complex: enzyme-E2-NADP+ and 1I5R, describing the binary complex: enzyme-steroidal hybride inhibitor (HYC), 
the latter being an adenosine moiety linked to an E2 core via a C9-linker. These three crystal structures differ mainly 
in the location of the amino acids belonging to the flexible loop αG’βF (Pro187-Pro200). Since this loop borders 
both the SUB and the COF, its conformational variations strongly influence the size of both binding cavities. It is 
therefore important to take care of the position of this loop in the structures used for the docking studies.  
In the X-ray structure 1FDT, the residues 187-200 are not well resolved, but two plausible conformations for the 
loop (noted 1FDT-A and 1FDT-B) have been described.35 The backbones of these two loops are similar (RMSD of 
~ 1 Å), while the main difference is given by the orientation of the side chains, mainly concerning the four amino 
acids Phe192, Met193, Glu194 and Lys195. In 1FDT-A, Phe192 and Met193 are turned toward the outer part of the 
enzyme while Glu194 and Lys195 are oriented toward the substrate and the cofactor (extending the substrate 
binding site = open conformation). On the other hand, in 1FDT-B these two pairs of residues show a reversed 
orientation limiting length and volume of the steroid binding site compared to 1FDT-A (= closed conformation). 
Although others22 have only considered 1FDT-B, we decided to investigate both conformations of this loop.  
Interestingly, the flexible loop in 1A27 shows a comparable geometry as observed in 1FDT-B, with Phe192 and 
Met193 oriented toward the nicotinamide moiety, also restricting the space in the substrate binding site. In case of 
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1I5R, the loop is shifted in direction of the cofactor, resulting in a different conformation compared to both 1FDT-A
and 1FDT-B. Although, like for 1FDT-A, it extends the SUB. 
The docking studies were performed with NADPH as cofactor, as it is described that NADPH is present in a 500 
fold higher concentration than its oxidized form NADP+ in living cells.43,44
Compound 23 was docked with NADPH into four different X-ray structures: 1FDT-A, 1FDT-B, 1A27 and 1I5R. 
Two different binding modes were observed for compound 23: in case of 1FDT-B and 1A27, the inhibitor is located 
exclusively in the steroid binding site (Figure 1) adopting a similar orientation as previously described for the 
bis(hydroxyphenyl) oxazole B27 (chart 1) while for 1FDT-A and 1I5R, the inhibitor is located in between the steroid 
and the cofactor binding sites, interacting with the nicotinamide moiety. In the following, this binding mode will be 
named as alternative binding mode (Figure 2).
Figure 1. Docking complex between 17β-HSD1 (X-ray 1FDT-B) and compound 23 (blue; SUB binding mode). 
NADPH, interacting residues and ribbon rendered tertiary structure of the active site are shown. Residues of the 
flexible loop are rendered in sticks and colored in yellow. Hydrogen bonds and π-π stackings (and hydrophobic 
interactions) are drawn in yellow and blue dashed lines, respectively. For comparison, E2 is depicted in magenta 
lines. Figures were generated with Pymol (http://www.pymol.org).
Figure 2. Docking complex between 17β-HSD1 (X-ray 1FDT-A) and compound 23 (green; alternative binding 
mode). NADPH, interacting residues and ribbon rendered tertiary structure of the active site are shown. Residues of 
the flexible loop are rendered in sticks and colored in blue. Hydrogen bonds and π-π stackings (and hydrophobic 
interactions) are drawn in yellow and blue dashed lines, respectively. For comparison, E2 is depicted in magenta 
lines.
In case of the steroidal binding mode (1FDT-B and 1A27, Figure 1) the following specific interactions can be 
observed: hydrogen bond interactions between the meta-hydroxy group of 23 and Ser142/Tyr155 (dO-O= 2.6 Å for 
both amino acids) and between the para-OH group and His221/Glu282 (dO-N= 2.8 Å and dO-O= 3.8 Å, Figure 1). 
Additionally, hydrophobic interactions and π-π stackings (Phe226, Phe259) are also involved.
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In the alternative binding mode obtained using 1FDT-A and 1I5R (Figure 2), compound 23 is also stabilized by 
hydrogen bond interactions: the meta-OH group forms a strong H-bond with the phosphate group of the cofactor 
(dO-O= 2.9 Å). The fluorine atom could establish halogen bonds with the backbone –NH- of Val143 and Gly144 (dF-
N= 3.2 Å and 3.8 Å, respectively), in addition to a halogen bond with the OH-group of Ser142 (dF-O= 3.5 Å) which is 
involved in the catalytic process. Further, the para-OH points perpendicular toward Phe259 (dO-centroid= 4.5 Å) 
indicating a possible OH-π interaction. This could explain the importance of this group observed in the SARs. 
Moreover, strong π-π stacking interactions seem to stabilize the inhibitor in this binding mode: between the meta-
OHphenyl-thiophene moiety and the nicotinamide part of the cofactor (parallel-displaced configuration; distance 
between the two ring centers, 4.3 Å) and between the para-OH-phenyl-thiophene moiety and Phe226 (T-shape 
conformation; closest C-C contact distance 3.7 Å). Moreover, electrostatic interactions between the sulfur atom of 
the heterocycle with the surrounding amino acids like Tyr155 and Ser142 might also play a role as described.45
The results presented so far suggest that both binding modes have to be considered as possible for this class of 
inhibitors. They depend mainly on the orientation of the flexible loop. There is only one conformation of the loop 
leading to a steroidal binding mode (1FDT-B/1A27). In case of 1FDT-A/1I5R the pose showing the alternative 
binding mode is obtained using two X-ray structures having two different conformations of the loop. Unfortunately, 
due to the almost identical scoring function values observed for both poses with the docking programs (Gold and 
Autodock), it was not possible to determine which model (1FDT-A/1I5R or 1FDT-B/1A27) is the most appropriate 
to describe the interactions between the inhibitor and the enzyme and therefore which is the most plausible binding 
mode. 
Comparing both poses obtained by docking of 23 in 1FDT-A and 1FDT-B shows that there is a common area in 
the neighbourhood of the catalytic tetrade which corresponds to the D-ring of the enzyme-substrate complex (Figure 
in Supporting Information).
Molecular Electrostatic Potential (MEP)
Recently we reported on the influence of the electronic density (MEP maps, “semi-QMAR”) on the potency of 
the inhibitors in this class of compounds.28 The 3D-structures of the inhibitors were virtually divided into three areas 
and a given optimal range of ESP values (in Hartree) was determined for each region (-1.7 to -1.2 × 10-2 for I, -1.6 
to -0.9 × 10-2 for II and -1.2 to -0.5 × 10-2 for III). The MEPs of compound 23 were calculated as shown in Figure 3. 
The molecular ESP distribution observed (-1.8 to -1.2 × 10-2 for I, -1.6 to -0.8 × 10-2 for II and -1.1 to -0.4 × 10-2 for 
III) fitted well to the optimal ranges identified previously, confirming the correlation between the ESP range and the 
potency of the compounds. The MEP maps of the natural substrate E1 and of E2 were also calculated (Figure 3) and 
compared to the one of 23. The finding that the ESP distribution of 23 and E2/E1 is very different might be an 
indication that compound 23 does not bind in the same way as the steroid. 
Figure 3. Structures and MEP maps of both ventral (steroidal α-side) and dorsal (steroidal β-side) views of 
truncated NADPH (A), thiophene 23 (B), E1 (C) and E2 (D). MEP surfaces were plotted with GaussView 3.09.
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According to the alternative binding mode, the meta-hydroxyphenyl thiophene part of 23 overlaps with the 
nicotinamide part of the cofactor and forms stabilizing π-π interactions. The ESP distribution of these two entities 
should therefore show complementarity. To get an insight into this, the MEP map of a truncated NADPH –the 
counterpart of the meta-OHphenyl-thiophene moiety- was calculated by ab initio methods. As can be seen in Figure 
3 a certain complementarity was observed. The NADPH MEP maps give the explanation for the observation28 that a 
strong polarization between the vertex and the base of the central ring of the inhibitors is negative for binding. 
Positive ESP values on the vertex side lead to repulsion effects with the nicotinamide and therefore reduce the 
inhibitory activity. This finding indicates that this class of compound might bind according to the alternative binding 
mode (Figure 2). However, this hypothesis needs to be further investigated. 
Discussion and Conclusion 
Structural optimizations of compound 1 led to the discovery of new substituted 2,5-bis(hydroxyphenyl)thiophene 
derivatives: the fluorinated 23 and the methylated 21 being the most active and selective inhibitors identified.  
From a previous work in this class of compounds28 it was demonstrated that removal of one of the two 
hydroxyphenyl moieties is detrimental for the activity. In this paper it was shown that replacement of the para-OH 
function by a bioisoteric group like F, NH2, SH, CN leads to a reduction of activity. The lack of hydrogen donating 
properties of the fluoro and cyano substituents might not be the only reason for this decrease in activity as the amino 
and the thiol derivatives are also less active than the parent compound 1. Interestingly, the omission of a C1-linker 
between the methylsulfonamide moiety and the phenyl ring (compound 9) resulted in an increase of potency. 
Deprivation of electrons from the phenyl ring, obviously is necessary for good inhibition. The relatively high 
activity observed for compound 11 (IC50= 350 nM) especially compared to compound 9 (IC50= 523 nM) 
demonstrates that in the protein there is some space available in this position for a bulky substituent. Furthermore, 
the tolyl group might also be involved in the stabilization of the inhibitor in the binding site, establishing π-π 
stacking interactions with appropriate amino acid residues present in this region. 
With the aim to increase the activity and the selectivity in this class of compounds, substituents were introduced 
on the 2,5-bis(hydroxyphenyl)thiophenes 1 and 7. This was successful for compound 15 (IC50= 119 nM vs. 7, IC50= 
216 nM). Apparently, the formation of an additional hydrogen bond is responsible for this increase in inhibitory 
activity, while a pure π-π stacking interaction as supposed for compound 14 is not sufficient. The 2,5-disubstituted 
thiophenes 12 and 15 differ only in the position of one hydroxy group (para: compound 12, meta: compound 15). 
The fact that compound 15 shows a much higher activity (IC50= 119 nM vs. 12, IC50> 1000 nM) indicates that only 
in case of 15 the geometry of the OH groups is acceptable for a reasonable interaction. It demonstrates, as observed 
already,24,27 a sharp SAR and a reduced flexibility in this region of the active site. 
The trisubstituted compound 14 bearing a phenyl substituent at the thiophene differs from the triazole A32 (Chart 
2) only in the nature of the heterocycle. The following comparisons highlight the importance of the heterocycle for 
the potency of the molecules: inactive compound A vs. thiophene 14 (IC50= 493 nM), thiophene 21 (IC50= 46 nM) 
vs. thiazole 37 (IC50= 143 nM) and thiophene 23 (IC50= 8 nM) vs. benzene 40 (IC50= 123 nM). It becomes apparent 
that the thiophene ring is the most appropriate heterocycle for high inhibitory activity. Provided that all compounds 
bind according to the same binding mode, there are different explanations for these results: 1. The presence and the 
position of one or several nitrogens in the heterocycle modulate the MEP distribution of the compound and in 
particular the electronic distribution of the meta-hydroxyphenyl moiety28 – in case of the compounds under 
consideration resulting to inadequate electronic properties for binding, 2. Similarly the replacement of the sulfur 
leads to an inadequate repartition of the electron density in the heterocycle 3. A reduced flexibility in the binding 
site is responsible that the enzyme can not adjust its geometry to the different hydroxyphenyl moieties (depending 
on the heterocycle, the angles between the phenyl-OHs are different). 
A high increase in activity and selectivity could be reached by introduction of substituents into the 
hydroxyphenyl moiety, especially when the substituent is located ortho- of the para-hydroxyphenyl group 
(compounds 21 to 24). Not all substituents are equally well tolerated: there is no space available for a phenyl group 
(compound 25). An additional OH group (compound 22) is obviously not able to establish specific interactions 
while small lipophilic substituents (methyl, 21; fluorine, 23 and trifluoromethyl, 24) are enhancing the activity. 
There is enough space in this region of the enzyme to introduce a flexible chain (26) but conjugation seems to be 
necessary to achieve a higher activity as already observed with the tolylsulfonamide substituent (compound 11).  
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The positive influence of the fluorine atom has often been demonstrated in medicinal chemistry46-48 and was also 
proven in this study with compound 23 (IC50= 8 nM). The position of the fluorine is decisive for an increase in 
activity: it has to be in meta-position (17 and 23). Highest activity was achieved in ortho- of the hydroxy group 
(compound 23). This indicates that either direct interactions of the fluorine with amino acid residues in this region of 
the active site or the increase of acidity of the neighbouring OH groups might be responsible for this effect. 
Introduction of a second fluorine atom into this fluorohydroxyphenyl ring (compound 31) does not enhance the 
activity suggesting that the effects of the fluorine are not additive. A second fluorine was also added to the other 
hydroxyphenyl moiety (in ortho- and meta- of the meta-OH group) leading to compounds 29 and 30. However, no 
enhancement of the activity compared to the monofluorinated 23 was observed indicating that there are no specific 
interactions of the second fluoro substituent. 
A close look at the X-ray structures of 17β-HSD1 crystallized in presence of different steroidal ligands showed 
that the flexible loop (amino acids 187-200) can adopt different geometries depending on the nature of the ligand 
and on the absence or presence of the cofactor in the catalytic region. It indicates that some parts of the enzyme can 
adapt their geometry to the molecule present in the active site in order to stabilize it. However, other parts are rigid, 
explaining the sharp SAR observed in this paper and previously.27,28 
Two plausible conformations of the loop in the ternary complex enzyme-E2-NADP+, PDB code: 1FDT, have 
been described (1FDT-A, 1FDT-B).We have shown that both can be used for docking studies. In case of 1FDT-A 
the substrate binding pocket is extended, enhancing the volume of the active site. It is therefore a good model to 
evaluate an alternative binding mode for inhibitors which are larger than the steroid. A binding mode as observed 
for steroids in the X-ray structures was found when the loop closes the SUB (1FDT-B). Surprisingly, when the 
inhibitors were docked to the protein with the loop in the open conformation, they interact with the nicotinamide 
part of the cofactor. MEP calculations showed a certain complementarity between the electronic density of 23 and of 
the nicotinamide moiety of the cofactor indicating that this alternative binding mode is not only plausible, it might 
be the one which is more likely.  
Up to now, designing compounds as potential 17β-HSD1 inhibitors, several groups37,49-51 tried to mimic the 
cofactor. Our finding of the above mentioned alternative binding mode makes another strategy very promising: the 
cofactor, which is likely to be present in the active site when the inhibitor is entering, could be used as partner to 
achieve additional interactions rather than trying to displace it.  
The most potent 17β-HSD1 inhibitors 21 and 23 exhibit a higher selectivity toward 17β-HSD2 compared to 
parent compound, (selectivity factors 49 and 118, respectively vs. 28 for 1). This indicates that the amino acids close 
to the CH3 or F substituents must have different properties in the two 17β-HSD enzymes, which could be further 
exploited to increase selectivity.  
The most potent inhibitors show only marginal to very little affinity to the ERα and no stimulation of cell 
proliferation (agonistic effect) in the ER-positive T47D cell line could be observed. The weak affinity of compound 
23 for ERβ may not be critical as it is reported that ERβ exhibits anti-proliferative effects in breast cancer cells.52 
Compound 23 might be used in an appropriate animal model to prove the concept of 17β-HSD1 inhibition with 
non-steroidal inhibitors. This compound shows a good pharmacokinetic profile in rats. 
In this paper, we described the synthesis of substituted bis(hydroxyphenyl)thiophenes, thiazoles and benzenes as 
inhibitors of 17β-HSD1 and the evaluation of their biological properties. The most promising compounds of this 
study, 21 and 23, exhibit high selectivity toward 17β-HSD2, marginal binding to ERα and excellent 
pharmacokinetic profiles in rats after peroral application. These new compounds provide useful tools to validate 
17β-HSD1 as a target for the treatment of estrogen-dependent diseases. 
Experimental section 
Chemical methods 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, 
Lancaster, Roth, Merck or Fluka and were used without purification.  
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Column chromatography (CC) was performed on silica gel (70-200 μm) coated with silica, preparative thin layer 
chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and reaction progress was 
monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel).  
IR spectra were recorded on a Bruker Vector 33 spectrometer (neat sample). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in δ (parts per million: ppm), by reference to the hydrogenated residues of deuteriated 
solvent as internal standard (CDCl3: δ = 7.24 ppm (1H NMR) and δ = 77 ppm (13C NMR), CD3OD: δ = 3.35 ppm 
(1H NMR) and δ = 49.3 ppm (13C NMR), CD3COCD3: δ = 2.05 ppm (1H NMR) and δ = 29.9 ppm (13C NMR), 
CD3SOCD3: δ = 2.50 ppm (1H NMR) and δ = 39.5 ppm (13C NMR)). Signals are described as s, d, t, q, dd, m, dt for 
singlet, doublet, triplet, quadruplet, doublet of doublets, multiplet and doublet of triplets, respectively. All coupling 
constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were recorded on a TSQ Quantum (Thermofischer) instrument. Elemental analyses (C, H, N) 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University. The purity of the 
compounds, which in all cases was higher than 95 %, was determined using 2 different methods: elemental analysis 
for compounds 3 to 6, 8 to 32, 34 and 37 and LC/MS for compounds 35, 39, 41 and 42. 
Compounds 2-bromo-5-(3-methoxyphenyl)thiophene (1b)28, 2-(3-methoxyphenyl)-5-(4-methoxyphenyl)-
thiophene (1a)28, 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol (1)28, 2-(3-methoxyphenyl)-5-phenylthiophene (2a)28, 3-
(5-phenyl-2-thienyl)phenol (2)28, 2,5-bis(3-methoxyphenyl)thiophene (7a)28, 3,3'-thiene-2,5-diyldiphenol (7)28, 2-
bromo-5-(4-methoxyphenyl)thiophene (16c)28 4-bromo-2-iodo-1-methoxy-benzene (25d)53, 5-bromo-2-
methoxybiphenyl (25c)54, [6-methoxy-1,1'-biphenyl-3-yl]boronic acid (25b)54, [3-(hydroxymethyl)-4-
methoxyphenyl]-boronic acid (26d)55, 4-bromo-2-(3-methoxyphenyl)thiophene (33b)28, 2-(3-methoxyphenyl)-4-(4-
methoxyphenyl)thiophene (33a)28, 3-[4-(4-hydroxyphenyl)-2-thienyl]phenol (29)28, 5-bromo-2-(3-methoxyphenyl)-
1,3-thiazole (36b)28, 2-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (36a)28, 3-[5-(4-hydroxyphenyl)-1,3-
thiazol-2-yl]phenol (36)28, 4'-bromo-3-methoxybiphenyl (38b)28, 3,4''-dimethoxy-1,1':4',1''-terphenyl (38a)28, 
1,1':4',1''-terphenyl-3,4''-diol (38)28, 3,3''-dimethoxy-1,1':4',1''-terphenyl (40a)28 and 1,1':4',1''-terphenyl-3,3''-diol 
(40)28 were prepared following described procedures. 
General procedure for Suzuki coupling 
Method A 
A mixture of aryl bromide (1 eq), aryl boronic acid (1.2 eq), caesium carbonate (2.2 eq) and 
tetrakis(triphenylphosphine) palladium (0.01 eq) was suspended in an oxygen free DME/EtOH/water (1:1:1) 
solution. The reaction mixture was exposed to microwave irradiation (15 min, 150 W, 150 °C, 15 bars). After 
cooling to rt, water was added and the aqueous layer was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered and concentrated to dryness. The product was 
purified by column chromatography (CC). 
Method B: 
A mixture of arylbromide (1 eq), aryl boronic acid (1 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.05 eq) in an oxygen free toluene/water (1:1) solution was stirred at 100 °C 
for 20 h under nitrogen atmosphere. The reaction mixture was cooled to rt. The aqueous layer was extracted with 
ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by CC. 
General procedure for ether cleavage 
Method C:  
To a solution of methoxyphenyl derivative (1 eq) in dry dichloromethane at -78 °C (dry ice/acetone bath), boron 
tribromide in dichloromethane (1 M, 3 eq per methoxy function) was added dropwise. The reaction mixture was 
stirred for 20 h at rt under nitrogen atmosphere. Water was added to quench the reaction, and the aqueous layer was 
extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, 
filtered and concentrated to dryness. The product was purified by preparative thin layer chromatography (TLC). 
2-(4-Fluorophenyl)-5-(3-methoxyphenyl)thiophene (3a). The title compound was prepared by reaction of 2-
bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 4-fluorophenylboronic acid (94 mg, 0.67 mmol), 
caesium carbonate (383 mg, 1.24 mmol) and tetrakis(triphenylphosphine) palladium (6.4 mg, 5.6 μmol) according to 
method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 75 % (120 mg). 
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3-[5-(4-Fluorophenyl)-2-thienyl]phenol (3). The title compound was prepared by reaction of 2-(4-
fluorophenyl)-5-(3-methoxyphenyl)thiophene (3a) (80 mg, 0.28 mmol) and boron tribromide (0.84 mmol) according 
to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 68 % (52 mg); MS 
(ESI): 270 (M+H)+; Anal. (C16H11FOS) C, H, N. 
4-[5-(3-Methoxyphenyl)-2-thienyl]aniline (4a). The title compound was prepared by reaction of 2-bromo-5-(3-
methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 4-aminophenylboronic acid (92 mg, 0.67 mmol), caesium 
carbonate (383 mg, 1.24 mmol) and tetrakis(triphenylphosphine) palladium (6.4 mg, 5.6 μmol) according to method 
A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 63 % (100 mg).  
3-[5-(4-Aminophenyl)-2-thienyl]phenol (4). The title compound was prepared by reaction of 4-[5-(3-
methoxyphenyl)-2-thienyl]aniline (4a) (100 mg, 0.37 mmol) and boron tribromide (1.11 mmol) according to method 
C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 82 % (82 mg); MS (ESI): 268 
(M+H)+; Anal. (C16H13NOS) C, H, N. 
4-[5-(3-Methoxyphenyl)-2-thienyl]benzenethiol (5a). The title compound was prepared by reaction of 2-
bromo-5-(3-methoxyphenyl)thiophene (1b) (250 mg, 0.93 mmol), 4-mercaptophenylboronic acid (172 mg, 1.12 
mmol), caesium carbonate (636 mg, 2.05 mmol) and tetrakis(triphenylphosphine) palladium (10.8 mg, 9.3 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 61 % (160 mg). 
3-[5-(4-Sulfanylphenyl)-2-thienyl]phenol (5). The title compound was prepared by reaction of 4-[5-(3-
methoxyphenyl)-2-thienyl]benzenethiol (5a) (150 mg, 0.50 mmol) and boron tribromide (1.50 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 81 % (115 mg); MS 
(ESI): 285 (M+H)+; Anal. (C16H12OS2) C, H, N. 
4-[5-(3-Methoxyphenyl)-2-thienyl]benzonitrile (6a). The title compound was prepared by reaction by reaction 
of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (200 mg, 0.74 mmol), 4-cyanophenylboronic acid (131 mg, 0.89 
mmol), caesium carbonate (508 mg, 1.64 mmol) and tetrakis(triphenylphosphine) palladium (8.5 mg, 7.4 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 27 % (60 mg).  
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzonitrile (6). The title compound was prepared by reaction of 4-[5-(3-
methoxyphenyl)-2-thienyl]benzonitrile (6a) (42 mg, 0.14 mmol) and boron tribromide (0.42 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 62 % (25 mg); MS 
(APCI): 277 (M)+; Anal. (C17H11NOS) C, H, N. 
2-(3-Fluorophenyl)-5-(3-methoxyphenyl)thiophene (8a). The title compound was prepared by reaction of 2-
bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3-fluorophenylboronic acid (94 mg, 0.67 mmol), 
caesium carbonate (381 mg, 1.22 mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 μmol) according to 
method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 82 % (130 mg).  
 3-[5-(3-Fluorophenyl)-2-thienyl]phenol (8). The title compound was prepared by reaction of 2-(3-
fluorophenyl)-5-(3-methoxyphenyl)thiophene (8a) (130 mg, 0.45 mmol) and boron tribromide (1.35 mmol) 
according to method C. The product was purified by preparative TLC (dichloromethane/methanol 99:1); yield: 66 % 
(82 mg); MS (ESI): 271 (M+H)+; Anal. (C16H11FOS) C, H, N.  
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (160 mg, 0.60 mmol), 3-
methylsulfonylaminophenylboronic acid (155 mg, 0.72 mmol), caesium carbonate (410 mg, 1.32 mmol) and 
tetrakis(triphenylphosphine) palladium (6.9 mg, 6.0 μmol) according to method A. The product was purified by CC 
(petroleum ether/ethyl acetate 6:4); yield: 75 % (150 mg). 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9). The title compound was prepared by 
reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9a) (150 mg, 0.44 mmol) and boron 
tribromide (1.32 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 
1:1); yield: 61 % (92 mg); MS (ESI): 346 (M+H)+; Anal. (C17H15NO3S2) C, H, N 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10a). The title compound was prepared 
by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3-
[(methylsulphonylamino)methyl]-benzeneboronic acid (153 mg, 0.67 mmol), caesium carbonate (382 mg, 1.23 
mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 μmol) according to method A. The product was 
purified by CC (petroleum ether/ethyl acetate 8:2); yield: 58 % (122 mg). 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10). The title compound was prepared by 
reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10a) (122 mg, 0.37 mmol) and boron 
tribromide (1.11 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 
1:1); yield: 33 % (44 mg); MS (ESI): 360 (M+H)+; Anal. (C18H17NO3S2) C, H, N. 
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N-(3-[5-(3-Methoxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), [3-[[(4-
methylphenyl)sulfonyl]amino]phenyl]-boronic acid (195 mg, 0.67 mmol), caesium carbonate (383 mg, 1.23 mmol) 
and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 μmol) according to method A. The product was purified by 
CC (petroleum ether/ethyl acetate 9:1); yield: 88 % (214 mg). 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11). The title compound was 
prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11a) (214 mg, 
0.49 mmol) and boron tribromide (1.47 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 75 % (156 mg); MS (APCI): 421 (M)+; Anal. (C23H19NO3S2) C, H, N. 
3,5-Dibromo-2-(3-methoxyphenyl)thiophene (12c). The title compound was prepared by reaction of 2,3,5-
tribromothiophene (100 mg, 0.31 mmol), 3-methoxybenzeneboronic acid (46 mg, 0.31 mmol), sodium carbonate (67 
mg, 0.62 mmol) and tetrakis(triphenylphosphine) palladium (17.9 mg, 15.5 μmol) according to method B heating 
the reaction 4 h instead of 20 h. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 23 % (25 
mg). 
3-Bromo-2-(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12b). The title compound was prepared by 
reaction of 3,5-dibromo-2-(3-methoxyphenyl)thiophene (12c) (500 mg, 1.43 mmol), 4-methoxybenzeneboronic acid 
(268 mg, 1.72 mmol), sodium carbonate (333 mg, 3.15 mmol) and tetrakis(triphenylphosphine) palladium (82.6 mg, 
71.5 μmol) according to method B. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 52 % 
(278 mg). 
2,3-Bis(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12a). The title compound was prepared by 
reaction of 3-bromo-2-(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12b) (250 mg, 0.67 mmol), 3-
methoxybenzeneboronic acid (124 mg, 0.80 mmol), sodium carbonate (142 mg, 1.34 mmol) and 
tetrakis(triphenylphosphine) palladium (38.7 mg, 33.5 μmol) according to method B. The product was purified by 
CC (petroleum ether/ethyl acetate 9:1); yield: 72 % (194 mg). 
3,3’-[5-(4-Hydroxyphenyl)thiene-2,3-diyl]diphenol (12). The title compound was prepared by reaction of 2,3-
bis(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12a) (100 mg, 0.24 mmol) and boron tribromide (2.16 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 92 % 
(79 mg); MS (ESI): 359 (M-H)+; Anal. (C22H16O3S) C, H, N. 
3,3’-(3-Methylthiene-2,5-diyl]diphenol (13). The title compound was prepared by reaction of 2,5-dibromo-3-
methylthiophene (150 mg, 0.58 mmol), 3-hydroxybenzeneboronic acid (179 mg, 1.27 mmol), caesium carbonate 
(868 mg, 2.79 mmol) and tetrakis(triphenylphosphine) palladium (6.7 mg, 5.8 μmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 4:6); yield: 45 % (73 mg); MS (ESI): 281 (M-H)+; Anal. 
(C17H14O2S) C, H, N. 
3-Bromo-2,5-bis(3-methoxyphenyl)thiophene (14b). The title compound was prepared by reaction of 3,5-
dibromo-2-(3-methoxyphenyl)thiophene (12c) (250 mg, 0.72 mmol), 3-methoxybenzeneboronic acid (134 mg, 0.86 
mmol), sodium carbonate (148 mg, 1.44 mmol) and tetrakis(triphenylphosphine) palladium (41.6 mg, 36.0 μmol) 
according to method B. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 72 % (194 mg). 
2,5-Bis(3-methoxyphenyl)-3-phenylthiophene (14a). The title compound was prepared by reaction of 3-
bromo-2,5-bis(3-methoxyphenyl)thiophene (14b) (102 mg, 0.27 mmol), benzeneboronic acid (38 mg, 0.27 mmol), 
sodium carbonate (58 mg, 0.54 mmol) and tetrakis(triphenylphosphine) palladium (15.6 mg, 13.5 μmol) according 
to method B. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 54 % (51 mg). 
3,3’-(3-Phenylthiene-2,5-diyl)diphenol (14). The title compound was prepared by reaction of 2,5-bis(3-
methoxyphenyl)-3-phenylthiophene (14a) (50 mg, 0.13 mmol) and boron tribromide (0.78 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 53 % (49 mg); MS (ESI): 
345 (M+H)+; Anal. (C22H16O2S) C, H, N. 
2,3,5-Tris(3-methoxyphenyl)thiophene (15a). The title compound was prepared by reaction of 3-bromo-2,5-
bis(3-methoxyphenyl)thiophene (14b) (102 mg, 0.27 mmol), 3-methoxybenzene boronic acid (42 mg, 0.27 mmol), 
sodium carbonate (58 mg, 0.54 mmol) and tetrakis(triphenylphosphine) palladium (15.6 mg, 13.5 μmol) according 
to method B. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 34 % (37 mg). 
3,3’,3’’-Thiene-2,3,5-triyltriphenol (15). The title compound was prepared by reaction of 2,3,5-tris(3-
methoxyphenyl)thiophene (15a) (37 mg, 0.09 mmol) and boron tribromide (0.81 mmol) according to method C. The 
product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 67 % (21 mg); MS (ESI): 361 (M+H)+; 
Anal. (C22H16O3S) C, H, N. 
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5-(4-Methoxyphenyl)-2-(boronic acid)thiophene (16b). To a solution of 2-bromo-5-(4-
methoxyphenyl)thiophene (16c) (100 mg, 0.37 mmol, 1 eq) in anhydrous THF cooled to -78 °C for 5 min, n-BuLi 
(1.6 M in hexane, 0.28 mL, 0.44 mmol, 1.2 eq) was added dropwise and stirred at -78 °C. After 15 min, triethyl 
borate (0.37 mL, 2.22 mmol, 6 eq) was added at -78°C and the mixture was stirred for 2 h. After warming to rt, the 
crude material was acidified with 20 mL of a 1N hydrochloric acid solution. The aqueous layer was washed with 
ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced 
pressure. The title compound was not characterized and used without further purification. 
2-(3-Methoxyphenyl-5-methylphenyl)-5-(4-methoxyphenyl)thiophene (16a). The title compound was 
prepared by reaction of 1-bromo-3-methoxy-5-methylbenzene (150 mg, 0.74 mmol), [5-(4-methoxyphenyl)-2-
thienyl]-boronic acid (16b) (206 mg, 0.88 mmol), sodium carbonate (181 mg, 1.76 mmol) and 
tetrakis(triphenylphosphine) palladium (42.7 mg, 37.0 μmol) according to method B. The product was purified by 
CC (hexane/ethyl acetate 7:3); yield: 22 % (50 mg). 
3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol (16). The title compound was prepared by reaction of 2-
(3-methoxyphenyl-5-methylphenyl)-5-(4-methoxyphenyl)thiophene (16a) (50 mg, 0.16 mmol) and boron tribromide 
(0.96 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 
90 % (41 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, N. 
2-(3-Fluoro-5-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (17a). The title compound was prepared by 
reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (200 mg, 0.75 mmol), 3-fluoro-5-methoxybenzeneboronic 
acid (152 mg, 0.89 mmol), caesium carbonate (513 mg, 1.65 mmol) and tetrakis(triphenylphosphine) palladium (8.7 
mg, 7.5 μmol) according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 43 % (122 
mg). 
3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol (17). The title compound was prepared by reaction of 2-(3-
fluoro-5-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (17a) (100 mg, 0.32 mmol) and boron tribromide (1.92 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 7:3); yield: 88 % 
(80 mg); MS (APCI): 286 M+; Anal. (C16H11FO2S) C, H, N. 
5-[5-(4-Methoxyphenyl)-2-thienyl]-2-methylphenol (18a). The title compound was prepared by reaction of 5-
bromo-2-methylphenol (250 mg, 1.34 mmol), [5-(4-methoxyphenyl)-2-thienyl]-boronic acid (16b) (690 mg, 2.95 
mmol), caesium carbonate (914 mg, 2.94 mmol) and tetrakis(triphenylphosphine) palladium (15.5 mg, 13.4 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 47 % (193 mg). 
5-[5-(4-Hydroxyphenyl)-2-thienyl]-2-methylphenol (18). The title compound was prepared by reaction of 5-
[5-(4-methoxyphenyl)-2-thienyl]-2-methylphenol (18a) (161 mg, 0.54 mmol) and boron tribromide (3.24 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 7:3); yield: 27 % (42 
mg); MS (ESI): 283 (M+H)+; Anal. (C17H14O2S) C, H, N. 
2-(4-Fluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (19a). The title compound was prepared by 
reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (200 mg, 0.75 mmol), 4-fluoro-3-methoxybenzeneboronic 
acid (152 mg, 0.89 mmol), caesium carbonate (553 mg, 1.78 mmol) and tetrakis(triphenylphosphine) palladium (8.7 
mg, 7.5 μmol) according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 49 % (149 
mg). 
2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol (19). The title compound was prepared by reaction of 2-(4-
fluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (19a) (100 mg, 0.32 mmol) and boron tribromide (1.92 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 7:3); yield: 88 % 
(80 mg); MS (ESI): 287 (M+H)+; Anal. (C16H11FO2S) C, H, N. 
2-(3,4-Dimethoxyphenyl)-5-(4-methoxyphenyl)thiophene (20a). The title compound was prepared by reaction 
of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (195 mg, 0.73 mmol), 3,4-dimethoxybenzene boronic acid (160 
mg, 0.88 mmol), caesium carbonate (500 mg, 1.61 mmol) and tetrakis(triphenylphosphine) palladium (8.4 mg, 7.3 
μmol) according to method A. The product was purified by CC (dichloromethane/methanol 99:1); yield: 46 % (119 
mg). 
4-[5-(4-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol (20). The title compound was prepared by reaction of 2-
(3,4-dimethoxyphenyl)-5-(4-methoxyphenyl)thiophene (20a) (100 mg, 0.31 mmol) and boron tribromide (2.79 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 17 % 
(49 mg); MS (ESI): 285 (M+H)+; Anal. (C16H12O3S) C, H, N. 
2-(4-Methoxy-3-methylphenyl)-5-(3-methoxyphenyl)thiophene (21a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (250 mg, 0.92 mmol), 3-methyl-4-methoxybenzeneboronic 
acid (152.8 mg, 0.92 mmol), sodium carbonate (243 mg, 2.36 mmol) and tetrakis(triphenylphosphine) palladium 
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(53.1 mg, 46.0 μmol) according to method B. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 54 
% (154 mg). 
4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol (21). The title compound was prepared by reaction of 2-
(4-methoxy-3-methylphenyl)-5-(3-methoxyphenyl)thiophene (21a) (100 mg, 0.32 mmol) and boron tribromide (1.92 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 79 % 
(72 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, N. 
2-(3,4-Dimethoxyphenyl)-5-(3-methoxyphenyl)thiophene (22a). The title compound was prepared by reaction 
of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (206 mg, 1.14 mmol), 3,4-dimethoxybenzeneboronic acid (247 mg, 
1.36 mmol), caesium carbonate (779 mg, 2.51 mmol) and tetrakis(triphenylphosphine) palladium (13.2 mg, 11.4 
μmol) according to method A. The product was purified by CC (dichloromethane/methanol 99:1); yield: 34 % (126 
mg). 
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol (22). The title compound was prepared by reaction of 2-
(3,4-dimethoxyphenyl)-5-(3-methoxyphenyl)thiophene (22a) (100 mg, 0.32 mmol) and boron tribromide (2.88 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 61 % 
(56 mg); MS (ESI): 283 (M-H)+; Anal. (C16H12O3S) C, H, N. 
2-(3-Fluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (23a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (370 mg, 1.37 mmol), 3-fluoro-4-methoxybenzeneboronic 
acid (255 mg, 1.50 mmol), caesium carbonate (717 mg, 3.01 mmol) and tetrakis(triphenylphosphine) palladium 
(15.8 mg, 13.7 μmol) according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 98 
% (421 mg). 
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol (23). The title compound was prepared by reaction of 2-(3-
fluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (23a) (240 mg, 0.76 mmol) and boron tribromide (4.56 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 90 % 
(195 mg); MS (ESI): 285 (M-H)+; Anal. (C16H11FO2S) C, H, N. 
2-(3-Methoxyphenyl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]thiophene (24a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (408 mg, 1.51 mmol), 3-trifluoromethyl-4-
methoxybenzeneboronic acid (398 mg, 1.81 mmol), caesium carbonate (1033 mg, 3.32 mmol) and 
tetrakis(triphenylphosphine) palladium (17.5 mg, 15.1 μmol) according to method A. The product was purified by 
CC (hexane/ethyl acetate 7:3); yield: 75 % (412 mg). 
4-[5-(3-Hydroxyphenyl)-2-thienyl]-2-(trifluoromethyl)phenol (24). The title compound was prepared by 
reaction of 2-(3-methoxyphenyl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]thiophene (24a) (300 mg, 0.82 mmol) and 
boron tribromide (4.95 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl 
acetate 1:1); yield: 98 % (272 mg); MS (ESI): 285 (M-H)+; Anal. (C17H11F3O2S) C, H, N. 
2-(6-Methoxybiphenyl-3-yl)-5-(3-methoxyphenyl)thiophene (25a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (287 mg, 1.07 mmol), [6-methoxy-1,1'-biphenyl-3-
yl]boronic acid (25b) (338 mg, 1.29 mmol), sodium carbonate (250 mg, 2.35 mmol) and 
tetrakis(triphenylphosphine) palladium (61.8 mg, 53.5 μmol) according to method B. The product was purified by 
CC (hexane/ethyl acetate 7:3); yield: 35 % (135 mg). 
5-[5-(3-Hydroxyphenyl)-2-thienyl]biphenyl-2-ol (25). The title compound was prepared by reaction of 2-(6-
methoxybiphenyl-3-yl)-5-(3-methoxyphenyl)thiophene (25a) (100 mg, 0.26 mmol) and boron tribromide (1.56 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 88 % 
(81 mg); MS (ESI): 343 (M-H)+; Anal. (C22H16O2S) C, H, N. 
[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]methanol (26c). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (408 mg, 1.51 mmol), [3-(hydroxymethyl)-4-
methoxyphenyl]-boronic acid (26d) (329 mg, 1.81 mmol), caesium carbonate (1032 mg, 3.32 mmol) and 
tetrakis(triphenylphosphine) palladium (17.5 mg, 15.1 μmol) according to method A. The product was purified by 
CC (hexane/ethyl acetate 8:2); yield: 12 % (59 mg).  
2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]benzaldehyde (26b). To a solution of [2-methoxy-5-[5-(3-
methoxyphenyl)-2-thienyl]phenyl]methanol (26c) (100 mg, 0.31 mmol, 1 eq) in dichloromethane, pyridium 
chlorochromate (66 mg, 0.31 mmol, 1 eq) was added in small portions over 5 min and stirred at rt. After 30 min, the 
reaction was quenched with water. The resulting organic layer was dried over sodium sulfate, filtered and 
concentrated to dryness. The title compound was not characterized and used in the next step without purification.  
Ethyl (2E)-3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a). To a solution of sodium 
hydride (10.4 mg, 0.43 mmol, 1 eq) in anhydrous THF triethyl phosphonoacetate (93 μL, 0.46 mmol, 1.1 eq) was 
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added dropwise and stirred at rt. After 15 min, 2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]benzaldehyde (26b) 
(100 mg, 0.31 mmol, 0.6 eq) was added and stirred for 4 h at rt. To quench the reaction water was added and the 
resulting organic layer was washed with brine, dried over sodium sulfate, filtered, evaporated and purified by CC 
(hexane/ethyl acetate 7:3); yield: 98 % (120 mg).  
Ethyl (2E)-3-[2-hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]acrylate (26). The title compound was 
prepared by reaction of ethyl (2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a) (60 mg, 
0.15 mmol) and boron tribromide (0.90 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 17 % (10 mg); MS (APCI): 366 (M)+; Anal. (C21H18O4S) C, H, N. 
(2E)-3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27a). Ethyl (2E)-3-[2-
methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a) (720 mg, 2.22 mmol, 1 eq) in a solution of 
THF/water (2:1), was refluxed for 20 h together with lithium hydroxide (320 mg, 13.33 mmol, 6 eq). After cooling 
to rt, ether was added, the aqueous layer was acidified with hydrochloric acid 1N and washed with dichloromethane. 
The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure. The 
resulting carboxylic acid was solubilized in dichloromethane (180 mg, 0.53 mmol, 1 eq) and refluxed for 20 h with 
EDCI (102 mg, 0.53 mmol, 1 eq) and HOBt (72 mg, 0.53 mmol, 1 eq). After cooling to rt, the organic layer was 
washed with a 1.5 M sodium hydrogenocarbonate solution, brine, dried over sodium sulfate, evaporated under 
reduced pressure and purified by CC (hexane/ethyl acetate 7:3); yield: 51 % (120 mg); MS (ESI): 442 (M+H)+. 
(2E)-3-[2-Hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27).  
The title compound was prepared by reaction of (2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-
N-phenylacrylamide (27a) (55 mg, 0.13 mmol) and boron tribromide (0.78 mmol) according to method C. The 
product was purified by preparative TLC (hexane/ethyl acetate 4:6); yield: 31 % (17 mg); MS (ESI): 414 (M+H)+; 
Anal. (C25H19NO3S) C, H, N. 
3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28a). (2E)-3-[2-Methoxy-
5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27a) (50 mg, 0.11 mmol, 1 eq) was solubilized in a 
mixture of THF/EtOH (1:1). After addition of palladium hydroxide (1.7 mg, 0.01 mmol, 0.1 eq) the reaction was 
stirred at rt under nitrogen atmosphere for 20 h. The crude mixture was filtered and the organic layer was evaporated 
under reduced pressure; yield: quantitative. 
3-[2-Hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28). The title compound 
was prepared by reaction of 3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28a) 
(55 mg, 0.13 mmol) and boron tribromide (0.78 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 20 % (10 mg); MS (ESI): 416 (M+H)+; Anal. (C25H21NO3S) C, H, 
N. 
2-Bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b). The title compound was prepared by reaction of 2,5-
dibromothiophene (500 mg, 2.10 mmol), 3-fluoro-4-methoxybenzeneboronic acid (357 mg, 2.10 mmol), sodium 
carbonate (432 mg, 4.20 mmol) and tetrakis(triphenylphosphine) palladium (121 mg, 1.05 mmol) according to 
method B. The product was purified by CC (hexane/ethyl acetate 95:5); yield: 85 % (427 mg). 
2-(3-Fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (29a). The title compound was 
prepared by reaction of 2-bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b) (100 mg, 0.41 mmol), 3-fluoro-5-
methoxybenzeneboronic acid (85 mg, 0.50 mmol), caesium carbonate (280 mg, 0.90 mmol) and 
tetrakis(triphenylphosphine) palladium (4.7 mg, 4.1 μmol) according to method A. The product was purified by CC 
(hexane/ethyl acetate 9:1); yield: 82 % (113 mg). 
2-Fluoro-4-[5-(3-fluoro-5-hydroxyphenyl)thien-2-yl]phenol (29). The title compound was prepared by 
reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (30a) (100 mg, 0.30 mmol) and 
boron tribromide (1.80 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl 
acetate 6:4); yield: 38 % (35 mg); MS (APCI): 304 (M)+; Anal. (C16H10F2O2S) C, H, N. 
2-(3-Fluoro-4-methoxyphenyl)-5-(4-fluoro-3-methoxyphenyl)thiophene (30a). The title compound was 
prepared by reaction of 2-bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b) (100 mg, 0.41 mmol), 4-fluoro-3-
methoxybenzeneboronic acid (85 mg, 0.50 mmol), caesium carbonate (279 mg, 0.90 mmol) and 
tetrakis(triphenylphosphine) palladium (4.7 mg, 4.1 μmol) according to method A. The product was purified by CC 
(hexane/ethyl acetate 9:1); yield: 72 % (100 mg). 
2-Fluoro-4-[5-(4-fluoro-3-hydroxyphenyl)thien-2-yl]phenol (30). The title compound was prepared by 
reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (30a) (100 mg, 0.30 mmol) and 
boron tribromide (1.80 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl 
acetate 6:4); yield: 75 % (69 mg); MS (APCI): 304 (M)+; Anal. (C16H10F2O2S) C, H, N.  
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2-(3,5-Difluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (31a). The title compound was prepared 
by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (430 mg, 1.60 mmol), 3,5-difluoro-4-
methoxybenzeneboronic acid (357 mg, 1.92 mmol), caesium carbonate (1094 mg, 3.52 mmol) and 
tetrakis(triphenylphosphine) palladium (18.5 mg, 16.0 μmol) according to method A. The product was purified by 
CC (petroleum ether/ethyl acetate 9:1); yield: 42 % (223 mg).  
2,6-Difluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol (31). The title compound was prepared by reaction of 
2-(3,5-difluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (31a) (220 mg, 0.62 mmol) and boron tribromide 
(3.72 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 
10 % (18 mg); MS (ESI): 305 (M+H)+; Anal. (C16H10F2O2S) C, H, N. 
2-(3,4-Difluorophenyl)-5-(3-methoxyphenyl)thiophene (32a). The title compound was prepared by reaction of 
2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3,4-difluorobenzeneboronic acid (105 mg, 0.67 
mmol), caesium carbonate (383 mg, 1.23 mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 90 % (152 mg). 
3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol (32). The title compound was prepared by reaction of 2-(3,4-
difluorophenyl)-5-(3-methoxyphenyl)thiophene (32a) (120 mg, 0.40 mmol) and boron tribromide (1.20 mmol) 
according to method C. The product was purified by CC (dichloromethane/methanol 99:1); yield: 85 % (98 mg); MS 
(ESI): 289 (M+H)+; Anal. (C16H9F2OS) C, H, N. 
4-(4-Methoxy-3-methylphenyl)-2-(3-methoxyphenyl)thiophene (34a). The title compound was prepared by 
reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (33b) (400 mg, 1.49 mmol), 3-methyl-4-
methoxybenzeneboronic acid (296 mg, 1.79 mmol), caesium carbonate (1019 mg, 3.27 mmol) and 
tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 μmol) according to method A. The product was purified by 
CC (hexane/ethyl acetate 7:3); yield: 69 % (320 mg). 
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol (34). The title compound was prepared by reaction of 4-
(4-methoxy-3-methylphenyl)-2-(3-methoxyphenyl)thiophene (34a) (180 mg, 0.58 mmol) and boron tribromide (3.48 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 54 % 
(88 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, N. 
4-(3-Fluoro-4-methoxyphenyl)-2-(3-methoxyphenyl)thiophene (35a). The title compound was prepared by 
reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (33b) (400 mg, 1.49 mmol), 3-fluoro-4-
methoxybenzeneboronic acid (303 mg, 1.78 mmol), caesium carbonate (1019 mg, 3.30 mmol) and 
tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 μmol) according to method A. The product was purified by 
CC (petroleum ether/ethyl acetate 9:1); yield: 80 % (403 mg). 
2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol (35). The title compound was prepared by reaction of 4-(3-
fluoro-4-methoxyphenyl)-2-(3-methoxyphenyl)thiophene (35a) (400 mg, 1.27 mmol) and boron tribromide (7.63 
mmol) according to method C. The product was purified by CC (dichloromethane/methanol 98:2); yield: 22 % (88 
mg); MS (ESI): 287 (M-H)- 
4-(4-Methoxy-3-methylphenyl)-2-(3-methoxyphenyl)-1,3-thiazole (37a). The title compound was prepared by 
reaction of 5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (36b) (402 mg, 1.49 mmol), 3-methyl-4-
methoxybenzeneboronic acid (247 mg, 1.79 mmol), caesium carbonate (1019 mg, 3.27 mmol) and 
tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 μmol) according to method A. The product was purified by 
CC (hexane/ethyl acetate 7:3); yield: 69 % (320 mg). 
4-[2-(3-Hydroxyphenyl)-1,3-thiazol-5-yl]-2-methylphenol (37). The title compound was prepared by reaction 
of 4-(4-methoxy-3-methylphenyl)-2-(3-methoxyphenyl)-1,3-thiazole (37a) (80 mg, 0.26 mmol) and boron 
tribromide (1.56 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 
3:7); yield: 16 % (11 mg), MS (ESI): 274 (M+H)+; Anal. (C16H13NO2S) C, H, N. 
3,4''-Dimethoxy-4-methyl-1,1':4',1''-terphenyl (39a). The title compound was prepared by reaction of 4'-
bromo-3-methoxybiphenyl (38b) (230 mg, 0.87 mmol), 4-methoxy-3-methylbenzeneboronic acid (172 mg, 1.04 
mmol), caesium carbonate (595 mg, 1.91 mmol) and tetrakis(triphenylphosphine) palladium (10.1 mg, 8.7 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 98:2); yield: 53 % (140 mg). 
4-Methyl-1,1':4',1''-terphenyl-3,4''-diol (39). The title compound was prepared by reaction of 3,3''-dimethoxy-
4-methyl-1,1':4',1''-terphenyl (41a) (120 mg, 0.39 mmol) and boron tribromide (2.34 mmol) according to method C. 
The product was purified by preparative TLC (dichloromethane/methanol 97:3); yield: 38 % (42 mg); MS (ESI): 
277 (M+H)+.  
3-Fluoro-3'',4-dimethoxy-1,1':4',1''-terphenyl (40a). The title compound was prepared by reaction of 4'-
bromo-3-methoxybiphenyl (38b) (175 mg, 0.67 mmol), 3-fluoro-4-methoxybenzeneboronic acid (136.7 mg, 0.88 
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mmol), caesium carbonate (457 mg, 1.47 mmol) and tetrakis(triphenylphosphine) palladium (7.7 mg, 6.7 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 98:2); yield: 58 % (117 mg). 
3''-Fluoro-1,1':4',1''-terphenyl-3,4''-diol (40). The title compound was prepared by reaction of 3-fluoro-3'',4-
dimethoxy-1,1':4',1''-terphenyl (40a) (115 mg, 0.37 mmol) and boron tribromide (2.22 mmol) according to method 
C. The product was purified by preparative TLC (dichloromethane/methanol 99:1); yield: 62 % (65 mg); MS (ESI): 
281 (M+H)+. 
4-Fluoro-3,3''-dimethoxy-1,1':4',1''-terphenyl (42a). The title compound was prepared by reaction of 4'-
bromo-3-methoxybiphenyl (38b) (200 mg, 0.76 mmol), 4-fluoro-3-methoxybenzeneboronic acid (154 mg, 0.91 
mmol), caesium carbonate (520 mg, 1.67 mmol) and tetrakis(triphenylphosphine) palladium (8.8 mg, 7.6 μmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 75 % (175 mg). 
4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol (42). The title compound was prepared by reaction of 4-fluoro-3,3''-
dimethoxy-1,1':4',1''-terphenyl (42a) (175 mg, 0.57 mmol) and boron tribromide solution (3.42 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 63 % (100 mg); MS 
(ESI): 281 (M+H)+. 
Biological Methods 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described 
procedures.31,37,56 Fresh human placenta was homogenized and centrifuged. The pellet fraction contains the 
microsomal 17β-HSD2, while 17β-HSD1 was obtained after precipitation with ammonium sulfate from the 
cytosolic fraction. 
Inhibition of 17β-HSD1  
Inhibitory activities were evaluated by a well established method with minor modifications.57-59 Briefly, the 
enzyme preparation was incubated with NADH [500 µM] in the presence of potential inhibitors at 37 °C in a 
phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA (1mM). Inhibitor stock solutions were 
prepared in DMSO. Final concentration of DMSO was adjusted to 1 % in all samples. The enzymatic reaction was 
started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]- E1 (final concentration: 500 nM, 0.15 μCi). After 
10 min, the incubation was stopped with HgCl2 and the mixture was extracted with ether. After evaporation, the 
steroids were dissolved in acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in 
a C18 rp chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a HPLC-
system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of the steroids were 
performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The conversion rate was calculated 
according to following equation: 100
1%2%
2%% ⋅
+
=
EE
Econversion . Each value was calculated from at least three 
independent experiments.  
Inhibition of 17β-HSD2 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal fraction 
was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 7-3H]-E2 (final 
concentration: 500 nM, 0.11 μCi) for 20 min at 37 °C. Further treatment of the samples and HPLC separation was 
carried out as mentioned above. 
ER affinity 
The binding affinity of selected compounds to the ERα and ERβ was determined according to Zimmermann et 
al.60 Briefly, 0.25 pmol of ERα or ERβ, respectively, were incubated with [2, 4, 6, 7-3H]-E2 (10 nM) and test 
compound for 1 h at rt. The potential inhibitors were dissolved in DMSO (5 % final concentration). Non-specific-
binding was performed with diethylstilbestrol (10 µM). After incubation, ligand-receptor complexes were 
selectively bound to hydroxyapatite (5 g/ 60 mL TE-buffer). The formed complex was separated, washed and 
resuspended in ethanol. For radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was 
added and samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). For 
determination of the relative binding affinity (RBA), inhibitor and E2 concentrations required to displace 50 % of 
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the receptor bound labelled E2 were determined. RBA values were calculated according to the following equation: 
[ ] ( )( ) 100
2%
50
50
⋅=
compoundIC
EICRBA . The RBA value for E2 was arbitrarily set at 100 %. 
Evaluation of the estrogenic activity using T-47D cells 
Phenol red-free medium was supplemented with sodium bicarbonate (2 g/L), streptomycin (100 µg/mL), insuline 
zinc salt (10 µg/mL), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 U/mL) and DCC-FCS 5% 
(v/v). RPMI 1640 (without phenol red) was used for the experiments. Cells were grown for 48 h in phenol red-free 
medium. Compound 21 was added at a final concentration of 100 nM. Inhibitors and E2 were diluted in ethanol 
(final ethanol concentration was adjusted to 1%). As a positive control E2 was added at a final concentration of 0.1 
nM. Ethanol was used as negative control. Medium was changed every two to three days and supplemented with the 
respective additive. After eight days of incubation, the cell viability was evaluated measuring the reduction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT). The cleavage of MTT to a blue formazan by 
mitochondrial succinat-dehydrogenase was quantified spectrophotometrically at 590 nm as described by Denizot 
and Lang61 with minor modifications. The control proliferation was arbitrarily set at 1 and the stimulation induced 
by the inhibitor was calculated according to following equation: 
( )[ ]
( )[ ] %10012
1% ⋅
−−
−−
=
inducedEionproliferat
inducedcompoundionproliferatnstimulatio . Each value is calculated as a mean value of at least three 
independent experiments 
Inhibition of human hepatic CYPs 
The commercially available P450 inhibition kits from BD GentestTM (Heidelberg, Germany) were used 
according to the instructions of the manufacturer. Compounds 21, 23 and 37 were tested for inhibition of the 
following enzymes: CYP3A4, 2D6 and 2C19. Inhibitory potencies were determined as IC50 values. 
In-Vivo Pharmacokinetics 
Male Wistar rats weighing 300-330 g (Janvier France) were housed in a temperature- controlled room (20-22 °C) 
and maintained in a 12 h light/12 h dark cycle. Food and water were available ad libitum. They were anesthetized 
with a ketamine (135 mg/kg)/ xylyzine (10 mg/kg) mixture and cannulated with silicone tubing via the right jugular 
vein and attached to the skull with dental cement. Prior to the first blood sampling, animals were connected to a 
counterbalanced system and tubing to perform blood sampling in the freely moving rat.  
Compounds 21 and 23 were applied orally in a cassette dosing in 4 rats at the dose of 10 mg/kg body weight by 
using a feeding needle. The compounds were dissolved in a mixture labrasol/water (1:1) and given at a volume of 
5mL/kg. Blood samples (0.2 mL) were taken at 0, 1, 2, 3, 4, 6, 8, 10 and 24 h postdose and collected in heparinised 
tubes. They were centrifuged at 3000g for 10 min, and plasma was harvested and kept at -20 °C until analyzed.  
HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor-HPLC-system coupled 
with a TSQ Quantum (Thermo/Fisher) triple quadrupole mass spectrometer equipped with an electrospray interface 
(ESI).  
Computational Chemistry 
Molecular Modelling 
All molecular modelling studies were performed on Intel(R) P4 CPU 3.00 GHz running Linux CentOS 5.2. The 
X-ray structures of 17β-HSD1 (PDB-ID: 1A27, 1FDT and 1I5R) were obtained from the Protein Databank62 and 
further prepared using the BIOPOLYMER module of SYBYL v8.0 (Sybyl, Tripos Inc., St. Louis, Missouri, USA). 
Water molecules, E2 (or HYC for 1I5R) and sulfate ions were stripped from the PDB files and missing protein 
atoms were added and correct atom types set. Finally hydrogen atoms and neutral end groups were added. All basic 
and acidic residues were considered protonated and deprotonated, respectively. Since almost all histidines are 
oriented toward the outer part of the enzyme, accessible for the surface, they were considered as protonated (HIP) 
after a prediction run made by MolProbity.63 For 1I5R the cofactor NADPH was merged into the enzyme after an 
accurate overlay with the hybrid inhibitor HYC and the X-rays 1A27 and 1FDT. Further, every crystal structure was 
minimized for 500 steps with the steepest descent minimizer as implemented in SYBYL with the backbone atoms 
 ~ 237 ~ 
 
kept at fixed positions in order to fix close contacts, followed by 2000 steps conjugate gradient minimization 
requested for an overall better starting structure. 
Inhibitor 23 was built with SYBYL and energy-minimized in MMFF94s force-field as implemented in Sybyl. 
Subsequently an ab-initio geometry optimizations was performed in gas phase at the B3LYP/6-311++G (d,p) level 
of density functional theory (DFT) by means of the Gaussian03 software,64,65 in order to obtain the RESP charges of 
compound 23. 
Two different softwares were used for docking studies: GOLDv3.266 and Autodock4,67,68 using the graphical 
user interface AutoDockTools (ADT 1.5.2). Since both allow flexible docking of ligands, no conformational search 
was employed to the ligand structure. For both programs the compound 23 was docked in 50 independent genetic 
algorithm (GA) runs.  
GOLDv3.2: Active-site origin was set at the center of the steroid binding site, while the radius was set equal to 
13 Å. The automatic active-site detection was switched on. Further, a slightly modified GOLDSCORE fitness 
function (increased scaling for hydrophobic contacts) was used and genetic algorithm default parameters were set as 
suggested by the GOLD authors.  
Autodock4: The docking area has been defined by a box, centered on the mass center of the CD-rings of the 
cocrystallized E2. Grids points of 60 × 70 × 74 with 0.375 Å spacing were calculated around the docking area for all 
the ligand atom types using AutoGrid4. The Lamarckian genetic algorithm local search (GALS) method was used. 
Each docking run was performed with a population size of 200. A mutation rate of 0.02 and a crossover rate of 0.8 
were used to generate new docking trials for subsequent generations. The GALS method evaluates a population of 
possible docking solutions and propagates the most successful individuals from each generation into the next one.  
Both programs performed in a similar way, supporting the herein suggested binding modes. The quality of the 
docked poses was evaluated based mainly on visual inspection of the putative binding modes of the ligand, and 
secondly on the scoring functions, which give a good measure to discriminate between the found binding modes for 
one single X-ray conformation, but do not help us to compare the poses of different X-rays.  
MEP 
For selected compounds ab-initio geometry optimisations were performed gas phase at the B3LYP/6-311++G 
(d,p) level of density functional theory (DFT) by means of the Gaussian03 software and the molecular electrostatics 
potential map (MEP) was plotted using GaussView3, the 3D molecular graphics package of Gaussian.69 These 
electrostatic potential surfaces were generated by mapping 6-311++G electrostatic potentials onto surfaces of 
molecular electron density (isovalue = 0.0002e/Å). The MEP maps are color coded, where red stands for negative 
values (3.1*10-2 Hartree) and blue for positive ones (4.5*10-2 Hartree).  
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ligand binding.
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Abstract
Bisubstrate enzymes, such as 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exist in solution as an 
ensemble of conformations. 17β-HSD1 catalyzes the last step of the biosynthesis of estradiol and, thus, it is a 
potentially attractive target for breast cancer treatment. To elucidate the conformational transitions of its catalytic 
cycle, a structural analysis of all available crystal structures was performed and representative conformations were 
assigned to each step of the putative kinetic mechanism. To best cover the conformational space, all-atom MD 
simulations and free energy calculations were performed, using the four crystallographic structures best describing 
apoform, opened, occluded and closed state of 17β-HSD1 as starting structure. With three of them binary and 
ternary complexes were built with NADPH and NADPH-estrone, respectively, while two were investigated as 
apoform. Remarkably, the comparison of the eight long range trajectories resulting from this multi-trajectory/-
complex approach revealed an essential role for backbone and side chain motions, especially of the βFαG’-loop, in 
cofactor and substrate binding. Thus, a selected-fit mechanism is suggested for 17β-HSD1, where ligand-binding 
induced concerted motions of the FG-segment and the C-terminal part guide the enzyme along its preferred catalytic 
pathway. Overall, we could assign enzyme conformations to the five steps of the random bi-bi kinetic cycle of 17β-
HSD1, identifying its preferred pathway. This study provides a useful guideline for other enzymes, characterized by 
a rigid core and a flexible region directing their catalysis.
Cytoplasmic proteins are present in solution as an ensemble of conformations, which are in a dynamic 
equilibrium, strongly influenced by the presence of ligands (in case of enzymes: cofactors, substrates, inhibitors, or 
other proteins). This is especially true for enzymes following a bisubstrate kinetic, like E. coli dihydrofolate 
reductase (DHFR) and human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), where concerted dynamic 
motions are necessary between the enzyme conformations responsible for specific kinetic steps. An in-depth 
knowledge of both protein dynamic and its influence on ligand binding could effectively speed up rational drug 
design (1). These new drugs might act not only by competing with the substrate for its binding site, but also by 
inducing a dynamic dysfunction of the enzyme by hindering the switch between its conformations.
In estrogen target cells 17β-HSD1 catalyzes the NADPH-dependent reduction of estrone (E1) to the biologically 
highly potent 17β-estradiol (E2) (2-3) (Fig. 1). It has been shown that in post-menopausal women with hormone-
dependent breast cancer tumor proliferation is driven by increased levels of E2 (4-5). As 17β-HSD1 is often 
overexpressed in breast tumor cells, it is considered as a novel therapeutic target (6-9).
Fig. 1. Reduction from E1 to E2 and non-steroidal and steroidal inhibitors.
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Recently, Cooper et al. elucidated the complete kinetic mechanism for the rat liver 3α-HSD and could assign 
different enzyme forms to the specific reaction coordinates (10). 3α-HSD and nearly all other HSD enzymes are 
described to follow a sequential ordered bi-bi kinetic mechanism, where the cofactor enters first and exits last. The 
kinetic mechanism of 17β-HSD1 is still not fully clarified, although it has been reported to follow a rapid 
equilibrium random bi-bi mechanism, a peculiarity compared to other HSDs (11-13). The high NADPH/NADP+ 
gradient (>500:1) and the excess of NADPH with respect to E1 in vivo, as well as the thermodynamically favoured 
NADPH oxidation (14-15), suggest the presence of NADPH in the enzyme prior to steroid binding. Asn114, 
Ser142, Tyr155 and Lys159 form the catalytic tetrad of 17β-HSD1, conserved in many HSD enzymes, and are 
involved in the pro-S hydride transfer from NADPH to the α-face of the C17 carbon as well as in the proton transfer 
between the OH group of Tyr155 and the C17 oxygen of E1 (16) (Fig. S1). 
Remarkably, the catalytic reaction of 17β-HSD1 is principally reversible; it is unidirectional, however in vivo, 
because of the abundance of NADPH. No crystal structure of the ternary complex enzyme (E)-NADPH-E1 exists, 
probably because of the very fast transfer rate observed for the reduction of E1 (kcat 1.5s-1) (17). E2 has a similar 
binding affinity to 17β-HSD1 as E1, as well as a comparable kcat, but due to the excess of NADPH the backward 
reaction E2 to E1 does not take place, thus explaining the several E-NADP+-E2 complexes. 
Steroidal and non-steroidal inhibitors of 17β-HSD1 have been reported (Fig. 1) (6-8, 18-22). The former mimic 
the substrate and are supposed to bind in the substrate binding site (SUB), a narrow hydrophobic tunnel. They are 
stabilized by hydrogen bonds with Tyr155/Ser142 and His221/Glu282, located on both ends of the pocket, and, 
further, by hydrophobic contacts. Recently, Poirier et al. published a series of hybrid inhibitors, based on a E1/E2 
core with substituents of various lengths in C16 position (22). These inhibitors occupy both substrate (SUB) and 
cofactor binding site (COF), competing with E1 and NADPH, as demonstrated by the binary complex E-HYC (PDB 
entry 1i5r). Up to now no crystallographic data exists describing the binding mode of non-steroidal inhibitors, 
although computational studies performed by various groups suggested some classes of non-steroidals to bind like 
their steroidal analogues in the SUB (6-8, 23-24) and others to occupy only partially the SUB protruding into the 
COF, like compound 1 (20). 
Herein, we present the first, to our knowledge, computational investigation of the kinetic mechanism of 17β-
HSD1, one of thirteen 17β-HSDs belonging to the short-chain dehydrogenases/reductases (SDR), a large 
superfamily of NAD(P)H-dependent enzymes. Furthermore, the linkage between representative enzyme 
conformations and the five steps described for the random bi-bi mechanism, an in-depth computational analysis of 
the flexible βFαG’-loop, and its role in enzyme catalysis and in ligand binding were elucidated. Thus, a multi-
trajectory/-complex molecular dynamic (MD) strategy was followed, based on four different enzyme conformations. 
Molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) methods (25), in combination with normal-
mode analysis (NMODE) (26), were exploited to calculate the free energies of the complexes. These substantiated 
our kinetic hypothesis and helped to determine the best enzyme conformation for binding of E1 and NADPH, 
respectively. 
Results and Discussion. 
Structural analysis of human 17β-HSD1 crystal structures. 17β-HSD1 is a homodimeric protein and shows 
the typical rigid β-α-β fold of the SDR-family with a core of parallel β-strands fanning across the center and α-
helices draped on the outside (27), resulting in a rigid COF at the N-terminus and a structurally variable C-terminus, 
hosting the SUB. The structurally conserved region comprises Rossman fold and GxxxGxG motif (G is glycine and 
x any other residue), characteristic of oxidation/reduction enzymes that bind nicotinamide cofactors, plus the YxxxK 
sequence (Y is Tyr155 and K Lys159) that participates in catalysis. In sharp contrast to other 17β-HSDs, type 1 is 
characterized by a long, flexible βFαG'-loop and a C-terminal helix, both delimiting the SUB and probably involved 
in enzymatic catalysis and in entrance and exit mechanisms of small molecules. 
Seventeen crystal structures of 17β-HSD1 are available in the Protein Data Bank (PDB; Nov.2009) as apoform, 
binary or ternary complex (Tab. S1). The loop residues Thr190-Gly198 of the PBD entry 1fdt (28) are modeled in 
two different conformations and have been considered as two different conformer, denoted hereafter as 1fdtA and 
1fdtB. Superimposition of all crystals gives a mean backbone RMSD (root mean-square distance) of ≈0.5 Å (all -
atom RMSD ≈1.5 Å). The only flexible p art is the above mentioned βFαG'-loop, which adopts different 
conformations, strongly modulating shape and volume of the active site (including both COF and SUB). Seven of 
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these crystal structures are incomplete, missing mainly the loop residues Phe192-Val196, while the remaining 
eleven show high b-factor values for this area, an additional hint for flexibility. In the fully resolved structures the 
loop occurs as a disordered random coil, but in some of them it is folded to a turn-helix-turn motif. Moreover, the 
loop is found in a stable orientation only for ternary complexes, which have enzyme, cofactor and steroidal product 
or inhibitor fully resolved (1a27, 1fdtA, 1fdtB, 1equA and 1fduC; cluster cl2 in Fig.2). For all other crystal 
structures no univocal loop conformation could be ascribed to the presence of either cofactor or ligand. 
Nevertheless, this multiplicity of conformations suggests various substates for 17β-HSD1, which are subjected to 
fast dynamic motions and secondary structure rearrangements of the loop. Most of the binary complexes E-E2 are 
fully resolved, while E-NAD(P)+ complexes lack part of the βFαG’-loop and no binary complex with NADPH or 
with E1 exists at all (Tab. S1). The numerous fully resolved E-E2 complexes suggest E2 to bind stronger to the 
enzyme than NADPH, which becomes tighter bound only after the steroid has entered the cavity and the loop has 
changed its conformation.
Fig. 2. Representative structures of the three βFαG’-loop conformations cl1 (yellow, 1iol), cl2 (magenta, 1a27) and 
cl3 (blue, 1i5r), clustered according to the backbone RMSD of the five residues Phe192-Val196. βFαG’-loop, αG’-
helix (green) and C-terminal helix (cyan) are rendered as cartoon, NADPH and E1 as sticks and the rest of the 
enzyme (active site) as electrostatic surface.
The eleven full-length crystal structures of 17β-HSD1 are superimposed and clustered according to the backbone 
RMSD (mean value ≈3 Ǻ) of the five loop residues Phe192 -Val196. Three clusters cl1, cl2 and cl3 (Fig. 2; 
representative structures: 1iol, 1a27 and 1i5r, respectively) could be identified, as well as the presence of three gates, 
two close to the loop (gate 1 and 2) and a third one (gate 3) close to the C-terminal helix (Fig. 3). However, this 
backbone classification disregards active site volume changes and is limited to ascribe the presence of opened gates 
for the three clusters cl1-cl3. Thus, clustering was repeated taking into account all atoms of the same loop residues, 
which resulted in a mean RMSD value of ≈6 Å. Five clusters could be identified (Fig. 3 and S2) and Phe192, in 
particular, emerged as an important marker for the conformational variations, since its side chain presented the 
largest RMSD deviation (≈10 Ǻ), as it rotates for about 200 degrees around the loop axis: it turns from the inner 
cavity, where it occludes the SUB and stabilizes the substrate in the correct position for hydride transfer (1fdtB), 
toward the outside, where it chaperones E1/E2 or the cofactor in and out of the active site (1fdtA). These two 
extremes in the orientation of the side chain of Phe192 correspond to the major changes of the active site volumes of 
all wild type E-NADPH-E2 complexes, where the volume ratio SUB/COF changes from 30:70 in 1fdtB to 37:63 in 
1fdtA (Tab. S1).
Rapid equilibrium random bi-bi kinetic cycle – a hypothesis. Since 17β-HSD1 is described to follow a five-
step random bi-bi kinetic mechanism (Fig. 3 and S3), we tried to assign an enzyme conformation to each step and to 
explain the specific role played by the flexible loop for each enzyme form present along its preferred reaction 
pathway. As stated before, we assume that NADPH will bind first, inducing a conformational rearrangement of the 
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βFαG’-loop, which would allow and favour the successive entrance and binding of E1. Therefore, the loop needs to 
move toward the COF (1bhs – step 1), opening gate 2. This will be closed again, after E1 enters (1i5r – step 2) and 
the loop slides back to its starting point. Now, Phe192 and Met193 stabilize the substrate in an optimal position for 
the pro-S hydride transfer, allowing the formation of the first ternary complex. The catalytic reaction takes place 
(1a27 - step 3), and subsequently the loop moves toward the SUB (1iol, 1fdtA – step 4) opening gate 1, the egress 
path for NADP+, which leaves the active site. The steroid is still stabilized in the SUB, shielded by Phe192 and 
Met193. In step 5, the steroid moves out of the active site through gate 3 (1fdtB). Interestingly, for all five substates 
the loop residues and Phe226 on the αG’-helix are oriented in a way to avoid solvent accessibility to the SUB.
Fig. 3. Random bi-bi kinetic cycle of 17β-HSD1. To each step one or more crystal structures were assigned. Side 
chains of the βFαG’-loop residues Phe192-Lys195 are rendered as sticks and the orientation of the loop (blue ball)
with respect to the αG’ helix (in gray) is shown as cartoon. The arrows 1-3 indicate the entrance and egress gates 
identified along the reaction pathway. 1fdtA is not included in the balloon of step 4 due to its different loop axis 
orientation with respect to 1iol.
Validation of the catalytic cycle by means of molecular dynamic simulations. MD simulations have been 
proven to be very useful tools in the analysis of dynamic motions of enzymes with flexible loops, which play a 
prominent role in either the catalytic cycle and/or ligand binding, as for example for E. coli DHFR (1, 29) or Cdk2 
(cyclin-dependent kinase type 2) (30). Moreover, the predictive capacity of MDs can be increased by free energy 
calculations and normal mode analysis. Herein, we apply these techniques pursuing as a main goal to substantiate 
the assignment of different enzyme conformations of 17β-HSD1 to the five steps encountered along the catalytic 
pathway and to determine complexes representing the transition states. To this end, eight MD simulations (models I-
III; SI Text) were designed based on the crystal structures 1fdtA, 1i5r, 1fdtB, and 1bhs, which differ strongly in the 
orientation of the βFαG’-loop (Fig. S4). In fact, the enzyme was investigated in its opened-state (1fdtA) -
characterized by a fused COF and SUB and by Phe192 turned outward, in a semi-opened/occluded state (1i5r) - with 
the loop shifted toward the COF and Phe192 more buried than in 1fdtA, and in its closed-state (1fdtB) - mimicking 
the catalytic moment with a closed SUB and Phe192 pointing inward perpendicular to the catalytic Tyr155. The MD 
simulations of apoform E (A), binary E-NADPH (B) and ternary complexes E-NADPH-E1 (C) of 17β-HSD1 were 
evaluated in terms of geometry (RMSD) and energy stability of the complexes, ligand and secondary structure 
displacement with respect to the starting pose, and the time required to reach a stable RMSD and energy plateau. For 
 ~ 247 ~ 
 
each stable sector of the MD trajectories longer than 4 ns snapshots were collected every 30th frame (every 30 ps) 
and used to calculate absolute free energy (ΔG) and relative binding affinity (ΔGbind) by means of MM-PBSA 
methods and NMODE. Thus, in order to determine whether a preferential enzyme conformation exists for the 
binding of NADPH and E1, we compared ΔG and ΔGbind values of the binary complexes B1-B3 and of the ternary 
C1-C3, respectively (Tab. 1). 
Tab. 1. Free energy calculations for the stable trajectories of the MD simulations B1-B3 and C1-C3 by means of 
MM-PBSA and NMODE. 
PDB 
code 
MD 
code 
ELE VDW GAS PBSOL PBTOT TSTOT ΔG 
mean std mean std mean std mean std mean std mean std  
enzyme-NADPH 
1fdtA B1 -380.08 75.8 -42.87 4.5 -371.65 74.7 386.95 68.8 15.3 12.6 -20.23 20.3 -35.53 
1i5r B2 -484.85 75.0 -70.11 6.5 -554.96 75.5 510.69 62.8 -44.27 16.5 -34.92 21.8 -9.35 
1fdtB B3 -358.75 53.8 -74.54 5.4 -433.29 54.5 411.6 50.2 -21.69 8.9 -37.16 20.1 -15.47 
enzyme-NADPH-E1 
1fdtA C1 0.35 4.5 -38.8 2.0 -38.58 4.6 18.12 5.4 -20.47 5.0 -17.87 22.2 -2.6 
1i5r C2 -12.75 6.3 -36.81 2.8 -49.53 6.3 25.88 5.7 -23.65 4.0 -22.69 20.1 -0.96 
1fdtB C3 -23.43 2.3 -36.75 2.8 -60.29 2.9 31.99 2.2 -28.3 2.8 -19.99 24.3 8.31 
(ELE) electrostatic contribution in gas phase; (VDW) Van der Waals contribution in gas phase; (GAS) free energy in vacuum; (PBSOL) 
solvation energy; (PBTOT) relative free binding energy (ΔGbind); (TSTOT) entropic contribution; (ΔG) absolute free binding energy; 
(mean) mean value; (std) standard deviation; all energies expressed in kcal/mol. 
For step 1 two MD simulations were performed with the enzyme only (1bhs – A1, 1fdtB – A2; Fig. S5). In the 
apoform crystal structure 1bhs (A1) the fully resolved βFαG’-loop lies in cluster cl1, presents a turn-helix-turn motif 
and the side chains of its residues are oriented along its axis. Thus, a 12 ns MD A1 was performed in order to verify 
the reliability of 1bhs as step 1 enzyme conformation. Remarkably, the loop evolved toward cluster cl2, shielding 
the COF and especially where the nicotinamide moiety is found. This led to a large active site suitable to host both 
cofactor and ligand. The enzyme showed the tendency to preserve the hydrophobic character of the SUB, turning the 
side chains of the apolar residues inward, especially of the aromatic ones, which occlude the SUB and avoid water 
to be placed in there. Met193 was deeply buried in the SUB, occupying the space where steroids are normally 
placed. On the contrary, all polar residues belonging to the FG segment and the C-terminal helix turned outside to 
form ion-pairs responsible for the closure of gate 2 and 3. The final stable complex of this MD has to be considered 
as a transition state of step 1, presenting an accessible COF, suitable to host NADPH, and an occluded SUB, not 
ready to accommodate the substrate. Moreover, the βFαG’-loop would drift toward the COF, in concert to NADPH 
entrance, resulting in a progressive closure of the COF (gate 1) and accessibility of the SUB (1i5r). 
The second MD A2 was performed on the apoform of the closed-state conformation 1fdtB, stripped of both 
cofactor and steroid. The aim was to investigate whether the starting enzyme conformations of A1 and A2 lead to 
different final tertiary structures or if they converge to a common folding and loop axis orientation. However, 
already after 1 ns of simulation a marked change in the tertiary structure of the 1fdtB apoform was observed 
involving FG segment and C-terminal helix. Phe192 remained turned inward, while Met193 rotated toward the αG’-
helix, becoming responsible for the disruption of the αG’-helix. Thus, the two simulations did not converge to a 
common conformation; moreover, the final complex of A2 resulted in a partially unfolded structure. This indicates 
that the presence of either cofactor or ligand is necessary to assure a correct transition between the five steps of the 
enzymatic cycle. 
For step 2, three 9 ns MDs were carried out on the binary complex E-NADPH (B) and another three, lasting 10 
ns, on the ternary complex E-NADPH-E1 (C), with the enzyme in its opened (1fdtA - B1, C1), semi-opened (1i5r - 
B2, C2) and closed (1fdtB - B3, C3) state, respectively. The aim was to obtain insights into the role played by the 
loop in the stabilization of NADPH, the shielding of the SUB and the stabilization of E1. 
Simulation B2 (1i5r-NADPH) was characterized by a quickly reached, very long stable RMSD plateau (Fig. S6), 
indicating a good stability of the complex. Also the loop showed a stable RMSD profile, although, while the lower 
part (Glu194-Ser199) still remained close to the cofactor in cluster cl3, the upper part (Thr190-Met193) drifted 
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toward the αG’-helix. One can see here a direct consequence of the outward rotation of Phe226, responsible to 
sustain the nicotinamide moiety in the starting complex, which is involved in opening gate 2, a prerequisite for E1 
entrance. The loop was folded to a short helix and stabilized by the ion-pair Lys195 and 2’-phosphate of the 
cofactor, which trapped the adenosine moiety. In the final structure the upper part of the loop, placed in cluster cl2, 
occluded part of gate 2, reducing the solvent accessible surface and preserving the hydrophobic character of the 
SUB. Nevertheless, a hydrophobic tunnel remained between loop and helix, suitable for steroid transition. The 
complex stability of B2 is also reflected by a good free energy ΔG (-9.35 kcal/mol) with respect to the positive 
values of B1 and B3 (Tab. 1), which substantiates our structural hypothesis for catalytic step 2.
The MD of the ternary complex 1i5r-NADPH-E1 (C2) describes very well the expected loop motion from 
cluster cl3, shielding the COF, to cluster cl2 (Fig. 4). Despite a suboptimal free energy (-0.96 kcal/mol) compared to 
that of the closed-state complex C3 (-8.31 kcal/mol), we consider the MD C2 as a valuable simulation of the 
transition state of step 2 from a binary state to the ternary complex (Fig. 4B). Effectively, this simulation ended in a 
stable complex with E1 properly bound in the SUB and with the loop oriented in cl2 occluding the active site.
Fig. 4. Motion of the βFαG’-loop in MD C2 (1i5r) from cluster cl3 to cl2. (A) Overlay of multiple snapshots of the 
trajectory C2 (color-coded in a range from red to blue, according to start and end of the MD, respectively). (B)
Important active site residues of the initial (violet, step 1), stable (orange, step 2) and final complex (yellow) are 
rendered as sticks.
For step 3, no tertiary structure rearrangements were expected, since in this step the hydride transfer takes place. 
Nevertheless, the three MDs of the ternary complex E-NADPH-E1 (C1-C3; Fig. S7) highlight very well the 
important role of Phe192 and Met193 in stabilizing E1 close to the cofactor to ensure an optimal distance necessary 
for hydride transfer. When these residues were turned outward, as happened for the opened and the semi-opened 
complexes, 1fdtA-NADPH-E1 (C1) and 1i5r-NADPH-E1 (C2) respectively, E1 had more space and was less stably 
bound. A combined analysis of the dynamic simulations C1 and C3 (1fdtB-NADPH-E1), which, despite of an 
opposite orientation of the side chains of the loop residues, present the loop axis (main chain) in the same starting 
conformation (cluster cl2), leads us to suggest a fine-tuned entrance mechanism for E1. Thus, the MDs C1 and C3 
were prolonged for ≈6 ns, with the purpose to evaluate the propensity of the substrate to escape. The RMSD values 
of MD C1 rose in this extended part, related to a large βFαG’-loop motion to shield the active site, whereas they 
decreased for the closed-state simulation C3 (Fig. 5A). Although, the second part of the simulation C3 was 
characterized by slow concerted motions of FG-segment and C-terminal helix, as shown by the gradual increase of 
the loop RMSD (Fig. 5B), which opened gate 2 and 3 with an increase of ΔG from -2.6 (at 10 ns) to -6.02 kcal/mol 
(at 16 ns). In the opened-state MD C1, we observed the progressive loss of the hydrogen bonds to Ser142 and 
His221, typical for steroid binding in the SUB, facilitated by the outward rotation of Met193, Phe192, and Phe226. 
E1 drifted beneath the cofactor slowly turning its D-ring toward gate 2, now opened, and bound to Lys195. Thus, 
backward analysis of simulation B1 suggests a “pull-and-push” mechanism, in which E1 seems to enter the binding 
site through gate 2, pulled by the inward rotation of Lys195 to which the steroid is bound with the C17 carbonyl. 
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Once E1 is in the SUB, this bond is released, Lys195 rotates toward the 2’-phosphate and Phe192 turns inward 
below the cofactor (1fdtB), pushing E1 in the SUB. Other residues delimiting gate 2 also adapted to the steroid, in 
particular Phe226, which turned from the outside (final complex of MD C1) to the inner cavity, closing gate 2 and 
stabilizing E1. The catalytic residues Ser142, Tyr155, and Lys159 showed small RMSD values for all three ternary 
complexes, even after 10 ns of dynamics (Fig. S7D). This is in accordance to experimental site-directed mutagenesis 
studies (31), where the enzymatic activity was abolished because of the mutation of one or more of these residues. 
Moreover, the conformational stability of these residues suggested them to be essential for the postulated catalytic 
mechanism (Fig. S1) (32), while other regions, for example the βFαG’-loop, seem to be the driving force that keeps 
the catalytic cycle running. Interestingly, the trajectories observed for Phe192, Lys195 and Phe226 in the three 
simulations C1-C3 confirmed this implication in ligand stabilization and expulsion. Furthermore, the poses of these 
residues in the three MDs overlap nicely with their orientation in the eighteen enzyme conformations and fitted very 
well with the conclusion of Mazza et al. (33), who suggested a direct involvement of Lys195 and Phe192 in the 
catalysis.
Fig. 5. Analysis of the last 7 ns of the MDs C1 (1fdtA) and C3 (1fdtB). (A) Time-dependent all-atom RMSD for all 
residues of complexes C1 (light green) and C3 (red) and (B) for the βFαG’-loop residues only of C1 (dark green) 
and C3 (orange).
Phe192 was observed to play a very important role for steroid stabilization, but also in the catalytic reaction. In 
most ternary complexes with E1, Phe192 pointed perpendicular toward Tyr155. In this T-shaped conformation, 
Phe192 is likely to increase the acidity of the phenol group of the catalytic Tyr155 from a pKa of ca 9 to 6 (34), 
which facilitates the hydride transfer to the estrone. The final pose of Phe192 in C2 and C3 is consistent with this 
observation and enforces its role in protecting the nicotinamide moiety and activating the catalysis.
In step 4 we expected to see the loop shift further toward the αG’-helix, opening gate 1, and NADP(H) to leave 
the COF. We considered both the simulations C1-C3 and B1-B3. Two of them were meaningful: 1fdtB-NADPH-E1 
(C3), which confirmed the loop motion with subsequent opening of gate 1 and the drift of E2 toward gate 3; and 
1fdtA-NADPH (B1), which showed the egress path of the cofactor due to gate 1 enlargement.
Although at this stage the steroid should be E2, we considered for step 4 the simulations C1-C3, where E1 and 
NADPH were used instead of E2 and NADP+. We consider this approximation as acceptable, because no differences 
between the hydrogen bond patterns of E1 and E2 with 17β-HSD1 exist and because forcefield based methods, such 
as MD simulation, are not sensitive enough to handle the electrostatic differences between ligand and cofactor forms 
(20). In all complexes, E1 was placed in the same pose, analogous to that of E2 in the crystals. Although the MDs 
C1-C3 reached a stable RMSD plateau after already 4 ns (Fig. S7), maintaining E1 placed in the SUB, the ΔG 
values for the stable segments varied notably for the three simulations (Tab.1). The MD of the ternary complex C3 
best described step 4, with a ΔG of -8.31 kcal/mol: E1 maintained its hydrogen bonds to Ser142/Tyr155 for the first 
10 ns of the simulation C3, until being pushed out of the SUB through gate 3 in the following 6 ns due to the loop 
motion toward the αG’-helix (Fig. 6).
Moreover, in simulation 1fdtA-NADPH (B1), characterized at its beginning by a wide access to the COF due to 
the outward rotated Phe192, we observed a concerted opening of gate 1 and closing of gate 2 due to the shift of the 
loop axis toward the αG’-helix. Thus, after a gradual increase in the first 5 ns, the all-atom RMSD reached a plateau 
and maintained it until the end of the simulation. Differently, the cofactor RMSD continued to rise (Fig. S6D), in 
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accordance to the movement of NADPH out of the COF, which was facilitated by the outward rotated Arg37, not 
burying the adenosine moiety in the COF anymore. Notably, the cofactor-stabilizing role of Arg37 had been 
previously demonstrated by site-directed mutagenesis studies (15). The αG’-helix rotated slightly rightward for 
about 30 degrees, adapting its residues to those of the loop. In this motion, His221 moved outward, breaking the salt 
bridge with Glu282 and enlarging gate 3. The free energy of complex B1 (+35.53 kcal/mol) clearly indicates that 
this enzyme conformation is disfavoured to stabilize NADPH, which ends up solvent exposed, suggesting complex 
B1 to be a good model to simulate the exit of the cofactor in step 4.
Fig. 6. Overlay of the representative structures of the initial position (yellow), the stable segment (blue, step 3) and 
the extended part (red, step 5) of the MD C3 (1fdtB).
In step 5 the exit of the product is required as well as a side-chain rearrangement to shield the empty SUB. This 
has already been observed for the last 7 ns of MD C3 (Fig. 5), where E2 drifted to exit gate 3, pushed by motions of 
the loop axis and by the rotation of the apolar residues Phe192, Met193, Phe226, and Phe259 into the SUB (Fig. 6). 
Moreover, with the progression of E1 to the end of the tunnel His221 and Glu282 turned outward enlarging gate 3. 
The loop remained close to the αG’-helix, revealing broad gates 1 and 3 and an occluded gate 2, as observed for 
1bhs, the representative crystal for step 1.
Conclusions.
The combined analysis of the crystal structures and of the biochemical data present in literature resulted in the 
identification of a preferred pathway for the random bi-bi kinetic cycle of 17β-HSD1. Thus, a multi-trajectory MD 
approach and free energy calculations were employed to substantiate the catalytic cycle. MD simulations were 
performed to gain a more complete set of protein conformers, in particular of those with a relatively high energy and 
which often are transition states between two kinetic steps. When ligands bind to such enzyme forms, they push the 
new complex into a favorable low energy conformation and influence so the choice of the catalytic pathway. The 
identification of such saddle points is therefore crucial for an accurate study of the kinetic-related motions of the 
enzyme.
Kinetic cycle and ligand-binding related motions of E. coli DHFR were intensively studied by means of both 
experimental and computational methods. The former (such as site-directed mutagenesis, isothermal calorimetry, 
NMR dispersion, crystallography, etc.) constituted the basis for the understanding of DHFR functionality and 
catalysis. Differently, computational methods (such as MD simulations, thermal fluctuation, thermodynamic 
integration, etc.) were applied with success in order to elucidate protein plasticity and allosteric mechanism, but also 
to address new strategies in drug design, as for example the inhibition of E. coli DHFR by functional disruption, 
where the enzyme is frozen in a conformer that stops the kinetic cycle. Especially MD simulations resulted as a 
sophisticated tool to investigate transition steps and enzyme motions influenced by starting conformation and ligand 
binding.
Very recently, a binary and a ternary complex of 17β-HSD1 (PDB entry 3hb4 and 3hb5) with the potent E2-
derived inhibitor E2B were published (36). In the ternary structure the βFαG’-loop was oriented in cluster cl2, in 
analogy to all other ternary complexes, confirming its importance in ligand stabilization, in particular of Phe192 and 
Met193.
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Small RMSD variations were observed for the catalytic residues Ser142, Tyr155 and Lys159 in all MDs, 
suggesting other regions of the enzyme to be responsible for the proceeding of the five-step catalytic cycle. Site-
directed mutagenesis studies indicated for His221 and Glu282 a prominent role in substrate recognition, but not in 
catalysis (31, 33). The motions of His221 observed in the simulations were in agreement with these results and 
allowed interesting conclusions regarding the role of His221 in substrate recognition and with respect to its 
chaperone function in guiding E1 out of the SUB (Fig. 6). The analysis of the trajectories of the eight MD 
simulations revealed the essential role for backbone and side chain motions, in particular of the flexible βFαG’-loop, 
in cofactor and substrate binding, and the existence of distinguished conformer ensembles related to the single steps 
of the catalysis. Thus, it suggested 17β-HSD1 to follow a selected-fit mechanism (36): E1 or NADPH binds to a 
transition state of the enzyme and induces concerted conformational rearrangements of FG-segment and C-terminal 
part, which guide the enzyme along its preferred catalytic pathway. 
Our multi-trajectory approach allowed an accurate assignment of enzyme conformers to each postulated step of 
the catalytic cycle of 17β-HSD1. It laid the basis not only for a deeper understanding of the kinetic mechanism, but 
also for more general strategies applicable in flexible protein drug discovery. Due to the facts that many enzymes 
are characterized by multiple transition conformations, and that some of them are inhibited by functional disruption, 
it became apparent why an exhaustive enzyme conformer search has to be considered as a necessity in 
computational protein functional studies. 
Methods. 
A detailed description of all of methods is given in SI Text. 
Initial coordinates for the MDs were taken from the crystal structures 1fdtA, 1i5r, 1fdtB and 1bhs, respectively, 
and prepared with the BIOPOLYMER module of SYBYLv8.0 (Sybyl, Tripos Inc., St. Louis, Missouri, USA). The 
crystallographic E2 and NADP+ were transformed into E1 and NADPH, except for 1i5r, where E1 and NADPH 
were merged from 1fdt after superimposition of all crystals. RESP charges were applied to E1, while for NADPH 
the parameters of Ulf Ryde (http://www.teokem.lu.se/~ulf/) were taken. All systems were solvated in a truncated 
octahedron box of waters with a buffer of 10 Å and neutralized with counterions with the xLeap module of the 
AMBER9 suite (37), and then minimized. 
MD simulations were performed by means of AMBER 9.0 with constant temperature and periodic boundary 
conditions. The systems were equilibrated at constant volume (NVT) with restraints on protein heavy atoms, 
NADPH and E1, whereas the production runs were performed at constant pressure (NPT). The Amber99SB force 
field (38) was applied for the proteins. Free energies were calculated by means of MM-PBSA and NMODE of the 
AMBER9 suite. 
The RMSD analysis of the trajectories of the MDs was done with PTRAJ module of the AMBER toolset , and 
the backbone and side chain classification was performed with the CONSENSUS utility of the Homology module of 
MOE (www.chemcomp.com). 
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3.3.6. Conclusions and Outlook 
The analysis of the crystal structures of 17β-HSD1 resulted in the hypothesis of a random bi-bi 
kinetic cycle, which was substantiated by a set of MD simulations performed on apoform, binary 
and ternary complexes between 17β-HSD1, NADPH and substrate estrone (E1). For each step of 
the cycle an enzyme conformation was identified. Moreover, insights were gained into the high 
adaptability of the loop to different steps and its importance in stabilizing the cofactor and 
substrate. 
Docking studies for the class of bis(hydroxyphenyl)-arenes on a small ensemble of enzyme 
conformations of 17β-HSD1 led to the identification of two plausible binding modes: a steroidal 
binding mode and an alternative one. MDs were applied to validate these two binding modes, 
resulting in compound 1 (representative for this class of 17β-HSD1 inhibitors) placed 
preferentially in the alternative binding mode, synergically interacting with the nicotinamide 
moiety of NADPH.  
A global picture emerged by combining the results of the MD studies and the quantum-chemical 
investigations of the MEPs of 5 catalytic residues-NADPH-inhibitor complexes suggesting for 
this class of inhibitors a new inhibition mechanism with respect to what observed for steroidal 
inhibitors. They seemed to dysfunction the enzyme dynamics, due to the simultaneous binding to 
active site and cofactor, strongly influenced by electrostatics, which could “freeze” the loop in a 
particular conformation, stabilizing the enzyme in a “half-switching” state. 
Concluding it can be stated that the application of different computational techniques, namely X-
ray clustering, molecular docking, MD simulations and quantum-chemical studies, resulted in 
very valuable results which helped pushing rational drug design forward and ensured insights in 
the kinetic cycle of 17β-HSD1 and the dynamic motions characterizing the enzyme. 
Nevertheless, still some work should be performed. 
From the computational point of view at least one approach would be advisable: steered or 
REMD simulations with E1 and compound 1, respectively, could help investigating the entrance 
and egress pathways, as well as the concerted βFαG’-motions as a consequence of the 
interactions occurring between enzyme, cofactor and E1 or compound 1. The results of such 
simulations would complete and validate the results presented in this doctoral thesis and in the 
papers IX-XI. 
From a biochemical point of view, site-directed mutagenesis studies focused on the loop residues 
Phe192-Lys195 and on Phe226, placed on the αG’-helix, could validate the hypothetical catalytic 
cycle described in this thesis and shed some new light on the role played by these residues in 
enzyme catalysis and ligand binding. Through concerted mutations the chaperone role of the 
βFαG’-loop should be clarified. 
The computational approach applied on 17β-HSD1 and presented in this thesis has to be seen in 
a more general perspective, namely as a guideline for drug design and biomolecular studies on 
similar enzymes. In particular, analogous studies might be helpful to study the dynamic behavior 
of members of the very large SDR/HSD family. These are characterized by highly flexible 
domains strongly influencing the space of the active site and subjected to conformational 
rearrangements as a consequence of their role in the various kinetic steps. 
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3.4 Congestive heart failure – selective CYP11B2 
inhibition
3.4.1. Pharmacophore-model – evolution and consequences 
for drug design
In the CYP11B2 project the in silico technique primarily used was the pharmacophore-
modelling. 
In paper XII a first pharmacophore (ph4) model was built based upon a series of indane-,
naphthalene- and tetrahydronaphthalene-derivatives. On the basis of a global superimposition, 
with a careful look to the aromatic nitrogen and its lone pair, a pharmacophore model could be 
established consisting of four pharmacophore points (Fig. 39).
Figure 39. First pharmacophore model, with the four pharmacophore points (N: heterocyclic nitrogen, C1: ring 
centroid, C2: ring centroid, C2b: ring centroid).
This pharmacophore model resulted as a valuable tool in the further development of potent non-
steroidal aldosterone synthetase inhibitors, leading to an increase of the molecular complexity.
Subsequently, this first pharmacophore model was expanded by including non-steroidal 
aromatase inhibitors with some CYP11B2-inhibitory potency, leading so to a new 
pharmacophore model (ph4 model) (Fig. 40), used as starting point for the design of new 
inhibitors. One aromatic (HY3) and three acceptor (AA) features were added to the first model, 
indicating that an additional part of the active site of the enzyme could be targeted as well. 
Combined ligand-based (ph4 model) and structure-based (docking simulations) virtual screening 
led in paper XIV to the development of a new class of pyridylnaphthalene derivatives with 
extended carbocyclic skeleton. Derivatives with para-functionalized benzyl moiety in 3-position 
of the naphthalene molecular scaffold thoroughly satisfied the spatial constraints imposed by the 
pharmacophore model and turned out to be highly potent aldosterone synthase inhibitors. The 
most active compound, para-cyanobenzyl derivative 17 (paper XIV), displayed nanomolar 
potency at the target enzyme (IC50 = 2.7 nM)
The selectivity versus CYP11B1 (up to a factor of 900) which is especially remarkable with 
respect to the high homology of the two CYP11B isoforms was found to be a consequence of 
para-substitution and hence of exploiting the AA3b pharmacophoric feature as well.
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Figure 40. Pharmacophore model (a) and compound 1 (paper XIV) mapped to the pharmacophore model (b). The 
newly identified hydrophobic feature HY3 as well as the acceptor atom features AA3a and AA3b are not exploited 
by inhibitors with a naphthalene molecular scaffold. Pharmacophoric features are color-coded: cyan for hydrophobic 
regions (HY0–HY3) and green for acceptor atom features (AA1–4).
3.4.2. MEP maps and rotational energy barriers
In paper XIII molecular electrostatic potential investigations and rotational energy calculations 
led to a series of pyridylnaphthalene derivatives with a substituted heterocyclic moiety with 
reduced CYP1A2 inhibition. Interesting structure-activity relationships could be observed with 
respect to electrostatic properties (Fig. 41). Compounds bearing protic substituents in 5’-position 
rather poorly inhibited CYP11B2 whereas bioisosteric exchange by aprotic residues gave rise to 
highly potent aldosterone synthase inhibitors, e.g., the inhibitory potency increased by a factor of 
40 from carboxamide 17 (IC50 = 94 nM) to the ethanone 18 (IC50 = 2.1 nM). Figure 41 shows the 
MEP maps of compounds 17, 10, and 21 and their bioisosteric analogues 18, 11, and 22. In the 
pyridine moiety of compounds 17, 10, and 21, showing low inhibitory potency, areas with a 
positive ESP are present, while for the highly potent bioisosters, these areas display less positive 
values with a more uniformly distributed electron charge. Hence, the difference in the 
electrostatic potential distribution is a reasonable explanation for the varying potency within this 
set of compounds.
Figure 41. MEP of compounds 17, 18, 10, 11, 21, and 22 (front and back view). The electrostatic potential surfaces 
were plotted with GaussView 3.0 in a range of –18.83 kcal/mol (red) to +21.96 kcal/mol (blue).
In the same paper we investigated also the rotational energy barriers with respect to the planarity 
between heterocycle and naphthalene core. It clearly emerged that the isoquinoline constrains the 
rotation around the carbon–carbon bond between the heterocycle and the naphthalene, especially 
in presence of the additional ortho-methyl groups in 29 and 30 (paper XIII), with rotational 
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barriers higher than 35 kcal/mol. Thus, a coplanar conformation for the isochinoline-substituted 
compounds becomes energetically disfavored compared to the pyridine analogues and the 
sterically demanding heterocycle rotates out of the naphthalene plane. This loss of planarity is a 
reasonable explanation for the reduced inhibitory potency since both CYP1A2 substrates and 
inhibitors are usually small-volume molecules with a planar shape (e.g., caffeine and 
furafylline). An even more drastic effect on the CYP1A2 potency was observed in case of the 
dihydronaphthalene type compounds, where the partly saturated core structure becomes flexible 
and disturbs the planarity. Since aromaticity has been identified to correlate positively with 
CYP1A2 inhibition in recent QSAR studies,139 factors other than steric might play an additional 
role for the decreased CYP1A2 inhibition, e.g., disturbed π-π-stacking contacts with aromatic 
amino acids in the CYP1A2 binding pocket due to the reduced number of aromatic carbons. 
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3.4.3. Articles published in CYP11B2 project –                  
paper XII-XIV 
3.4.3.1. Paper XII. 
 
Development and evaluation of a pharmacophore model for inhibitors of aldosterone 
synthase (CYP11B2). 
 
Sarah Ulmschneider, Matthias Negri, Marieke Voets and Rolf W. Hartmann 
This article is protected by copyrights of ‘Bioorganic and Medicinal Chemistry Letters.’ 
Bioorg. Med. Chem. Lett. 2006, 16, 25–30 
Abstract 
Recently, we proposed inhibition of aldosterone synthase (CYP11B2) as a novel strategy for the treatment 
of congestive heart failure and myocardial fibrosis and synthesized a large number of inhibitors. In this work, a 
pharmacophore model for CYP11B2 inhibitors was developed by superimposition of active and non-active 
compounds. This model was confirmed by the synthesis of two pyridyl substituted acenaphthene derivatives 
(A, B). This new class of compounds as well as the pharmacophore could be helpful for the discovery of novel 
inhibitors. 
Aldosterone synthase (CYP11B2) is the key enzyme of mineralocorticoid biosynthesis. It catalyzes the 
conversion of 11-deoxycorticosterone to the most potent mineralocorticoid aldosterone.1 Pathological elevations in 
plasma aldosterone levels increase blood pressure and play a detrimental role in cardiovascular diseases.2 In two 
recent clinical studies, the aldosterone receptor antagonists spironolactone and eplerenone were found to reduce 
mortality in patients with chronic congestive heart failure and in patients after myocardial infarction, respectively.3,4 
The treatment with these antagonists however, is accompanied with severe side effects like hyperkalemia.5 A new 
pharmacological approach for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis 
was recently suggested by us: inhibition of aldosterone formation with CYP11B2-inhibitors.6,7 Non-steroidal, 
selective inhibitors are to be preferred, because they can be expected to have less side effects on the endocrine 
system. The inhibitors must not affect other P450 (CYP) enzymes. In case of 11-β-hydroxylase (key enzyme of 
glucocorticoid biosynthesis, CYP11B1) this was very difficult to achieve, since it has a sequence homology of more 
than 93% compared to CYP11B2.8 Therefore we initiated a drug discovery program6,7 which finally resulted in 
potent and selective inhibitors originating from three classes of compounds: E- and Z- heterocyclic substituted 
methylene-tetrahydronaphthalenes and -indanes and heterocyclic substituted naphthalene derivatives.9-11 
Here, we describe a pharmacophore model to get insight in the 3-dimensional shape of the binding pocket. 
Compounds named ‘inhibitors‘ were highly active in V79MZh11B2 cells,12 expressing human CYP11B2 (IC50 
values < 100 nM).9-11 ‘Non-inhibitors’ showed little to no activity (IC50 values > 300 nM).9-11 
These compounds are supposed to occupy the substrate binding site in the apoprotein moiety. They also complex 
with their aromatic nitrogen (pharmacophore point N, Fig. 1b) the iron ion of the heme, which is located in the 
active site as well. This complexation mechanism does not only increase binding affinity of the inhibitors but also 
prevents oxygen activation at the heme, which is required for the catalytic process. No X-ray structure of CYP11B2, 
which is located in the inner mitochondrial membrane, is available. Homology approach based protein models have 
been improved continuously,9–11,13 but still are of limited predictive value.  
The compounds shown in Table 1 were first built in Sybyl 7.0 (Tripos Associates; Inc., St. Louis, MO 2001, USA) 
and then optimized in conjugate-gradient modus. Subsequently all molecules underwent a conformational analysis 
with MacroModel V7.0 (1999 Schrödinger, Inc.) and were energy-minimized in MMFF94s14 forcefield as 
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implemented in Sybyl 7.0. A dielectric constant of 1.0 has been used throughout and the optimizations have been 
terminated at a gradient of 0.001 kcal/mol. After defining the ring centroids for each compound of the three classes  
(C1, C2, and C2b, Fig. 1b), the compounds 17–39 - with the exception of the non-inhibitors - were first 
superimposed on compounds 20 and 21 with Sybyl by a three-point-fit strategy using the very same atoms for E-
(red) and Z-(green) 3-pyridyl substituted tetrahydronaphthalenes and -indanes (Fig. 1a).15 
Table 1. Inhibitors and non-inhibitors of aldosterone synthase (CYP11B2) 
Het
Het Het
Het
X X
5
6
6
7
4 X
X
Y
2
34
5
6
8
3 Y
1, 2, 5-7, 10, 19,  27,
  28, 30, 50, 51, 54
3, 4, 8, 9, 11-18, 20-26,
 29, 31-49, 52, 53,  
    55-58, 63-65 
59-62 66-81
7
2
8
3a
7a 7
3a
7a
 
no X, Y Heta Isomer 
IC50 
[nM]b 
no X, Y Heta Isomer 
IC50 
[nM]b 
no X, Y Heta Isomer 
IC50 
[nM]b 
1 H Im E 25 28 6-OMe 3-Py Z 878 55 6-Me 4-Py E >500 
2 H Im Z 10 29 6-OMe 3-Py E >500 56 6-Me 4-Py Z >500 
3 H Im E 41 30 6,7-diOMe 3-Py E >500 57 5-F Pyrim E 27 
4 H Im Z 11 31 5-OEt 3-Py E 79 58 5-F Pyrim Z >500 
5 7-CN Im E >500 32 5-OBn 3-Py E >500 59 bond 3-Py - >500 
6 7-CN Im Z 13 33 6-Me 3-Py E >500 60 no bond 3-Py - >500 
7 6-CN Im Z 23 34 6-Me 3-Py Z >500 61 bond 4-Py - >500 
8 5-CN Im E 36 35 4-Me 3-Py Z >500 62 no bond 4-Py - >500 
9 5-CN Im Z 36 36 4-F 3-Py E 21 63 3-Me 3-Py E >500 
10 7-Cl Im E 47 37 4-Cl 3-Py E 9 64 3-Me 3-Py Z >500 
11 5-F Im E 17 38 4-Cl 3-Py Z 31 65 3-Phenyl 3-Py E >500 
12 5-F Im Z 14 39 7-OMe 3-Py E 27 66 H 3-Py - 28 
13 5-Cl Im E 89 40 H 4-Py E >500 67 5-OH 3-Py - 23 
14 5-Cl Im Z 4 41 H 4-Py Z 931 68 5-OMe 3-Py - 6 
15 5-Br Im E 93 42 5-F 4-Py E 1098 69 5-OEt 3-Py - 12 
16 5-Br Im Z 10 43 5-F 4-Py Z 34 70 5-OPr 3-Py - >500 
17 H 3-Py E 11 44 5-Cl 4-Py E 1515 71 5-OBn 3-Py - >500 
18 H 3-Py Z 92 45 5-Cl 4-Py Z 301 72 5-COOMe 3-Py - 72 
19 H 3-Py E 22 46 5-Br 4-Py E 2640 73 5-Br 3-Py - 15 
20 5-F 3-Py E 7 47 5-Br 4-Py Z 484 74 5-CN 3-Py - 3 
21 5-F 3-Py Z 11 48 5-OMe 4-Py E >500 75 6-OMe 3-Py - >500 
22 5-Cl 3-Py E 26 49 5-OMe 4-Py Z >500 76 
4-Cl, 5-
OMe 3-Py - 13 
23 5-Cl 3-Py Z 73 50 6-OMe 4-Py E >500 77 
4-Cl, 5-
OMe, 8-Cl 3-Py - 28 
24 5-Br 3-Py E 37 51 6-OMe 4-Py Z >500 78 
4-Br, 5-
OMe 
3-Py - 33 
25 5-OMe 3-Py E 34 52 6-OMe 4-Py E >500 79 
4-(3-
Pyridyl) 3-Py - >500 
26 5-OMe 3-Py Z 26 53 6-OMe 4-Py Z >500 80 
2,3-
Benzene-
annelated 
3-Py - >500 
27 6-OMe 3-Py E 57 54 6,7-diOMe 4-Py E >500 81 5-OMe 4-Py - >500 
a Heterocycle: Im= imidazole, 3-Py= 3-pyridine, 4-Py= 4-pyridine, Pyrim= pyrimidine;  
b Activity determined in V79MZh 11B2 cells as described.9-11 
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Figure 1. Superimposition of compounds: (a) alignment of inhibitors from 17 to 39 and 66 to 81 (see Table 1); (b) 
skeletal structure of the pharmacophore model: overlay of the unsubstituted 2-(3-pyridyl) naphthalene (66 yellow) 
and the unsubstituted E- and Z-3-pyridylmethylene-indane (17 and 18; red and green); the pharmacophore 
(magenta) is built by connecting the ring centroids (C1, C2, and C2b) and the aromatic nitrogen N; (c) sideview of 
the pharmacophore.
The naphthalene inhibitors (66–69, 72–74, and 76–78; yellow, Fig. 1a) were aligned with both E- and Z-(3-
pyridyl)methylene-indanes and -tetrahydronaphthalenes, respectively.16,17 These naphthalenes as well as the Eand Z-
imidazolyl substituted tetrahydronaphthalene and -indane inhibitors (not shown) fitted very well into the 
pharmacophore (Fig. 1b). The superimposition of non-inhibitors - using the same procedure as applied for the 
inhibitors - revealed that the corresponding substituents did not match with the model (Table 2).
Table 2. Substitution patterns of inhibitors and non-inhibitors of CYP11B2
Het
n
Het
R1
R3
R4
R5 R6
R7
R8
R9
n=0,1
Inhibitors: Het= 3-Pyridine, Imidazole, Pyrimidine
      Non-Inhibitors: Het= 4-Pyridine 
R2
R10
R appropriate substituents inappropriate substituents
R1 H,CH3, Phenyl, anellated rings (R
1 to R2)
R2 - -
R3 H, F, Cl, CH3, OMe -
R4
H, F, Cl, Br, CN, OH,
OMe, OEt, COOMe
OPr, OBn
R5 H, Cl, Br Me, OMe, CN, 3-Pyridyl
R6 H, Cl -
R7 H, OMe -
R8 H, F, Cl, Br, CN, OMe anellated rings (R8 to R9)
R9 H, CN Me
R10 Cl -
The pharmacophore model (Fig. 1b) was built on four pharmacophore points, chosen on the basis of the global
superimposition (Fig. 1):
• N: heterocyclic nitrogen (all inhibitors).
• C1: ring centroid (E-(3-pyridyl)methylene-tetrahydronaphthalenes and -indanes and naphthalenederivatives).
• C2: ring centroid (E- and Z-(3-pyridyl)-methyleneindanesand -tetrahydronaphthalenes).
• C2b: ring centroid (Z-(3-pyridyl)methylene-tetrahydronaphthalenes and -indanes and naphthalenederivatives).
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Each compound fits with three of these points and has nitrogen N in common. The lone pair of the heterocyclic
nitrogen of all compounds has to point in almost the same direction (Fig. 1a) for complexing the heme iron. The 
three ring centroids (C1, C2, and C2b) are located in one plane, P0, forming a planar three-ring-system (ace-
naphthene or dihydro-phenalene), while the aromatic nitrogen N is located slightly above plane P0 (see geometric 
parameters, Table 3). Actually, the whole pharmacophore seems to be quite planar.
Table 3. Geometric parameters of the pharmacophore
Distances (Å) Angles (°) Angles respectto the planes (°)
C1–C2 2.0–2.3 C1–N–C2 12.5–15 P0–P1 13.3
C1–C2b 2.2–2.4 C1–N–C2b 10–12 P0–P2 11.9
C2–C2b 2.1–2.3 C2–N–C2b 23.5–25 P1–P2 157.8
C1–N 7.1–8.1
C2–N 5.2–6.0
C2b–N 5.2–6.4
where:
• P0: plane containing C1, C2, and C2b;
• P1: plane containing C1, N, and C2;
• P2: plane containing C1, N, and C2b;
• P3: plane containing C2, N, and C2b.
The steric features of active and non-active CYP11B2-inhibitors were further explored by the ʽsteric inclusion 
area (SIA)’ and the ʽsteric exclusion area (SEA)’, respectively (Figs. 2a and b). The SIA is mainly located in the 
region of substituents R3, R4 and R8 (see Table 2). Larger groups as formic acid methyl ester can only be 
introduced in position R4 (72), whereas position R8 is of limited size. The SEA is located at the non-aromatic ring 
and the exocyclic double bond of the Z-isomer (substituents R1 and R2, Table 2). Additionally, large substituents as 
benzyloxy- or 3-pyridyl-groups in the region of R4 and R5 are not suitable for proper inhibitor binding (32 and 79). 
The SEA is also located close to R9, since methyl-groups lead to a strong decrease of activity (34).
Figure 2. Unsubstituted hybrid-structure with: a) the steric inclusion area (SIA); b) the steric exclusion area (SEA).
To validate the model, a compound was generated as a hybrid structure of the used E- and Z-isomers as well as 
the naphthalene compounds, the acenaphthene derivative (A). Compound A was synthesized in four steps: nitration 
of acenaphthene16 and subsequently hydrogenation17 leading to a mixture of two isomers: 3- and 5-
aminoacenaphthene. In the following Sandmeyer reaction the bromo derivatives were formed and used for Suzuki
coupling with 3-pyridine boronic acid. The resulting mixture was subsequently chromatographed and the isomers A
and B were isolated (Scheme 1).
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Scheme 1. 
NH2
NH2
Br
Br
N
N
+
++
(a)
(b)
(c)
(d)
BA
A.1 B.1
(e)
 
Reagents and Conditions: (a) HNO3, in acetic anhydride, 20 h at 10°C; (b) H2, Pt/C (5%), in THF; (c) 1. NaNO2, in HBr, 0°C, 2. CuBr, in 
HBr/toluene, 0°C, addition of the diazonium salt, 10 min at 0°C, 2h at 100°C; (d) Na2CO3-solution, 3-pyridine-boronic acid, in methanol, 
tetrakis(triphenyl-phosphin)palladium, N2, reflux, 12 h; (e) separation of A and B using column chromatgraphy. 
Both isomers were tested for activity in V79 cells,12 expressing human CYP11B2.6 The IC50 values of the 
compounds are given in Table 4. 
Table 4. Biological evaluation of hybrid compounds A and B 
 IC50-value [nM) a Selectivityd 
Compound CYP11B1b CYP11B2c  
A 
B 
2452 
2896 
10 
14 
245 
207 
a Mean value of four determinations, standard deviation less than 20%. b Hamster fibroblasts (V79 cells) expressing human CYP11B1; 
substrate deoxycorticosterone, 100 nM. c Hamster fibroblasts (V79 cells) expressing human CYP11B2; substrate deoxycorticosterone, 100 
nM; d IC50 CYP11B1/IC50 CYP11B2. 
As expected compound A exhibited strong inhibitory activity (IC50 = 10 nM), thus confirming the validity of the 
pharmacophore model. Surprisingly the isomer B was also very potent. This can be explained by the alignment of 
the acenaphthene derivatives A and B (Fig. 3). The compounds display a very similar shape, they only differ in the 
position of the non-aromatic cyclopentene-ring. 
 
Figure 3. Alignment of hybrid compound A (black) and its isomer B (grey). 
After having discovered the acenaphthene isomers as highly potent lead compounds we wanted to know about 
their selectivity towards CYP11B1 (Table 4). Both inhibitors showed little inhibition of CYP11B1 which makes 
them interesting candidates for further development. 
Summarizing, the first pharmacophore model for inhibitors of aldosterone synthase (CYP11B2) was built by 
superimposition of a series of compounds synthesized by our group. This pharmacophore could be confirmed by 
synthesis and biological evaluation of two hybrid compounds derived from the model. 
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Abstract 
Recently, we reported on the development of potent and selective inhibitors of aldosterone synthase (CYP11B2) 
for the treatment of congestive heart failure and myocardial fibrosis. A major drawback of these non-steroidal 
compounds was a strong inhibition of the hepatic drug-metabolizing enzyme CYP1A2. In the present study, we 
examined the influence of substituents in the heterocycle of lead structures with a naphthalene molecular scaffold to 
overcome this unwanted side effect. With respect to CYP11B2 inhibition, some substituents induced a dramatic 
increase in inhibitory potency. The methoxyalkyl derivatives 22 and 26 are the most potent CYP11B2 inhibitors up 
to now (IC50 = 0.2 nM). Most compounds also clearly discriminated between CYP11B2 and CYP11B1 and the 
CYP1A2 potency significantly decreased in some cases (e.g., isoquinoline derivative 30 displayed only 6 % 
CYP1A2 inhibition at 2 μM concentration). Furthermore, isoquinoline derivative 28 proved to be capable of passing 
the gastrointestinal tract and reached the general circulation after peroral administration to male Wistar rats. 
Introduction 
The most important circulating mineralocorticoid aldosterone is secreted by the zona glomerulosa of the adrenal 
gland and is to a minor extent also synthesized in the cardiovascular system.1 The hormone plays a key role in the 
electrolyte and fluid homeostasis and thus for the regulation of blood pressure. Its biosynthesis is accomplished by 
the mitochondrial cytochrome P450 enzyme aldosterone synthase (CYP11B2) and proceeds via catalytic oxidation 
of the substrate 11-deoxycorticosterone to corticosterone and subsequently to aldosterone.2 The adrenal aldosterone 
synthesis is regulated by several physiological parameters such as the renin-angiotensin-aldosterone system (RAAS) 
and the plasma potassium concentration. Chronically elevated plasma aldosterone levels increase the blood pressure 
and are closely associated with certain forms of myocardial fibrosis and congestive heart failure.3 An insufficient 
renal flow chronically activates the RAAS and aldosterone is excessively released. The therapeutic benefit of 
reducing aldosterone effects by use of the mineralocorticoid receptor (MR) antagonists spironolactone and 
eplerenone has been reported in two recent clinical studies (RALES and EPHESUS).4,5 The studies showed that 
treatment with these antagonists reduces mortality in patients with chronic congestive heart failure and in patients 
after myocardial infarction, respectively. Spironolactone, however, showed severe side effects presumably due to its 
steroidal structure.4,6 Although the development of non-steroidal aldosterone receptor antagonists has been reported 
recently,7 several issues associated with the unaffected and pathophysiologically elevated plasma aldosterone levels 
remain unsolved by this therapeutic strategy such as the up-regulation of the mineralocorticoid receptor expression8 
and non-genomic aldosterone effects.9 A novel approach for the treatment of diseases affected by elevated 
aldosterone levels is the blockade of aldosterone biosynthesis by inhibition of CYP11B2.10,11 Aldosterone synthase 
has previously been proposed as a potential pharmacological target,12 and preliminary work focused on the 
development of steroidal inhibitors, i.e., progesterone13 and deoxycorticosterone14 derivatives with unsaturated C18-
substituents. These compounds were found to be mechanism-based inhibitors binding covalently to the active site of 
bovine CYP11B, however, data on inhibitory action towards human enzyme are essentially absent in these studies. 
The strategy of inhibiting the aldosterone formation has two main advantages compared to MR antagonism. First, 
there is no non-steroidal inhibitor of a steroidogenic CYP enzyme known to have affinity to a steroid receptor. For 
this reason, fewer side effects on the endocrine system should be expected. Furthermore, CYP11B2 inhibition can 
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reduce the pathologically elevated aldosterone levels whereas the latter remain unaffected by interfering one step 
later at the receptor level. By this approach, however, it is a challenge to reach selectivity versus other CYP 
enzymes. Taking into consideration that the key enzyme of glucocorticoid biosynthesis, 11β-hydroxylase 
(CYP11B1), and CYP11B2 have a sequence homology of more than 93 %,15 the selectivity issue becomes 
especially critical for the design of CYP11B2 inhibitors. 
The aromatase (CYP19) inhibitor fadrozole (I, Chart 1) which is used in the therapy of breast cancer was found 
to significantly reduce the corticoid formation.16 This compound is a potent inhibitor of CYP11B2 displaying an 
IC50 value of 1 nM (Table 1). The R(+)-enantiomer of fadrozole (FAD 286) was recently shown to reduce mortality 
and to ameliorate angiotensin II-induced organ damage in transgenic rats overexpressing both the human renin and 
angiotensinogen genes.17 These findings underline the potential therapeutic utility of aldosterone synthase inhibition, 
and up to now, several structurally modified fadrozole derivatives are investigated as CYP11B2 inhibitors.18,19 
Recently, the development of imidazolyl- and pyridylmethylenetetrahydronaphthalenes and -indanes as highly 
active and in some cases selective CYP11B2 inhibitors has been described by our group.20,21 By keeping the 
pharmacophore and rigidization of the core structure, pyridine substituted naphthalenes22 II and 
dihydronaphthalenes23 III were shown to be potent and selective CYP11B2 inhibitors (Chart 1). Combining the 
structural features of these substance classes to a hybrid core structure led to pyridine substituted acenaphthenes as 
potent CYP11B2 inhibitors with remarkable selectivity.24 Furthermore, most of the naphthalene and 
dihydronaphthalene type compounds exhibited a favorable selectivity profile versus selected hepatic CYP enzymes. 
However, they turned out to be potent inhibitors of the hepatic CYP1A2 enzyme (see examples 1, 3, and 4 in Table 
1). CYP1A2 makes up about 10 % of the overall cytochrome P450 content in the liver and metabolizes aromatic and 
heterocyclic amines as well as polycyclic aromatic hydrocarbons.25 This experimental result turned these 
naphthalene type aldosterone synthase inhibitors into unsuitable drug candidates since adverse drug-drug 
interactions are mainly caused by inhibition of hepatic cytochrome P450 enzymes and have to be avoided in either 
case. In our preceding studies, the attention was focused on the optimization of the naphthalene skeleton, the 
substitution pattern of the heme complexing 3-pyridine moiety, however, was not investigated in detail. Herein, we 
describe the synthesis of a series of naphthalenes and dihydronaphthalenes with various substituents in the pyridine 
heterocycle to examine their influence on potency and selectivity (Table 1). The biological activity of the 
synthesized compounds was determined in vitro on human CYP11B2 for potency and human CYP11B1 and 
CYP1A2 for selectivity. In addition, selected compounds were tested for inhibitory activity at human CYP17 (17α-
hydroxylase-C17,20-lyase), CYP19, and selected hepatic CYP enzymes (CYP2B6, CYP2C9, CYP2C19, CYP2D6, 
CYP3A4). The in vivo pharmacokinetic profile of two promising compounds was determined in a cassette dosing 
experiment using male Wistar rats. 
Chart 1. Non-steroidal inhibitors of CYP11B2. 
 
Results 
Chemistry 
The key step for the synthesis of pyridine substituted naphthalenes was a Suzuki cross coupling (Scheme 1).26 A 
microwave enhanced method developed by van der Eycken et al. was chosen for this purpose.27 By applying this 
method, various substituted bromopyridines were coupled with 6-methoxy-2-naphthaleneboronic acid to afford 
compounds 7, 9–11, 14, 15, 17–19, 21, 23, 27, and 28. Compound 8 was obtained by coupling of 4-methyl-3-
pyridineboronic acid with triflate 8a which was accessible by treating 6-cyano-2-naphthol with Tf2NPh and K2CO3 
in THF under microwave irradiation.28 The bromopyridines could be derivatized prior to Suzuki coupling according 
to Scheme 2 to provide heterocycles bearing a hydroxy, ethoxy or hydroxymethyl substituent (10a, 14a, 21a, and 
23a).29 
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Scheme 1. 
 
Reagents and conditions: i) Pd(PPh3)4, DMF, aq. NaHCO3, μw, 150 °C; ii) Tf2NPh, K2CO3, THF, μw, 120 °C; iii) Pd(dppf)Cl2, 
toluene/acetone, aq. Na2CO3, μw, 150 °C. 
Scheme 2. 
 
Reagents and conditions: i) conc. HBr, reflux; ii) EtBr, K2CO3, DMF, rt; iii) NaBH4, methanol, 0 °C.  
For compounds 21–26, the substitution pattern was modified after the cross-coupling reaction as shown in 
Scheme 3 by sodium borohydride reduction and optional methylation. Esterification of the carboxylic acids 15 and 
19 by refluxing in methanol under acid catalysis afforded the corresponding methyl esters 16 and 20. The synthesis 
of 6-cyanodihydronaphthalene 6 was accomplished by the sequence shown in Scheme 4. Using 6-bromo-2-tetralone, 
Pd-catalyzed cyanation30 led to intermediate 6b which was transformed into the alkenyltriflate 6a by deprotonation 
with KHMDS and subsequent treatment with Tf2NPh.31 Compound 6a underwent Suzuki coupling with 3-
pyridineboronic acid to afford 6. 
Scheme 3. 
 
Reagents and conditions: i) NaBH4, methanol, 0 °C; ii) MeI, NaH, THF, rt; iii) methanol, H2SO4, reflux. 
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Scheme 4. 
 
Reagents and conditions: i) Zn(CN)2, Pd(PPh3)4, DMF, 100 °C; ii) Tf2NPh, KHMDS, THF/toluene, –78 °C; iii) 3-pyridineboronic acid, 
Pd(PPh3)4, DMF, aq. NaHCO3, μw, 150 °C. 
The naphthalenes 2, 12, 29 and the dihydronaphthalenes 5, 13, 30 were obtained as shown in Scheme 5. The 
sequence for the synthesis of intermediate 2e was described previously and was only slightly modified by us (see 
supplementary material).32 Regioselective α-bromination was accomplished by treating 2e with CuBr2 in refluxing 
ethyl acetate/CHCl3.33 After a subsequent reduction/elimination step,23 the intermediate alkenylbromide 2b 
underwent Suzuki coupling34 with the appropriate boronic acid to afford the dihydronaphthalenes 5, 13, and 30. The 
corresponding naphthalenes 2, 12, and 29 were obtained by aromatization of 2b with DDQ in refluxing toluene35 
followed by Suzuki coupling.27 The synthesis of compounds 1, 3, and 4 has been reported previously by our 
group.22,23 
Scheme 5. 
 
Reagents and conditions: i) 3-methoxyphenylmagnesium bromide, THF, –5 °C; ii) KOH, NaOH/water, reflux; iii) H2, Pd/C, AcOH, 60 
°C; iv) (COCl)2, CH2Cl2, rt, then AlCl3, CH2Cl2, –10 °C; v) CuBr2, ethyl acetate/CHCl3, reflux; vi) NaBH4, methanol, 0 °C; vii) p-
toluenesulfonic acid, toluene, reflux; viii) boronic acid, Pd(OAc)2, TBAB, acetone, aq. Na2CO3, μw, 150 °C; ix) DDQ, toluene, reflux; x) 
boronic acid, Pd(PPh3)4, DMF, aq. NaHCO3, μw, 150 °C. 
Biological Results 
Inhibition of Human Adrenal Corticoid Producing CYP11B2 and CYP11B1 In Vitro (Table 1). The 
inhibitory activities of the compounds were determined in V79 MZh cells expressing either human CYP11B2 or 
CYP11B1.10,36 The V79 MZh cells were incubated with [14C]-deoxycorticosterone as substrate and the inhibitor at 
different concentrations. The product formation was monitored by HPTLC using a phosphoimager. Fadrozole, an 
aromatase (CYP19) inhibitor with proven ability to reduce corticoid formation in vitro and in vivo was used as a 
reference compound (CYP11B2, IC50 = 1 nM; CYP11B1, IC50 = 10 nM).16  
Most of the substituted pyridylnaphthalenes showed a high inhibitory activity at the target enzyme CYP11B2 
with IC50 values in the low nanomolar range (Table 1). Some of the compounds displayed subnanomolar potency 
(IC50 < 1 nM) and turned out to be even stronger aldosterone synthase inhibitors than the reference substance 
fadrozole. The methoxyalkyl substituted compounds 22 and 26 exhibited IC50 values of 0.2 nM each. Hence, they 
are 5-fold more active than fadrozole (IC50 = 1 nM) and 30-fold more active than the unsubstituted parent compound 
1 (IC50 = 6.2 nM). However, derivatization by polar and acidic residues in 5’-position resulted in a decrease in 
potency. This particularly applies to the carboxylic acids 15 and 19 showing no or only low inhibitory activity and to 
a minor extent also to the phenolic compound 10 and the carboxamide 17 with IC50 values of 94 nM each. 
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Table 1. Inhibition of human adrenal CYP11B2, CYP11B1 and human CYP1A2 in vitro 
 
   IC50 valuea (nM)   
   V79 11B2b V79 11B1c selectivity % inhibitione 
compd R1 R2 hCYP11B2 hCYP11B1 factord CYP1A2f 
1g 6-OMe H 6.2 1577 254 98 
2 6-OMe-3-Me H 7.0 1047 150 93 
3g 6-CN H 2.9 691 239 97 
4g 6-OMe H 2.1 578 275 98 
5 6-OMe-3-Me H 3.3 248 79 73 
6 6-CN H 4.5 461 103 91 
7 6-OMe 4’-Me 0.8 114 143 98 
8 6-CN 4’-Me 0.6 52 87 86 
9 6-OMe 4’-NH2 13 1521 117 58 
10 6-OMe 5’-OH 94 8925 95 93 
11 6-OMe 5’-OMe 4.2 238 57 91 
12 6-OMe-3-Me 5’-OMe 3.8 875 230 91 
13 6-OMe-3-Me 5’-OMe 1.2 100 83 18 
14 6-OMe 5’-OEt 5.1 373 73 85 
15 6-OMe 5’-COOH n.a.h n.d. n.d. n.d. 
16 6-OMe 5’-COOMe 0.8 15 19 n.d. 
17 6-OMe 5’-CONH2 94 41557 442 n.d. 
18 6-OMe 5’-COMe 2.1 255 121 80 
19 6-OMe 5’-CH2COOH 1216 37796 31 n.d. 
20 6-OMe 5’-CH2COOMe 6.9 199 29 n.d. 
21 6-OMe 5’-CH2OH 9.1 614 68 93 
22 6-OMe 5’-CH2OMe 0.2 31 155 83 
23 6-OMe 4’-CH2OH 22 1760 80 92 
24 6-OMe 4’-CH2OMe 2.2 435 198 97 
25 6-OMe 5’-CH(OH)Me 0.5 99 198 78 
26 6-OMe 5’-CH(OMe)Me 0.2 10 50 n.d. 
27 6-OMe 5’-Ph 4.8 151 32 n.d. 
28 6-OMe - 0.6 67 112 57 
29 6-OMe-3-Me - 3.1 843 272 45 
30 - - 0.5 64 128 6 
fadrozole - - 1.0 10 10 8 
a Mean value of four experiments, standard deviation usually less than 25 %, n.d. = not determined. b Hamster fibroblasts expressing 
human CYP11B2; substrate deoxycorticosterone, 100 nM. c Hamster fibroblasts expressing human CYP11B1; substrate 
deoxycorticosterone, 100 nM. d IC50 CYP11B1/IC50 CYP11B2. e Mean value of two experiments, standard deviation less than 5 %; n.d. = 
not determined. f Recombinantly expressed enzyme from baculovirus-infected insect microsomes (Supersomes); inhibitor concentration, 
2.0 μM; furafylline, 55 % inhibition. g These compounds were described previously.22,23 h n.a. = no acivity (7 % inhibition at an inhibitor 
concentration of 500 nM). 
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Beside introduction of small residues in 4’- and 5’-position, an extension of the heterocyclic moiety by a 
condensed phenyl ring afforded the extraordinary potent isoquinoline compounds 28–30 with IC50 values in the 
range of 0.5–3.1 nM. Even the sterically demanding 5’-phenyl residue of compound 27 was still tolerated (IC50 = 4.8 
nM). In general, changing the carbocyclic core (naphthalene, 3-methyl- or dihydro-derivative) while simultaneously 
keeping the substitution pattern of the heterocycle had only little effect on the CYP11B2 inhibition as shown by the 
series 11–13 (IC50 = 1.2–4.2 nM) and 28–30 (IC50 = 0.5–3.1 nM). With regard to the inhibitory activity at the highly 
homologous CYP11B1, most of the tested compounds were less active than at CYP11B2. However, a noticeable 
inhibition with IC50 values in the range of 10–100 nM was observed in some cases. In particular, the 5’-
methoxyalkylpyridine derivatives 22 (IC50 = 31 nM) and 26 (IC50 = 10 nM) as well as the methyl ester 16 (IC50 = 15 
nM) turned out to be potent CYP11B1 inhibitors. Although introduction of substituents in the heterocyclic moiety 
mostly resulted in a moderate decrease in selectivity compared to the unsubstituted derivatives, the selectivity 
factors were still high for most of the tested compounds (factor 100–200). In case of 6-methoxy-3-
methylnaphthalene 2, the introduction of substituents in the heterocyclic moiety led to an enhanced selectivity. A 
methoxy substituent in 5’-position as accomplished in compound 12 increased the selectivity factor from 150 to 230 
and the isoquinoline derivative 29 proved to be one of the most selective CYP11B2 inhibitors of the series with a 
selectivity factor of 272, thus being 27-fold more selective than fadrozole (selectivity factor = 10). 
Inhibition of Hepatic and Steroidogenic CYP Enzymes (Tables 1 and 2). In order to further examine the 
influence of heteroaryl substitution on selectivity, the compounds were tested for inhibition of the hepatic CYP1A2 
enzyme. CYP1A2 was strongly inhibited by all previous CYP11B2 inhibitors of the naphthalene and 
dihydronaphthalene type with unsubstituted heme-coordinating heterocycle, e.g., 1–4 exhibited more than 90 % 
inhibition at an inhibitor concentration of 2 μM (Table 1). With regard to the potent CYP1A2 inhibitor 1, 
derivatization of the heterocycle gave rise to compounds with a slightly reduced inhibitory potency, e.g., compounds 
14, 18, 22, and 25 displaying approximately 80 % inhibition. A pronounced decrease of CYP1A2 inhibition was 
observed in case of compounds 9, 13, and 29–30 (6 –57 %). However, the dihydronaphthalenes 6, 13, and 30 turned 
out to be chemically unstable and decomposition in DMSO solution was observed after storage at 2 °C (~80 % 
purity after three days) yielding considerable amounts of the aromatized analogues and traces of unidentified 
degradation products. Therefore, they were not taken into account for further biological evaluations despite their 
outstanding CYP1A2 selectivity. The CYP1A2 inhibition of some compounds was not determined at all due to 
either a low CYP11B2 potency (15, 17, and 19) or low CYP11B1 selectivity (16, 20, 26, and 27). 
For a set of four structurally diverse compounds (9, 11, 18, and 28), an extended selectivity profile including 
inhibition of the steroidogenic enzymes CYP17 and CYP19 as well as inhibition of some crucial hepatic CYP 
enzymes (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4) was determined (Table 2). The inhibition of CYP17 
was determined with the 50,000 g sediment of the E. coli homogenate recombinantly expressing human CYP17, 
progesterone (25 µM) as substrate, and the inhibitors at a concentration of 2 μM.37 The tested compounds turned out 
to be moderately potent inhibitors of CYP17. The inhibition values ranked around 40 % corresponding with IC50 
values of approximately 2000 nM or higher. The inhibition of CYP19 at an inhibitor concentration of 500 nM was 
determined in vitro by use of human placental microsomes and [1β-3H]androstenedione as substrate as described by 
Thompson and Siiteri38 using our modification.39 In this assay, no inhibition of CYP19 was observed for compounds 
11, 18, and 28. Only the amino substituted compound 9 displayed a moderate inhibition of 47 %. The IC50 values of 
the compounds for the inhibition of the hepatic CYP enzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, 
and CYP3A4 were determined using recombinantly expressed enzymes from baculovirus-infected insect 
microsomes (Supersomes). The values of the CYP1A2 inhibition matched well the previously determined percental 
inhibition (Table 1). Methoxy compound 11 with 91 % inhibition at 500 nM turned out to be a potent CYP1A2 
inhibitor (IC50 = 83 nM) whereas the inhibitory potency decreased to 488 nM in case of the ketone derivative 18. A 
pronounced selectivity regarding the CYP1A2 inhibition was observed in case of compounds 9 and 28 with IC50 
values of approximately 1.5 μM. In most cases, the other investigated CYP enzymes were unaffected, e.g., IC50 
values of 9 were greater than 10 μM versus CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
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Table 2. Inhibition of selected steroidogenic and hepatic CYP enzymes in vitro 
 % inhibitiona  IC50 valueb (nM) 
compd CYP17c CYP19d  CYP1A2e,f CYP2B6e,g CYP2C9e,h CYP2C19e,i CYP2D6e,j CYP3A4e,k 
9 42 47  1420 > 50000 48970 45800 11100 21070 
11 41 14  83 > 25000 1888 > 25000 > 25000 1913 
18 36 < 5  488 > 50000 > 200000 > 200000 > 200000 9070 
28 39 7  1619 16540 1270 3540 33110 3540 
a Mean value of four experiments, standard deviation less than 10 %. b Mean value of two experiments, standard deviation less than 5 %. c 
E. coli expressing human CYP17; substrate progesterone, 25 μM; inhibitor concentration 2.0 μM; ketoconazole, IC50 = 2780 nM. d Human 
placental CYP19; substrate androstenedione, 500 nM, inhibitor concentration 500 nM; fadrozole, IC50 = 30 nM. e Recombinantly expressed 
enzymes from baculovirus-infected insect microsomes (Supersomes). f Furafylline, IC50 = 2419 nM. g Tranylcypromine, IC50 = 6240 nM. h 
Sulfaphenazole, IC50 = 318 nM. i Tranylcypromine, IC50 = 5950 nM. j Quinidine, IC50 = 14 nM. k Ketoconazole, IC50 = 57 nM. 
Pharmacokinetic Profile of Compounds 1, 9, and 28 (Table 3). The pharmacokinetic profile of compounds 9 
and 28 was determined after peroral application to male Wistar rats and compared to the unsubstituted parent 
compound 1. After administration of a 5 mg/kg dose in a cassette (N = 5), plasma samples were collected over 24 h 
and plasma concentrations were determined by HPLC-MS/MS. Fadrozole which was used as a reference compound 
displayed the highest plasma levels (AUC0-∞ = 3575 ng∙h/mL), followed by 1 (1544 ng∙h/mL) and 28 (762 
ng∙h/mL). At all sampling points, the amounts of 9 detected were found below the limit of quantification (1.5 ng per 
mL plasma). This experimental result may be either due to a fast metabolism of the aromatic amine or due to a 
lacking ability of this compound to permeate the cell membrane under physiological conditions. The half-lives were 
between 2.2–5.4 h in which the elimination of fadrozole occurs faster than the elimination of the naphthalenes 1 and 
28. Compound 28 is slowly absorbed as indicated by the tmax of 6 h whereas 1 is absorbed as fast as fadrozole (tmax = 
1 h). Furthermore, no obvious sign of toxicity was noted in any animal over the duration of the experiment (24 h). 
Table 3. Pharmacokinetic profile of compounds 1, 9, and 28 
compda t1/2 z (h)b tmax (h)c Cmax (ng/mL)d AUC0-∞ (ng∙h/mL)e 
1 5.4 1.0 222 1544 
9 n.d.f n.d. f < 1.5g n.d. f 
28 3.2 6.0 81 762 
fadrozole 2.2 1.0 454 3575 
a All compounds were applied perorally at a dose of 5 mg per kg body weight in four different cassette dosing experiments using male 
Wistar rats. b Terminal half-life. c Time of maximal concentration. d Maximal concentration. e Area under the curve. f n.d. = not 
detectable. g Below the limit of quantification. 
Discussion and Conclusion 
The results obtained in the present study revealed that a variety of substituents in 4’- and 5’-position is tolerated 
with regard to the CYP11B2 potency. Most of the tested compounds were more potent than the unsubstituted parent 
compounds and IC50 values less than 1 nM were observed in 7 cases (e.g., 22 and 26, IC50 = 0.2 nM). Some of the 
compounds were also potent CYP11B1 inhibitors (e.g., 26, IC50 = 10 nM). Interestingly, a precise relationship 
between the inhibition of CYP11B2 and CYP11B1 was observed: An increased or decreased inhibitory activity at 
the one enzyme was accompanied by an increased or decreased inhibitory activity at the other enzyme. For instance, 
based on the unsubstituted parent compound 1, introduction of the methoxyalkyl substituent in compound 26 
resulted in an enhanced inhibition of both CYP11B2 (IC50 = 0.2 nM) and CYP11B1 (IC50 = 10 nM), whereas 
introduction of the hydroxy group in compound 10 resulted in a decreased inhibitory potency at both CYP11B 
isoforms in a comparable order of magnitude (CYP11B2, IC50 = 94 nM; CYP11B1, IC50 = 8925 nM). This trend 
becomes particularly evident when plotting the CYP11B2 versus the CYP11B1 pIC50 values of the compounds 
presented in Table 1 revealing a reasonable linear correlation (r2 = 0.86, n = 29). The finding that it is to some extent 
possible to change the inhibitory potency by the heteroaryl derivatization without significantly changing the 
selectivity versus either CYP11B2 or CYP11B1 is an indication that the inhibitor binding proceeds via similar 
protein-inhibitor interactions of the heterocyclic moiety with both CYP11B isoforms. Contrariwise, it has been 
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shown earlier by us that variation of the carbocyclic skeleton instead of the heterocycle can significantly influence 
the selectivity. Therefore, no correlation is observed for a plot of the CYP11B2 and CYP11B1 pIC50 values of the 
naphthalenes22 and dihydronaphthalenes23 described previously by us that are functionalized with an unsubstituted 
3-pyridine as heme complexing heterocycle (r2 = 0.30, n = 20). Consistent with these findings, it can be assumed
that both enzymes, CYP11B2 and CYP11B1, are structurally more diverse in the naphthalene binding site than in 
the heterocyclic binding site. Interesting structure-activity relationships could also be observed with respect to 
electronic properties. Compounds bearing protic substituents in 5’-position rather poorly inhibited CYP11B2 
whereas bioisosteric exchange by aprotic residues gave rise to highly potent aldosterone synthase inhibitors, e.g., the 
inhibitory potency increased by a factor of 40 from carboxamide 17 (IC50 = 94 nM) to the ethanone 18 (IC50 = 2.1 
nM). A comparable increase of potency was observed when the protic hydroxy group was replaced by the aprotic 
methoxy group, e.g., the IC50 value decreased by a factor of 20 in case of compound 11 compared to the phenol 10
or by a factor of 40 in case of compound 22 compared to the primary alcohol 21. Similarly, the methyl esters 16 and 
20 were more active than the corresponding carboxylic acids 15 and 19. However, a lack of membrane permeability 
must be taken into consideration as an alternative explanation. Figure 1 shows the molecular electrostatic potentials 
(MEP) mapped on the electron density surface of compounds 17, 10, and 21 and their bioisosteric analogues 18, 11,
and 22. Both the shape and the geometry of the compounds as well as the electrostatic potential distribution in the 
naphthalene moiety are very similar. In addition, all compounds contain a region in which the nitrogen of the 
pyridine ring presents a negative potential. However, areas with a distinct positive potential in the pyridine moiety 
are present in compounds 17, 10, and 21 showing low inhibitory potency. In case of the highly potent bioisosters, 
these areas display less positive potential values with a more uniformly distributed electron charge. Hence, the 
difference in the electrostatic potential distribution is a reasonable explanation for the varying binding behavior 
within this set of compounds.
Figure 1. MEP of compounds 17, 18, 10, 11, 21, and 22 (front and back view). The electrostatic potential surfaces 
were plotted with GaussView 3.0 in a range of –18.83 kcal/mol (red) to +21.96 kcal/mol (blue).
The heteroaryl derivatization had also a noticeable influence on the CYP1A2 potency of the compounds. Most of 
the substituted derivatives were still inhibiting CYP1A2 for more than 90 % at a concentration of 2 μM. With 
respect to the compounds with a 6-methoxynaphthalene core, a slight decrease to approximately 80 % inhibition was 
observed in some cases. This effect was due to the introduction of substituents in 5’-position of the heterocycle. 
While no decrease of CYP1A2 inhibition was observed in case of the rather small substituents in compounds 10, 11,
and 21 (hydroxy, methoxy, and hydroxymethyl), a slight increase of the sterical bulk in compounds 14, 18, 22, and 
25 (ethoxy, acetyl, methoxymethyl, and hydroxyethyl) resulted in a decrease in CYP1A2 inhibition to 78–85 %. On 
the other hand, some derivatives proved to be significantly less active with approximately 50 % inhibition of 
CYP1A2, including the 4’-amino-substituted compound 9 and the isoquinoline 28 with IC50 values of 1420 nM and 
1619 nM, respectively. The effect of changing 3-pyridine by 4-isoquinoline as heme-complexing heterocycle is 
particularly noteworthy. The three isoquinoline derivatives 28, 29, and 30 are considerably less active at CYP1A2 
(6–57 % inhibition) than their unsubstituted analogues 1, 2, and 5 (73–98 % inhibition). An explanation might be 
found in the geometry of these molecules. The isoquinoline constrains the rotation around the carbon–carbon bond 
between the heterocycle and the naphthalene, especially in presence of the additional ortho-methyl groups in 29 and 
30. Thus, a coplanar conformation becomes energetically disfavored compared to the pyridine analogues and the 
sterically demanding heterocycle rotates out of the naphthalene plane. This loss of planarity is a reasonable 
explanation for the reduced inhibitory potency since both CYP1A2 substrates and inhibitors are usually small-
volume molecules with a planar shape (e.g., caffeine40 and furafylline41). An even more drastic effect on the 
 ~ 275 ~ 
 
CYP1A2 potency was observed in case of the dihydronaphthalene type compounds. While the unsubstituted parent 
compound 5 exhibited 74 % inhibition, introduction of the methoxy substituent in compound 13 led to a reduction to 
18 % and the isoquinoline derivative 30 displayed only 6 % inhibition. The partly saturated core structure becomes 
flexible and disturbs the planarity. Factors other than steric might play an additional role for the decreased CYP1A2 
inhibition, e.g., disturbed π-π-stacking contacts with aromatic amino acids in the CYP1A2 binding pocket due to the 
reduced number of aromatic carbons. Aromaticity has been identified to correlate positively with CYP1A2 
inhibition in recent QSAR studies.42 As dihydronaphthalenes 13 and 30 were found to be unstable in DMSO 
solution, the low potencies might be due to substance degradation. However, the decomposition (~20 % after three 
days) afforded mainly the aromatized naphthalene analogues, i.e., 12 and 29 both displaying higher CYP1A2 
inhibition than 13 and 30. 
In conclusion, we have shown that modifying the lead compounds I and II by introduction of substituents in the 
heterocyclic moiety has a clear effect on the activity and selectivity profile. Some substituents induced a significant 
increase in inhibitory potency versus CYP11B2. Compounds 22 and 26 with subnanomolar IC50 values are the most 
potent aldosterone synthase inhibitors so far. The undesirable high CYP1A2 inhibition that is present in the 
previously investigated derivatives could be overcome by certain residues, giving rise to compounds with an 
advantageous overall selectivity profile. It was also demonstrated that the naphthalene type aldosterone synthase 
inhibitors 1 and 28 were able to cross the gastrointestinal tract and reached the general circulation. Presently, the 
elucidated concepts are used to systematically modify other lead structures whereof some are under investigation for 
their ability to reduce aldosterone levels in vivo.  
Experimental Section 
Chemical and Analytical Methods. Melting points were measured on a Mettler FP1 melting point apparatus 
and are uncorrected. 1H NMR and 13C spectra were recorded on a Bruker DRX-500 instrument. Chemical shifts are 
given in parts per million (ppm), and tetramethylsilane (TMS) was used as internal standard for spectra obtained in 
DMSO-d6 and CDCl3. All coupling constants (J) are given in hertz. Mass spectra (LC/MS) were measured on a TSQ 
Quantum (Thermo Electron Corporation) instrument with a RP18 100-3 column (Macherey Nagel) and with 
water/acetonitrile mixtures as eluents. Elemental analyses were carried out at the Department of Chemistry, 
University of Saarbrücken. Reagents were used as obtained from commercial suppliers without further purification. 
Solvents were distilled before use. Dry solvents were obtained by distillation from appropriate drying reagents and 
stored over molecular sieves. Flash chromatography was performed on silica gel 40 (35/40–63/70 µM) with 
hexane/ethyl acetate mixtures as eluents, and the reaction progress was determined by thin-layer chromatography 
analyses on Alugram SIL G/UV254 (Macherey Nagel). Visualization was accomplished with UV light and KMnO4 
solution. All microwave irradiation experiments were carried out in a CEM-Discover monomode microwave 
apparatus.  
The following compounds were prepared according to previously described procedures: 6-Methoxy-3-methyl-
3,4-dihydronaphthalen-1(2H)-one (2e),32 (2E)-4-hydroxy-4-(3-methoxyphenyl)-3-methyl-2-butenoic acid (2g),32 5-
bromopyridin-3-ol (10a).29  
Synthesis of the Target Compounds 
Procedure A.27 Pyridine boronic acid (0.75 mmol, 1 equivalent), aryl bromide or -triflate (0.9–1.3 equivalents), 
and tetrakis(triphenylphosphane)palladium(0) (43 mg, 37.5 μmol, 5 mol %) were suspended in 1.5 mL DMF in a 10 
mL septum-capped tube containing a stirring magnet. To this was added a solution of NaHCO3 (189 mg, 2.25 mmol, 
3 equivalents) in 1.5 mL water and the vial was sealed with a Teflon cap. The mixture was irradiated with 
microwaves for 15 min at a temperature of 150 °C with an initial irradiation power of 100 W. After the reaction, the 
vial was cooled to 40 °C, the crude mixture was partitioned between ethyl acetate and water and the aqueous layer 
was extracted three times with ethyl acetate. The combined organic layers were dried over MgSO4 and the solvents 
were removed in vacuo. The coupling products were obtained after flash chromatography on silica gel (petroleum 
ether/ethyl acetate mixtures) and/or crystallization. If an oil was obtained, it was transferred into the hydrochloride 
salt by 1N HCl solution in diethyl ether. 
Procedure B.34 In a microwave tube alkenyl bromide 7 (1 equivalent), pyridine boronic acid (1.3 equivalent), 
tetrabutylammonium bromide (1 equivalent), sodium carbonate (3.5 equivalents) and palladium acetate (1.5 mol %) 
were suspended in water/acetone 3.5/3 to give a 0.15 M solution of bromide 7 under an atmosphere of nitrogen. The 
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septum sealed vessel was irradiated under stirring and simultaneous cooling for 15 min at 150 °C with an initial 
irradiation power of 150 W. The reaction mixture was cooled to room temperature, diluted with a saturated 
ammonium chloride solution and extracted several times with diethyl ether. The combined extracts were washed 
with brine, dried over MgSO4, concentrated and purified by flash chromatography on silica gel. The resulting oil 
was transferred into the hydrochloride salt by a 5-6 N HCl solution in 2-propanol and crystallized from ethanol. 
Procedure C. To a suspension of NaH (1.15 equivalents, 60 % dispersion in oil) in 5 mL dry THF at was added 
dropwise a solution of alcohol (1 equivalent) in 5 mL THF at room temperature under an atmosphere of nitrogen. 
After hydrogen evolution ceased, a solution of methyliodide (3.3 equivalents) in 5 mL THF was added dropwise, 
and the resulting mixture was stirred for 5 h at room temperature. The mixture was then treated with saturated 
aqueous NH4Cl solution and extracted three times with ethyl acetate. The combined organic layers were washed 
with water and brine, dried over MgSO4 and the solvent was evaporated in vacuo. The crude product was flash 
chromatographed on silica gel (petroleum ether/ethyl acetate mixtures) to afford the pure methylether. If an oil was 
obtained, it was transferred into the hydrochloride salt by 1N HCl solution in diethyl ether. 
Procedure D. To a 0.05 M solution of carbonyl compound in dry methanol was added sodium borohydride (2 
equivalents). The reaction mixture was stirred for 1 h, diluted with diehtylether and treated with saturated aqueous 
NaHCO3 solution. The mixture was then extracted three times with ethyl acetate, washed twice with saturated 
aqueous NaHCO3 solution and once with brine and dried over MgSO4. The filtrate was concentrated in vacuo, and 
the residue was filtered through a short pad of silica gel or flash chromatographed on silica gel (petroleum 
ether/ethyl acetate mixtures) to afford the corresponding alcohols. 
3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine (2) was obtained according to procedure A starting from 2a 
(377 mg, 1.50 mmol) and 3-pyridineboronic acid (240 mg, 1.95 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 4/1, Rf = 0.16) as a white solid (304 mg, 1.22 mmol, 81 %), mp 106–107 °C. MS m/z 
250.06 (MH+). Anal. (C17H15NO) C, H, N. 
3-(6-Methoxy-3-methyl-3,4-dihydronaphthalen-2-yl)pyridine (5) was obtained according to procedure B 
starting from 2b (127 mg, 0.50 mmol) and 3-pyridineboronic acid (80 mg, 0.65 mmol) after flash chromatography 
on silica gel (petroleum ether/ethyl acetate, 4/1, Rf = 0.20), precipitation as HCl salt and crystallization from 
ethanol as a white solid (50 mg, 0.17 mmol, 35 %), mp (HCl salt) 186–187 °C. MS m/z 252.02 (MH+). Anal. 
(C17H17NO·HCl·0.2H2O) C, H, N.  
6-(Pyridin-3-yl)-7,8-dihydronaphthalene-2-carbonitrile (6) was prepared according to procedure A starting 
from 3-pyridineboronic acid (107 mg, 0.87 mmol) and 6a (189 mg, 0.62 mmol). After flash chromatography on 
silica gel (petroleum ether/ethyl acetate, 2/1, Rf = 0.10) pure 6 was obtained as a white, crystalline solid (100 mg, 
0.43 mmol, 69 %). Treatment with hydrochloride acid (0.1 N in Et2O) yielded the hydrochloride salt of 6 (110 mg, 
0.41 mmol, 66 %) as a white solid, mp (HCl salt) 264–268 °C. MS m/z 223.23 (MH+). Anal. 
(C16H12N2·HCl·0.4H2O) C, H, N. 
3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine (7) was prepared according to procedure A starting from 6-
methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 3-bromo-4-methylpyridine (86 mg, 0.50 mmol). 
After flash chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.10) pure 7 was obtained as a 
white solid (65 mg, 0.26 mmol, 52 %), mp (HCl salt) 172–174 °C. MS m/z 250.30 (MH+). Anal. 
(C17H15NO·HCl·0.1H2O) C, H, N. 
6-(4-Methylpyridin-3-yl)-2-naphthonitrile (8). Triflate 8a (151 mg, 0.50 mmol), 4-methyl-3-pyridineboronic 
acid (89 mg, 0.65 mmol), K2CO3 (138 mg, 1.0 mmol) and Pd(dppf)Cl2 (37 mg, 0.05 mmol) were suspended in 4.0 
mL of a 4:4:1 mixture of toluene/acetone/water. This mixture was heated to 125 °C by microwave irradiation for 15 
minutes (initial irradiation power 150 W). After cooling to room temperature, 15 mL of distilled water were added 
and the reaction mixture was extracted four times with 10 mL of Et2O. After washing the combined organic 
fractions with water (twice) and brine, drying over MgSO4 and evaporation of the solvent crude product 8 was 
obtained as a yellow solid (127 mg). Further purification by flash chromatography on silica gel (petroleum 
ether/ethyl acetate, 2/5, Rf = 0.20) and subsequent crystallization of the free base as hydrochloride salt gave 52 
mg (0.19 mmol, 37 %) of pure 8 (HCl salt) as an yellowish solid, mp (HCl salt) decomposition above 210 °C. MS 
m/z 245.30 (MH+). Anal. (C17H12N2·HCl·0.5H2O) C, H, N. 
3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine (9) was prepared according to procedure A starting from 6-
methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 3-bromopyridin-4-amine (86 mg, 0.50 mmol). After 
crystallization from acetone pure 9 was obtained as a white solid (39 mg, 0.16 mmol, 31 %), mp 155–156 °C. MS 
m/z 251.28 (MH+). Anal. (C16H14N2O) C, H, N. 
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5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol (10) was prepared according to procedure A starting from 6-
methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 10a (87 mg, 0.50 mmol). After crystallization from 
acetone/diethyl ether pure 10 was obtained as an off-white solid (86 mg, 0.34 mmol, 68 %), mp 172–175 °C. MS 
m/z 252.02 (MH+). Anal. (C16H13NO2·0.7H2O) C, H, N: calcd, 5.31, found, 5.79. 
3-Methoxy-5-(6-methoxynaphthalen-2-yl)pyridine (11) was prepared according to procedure A starting from 
6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 3-bromo-5-methoxypyridine (94 mg, 0.50 mmol). 
After flash chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.10) pure 11 was obtained as a 
white solid (80 mg, 0.30 mmol, 60 %), mp (HCl salt) 211–214 °C. 1H-NMR (500 MHz, CD3OD): δ = 3.96 (s, 3H), 
4.15 (s, 3H), 7.23 (dd, 3J = 9.1 Hz, 4J = 2.5 Hz, 1H), 7.32 (d, 4J = 2.2 Hz, 1H), 7.85 (dd, 3J = 8.5 Hz, 4J = 1.9 Hz, 
1H), 7.92 (d, 3J = 8.8 Hz, 1H), 7.97 (d, 3J = 8.5 Hz, 1H), 8.29 (d, 4J = 1.5 Hz, 1H), 8.52 (s, 1H), 8.54 (s, 1H), 8.86 (s, 
1H). 13C-NMR (125 MHz, CD3OD): δ = 57.9, 58.3, 108.5, 120.9, 121.9, 128.1, 128.5, 130.2, 131.4, 132.5, 134.5, 
136.7, 138.9, 139.1, 142.6, 158.4, 160.4. MS m/z 266.26 (MH+). Anal. (C17H15NO2·HCl·0.3H2O) C, H, N. 
3-Methoxy-5-(6-methoxy-3-methylnaphthalen-2-yl)pyridine (12) was obtained according to procedure A 
starting from 2a (377 mg, 1.50 mmol) and 5-methoxy-3-pyridineboronic acid (298 mg, 1.95 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 3/1, Rf = 0.16) as a white solid (328 mg, 1.17 mmol, 78 
%), mp 106–107 °C. 1H-NMR (500 MHz, CDCl3): δ = 2.40 (s, 3H), 3.91 (s, 3H), 3.94 (s, 3H), 7.12 (m, 2H), 7.23 
(dd, 4J = 2.8 Hz, 4J = 1.9 Hz, 1H), 7.62 (s, 1H), 7.64 (s, 1H), 7.71 (d, 3J = 8.8 Hz, 1H), 8.28 (d, 4J = 1.9 Hz, 1H), 
8.33 (d, 4J = 2.8 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ = 21.0, 55.3, 55.6, 104.9, 118.6, 121.5, 127.4, 127.5, 
128.6, 129.2, 134.1, 134.4, 134.5, 135.8, 138.0, 142.6, 155.2, 158.1. MS m/z 280.08 (MH+). Anal. (C18H17NO2) C, 
H, N. 
3-Methoxy-5-(6-methoxy-3-methyl-3,4-dihydronaphthalen-2-yl)pyridine (13) was obtained according to 
procedure B starting from 2b (253 mg, 1.00 mmol) and 5-methoxy-3-pyridineboronic acid (199 mg, 1.30 mmol) 
after flash chromatography on silica gel (petroleum ether/ethyl acetate, 4/1, Rf = 0.14), precipitation as HCl salt and 
crystallization from ethanol as a yellow solid (84 mg, 0.26 mmol, 26 %), mp (HCl salt) 181–182 °C. 1H-NMR (500 
MHz, CD3OD): δ = 0.94 (d, 3J = 7.0 Hz, 3H), 2.71 (dd, 2J = 15.3 Hz, 3J = 1.2 Hz, 1H), 3.02 (m, 1H), 3.13 (dd, 2J = 
15.5 Hz, 3J = 6.4 Hz, 1H), 3.74 (s, 3H), 4.01 (s, 3H), 6.72 (m, 2H), 7.15 (d, 3J = 8.2 Hz, 1H), 7.19 (s, 1H), 8.22 (m, 
1H), 8.34 (d, 4J = 2.4 Hz, 1H), 8.59 (d, 4J = 1.5 Hz, 1H). 13C-NMR (125 MHz, CD3OD): δ = 17.8, 30.6, 36.7, 55.8, 
57.9, 112.9, 115.6, 116.6, 127.0, 127.2, 127.8, 129.8, 130.3, 132.3, 137.1, 137.2, 150.9, 160.1. MS m/z 281.96 
(MH+). Anal. (C18H19NO2·HCl·0.2H2O) C, H, N. 
3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine (14) was prepared according to procedure A starting from 6-
methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 14a (101 mg, 0.50 mmol). After crystallization from 
ethyl acetate/petroleum ether pure 14 was obtained as a white solid (33 mg, 0.17 mmol, 23 %), mp decomposition 
above 130 °C. MS m/z 280.05 (MH+). Anal. (C18H17NO2·0.2H2O) C, H, N. 
5-(6-Methoxynaphthalen-2-yl)pyridine-3-carboxylic acid (15) was prepared according to procedure A starting 
from 6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 5-bromonicotinic acid (101 mg, 0.50 mmol). 
After crystallization from methanol/water pure 15 was obtained as an off-white solid (74 mg, 0.26 mmol, 53 %), mp 
decomposition above 300 °C. MS m/z 279.98 (MH+). Anal. (C17H13NO3·HCl·0.3H2O) C, H, N. 
Methyl 5-(6-methoxynaphthalen-2-yl)pyridine-3-carboxylate (16). Carboxylic acid 15 (45 mg, 0.16 mmol) 
was dissolved in 20 mL dry methanol and 0.05 mL concentrated H2SO4 (98%) was added. The whole mixture was 
refluxed for 10 h and thereafter the excess methanol was distilled off. The residue was taken up in 50 mL ethyl 
acetate and the organic layer was washed several times with 5 % aqueous Na2CO3 solution, water and brine. After 
drying over MgSO4, the solvent was evaporated in vacuo. After flash chromatography on silica gel (petroleum 
ether/ethyl acetate, 7/3, Rf = 0.34) pure 16 was obtained as an off-white solid (28 mg, 0.10 mmol, 60 %), mp 150–
151 °C. MS m/z 293.97 (MH+). Anal. (C18H14NO3) C, H, N. 
5-(6-Methoxynaphthalen-2-yl)pyridine-3-carboxamide (17) was prepared according to procedure A starting 
from 6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 5-bromonicotinamide (92 mg, 0.50 mmol). 
After crystallization from acetone/diethyl ether pure 17 was obtained as a white solid (55 mg, 0.20 mmol, 40 %), mp 
245–247 °C. MS m/z 279.07 (MH+). Anal. (C17H14N2O2) C, H, N. 
1-[5-(6-Methoxynaphthalen-2-yl)pyridin-3-yl]ethanone (18) was prepared according to procedure A starting 
from 6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 3-acetyl-5-bromopyridine (100 mg, 0.50 
mmol). After crystallization from acetone/diethyl ether pure 18 was obtained as a white solid (75 mg, 0.27 mmol, 54 
%), mp 159–160 °C. MS m/z 278.09 (MH+). Anal. (C18H15NO2·0.1H2O) C, H, N. 
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[5-(6-Methoxynaphthalen-2-yl)pyridin-3-yl]acetic acid (19) was prepared according to procedure A starting 
from 6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 5-bromo-3-pyridineacetic acid (108 mg, 0.50 
mmol). After crystallization from methanol/water pure 19 was obtained as a white solid (70 mg, 0.24 mmol, 48 %), 
mp decomposition above 210 °C. MS m/z 293.97 (MH+). Anal. (C18H15NO3·0.5H2O) C, H, N. 
Methyl [5-(6-methoxynaphthalen-2-yl)pyridin-3-yl]acetate (20) was prepared as described for 16 starting 
from 19 (145 mg, 0.49 mmol). After flash chromatography on silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 
0.18) pure 20 was obtained as a white solid (81 mg, 0.26 mmol, 53 %), mp 145–146 °C. MS m/z 308.04 (MH+). 
Anal. (C19H17NO3) C: calcd, 74.25, found, 74.72, H, N. 
[5-(6-Methoxynaphthalen-2-yl)pyridin-3-yl]methanol (21) was prepared according to procedure A starting 
from 6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 21a (94 mg, 0.50 mmol). After crystallization 
from acetone/diethyl ether pure 21 was obtained as a white solid (86 mg, 0.32 mmol, 65 %), mp 193–194 °C. MS 
m/z 266.05 (MH+). Anal. (C17H15NO2·0.1H2O) C, H, N. 
3-(Methoxymethyl)-5-(6-methoxynaphthalen-2-yl)pyridine (22) was prepared according to procedure C 
starting from 21 (150 mg, 0.57 mmol) using methyl iodide (82 μL, 1.32 mmol). After flash chromatography on 
silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.22) pure 22 was obtained as an off-white solid (80 mg, 0.29 
mmol, 50 %), mp 121–122 °C. MS m/z 279.91 (MH+). Anal. (C18H17NO2) C, H, N. 
[4-(6-Methoxynaphthalen-2-yl)pyridin-3-yl]methanol (23) was prepared according to procedure A starting 
from 6-methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 23a (94 mg, 0.50 mmol). After crystallization 
from acetone/diethyl ether pure 23 was obtained as a white solid (90 mg, 0.34 mmol, 68 %), mp decomposition 
above 240 °C. MS m/z 266.05 (MH+). Anal. (C17H15NO2·0.2H2O) C, H, N. 
4-(Methoxymethyl)-3-(6-methoxynaphthalen-2-yl)pyridine (24) was prepared according to procedure C 
starting from 23 (150 mg, 0.57 mmol) using methyl iodide (82 μL, 1.32 mmol). After flash chromatography on 
silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.23) pure 24 was obtained as an off-white solid (74 mg, 0.26 
mmol, 46 %), mp (HCl salt) 174–177 °C. MS m/z 279.91 (MH+). Anal. (C18H17NO2·0.2H2O) C, H, N. 
1-[5-(6-Methoxynaphthalen-2-yl)-pyridin-3-yl]ethanol (25) was prepared according to procedure D starting 
from 18 (50 mg, 0.18 mmol) using NaBH4 (8.0 mg, 0.21 mmol). After flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 1/1, Rf = 0.24) pure 25 was obtained as a white solid (28 mg, 0.10 mmol, 56 %), mp 
154–155 °C. MS m/z 280.05 (MH+). Anal. (C18H17NO2) C, H, N. 
3-(1-Methoxyethyl)-5-(6-methoxynaphthalen-2-yl)pyridine (26) was prepared according to procedure C 
starting from 25 (70 mg, 0.25 mmol) using methyl iodide (41 μL, 0.66 mmol). After flash chromatography on silica 
gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.23) pure 26 was obtained as an yellowish solid (26 mg, 0.08 mmol, 35 
%), mp 124–125 °C. MS m/z 294.11 (MH+). Anal. (C19H19NO2) C, H, N. 
3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine (27) was prepared according to procedure A starting from 6-
methoxy-2-naphthaleneboronic acid (394 mg, 1.95 mmol) and 3-bromo-5-phenylpyridine (351 mg, 1.50 mmol). 
After flash chromatography on silica gel (petroleum ether/ethyl acetate, 2/1, Rf = 0.23) pure 27 was obtained as a 
white, crystalline solid (455 mg, 1.46 mmol, 97 %), mp 216–217 °C. MS m/z 312.09 (MH+). Anal. 
(C22H17NO·0.4H2O) C, H, N. 
4-(6-Methoxynaphthalen-2-yl)isoquinoline (28) was prepared according to procedure A starting from 6-
methoxy-2-naphthaleneboronic acid (131 mg, 0.65 mmol) and 4-bromoisoquinoline (104 mg, 0.50 mmol). After 
flash chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.21) pure 28 was obtained as a white 
solid (44 mg, 0.16 mmol, 31 %), mp 185–186 °C. MS m/z 286.07 (MH+). Anal. (C20H15NO·0.1H2O) C, H, N. 
4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline (29) was obtained according to procedure A starting 
from 2a (377 mg, 1.50 mmol) and 4-isoquinolineboronic acid (337 mg, 1.95 mmol) after flash chromatography on 
silica gel (dichloromethane/methanol 99/1, Rf = 0.26) as yellow oil which solidified with diethyl ether as a pale 
yellow solid (178 mg, 0.59 mmol, 40 %), mp 156–157 °C. MS m/z 300.10 (MH+). Anal. (C21H11NO) C, H, N. 
4-(6-Methoxy-3-methyl-3,4-dihydronaphthalen-2-yl)isoquinoline (30) was obtained according to procedure B 
starting from 2b (253 mg, 1.00 mmol) and 4-isoquinolineboronic acid (225 mg, 1.30 mmol) after two flash 
chromatographical separations on silica gel (petroleum ether/ethyl acetate, 5/1, Rf = 0.20 and 
dichloromethane/methanol 99/1, Rf = 0.27) and precipitation as HCl salt as a yellow solid (112 mg, 0.33 mmol, 17 
%), mp 149–150 °C. MS m/z 302.18 (MH+). Anal. (C21H19NO·HCl·0.2H2O) C, H, N. 
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Biological Methods. 1. Enzyme Preparations. CYP17 and CYP19 preparations were obtained by described 
methods: the 50,000 g sediment of E. coli expressing human CYP1737 and microsomes from human placenta for 
CYP19.39 2. Enzyme Assays. The following enzyme assays were performed as previously described: CY1737 and 
CYP19.39 3. Activity and Selectivity Assay Using V79 Cells. V79 MZh 11B1 and V79 MZh 11B2 cells36 were 
incubated with [4-14C]-11-deoxycorticosterone as substrate and inhibitor in at least three different concentrations. 
The enzyme reactions were stopped by addition of ethyl acetate. After vigorous shaking and a centrifugation step 
(10,000 g, 2 min), the steroids were extracted into the organic phase, which was then separated. The conversion of 
the substrate was analyzed by HPTLC and a phosphoimaging system as described.10,22 4. Inhibition of Human 
Hepatic CYP Enzymes. The recombinantly expressed enzymes from baculovirus-infected insect microsomes 
(Supersomes) were used and the manufacturer’s instructions (www.gentest.com) were followed. 5. In Vivo 
Pharmacokinetics. Animal trials were conducted in accordance with institutional and international ethical 
guidelines for the use of laboratory animals. Male Wistar rats weighing 317–322 g (Janvier, France) were housed in 
a temperature-controlled room (20–22 °C) and maintained in a 12 h light/12 h dark cycle. Food and water were 
available ad libitum. The animals were anaesthetised with a ketamine (135mg/kg)/xylazine (10mg/kg) mixture, and 
cannulated with silicone tubing via the right jugular vein. Prior to the first blood sampling, animals were connected 
to a counterbalanced system and tubing, to perform blood sampling in the freely moving rat. Separate stock 
solutions (5 mg/mL) were prepared for the tested compounds in Labrasol/Water (1:1; v/v), leading to a clear 
solution. Immediately before application, the cassette dosing mixture was prepared by adding equal volumes of the 5 
stock solutions to end up with a final concentration of 1 mg/mL for each compound. The mixture was applied 
perorally to 3 rats with an injection volume of 5 mL/kg (Time 0). 400 µL of blood were taken via jugularis catheter 
1 hour before application and then 1 and 2 hours after application. Immediately, equal volume (400 µL) of 0.9 % 
NaCl (37 °C) was re-injected intravenously to keep the blood volume stable. 4, 6, 8, 10 and 24 hours after 
application 250 µL of blood were sampled without balancing the blood volume. Blood samples were centrifuged at 
3000 g for 10 minutes at 4 °C. Plasma was harvested and kept at –20 °C until analysis. The mean of absolute plasma 
concentrations (±SEM) was calculated for the 3 rats and the regression was performed on group mean values. The 
pharmacokinetic analysis was performed using a noncompartment model (PK Solutions 2.0, Summit Research 
Services). HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor-HPLC-system 
coupled with a TSQ Quantum (ThermoFinnigan) triple quadrupole mass spectrometer equipped with an electrospray 
interface (ESI). 
Computational Methods. MEP. For each docked compound geometry optimization was performed at the 
B3LYP/6-31G* density functional levels by means of the Gaussian03 software and the molecular electrostatic 
potential (MEP) maps were plotted using GaussView3, the 3-D molecular graphics package of Gaussian.43 These 
electrostatic potential surfaces were generated by mapping 6-31G* electrostatic potentials onto surfaces of 
molecular electron density (isovalue = 0.002 electron/Å).44 
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Abstract 
Pharmacophore modeling of a series of aldosterone synthase (CYP11B2) inhibitors triggered the design of 
compounds 11 and 12 by extending a previously established naphthalene molecular scaffold (e.g., present in 
molecules 1 and 2) via introduction of a phenyl or benzyl residue in 3-position. These additional aromatic moieties 
have been hypothesized to fit into the newly identified hydrophobic pharmacophore feature HY3. Subsequent 
docking studies in our refined CYP11B2 protein model have been performed prior to synthesis to estimate the 
inhibitory properties of the proposed molecules. While phenyl-substituted compound 11 (IC50 > 500 nM) did not 
dock under the given pharmacophore constraint (i.e., the Fe(heme)-N(ligand) interaction), benzyl-substituted 
compound 12 (IC50 = 154 nM) was found to exploit a previously unexplored sub-pocket of the inhibitor binding site. 
By structural optimization based on the pharmacophore hypothesis, 25 novel compounds were synthesized, amongst 
them highly potent CYP11B2 inhibitors (e.g., 17, IC50 = 2.7 nM) with pronounced selectivity toward the most 
important steroidogenic and hepatic CYP enzymes 
 
Introduction 
Aldosterone synthase (CYP11B2), a mitochondrial cytochrome P450 enzyme that is localized mainly in the 
adrenal cortex, is the key enzyme of mineralocorticoid biosynthesis. It catalyzes the terminal three oxidation steps in 
the biogenesis of aldosterone in humans.1 This hormone is the most important circulating mineralocorticoid and 
plays a crucial role in the electrolyte and fluid homeostasis mainly by binding to epithelial mineralocorticoid 
receptors (MR) promoting sodium reabsorption and potassium secretion. Since the sodium movement is followed by 
water via osmosis, aldosterone is a key regulator of blood volume and blood pressure. Abnormally increased plasma 
levels of aldosterone have been diagnosed in different cardiovascular diseases such as elevated blood pressure, 
congestive heart failure, and myocardial fibrosis.2 Inhibitors of the angiotensin-converting enzyme (ACE) which are 
in use for the treatment of hypertension and congestive heart failure can initially induce a down-regulation of 
circulating aldosterone. However, increased levels of aldosterone are frequently observed after several months of 
therapy.3 This phenomenon termed ‘aldosterone escape’ is a limiting factor of ACE inhibitors and shows that novel 
therapeutic concepts combating the effects of elevated aldosterone levels are needed. Two recent clinical studies 
(RALES and EPHESUS) demonstrated that treatment with mineralocorticoid receptor antagonists in addition to the 
standard therapy resulted in a decrease of mortality in patients with chronic congestive heart failure and in patients 
after myocardial infarction, respectively.4,5 The use of spironolactone, however, is accompanied by severe 
progestational and antiandrogenic side effects due to its affinity to other steroid receptors. Moreover, the elevated 
plasma aldosterone concentrations are left unaffected on a pathological level which raises several issues. First, the 
elevated aldosterone plasma levels do not induce a homologous down-regulation but an up-regulation of the 
aldosterone receptor.6 This fact complicates a long-term therapy as MR antagonists are likely to become ineffective. 
Furthermore, the high concentrations promote nongenomic actions of aldosterone which are in general not blocked 
by receptor antagonists.7 Pathological aldosterone concentrations have been identified to induce a negative inotropic 
effect in human trabeculae and to potentiate the vasoconstrictor effect of angiotensinII in coronary arteries in rapid, 
nongenomic manner.8 Thus, aldosterone is intrinsically capable to further deteriorate heart function by acting 
nongenomically. 
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A novel therapeutic strategy with potential to overcome the drawbacks of MR antagonists is the blockade of 
aldosterone formation, preferably by inhibiting CYP11B2, the key enzyme of its biosynthesis. Aldosterone synthase 
has been proposed as a potential pharmacological target by our group as early as 1994,9 followed soon thereafter by 
the hypothesis that inhibitors of CYP11B2 could serve as drugs for the treatment of hyperaldosteronism, congestive 
heart failure and myocardial fibrosis.10,11 Consequent structural optimization of a hit discovered by a compound 
library screening led to a series of nonsteroidal aldosterone synthase inhibitors with high selectivity toward other 
cytochrome P450 enzymes.12–15 
In the present study, we describe the design and synthesis of a series of 3-benzyl-substituted pyridylnaphthalenes 
and structurally related compounds (Chart 1) by a combined ligand-based and structure-based drug design approach 
as well as the determination of their biological activity regarding human CYP11B2 for potency. Selectivity is a 
prerequisite for a CYP11B2 inhibitor, especially with regard to other cytochrome P450 enzymes as they are likely to 
interact with other CYP enzymes in a similar way (e.g., by complexation of the heme iron). Taking into 
consideration that the key enzyme of glucocorticoid biosynthesis, 11β-hydroxylase (CYP11B1), and CYP11B2 have 
a sequence homology of approximately 93 %,16 the selectivity issue becomes especially critical for the design of 
CYP11B2 inhibitors. On that account, all compounds were tested for their inhibitory potency versus CYP11B1 to 
determine their selectivity. A set of compounds was additionally tested for inhibitory activity versus the 
steroidogenic enzymes CYP17 (17α-hydroxylase-C17,20-lyase) and CYP19 (aromatase) as well as selected hepatic 
drug-metabolizing CYP enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). 
Results  
Inhibitor Design Concept 
In our search for new lead compounds as CYP11B2 inhibitors structurally differing from the previously 
discovered pyridylnaphthalenes such as 1 and 2,14 we identified imidazolylmethylene-substituted flavones (e.g., 3–
10) to be aldosterone synthase inhibitors with moderate to high inhibitory potency by compound library screening 
(Table 1). These compounds that originally have been described as aromatase inhibitors17 display CYP11B2 
inhibition in a range of 73–94 % at a concentration of 500 nM with methoxy-functionalized 6 being most active 
(IC50 = 11 nM), albeit without showing selectivity versus the highly homologous CYP11B1 (see supplementary 
material for selectivity data). 
Chart 1. Title Compounds 
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Table 1. Inhibition of Human Adrenal CYP11B2 in vitro (Compounds 1–10) 
 
  % inhibitiona CYP11B2b  
compd R [IC50 (nM)c] 
1 H 92 [28] 
2 OMe 91 [6.2] 
3 H 88 [28] 
4 NO2 81 [95] 
5 Br 90 [25] 
6 OMe 94 [11] 
7 H 86 [124] 
8 Br 80 [n.d.] 
9 NO2 73 [n.d.] 
10  77 [187] 
a Mean value of at least two experiments, standard deviation usually less than 10 %; inhibitor concentration, 500 nM. b Hamster fibroblasts 
expressing human CYP11B2; substrate deoxycorticosterone, 100 nM. c Mean value of at least four experiments, standard deviation usually 
less than 25 %, n.d. = not determined; fadrozole, IC50 = 1 nM. 
Recently, a pharmacophore model for aldosterone synthase inhibitors was built by superimposition of a series of 
heteroaryl-substituted methyleneindanes12,13 and naphthalenes14,15 synthesized in our laboratory and subsequently 
validated by pyridine-substituted acenaphthenes as hybrid structures that fit into the four identified pharmacophoric 
points (i.e., a heterocyclic nitrogen and three ring centroids).18 The most potent compounds of the latter substance 
classes together with the most potent flavone type inhibitors were used as training set for the generation of an 
extended pharmacophore model by applying the GALAHAD19 pharmacophore generation module of SYBYL 
molecular modeling software. In the top ranked pharmacophore model, best in three of the most indicative ranking 
criteria of this software (Pareto ranking,20 Specificity, and Mol-query), the earlier pharmacophoric points18 were 
confirmed, namely the hydrophobic features HY0, HY1, HY2a, HY2b as well as the acceptor atom features AA1, 
AA2a, and AA2b (Figure 1). 
 
Figure 1. Compound 1 mapped to the pharmacophore model. The newly identified hydrophobic feature HY3 as 
well as the acceptor atom features AA3a and AA3b are not exploited by inhibitors with a naphthalene molecular 
scaffold. Pharmacophoric features are color-coded: cyan for hydrophobic regions (HY0–HY3) and green for 
acceptor atom features (AA1–4). 
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A novel and voluminous hydrophobic area HY3 was identified next to HY1, along with the acceptor atom 
features AA3a and AA3b (see supplementary material for exact pharmacophore geometric properties) as well as an 
additional acceptor atom feature AA4. Rationalizing the given information, the two sample compounds 11 and 12 
(Chart 2) were designed by modifying our previously reported naphthalene derivatives 1 and 2 to exploit the newly 
discovered pharmacophoric feature HY3. As suggested by the model and visualized in Figure 1, introduction of a 
hydrophobic substituent in 3-position of the naphthalene skeleton should be favorable to exploit the voluminous 
hydrophobic feature HY3 of the pharmacophore. The phenyl residue directly bound to the naphthalene core in 
compound 11 creates a conformationally constrained structure in which both rotational degrees of freedom of the 
two aryl–aryl bonds are limited since they are located ortho to each other. The benzyl motive in compound 12 leads 
to an increased flexibility of the spatial property distribution by rotation around the two benzylic carbon–carbon 
bonds. Furthermore, the aromatic ring moves apart from the naphthalene core by one methylene unit.  
Chart 2. Proposed Lead Structures 11 and 12. 
 
In order to elucidate the role of conformational flexibility and the exact position of the aryl moiety for optimal 
inhibitor binding, docking studies were performed (Figure 2). For this purpose, we used the CYP11B2 protein 
model that has been built12 and subsequently validated13–15 by our group as well as the same docking calculations 
that have been performed in these studies. 
Previous investigations have identified the binding affinity to the target enzyme to be highly dependent on the 
geometry of the coordinative bond between the heme iron and the heterocyclic nitrogen. An angle of the Fe–N 
straight line with the porphyrin plane close to 90° (i.e., the heterocyclic nitrogen lone pair arranges perpendicular to 
the heme group) provides an optimal orbital overlap corresponding to a high inhibitory potency.14,15 The analysis of 
the docking mode of compound 3 led to the identification of a new sub-pocket which interacts with the aryl moiety 
(Figure 2a). This sub-pocket was not considered as potential binding site during our previous design efforts due to 
the fact that the formerly investigated compounds such as 2 did not occupy this binding site (Figure 2b). The above 
considerations led to the design of compounds 11 and 12. Both compounds combine the pyridylnaphthalene skeleton 
of compound 1 with an additional aryl motive which should be able to interact with the newly identified sub-pocket. 
However, compound 11 proved to be too rigid to fit into the binding site and could thus not be docked successfully 
into the binding pocket under the given pharmacophore constraint, that is the Fe(heme)-N(ligand) interaction. A 
directed heme-Fe–N interaction was defined perpendicular to the heme-plane. This pharmacophore constraint was 
applied to ensure the right binding mode of the inhibitors with the heme-cofactor. The constraint requires the 
existence of an inhibitor-nitrogen-atom on the surface of an interaction cone with a 20 degree radius, which has its 
origin at the Fe-atom and points perpendicular to the heme-plane (with a length of 2.2 Å). Obviously, the 
conformationally restricted phenyl moiety of compound 11 undergoes repulsive interaction with amino acids of the 
binding pocket or with the heme-cofactor under the above mentioned constraint (i.e., when the pyridine moiety 
forms a coordinative bond to the heme iron), thus preventing that the molecule successfully docks into the 
CYP11B2 protein model. Contrariwise, the 3-benzyl substituted analog 12 is more flexible due to an additional 
methylene spacer between the two ring systems and thus fitted adequately into the binding site (Figure 2c). From 
these docking results we concluded that the methylene group of the potential inhibitor should provide the flexibility 
necessary to adapt to the binding site geometry. 
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Figure 2. Structure of the CYP11B2–inhibitor complexes of 3 (a), 2 (b) and 12 (c). Surface of the binding pocket 
(grey) surrounding the inhibitor and the heme co-factor (light blue). The inhibitors are presented in yellow; nitrogen 
atoms are colored in blue and oxygen atoms are in red. Unlike 2, the inhibitors 3 and 12 exploit an additional sub-
pocket of the inhibitor binding site. 
Chemistry 
The phenyl-substituted pyridylnaphthalene 11 was obtained as shown in Scheme 1 by two subsequent Suzuki 
coupling21 steps, whereof the first proceeded between 3-bromopyridine and 3-methoxy-2-naphthaleneboronic acid 
11d. The boronic acid 11d was accessible by ortho-lithiation of 2-methoxynaphthalene and in situ addition of 
trimethylborate as described previously.22 After demethylation of 11c by refluxing in concentrated hydrobromic 
acid, the intermediate naphthol was transferred into the triflate 11a by a microwave-enhanced method described by 
Bengtson et al.23 A second Suzuki coupling using controlled microwave heating afforded compound 11.24 
The benzyl-substituted derivatives 12–16, 19, and 21–25 were synthesized by the route shown in Scheme 2. 
Starting from a 3-hydroxy-2-naphtoic acid, few functional group inversions led to the carbaldehydes 12e–14e. These 
transformations were performed by a 4-step sequence starting with an esterification25 and subsequent introduction of 
a protection group to the naphthalene hydroxy group of 12h and 13h (i.e., methyl in 12g or benzyl in 13g and 
14g).26 Lithium borohydride reduction27 followed by TEMPO oxidation28 (of primary alcohol 12f) or Parik-
Doehring oxidation29 (of 13f and 14f) afforded the corresponding carbaldehydes 12e–14e. Grignard reaction with 
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various substituted phenylmagnesium halogenides afforded the phenyl-naphthylalcohols 12d–16d, and 19d. 
Hydrogenolytic removal of the hydroxy group was accomplished by treatment with NaBH4 and AlCl3 in refluxing 
THF.30 After deprotection using BBr3 (for de-methylation of 12c) or ammonium formate under Pd-catalysis31 (for 
de-benzylation of 13c–16c, and 19c) and subsequent triflate formation,23 the heterocycle was introduced by 
microwave-enhanced Suzuki coupling24 giving rise to the benzyl-substituted pyridylnaphthalenes 12–16, 19, and 
21–25. 
Scheme 1a 
 
a Reagents and conditions: i) nBuLi, B(OMe)3, THF, –78 °C, then HCl/water; ii) 3-bromopyridine, Pd(PPh3)4, toluene/ethanol, aq. Na2CO3, 
reflux; iii) conc. HBr, reflux; iv) Tf2NPh, K2CO2, THF, μw, 120 °C; v) phenylboronic acid, Pd(PPh3)4, aq. NaHCO3, DMF, μw, 150 °C. 
Scheme 2a 
 
a Reagents and conditions: i) methanol, H2SO4, reflux; ii) MeI, K2CO3, 18-crown-6,  acetone, reflux (for R = Me); iii) BnBr, K2CO3, 18-
crown-6, acetone, reflux (for R = Bn); iv) LiBH4, THF/toluene, reflux; v) NCS, TEMPO, nBu4NCl, aq. Na2CO3/NaHCO3, CH2Cl2; rt (for 
R = Me); vi) SO3∙py, NEt3, DMSO, rt (for R = Bn); vii) ArMgX, THF, 0 °C, then aq. NH4Cl; viii) NaBH4, AlCl3, THF, reflux; ix) BBr3, 
CH2Cl2, –20 °C; x) Tf2NPh, K2CO2, THF, μw, 120 °C; xi) ammonium formate, Pd/C, THF/methanol, reflux; xii) heteroarylboronic acid, 
Pd(PPh3)4, aq. NaHCO3, DMF, μw, 150 °C. 
Alternatively, the benzyl-substituted pyridylnaphthalenes 17, 18, and 20 were obtained by the route shown in 
Scheme 3. Applying the presented transformations afforded the benzoyl-substituted derivatives 26–30 and the 
corresponding hydroxymethylene analogues 31–34 as reaction intermediates. The sequence toward the 3-benzoyl-
substituted 2-naphthols 26b–30b was reported previously by Li et al. and starts with an ortho-lithiation of 2-
methoxy- or 2,7-dimethoxynaphthalene, followed by in situ addition of a Weinreb amide. Regioselective 
demethylation of the obtained methanones 26c–30c at the naphthalene-position ortho to the benzoyl residue was 
accomplished by treatment with BCl3/nBu4NI at –78 °C.32 After triflate formation, a 3-pyridyl residue was 
introduced by Suzuki coupling to afford compounds 26–30. The corresponding alcohols 20a and 31–34 were 
obtained by sodium borohydride reduction. The methyl ether 35 was synthesized by treating 31 with methyl iodide 
and NaH in THF. The benzyl-substituted pyridylnaphthalenes 17, 18, and 20 were obtained by in situ iodotrimethyl-
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silane mediated reduction.33,34 However, reduction by this method did not succeed in the case of 32, neither by other 
commonly used hydrogenolysis protocols.30,35 
Scheme 3a 
 
a Reagents and conditions: i) N,O-dimethylhydroxylamine hydrochloride, NEt3, CH2Cl2, rt; ii) nBuLi, 2-methoxynaphthalene (for R1 = 
H) or 2,7-dimethoxynaphthalene (for R1 = OMe), TMEDA, THF, –78 °C, then HCl/water; iii) BCl3, nBu4NI, CH2Cl2, –78 °C to rt; iv) 
Tf2O, pyridine, CH2Cl2, 0 °C; v) pyridineboronic acid, Pd(PPh3)4, aq. Na2CO3, toluene/ethanol, reflux; vi) NaBH4, methanol, 0 °C; vii) 
Me3SiCl, NaI, CH3CN, 55 °C; viii) MeI, NaH, THF, rt. 
Biological Results 
Inhibition of Human Adrenal Corticoid Producing CYP11B2 and CYP11B1 In Vitro (Table 2). The 
inhibitory activities of the compounds were determined in V79 MZh cells expressing either human CYP11B2 or 
CYP11B1.10,36 The V79 MZh cells were incubated with [14C]-deoxycorticosterone as substrate and the inhibitor in 
different concentrations. The product formation was monitored by HPTLC using a phosphoimager. Fadrozole, an 
aromatase (CYP19) inhibitor with proven ability to reduce corticoid formation in vitro37 and in vivo38 was used as a 
reference (CYP11B2, IC50 = 1 nM; CYP11B1, IC50 = 10 nM).  
Compound 11 with a phenyl residue directly bound to the naphthalene core shows no significant activity at the 
target enzyme with only 8 % inhibition at an inhibitor concentration of 500 nM (Table 2). Insertion of a methylene 
linker into the biaryl bond results in an increased inhibitory potency at CYP11B2 in compound 12 (IC50 = 154 nM). 
Introduction of a methoxy residue in ortho- or meta-position of the benzylic moiety as accomplished in compounds 
14 and 15 results in a significantly decreased inhibitory potency whereas the same substituent in para-position gives 
rise to the highly potent CYP11B2 inhibitor 16 (IC50 = 7.8 nM) with pronounced selectivity versus CYP11B1 (IC50 
= 2804). The cyano and trifluoromethoxy-substituted analogues 17 and 18 are highly potent as well and about 700-
fold and 900-fold more selective for CYP11B2. Derivatization of the naphthalene core by a methoxy group is 
readily tolerated in 6-position as accomplished in compounds 13, 19, 22, 23, and 25. The inhibitory profile of the 6-
methoxy derivatives regarding the two CYP11B isoforms is thereby comparable to the corresponding hydrogen 
analogues with a slightly increased selectivity factor in most cases. On the other hand, introduction of methoxy in 7-
position results in a decrease of the inhibition to less than 40 % at an inhibitor concentration of 500 nM (20 and 30). 
Modification of the pyridine moiety which has recently been shown to increase the activity and selectivity of 
naphthalene type CYP11B2 inhibitors39 affords compounds 21–25 with IC50 values in the range of 3–24 nM. 
Replacing the methylene linker by a carbonyl group as accomplished in compounds 26–29 results in a slightly 
reduced inhibitory potency (IC50 = 16–118 nM), albeit the high CYP11B1 selectivity is retained (factor 200–500). 
Introducing hydroxymethylene (31–34) or methoxymethylene (35) as linker between the aryls leads to a significant 
loss of inhibitory activity to approximately 60 % at an inhibitor concentration of 500 nM in the case of compounds 
31–34 and to an almost complete loss in the case of compound 35. 
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Table 2. Inhibition of Human Adrenal CYP11B2 and CYP11B1 In Vitro (Compounds 11–35) 
 
     % 
a 
IC50 valueb (nM)  
     V79 11B2c V79 11B2c V79 11B1d selectivity 
compd R1 R2 R3 R hCYP11B2 hCYP11B2 hCYP11B1 factore 
11     8 n.d. n.d. n.d. 
12 H H H H 76 154 953 6 
13 6-OMe H H H 85 53 640 12 
14 H o-OMe H H 24 n.d. n.d. n.d. 
15 H m-OMe H H 62 n.d. n.d. n.d. 
16 H p-OMe H H 89 7.8 2804 359 
17 H p-CN H H 93 2.7 1956 724 
18 H p-OCF3 H H 95 3.9 3559 913 
19 6-OMe p-OMe H H 95 11 4329 394 
20 7-OMe p-OMe H H 35 n.d. n.d. n.d. 
21 H p-OMe OMe H 93 7.7 1811 235 
22 6-OMe p-OMe OMe H 96 7.6 2452 322 
23 6-OMe H OMe H 90 24 2936 122 
24 H    98 3.0 785 262 
25 OMe    94 5.0 735 147 
26 H p-OMe H  79 119 24003 202 
27 H m-F-p-OMe H  78 65 19816 305 
28 H p-CN H  88 30 9639 321 
29 H p-OCF3 H  91 28 11307 404 
30 OMe p-OMe H  25 n.d. n.d. n.d. 
31 H p-OMe H OH 57 n.d. n.d. n.d. 
32 H m-F-p-OMe H OH 51 n.d. n.d. n.d. 
33 H p-CN H OH 59 n.d. n.d. n.d. 
34 H p-OCF3 H OH 63 n.d. n.d. n.d. 
35 H p-OMe H OM
 
23 n.d. n.d. n.d. 
fadrozol
 
    - 1 10 10 
a Mean value of at least two experiments, standard deviation usually less than 10 %; inhibitor concentration, 500 nM. b Mean value of at 
least four experiments, standard deviation usually less than 25 %, n.d. = not determined. c Hamster fibroblasts expressing human 
CYP11B2; substrate deoxycorticosterone, 100 nM. d Hamster fibroblasts expressing human CYP11B1; substrate deoxycorticosterone, 
100 nM. e IC50 CYP11B1/IC50 CYP11B2, n.d. = not determined.  
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Inhibition of Steroidogenic and Hepatic CYP Enzymes (Tables 3 and 4). A set of 12 compounds was 
investigated for inhibition of the steroidogenic enzymes CYP17 and CYP19 (Table 3). The inhibition of CYP17 was 
investigated using the 50,000 g sediment of the E. coli homogenate recombinantly expressing human CYP17 and 
progesterone (25 µM) as substrate.40 The inhibition values were measured at an inhibitor concentration of 2 μM. In 
general, the compounds show no or only little inhibition of less than 25 %. As an exception, compound 22 exhibits 
51 % inhibition which is in the range of the reference ketoconazole (IC50 = 2780 nM). The inhibition of CYP19 at an 
inhibitor concentration of 500 nM was determined in vitro with human placental microsomes and [1β-
3H]androstenedione as substrate as described by Thompson and Siiteri41 using our modification.42 Most of the 
compounds display only a moderate aromatase inhibition of less than 40 % whereof four compounds do not inhibit 
CYP19 at all (21, 24, 25, and 28). The para-cyano-substituted derivative 17 shows a pronounced activity (60 %) and 
introduction of methoxy in 6-position of the naphthalene core as accomplished in compounds 19, 22, and 23 results 
likewise in a remarkably increased inhibition. Most notably, compound 19 is a highly potent CYP19 inhibitor 
exhibiting an IC50 value of 38 nM, thus being almost as active as the reference fadrozole (IC50 = 30 nM). 
Table 3. Inhibition of Human CYP17 and CYP19 in vitro 
 % inhibitiona   % inhibitiona 
compd CYP17b CYP19c  compd CYP17b CYP19c 
16 < 5 39  23 26 73 
17 25 60  24 < 5 < 5 
18 10 45  25 21 6 
19 < 5 92d  26 5 19 
21 28 6  28 7 < 5 
22 51 49  29 8 17 
a Mean value of three experiments, standard deviation usually less than 10 %. b E. coli expressing human CYP17; substrate progesterone, 
25 μM; inhibitor concentration, 2.0 μM; ketoconazole, IC50 = 2.78 μM. c Human placental CYP19; substrate androstenedione, 500 nM; 
inhibitor concentration, 500 nM; fadrozole, IC50 = 30 nM. d IC50 = 38 nM. 
A selectivity profile relating to inhibition of crucial hepatic CYP enzymes (CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4) was determined for compounds 16, 17, 19, and 28 by use of recombinantly 
expressed enzymes from baculovirus-infected insect microsomes. Table 4 shows the inhibition at a concentration of 
10 μM and 1 μM. It becomes apparent that some enzymes are affected only to a minor degree by all compounds 
including CYB2B6 and CYP2D6. On the other hand, CYP2C9 is strongly inhibited in most cases. The benzoyl 
derivative 28 with less than 40 % inhibition at 1 μM concentration at all CYP enzymes is the most selective 
compound within this series. The worst selectivity profile is observed in the case of 19 inhibiting CYP2C9, 
CYP2C19, and CYP3A4 with pronounced potency. 
Table 4. Inhibition of Selected Hepatic CYP Enzymes in vitro 
      % inhibitiona      
 CYP1A2b,c CYP2B6b,d CYP2C9b,e CYP2C19b,f CYP2D6b,g CYP3A4b,h 
compd 10 
M 
1 μM 10 
M 
1 μM 10 
M 
1 μM 10 
M 
1 μM 10 
M 
1 μM 10 
M 
1 
M 16 77 23 48 < 5 92 51 32 < 5 6 < 5 79 30 
17 83 41 69 24 96 78 87 62 62 23 17 9 
19 59 13 61 8 98i 96i 96 74 7 < 5 89 60 
28 47 22 43 14 74 35 43 < 5 51 23 62 23 
a Mean value of two experiments, standard deviation usually less than 10 %. b Recombinantly expressed enzymes from baculovirus-
infected insect microsomes (Supersomes). c Furafylline, IC50 = 2.42 μM. d Tranylcypromine, IC50 = 6.24 μM. e Sulfaphenazole, IC50 = 318 
nM. f Tranylcypromine, IC50 = 5.95 μM. g Quinidine, IC50 = 14 nM. h Ketoconazole, IC50 = 57 nM. i IC50 = 64 nM. 
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Discussion and Conclusion 
The inhibitor design concept of the present study triggered the synthesis of compounds 11 and 12 as potential 
new lead structures by extending a previously established naphthalene molecular scaffold via introduction of a 
phenyl or benzyl residue in 3-position. Subsequently, docking studies in our CYP11B2 protein model were 
performed in order to check for spatial consistency with the pharmacophore hypothesis. It was found that while 
phenyl-substituted 11 did not dock under the given pharmacophore constraint (Fe(heme)-N(ligand) interaction), 
benzyl-substituted 12 adequately fits into the binding site by exploiting a previously unexplored sub-pocket. These 
findings were confirmed by experimental results showing that 3-phenyl-substituted pyridylnaphthalene 11 exhibits 
no significant CYP11B2 inhibition in vitro. In accordance with the docking results, benzyl analog 12 is a moderately 
potent aldosterone synthase inhibitor (IC50 = 154 nM). The selectivity versus CYP11B1, however, is rather poor 
with an only 6-fold increased IC50 value compared to CYP11B2. The following lead optimization was accomplished 
by considering the SAR results obtained previously from the structures of the known inhibitors which have been 
used for the generation of the pharmacophore model (e.g., 1–10). Methoxy substitution in compound 6 afforded the 
most active compound of the flavone series (IC50 = 11 nM) and was therefore chosen as a model substituent to 
figure out the optimal substituent position in the benzyl moiety of 12. In case of the pyridylnaphthalenes, methoxy in 
6-position as accomplished in 2 proved to be favorable in terms of both inhibitory potency and selectivity.14 
Within the present set of compounds, interesting structure-activity and structure-selectivity relationships can be 
observed, particularly with regard to the benzyl and the naphthalene moieties. The benzylic part of the investigated 
molecules represents a pivotal region for structural optimization and is to a great extent dependent on the position of 
substituents in terms of both inhibitory activity and selectivity toward the highly homologous CYP11B1. Placing 
methoxy in ortho- or meta-position of the benzyl residue significantly reduces the inhibitory potency. Most notably, 
the inhibition decreases to 24 % at an inhibitor concentration of 500 nM in case of ortho-methoxy-derivatized 
compound 14. Contrariwise, methoxy in para-position as accomplished in compound 16 increases the CYP11B2 
activity by a factor of 20 compared to the hydrogen analog 12 and the selectivity toward CYP11B1 clearly improves 
(selectivity factor = 359). The experimental observations can be explained by the docking results of compounds 16 
and 19, both bearing a para-methoxy group (Figure 3). The introduction of this substituent into the benzyl moiety as 
accomplished in 16 leads to interactions of the compound with the residues of Pro452, Val339, and Thr279, thus 
stabilizing the complex formed by coordination of the heme iron by the heterocyclic nitrogen considerably (Figure 
3a). In compound 19, a second methoxy group was introduced at the 6-position of the naphthalene scaffold (Figure 
3b). This leads to no additional stabilization of the complex, but to a slightly increased selectivity versus CYP11B1. 
The same trend was observed previously for the binding properties of a series of substituted 
pyridylnaphthalenes.14,15 The para-cyano and para-trifluoromethoxy derivatives 17 and 18 are likewise highly 
potent and display IC50 values of 2.7 nM and 3.9 nM, respectively, which corroborates the importance of para-
substitution for activity. Keeping in mind the high homology of the two CYP11B isoforms, the selectivity factors 
relating to CYP11B1 inhibition of the latter compounds are particularly noteworthy. Compound 17 displays an 
approximately 700-fold and compound 18 a 900-fold stronger inhibition of CYP11B2 versus CYP11B1.  
In the naphthalene molecular scaffold, introduction of a methoxy substituent in 7-position results in a decreased 
inhibitory potency (20, 30) whereas the same substituent is readily tolerated in 6-position and even slightly increases 
the CYP11B1 selectivity in most cases. Figure 4 shows the 6-methoxy substituted derivative 19 mapped to the 
pharmacophore model. It is obvious that this compound nearly perfectly exploits both the well known (HY0, HY1, 
HY2a, AA1, AA2a) and the newly identified (HY3, AA3b) interaction areas which is reflected by the high 
inhibitory potency of this compound and underlines the predictive power of our pharmacophore hypothesis.  
The para-methoxy group in the benzyl moiety of 19 which has been found to be responsible for both high 
inhibitory activity at CYP11B2 and selectivity versus CYP11B1 fits to the acceptor atom feature AA3b. Hence, 
targeting this interaction area is a promising strategy in the future design of potent and selective aldosterone 
synthase inhibitors. With respect to the selectivity profile relating to inhibition of several other CYP enzymes, it 
becomes apparent that 6-methoxylation endows the benzylnaphthalenes with an increased inhibitory potency at 
CYP19 as in the case of compounds 19, 22, and 23, for example 6-methoxy derivative 19 is a highly potent CYP19 
inhibitor displaying an activity similar to fadrozole. In addition, the latter compound strongly inhibits several hepatic 
CYP enzymes (i.e., CYP2C9, CYP2C19, and CYP3A4).  
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Figure 3. Structure of the CYP11B2 binding pocket with the docked inhibitors 16 (a) and 19 (b). Details of the 
active site, showing inhibitor, heme co-factor and the interacting residues of Pro452, Val339, and Thr279. 
 
Figure 4. Compound 19 shows an enhanced fit to the pharmacophore hypothesis compared to 1 by additionally 
exploiting the features HY3 and AA3b. Pharmacophoric features are color-coded: Cyan for hydrophobic regions 
(HY0–HY3) and green for acceptor atom features (AA1–4). 
Varying the substitution pattern of the pyridine site induces no distinct changes of the CYP11B2 potency in case 
of 21 and 22. Again, 6-methoxylation in compound 22 increases the selectivity versus CYP11B1 compared to 21. A 
slightly decreased selectivity versus CYP11B1 is observable in case of the isoquinoline derivatives 24 and 25 due to 
a moderate increase in CYP11B1 potency (IC50 < 1000 nM) which corresponds to previously observed results 
within the pyridylnaphthalene series.39 Contrary to the finding that 6-methoxylation effects a slightly improved 
selectivity (as shown in previous studies14,15 and observed in case of compounds 13, 19, and 22 compared to 12, 16, 
and 21), the 6-methoxynaphthalene compound 25 is less selective than the hydrogen analog 24. Derivatization of the 
methylene linker in compounds 26–35 leads to a decrease in inhibitory potency. The carbonyl analogues 26, 28, and 
29 are slightly less active than their methylene analogues. On the other hand, CYP11B1 inhibition is reduced to the 
same degree and the high selectivity is maintained. Again, para-trifluoromethoxy has the strongest effect on the 
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inhibitory discrimination between the two CYP11B isoforms and derivative 29 is approximately 400-fold less active 
at CYP11B1 compared to CYP11B2. In case of the para-cyanobenzoyl compound 28, a decreased inhibition of the 
sex-hormone producing CYP17, CYP19 as well as the hepatic CYP1A2, CYP2B6, CYP2C9, CYP2C19, and 
CYP2D6 enzymes is found compared to the benzyl analog 17, thus providing an advantageous overall CYP 
selectivity profile for this compound. Other variations of the methylene moiety as accomplished in the hydroxy- and 
methoxymethylene derivatives 30–35 lead to a pronounced decrease of inhibitory activity compared to the 
unsubstituted analogues. These compounds display 51–63 % inhibition at an inhibitor concentration of 500 nM in 
case of hydroxy substitution (30–34) and only 23 % in case of methoxy substitution (35). Obviously, the decrease in 
potency with increasing substituent size (hydrogen < carbonyl < hydroxy < methoxy) reflects the increase of steric 
repulsion between the aryl–aryl spacer and the enzyme parts (i.e., Leu343 and heme co-factor) separating the 
naphthalene binding site from the sub-pocket interacting with the benzyl residue. 
In summary, it has been shown that our CYP11B2 pharmacophore model has predictive power to identify 
prospective lead structures. Based on the results of the pharmacophore model, a new class of pyridylnaphthalene 
derivatives with extended carbocyclic skeleton was synthesized. Derivatives with para-functionalized benzyl moiety 
in 3-position of the naphthalene molecular scaffold thoroughly satisfied the spatial constraints imposed by the 
pharmacophore model and turned out to be highly potent aldosterone synthase inhibitors. The most active 
compound, para-cyanobenzyl derivative 17, displayed nanomolar potency at the target enzyme (IC50 = 2.7 nM). In 
addition, docking studies using our CYP11B2 protein model proved to be a useful tool to estimate the inhibitory 
properties of proposed new molecules and to explain structure-activity relationships. The binding behavior of 
compounds 11 and 12 was adequately predicted by the docking results. Furthermore, it was shown that the high 
inhibitory potency of the para-substituted derivative 16 is the outcome of stabilizing interactions with the residues 
of Pro452, Val339, and Thr279. The selectivity versus CYP11B1 (up to a factor of 900) which is especially 
remarkable with respect to the high homology of the two CYP11B isoforms was found to be a consequence of para-
substitution and hence of exploiting the AA3b pharmacophoric feature as well. Currently, further studies are 
underway to evaluate selected compounds for their in vivo properties.  
Experimental Section 
Chemical and Analytical Methods. Melting points were measured on a Mettler FP1 melting point apparatus 
and are uncorrected. 1H NMR and 13C spectra were recorded on a Bruker DRX-500 instrument. Chemical shifts are 
given in parts per million (ppm), and tetramethylsilane (TMS) was used as internal standard for spectra obtained in 
DMSO-d6 and CDCl3. All coupling constants (J) are given in Hertz. Mass spectra (LC/MS) were measured on a 
TSQ Quantum (Thermo Electron Corporation) instrument with a RP18 100-3 column (Macherey Nagel) and with 
water/acetonitrile mixtures as eluents. Elemental analyses were carried out at the Department of Chemistry, 
University of Saarbrücken. Reagents were used as obtained from commercial suppliers without further purification. 
Solvents were distilled before use. Dry solvents were obtained by distillation from appropriate drying reagents and 
stored over molecular sieves. Flash chromatography was performed on silica gel 40 (35/40–63/70 µM) with 
petroleum ether/ethyl acetate mixtures as eluents, and the reaction progress was determined by thin-layer 
chromatography analyses on Alugram SIL G/UV254 (Macherey Nagel). Visualization was accomplished with UV 
light and KMnO4 solution. All microwave irradiation experiments were carried out in a CEM-Discover monomode 
microwave apparatus. 
The following compounds were prepared according to previously described procedures: 3-(3-
methoxynaphthalen-2-yl)pyridine (11c),14 (3-methoxynaphtalene-2-yl)boronic acid (11d),22 methyl 3-
methoxynaphthalene-2-carboxylate (12g),26 methyl 3-hydroxynaphthalene-2-carboxylate (12h),25 (3-
hydroxynaphthalen-2-yl)(4-methoxyphenyl)methanone (26b),32 (3-methoxynaphthalen-2-yl)(4-
methoxyphenyl)methanone (26c),32 N,4-Dimethoxy-N-methylbenzamide (26d),32 4-[(3-hydroxynaphthalen-2-
yl)carbonyl]benzonitrile (28b),32 4-[(3-mehoxynaphthalen-2-yl)carbonyl]benzonitrile (28c),32 4-Cyano-N-methoxy-
N-methylbenzamide (28d).32  
Synthesis of the Target Compounds 
Procedure A.24 Boronic acid (0.75 mmol, 1 equivalent), aryl bromide or -triflate (0.9–1.3 equivalents), and 
tetrakis(triphenylphosphane)palladium(0) (43 mg, 37.5 μmol, 5 mol %) were suspended in 1.5 mL DMF in a 10 mL 
septum-capped tube containing a stirring magnet. To this was added a solution of NaHCO3 (189 mg, 2.25 mmol, 3 
equivalents) in 1.5 mL water and the vial was sealed with an Teflon cap. The mixture was irradiated with 
 ~ 297 ~ 
 
microwaves for 15 min at a temperature of 150 °C with an initial irradiation power of 100 W. After the reaction, the 
vial was cooled to 40 °C, the crude mixture was partitioned between ethyl acetate and water and the aqueous layer 
was extracted three times with ethyl acetate. The combined organic layers were dried over MgSO4 and the solvents 
were removed in vacuo. The coupling products were obtained after flash chromatography on silica gel (petroleum 
ether/ethyl acetate mixtures) and/or crystallization. If an oil was obtained, it was dissolved in diethyl ether/methanol 
and tranferred into the hydrochloride salt by 1N HCl solution in isopropanol/diethyl ether, followed by filtration and 
optional crystallization from acetone. Analytical data refer to the free base unless otherwise noted. 
Procedure B. Boronic acid (1 equivalent), aryl bromide or -triflate (1.3–1.5 equivalents), and 
tetrakis(triphenylphosphane)palladium(0) (5 mol %) were suspended in toluene/ethanol 4/1 to give a 0.07–0.1 M 
solution of boronic acid under an atosphere of nitrogen. To this was added a 1 N aqueous solution of Na2CO3 (6 
equivalents). The mixture was then refluxed for 12–18 h, cooled to room temperature, diluted with water and 
extracted several times with ethyl acetate. The combined extracts were dried over MgSO4, concentrated and purified 
by flash chromatography on silica gel (petroleum ether/ethyl acetate mixtures) and/or crystallization. If an oil was 
obtained, it was dissolved in diethyl ether/methanol and tranferred into the hydrochloride salt by 1N HCl solution in 
isopropanol/diethyl ether, followed by filtration and optional crystallization from acetone. Analytical data refer to 
the free base unless otherwise noted. 
Procedure C.33,34 To a 0.6 M solution of NaI (6 equivalents) in acetonitrile was added chlorotrimethylsilane (6 
equivalents) at room temperature, and the mixture was stirred for 30 min before cooling to 0 °C with an ice-water 
bath. Then, a 1 M solution of the phenylnaphthylalcohol (1 equivalent) in acetonitrile was added dropwise. After 
complete addition the mixture was heated at 55 °C for 3 h. After recooling to room temperature, the reaction was 
quenched by addition of saturated aqueous NaHCO3 solution. The layers were separated, and the aqueous layer 
extracted twice with ethyl acetate The combined organic layers were washed with a solution of Na2S2O3, water and 
brine. The extracts were dried over MgSO4, concentrated and purified by flash chromatography on silica gel 
(petroleum ether/ethyl acetate mixtures). If an oil was obtained, it was dissolved in diethyl ether/methanol and 
tranferred into the hydrochloride salt by 1N HCl solution in isopropanol/diethyl ether, followed by filtration and 
optional crystallization from acetone. Analytical data refer to the free base unless otherwise noted. 
Procedure D. To a 0.05 M solution of benzoylnaphthalene in dry methanol was added sodium borohydride (2 
equivalents) at such a rate as to maintain the internal reaction temperature below 5 °C. The reaction mixture was 
stirred for 1 h, diluted with diehtylether and treated with saturated aqueous NaHCO3 solution. The mixture was then 
extracted three times with ethyl acetate, washed twice with saturated aqueous NaHCO3 solution and once with brine 
and dried over MgSO4. The filtrate was concentrated in vacuo, and the residue was flash chromatographed on silica 
gel (petroleum ether/ethyl acetate mixtures) to afford the corresponding alcohols. 
3-(3-Phenylnaphthalen-2-yl)pyridine (11) was obtained according to procedure A from 11a (657 mg, 1.86 
mmol) and phenylboronic acid (854 mg, 4.00 mmol) after flash chromatography on silica gel (petroleum ether/ethyl 
acetate, 7/3, Rf = 0.22) as a colorless oil (195 mg, 0.69 mmol, 37 %), precipitation of the hydrochloride salt afforded 
a highly hygroscopic solid, mp (HCl salt) 106–109 °C. MS m/z 282.70 (MH+). Anal. (C21H15N·HCl∙1.5H2O) C, H, 
N. 
3-(3-Benzylnaphthalen-2-yl)pyridine (12) was obtained according to procedure A from 12a (433 mg, 1.18 
mmol) and 3-pyridineboronic acid (105 mg, 0.85 mmol) after flash chromatography on silica gel (petroleum 
ether/ethyl acetate, 4/1, Rf = 0.19) as a colorless oil (186 mg, 0.63 mmol, 74 %), mp (HCl salt) 197–198 °C. MS m/z 
296.14 (MH+). Anal. (C22H17N·HCl∙0.6H2O) C, H, N. 
3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine (13) was obtained according to procedure A from 13a (462 
mg, 1.17 mmol) and 3-pyridineboronic acid (100 mg, 0.81 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 4/1, Rf = 0.18) as a colorless oil (196 mg, 0.60 mmol, 74 %), mp (HCl salt) 170–172 
°C. MS m/z  326.09 (MH+). Anal. (C23H19NO∙HCl∙0.6H2O) C, H, N. 
3-[3-(2-Methoxybenzyl)naphthalen-2-yl]pyridine (14) was obtained according to procedure A from 14a (462 
mg, 1.17 mmol) and 3-pyridineboronic acid (100 mg, 0.81 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 7/3, Rf = 0.26) as colorless oil (161 mg, 0.50 mmol, 61 %), mp (HCl salt) 214–216 
°C. MS m/z  326.02 (MH+). Anal. (C23H19NO∙HCl∙0.6H2O) C, H, N. 
3-[3-(3-Methoxybenzyl)naphthalen-2-yl]pyridine (15) was obtained according to procedure A from 15a (433 
mg, 1.09 mmol) and 3-pyridineboronic acid (92 mg, 0.75 mmol) after flash chromatography on silica gel (petroleum 
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ether/ethyl acetate, 4/1, Rf = 0.13) as a colorless oil (162 mg, 0.50 mmol, 66 %), mp (HCl salt) 161–162 °C. MS m/z 
326.02 (MH+). Anal. (C23H19NO∙HCl∙0.6H2O) C, H, N. 
3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine (16) was obtained according to procedure A from 16a (476 
mg, 1.20 mmol) and 3-pyridineboronic acid (92 mg, 0.75 mmol) after flash chromatography on silica gel (petroleum 
ether/ethyl acetate, 4/1, Rf = 0.14) as a colorless oil (199 mg, 0.56 mmol, 75 %), mp (HCl salt) 180–182 °C. 1H-
NMR (500 MHz, CDCl3): δ = 3.75 (s, 3H), 4.00 (s, 2H), 6.72 (d, 3J = 8.8 Hz, 2H), 6.82 (d, 3J = 8.8 Hz, 2H), 7.26 
(ddd, 3J = 7.9 Hz, 3J = 4.7 Hz, 5J = 0.9 Hz, 1H), 7.45–7.52 (m, 3H), 7.68 (s, 1H), 7.70 (s, 1H), 7.79–7.83 (m, 2H), 
8.55 (dd, 4J = 2.2 Hz, 5J = 0.9 Hz, 1H), 8.59 (dd, 3J = 4.7 Hz, 4J = 1.9 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ = 
39.0, 55.2, 113.7, 122.7, 126.0, 126.4, 127.3, 127.6, 128.9, 129.4, 129.7, 132.0, 132.4, 133.1, 136.6, 137.06, 137.13, 
148.2, 149.9, 157.9. MS m/z 326.16 (MH+). Anal. (C23H19NO∙HCl∙0.6H2O) C, H, N. 
4-(3-Pyridin-3-yl-naphthalen-2-ylmethyl)benzonitrile (17) was obtained according to procedure C from 33 
(841 mg, 2.50 mmol), sodium iodide (2.25 g, 15.0 mmol) and chlorotrimethylsilane (1.63 g, 15.0 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.15) as a colorless oil (486 mg, 1.52 mmol, 
61 %), mp (HCl salt) 130–131 °C. MS m/z 321.33 (MH+). Anal. (C23H16N2·HCl∙0.8H2O) C, H, N. 
3-[3-(4-Trifluoromethoxybenzyl)naphthalen-2-yl]pyridine (18) was obtained according to procedure C from 
34 (395 mg, 1.00 mmol), sodium iodide (899 mg, 6.0 mmol) and chlorotrimethylsilane (652 mg, 6.0 mmol) after 
flash chromatography on silica gel (petroleum ether/ethyl acetate, 4/1, Rf = 0.28) as a colorless oil (292 mg, 0.77 
mmol, 77 %), precipitation of the hydrochloride salt afforded a highly hygroscopic solid, mp (HCl salt) 139–142 °C. 
MS m/z 379.90 (MH+). Anal. (C24H17F3NO·HCl·0.2H2O) C, H, N. 
3-[6-Methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]pyridine (19) was obtained according to procedure A 
from 19a (512 mg, 1.20 mmol) and 3-pyridineboronic acid (113 mg, 0.92 mmol) after flash chromatography on 
silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.18) as a colorless oil (189 mg, 0.55 mmol, 60 %), mp (HCl salt) 
114–115 °C. 1H-NMR (500 MHz, CDCl3): δ = 3.75 (s, 3H), 3.91 (s, 3H), 3.98 (s, 2H), 6.73 (d, 3J = 8.5 Hz, 2H), 
6.84 (d, 3J = 8.5 Hz, 2H), 7.09 (d, 4J = 2.5 Hz, 1H), 7.13 (dd, 3J = 9.0 Hz, 4J = 2.5 Hz, 1H), 7.25 (dd, 3J = 8.0 Hz, 3J 
= 4.8 Hz, 1H), 7.51 (m, 1H), 7.57 (s, 1H), 7.60 (s, 1H), 7.71 (d, 3J = 8.9 Hz, 1H), 8.54 (d, 4J = 1.9 Hz, 1H), 8.56 (dd, 
3J = 4.8 Hz, 4J = 1.5 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ = 38.9, 55.2, 55.3, 105.2, 113.7, 119.0, 122.8, 127.5, 
127.8, 129.1, 129.2, 129.8, 132.6, 134.4, 134.8, 136.8, 137.3, 137.6, 148.1, 150.1, 157.9, 158.1. MS m/z 356.25 
(MH+). Anal. (C24H21NO2∙HCl∙0.8H2O) C, H, N. 
3-[7-Methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]pyridine (20) was obtained according to procedure C 
from 20a (400 mg, 1.08 mmol), sodium iodide (1.65 g, 11.0 mmol) and chlorotrimethylsilane (1.20 g, 11.0 mmol) 
after flash chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.11) as a colorless oil (148 mg, 
0.42 mmol, 39 %), mp (HCl salt) 101–103 °C. MS m/z 356.04 (MH+). Anal. (C24H21NO2∙HCl∙0.1H2O) C, H, N. 
3-Methoxy-5-[3-(4-methoxybenzyl)naphthalen-2-yl]pyridine (21) was obtained according to procedure A 
from 16a (396 mg, 1.00 mmol) and 5-methoxy-3-pyridineboronic acid acid (130 mg, 0.85 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.21) as a colorless oil (149 mg, 0.42 mmol, 
49 %), mp (HCl salt) 106–108 °C. MS m/z 356.09 (MH+). Anal. (C24H21NO2∙HCl∙0.5H2O) C, H, N. 
3-Methoxy-5-[6-methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]pyridine (22) was obtained according to 
procedure A from 19a (426 mg, 1.00 mmol) and 5-methoxy-3-pyridineboronic acid acid (130 mg, 0.85 mmol) after 
flash chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.18) as colorless plates (244 mg, 0.63 
mmol, 75 %), mp 129–130 °C. MS m/z 385.91 (MH+). Anal. (C25H23NO3) C, H, N. 
3-(3-Benzyl-6-methoxynaphthalen-2-yl)5-methoxypyridine (23) was obtained according to procedure A from 
13a (396 mg, 1.00 mmol) and 5-methoxy-3-pyridineboronic acid acid (130 mg, 0.85 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.21) as a colorless oil (221 mg, 0.62 mmol, 
73 %), mp (HCl salt) 119–121 °C. MS m/z 356.09 (MH+). Anal. (C24H21NO2∙HCl∙0.2H2O) C, H, N. 
4-[3-(4-Methoxybenzyl)naphthalen-2-yl]isoquinoline (24) was obtained according to procedure A from 16a 
(396 mg, 1.00 mmol) and 4-isoquinolineboronic acid (130 mg, 0.75 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 7/3, Rf = 0.20) as a colorless oil (178 mg, 0.47 mmol, 63 %), mp (HCl salt) 202–203 
°C. MS m/z 376.12 (MH+). Anal. (C27H21NO∙HCl∙0.5H2O) C, H, N. 
4-[6-Methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]isoquinoline (25) was obtained according to procedure A 
from 19a (456 mg, 1.07 mmol) and 4-isoquinolineboronic acid (130 mg, 0.75 mmol) after flash chromatography on 
silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.18) and crystallization from acetone/diethyl ether as colorless 
plates (178 mg, 0.44 mmol, 59 %), mp 158–159 °C. MS m/z 406.00 (MH+). Anal. (C28H23NO2) C, H, N. 
(4-Methoxyphenyl)(3-pyridin-3-yl-naphthalen-2-yl)methanone (26) was obtained according to procedure B 
from 26a (4.02 g, 9.80 mmol) and 3-pyridineboronic acid (1.02 g, 8.33 mmol) after flash chromatography on silica 
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gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.22) as an off-white solid (2.66 g, 7.84 mmol, 94 %), mp 69–72 °C. MS 
m/z 340.07 (MH+). Anal. (C23H17NO2∙0.2H2O) C, H, N.  
(3-Fluoro-4-methoxyphenyl)(3-pyridin-3-yl-naphthalen-2-yl)methanone (27) was obtained according to 
procedure B from 27a (4.19 g, 9.78 mmol) and 3-pyridineboronic acid (1.02 g, 8.33 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.16) as an off-white solid (2.52 g, 7.05 mmol, 
85 %), mp 96–97 °C.  MS m/z 358.00 (MH+). Anal. (C23H16FNO2∙0.1H2O) C, H, N. 
4-(3-Pyridin-3-yl-naphthalene-2-carbonyl)benzonitrile (28) was obtained according to procedure B from 28a 
(3.0 g, 7.40 mmol) and 3-pyridineboronic acid (1.0 g, 8.20 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 7/3, Rf = 0.15) as yellowish needles (1.67 g, 5.0 mmol, 68 %), mp 135–136 °C. MS 
m/z 335.05 (MH+). Anal. (C23H14N2O∙0.1H2O) C, H, N. 
(3-Pyridin-3-yl-naphthalen-2-yl)(4-trifluoromethoxyphenyl)methanone (29) was obtained according to 
procedure B from 29a (4.57 g, 9.84 mmol) and 3-pyridineboronic acid (1.02 g, 8.33 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 7/3, Rf = 0.20) as a colorless oil (3.20 g, 8.14 mmol, 98 
%), precipitation of the hydrochloride salt afforded a highly hygroscopic solid, mp (HCl salt) 116–118 °C.  MS m/z 
393.89 (MH+). Anal. (C23H14F3NO2·HCl) C, H, N. 
(4-Methoxyphenyl)(6-methoxy-3-pyridin-3-yl-naphthalen-2-yl)methanone (30) was obtained according to 
procedure B from 30a (1.54 g, 3.50 mmol) and 3-pyridineboronic acid (374 mg, 3.0 mmol) after flash 
chromatography on silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.08) and crystallization from methanol as a 
white solid (723 mg, 1.96 mmol, 65 %), mp 140–141 °C. MS m/z 370.10 (MH+). Anal. (C24H19NO3·0.2H2O) C, H, 
N. 
 (4-Methoxyphenyl)(3-pyridin-3-yl-naphthalen-2-yl)methanol (31) was obtained according to pocedure D 
from 26 (1.02 g, 3.0 mmol) and sodium borohydride (226 mg, 6.0 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 1/1, Rf = 0.18) as a colorless solid (597 mg, 1.75 mmol, 58 %), mp 77–78 °C. MS m/z 
342.10 (MH+). Anal. (C23H19NO2∙0.3H2O) C, H, N. 
(3-Fluoro-4-methoxyphenyl)(3-pyridin-3-yl-naphthalen-2-yl)methanol (32) was obtained according to 
procedure D from 27 (2.11 g, 5.91 mmol) and sodium borohydride (246 mg, 6.50 mmol) after flash chromatography 
on silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.19) as a yellowish solid (543 mg, 1.51 mmol, 26 %), mp 75–
76 °C. MS m/z 359.96 (MH+). Anal. (C23H18FNO2∙0.5H2O) C, H, N. 
4-[Hydroxy-(3-pyridin-3-yl-naphthalen-2-yl)methyl]benzonitrile (33) was obtained according to procedure D 
from 28 (1.46 g, 4.37 mmol) and sodium borohydride (182 mg, 4.80 mmol) after flash chromatography on silica gel 
(petroleum ether/ethyl acetate, 1/1, Rf = 0.16) as a colorless solid (1.22 g, 3.63 mmol, 83 %), mp 101–103 °C. MS 
m/z 336.93 (MH+). Anal. (C23H16N2O∙0.5H2O) C, H, N. 
(3-Pyridin-3-yl-naphthalen-2-yl)(4-trifluoromethoxyphenyl)methanol (34) was obtained according to 
Procedure D from 29 (2.80 g, 7.12 mmol) and sodium borohydride (295 mg, 7.80 mmol) after flash chromatography 
on silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.32) as a colorless solid (1.86 g, 4.70 mmol, 66 %), mp 65–66 
°C. MS m/z 396.20 (MH+). Anal. (C23H16F3NO2∙0.2H2O) C, H, N. 
3-{3-[Methoxy-(4-methoxyphenyl)methyl]naphthalen-2-yl}pyridine (35). To a suspension of NaH (40 mg, 
1.0 mmol, 60% dispersion in oil) in 5 mL dry THF at was added dropwise a solution of 31 (300 mg, 0.88 mmol) in 5 
mL THF at room temperature under an atmosphere of nitrogen. After hydrogen evolution ceased, a solution of 
methyliodide (59 μL, 0.95 mmol) in 5 mL THF was added dropwise, and the resulting mixture was stirred for 5 h at 
room temperature. After 2 h an additional 59 μl methyliodide was added. The mixture was then treated with 
saturated aqueous NH4Cl solution and extracted three times with ethyl acetate. The combined organic layers were 
washed with water and brine, dried over MgSO4 and the solvent was evaporated in vacuo. 35 was obtained after 
flash chromatography on silica gel (petroleum ether/ethyl acetate, 1/1, Rf = 0.39) as colorless oil (226 mg, 0.64 
mmol, 72 %), mp (HCl salt) 113–114 °C. MS m/z 356.11 (MH+). Anal. (C24H21NO2·HCl∙0.7H2O) C, H, N. 
Biological Methods. 1. Enzyme Preparations. CYP17 and CYP19 preparations were obtained by described 
methods: the 50,000 g sediment of E. coli expressing human CYP1740 and microsomes from human placenta for 
CYP19.42 2. Enzyme Assays. The following enzyme assays were performed as previously described: CY1740 and 
CYP19.42 3. Activity and Selectivity Assay Using V79 Cells. V79 MZh 11B1 and V79 MZh 11B2 cells36 were 
incubated with [4-14C]-11-deoxycorticosterone as substrate and inhibitor in at least three different concentrations. 
The enzyme reactions were stopped by addition of ethyl acetate. After vigorous shaking and a centrifugation step 
(10,000 g, 2 min), the steroids were extracted into the organic phase, which was then separated. The conversion of 
the substrate was analyzed by HPTLC and a phosphoimaging system as described.10,36 4. Inhibition of Human 
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Hepatic CYP Enzymes. The recombinantly expressed enzymes from baculovirus-infected insect microsomes 
(Supersomes) were used and the manufacturer’s instructions (www.gentest.com) were followed.  
Computational Methods. 1. Pharmacophore Modeling. The most potent compounds of the heteroaryl 
substituted methyleneindane and naphthalene derivatives and the most potent flavones were selected as training set 
(see  supplementary material for composition of  the training set) for the generation of an extended pharmacophore 
model. GALAHAD,19 the pharmacophore generation module of SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, 
Missouri, USA), was used to generate pharmacophore hypotheses of the series of inhibitors form hypermolecules 
incorporating the structural information of the dataset and alignments from sets of ligand molecules. In the genetic 
algorithm, default values were used. In the present case, 100 models were generated and the best 20 pharmacophore-
hypotheses were saved. GALAHAD takes into account energetics, steric similarity, and pharmacophoric overlap, 
while accommodating conformational flexibility, ambiguous stereochemistry, alternative ring configurations, 
multiple partial match constraints, and alternative feature mappings among molecules. All the other molecules of the 
library were then aligned using each of the 20 pharmacophores as a template, and the best pharmacophore was 
selected. The top ranked model was the best in three of the most indicative ranking criteria of the used software 
(Pareto ranking,20 Specificity, and Mol-query). An additional donor site feature not shown in the figures) was 
manually added to simulate the complexation of the heme iron by the sp2-hybridized nitrogen (AA1) in order to fix 
the orientation of the lone pair of the sp2-hybridized nitrogen. This refined pharmacophore model was selected as 
molecular query for the alignment of our database library. The core of the pharmacophoric scheme is formed by five 
hydrophobic features (HY0, HY1, HY2a, HY2b) and the acceptor atom (AA) spheres represent the H-bond 
acceptors. In some cases, the acceptor feature AA2a overlapped a donor feature (data not shown), indicating the 
presence of an OH function. The final pharmacophore model consists of 12 pharmacophoric features: 4 essential 
ones (HY0, AA1, HY1), necessary for basal inhibitory potency, and 8 partial matches (HY2, HY2b, AA2a, AA2b, 
HY3, AA3a, AA3b, and AA4). 2. Protein Modeling and Docking. Using the resolved human cytochrome CYP2C9 
structure (PDB code: 1OG5)43 as template, a homology model was build and refined for CYP11B2. This work has 
been described in more detail by our group in four recent papers.12–15 In this study selected compounds were docked 
into the refined homology model using FlexX-Pharm.44 A pharmacophore constraint was applied to ensure the right 
binding mode of the inhibitors with the heme-cofactor. For this purpose the standard Fe–N interaction parameters of 
FlexX45,46 were modified and a directed heme-Fe–N interaction was defined perpendicular to the heme-plane. The 
constraint requires the existence of an inhibitor-nitrogen-atom on the surface of an interaction cone with a 20 degree 
radius, which has its origin at the Fe-atom and points perpendicular to the heme-plane (with a length of 2.2 Ǻ). Only 
docking solutions were accepted, which fulfill this constraint. For all other ligand-protein interactions the standard 
FlexX interaction parameters and geometries were used. The protein-ligand interactions were analyzed using the 
FlexX software. 
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3.4.4. Conclusions and Outlook. 
In this project two pharmacophore models have been established, which resulted very helpful in 
the drug design process. Especially the second pharmacophore (paper XIV), in combination with 
docking studies, led to the development of a new class of aldosterone synthase inhibitors with an 
increased molecular complexity and a very good selectivity and activity profile. 
Nevertheless, in the light of already newly synthesized inhibitors of CYP11B2, not included in 
the two pharmacophores presented herein, and of the recently solved crystal structure of 
aromatase, first steroidogenic CYP enzyme crystallized so far, two main computational 
approaches could be advisable for the future.  
In first line, the pharmacophore model should be extended by including the above mentioned 
new inhibitor classes developed in house, but also by including inhibitors published in literature 
and included in patents of Speedel and Novartis. Especially the stereospecific characteristics of 
the chiral inhibitors should be addressed, since these are often responsible for selectivity between 
CYP11B2, CYP11B1 and aromatase (i.e. R/S-fadrozole).  
Most of the homology models of CYP11B2 reported in literature are based on bacterial CYP 
enzymes as templates or at best on a hepatic mammalian (CYP2C9) one. The aromatase x-ray 
structure 3EQM might be a valid alternative for the creation of a new homology model of 
CYP11B2 and CYP11B1. This should take into consideration the inhibitors subject of paper 
XIII and XIV and in some extend also the high flexibility characterizing the BC-loop, FG-
segment and C-terminal region of the CYP enzymes.  
A high gain of informations useful in drug design could be expected from these two suggested 
approaches, which are already an ongoing work in our research group. 
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Chapter Four. GENERAL CONCLUSIONS. 
 
Several pathologies related to the fields of oncology, congestive heart failure and blood pressure 
regulation are steroid hormone-dependent. Thus, steroidogenic enzymes involved in the last 
steps of the biosynthesis of the steroidal hormones could be indicated as valid pharmaceutical 
targets. Currently several inhibitors of such enzymes are used in clinics or at least in clinical 
trials, but most of them are based on a steroidal scaffold, which might implicate systemic side 
effects and reduced target selectivities. 
In this work, several computational methodologies were applied in order to rationalize and 
increase the knowledge of the trhree-dimensional structure of the active site of four steroidogenic 
enzymes, namely CYP17, CYP19, CYP11B2 and 17β-HSD1, as well as to investigate the 
fundamental functional and structural features required by different classes of non-steroidal 
inhibitors of the mentioned enzymes in order to reach high potency and good selectivity. The 
final aim was to speed up the rational drug design process of non-steroidal lead candidates to be 
applied in hormone-dependent pathologies, like breast and prostate cancer, endometriosis, 
congestive heart failure and hypertension. 
As a part of this thesis the tridensional structure of the androgen-producing enzyme cytochrome 
P450 17 (17α-hydroxylase/17,20-lyase) was built using as a core template the mammalian 
CYP2C9 crystal structure. Further, this homology model of CYP17 could plausibly explain the 
binding mode of the substrate pregnenolone and the differences in the binding affinities of 
different classes of non-steroidal CYP17 inhibitors as an output of docking studies. This 
substantially speeded up the drug design process of a new non-steroidal inhibitors of CYP17, 
resulting in an increase of their molecular complexity and inhibitory potency. 
An analogous study has been performed on aromatase, where a series of imidazolylmethylen-
benzophenones was investigated by docking studies performed on the aromatase model (PDB 
entry 1tqa). This investigation sustained the development of new non-steroidal AI presenting 
with a very high inhibitory potency. 
A combination of ligand- and structure based techniques was used in the CYP11B2 project, 
which resulted into two pharmacophore models with a good predictive capacity, and into a new 
class of aldosterone synthase inhibitors with an increased selectivity versus the highly 
homologous isoform CYP11B1 and the hepatic CYP enzymes in general. These pharmacophore 
models, in particular the second one, might be suitable for virtual screening of 3D databases, 
searching for new lead candidates. 
In the 17β-HSD1 project, an in-depth structural analysis of existing crystal structures was the 
basis for mechanistic studies concerning the catalytic cycle, as well as for the drug design 
process. The combination of molecular dynamic simulations, quantum chemical investigations, 
and docking studies led to the hypothesis of the kinetic cycle of the enzyme and to the 
identification of an alternative binding mode for a class of non-steroidal 17β-HSD1 inhibitors, 
which might act by functional disruption of the enzyme. 
Altogether, this work shows the power of computational methodologies in modern 
macromolecular, as well as drug design research, especially when these methods are used in 
combination. They are a perfect complement to traditional medicinal chemistry and can 
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contribute strongly to the multidisciplinary research efforts in the field of steroidogenic enzymes 
and hormone-dependent diseases. 
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(too less!) in Bologna and to learn on how to stand on my feets (scientifically speaking).. and this 
considering you are from Trento! I did not regret ones my decision to do my diploma thesis in 
the QSAR and modeling lab in Bologna (long time ago) and if I finally “PhD”-myself, well part 
of the credits deserve to you. By the way, I wish also to thank Andrea Cavalli for his generosity  
and our fruitful discussions and I’m looking forward for further good cooperations. 
An important period of my PhD was embossed by two of my group leaders, Carsten Jagusch and 
Ralf Heim. Both of you showed me the importance of loyality and team-work and how strong a 
group has to work together to reach its goals. Therefore, and not to forget due to several pleasant 
evenings spent drinking a bottle of wine, you deserve my friendship and gratitude. 
Same has to said about the former lab 1 members,Erika, Mariano, Marcel and Ulli, ouff, our 
Friday after-works were simply great! I’m very thankful for all your precious advices (not only 
in synthesis) and the long discussion we had about work, love and life. 
I wish to thank all my former and present co-workers, in Saarbrücken as well as in Bologna, 
which had the patience to follow me along the tortuous paths of my mind, and in particular the 
biology group (Christina, Martina, Sabrina, Sigrid, Patricia, etc..), Emmanuel, Sandrine, 
Matthias, Adriane, Vittorio, Luisa, etc. They really supported me each time I had to deal with 
biological aspects (kinetics, testings, etc) or computational approaches concerning my work. 
A special thanks then goes to Corina and Martina, the right hands of our “chief” in Saarbrücken. 
Corina, enjoy becoming a mama and if you will rise your daughter like you were supporting us, 
well, then I think she’ll become a great girl. 
Well, to all other AK-Hartmann and QSAR-lab members: listing all of you in the space left is 
pretty hard, especially because I hate simply setting up lists.. but you all have my gratitude and 
friendship for the years spend together.. sometimes they were a bit harsh, more often nice and 
pleased, and this is how I will remind them. 
Last annotation goes to my far-far-away friends: Raby, Alex, Max, Paolino, Andi, Paolo, Luke, 
Heini, etc etc etc.. you are the reason why I don’t feel lonely even if I live far-far away. Every 
time I’m back home or to Italy, it’s like we have seen us the day before.. I appreciate and are 
really grateful that our friendship had last so long, and I hope it will still be like that. 
 
Well, that’s all folks. 
       Matthias 
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Chapter Seven. APPENDIX 
APPENDIX A. CYP families in humans  
57 genes divided among 18 families of cytochrome P450 genes and 43 subfamilies.  
Family Function Members Names 
CYP1 
drug and steroid (especially 
estrogen) metabolism 
3 subfamilies, 3 genes, 
1 pseudogene 
CYP1A1, CYP1A2, CYP1B1 
CYP2 drug and steroid metabolism 
13 subfamilies, 16 
genes, 16 pseudogenes 
CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C8, 
CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, 
CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2U1, CYP2W1 
CYP3 
drug and steroid (including 
testosterone) metabolism 
1 subfamily, 4 genes, 2 
pseudogenes 
CYP3A4, CYP3A5, CYP3A7, CY3A43 
CYP4 
arachidonic acid or fatty acid 
metabolism 
6 subfamilies, 11 genes, 
10 pseudogenes 
CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP4F3, 
CYP4F8, CYP4F11, CYP4F12, CYP4F22, CYP4V2, 
CYP4X1, CYP4Z1 
CYP5 thromboxane A2 synthase 1 subfamily, 1 gene CYP5A1 
CYP7 
bile acid biosynthesis 7-alpha 
hydroxylase of steroid nucleus 
2 subfamilies, 2 genes CYP7A1, CYP7B1 
CYP8 varied 2 subfamilies, 2 genes 
CYP8A1 (prostacyclin synthase), CYP8B1 (bile acid 
biosynthesis) 
CYP11 steroid biosynthesis 2 subfamilies, 3 genes CYP11A1, CYP11B1, CYP11B2 
CYP17 
steroid biosynthesis, 17-alpha 
hydroxylase 1 subfamily, 1 gene CYP17A1 
CYP19 
steroid biosynthesis: aromatase 
synthesizes estrogen 
1 subfamily, 1 gene CYP19A1 
CYP20 unknown function 1 subfamily, 1 gene CYP20A1 
CYP21 steroid biosynthesis 
2 subfamilies, 2 genes, 
1 pseudogene 
CYP21A2 
CYP24 vitamin D degradation 1 subfamily, 1 gene CYP24A1 
CYP26 retinoic acid hydroxylase 3 subfamilies, 3 genes CYP26A1, CYP26B1, CYP26C1 
CYP27 varied 3 subfamilies, 3 genes 
CYP27A1 (bile acid biosynthesis), CYP27B1 (vitamin D3 1-
alpha hydroxylase, activates vitamin D3), CYP27C1 
(unknown function) 
CYP39 
7-alpha hydroxylation of 24-
hydroxycholesterol 
1 subfamily, 1 gene CYP39A1 
CYP46 cholesterol 24-hydroxylase 1 subfamily, 1 gene CYP46A1 
CYP51 cholesterol biosynthesis 
1 subfamily, 1 gene, 3 
pseudogenes CYP51A1 (lanosterol 14-alpha demethylase) 
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APPENDIX B. Catalytic cycle of CYPs
1: The substrate binds to the 
active site of the enzyme, in 
close proximity to the heme 
group, on the side opposite to the 
peptide chain. The bound 
substrate induces a change in the 
conformation of the active site, 
often displacing a water 
molecule from the distal axial 
coordination position of the 
heme iron, and sometimes 
changing the state of the heme 
iron from low-spin to high-spin.
2: The change in the electronic 
state of the active site favors the 
transfer of an electron from NAD(P)H via cytochrome P450 reductase or another associated This 
takes place by way of the electron transfer chain, as described above, reducing the ferric heme 
iron to the ferrous state.
3: Molecular oxygen binds covalently to the distal axial coordination position of the heme iron. 
The cysteine ligand is a better electron donor than histidine, with the oxygen consequently being 
activated to a greater extent than in other heme proteins. However, this sometimes allows the 
bond to dissociate, the so-called "decoupling reaction", releasing a reactive superoxide radical, 
interrupting the catalytic cycle.
4: A second electron is transferred via the electron-transport system, either from cytochrome 
P450 reductase, ferredoxins, or cytochrome b5, reducing the dioxygen adduct to a negatively 
charged peroxo group. This is a short-lived intermediate state.
5: The peroxo group formed in step 4 is rapidly protonated twice by local transfer from water or 
from surrounding amino-acid side chains, releasing one water molecule, and forming a highly 
reactive iron(V)-oxo species. 
6: Depending on the substrate and enzyme involved, P450 enzymes can catalyse any of a wide 
variety of reactions. A hypothetical hydroxylation is shown in this illustration. After the product 
has been released from the active site, the enzyme returns to its original state, with a water 
molecule returning to occupy the distal coordination position of the iron nucleus.
S: An alternative route for mono-oxygenation is via the "peroxide shunt": interaction with single-
oxygen donors such as peroxides and hypochlorites can lead directly to the formation of the iron-
oxo intermediate, allowing the catalytic cycle to be completed without going through steps 3, 4 
and 5. A hypothetical peroxide "XOOH" is shown in the diagram.
C: If carbon monoxide (CO) binds to reduced P450, the catalytic cycle is interrupted. This 
reaction yields the classic CO difference spectrum with a maximum at 450 nm.
